bioworld - medical device daily · pdf filethe bioworld executive compensation report –...

BioWorld®

INDUSTRIAL BIOTECHNOLGY

STATREPORT

IMMEDIATE AND COMPREHENSIVE INDUSTRY INFORMATION

BioWorld® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information Michael Harris, Senior Managing Editor Amanda Lyle, Senior Editor Copyright © 2007 AHC Media LLC® BioWorld Today 3525 Piedmont Road, N.E. Building Six, Suite 400 Atlanta, GA 30305 U.S.A. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher. Product code: SO7429 ISBN-10: 1-933040-67-X ISBN-13: 978-1-933040-67-7

BioWorld® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information is published by AHC Media LLC®, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those of the publication. Mention of products or services does not constitute endorsement. (GST Registration Number R128870672) Senior Managing Editor: Michael Harris Senior Editor: Amanda Lyle Marketing Manager: Chris Walker Account Representatives: Steve Roberts, Bob Sobel, Chris Wiley Vice President/Group Publisher: Donald R. Johnston Customer Service: (800) 879-8790 or (404) 262-5526 Please visit our web site: www.bioworld.com

Please note: BioWorld has made every effort to ensure that the information in this report is accurate and up-to-date, but cannot be responsible for errors, inaccuracies or changes in the data. If the reader identifies any information that is incorrect or has changed, please notify BioWorld so that it can be corrected for future editions. Notice: This report is an information tool, and the user should make business decisions based on an independent investigation, verification and evaluation of this as well as other information relevant to the user’s business interest. BioWorld has gathered information for this work from many different sources and quotes information which has been gathered by other sources. Although BioWorld has taken reasonable steps to ensure the accuracy of this report, due to the tremendous amount of information, and the third-party control of some information, BioWorld cannot verify the accuracy of all information that it gathers and reports and thus does not warrant that the information is error-free. AS A RESULT, BIOWORLD DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR PURPOSE.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information

ABOUT BIOWORLD®

BioWorld Today, the newspaper of record for the biotechnology industry, is read by

biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today

is delivered by e-mail and fax every business morning, and is also found exclusively online at

www.bioworld.com. The BioWorld Online website has been internationally recognized as the most

comprehensive resource for strategic biotechnology news and information available today. In

addition to original daily news reporting, BioWorld offers an extensive searchable database with

more than 15 years of biotechnology archives. This site is not only a great source for insightful, up-

to-the-minute news coverage, but a veritable library of information on the developments of the

industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of

biotechnology market intelligence from every biotech hotspot around the globe.

BioWorld does not post press releases, but rather uses information that is researched and written

by the top business and science reporters in the industry. With nearly 20 writers spread throughout

eight countries, BioWorld covers news on public companies and hard-to-find information on private

companies. Our seasoned reporters get the inside scoop on what’s happening within the corporate

walls, on regulatory issues in Washington and elsewhere, and on scientific breakthroughs

worldwide. This news coverage of the biotechnology industry is 100 percent original and available

only at BioWorld.

All of the BioWorld resources are available for easy online searching, including:

BioWorld Today – The daily biotechnology newspaper.

BioWorld International – The weekly monitor of global biotechnology developments.

BioWorld Financial Watch – The weekly report on all market data and business trends in

biotechnology.

BioScan: The Worldwide Biotech Industry Reporting Service – The most comprehensive

directory of biotechnology companies available.

The BioWorld Biotechnology State of the Industry Report – A must-have annual report

reviewing financial trends in the biotechnology industry.

The BioWorld Executive Compensation Report – An annual report revealing executive

compensation data at biotechnology companies in the U.S.

The BioWorld RNA/DNA Therapeutics & Technologies Report 2006 – An in-depth look at

major market opportunities in RNAi, pharmacogenomics and forensics.


The BioWorld Phase III Report – A quarterly compilation of biotechnology products in

late-stage clinical trials.

BioWorld Snapshots – An exclusive online product updated daily with market data, such

as collaborations, mergers, acquisitions, financings, market cap rankings and more.

BioWorld StatReports – Industry-specific reports including contact information and

names, R&D focus, products on the market and in development, agreements and

financial information.

Medical Device Daily – The daily medical technology newspaper. Available every

business morning via fax or online at www.medicaldevicedaily.com.

For more information on BioWorld®, please contact:

Donald R. Johnston, VP/Group Publisher AHC Media LLC 3525 Piedmont Road Building Six, Suite 400 Atlanta, GA 30305 USA Phone: 404-262-5439 Fax: 404-262-5510 E-mail: [email protected] or [email protected]

Website: www.bioworld.com


Copyright ©2006 AHC Media® 5

TABLE OF CONTENTS How to Use BioWorld StatReports…………………………………………………………………6 List of Companies……………………………………………………………………………………9 Company Profiles…………………………………………………………………………………..13 Subject Index………………………………………………………………………………………397



BioWorld®

INDUSTRIAL BIOTECHNOLOGY

STATREPORT

HOW TO USE

BIOWORLD STATREPORTS



HOW TO USE BIOWORLD STATREPORTS BioWorld StatReports are fully searchable through Adobe Acrobat Reader by using its search feature (Ctrl. + Shift + F). Companies may also be located using the list of company names at the beginning of the report. This useful feature provides a quick reference guide to coverage. It is an alphabetical listing of all companies in the directory and allows the reader to summarily determine if a specific company is represented in the directory. The Main Entry section is arranged alphabetically by company name. FIELDS AND THEIR DESCRIPTIONS Company records include only those fields for which information has been obtained. Where possible, dates are included to reflect the approximate occurrence of events. Company Name and Address Gives the main address, telephone number(s), fax, web site address, and e-mail address, if known. Second addresses are given for major research facilities, U.S. facilities of non-U.S. companies, and some subsidiaries and divisions. Management Lists management involved in relevant marketing and R&D areas, such as the Chairman of the Board, Chief Executive Officer (CEO), President, Chief Operating Officer (COO), Chief Financial Officer (CFO), Executive or Senior Vice Presidents, Vice President or Director of R&D, and Vice President or Director of Marketing. May also include names of senior scientists/researchers. Employees Gives the approximate number employees and, when known, the number of Ph.D.s, M.D.s, and D.V.M.s on staff. History Contains information on founding date, name changes, major acquisitions, previous subsidiaries or investments and organization memberships. Facilities Includes facilities involved in biotechnology. Often provides size (in square feet or square meters). Stock-Financial History Contains information on public-private status; initial funding; stock exchange and ticker symbol; public offerings, including date, price of stock at issuance, number of shares offered and dollar value. For public companies, information includes financials for most recently completed fiscal year, including revenue, net income or loss, earnings or loss per share, average shares outstanding and total assets. These figures are compared with the corresponding figures for the previous year. Private Placements Usually these arrangements are made through investment firms to fund clinical research for products in development. Information may include date, dollar value and use of funds. Subsidiaries/Divisions Includes subsidiaries of biotechnology companies and often the location of the subsidiary. The address, management and research interests are listed if readily available. (A company is usually considered a subsidiary if 51% or more is owned by the parent company.) Also included are divisions of large companies that focus on biotechnology. Subsidiary Of Lists the parent company and percentage owned when applicable.



Investments Lists investments by biotechnology companies. For nonbiotechnology companies, generally limited to investments in the biotechnology industry. Joint ventures are also listed here. Principal Investors Includes the principal investors in the biotechnology company profiled. Financial Information General information, which may include R&D budget, nonprofit offshoots or investment arms of the company. Business Strategy Reflects new or changed directions of the company, or the company’s mission. Agreements Consists of a brief summary of the research and contents of the agreement and the date agreement commenced. Agreements are arranged alphabetically by company/organization. May contain agreements outside of the focus area of the StatReport to ensure completeness. Research and Development Briefly describes general research interests and technologies worked on by the company or its subsidiaries. Research done through agreements with other companies is also included. Products on the Market Includes (1) all products of biotechnology companies and (2) biotechnology products of nonbiotechnology (e.g., chemical and pharmaceutical) companies. May contain products outside of the focus area of the StatReport to ensure completeness. Products in Development Column 1 includes the generic, trade names and uses of the product. The status indicated in column 2 refers to the standard stages for a U.S. drug or other product in development. Generally, only products in development related to the industry of the StatReport are included. Subject Index Categorizes companies involved in various aspects of biotechnology.



BioWorld®


STATREPORT

LIST OF COMPANIES



LIST OF COMPANIES 3DM Inc. A/F Protein Inc. AB Enzymes Oy Abbott GmbH & Co. KG Abengoa SA Acadian Seaplants Ltd. ADI Group Inc. ADI Systems Inc. Advanced Product Enterprises LLC Advanta Seeds UK Ltd. AEA Technology plc AGI Dermatics AgResearch Ltd. AgriSense-BCS Ltd. Agrium Inc. Ag-West Bio Inc. Ajinomoto Co. Inc. Akzo Nobel NV Alberta Research Council Inc. Alderon Biosciences Inc. Alltech Inc. Altair Nanotechnologies Inc. Altus Pharmaceuticals Inc. Aluline Ltd. AMDL Inc. American Radiolabeled Chemicals Inc. Analox Instruments Ltd. Analox Instruments U.S.A. Applera Corp. Applied Biosystems Inc. Applikon Biotechnology Inc. Arch Chemicals Inc. Arch Personal Care Products LP Archer Daniels Midland Argonne National Laboratory Arysta LifeScience Corp. Asahi Kasei Corp. Associates of Cape Cod Inc. Astellas Pharma Inc. astre Corp. Athenix Corp. Atrium Biotechnologies Inc. Axxora Life Science Inc. BAC BV (Biotechnology Application Centre) BACHEM AG Bachem California Inc. Bangs Laboratories Inc. BASF AG Bayer Corp. Bayer CropScience AG Bayou Biolabs Be-Long Group BioAssay Works LLC Biocatalysts Ltd. Bioclear BV BioForce Nanosciences Inc. BioGenes GmbH BioGenesis Enterprises Inc. Biogenie Inc. Bio-Lab Ltd. Biolog Inc. Biologos Inc.

BioMed Diagnostics Inc. Biomeda Corp. Biomedical Technologies Inc. BioMerieux INDUSTRY BioMerieux SA Biomol GmbH Bionas GmbH Bionov CNP Inc. BIOPAC Systems Inc. BioPro International Inc. Bioriginal Food & Science Corp. Bioscience Inc. BioScreen Testing Services Inc. BioSure Inc. Biosynth International Inc. Biotal Ltd. Bio-Technical Resources Biotechnology Research Institute Biotecx Laboratories Inc. Biotehnos SA Biothane Corp. BioTime Inc. BioVectra dcl Bioxel Pharma Inc. Biozyme Laboratories Ltd. Boojum Research Ltd. Boston Life Sciences Inc. BRAIN (Biotechnology Research and Information Network AG) Bunge Ltd. CABI Calzyme Laboratories Inc. Cambio Ltd. Cambrex Corp. Canadian Forest Service Canadian Seed Coaters Cantest Ltd. Cardinal Health - Middleton Cargill Inc. Ceapro Inc. Celsis International plc Centre for Innovative Biology and Environmental Technology Ceres Inc. Chembiotech Ltd. Chemeq Ltd. ChemGenes Corp. Chr. Hansen Inc. Chunghwa Chemical Synthesis & Biotech Co. Ltd. Codexis Inc. Codon Devices CombiMatrix Corp. Commercial Microbiology Ltd. Cornell Institute for Biotechnology and Life Science Technologies Cosmo Bio Co. Ltd. CryoLife Inc. CUBIA (University Centre for Algal Biotechnology) Cuno Inc. Cyanotech Corp. Daiichi Pharmaceutical Co. Ltd. Dainippon Sumitomo Pharma Co. Ltd.



Dalton Pharma Services Dextra Laboratories Ltd. Dextran Products Ltd. Diagnostic Chemicals Ltd. Digene Corp. Diversa Corp. DNA Technologies Inc. DOE Joint Genome Institute Dojindo Laboratories Don Whitley Scientific Ltd. Dong-A Pharmaceutical Co. Ltd. Dow AgroSciences LLC Dragon Pharmaceutical Inc. Droycon BioConcepts Inc. DSM DSM Fine Chemicals DuPont Dyadic International (USA) Inc. Dynavax Europe EMD Biosciences Inc./Merck Biosciences eMembrane Inc. Encelle Inc. EnSolve Biosystems Inc. Enviro-Zyme International LLC Enzyme Research Laboratories Ltd Epicore Networks (U.S.A.) Inc. Epidauros Biotechnologie AG Eurogentec SA EvoGenix Ltd. Evolva SA F. Hoffmann-La Roche Ltd. FibroGen Inc. First Link (UK) Ltd. Fraunhofer Institute for Interfacial Engineering and Biotechnology Galderma SA Genencor International Inc. General Electric Global Research Genesearch Pty. Ltd. Geneva Scientific Genomatica Inc. Gentra Systems Inc. Genzyme Corp. GL Biochem (Shanghai) Ltd. HaloSource Inc. Hammen Corp. Harvard Bioscience Inc. Hawaii Biotech Inc. Helmholtz Centre for Infection Research Hercules Inc. Hidex Oy Huntingdon Life Sciences Hybrizyme Corp. ICPbio Idaho National Laboratory Idexx Laboratories Inc. IGENE Biotechnology Inc. Imperial Innovations Ltd. Industrial Biotechnology Corp. Industrial Technology Research Institute – Biomedical Engineering Center inGenious Targeting Laboratory Inc. Institute for Biological Research and Institute for Biological Research and Technology Institute of Food Research

International Flavors & Fragrances Inc. Iogen Corp. Isolagen Inc. Israel Institute for Biological Research (IIBR) Itochu Corp. J. Craig Venter Institute Johnson Matthey Pharma Services Kanebo Ltd. Kaneka Corp. Kikkoman Corp. (Biochemicals Division) Kraeber GmbH & Co. Kuraray Co. Ltd. Kyorin Pharmaceutical Co. Ltd. Kyowa Hakko Kogyo Co. Ltd. Laboratoires Eurobio Lake States LANXESS AG Lavipharm SA Lawrence Berkeley National Laboratory LG Chem Ltd. LG Life Sciences Ltd. LGC (Laboratory of the Government Chemist) LifeCell Corp. LifeSensors Inc. Link Technologies Ltd. Lonza Group Ltd. Maine Biotechnology Services Inc. Mallinckrodt Inc. Marcor Development Corp. Maruzen Pharmaceuticals Co. Ltd. Mascoma Corp. Matreya LLC Maxxam Analytics Inc. MBI International MDS Pharma Services MedPharm Ltd. Megabase Research Products Meiji Seika Kaisha Ltd. Mercian Corp. Merck KgaA Metabolix Inc. Microbe Inotech Laboratories Inc. Microbia Inc. Mo Bio Laboratories Inc. MoBiTec GmbH Molecular Devices Corp. Molecular Probes Inc. Monsanto Co. Morishita Jintan Co. Ltd. M-Scan Ltd. MSE Technology Applications Inc. Nanogen Inc. NanoHorizons Inc. NanoLogix Inc. Nanophase Technologies Corp. National Collection of Yeast Cultures (NCYC) National Institute of Advanced Industrial Science and Technology (AIST) National Institutes of Health (NIH) National Research Council of Canada Nature Plus Inc. NatureWorks LLC Neogen Corp. New Brunswick Scientific Co. Inc. New England BioLabs Inc.



New Horizons Diagnostics Corp. New Zealand Pharmaceuticals Ltd. Nigu Bioselect Nippon Kayaku Co. Ltd. Nitto Denko Corp. Norac Technologies Inc. North Carolina Biotechnology Center NOVA Chemicals Corp. NovaSep Process november AG Noven Pharmaceuticals Inc. Novozymes A/S Novozymes Inc. Omex Environmental Ltd. OmniChem OmniGene Bioproducts Inc. Optigenex Inc. Optronics Organo Corp. Pacific Biodiesel Inc. Pacific Northwest National Laboratory Pall Corp. Paprican PBR Laboratories Inc. (PBR) PCI Membranes Pentapharm Ltd. PeproTech Inc. Peptides International Inc. Pfeiffer Vacuum Ltd. Pfizer Inc. Pharmbiodyn Consulting Group Pioneer Hi-Bred International Inc. PLANTON GmbH Polium Technologies Inc. Polydex Pharmaceuticals Ltd. Polysciences Inc. POS Pilot Plant Corp. PrimeSyn Lab Inc. Primm S.R.L. Procter & Gamble Co. Prokaria ehf Prometic BioSciences Inc. Proteus SA Qbiogene Quip Laboratories Inc. Ramot at Tel Aviv University Ltd. Randox Laboratories Ltd. Reanal Finechemical Co. RECO Biotechnology Recordati SpA Regis Technologies Inc. Renessen LLC Renovo Group plc Research Organics Inc. Research Triangle Park Laboratories Inc.

Response Biomedical Corp. Roal Oy RTI International SafePath Laboratories LLC Sakai Chemical Industry Co. Ltd. Sanyo Chemical Industries Ltd. (Sanyo Kasei) Scion - Cellwall Biotechnology Centre Sensient Technologies Corp. Severn Biotech Ltd. Showa Denko KK SibEnzyme Ltd. Solomon Park Research Laboratories Spark Holland BV Spherix Inc. SRI International Stewart Agricultural Research Services Inc. Stratagene Corp. Strategic Diagnostics Inc. Sumitomo Chemical Co. Ltd. SunOpta Inc. Symbio Syngenta International AG Synthetech Inc. Synthetic Genomics Inc. Takeda Pharmaceutical Co. Ltd. Teledyne Isco The Dow Chemical Co. The Nitrate Elimination Co. Inc. TNO Quality of Life Toray Industries Inc. Toronto Research Chemicals Inc. Union Chemical Laboratories (UCL) UniQuest Pty. Ltd. University of Nebraska-Lincoln, Center for Biotechnology UVP Inc. Valeant Pharmaceuticals International Inc. Varied Industries Corp. VECTOR State Research Centre of Virology/Biotechnology Virinova GbR Vitrolife AB Vizon SciTec Inc. Wako Chemicals U.S.A. Inc. Waste Stream Technology Inc. Webs Ltd. Wedgewood Analytical Inc. Westbridge Research Group Weyerhaeuser Co. Xethanol Corp. Yeda Research and Development Co. Ltd. Yissum Research Development Co. YMC Co. Ltd. Zeltia SA Zeon Corp. Zuckerforschung Tulln GmbH



BioWorld®


STATREPORT

COMPANY PROFILES



3DM Inc.

P.O. Box 425025 Cambridge MA 02142, US Phone: (877) 430-9595; Fax: (877) 430-9595 Toll-free phone: (877) 430-9595 Web: www.puramatrix.com E-mail: [email protected]

KEY PERSONNEL: Shuguang Zhang, Ph.D.; Chairman Zen Chu; President Lisa Spirio, Ph.D.; Director, R&D

EMPLOYEES: 8 employees

HISTORY: Founded in 2001 Began biotech R&D in 1994

FACILITIES: 2,000 sq. ft. headquartes and R&D facilities Manufacturing is outsourced

STOCK-FINANCIAL HISTORY: Privately held

PRIVATE PLACEMENTS: Raised $1.7M in first round of financing (10/04)

PRINCIPAL INVESTORS: Bain Capital Monitor Ventures NMJ Japan Technology Directors Inc.

BUSINESS STRATEGY: Establish and maintain a position as the leading synthetic cell culture scaffold for bioproduction, life science R&D and stem cell therapies, through a worldwide marketing and distribution partnership with Becton Dickinson BDBiosciences. 3DM is developing a pipeline of medical devices for orthopedic and cardiac therapies with industry-leading companies.

AGREEMENTS: Name Products Content of Agreement Date Becton Dickinson BD PuraMatrix worldwide marketing

and distribution agreement

2004

Becton Dickinson PuraMatrix Synthetic Peptide Hydrogel

worldwide marketing and distribution agreement

2004

RESEARCH & DEVELOPMENT: Orthopedic and reconstructive surgery medical devices Cardiac regeneration therapies Cancer invasion assays High-content screening Collagen plug assays Stem cell expansion and delivery Bioproduction Tissue engineering

PRODUCTS ON MARKET: PuraMatrix PuraMatrixCST PuraMatrixGMP BD PuraMatrix

PRODUCTS IN DEVELOPMENT: Name Status PuraMatrixCST in preclinicals PuraMatrixRGD in preclinicals



A/F Protein Inc.

935 Main Street Waltham MA 02451, US Phone: (781) 899-7755; Fax: (781) 899-8482 Web: www.afprotein.com; E-mail: [email protected]

KEY PERSONNEL: Elliot Entis; Chairman, President and CEO Michael Erisman, Ph.D.; Exec. VP, Science and Technology Ronald M. Slate; COO Choy L. Hew, Ph.D.; Director and Consultant to A/F Protein Garth Fletcher, Ph.D.; President, A/F Protein Canada, and VP Boris Rubinsky, Ph.D.; Director and Consultant to A/F Protein


HISTORY: Founded and began biotech R&D in 1992 Member--Biotechnology Industry Organization


PRIVATE PLACEMENTS: Raised $1.2M in private placement of Reg D stock (1993, 1994) Raised $4.0M in private placement of Reg D stock (1996)

SUBSIDIARIES/DIVISIONS: A/F Protein Canada P.O. Box 13422 St. John's, NL A1B 4B7 Canada Phone: (709) 738-4638 Fax: (709) 738-4644 E-mail: [email protected]

BUSINESS STRATEGY: Develop the use of antifreeze proteins for the control of cold-induced damage in medical, food and cosmetic products Seeking partners to pursue the development of an AFP-based medium for hypothermic preservation of human platelets and AFP-based strategies for improved methods of cryosurgery

RESEARCH & DEVELOPMENT: Hypothermic-cryogenic preservation of mammalian cells, tissues and whole

organs Enhanced cryosurgical ablation of tumours Food preservation Preservation of reproductive materials Enhancement of the protective capacity of skin-care products

PRODUCTS ON MARKET: Antifreeze Protein Type I Antifreeze Protein Type III Antifreeze Glycoprotein

AB Enzymes Oy

P.O. Box 26 Rajamaki FIN-05207, Finland Phone: +358 9 290 22 510; Fax: +358 9 290 22 550 Web: www.abenzymes.com; E-mail: [email protected]

KEY PERSONNEL: Ralf Lundell; President and CEO


HISTORY: Formed in 1987 Changed name from Alko Ltd./Biotechnology (1995) Changed name from Primalco Ltd. Biotec (9/97) Changed name from Rohm Enzyme (10/01) Acquired GAMMA CHEMIE GmbH (2002)




SUBSIDIARIES/DIVISIONS: AB Enzymes GmbH Beijing Representative Office Room 320B, B Tower, Grand Pacific Building 8A Guanghua Road, Chaoyang District Beijing 100026 China Phone: +86 10 65814225; Fax: +86 10 65814227 E-mail: [email protected] Main Office of ABF Ingredients Corp. Enzyme Division 214 Rockmont Drive Fort Mill, SC 29708-7934 Phone: (803) 547-7800 or (803) 547-0852 Fax: (803) 547-0891; Cell phone: (704) 400-8099 E-mail: [email protected] AB Enzymes GmbH Guangzhou Representative Office Room 2715, Bank of America Plaza 555 Renminzhong Road Guangzhou City 510145 China Phone: +86 20 81302718 Fax: +86 20 81302303 E-mail: [email protected] AB Enzimas Brasil Comercial Ltda. Al. Amazonas, 938 Bloco A, 3. andar 06454 – 070, Barueri, SP Brazil Phone: +55 11 4688 2555; Fax: +55 11 4688 2259 E-mail: [email protected] AB Enzymes Singapore Branch 3 International Business Park # 07-18 Nordic European Centre Singapore 609927 Phone: +65 6890 6831; Fax: +65 6890 6846 E-mail: [email protected] AB Enzymes Poland Sp. Z.o.o. Ul. POW 35 PL 98-200 Sieradz Phone: +48 43 8223094 Fax: +48 43 8273808 E-mail: [email protected] AB Enzymes GmbH Feldbergstrasse 78 D-64293 Darmstadt Germany Phone: +49 (0) 61 51-36 80-100 Fax: +49 (0) 61 51-36 80-120

SUBSIDIARY OF: Abitec Group

PRINCIPAL INVESTORS: Associated British Foods plc

BUSINESS STRATEGY: Develop and market industrial enzymes for feed, textile, and pulp and paper applications

RESEARCH & DEVELOPMENT: Development of technical enzyme applications

PRODUCTS ON MARKET: Biotouch enzymes for textile biofinishing Econase enzymes for feed and food Ecostone enzymes for textile stonewash and finishing Ecopulp enzymes for pulp bleaching



Finase enzymes for feed and food Veron enzymes for baking Rohapect, Rohament, Rohavin and Corolase enzymes for fruit/vegetable processing, cleaning of ultrafiltration membranes and winemaking Corolase enzymes for protein modification

Abbott GmbH & Co. KG

Max-Planck-Ring 2 Wiesbaden 65205, Germany Phone: +49 6122-58-0; Fax: +49-6122-58-1244 Web: www.abbott.de E-mail: [email protected]

KEY PERSONNEL: Holger Liepmann; Chairman, Supervisory Board and Sr. VP, International Operations Jaime Contreras; Managing Director Siegfried Brune; Managing Director Geert Walther Nygaard; Managing Director Rodolfo Viana; Managing Director

EMPLOYEES: 4,000 employees

HISTORY: Formed from the merger of Abbott GmbH, Knoll GmbH and Knoll Deutschland GmbH (2001)


BUSINESS STRATEGY: Discover, develop, manufacture and market innovative medicines Establish global network of strategic alliances and partnerships with biotech companies Manufacture and market pharma active ingredients Market proprietary oral drug delivery and process technology of melt extrusion Build European generic business

AGREEMENTS: Name Products Content of Agreement Date Alza Corp. Oros hydromorphone joint development

and marketing agreement for the U.S.

2/97

Cambridge Antibody Technology plc

therapeutic antibodies joint research agreement

8/93

Center for Molecular Biology, Heidelberg

TET system for regulating gene expression

licensing research agreement

5/96

Eisai Co. Ltd. sibutramine joint development and marketing agreement for Japan

1/98

PharmaNetics Inc. thrombin inhibitors R&D collaboration 1996 PharmaNetics Inc. stoke therapy R&D collaboration 1997 Warner-Lambert Co.

interleukin-1 converting enzyme inhibitors

joint research agreement

5/95

PRODUCTS ON MARKET: Pharmaceuticals worldwide: Synthroid® (hypothyroidism) Isoptin® (coronary heart disease, hypertension, cardiac arrythmia) Rytmonorm®/Rythmol® (cardiac arrthmia) Reductil®/ Merida® (obesity) Vicodin® Vicaprotein (pain) Bruten® (pain) Iruxol® (wound healing) Gopten®/Mavik® (hypertension)



Dilaudid® (pain) Akineton® (parkinson) Cerebrdysin (cerebral insuffiency) Pharma active ingredients worldwide: Ephedrine Caffeine Ibuprofen Theophylline

Abengoa SA

Avenida de la Buhaira 2 Seville 41018, Spain Phone: +34 954 937 111; Fax: +34 954 937 020 Web: www.abengoa.com; E-mail: [email protected]

KEY PERSONNEL: Felipe Benjumea Llorente; Co-chairman Javier Benjumea Llorente; Co-chairman Amando Sanchez Falcon, Financial Director Juan Carlos Jimenez Lora; Director, Investor Relations Santiago Seage Medela; Head, Corp. Strategy and Development Javier Salgado Leirado; President and CEO, Abengoa Bioenergia SA, Abengoa Bioenergy Corp. and Abengoa Bioenergy R&D Ignacio Garcia Alvear; CFO, Abengoa Bioenergia SA Francisco A. Morillo Leon; CTO, Abengoa Bioenergia SA Gerson Santos-Leon; Director, R&D, Abengoa Bioenergia SA Joel Stone; COO, Abengoa Bioenergy Corp. Santiago Ortiz Dominguez; GM, Industrial Waste Management


HISTORY: Acquired Befesa for EUR300M (2000) Started the first bioethanol facility in Spain (2000) Acquired High Plains Corp. (now Abengoa Bioenergy Corp.) (2002) Started the second bioethanol facility in Spain (2002) Acquired Metso Corp.’s Network Management Solutions Division (now Telvent Canada and Telvent USA) (2003) Started construction of the third bioethanol facility in Spain (2003) Acquired Miner & Miner Consulting Engineers Inc. (2004) Started construction of the fourth bioethanol facility in Nebraska (2004) Acquired Almos Systems (2004) Acquired Energoprojekt Gliwice (EPG) (7/06)

STOCK-FINANCIAL HISTORY: Listed on the Madrid and Barcelona stock exchanges IPO-1996 Sales EUR2.024b (YE 05) compared to EUR1.746b (YE 04) Earnings per share EUR0.73/share (YE 05) compared to EUR0.58/share (YE 04)

SUBSIDIARIES/DIVISIONS: Five business units: Industrial Engineering and Construction, Information Technology, Environmental Services, Solar and Bioenergy Six operational fields: Energy, Environment, Transport, Services, Industry and Telecommunications Bioenergy subsidiaries: Ecocarburantes Espanoles SA Ecoagricola SA Bioetanol Galicia SA Biocarburantes de Castilla y Leon SA ETBE Huelva SA Abengoa Bioenergia SA Abengoa Bioenergy Corp.



Abengoa Bioenergy France Abengoa Bioenergy of Hanover Abengoa Bioenergy R&D Inc. Greencell SA

BUSINESS STRATEGY: Solar: Design, promote, attain financing for, construct and operate electric

energy generating plants that utilize the sun as the primary energy source Bioenergy: Produce and develop biofuels for transport--bioethanol and biodiesel, among others that utilize biomass (cereals, cellulosic biomass and oleaginous seeds) as the raw material Environmental Services: Provide environmental services for industry and for the construction of environmental infrastructures, while conducting aluminum waste recycling, zinc recycling, industrial waste management and environmental engineering activities Information Technology: Provide high value-added solutions in four industrial sectors: energy, traffic, transport and the environment) Industrial Engineering and Construction: Engineer, construct and maintain electric, mechanical and instrumentation infrastructures for the energy, industry, transport and services sectors; Promote, construct and operate industrial and conventional (cogeneration and combined cycle) power plants and renewable energy (bioethanol, biodiesel, biomass, wind, solar and geothermal) power plants; Turnkey telecommunication networks and projects

RESEARCH & DEVELOPMENT: Abengoa Bioenergy R&D Inc.:

Improve actual production process yields and coproduct quality at existing dry-mills Increase ethanol capacity and develop new feed co-products Develop and demonstrate cost competitive technologies for new biomass facilities Develop demonstration programs which permit an increase in the field of ethanol utilization (for example, diesel and hydrogen fuel cells)

Acadian Seaplants Ltd.

30 Brown Avenue Dartmouth B3B IX8, Canada Phone: (902) 468-2840; Fax: (902) 468-3474 Toll-free phone: (800) 575-9100 Web: www.acadianseaplants.com E-mail: [email protected]

KEY PERSONNEL: Louis Deveau; Chairman Jean-Paul Deveau; President Perry Bevin; CFO Scott Myers; VP, Sales, Plant Science Division Glen Gabriel; VP, Sales, Animal Science Division John Sewuster; VP, Sales, Food and Food Ingredients Divisions Dr. Alan Critchley; VP, Research Bill Smith; VP, Manufacturing

EMPLOYEES: 310 employees, 8 Ph.D.s

HISTORY: Founded and began biotech R&D in 1981

FACILITIES: Head office Five processing plants Research facility Cultivation site




BUSINESS STRATEGY: Research and application of technology to develop unique marine plant applications and strains of cultivated, food-grade seaweed Manufacture agricultural (feed and fertilizers) and food ingredient products from seaweed

AGREEMENTS: Name Products Content of Agreement Date NRC Institute for Marine Bioscience

plant growth regulators, seaweed vegetable

consulting and licensing agreement

1990

RESEARCH & DEVELOPMENT: Seaweed cultivation and processing Chemical extraction/biostimulants from seaweed

PRODUCTS ON MARKET: Carrageenan-bearing seaweed Natural plant growth regulators Hana-nori--edible seaweeds Ascophyllum nodosum and Chondrus crispus seaweeds--meals, fine-milled powders, extracts for feed, food and cosmetic and health ingredients Cultivated edible sea vegetables

ADI Group Inc.

1133 Regent Street, Suite 300 Fredericton E3B 3Z2, Canada Phone: (506) 452-9000; Fax: (506) 451-7451 Web: www.adi.ca E-mail: [email protected]

KEY PERSONNEL: Hollis B. Cole; President and CEO A.L. Steeves; VP, Administration and Secretary-Treasurer Hazen G. Hawker, CFO Paul D. Morrison; President and COO, ADI Limited Graham J. Brown, President and COO, ADI Systems Inc. Brian MacLean, Operations Manager, Geomembrane Technologies Inc.


HISTORY: Founded in 1945 Since 1981, ADI has conducted R&D into the use of innovative and cost-effective processes for wastewater treatment as well as removal of arsenic and other contaminants from drinking water.

FACILITIES: Environmental laboratory


SUBSIDIARIES/DIVISIONS: ADI Systems Inc. (see separate entry) ADI International Inc. Geomembrane Technologies Inc.

FINANCIAL INFORMATION: ADI is 100% employee-owned

BUSINESS STRATEGY: Promote and apply its anaerobic and aerobic technologies in the treatment of high-strength wastewater Promote and apply water treatment (arsenic, manganese removal) Continue R&D efforts and develop new treatment processes and systems Continue to develop innovative monitoring and control systems

RESEARCH & DEVELOPMENT: Wastewater treatment processes

Water treatment processes Conceptual planning, implementation, supervision, and monitoring of mineral exploration programs Evaluation of mining properties and assessment of investment properties



PRODUCTS ON MARKET: Patents are held and pending on several of the following systems: ADI-BVF® ADI-Hybrid ADI-SBR Floating and structurally supported insulated membrane covers Media G2 arsenic removal Sulpha Bind H2S removal

ADI Systems Inc.

1133 Regent Street, Suite 300 Fredericton E3B 3Z2, Canada Phone: (506) 452-7307; Fax: (506) 452-7308 Toll-free phone: (800) 561-2831 Web: www.adisystems.ca E-mail: [email protected]

KEY PERSONNEL: Graham Brown; President


HISTORY: Founded in 1989


SUBSIDIARIES/DIVISIONS: U.S. office: 182 Main Street, Unit 6 Salem, NH 03079 Phone: (603) 893-2134 Fax: (603) 898-3991 ADI Systems Inc. Laboratory 6 Lewis Street Oromocto, NB E2V 2X5 Canada Phone: (506) 357-2470 Contact: Jonathan Dargavel E-mail: [email protected]

SUBSIDIARY OF: ADI Group Inc. (see separate entry)

BUSINESS STRATEGY: Supply and install anaerobic and aerobic systems for industrial wastewater treatment Seek suitable overseas companies to license ADI wastewater treatment technology

RESEARCH & DEVELOPMENT: Design anaerobic treatment systems, biogas handling and SBR decanters

PRODUCTS ON MARKET: Proprietary ADI-BVF® low-rate anaerobic system, ADI-Hybrid high-rate anaerobic system, ADI-SBR (Sequencing Batch Reactor) technology, ADI-AMR (Anaerobic Modular Reactor), ADI-MBR (Membrane Biological Reactor), generic and package wastewater treatment systems Conducts treatability studies, pilot testing, bench-scale studies, operator training and aftercare services



Advanced Product Enterprises LLC

5716-F Industry Lane Frederick MD 21704, US Phone: (888) 496-8333; Fax: (888) 496-8333 Toll-free phone: (888) 496-8333 Web: www.ape-bio.com E-mail: [email protected]

KEY PERSONNEL: Joseph N. Garner, Ph.D.; President and CEO Bhavesh Joshi, Ph.D.; CSO



BUSINESS STRATEGY: Advanced Product Enterprises LLC (or APE) is a Maryland-based biotechnology company involved in the identification, testing, development, and production of biomolecular and molecular biology products for industrial and academic partners. With the provision of services such as antibiotic assessment, cell based assay development, endotoxin testing, and pharmaceutical assessment we assist pharmaceutical companies with their research and development, preclinical testing, and quality control and assurance needs. The provision of services which include animal model elucidation, recombinant protein, antibody and virus production APE is capable of assisting vaccine development companies with all of their preclinical needs. As services can be bundled or provided individually, we can assist any individual or company with a project of any size.

PRODUCTS IN DEVELOPMENT: Name Status

Sorbitase in preclinicals Varimentix in preclinicals

Advanta Seeds UK Ltd.

Off Southgate Sleaford NG34 7HA, UK Phone: +44 1529 304511; Fax: +44 1529 303908 Web: www.advantaseeds.co.uk E-mail: [email protected]

KEY PERSONNEL: Dr. Thomas Jolliffe; General Manager


HISTORY: Founded in January 1997 from the merger of Sharpes International Seeds Ltd. and Zeneca Seeds UK Ltd.

FACILITIES: 2,000 sq. m. headquarters 1,000 sq. m. R&D facility 20,000 sq. m. manufacturing facility


SUBSIDIARY OF: Limagrain Group (France)

PRINCIPAL INVESTORS: Limagrain Group

INVESTMENTS: Plant Breeding--major U.K. crops

BUSINESS STRATEGY: Produce wholesale and multiplication grade seed and conduct plant breeding

RESEARCH & DEVELOPMENT: Plant breeding

Crop biotechnology



PRODUCTS ON MARKET: Crop varieties for U.K. agriculture

PRODUCTS IN DEVELOPMENT: Name Status Crop varieties in development

AEA Technology plc

Harwell Business Centre Didcot OX11 ORA, UK Phone: +44 (0) 870 190 1900; Fax: +44 (0) 870 190 8261 Web: www.aeat.com; E-mail: [email protected]

KEY PERSONNEL: Bernard Bulkin; Chairman Andrew McCree; CEO David Lindsay; Group Finance Director Keith Russell; Director, Corporate Resources and Company Secretary Stuart Hill; Managing Director, Rail Robert Bell; Managing Director, Environment Ralph Watts; Managing Director, Nuclear Programs


HISTORY: Evolved from U.K. Atomic Energy Authority, Harwell Laboratory--separated in 1994 Acquired biotech expertise and facilities of Warren Spring Laboratory (1994) Acquired the British Rail Research Centre (1996) Privatized as AEA Technology plc. (1996) Sold AEA Technology Battery Systems Ltd, AEA HK, QSA, nCode, Accentus, Engineering, Safety and Risk, Risk Solutions, Safeguard International, EASA and Lexware International Ltd. to Coller Capital (10/05)

STOCK-FINANCIAL HISTORY: Traded on the London Stock Exchange--AAT IPO--1996 Turnover £236.7M (YE 05) compared to £251.6M (YE 04) Net loss <£25.1M> (YE 05) compared to <£2.3M> (YE 04) Earnings per share 35.7p/share (YE 05) compared to 3.4p/share (YE 04)

SUBSIDIARIES/DIVISIONS: Two core businesses: Rail Environment: Future Energy Solutions (FES), Netcen, Waste and Resource Management, National Chemical Emergency Centre (NCEC), Momenta Nuclear programmes--One business unit: Waste Management Technology

PRINCIPAL INVESTORS: M&G Investment Management Invesco Perpetual Deutsche Asset Management Ltd. Newton Investment Management Ltd.

BUSINESS STRATEGY: Environmental business--Supply energy and environmental services to the U.K. government and agencies



AGI Dermatics

205 Buffalo Avenue Freeport NY 11520, US Phone: (516) 868-9026; Fax: (516) 868-9143 Web: www.agiderm.com E-mail: [email protected]

KEY PERSONNEL: Daniel B. Yarosh, Ph.D.; Chairman and President Jonathan D. Klein; VP, Operations Adrienne O’Connor; Director, Quality Control and Assurance Georgia W. Binns; Director, Production Nick Bizios; Director, Process Development Frederic Carr; Director, Sales and Marketing


HISTORY: Founded in May 1985 to focus on DNA repair technology Changed name from Applied Genetics Inc. (1998)

FACILITIES: Liposome manufacturing facility Molecular biology, fermentation and enzyme purification


BUSINESS STRATEGY: Form strategic alliances with cosmetic/dermatology companies for marketing

RESEARCH & DEVELOPMENT: Bicyclic monoterpene diols

DNA repair enzyme delivery

PRODUCTS ON MARKET: Cosmetic ingredients: Photosomes®, Ultrasomes®, Oxysomes®, Roxisomes™, Thiotaine®, Merospheres®, VitAine®, Evodiox™, Pinoxide™ Pharmaceutical products: Dimericine® (T4N5 Liposome Lotion)


Dimericene for xeroderma pigmentosum completed Phase III Dimericene for renal transplant in Phase II clinicals Dimericene for at-risk populations to begin Phase II

AgResearch Ltd.

5th Floor, Tower Block, Ruakura Research Centre, East Street Hamilton 3123, New Zealand Phone: +64 7-834-6600; Fax: +64 7-834-6640 Web: www.agresearch.co.nz; E-mail: [email protected]

KEY PERSONNEL: Rick Christie; Chairman Andrew West, Ph.D.; CEO Dr. Stephen Goldson; Chief Science Strategist Jimmy Suttie, Ph.D.; GM, Science and Technology, Applied Biotechnologies Mark Ward; GM, Sience and Technology, Food and Health Peter Benfell; GM, Science and Technology, Agriculture and Environment Ian Boddy, Ph.D.; GM, Commercial Services Geoff Balme; CFO Phillip Lindsay, Ph.D.; CIO Allanah James; Corporate Affairs Manager

EMPLOYEES: 1,000+ employees

HISTORY: Founded in 1992 in a restructuring of the former Ministry of Agriculture and the Department of Scientific and Industrial Research (DSIR) Sold AgVax (8/05)



FACILITIES: Five campuses

STOCK-FINANCIAL HISTORY: Government-owned company established under the Crown Research Institutes Act

SUBSIDIARIES/DIVISIONS: BioPacificVentures--50% EnCoate--50% Clone International--25% Grasslanz Technology Ltd.--100% Farmax--50%

BUSINESS STRATEGY: Three main objectives: To underpin the New Zealand pastoral sector’s sustainability and profitability To establish a range of biotechnologies and systems in New Zealand To export AgResearch biotechnologies and systems where appropriate

AGREEMENTS: Name Products Content of Agreement Date

Pharming Group NV

recombinant human lactoferrin

manufacturing agreement

6/05

RESEARCH & DEVELOPMENT: Agriculture and environment Applied biotechnologies Food and health

PRODUCTS ON MARKET: Licensing opportunities: AGR-0100: Device for Administration of Beneficial Materials to Ruminants AGR-0101: Delivery Mechanism AGR-0200: A Thermostable Biomatrix AGR-0201: Stable Bio-Matrix Composition and Method of Preparation AGR-0202: A Granulated Composition AGR-0300: A Method of Processing Data from a Spectrophotometer AGR-0301: Compound Preparation Method AGR-0400: Method and Kitset for Sampling and Storage of Biological Samples AGR-0401: Improvements in and Relating to a Method of DNA Testing AGR 0402: Controlled Release Vitamin B12 Compositions and Methods of Using Them AGR-0403: Serratia Proteins AGR-0404: A Novel Drug Dosing Regimen AGR-0405: Mycobacterial Vaccines AGR-0406: Hydatids Vaccine AGR-0407: An Animal Repellent AGR-0408: Process for Production of Immunoglobulin A in Milk AGR-0409: Animal Treatment AGR-0410: Mammary-Specific Transcription Factor BrEts AGR-0411: Nuclear Transfer with Selected Donor Cells AGR-0412: Methods and Compositions for Improving the Developmental Ability and Quality of Pre-Implantation Embryos AGR-0413: Compositions Isolated from Bovine Tissue and Methods for Their Use AGR-0500: Rapid Method for Measuring Complex Carbohydrates in Mammalian Tissue AGR-0501: A Homogeniser AGR-0502: A Sampling Tool AGR-0503: Apparatus for the Removal of Bone AGR-0504: Carcass Management AGR-0505: Neck Breaker Machine AGR-0506: A Method and Means for the Processing of the Head Portion of an Animal Carcass AGR-0507: A Cutting Machine AGR-0508: A Method and Apparatus for Removing Meat AGR-0601: Genetically Modified Plants having Modulated Flower Development AGR-0602: Flowering Locus T (FT) and Genetically Modified Plants having Modulated Flower Development



AgriSense-BCS Ltd.

Taffs Mead Road, Treforest Industrial Estate Pontypridd CF37 5SU, UK Phone: +44 (0)1443 841 155; Fax: +44 (0)1443 841 152 Web: www.agrisense.co.uk E-mail: [email protected]

KEY PERSONNEL: Owen Jones, Ph.D.; GM and Director, Business Development David Judd; Director, Sales and Marketing, Retail David Loughlin; Director, Sales and Marketing, PCO David Avery; Business Development Manager Enzo Casagrande; Director, Technology Nap Coverdale; Director, Operations Neil Bryan; Director, Finance


HISTORY: Established in 1984 Formerly Biological Control Systems Ltd., acquired by AgriSense in 1989 Acquired by biosys (1993) Acquired by Thermo Trilogy (1/97) Acquired by Mitsui (5/01) Acquired by Suterra (6/06)

FACILITIES: 20,000 sq. ft. factory with offices, laboratory and production facilities


SUBSIDIARY OF: wholly-owned subsidiary of Suterra LLC

BUSINESS STRATEGY: AgriSense is a major developer and manufacturer of bio-rational insect pest monitoring and control products for the agricultural, industrial and home and garden market sectors

RESEARCH & DEVELOPMENT: Insect behavior-modifying chemicals (semiochemicals, attractants and

repellents) Controlled-release technology for semiochemicals and other volatile compounds Insect glue technology Trap design

PRODUCTS ON MARKET: Trappit™ range of pest trapping systems Polycore™ range of liquid controlled-release pheromone formulations Selibate™ range of hand-applied, controlled-release pheromone formulations Frustrate™ range of hand-applied, controlled-release pheromone formulations

Agrium Inc.

13131 Lake Fraser Drive SE Calgary T2J 7E8, Canada Phone: (403) 225-7000 Fax: (403) 225-7609 Toll-free phone: (877) 247-4861 Web: www.agrium.com E-mail: [email protected]

KEY PERSONNEL: Frank W. Proto; Chairman Michael Wilson; President and CEO Bruce G. Waterman; Sr. VP, Finance and CFO Richard L. Gearheard; Sr. VP and President, Retail Ron Wilkinson; Sr. VP and President, Wholesale



Andrew K. Mittag; Sr. VP, Corporate Development and Strategy Kevin Helash; VP, Marketing and Distribution Stephen Dyer; VP, Manufacturing


HISTORY: Founded in 1990 Acquired AgBiologicals division of Esso/Exxon Acquired Microbials Division of Allelix Crop Technologies Changed name from Cominco Fertilizers Ltd. AgBiologicals (1995) Changed name from Agrium Inc. AgBiologicals (1996) Acquired Nu-Gro fertilizer technology and professional products businesses from Spectrum Brands Inc. (1/06)

STOCK-FINANCIAL HISTORY: NYSE--AGU / TSX--AGU Net sales $3.294b (YE 05) compared to $2.838b (YE 04) Net earnings $283M (YE 05) compared to $266M (YE 04) Earnings per share $2.14/share (YE 05) compared to $2.03/share (YE 04) Total assets $2.785b (YE 05) compared to $2.661b (YE 04)

BUSINESS STRATEGY: Develop and commercialize new products and services for agricultural crops

RESEARCH & DEVELOPMENT: Specialty controlled-release fertilizers

Microbial inoculants for nutritional, environmental, pest and disease stresses

PRODUCTS ON MARKET: RhizUp™ legume inoculant Enfix™ legume inoculant AtEze™ bacterial inoculant

PRODUCTS IN DEVELOPMENT: Name Status Controlled-release fertilizers test market Biological control agents test market High-sulfur fertilizers test market Plant growth promoters test market Insect pheromone mating disruption test market

Ag-West Bio Inc.

101-111 Research Drive Saskatoon S7N 3R2, Canada Phone: (306) 975-1939; Fax: (306) 975-1966 Web: www.agwest.sk.ca E-mail: [email protected]

KEY PERSONNEL: Armand Lavoie; Chairman Dr. Ashley O'Sullivan; CEO and President Ron Kehrig; VP, BioProducts and BioProcesses Dr. Lisette Mascarenhas; VP, Health and Nutrition Muriel Adams; GM Janice Tranburg; Director, Regulatory Affairs

EMPLOYEES: 10+ employees

HISTORY: Ag-West Botech Inc. was founded in 1989 as nonprofit company in partnership with the government of Saskatchewan to bring new technologies to Saskatchewan as well as commercialize technologies developed in the province Joined forces with Bio-Products Saskatchewan and Saskatchewan Nutraceutical Network to create Ag-West Bio Inc. (4/04) Member--Biotechnology Industry Organization

STOCK-FINANCIAL HISTORY: Nonprofit agency

FINANCIAL INFORMATION: Funding provided by Saskatchewan Agriculture and Food



BUSINESS STRATEGY: Ag-West Bio Inc., at the forefront of Saskatchewan's bio-economy, works as a catalyst for industry growth through investments, aiding strategic alliances, regulatory advice, communications and education. Ag-West's leadership goes beyond biotech to support agriculture, food, health and bio-based industries to be a complete resource for bioscience information in Saskatchewan

RESEARCH & DEVELOPMENT: Promote and facilitate other companies and organizations in research and

development in the sectors of agriculture, environment and natural health products

Ajinomoto Co. Inc.

15-1 Kyobashi, 1-chome, Chuo-ku Tokyo 104-8315, Japan Phone: +81 (3) 5250-8180; Fax: +81 (3) 3297-8720 Web: www.ajinomoto.com E-mail: [email protected]

KEY PERSONNEL: Kunio Egashira; Chairman Norio Yamaguchi; President and CEO Takashi Kurematsu; Exec. Officer, Corporate Planning Dept. Toshio Takahashi ; Exec. Officer, Specialty Chemical Dept. Takashi Utagawa; Exec. Officer, Fermentation and Biotechnology Laboratories Keiichi Yokoyama; Exec. Officer, Marketing Division Yutaka Kunimoto; Amino Acid Division Hirozumi Eto; R&D Management Dept. Yasuhiko Koda; Public Relations Dept. Kanji Mimoto; Asean Division Koichi Maeda; China Division Hiroaki Nomura; Europe and Africa Division Tomoyasu Toyoda ; Pharmaceutical Dept. Kiyoshi Miwa; Exec. Officer, Institute of Life Sciences Tomoaki Hisatsuka; Food Research and Development Laboratories Keisuke Nagai; Exec. Officer; International Production and Biotechnology Center


HISTORY: Formed in May 1909 Established in December 1925 Began biotech research in 1955 Acquired Amoy Food Group Companies from Groupe Danone (1/06)

FACILITIES: 102 plants in 16 countries and regions

STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange IPO--5/49 Net sales ¥1,073b (YE 05) compared to ¥1,040b (YE 04) Net income ¥44.817b (YE 05) compared to ¥36.276b (YE 04) Earnings per share ¥68.8 (YE 05) compared to ¥55.6/share (YE 04) Total assets ¥903.542b (YE 05) compared to ¥871.780b (YE 04)

SUBSIDIARIES/DIVISIONS: Ajinomoto U.S.A. Inc.

BUSINESS STRATEGY: Maintain a worldwide leadership position as a global food and amino acid products company

AGREEMENTS: Name Products Content of Agreement Date Apex Bioscience Inc.

hemoglobin to treat various diseases

collaboration agreement

3/95

Biotech Research Labs, Fujirebio

MAbs (against human tumor antigens) for cancer treatment and as antiviral agent

joint venture to develop and market



Orsan lysine and feed additives

joint venture called Heartland Lysine, Inc.

Orsan lysine and amino acid feed additives

joint venture called Eurolysine

Sankyo Co. Ltd. development, manufacturing and marketing of AJD101 and related compounds

exclusive global licensing agreement

8/06

Scotia Holdings plc

Scotia's SC103 for treating diabetes complications

development and marketing agreement--Ajinomoto gets exclusive rights in Japan and several other Asian countries, Scotia gets up-front fee and milestones

3/97

Senomyx Inc. discovery and development of novel flavor ingredients

R&D, commercialization and licensing

3/06

Seragen Inc. IL-2 gene patents for fusion toxin

worldwide licensing agreements (12/94), restructured to reduce and defer Seragen's financial obligations to Ajinomoto (including royalties on product sales), Seragen's partner Eli Lilly has signed separate licensing agreement with Ajinomoto and assumed most of Seragen's remaining obligations to Ajinomoto

6/97

Tadamitsu Kishimoto

IL-6 joint research agreement

2/97

PRODUCTS ON MARKET: Food products

Amino acids Pharmaceuticals

Akzo Nobel NV

Velperweg 76, P.O. Box 9300 Arnhem 6824 BM, Netherlands Phone: +31 26 366 44 33; Fax: +31 26 3663250 Web: www.akzonobel.com; E-mail: [email protected]

KEY PERSONNEL: Hans Wijers; Chairman and CEO Rob Frohn; CFO Keith Nichols; Sr. VP, Finance




HISTORY: Algemeene Kunstzijde Unie N.V. merged with Koninklijke Zwanenberg Organon to form Akzo (1969) Akzo and Nobel Industries merged to form Akzo Nobel (1994) Acquired Courtaulds (1998) Intervet subsidiary acquired Hoechst Roussel Vet (1999) Technical Services department in Rotterdam, the Netherlands, acquired by Stork NV Divested its Polymerization Catalysts & Components business in the U.S. to Basell Polyolefins (4/06) Acquired remaining shares of its Asian Akzo Nobel Chang Cheng Coatings joint venture (5/06) Divested its Ink and Adhesive Resins business to Hexion Specialty Chemicals (6/06)

STOCK-FINANCIAL HISTORY: NASDAQ--AKZOY / Euronext Amsterdam--AKZ Revenue EUR13.0M (YE 05) compared to EUR12.833M (YE 04) Net income EUR 961M (YE 05) compared to EUR945M (YE 04) Earnings per share EUR3.36/share (YE 05) compared to EUR3.31/share (YE 04)

SUBSIDIARIES/DIVISIONS: 13 business units Subsidiaries in more than 80 countries

AGREEMENTS: Name Products Content of Agreement Date Feixiang Chemicals (Zhangjiagang) Co. Ltd.

to form a 50/50 joint venture

strategic alliance 8/06

PRODUCTS ON MARKET: HUMAN HEALTHCARE: Andriol®, Cerazette®, Desogen® (US), Esmeron®, Follistim® (US/Japan), Gracial®, Implanon®, Laurina®, Livial®, Marvelon®, Mercilon®, Norcuron®, NuvaRing®, OncoTice / Tice BCG, Orgalutran®, Ovestin®, Pregnyl®, Puregon®, Remeron SolTab®, Remeron®, Riselle®, TOF-watch, Zemuron® (US) Animal healthcare products Coatings products Chemicals products

Alberta Research Council Inc.

NuRx Services, 250 Karl Clark Road Edmonton T6N 1E4, Canada Phone: (780) 450-5111; Fax: (780) 450-5333 Web: www.arc.ab.ca/nurx E-mail: [email protected]

KEY PERSONNEL: Tom Facklam; VP, Life Sciences Donna M. Day; Manager, NuRx Services


HISTORY: Founded in 1921 Began biotech R&D in 1985 Member--Biotechnology Industry Organization Member--Society for Industrial Microbiology Established western Canada's first large-scale biologics manufacturing facility for development, scale-up and manufacturing

FACILITIES: 1,400 sq. m. pilot plant housing highly instrumented fermenters (oxygen enrichment and process monitoring) ranging in scale from 20 liters to 5,000 liters Biotechnology lab that includes a fermentation suite for small-scale research QC lab has Health Canada establishment license for CGMP analysis



STOCK-FINANCIAL HISTORY: Government agency

SUBSIDIARIES/DIVISIONS: NuRx Services

BUSINESS STRATEGY: Provide contract R&D, scale-up and manufacturing services for companies using bacterial, yeast (including pichia), algal, fungal, insect cell and rDNA fermentation processes

AGREEMENTS: Name Products Content of Agreement Date Biowest Inc. animal vaccine five-year


12/97

MicroBio RhizoGen Corp.

Rhizobium manufacturing agreement

1/95

Nuvotech Ventures International


12/93

Veterinary Infectious Diseases Organization

memorandum of understanding to develop animal vaccines

3/98

RESEARCH & DEVELOPMENT: Contract R&D using bacterial, yeast (including Pichia), algal, fungal and

rDNA processes Carbohydrate chemistry, process engineering, fermentation optimization and scale-up manufacturing, including biopharmaceuticals, and enzymes

Alderon Biosciences Inc.

2810 Meridian Parkway, Suite 152 Durham NC 27713, US Phone: (919) 544-8220; Fax: (919) 544-9808 Web: www.alderonbiosciences.com E-mail: [email protected]

KEY PERSONNEL: Robert Henkens, Ph.D.; President and CEO John O'Daly; VP and COO Marek Wojciechowski; Director, R&D


HISTORY: Founded in August 2001, building on technology of AndCare (now a division

of Alderon Biosciences) STOCK-FINANCIAL HISTORY: Privately held

SUBSIDIARIES/DIVISIONS: Beaufort, N.C. location: Alderon Biosciences Inc. 120 Turner Street Beaufort, NC 28516 Phone: (252) 728-2964 Fax: (252) 728-2109

BUSINESS STRATEGY: Provide alternative, low-cost, simple to use diagnostic systems for medical, environmental, and laboratory research and testing needs

RESEARCH & DEVELOPMENT: Technologies include unique electrode surfaces modified with colloidal gold

or biomaterials (such as gene probes, enzymes, antibodies, other proteins, etc.) and proprietary electroanalytical techniques

PRODUCTS ON MARKET: Portable electrochemical instruments Disposable electrochemical sensors Test kits Assay reagents and accessories Instrument accessories



Alltech Inc.

3031 Catnip Hill Pike Nicholasville KY 40356-9769, US Phone: (859) 885-9613; Fax: (859) 885-6736 Web: www.alltech.com E-mail: [email protected]

KEY PERSONNEL: Dr. T. P. Lyons; President W. J. Cheek; VP, Marketing N. Hohman; VP, Finance K. A. Jacques, Ph.D.; Director, Nutrition Dr. Karl Dawson; Director, Worldwide Research Dr. Ronan Power; Director, Research


HISTORY: Founded in 1980 as a private company Conducts research and product development at 25 universities Sells products to more than 85 different countries Holds annual symposium on biotechnology in feed industry

FACILITIES: 100,000 sq. ft. biotechnology center; 140 acres of property (over $20M invested in property) 56,000 sq. ft. corporate headquarters (opened in 2004) Research farm Opened fermentation block with $2M capital investment (3/88), since increased capital North American Bioscience Center in Nicholasville, KY--50 employees European Bioscience Center in Dublin, Ireland--40 employees Chinese Bioscience Center Beijing--25 employees 14 production facilities around the world


SUBSIDIARIES/DIVISIONS: Subsidiaries in 35 countries Animal Nutrition Division, Human Nutrition Division, Agronomic Division, Alltech Aquaculture

BUSINESS STRATEGY: Improve animal health and performance by adding nutritional value to animal feed, enhancing the performance of the animal and increasing animal production

RESEARCH & DEVELOPMENT: Yeast-derived products to maximize animal health through nutrition

PRODUCTS ON MARKET: TOP BRANDS: ANIMAL NUTRITION: Bio-Mos®, Bioplex® Mineral Range, MTB-100®, Mycosorb®, Sel-Plex®, Sil-All®, Yea-Sacc®1026 HUMAN NUTRITION: ExlPrime™, Preventox™, All-BGY™, Bio-Mos FG™ AGRONOMIC: Crop-Set™, Turf-Set™, Stubble-Aid™, Grain- Set™, Agro-Mos™, Compost-Aid™ AQUA: Bio-Mos™ Aqua Grade, Aqua-Mos™, NuPro®, De-Odorase™, Bioplex®, Sel-Plex®, Mycosorb®, Shrimp-Pak 604™, Allzyme® SSF

PRODUCTS IN DEVELOPMENT: Name Status Lactoferrin in development Antisalmonella program in development New bioherbicide in development New phytase enzyme in development Range of immune modulators in development



Altair Nanotechnologies Inc.

204 Edison Way Reno NV 89502, US Phone: (775) 856-2500; Fax: (775) 856-1619 Web: www.altairnano.com

KEY PERSONNEL: Jon Bengston; Chairman Alan J. Gotcher, Ph.D.; CEO and President Edward H. Dickinson; CFO Douglas K. Ellsworth; Sr. VP, Performance Materials Roy Graham; Sr. VP, Commercial Development Ken Lyon; VP, Business Development Bruce Sabacky, Ph.D.; CTO Dennis Nagle; VP, Manufacturing


HISTORY: Changed name from Altair International (8/01)

STOCK-FINANCIAL HISTORY: NASDAQ--ALTI (Capital Market) Revenue $2.807M (YE 05) compared to $1.152M (YE 04) Net loss <$9.937M> (YE 05) compared to <$7.002M> (YE 04) Loss per share <$0.17/share> (YE 05) compared to <$0.14/share> (YE 04) Average shares outstanding 57.767M (YE 05) compared to 48.677M (YE 04) Total assets $33.464M (YE 05) compared to $15.547M (YE 04)

SUBSIDIARIES/DIVISIONS: Life Sciences division Performance Materials division

INVESTMENTS: Altairnano Bateman Titania, Inc.--joint venture with Bateman Engineering

BV

AGREEMENTS: Name Products Content of Agreement Date Elanco Animal Health Division (Eli Lilly and Co.)

development of animal health products using Altairnano's nanotechnology-based products

research, licensing and commercialization agreement

5/06

Spectrum Pharmaceuticals Inc.

human therapeutic and diagnostic applications to develop, market and sell RenaZorb™ product line

exclusive worldwide licensing agreement

1/05

PRODUCTS ON MARKET: RenaZorb™ products for phosphate control in patients with Chronic Kidney Disease and hyperphosphatemia associated with End Stage Renal Disease Renalan products for phosphate control in companion animals suffering from Chronic Renal Failure Altium TiNano 40 Series nano-sized TiO2 products NanoCheck™ for phosphate control in water treatment TiNano Spheres for drug and chemical delivery Titanium dioxide and Zirconia based thermal spray grade powders



Altus Pharmaceuticals Inc.

125 Sidney Street Cambridge MA 02139-4807, US Phone: (617) 299-2900; Fax: (617) 299-2999 Toll-free phone: (888) ALT-CLEC Web: www.altus.com; E-mail: [email protected]

KEY PERSONNEL: John Richard; Chairman Sheldon Berkle; President and CEO Jonathan Lieber; VP, CFO and Treasurer Alexey L. Margolin, Ph.D.; Sr. VP, Research and Preclinical Development and CSO Burkhard Blank, M.D.; Sr. VP, Medicine, Regulatory Affairs and Project Management Renato Fuchs; Sr. VP, Manufacturing and Technical Operations Don G. Burstyn, Ph.D.; VP, Regulatory Affairs and Quality Assurance Alan Kimura, M.D., Ph.D.; VP, Clinical Development and Medical Affairs Robert Gallotto; VP, Commercial Development and Alliance Management Lauren Sabella; VP, Commercial Development John M. Sorvillo, Ph.D.; VP, Business Development


HISTORY: Founded in December 1992

FACILITIES: 3,000 sq. ft. fully equipped facility

STOCK-FINANCIAL HISTORY: NASDAQ--ALTU IPO--7M shares at $15/share, $105M (1/06) Revenue $8.288M (YE 05) compared to $4.230M (YE 04) Net loss <$27.124M> (YE 05) compared to <$20.957M> (YE 04) Loss per share <$22.13/share> (YE 05) compared to <$17.33/share> (YE 04) Average shares outstanding 1.719M (YE 05) compared to 1.704M (YE 04) Total assets $40.584M (YE 05) compared to $62.824M (YE 04)

PRIVATE PLACEMENTS: Raised $35M in private financing (10/01) Raised $15M in second closing of Series B financing (12/01) Raised $51M in Series C financing (5/04)

SUBSIDIARY OF: Vertex Pharmaceuticals Inc. (see separate entry)

PRINCIPAL INVESTORS: BankInvest China Development Industrial Bank (CDIB) Clariden Bank CMEA Ventures Hotung International Co. Ltd. Nomura International Palladin Group U.S. Venture Partners Vertex Pharmaceuticals Warburg Pincus

FINANCIAL INFORMATION: Awarded $500K grant to develop catalysts to neutralize nerve agents using Cross-Linked Enzyme Crystal technology (1/97) Received $51M in Series C financing led by Warburg Pincus and including U.S. Venture Partners, Nomura Phase4 Ventures, BankInvest, CMEA Ventures and Clariden Bank (5/04)

BUSINESS STRATEGY: Develop a series of products jointly with potential users while retaining broad rights to distribute to entire market


Dr. Falk Pharma GmbH

TheraCLEC development and commercialization agreement

2/03



GlaxoSmithKline plc

biocatalysts development agreement

7/93

Nagase & Co. biocatalysts joint development agreement

11/93

Novartis AG cross-linked enzyme crystal brand forms of subtilisin for use in detergents

two-year R&D collaboration

5/96

U.S. Department of Defense

CLEC technology for high performance catalysts to detoxify nerve agents

$100K research grant

1/96

RESEARCH & DEVELOPMENT: Develop highly stable forms of enzymes used in chemical synthesis

PRODUCTS ON MARKET: ChiroCLEC™-BL for performing chiral resolutions and regioselective

reactions in aqueous and organic media ChiroCLEC™-CR for performing resolutions of chiral chemicals primarily esters, alcohols, and acids ChiroCLEC™-EC for resolving alcohols, amines, and acids ChiroCLEC™-PC for resolving alcohols, acids, and esters under a variety of reaction conditions ChiroKit™-EH for performing resolutions of alcohols, acids, and esters by ester hydrolysis ChiroKit™-TE for performing resolutions of alcohols and amines by acylation reactions PeptiCLEC™-BL for synthesizing peptides and peptidomimetics PeptiCLEC™-TR for performing peptide coupling of both protected and unprotected peptides PeptiKit™ for performing quick identification of best catalyst for peptide coupling chemistry SynthaCLEC-PA catalyst for bulk manufacture of semi-synthetic penicillin antibiotics

PRODUCTS IN DEVELOPMENT: Name Status TheraCLEC (ALTU-135) in Phase II clinicals, orphan

drug status ALTU-238 for growth deficiency in Phase II clinicals ALTU-237 for kidney stones/primary hyperoxaluria (oral)

in preclinicals

ALTU-236 for phenylketonuria (oral) in preclinicals

Aluline Ltd.

Harbour House, 1 Aldborough Street Blyth NE24 2EU, UK Phone: +44 (0) 1670 544 322; Fax: +44 (0) 1670 544 340 Web: www.aluline.co.uk E-mail: [email protected]

KEY PERSONNEL: William G. Clark; President Caroline Clark; Exec. VP P. Abdo; Purchasing Manager Ian Richardson; Scientist



FACILITIES: 1,200 sq. ft. headquarters 6,000 sq. ft. manufacturing facility




SUBSIDIARIES/DIVISIONS: Aluline LDA--Portugal Aluline LLC--Dubai

BUSINESS STRATEGY: Supply and manufacture products that do not harm microorganisms in drainage

RESEARCH & DEVELOPMENT: Chemicals for industrial use

PRODUCTS ON MARKET: Alucleanse stain and odor remover Aluclean multipurpose detergent Aluzyme grease trap and drain treatment Aluclear dish cleaner Alurinse rinse aid Alucare cleaner Aluscale scale build-up remover Alusoil crystal granules Alupro biological urinal tablets Freshloo toilet cleaner Aquaflush cleaner Aluclean degreaser Aluwash Alubac Aluline spray polish Aluclean drain cleaner Aluglaze Aluline beerline cleaner Aluextract

AMDL Inc.

2492 Walnut Avenue, Suite 100 Tustin CA 92780-6953, US Phone: (714) 505-4460; Fax: (714) 505-4464 Web: www.amdl.com E-mail: [email protected]

KEY PERSONNEL: William M. Thompson III, J.D., M.D.; Chairman Gary L. Dreher; President and CEO Akio Ariura; CFO


HISTORY: Founded in June 1987 Began biotech R&D in 1988 To acquire Jiangxi Jade Biochemistry Pharmacy Co. Ltd. and Yangbian Yiqiao Biochemistry Pharmacy Co. Ltd. (as of 5/06)

FACILITIES: 2,000 sq. ft. headquarters 4,000 sq. ft. R&D and manufacturing facilities

STOCK-FINANCIAL HISTORY: AMEX--ADL Revenue $67.565K (YE 05) compared to $186.182K (YE 04) Net loss <$2.5M> (YE 05) compared to <$2.6M> (YE 04) Loss per share <$0.10/share> (YE 05) compared to <$0.12/share> (YE 04)

PRIVATE PLACEMENTS: Raised $1.2M from combined Regulation D/Regulation S private offering of shares and warrants (12/04) Raised $1.07M from combined Regulation D/Regulation S private offering of shares and warrants (8/05) Raised $1.812M from combined Regulation D/Regulation S private offering of shares and warrants (4/06)

BUSINESS STRATEGY: Supply countries with underserved medical markets with premier diagnostic products that are accurate, fast and easy to use



RESEARCH & DEVELOPMENT: Tumor-marker technology for cancer

PRODUCTS ON MARKET: DR-70 - tumor-marker detection test PyloriProbe - IVD test for antibodies to H. pylori More than 300 nonproprietary tests, including CEA for colon cancer, PSA for prostate cancer and AFP for liver cancer

PRODUCTS IN DEVELOPMENT: Name Status DR-70 tumor marker for lung cancer filed 510K application

American Radiolabeled Chemicals Inc.

101 ARC Dr. St. Louis MO 63146, US Phone: (314) 991-4545; Fax: (314) 991-4692 Toll-free phone: (800) 331-6661 Web: www.arc-inc.com; E-mail: [email protected]

KEY PERSONNEL: Surendra Gupta, Ph.D.; Chairman, President, CEO and Purchasing Manager Karen Gupta; Exec. VP Kamal Das, Ph.D.; Sr. Scientist Chan Vora, Ph.D.; Sr. Scientist Phil Korb; Scientist


HISTORY: Founded in September 1983 Acquired Radiochemicals Business from Tocris Bioscience (7/05)

FACILITIES: 2,000 sq. ft. headquarters 2,500 sq. ft. R&D facilities 4,000 sq. ft. manufacturing facilities 20,000 sq. ft. office warehouse building


BUSINESS STRATEGY: Provide high-quality radiolabeled products for biomedical research

RESEARCH & DEVELOPMENT: Radiolabeled drugs

PRODUCTS ON MARKET: Catalog of more than 2,500 different radiolabeled products

Analox Instruments Ltd.

8 Goldhawk Industrial Estate, Brackenbury Road London W6 0BA, UK Phone: +44 (0)20-8749-7635; Fax: +44 (0)20-8740-6608 Web: www.analox.com E-mail: [email protected]

KEY PERSONNEL: Dr. David Redstone; President Dr. Stuart Price; Director, R&D




SUBSIDIARIES/DIVISIONS: Analox Instruments U.S.A. (see separate entry) P.O. Box 208 Lunenburg, MA 01462-0208 Phone: (978) 582-9368; Fax: (978) 582-9588



BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science and industrial applications

RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques

PRODUCTS ON MARKET: Clinical analyzers: GM9 for the analysis of glucose LM5 for the analysis of lactate AM1 for the analysis of alcohol in blood GL5 for the analysis of glucose, lactate, cholesterol, uric acid and alcohol GM7 for the analysis of glucose, lactate, urea, uric acid, cholesterol, alcohol, acetoacetate, 3-hydroxybutyrate, creatinine, pyruvate, ammonia, glutamine, glycerol and triglycerides. Industrial/Biotech analyzers: AM2/AM3 for the analysis of ethanol AM5 for the analysis of methanol LM5 for the analysis of lactate GL6 for the analysis of glucose, lactate, methanol, glycerol and ethanol GM8 for the analysis of glucose, lactate, methanol, glycerol, urea, ethanol, sucrose, lactose, pyruvate, ammonia and glutamine

Analox Instruments U.S.A.

P.O. Box 208 Lunenburg MA 01462-0208, US Phone: (978) 582-9368; Fax: (978) 582-9588 Web: www.analox.com E-mail: [email protected]

KEY PERSONNEL: Dr. David Redstone; President Martin Widdowson; Exec. VP Dr. Stuart Price; Director, R&D




SUBSIDIARY OF: Analox Instruments Ltd. (see separate entry)

BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science and industry

RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques

PRODUCTS ON MARKET: Metabolite analyzers GM9-glucose LM5-lactate GM7 microstat (ammonia, ketones, glucose, lactate, cholesterol and alcohol) AM1-alcohol GL5 microstat (glucose, lactate, cholesterol, uric acid and alcohol)



Applera Corp.

P. O Box 5435, 301 Merrit 7 Norwalk CT 06856-5435, US Phone: (203) 840-2000; Fax: (203) 762-6000 Toll-free phone: (800) 761-5381 Web: www.applera.com

KEY PERSONNEL: Tony L. White; Chairman, President and CEO Dennis Winger; Sr. VP and CFO Kathy Ordonez; Sr. VP and President, Celera Genomics Group Catherine M. Burzik; Sr. VP and President, Applied Biosystems Group Barbara J. Kerr; VP, Human Resources William B. Sawch; Sr. VP and General Counsel Peter Dworkin, VP, Investor Relations and Corporate Communications

EMPLOYEES: 5.024 employees

HISTORY: Member--Biotechnology Industry Organization Member--Personalized Medicine Coalition Acquired Applied Biosystems Inc. (2/93) Acquired Tropix Acquired amplified fragment-length polymorphisms (AFLP) technology from Keygene NV in takeover of GenScope Inc. (2/97) Acquired PerSeptive Biosystems Inc. for $13/share in stock exchange worth $360M (1/98) Acquired Molecular Informatics Inc. (11/97) Formed genomics company with The Institute for Genomic Research (TIGR) (5/98) Changed name from PE Corp. to Applera Corp. (11/00)

STOCK-FINANCIAL HISTORY: Applera has two classes of stock: Applera-Applied Biosystems stock and Applera-Celera Genomics stock. Applera-Applied Biosystems stock is listed on the New York Stock Exchange under the ticker symbol 'ABI' and is intended to reflect the relative performance of the Applied Biosystems Group. Applera-Celera Genomics stock is listed on the New York Stock Exchange under the ticker symbol 'CRA' and is intended to reflect the relative performance of the Celera Genomics Group. There is no single security that represents the performance of Applera Corp. as a whole

SUBSIDIARIES/DIVISIONS: Celera Genomics (see separate entry) Applied Biosystems Inc. (see separate entry)

BUSINESS STRATEGY: Improve human health and society by understanding and applying the power of biology to develop breakthrough research technologies, diagnostic products and drugs

PRODUCTS ON MARKET: DNA and PCR-related systems

Applied Biosystems-MDS SCIEX LC/MS systems Protein analysis systems Custom oligosynthesis service Genetic analysis systems for forensic, animal and plant breeding Bioinformatics systems for genetic research and genomic drug discovery Forensics--human identification Functional genomics systems Certain infectious disease assays and genetic assays



Applied Biosystems Inc.

850 Lincoln Centre Drive Foster City CA 94404, US Phone: (650) 638-5800; Fax: (650) 638-5884 Toll-free phone: (800) 345-5224 Web: www.appliedbiosystems.com

KEY PERSONNEL: Tony L. White; Chairman, President and CEO, Applera Corp. Catherine M. Burzik; President Dennis A. Gilbert, Ph.D.; CSO Paul D. Grossman, Ph.D.; VP, Strategiic Planning and Business Development John Duddy; VP, Global Marketing Laura Lauman; Division President, Proteomics and Small Molecule Sandeep Nayyar; VP, Finance Michael G. Schneider; Division President, Service Mark P. Stevenson; Division President, Molecular and Cell Biology Leonard Klevan; Division President, Applied Markets


HISTORY: Founded in 1981 in Foster City, Calif. Sold interest in Celera Diagnostics joint venture to Celera Genomics (1/06) Acquired the research products division (now called Asuragen Inc.) of Ambion Inc. (3/06) Acquired Agencourt Personal Genomics Inc. (7/06) Member--Biotechnology Industry Organization

FACILITIES: US main facilities: -Foster City, Calif. (headquarters) -Pleasanton, Calif. -Bedford, Mass. -Framingham, Mass. -Austin, Texas

STOCK-FINANCIAL HISTORY: NYSE--ABI IPO--Raised $22M (1983) Revenue $1.8b (YE 05) compared to $1.7b (YE 04) Net income $236.9M (YE 05) compared to $182.9M (YE 04)

SUBSIDIARIES/DIVISIONS: Applied Biosystems Inc. is one of two businesses of Applera Corp.

SUBSIDIARY OF: Applera Corp. (see separate entry)

PRINCIPAL INVESTORS: Asset Management Co.

BUSINESS STRATEGY: The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as 'applied markets,' such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, Calif., and reported sales of nearly $1.8 billion during fiscal 2005.


Affymetrix Inc. manufacturing, sales and use of microarrays for gene expression analysis

nonexclusive, worldwide licensing agreement

12/05



Dionex Corp. (with MDS Sciex)

development of IC-MS/MS and LC/MS/MS solutions for emerging market opportunities

alliance 6/05

DuPont Qualicon development of next-generation DNA detection tests and systems for food testing, targeted food quality and safety assessment


Geospiza Inc. integration of genetic analysis products

platform collaboration agreement, expanded 8/06

2005

Hitachi High-Technologies Corp.

development and commercialization of capillary electrophoresis-based DNA analysis technologies

exclusive collaboration agreement

1/06

Invitrogen Corp. Deliver advanced proteomic solutions for biomarker discovery and validation


National Center for Toxicological Research of the FDA

investigation of toxicity of diabetes drugs

collaboration 3/05

National Institute of Genomic Medicine (Mexico)

pharmacogenomic therapeutics

R&D agreement 6/05

Qiagen NV PCR and PCR-related technologies

expanded licensing agreement

12/05

VisiGen Biotechnologies

sequencing technologies

equity investment 10/05

RESEARCH & DEVELOPMENT: Focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and standardized testing, including forensic human identification, paternity testing and food testing Development and marketing of instrument-based systems, consumables, software and services to the life science industry and research community

PRODUCTS ON MARKET: Products for: DNA Sequencing Gene Expression SNP Genotyping Gene Expression Array Biochromatography Cellular Detection Systems Human Identification/Forensics BioSecurity (infectious disease identification) Informatics Software Mass Spectrometry Molecular Diagnostics Molecular Microbiology Nucleic Acid Sample Preparation PCR Peptide Synthesis Protein Quantitation Protein Sequencing Real-Time PCR Surface Plasmon Resonance



Services include: Custom Services Support Plans Service Call Center Financing Solutions

Applikon Biotechnology Inc.

1180 Chess Drive Foster City CA 94404, US Phone: (650) 578-1396; Fax: (650) 578-8836 Web: www.applikon.com E-mail: [email protected]

KEY PERSONNEL: John Chory; President Vickie Sanchez; Purchasing Manager Arthur Oudshoorn; Director, Biotechnology Division Christine Corsette; Director, Product Development



FACILITIES: 10,000 sq. ft. facility


SUBSIDIARY OF: Applikon BV Netherlands

BUSINESS STRATEGY: Develop, manufacture and supply bioreactor systems for both research and production use. Focus on development of innovative technologies and products compliant with cGMP regulations

AGREEMENTS: Name Products Content of Agreement Date Finesse LLC TruBio O/S--Bioreactor

Control Operating System

licensing agreement 9/06

PRODUCTS ON MARKET: Fermentors, cell culture reactors, single use bioreactors, micro-bioreactors, controllers, PLC integration, fieldbus I/O, sensors, software, biomass monitor and cell separation

Arch Chemicals Inc.

501 Merritt 7 Norwalk CT 06856-5204, US Phone: (203) 229-2900; Fax: (203) 229-3652 Web: www.archchemicals.com

KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President Paul J. Craney; Exec. VP Louis S. Massimo; Exec. VP Hayes Anderson; VP, Human Resources Sarah A. O’Connor; VP, General Counsel and Secretary W. Paul Bush; VP and Treasurer Steven C. Giuliano; Controller


HISTORY: Founded in August 1998 as a wholly-owned subsidiary of Olin Corp. Became a separate, publicly-held company in February 1999 Acquired remaining 50 percent share of Nordesclor SA joint venture (12/05)



FACILITIES: Research sites in Cheshire, Conn.; New Castle, Dela.; South Plainfield, N.J.; Conley, Ga.; Blackley, U.K.; and Pianoro, Italy

STOCK-FINANCIAL HISTORY: NYSE--ARJ Sales $1.305b (YE 05) compared to $1.121b (YE 04) Net income $40.5M (YE 05) compared to $19.9M (YE 04) Earnings per share $1.70/share (YE 05) compared to $0.84/share (YE 04) Average shares outstanding 23.6M (YE 05) compared to 23.2M (YE 04) Total assets $1.062b (YE 05) compared to $1.100b (YE 04)

BUSINESS STRATEGY: Provide innovative, chemistry-based solutions to control the growth of

harmful microbes. Concentration is in water, hair and skin care products, pressure-treated wood, paints and building products, and health and hygiene applications.

PRODUCTS ON MARKET: Treatment products: HTH water products (HTH®, Poolife®, Baquacil® and

Baqua Spa®) Personal care and industrial biocides: Omadine®, Omacide®, Triadine®, Proxel®, Purista®, Vantocil®, Reputex®, Cosmocil® and Densil® biocides Wood protection and industrial coatings: Wolman®, Dricon®, Tanalith®, Vacsol® and Resistol® Performance products: Urethane intermediate products, hydrazine hydrates and derivatives

Arch Personal Care Products LP

70 Tyler Place South Plainfield NJ 07080, US Phone: (908) 561-5200; Fax: (908) 561-9174 Toll-free phone: (800) 561-5201 Web: www.archpersonalcare.com E-mail: [email protected]

KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President, Arch Chemicals Paul J. Craney; Exec. VP, Arch Chemicals Louis S. Massimo; Exec. VP, Arch Chemicals


HISTORY: Founded in 1984 Formerly Brooks Industries Inc. Acquired by Arch Chemicals Inc. (2000)


SUBSIDIARY OF: Arch Chemicals Inc. (see separate entry)


Ausimont SpA Fomblin sales agreement 1992 Knoll Microcheck protective enzyme

system sales agreement 1992

Polymedica Inc. Pu/Meth entrapment technology

joint venture 1991

Quest ceramides sales agreement 1997

PRODUCTS ON MARKET: Zinc Omadine® anti-dandruff actives Animal, marine, milk, plant and silk proteins



Biotechnological actives: Acqua-Biomin® Calcium Y3, Acqua-Biomin®, βetavera®, Biocell SOD, Biodynes®, Biomin® Acquacinque Liquid, Biomin® Marine, Bio-Oil® HBSL, Biophos 35, Bio-Plex NMF, Bio-Plex RNA, Bio-Pol®, Hydromide™ Blend, Kudzu Zymbiozome® Fermentum, Lotus Zymbiozome® Fermentum, Musol 20, Peptamide™ 6, Phytohyaluronate, Pseudocollagen, Pseudofilaggrin, Soy Zymbiozome® Fermentum, Vegepol, Vitazyme® Deliver systems: Brookosome® ACE, Brookosome® ACEBC, Brookosome® EPO, Brookosome® P, Brookosome® Retinol, Brookosome® SOD, Brookosome® TA, Brookosome® TRF®, Brookosome® V, Brookosome® Willowbark, Cationic SMEC, ChronoSphere® Bio-Pol® OE, ChronoSphere® Hyaluronic, ChronoSphere® Sal, Emollient SMEC, Liposome Cocoa Extract / Caffeine, SMEC Concentrate #1, SMEC DHA, SMEC Sun, Spiraplex® technology Functional ingredients: AquaPhos TD, Brookswax™ D, Brookswax™ P/P, CT-100, Gel Base, Gel Base 2, Gel Base BSM 5, Gel Base BSM PE, Gel Base BSM PT, Gel Base BSM VT, Gel Base Product Line, Gel Base SIL, KeraCoat, Liquiwax™, Liquipure™ EDG NF, Liquiwax™, Quamectant AM-50, Relaxer Concentrate Product Line, SilSlip™, ViscUp® 160 Rheology modifiers: β-Gel™, ViscUp® EZ Natural and Plant Actives: Genti-Fol® SA, Honeyquat 50, Marula Oil, Multifruit® BSC, NAB® Arnica Extract, NAB® Asafetida Extract, NAB® Clintonia Borealis Extract, NAB® Fennel Seed Extract, NAB® Grape Extract, NAB® GrassRoots Extract, NAB® Hawthorn Extract, NAB® Jewelweed Extract, NAB® Mushroom Extract, NAB® Pikea Robusta, NAB® Queen of the Prairie Extract, NAB® Red Clover Isoflavones, NAB® Rhodiola Extract, NAB® Siberian Ginseng Extract, NAB® Spotted Geranium Extract, NAB® Willowbark Extract, NAB® Yucca Glauca Extract, Oligoquat M, Planell® Oil, ProCircul8, Vital Hair & Scalp Complex Preservation systems: Biovert® Enzyme and Substrate, Cosmocil® CQ, Mikrokill™ COS, Mikrokill™ PCC

Archer Daniels Midland

4666 Faries Parkway Decatur IL 62526, US Phone: (217) 424-5200; Fax: (217) 424-4004 Toll-free phone: (800) 637-5843 Web: www.admworld.com; E-mail: [email protected]

KEY PERSONNEL: G. Allen Andreas; Chairman Patricia A. Woertz; CEO and President David J. Smith; Exec. VP, Secretary and General Counsel William H. Camp; Exec. VP, Global Processing John D. Rice; Exec. VP, Global Marketing and Risk Management Lewis W. Batchelder; Sr. VP, Agricultural Services Edward A. Harjehausen; Sr. VP, Food and Feed Ingredients Brian F. Peterson; Sr. VP, Corporate Affairs Douglas J. Schmalz; Sr. VP and CFO


HISTORY: Formed from the acquisition of Midland Linseed Products Company by Archer-Daniels Linseed Company (1923)



STOCK-FINANCIAL HISTORY: NYSE--ADM Net sales $35.944b (YE 05) compared to $36.151b (YE 04) Net earnings $1.044b (YE 05) compared to $494.710M (YE 04) Earnings per share $1.59/share (YE 05) compared to $0.76/share (YE 04) Average shares outstanding 656.123K (YE 05) compared to 649.810K (YE 04)

AGREEMENTS: Name Products Content of Agreement Date Metabolix Inc. eco-friendly, high-

performance natural plastics

commercialization agreement

11/04

RESEARCH & DEVELOPMENT: Fermentation for alcohol production, ethanol High-fructose corn syrup, enzymes, amino acids Protein research

PRODUCTS ON MARKET: Feed-grade amino acids, vitamins/colorants Lysine, threonine, astaxanthan Food additives: citric acid, lactic acid, xantham gum Distilled monoglycerides, sodium stearyl lactate, isoflavones

Argonne National Laboratory

9700 South Cass Avenue Argonne IL 60439, US Phone: (630) 252-2000; Fax: (630) 252-5230 Toll-free phone: (800) 627-2596 Web: www.anl.gov; E-mail: [email protected]

KEY PERSONNEL: Robert Rosner; Laboratory Director Donald Joyce; Deputy Laboratory Director Adam Cohen; COO Stuart A. Rice; Scientific Advisor to the Directorate Phillip Finck; Associate Laboratory Director, Applied Science and Technology J. Murray Gibson; Associate Laboratory Director, Scientific User Facilities Alfred P. Sattelberger; Associate Laboratory Director, Physical Sciences Rick Stevens; Associate Laboratory Director, Computing and Life Sciences


HISTORY: Founded in 1941 Member--Biotechnology Industry Organization

FACILITIES: 1,500-acre facilities site owned by DOE and operated by the University of Chicago

STOCK-FINANCIAL HISTORY: Government agency (U.S. Department of Energy)

SUBSIDIARIES/DIVISIONS: Argonne National Laboratory West (Idaho, U.S.)

BUSINESS STRATEGY: Engage in multi-disciplinary research that further increases understanding of the fundamental mechanisms of life and enables valuable advances in health protection, environmental restoration, energy production, industrial processing and other applications Conduct clinical studies in the areas of bioinformatics, genomics, protein engineering, biochips, proteomics, bio-based chemicals, structural biology, and environmental technologies, while maintaining a technology transfer program that is directed toward enhancing the Laboratory's research and development programs, meeting federal, national, and international research needs, and increasing the worldwide competitiveness of U.S. industry



AGREEMENTS: Name Products Content of Agreement Date Ongoing technology transfer collaborations for drug discovery, contract R&D, patent licensing, etc.

multi-disciplinary technology transfer agreements

RESEARCH & DEVELOPMENT: Bio-chemicals Nanobiotechnology Biomimetic membranes Structural biology Structural genomics RNAi technology Biodefense applications Environmental biotechnologies Biochip technology Batteries and fuel cells Materials Nuclear reactor testing

PRODUCTS ON MARKET: Marketable services include technology transfer comprised of:

Cost-shared research and development Reimbursable R&D (Work-for-Others) Licensing Technical assistance Personnel exchange

Arysta LifeScience Corp.

38/39th Floor, St. Luke's Tower, 8-1, Akashicho, Chuo-Ku Tokyo 104-6591, Japan Phone: +81 3-3547-4500; Fax: +81 3-3547-4699 Web: www.arystalifescience.com E-mail: [email protected]

KEY PERSONNEL: John Hagaman; Chairman Dr. Christopher Richards; President and CEO Rudorf Van Houten; CFO Dipak Amin; Global Head, Strategy Robert Lence; General Counsel Makoto Saji; Global Head, Corporate Affairs Tatsumi Ikeda; Global Head, Acquisitions and Licensing John Killmer; Global Head, Marketing and Supply Chain Itaru Hori; Head, Japan Nobumasa Ishiai; Global Head, Life Science William Lewis; Head, North America and Australasia Eric Barbedette; Head, Europe, Africa and Middle East Yukio Arai; Head, South America

EMPLOYEES: 2,300 employees (including affiliated companies)

HISTORY: Founded in 2000 through a consolidation of the Tomen and Nichimen Agro and LifeSciences businesses Acquired Azocyclotin from Bayer CropScience (10/05) Acquired Prothiofos from Bayer CropScience (11/05) Acquired Omethoate from Bayer CropScience (1/06) Acquired major sssets of Micro Flo Co. LLC from BASF Corp. (3/06)




SUBSIDIARIES/DIVISIONS: Arysta LifeScience North America (www.arystalifescience-na.com) Arysta LifeScience Europe, Africa and Middle East (www.arysta-eame.com) Arysta LifeScience South America (www.arystalifescience-sa.com)

PRINCIPAL INVESTORS: Olympus Capital

BUSINESS STRATEGY: Develop, market and distribute high quality crop protection and lifescience products to global markets

AGREEMENTS: Name Products Content of Agreement Date Bayer CropScience

amitraz, marketing of fluoxastrobin and co-marketing of deltamethrin

licensing agreements

4/05

PRODUCTS ON MARKET: Select® Captan Everest® Orthene® Elevate®

Asahi Kasei Corp.

1-2 Yurakucho 1-chome, Chiyoda-ku Tokyo , Japan Phone: +81 3-3507-2060; Fax: +81 3-3507-2495 Web: www.asahi-kasei.co.jp

KEY PERSONNEL: Nobuo Yamaguchi; Chairman Shiro Hiruta; President Masaki Sakamoto; President, Asahi Kasei Fibers Taketsugu Fujiwara; President, Asahi Kasei Chemicals Keiji Kamei; President, Asahi Kasei Life & Living Yoichi Saji; President, Asahi Kasei Construction Materials Shingo Hatano; President, Asahi Kasei Homes Makoto Konosu; President, Asahi Kasei EMD Kei Ohe; President, Asahi Kasei Pharma


HISTORY: Founded in May 1931

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka, Sapporo stock exchanges Net sales ¥1,499b (YE 06) compared to ¥1,378b (YE 05) Net <loss> income ¥59.67b (YE 06) comapred to ¥56.45b> (YE 05) Earnings <loss> per share ¥42.46/share (YE 06) compared to ¥40.16/share (YE 05) Total assets ¥1,376b (YE 06) compared to ¥1,270b (YE 05)

SUBSIDIARIES/DIVISIONS: Group companies: Asahi Kasei Fibers Asahi Kasei Chemicals Asahi Kasei Life & Living Asahi Kasei Construction Materials Asahi Kasei Homes Asahi Kasei EMD Asahi Kasei Pharma

AGREEMENTS: Name Products Content of Agreement Date BioStar Inc. POC infectious disease,

instrumented development agreement

8/97

City of Hope human gene deletion technology

funding basic research



Dainippon, Tokyo University

rabbit TNF joint development agreement

Diffchamb SA fish freshness test distribution agreement

3/90

G. D. Searle & Co. Angiotensin II antagonist

licensing agreement for Japan

1994

GenVec Inc. Asahi's gene therapy applications of tumor necrosis factor alpha gene

licensing agreement for the U.S.

4/98

Kowa Co. Ltd. tPA as an intravenous injection for thrombolysis

joint development agreement

1990

Kyowa Hakko Kogyo

tissue plasminogen activator (tPA)


1/86

Memorial Sloan-Kettering

TNF technology transfer agreement

Mie University thrombomodulin R&D agreement Molecumetics Ltd. oral factor VIIA

inhibitors research and licensing agreement

5/97

Purely Proteins Ltd.

methods for purifying proteins using Purely Proteins' ligand discovery systems

R&D agreement 12/04

Queens University (Canada)

atrial natriuretic polypeptide

patent licensing agreement

5/87

Samuel Lunenfel Research Foundation

cancer cell communication

two-year research agreement

3/96

RESEARCH & DEVELOPMENT: Directed toward the creation of customer value through high-performance products based in competitive chemical technology, with emphasis on the development of new businesses in the growing fields of electronics, medicine, and energy and ecology, for the future development and growth of the Asahi Kasei Group All R&D is guided by the principles of green and sustainable chemistry Main research fields are: material science and polymer science, microelectronics, electrochemistry, microbiology, µTAS (micro total analysis), medical care, biochemistry, residential materials, membrane science and technology, information technology, analysis and simulation

PRODUCTS ON MARKET: Asahi Kasei Pharma: Elcitonin™, Bredinin™, Flivas™, Toledomin™, Planova™ virus removal filters, artificial kidneys, Sepacell™, leukocyte reduction filters, blood and plasma filters, contact lenses Asahi Kasei Chemicals: Suntec™ polyethylene, Tenac™ polyacetal, Xyron™ modified polyphenylene ether (mPPE), Leona™ nylon 66, Duranate™, Ceolus™, APR™ photosensitive resins, AFP™ photosensitive plates, printing plate making systems, Microza™ ultrafiltration and microfiltration membranes and systems, Hipore™ fine porous membranes Asahi Kasei EMD: Sunfort™ photosensitive dry film resist (DFR), Pimel™ photosensitive polyimide, Fine pattern coils, Luminous™ plastic optical fiber



Associates of Cape Cod Inc.

Falmouth Technology Park, 124 Bernard E. Saint Jean Drive East Falmouth MA 02536-4445, US Phone: (508) 540-3444; Fax: (508) 540-8680 Toll-free phone: (888) 395-2221 Web: www.acciusa.com; E-mail: [email protected]

KEY PERSONNEL: A.J. Meuse, Ph.D.; President and CEO Michelle Knuth; Director, Finance Peter Langlais; VP, Business Development and Global Distribution Alison Skinner, Ph.D.; Exec. VP


HISTORY: Founded in 1974 While a senior scientist at Woods Hole Oceanographic Institute, Dr. Stanley Watson, the founder of ACC, developed LAL (limulus amebocyte lysate) for enumeration of gram-negative bacteria. Recognizing its use for monitoring lipopolysaccharides in pharmaceutical products, he formed his own company and was the first licensed by the FDA for sales of LAL



SUBSIDIARY OF: Seikagaku Corp.

BUSINESS STRATEGY: Develop innovative products from the marine environment for the health care industry

AGREEMENTS: Name Products Content of Agreement Date IBEX Technologies Inc.

IBEX's glycobiology enzymes

distribution agreement

9/05

RESEARCH & DEVELOPMENT: LAL methodology and test instrumentation LAL biochemistry New products from marine organisms Endotoxin detection

PRODUCTS ON MARKET: Pyrotell® LAL LAL-5000 automatic endotoxin detection system Pyrosol® LAL reconstitution buffer Endotoxin control standard LAL reagent water (LRW) Depyrogenated reaction tubes Pyroplates, pyroblocks Pyrochrome® chromogenic LAL test kits Pyrotell-T® turbidimetirc lysate Fungitell™

Astellas Pharma Inc.

3-11 Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411, Japan Phone: +81 3-3244-3000; Fax: +81 3-3244-3272 Web: www.astellas.com

KEY PERSONNEL: Hatsuo Aoki, Ph.D.; Chairman Toichi Takenaka, Ph.D.; President and CEO Makoto Nishimura, Ph.D.; Chairman and CEO, Astellas Pharma US, Inc. Toshinari Tamura, Ph. D.; Exec. VP Masafumi Nogimori; Exec. VP Sef Kurstjens, M.D., Ph.D.; Head, R&D, US




HISTORY: Created from the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. (4/05) To sell all rights to Aczone gel to QLT Inc. (as of 7/05) To sell Zepharma Inc. to Daiichi Sankyo Co. (as of 3/06) Acquired North Carolina-based research facility of Dynogen Pharmaceuticals Inc. (3/06) Astellas Pharma U.S. Inc. to acquire Amevive® (alefacept) from Biogen Idec Inc. (as of 4/06) Yamanouchi Pharmaceutical Co. Ltd.: Founded in 1923 Acquired Shaklee Japan K.K. (1989) Acquired Shaklee Corp. (USA) (1989) Fujisawa Pharmaceutical Co. Ltd.: Founded in 1894

SUBSIDIARIES/DIVISIONS: Astellas US LLC--Ill., U.S. Astellas Pharma US Inc.--Ill., U.S. Astellas Pharma Manufacturing Inc.--N.Y., U.S. Astellas Pharma Technologies Inc.--Okla., U.S. Astellas Research Institute of America LLC--Ill., U.S. Astellas Pharma Canada Inc.--Ontario, Canada Astellas Pharma Europe Ltd.--London, U.K. Astellas BV--The Netherlands Astellas Pharma Europe BV--The Netherlands Astellas Pharma GmbH--Germany Astellas Ireland Ltd.--Ireland Astellas Pharma SpA--Italy Astellas Pharma Korea Inc. Astellas Pharma Taiwan Inc. Astellas Pharma China Inc. Astellas Pharma Hong Kong Ltd. Astellas Pharma Philippines Inc. Astellas Pharma (Thailand) Co. Ltd. P.T. Astellas Pharma Indonesia Astellas Pharma Chemicals Co. Ltd.

BUSINESS STRATEGY: Develop breakthrough products in the areas of immunology, infectious disease, dermatology, urology and cardiovascular disease while continuing to explore unmet needs in other areas

AGREEMENTS: Name Products Content of Agreement Date Apoxis SA development and

marketing of FIK866 licensing agreement

12/05

AtheroGenics Inc. AGI-1096 as an oral treatment for the prevention of organ transplant rejection

R&D agreement, extended 2/06

1/04

Ferring Pharmaceuticals

developing and marketing of degarelix in Japan

licensing agreement

1/06

FibroGen Inc. FG-2216 in Japan licensing agreement

9/04

FibroGen Inc. rights to certain hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of anemia, including FG-2216 and FG-4592, in Europe, CIS, Middle East and South Africa

licensing agreement

4/06

Ilypsa Inc. ILY101 in Japan licensing agreement

4/06



MerLion Pharmaceuticals Pte. Ltd.

new drug candidates derived from natural products chemistry

discovery and development agreement

10/05

Metabolex Inc. validation of novel drug targets identified through Metabolex's discovery program, for diabetes and obesity

multi-year research collaboration, expanded 5/05

3/02

Nippon Kayaku Gelpart exclusive licensing agreement

2/05

Portola Pharmaceuticals Inc.

development of a series of Astelas preclinical compounds

licensing agreement

6/05

Suntory Ltd. Farom (antibiotic) marketing agreement

6/97

Theravance Inc. Theravance's telavancin development and commercialization agreement, expanded 7/06

11/05

Toyama Chemical Co. Ltd.

marketing. development of oral formulations of T-3811 in Japan

licensing agreement

3/06

XenoPort Inc. development and commercialization of XP13512 in Japan and other Asian countries

licensing agreement

12/05

RESEARCH & DEVELOPMENT: Diabetes, infectious diseases, gastrointestinal disorders, disorders of the

central nervous system, urology, inflammatory disorders and immunology (transplants)

PRODUCTS ON MARKET: Adenoscan® AmBisome® Flomax® Prograf® Protopic® VESIcare®

astre Corp.

3801 Mount Vernon Avenue, P.O. Box 25766 Alexandria VA 22313-5766, US Phone: (703) 548-1343; Fax: (703) 783-1340 Web: www.astrecg.com E-mail: [email protected]

KEY PERSONNEL: R. A. Ackerman; Chairman and Director, R&D K. Smith; CEO




BUSINESS STRATEGY: Provide research, development, consulting and production of biotechnology products/process in environmental and medical domains

PRODUCTS ON MARKET: Process and product design services



Athenix Corp.

2202 Ellis Road, Suite B Durham NC 27703, US Phone: (919) 281-0900; Fax: (919) 281-0901 Web: www.athenixcorp.com E-mail: [email protected]

KEY PERSONNEL: Jerry Caulder; Chairman Mike Koziel; President and CEO Markus Andres; COO Nadine Carozzi; VP, Product Development Nicholas Duck; VP, Research and Business Development Mike Schierbeek; CFO



FACILITIES: 11,000 sq. ft. of laboratory and office space


PRIVATE PLACEMENTS: Raised $8M in financing (9/01) Raised $12.5M in Series B financing (1/04) Raised $13M in Series C financing (1/06)

SUBSIDIARIES/DIVISIONS: Agriculture Industrial

PRINCIPAL INVESTORS: Boston Millennia Partners Eastman Ventures Finistere Partners Hunt Ventures Intersouth Partners Polaris Venture Partners

BUSINESS STRATEGY: Develop novel products, technologies and processes for agricultural and chemical applications

AGREEMENTS: Name Products Content of Agreement Date Iowa Corn Promotion Board

applying innovative technologies to corn

research cooperation

2/05

RESEARCH & DEVELOPMENT: Athenix is a leading biotechnology company that discovers and develops novel products, technologies and processes for the agricultural and chemical businesses. Athenix is focused on enhanced plants, microbes, enzymes and processes for a variety of industry sectors with emphasis on two major market opportunities: 1) the discovery of genes and proteins for novel input traits such as insect resistance, nematode resistance and herbicide tolerance, and their use to develop transgenic plants for the agricultural chemical and seed industries, and 2) the discovery of genes and proteins for use in the chemical and animal feed industries.


Herbicide resistant crops (corn, soybean and cotton)

in greenhouse testing, field testing

Insect resistant crops (corn, soybean, cotton and rice)

in greenhouse testing

Nematode resistant crops (soybean) in laboratory testing, plant testing



Atrium Biotechnologies Inc.

1405 boul. du Parc-Technologique Quebec G1P 4P5, Canada Phone: (418) 652-1116; Fax: (418) 652-0151 Web: www.atrium-bio.com E-mail: [email protected]

KEY PERSONNEL: Pierre Laurin, Ph.D.; Chairman Luc Dupont; President and CEO Richard Bordeleau; President, Health and Nutrition Charles Boulanger; President, Active Ingredients and Specialty Chemicals John Dempsey; VP, Finance and CFO


HISTORY: Founded in January 2000 Member--Biotechnology Industry Organization Acquired ADF Chimie S/A (5/02) Acquired Siricie SA (11/03) Acquired Pure Encapsulations Inc. (3/04) Acquired Multichem (1/05) Acquired HVL Inc. and Douglas Laboratories (12/05) MultiChem subsidiary acquired Amisol Co. Ltd. (5/06) Acquired assets of Douglas Laboratories Canada (9/06)

STOCK-FINANCIAL HISTORY: TSX--ATB IPO--6.250M shares at $12/share, $75M (3/05) Revenue $200.9M (YE 05) compared to $136.2M (YE 04) Net income $14.3M (YE 05) compared to $10.1M (YE 04) Earnings per share $0.51/share (YE 05) compared to $0.44/share (YE 04) Total assets $298.2M (YE 05) compared to $138.9M (YE 04)

SUBSIDIARIES/DIVISIONS: Atrium Biotech USA--Fairfield, N.J. Unipex SA--Ruiel-Malmaison, France Pure Encapsulations Inc.--Sudbury, Mass. Chimiray--Ruiel-Malmaison, France Atrium Biotech Europe--Marly le Roi, France Multichem - Quebec--Boucherville, Canada

SUBSIDIARY OF: Aeterna Zentaris Inc. (see separate entry)

BUSINESS STRATEGY: Acquisition program: -Acquisition of nutritional supplement products or companies -Acquisition of companies specializing in the manufacturing of active ingredients and specialty products -Acquisition of cosmetic active ingredient lines or companies Inlicensing program: -Prospect for new products and new technologies among established or emerging biotech companies and specialized research centres. Atrium Biotechnologies can offer its strategic partners rapid access to a network of leading customers

RESEARCH & DEVELOPMENT: New products and new versions of existing products in response to client

requests Atrium has a patented molecular separation technology platform

PRODUCTS ON MARKET: More than 1,500 active ingredients and specialty chemicals and 400 health and nutrition finished products



Axxora Life Science Inc.

6181 Cornerstone Court East, Suite 103 San Diego CA 92121, US Phone: (858) 550-8830; Fax: (858) 550-8825 Toll-free phone: (800) 550-3033 Web: www.axxora.com E-mail: [email protected]

KEY PERSONNEL: Georges Chappuis, Ph.D.; CEO and President Tamara Sales; CFO Brian Conkle; President, Axxora LLC Wilfried Boecher; Managing Director, Axxora Deutschland GmbH and Axxora Ltd. Silvia Dettwiler; President, Alexis Corp. Ravi Kalahasthi; Managing Director, Alexis Laboratories




SUBSIDIARIES/DIVISIONS: Axxora LLC--U.S. Alexis Corp.--Switzerland Apotech Corp--Switzerland Axxora Deutschland GmbH--Germany Axxora Ltd.--U.K. Alexis Laboratories--U.S. Apotech Laboratories--Switzerland

PRINCIPAL INVESTORS: Ampersand Ventures Ventana Growth Fund

BUSINESS STRATEGY: Develop, produce, market and sell life science research reagents worldwide

RESEARCH & DEVELOPMENT: Life science reagents and fine chemical raw materials

PRODUCTS ON MARKET: Nitric oxide pathway reagents Neurochemicals Apoptosis Signal transduction reagents Endothelins Human plasma protein and enzymes Lipids Phospholipids Glycolipids

BAC BV (Biotechnology Application Centre)

Huizerstraatweg 28 Naarden 1411 GP, Netherlands Phone: +31 35-69-92595; Fax: +31 35-69-49576 Web: www.bac.nl, www.captureselect.com E-mail: [email protected]

KEY PERSONNEL: Dr. Laurens Sierkstra; CEO Dr. Ingeborg van Gemeren; VP, Business Development


HISTORY: Founded in 1995 as a subsidiary of Unilever Spun off from Unilever



FACILITIES: Production facility comprises a fermentation development laboratory (10L fermenters), a dedicated quality control laboratory, and a fully contained processing plant (with medium preparation and continuous sterilization, fermentation and downstream processing and aseptic packaging)


PRIVATE PLACEMENTS: Raised EUR3.5M in private financing (2/05)

SUBSIDIARY OF: Unilever

BUSINESS STRATEGY: Development and manufacture of ligands for Affinity Separation applications

RESEARCH & DEVELOPMENT: CaptureSelect® products are based on the company's proprietary single

domain antibody fragments and efficiently produced in-house using Saccharomyces cerevisiae Expression systems and fermentation production systems Industrial scale 15,000l for production of novel single-chain Llama antibody fragments, peptides, fusion proteins

PRODUCTS ON MARKET: Products: CaptureSelect® products possess a combination of unique properties such as stability, affinity, and selectivity that provides competitive benefits in terms of reduced cost of purification, higher quality product, and increased flexibility in the purification process. BAC offers a wide range of CaptureSelect® products for different applications: -Life science research such as sample preparation and small scale purification -Biopharma manufacturing including monoclonal antibodies and viruses -Healthcare applications such as therapeutic apheresis -Custom tailored purification solutions Services: Custom manufacturing and upscaling of production of biotechnological molecules through microbial fermentations Plug-in of genes into yeasts, followed by process development and scale up

BACHEM AG

Hauptstrasse 144 Bubendorf CH-4416, Switzerland Phone: +41 61 935 2323; Fax: +41 61 935 2325 Web: www.bachem.com E-mail: [email protected]

KEY PERSONNEL: Dr. Peter Grogg; Chairman Rolf Nyfeler, Ph.D.;CEO Michael Husler; CFO Dr. Daniel Erne; CTO Thomas Fruh, Ph.D; Exec. VP and COO, BACHEM AG Jose de Chastonay, Ph.D.; President, BACHEM Americas Philip Ottiger; President and COO, Bachem California Inc. Dr. Mike Pennington; President and COO, Bachem Bioscience Inc. Dr. Damir Vidovic; President and COO, Peninsula Laboratories Inc. Dr. Stanley Moore; COO, Bachem (UK) Ltd. Dr. Jacques-Alain Cotting; COO, Sochinaz SA


HISTORY: Founded in 1971 Founded BACHEM Bioscience in Philadelphia, Pa. (1987) Founded BACHEM Biochemica in Heidelberg, Germany (1988) Founded BACHEM Biochimie in Voisins-le-Bretonneux, France (1993) Acquired BACHEM California Inc in Torrance, Calif., and its U.K. subsidiary in Saffron Walden (1996)



Changed name from BACHEM Feinchemikalien AG to BACHEM AG Acquired Peninsula Laboratories Inc. and Peninsula Laboratories Ltd. (12/99) Merger of Peninsula Laboratories Europe Ltd. and Bachem (UK) Ltd. (8/00) Acquired Sochinaz SA (2001)

FACILITIES: 218,000 sq. ft. facility including GMP production facilities in Bubendorf, Switzerland, and Torrance, Calif., for large-scale solid phase and solution phase peptide synthesis

STOCK-FINANCIAL HISTORY: SWX--BANB Sales CHF153.7M (YE 05) compared to CHF147.8M (YE 04) Net income CHF39.2M (YE 05) compared to CHF30.7M (YE 04) Earnings per share CHF2.98/share (YE 05) compared to CHF2.33/share (YE 04)

SUBSIDIARIES/DIVISIONS: BACHEM California Inc. (see separate entry) 3132 Kashiwa Street Torrance, CA 90505 Phone: (310) 539-4171; Toll-free phone: (888) 422-2436 Fax: (310) 530-1571; E-mail: [email protected] BACHEM Bioscience Inc. 3700 Horizon Drive King of Prussia, PA 19406 USA Phone: (610) 239-0300; Toll-free phone: (800) 634-3183 Fax: (610) 239-0800; E-mail: [email protected] BACHEM Biochemica GmbH Haberstrasse 6 Heidelberg D-69126 Germany Phone: +49 06221 33 05 0; Fax: +49 06221/33 05 99 E-mail: [email protected] BACHEM Biochimie SARL 136, ave. Joseph Kessel Voisins-le-Bretonneux F-78960 France Phone: +33 (0)1 30 12 15 95; Fax: +33 (0)1 30 57 38 82 E-mail: [email protected] BACHEM (U.K.) Ltd. 69 High Street Saffron Walden, Essex CB10 1AA UK Phone: +44 (0)1 799 52 64 65; Fax: +44 (0)1 799 52 63 51 E-mail: [email protected]

BUSINESS STRATEGY: Supply peptides, peptidomimetics, proteins, amino acid derivatives and related biologicals to the research market

AGREEMENTS: Name Products Content of Agreement Date AstraZeneca plc Goserelin extended supply

agreement 1/03

Jerini AG Jerini's Icatibant production and supply agreement

3/04

mondoBiotech Holding SA

Thymopentin production and supply agreement

4/05


mondoBiotech's Aviptadil

production and supply agreement

7/04


mondoBiotech's Thymopentin (TP-5)

production and supply agreement

4/05


new peptide projects for potential therapeutic use

development agreement

3/06



RESEARCH & DEVELOPMENT: Growth factors, lymphokines Bioactive peptides, enzyme substrates and inhibitors, cytokines, related biologicals GMP production of peptides and related compounds GMP Contract manufacturing Peptides and proteins for diagnostics

PRODUCTS ON MARKET: More than 7,000 products including biologically active peptides, proteins, amino acid derivatives, enzyme substrates and inhibitors, neuropeptides, cytokines, lymphokines, growth factors, HIV proteins, monoclonal and polyclonal antibodies

Bachem California Inc.

3132 Kashiwa Street Torrance CA 90505, US Phone: (310) 539-4171; Fax: (310) 530-1571 Toll-free phone: (888) 422-2436 Web: www.bachem.com E-mail: [email protected]

KEY PERSONNEL: Philip Ottiger; President and COO


HISTORY: Founded in 1971 Acquired by Bachem in 1996


RESEARCH & DEVELOPMENT: Synthetic peptides, reagents, bulk pharmaceuticals, synthetic intermediates

and recombinant growth factors and cytokines

PRODUCTS ON MARKET: Clinical grade peptides (CRF, GRF, somatostatin, LHRH, ANF, calcitonin, parathyroid hormone, peptide T) Bioactive peptides Synthetic intermediates Recombinant growth factors and cytokines Large-scale custom synthesis service

Bangs Laboratories Inc.

9025 Technology Drive Fisher IN 46038-2886, US Phone: (317) 570-7020; Fax: (317) 570-7034 Toll-free phone: (800) 387-0672 Web: www.bangslabs.com E-mail: [email protected]

KEY PERSONNEL: Michael H. Ott; Chairman and CEO Chad Owen; President Kate Edwards; Product Manager Sharmi Isaiah; Scientist and Lab Coordinator Mary Meza; Technology Manager Yun Qiu; Scientist Kathy Turner; Technical Service Manager


HISTORY: Founded in April 1988 Acquired by Polysciences Inc. (7/03)




SUBSIDIARY OF: Polysciences Inc.

PRODUCTS ON MARKET: More than 2,000 varieties of microspheres

BASF AG

Carl Bosch Strasse 38 Ludwigshafen D-67056, Germany Phone: +49 (0)621 60-0 Fax: +49 (0)621 60-42525 Web: www.basf.de E-mail: [email protected]

KEY PERSONNEL: Dr. Jurgen Hambrecht; Chairman Dr. Thorlef Spickschen; Managing Director, Pharmaceuticals Dr. Friedrich Vogel; Managing Director, Crop Protection Peter Oakley; Chairman, President and CEO, BASF Corp. Dr. Stefan Marcinowski; Head, Research Prof. Dr. Werner Kusters; Head, Main Laboratory Dr. Robert Kamen; President, BASF Bioresearch Corp.

EMPLOYEES: 94,000 employees worldwide

HISTORY: Founded in January 1952 Member--Biotechnology Industry Organization Acquired Knoll AG (1982) Acquired Blazer® herbicide business from Rohm and Haas (12/87) Genzyme Corp. reacquired rights to Protein C (8/88) Acquired majority interest in BioResearch, an Italian pharmaceutical group (spring 1990) International pharmaceutical business combined under BASF Pharma (1993) Acquired Boots Pharmaceuticals (3/95) Acquired Hokuriku Seiyaku (4/96) Acquired global electronic chemicals business of Merck KGaA (1/05) To acquire Johnson Polymer from JohnsonDiversey Inc. (as of 5/06) Acquired Engelhard Corp. (6/06)

FACILITIES: Commercial-scale biotechnology fermentation facility in Ludwigshafen, Germany, and Worcester, Mass. Agricultural Research Center in Research Triangle Park, N.C. Latin American headquarters located in Mexico, and Asian/Australian regional division headquarters located in Singapore Nanotechnology research center in Singapore

STOCK-FINANCIAL HISTORY: NYSE and Frankfurt Stock Exchange--BASF Sales EUR42.745b (YE 05) compared to EUR37.537b (YE 04) Net income EUR3,007b (YE 05) compared to EUR2.004b (YE 04) Earnings per share EUR5.73/share (YE 05) compared to EUR3.65/share (YE 04)

SUBSIDIARIES/DIVISIONS: Five business segments: Chemicals, Plastics, Performance Products, Agricultural Products and Nutrition, and Oil and Gas KNOLL Belgium Avenue Hamoir 14 B-1180 Bruxelles, Belgium Phone: +32 2373-1471; Fax: +32 2373-1489 Knoll France S.A. 49, Avenue Georges Pompidou F-92593, Levallois-Perret, Cedex, France Phone: +33 1496-45880; Fax: +33 1496-45919



Knoll Pharmaceuticals/BASFIN St. Nicholas Court, 25-27 Castle Gate Nottingham NG1 7AR, Great Britain Phone: +44 115-912-4000; Fax: +44 115-912-4816 Ravizza Farmaceutici spa Via Europa 35 I-20053 Muggio, Italy Phone: +39 39-24421; Fax: +39 39-791824 Knoll Farmaceutici Spa Via Europa 35 I-20053 Muggio, Italy Phone: +39 39-24426; Fax: +39 39-79-5014 Knoll Farmaceutici Spa Via Lorenteggio 270A I-20152 Milano, Italy Phone: +39 24-831-6301; Fax: +39 24-830-1976 Knoll Zagrel Planinska bb, 10000 Zagreb, Croatia Phone: +385 1233-3733; Fax: +385 1233-38279 Knoll Pharma Postbus 22622 NL-1100 DC Amsterdam Z.O., Netherlands Phone: +31 2056-40101; Fax: +31 2069-14311 EBEWE Arzneimittel GmbH A-4866 Unterach, Austria Phone: +43 7665-81230; Fax: +43 7665-812311 Przedstawicielstwo Knoll AG w Polsce, Aleje Jerozolimskie 154 02-326 Warsaw, Poland Phone: +48 22-822-462123; Fax: +48 22-822-4624 Knoll Lusitana Lda. Rua Alfredo da Silva 3 C e D 2 P-1300 Lisboa, Portugal Phone: +35 1136-15350; Fax: +35 1136-16378 BASF/Knoll AG ul. Malaja Trubezkaja 8 119881 Moscow, Russia Phone: +7 95-234-9666; Fax: +7 95-234-9667 Knoll-BioResearch S.A. Succursale di San Antonino CH-6592 San Antonino, Switzerland Phone: +41 9185-19191; Fax: +41 9185-19192 Knoll AG Postfach 631 CH-4410 Liestal, Switzerland Phone: +41 6192-50505; Fax: +41 6192-12563 Knoll Prag Frana Krala 35 81105 Bratislava, Slovak Republic Phone: +427 398-837; Fax: +427 398-850



Laboratoires Knoll S.A. Avenida Burgos 91 E-28050 Madrid 34, Spain Phone: +34 91334-3900; Fax: +34 91766-1973 Knoll Alman Ltd. TR-80040 Tophane-Istanbul, Turkey Phone: +90 216-492-9400; Fax: +90 216-492-5768 Knoll spol. Sr. o. Kounicka 70 10000 Prague, Czech Republic Phone: +420 27822-539; Fax: +420 27822-595 BASF Hungaria Kft./Knoll Divizio H-1036 Budapest, Galagonya u.5., Hungary Phone: +36 1-436-0820; Fax: +36 1-436-0830 Knoll Pharma Inc. 100 Allstate Parkway, Suite 600 Markham, ON L3R 6H3, Canada Phone: (905) 475-7070; Fax: (905) 475-3064 Knoll Pharmaceutical Co. 3000 Continental Drive N. Mount Olive, NJ 07828-1234 USA Phone: (973) 428-4000; Fax: (973) 887-8131 BASF Bioresearch Corp. 100 Research Drive Worcester, MA 01605-4314 USA Phone: (508) 849-2500

INVESTMENTS: BASF-LYNX Bioscience AG--joint venture with Lynx Therapeutics Inc. (10/96)

AGREEMENTS: Name Products Content of Agreement Date AgBioChem Inc. Gallex distribution

agreement

Ares Sorono human growth hormone (hGH)


8/96

BioBase GmbH Brenda enzyme database

licensing agreement

6/04

Bujard University of Heidelberg

gene regulation for CNS disorders

research agreement

8/92

Clontech Laboratories Inc.

tetracycline-controlled gene expression system

semi-exclusive licensing agreement

8/96

Diversa Corp. Diversa to discover and optimize new enzymes, BASF responsible for product and process development and commercialization

alliance 2/06

IBEX Technologies Inc.

Neutralase production and supply agreement

10/94

Incyte Pharmaceuticals Inc.

Incyte's LifeSeq genomics database

research agreement

6/96

Intercardia Inc. Bextra for CHF development and marketing agreement for outside the U.S. and Japan

12/96



Lynx Therapeutics Inc. (now Solexa Inc.)

access to Lynx's cloning and sequencing technologies

technology development and services agreement

10/96

Mitotix Inc. inhibitors of the cell cycle enzymes cdc 25

research agreement

5/96

Mitsui Toatsu Chemicals Inc.

multiple drug resistance suppressors for cancer chemotherapy

cross-licensing agreement

6/94

Norak Biosciences Inc.

Norak's Transfluor technology to screen GPCR targets developed by BASF

collaboration 8/04

Warner-Lambert Co.

ICE inhibitors R&D and marketing agreement

3/95

RESEARCH & DEVELOPMENT: Specialty chemicals, agricultural chemicals, including herbicides for rice and

cereal crops via biotechnology Vitamin B2 by fermentation MAb of tumor necrosis factor PEG-hirudin by recombinant fermentation Cardiovascular, central nervous system, oncology, and immunology research Molecular biology, bioengineering, biophysics, drug design, medicinal chemistry, combinatorial chemistry, preclinical and clinical development Thyroid hormone replacement Drugs for metabolic and immunological diseases

PRODUCTS ON MARKET: INORGANIC CHEMICALS: Adhesives and impregnating resins, alcoholates, alkali metal amides, alkali metal compounds, ammonium salts, boron compounds, carbonyl iron powders, catalysts, chlorine compounds, developmental products, electronic chemicals, food additives, hydroxyacetophenone, hydroxylamine compounds, nitrogen oxide derivatives, powder injection molding, sodium carbonate, sodium hydroxide, potassium hydroxide, sulfur products PETROCHEMICALS: Alkylen oxide and glycols, cracker products, plasticizers and plasticizer raw materials, solvents, technical gases AGRICULTURAL PRODUCTS AND NUTRITION: Herbicides, fungicides, insecticides, vitamins, pharmaceutical active ingredients and UV absorbers ANIMAL NUTRITION PRODUCTS COSMETIC INGREDIENTS/AROMA CHEMICALS PLASTICS COATINGS PERFORMANCE CHEMICALS FUNCTIONAL POLYMERS

Bayer Corp.

100 Bayer Road Pittsburgh PA 15205-9741, US Phone: (412) 777-2000 Web: www.bayerus.com

KEY PERSONNEL: Werner Wenning, Ph.D.; Chairman, Management Board, Bayer AG Attila Molnar; President and CEO George J. Lykos; Chief Legal Officer




HISTORY: Member--Biotechnology Industry Organization Name changed from Miles Inc. (4/95) Bayer AG acquired Microbial Developments Ltd. (Malvern, U.K.) (12/95) Spun off most of chemicals business and about one-third of polymer business (1/05)


SUBSIDIARIES/DIVISIONS: Business areas:

Bayer HealthCare Bayer MaterialScience Bayer CropScience Service areas: Bayer Business Services Bayer Technology Services Bayer Site Services

SUBSIDIARY OF: Bayer Group AG (see separate entry)

BUSINESS STRATEGY: Improve lives through a broad range of essential products that help diagnose and treat diseases, protect crops and advance automobile safety and durability


ALZA Corp. Mycelex antifungal marketing agreement

4/96

Axys Pharmaceutical Inc.

tryptase and chymase inhibitors

five-year, $70M R&D agreement (12/94), expanded to include oral and inhaled therapeutics (10/96), modified--Bayer returned to Axys rights to tryptase inhibitors for psoriasis and inflammatory bowel disease

7/97

Celltech Group plc anti-TNF MAbs to treat septic shock

$47.8M development and marketing agreement

5/92

Chiron Corp. anti-TNF MAbs to treat septic shock

licensing agreement

1989

Cortex Biochem Inc.

immunoreagents 1995

CV Technologies Inc.

cardiovascular product research agreement

12/92

Dharmacon Inc. siRNAs for drug discovery research

supply agreement 3/04

Genetics Institute DiscoverEase program--provides Bayer access to GI's library of novel human secreted proteins and related database for identifying novel human therapeutics

partnership agreement

8/97

GlaxoSmithKline plc

cerivastatin reductase inhibiting compound

co-promotion agreement for the U.S.

1997



The Immune Response Corp.

gene therapy for hemophilia A

exclusive licensing agreement

7/96

Molecular Simulations Inc.

computer software for use in combinatorial chemistry

three-year development agreement

4/97

Myriad Genetics Inc.

obesity, osteoporosis, and asthma gene discovery

research collaboration

9/95

Myriad Genetics Inc.

Myriad's ProNet protein interaction database

five-year, $54M database subscription--Bayer gets worldwide therapeutic rights for discoveries in dementia and depression, Myriad retains diagnostic rights and keeps all rights to discoveries outside the fields of dementia and depression

11/97

Nabi Biopharm-aceuticals

source plasma and certain immune plasmas

five-year contract 2/95

Onyx Pharmaceuticals

RAS proteins to treat cancer

five-year R&D agreement

5/94

OSI Pharmaceuticals Inc.

tumor markers and protein products of oncogenes, tumor suppressor genes and others in cancer diagnostic tests

R&D agreement 12/96

Pharmacia & Upjohn (now part of Pfizer Inc.)

animal health acquisition agreement--Bayer to acquire selected assets of P&U's animal health biologicals business including production and research facilities

1997

Pharmacopeia Inc.

Pharmacopeia's combinatorial chemistry and high-throughput screening technology for new drug discovery

research collaboration and library out-licensing

2/96

PharmaNetics Inc. test cards and analyzers


1998

Serologicals Corp. IVIG five-year supply agreement

12/94

Takeda Chemical Industries, Ltd.

cerivastatin codevelopment agreement

1993

VI Technologies contract fractionation take-or-pay processing agreement to produce intermediate plasma fractions

1995



PRODUCTS ON MARKET: 10,000+ products, including: Animal Health: Advantage®, Baytril®, CheckMite+™ Bee Hive Pest Control Strip, Clout™ (bromethalin) Rodenticide, Co-Ral® (coumaphos) Fly and Tick Spray, Co-Ral® Plus Insecticide Cattle Ear Tag, CyLence® (cyfluthrin) Pour-On Insecticide, CyLence® Ultra Insecticide Cattle Ear Tags, Droncit®, Drontal®, K9Advantix™, Legend®, Lysoff™ Pour-On Insectide, Marquis®, QuickBayt™, Spotton® (fenthion) Cattle, Tempo® (cyfluthrin) Insecticide Biological products: Gaminmune® N, 10%, Kogenate® FS and Kogenate®, Koate®-DVI, Plasbumin®-5, Albumin (human) 5%, USP, Plasbumin®-20, Albumin (human) 20%, USP, Plasbumin®-25, Albumin (human) 25%, USP, Plasmanate®, Plasma Protein Fraction (human) 5%, USP, Prolastin® Consumer care: Aleve®, Bayer® Aspirin, Vanquish®, Aleve® Cold & Sinus, Alka-Seltzer Plus®, NaSal™, Alka-Mints®, Alka-Seltzer®, Phillips'®, Phillip's M-O®, Bactine®, Campho-phenique®, Domeboro®, Flintstones® Vitamins, Bugs Bunny™ Vitamins, One-A-Day® Vitamins, Fergon®, Midol®, Mycelex®-7, Mycelex®-3, Femstat® 3 Diagnostics: ADVIA® systems, Technicon H*® Systems, Bayer Immuno 1® Immunoassay Analyzer, ADVIA CentraLink® Networking Solution, Rapidlink® Critical Care Information Management System, CLINITEK® analyzers, Rapidlab® systems, Multistix® reagent strips, TRUGENE® tests and kits, VERSANT® assays, Bayer ® System 340 (bDNA Analyzer), OpenGene® DNA Sequencing System, Ascensia® blood glucose monitoring systems, diabetes self-care software and lancing devices Bayer MaterialScience: Coating, Adhesive and Sealant Raw Materials, Inorganic Basic Chemicals, Polycarbonates, Polyurethanes, Thermoplastic Polyurethanes (TPU) Bayer CropScience: products for lawn, garden and home care and crop protection

Bayer CropScience AG

Alfred-Nobel-Str. 50 Monheim am Rhein D-40789, Germany Phone: +49 (0) 21 73-38-0 Web: www.bayercropscience.com E-mail: [email protected]

KEY PERSONNEL: Prof. Dr. Friedrich Berschauer; Chairman Dr. Rudiger Scheitza; Portfolio Management and Labor Director Dr. Dirk Suwelack; Business Planning and Administration Dr. Wolfgang Welter; Industrial Operations and Investments


HISTORY: Formed from a merger of Bayer Crop Protection and Aventis CropScience in June 2002 Acquired assets of Associated Farmers Delinting Inc. (2/05) Acquisition of Icon Genetics AG (1/06) Member--Biotechnology Industry Organization

FACILITIES: R&D centers in Monheim, Frankfurt and Potsdam, Germany; Lyon and Sophia Antipolis, France; Gent, Belgium; Yuki, Japan; Haelen, the Netherlands; and Stilwell, Kan., USA Major sites in Monheim, Germany; Lyon, France; Singapore; Research Triangle Park, N.C., USA; and Sao Paulo, Brazil

STOCK-FINANCIAL HISTORY: Privately held by Bayer AG



SUBSIDIARIES/DIVISIONS: Crop protection business (Insecticides, Herbicides, Fungicides, Seed Treatment) BioScience (Green Biotech) Environmental Science (non-agricultural pest and weed control products)

SUBSIDIARY OF: Bayer Group AG (see separate entry)

AGREEMENTS: Name Products Content of Agreement Date Arysta LifeScience amitraz, marketing of

fluoxastrobin and co-marketing of deltamethrin


4/05

Commonwealth Scientific and Industrial Research Organisation

RNAi gene-silencing technology for crops

worldwide licensing agreement

4/04

Cresset BioMolecular Discovery Ltd.

use of Cresset's molecular field technology for the discovery of agrochemicals

discovery and licensing agreement

1/06

Icon Genetics AG evaluation of expression levels and quality of selected preclinical pharmaceutical proteins

collaborative agreement

1/05

Large Scale Biology Corp.

investigation of the plant-based expression of lysosomal acid lipase

CRADA 4/05

Medicago Inc. feasibility of using Medicago technology for producing human therapeutic protein

research agreement

1/05

RESEARCH & DEVELOPMENT: Crop protection (herbicides, fungicides, insecticides), seed treatment, seeds,

green biotechnology and non-agricultural pest control

PRODUCTS ON MARKET: Nunhems vegetable seeds (main crops: onions, carrots, melons and leeks), FiberMax cottonseed (incorporating LibertyLink, Round Up Ready and Bollgard technologies), InVigor canola (with SeedLink hybridization technology), hybrid rice seed, pest control and crop protection products

Bayou Biolabs

1500 Edwards Avenue, Suite Q Harahan LA 70123, US Phone: (504) 733-3849; Fax: (504) 734-5106 Toll-free phone: (800) 966-9738 Web: www.bayoubiolabs.com E-mail: [email protected]

KEY PERSONNEL: Edward David Hyman; President


HISTORY: Founded in 1987 Changed name from Sybtrel Biotechnology (1995)

FACILITIES: 1,500 sq. ft. laboratory research facility


BUSINESS STRATEGY: Offer custom plasmid preparation service, including bulk quantities of all types and sizes



RESEARCH & DEVELOPMENT: Custom plasmid preparation Oligonucleotide synthesis technology Manufacture of biochemical reagents

PRODUCTS ON MARKET: DNA Ladders for conventional electrophoresis DNA Ladders for pulsed field gel electrophoresis Vectors Lederberg Plasmid Collection Custom plasmid preparation

Be-Long Group

P.O. Box 139 Gulou Post Office Nanjing 210008, China Phone: +86 25 8471 2602; Fax: +86 25 8470 9922 Web: www.be-longgroup.com E-mail: [email protected]

KEY PERSONNEL: Michael Song; President



FACILITIES: Headquarters in Nanjing, China Branches in Shanghai, Tianjin, Hong Kong, Hebei Langfang and Zhejiang Wenzhou Produce plant in Shandong


BUSINESS STRATEGY: Produce and market feed additives, food additives, chemical raw materials, pharmaceutical raw materials, pearl pigments and traffic marking materials

PRODUCTS ON MARKET: Choline chloride

Zinc bacitracin Bacitracin methylene dicalicylate Dicalcium phosphate Vitamins Amino-acids Gelatine Pearl luster pigments

BioAssay Works LLC

10075 Tyler Place, #18 Ijamsville MD 21754, US Phone: (301) 874-8888; Fax: (301) 874-8889 Web: www.bioassayworks.com E-mail: [email protected]

KEY PERSONNEL: Leslie Kirkegaard, Ph.D.; President Glen Ford; VP, Operations Stephen Mefferd; VP, Business Development Leslie Kirkegaard, Ph.D.; Director, R&D Rachael Keesey; Purchasing Manager

EMPLOYEES: 7 employees, 2 Ph.D.s, 1 M.D.

HISTORY: Founded in May 2005 Began biotech R&D in June 2005




BUSINESS STRATEGY: Patents in process for novel gold particle production and new rapid assay, lateral flow technology. BioAssay Works intends to combine the improved technologies with assay development experience for contract assay development.

Biocatalysts Ltd.

Cefn Coed, Parc Nantgarw Wales CF15 7QQ, UK Phone: +44 (0)1443 843 712; Fax: +44 (0)1443 846 500 Web: www.biocatalysts.com E-mail: [email protected]

KEY PERSONNEL: W. Salisbury; Chairman Stuart West; Managing Director Martin Duff; Sales Manager Mike Clay; General Manager


HISTORY: Originally founded in 1983 as part of Grand Metropolitan plc

Acquired by Shell Ventures (9/89) Regained independence (2/91) Member--Biotechnology Industry Organization

FACILITIES: Laboratory, production and warehouse facilities


BUSINESS STRATEGY: Manufacture and supply industrial enzymes to the food, diagnostic and pharmaceuticals industries

RESEARCH & DEVELOPMENT: New enzymes for biotransformations, biosensors, diagnostics, chiral

separations and environmental applications Products include Depol™, Lipomod™, Promod™, Combizyme, food processing enzymes, tissue culture enzymes including virus-free trypsin, microbial lipases and xylanase

PRODUCTS ON MARKET: Extensive range of lipases: xylanase, myrosinase, phenylalanine dehydrogenase, and secondary alcohol dehydrogenase (chiral synthesis catalysts), galactose dehydrogenase

Bioclear BV

P.O. Box 2262 Groningen 9704 CG, Netherlands Phone: +31 (0) 50-571 84 55; Fax: +31 (0) 50-571 79 20 Web: www.bioclear.nl E-mail: [email protected]

KEY PERSONNEL: Dr. Sytze Keuning; Managing Director Dr. Janneke Krooneman; Project Manager Maurice Henssen; Associate Director and Project Manager






RESEARCH & DEVELOPMENT: Environmental biotechnology Microbial identification Bioreactor development Biological treatment processes Microbiological detection and monitoring

BioForce Nanosciences Inc.

1615 Golden Aspen Drive, Suite 101 Ames IA 50010, US Phone: (515) 233-8333; Fax: (515) 233-8337 Web: www.bioforcenano.com; E-mail: [email protected]

KEY PERSONNEL: Eric Henderson, Ph.D.; Chairman and CEO Kerry Frey; COO Curtis Mosher, Ph.D.; VP, R&D Asrun Kristmundsdottir; Human Resources Manager Mike Lynch; NanoArrayer Product Manager Saju Nettikadan, Ph.D.; Director, Applications Development Collin Dettmann; Production Manager


HISTORY: Founded in 1994 Member--Biotechnology Industry Organization Merged with BioForce Nanoscience Holdings Inc. (formerly Silver River Ventures Inc.) (3/06)

STOCK-FINANCIAL HISTORY: OTC BB--BFNH Net loss <$19.221K> (YE 05) compared to <$15.490K> (YE 04) Loss per share $0.00/share (YE 05) compared to $0.00/share (YE 04) Average shares outstanding 4M (YE 05) compared to $4M (YE 04)

PRIVATE PLACEMENTS: Raised $6M in private placement of restricted common shares at ~$1.50/share (3/06)

SUBSIDIARY OF: BioForce Nanosciences Holdings Inc.

PRINCIPAL INVESTORS: Gulfstream Capital Management Societe Generale Asset Management Iowa First Capital Fund

FINANCIAL INFORMATION: $4.7M NIH/SBIR; $11M private and institutional investors

BUSINESS STRATEGY: Develop logical business units with synergistic potential. Provide the NanoArrayer™ System for precise delivery of femtoliter volumes of liquids to surfaces to enable the production of ultraminiaturized biomedical devices and other ultraminiaturized sensors and constructs. Ultraminiaturized biodevices allow biomarker-based disease detection and monitoring with high sensitivity and accuracy while reducing sample requirements to a few cells and thereby reducing cost and patient impact.

RESEARCH & DEVELOPMENT: Instrumentation for creating ultraminiaturized diagnostics and devices

Nanotechnology for drug discovery Nanotechnology for direct pathogen sensing

PRODUCTS ON MARKET: NanoArrayer™ System (NanoArrayer™, Surface Patterning Tools [SPTs™] and Sindex™ chips) UV TipCleaner AFM Solutions (Products and applications for atomic force microscopy)



BioGenes GmbH

Kopenicker Strabe 325 Berlin 12555, Germany Phone: +49 (0)30 65762396; Fax: +49 (0)30 65762397 Web: www.biogenes.de E-mail: [email protected]

KEY PERSONNEL: Dr. Alexander Knoll; CEO Dr. Sergej Ovodov; CSO Dagmar Schwertner; Marketing Director Dr. Sabine Steinbach; Head, Quality Management


HISTORY: Founded and began biotech R&D in July 1992

STOCK-FINANCIAL HISTORY: Private foundation

PRINCIPAL INVESTORS: Essential Management GmbH IBB Beteiligungsgesellschaft mbH

BUSINESS STRATEGY: Outsourcing partner for pharmaceutical companies

PRODUCTS ON MARKET: Immunological and biochemical services

BioGenesis Enterprises Inc.

610 West Rawson Avenue Oak Creek WI 53154, US Phone: (414) 571-6230; Fax: (414) 571-6231 Web: www.biogenesis.com E-mail: [email protected]

KEY PERSONNEL: Paul N. Temple; Chairman Mohsen C. Amiran, Ph.D.; President, CEO and Technical Director Charles L. Wilde; COO Michael Dubey; Operations Manager

EMPLOYEES: 9 employees, 1 Ph.D.


FACILITIES: 20,000 sq. ft. headquarters Additional offices in Washington, D.C., and Chicago

STOCK-FINANCIAL HISTORY: Privately held SUBSIDIARIES/DIVISIONS: Washington, D.C. office:

7420 Alban Station Blvd., B-208 Springfield, VA 22150 Phone: (703) 913-9700 Fax: (703) 913-9704

BUSINESS STRATEGY: Develop, manufacture and provide products and services for industrial cleaning, odor control and soil and sediment remediation

PRODUCTS ON MARKET: Soil washing, sediment washing, water treatment, filtration, fire

suppressants, odor control, specialty extractants



Biogenie Inc.

350 Franquet Street Quebec G1P 4P3, Canada Phone: (418) 653-2074; Fax: (418) 653-2675 Toll-free phone: (877) 653-2074 Web: www.biogenie-env.com E-mail: [email protected]

KEY PERSONNEL: Benoit Cyr; President Carl Rodzewich; GM, U.S. Dominic Belanger; GM, Paris Graham Holtom; GM, U.K. Richard Corbin; Corporate Director Bryan O’Gallagher; Project Director


HISTORY: Founded in 1986 FACILITIES: 28,000 sq. ft. facility including engineering and laboratory space for chemical

analysis, microbiology and process simulation Operates mobile units for soil biotreatment studies

STOCK-FINANCIAL HISTORY: Privately held BUSINESS STRATEGY: Develop biological processes for the treatment of soil, water effluents and air

Seek research contracts, joint ventures and technology transfer

RESEARCH & DEVELOPMENT: Microorganisms, bioreactors, biological and physical/chemical processes for

treatment of contaminated soil, water and air

PRODUCTS ON MARKET: Soil and groundwater decontamination for organic contaminants: hydrocarbons, solvents, pentachlorophenol, creosote, polyaromatic hydrocarbons (PAH), nitroaromatics and inorganic contaminants such as mercury Waste gas biofilters and air quality services

Bio-Lab Ltd.

P.O. Box 34038 Jerusalem 91340, Israel Phone: +972 2-584 1110; Fax: +972 2-584 1111 Web: www.bio-lab.co.il; E-mail: [email protected]

KEY PERSONNEL: Dr. Leo Samuel; Managing Director Dr. Michel Ehrenfreund; Managing Director Dr. Jean Hildesheim; Director, Biotech and R&D



FACILITIES: 7,000 sq. m. facility in Jerusalem


BUSINESS STRATEGY: Produce and distribute high purity solvents and chemicals for research, routine laboratories and industries

RESEARCH & DEVELOPMENT: HPLC: Up-grading of current specifications, introduction of new products

Molecular biology: Up grading of current specifications, introduction of new products DNA synthesis: Up grading of current specifications, introduction of new products, synthesis of new reagents Peptide synthesis: Development of formulations, quality up grading of reagents, blocked amino-acid



PRODUCTS ON MARKET: Solvents and chemicals Solvents and formulations for HPLC Environmental solvents Dry solvents Chiral solvents Molecular biology solvents, chemicals and formulations Peptide synthesis solvents and formulations DNA synthesis solvents Reagents Custom synthesis

Biolog Inc.

21124 Cabot Blvd. Hayward CA 94545, US Phone: (510) 785-2564; Fax: (510) 782-4639 Web: www.biolog.com; E-mail: [email protected]

KEY PERSONNEL: Barry R. Bochner, Ph.D.; President, CEO and CSO Douglas E. Rife; VP, Operations Edwin Fineman; VP, Finance and CFO John D. Groat; VP, Global Sales


HISTORY: Founded in January 1981 R&D facilities opened in July 1984 Member--Biotechnology Industry Organization

FACILITIES: Offices, laboratory, R&D and manufacturing facilities


FINANCIAL INFORMATION: Funding from equity, SBIR grants and development contracts

BUSINESS STRATEGY: Continue growing as the recognized authority in cellular phenotype analysis with particular emphasis in functional genomics and drug discovery, microbial identification and analysis of microbial ecosystems

AGREEMENTS: Name Products Content of Agreement Date Axiohelix and the NARA Institute

E. coli genome--phenotyping and determining the function of each gene

research agreement

11/04

RESEARCH & DEVELOPMENT: Broad spectrum kits and phenotype MicroArrays ™ based on a patented

technology for the characterization and identification of microorganisms (gram-negative, gram-positive, yeast and anaerobe) at the species and subspecies level, as well as custom kits for specific applications or groups of microorganisms Functional genomics, phenotype testing and contamination identification

PRODUCTS ON MARKET: GN2 MicroPlate™--test panel for identification/characterization of 566 gram-negative bacteria GP2 MicroPlate™--test panel for identification/characterization of 250 gram-positive bacteria plus 57 lactic acid bacteria AN MicroPlate™--test panel for identification/characterization of 300 species of anaerobic bacteria YT MicroPlate™--test panel for identification/characterization of 267 yeast species FF Microplate™-- test panel for identification/ characterization of filamentons fungi MT2 MicroPlate™--test panel for catabolic surveys and bioremediation studies ECO MicroPlate™--test panel for microbial community characterization and analysis



BUG™--universal growth medium for growing a broad range of microorganisms BUA™--universal growth medium for anaerobes BUY™ Agar--universal growth medium for yeast Rainbow® Agar O157--selective chromogenic culture medium for toxigenic strains of E. coli such as O157:H7 Rainbow® Agar Salmonella--selective chromogenic medium for H2S+ Salmonella species Rainbow® Agar UTI--non-selective chromogenic medium for enumeration and identification of urinary tract pathogens MicroLog™--manual system for reading and interpreting MicroPlate™ tests MicroStation™--automated microbiology workstation for reading and interpreting MicroPlate™ tests OmniLog ID System--rapid automated incubation and identification of aerobic bacteria OmniLog PM System--automated instrument and software for kinetic analysis of 2000 cellular phenotypes Phenotype MicroArray Panels--MicroPlates for metabolic analysis of bacterial, fungal and mammalian cells

Biologos Inc.

2235 Cornell Avenue Montgomery IL 60538-3201, US Phone: (800) 246-4088; Fax: (630)-801-4766 Toll-free phone: (800) 246-4088 Web: www.biologos.com; E-mail: [email protected]

KEY PERSONNEL: Dennis Raine; President



FACILITIES: 15,000 sq. ft. headquarters


RESEARCH & DEVELOPMENT: Animal tissue culture

PRODUCTS ON MARKET: Normal animal sera Tissue culture media Antibiotic solutions Enzyme solutions Growth additives Miscellaneous biologicals

BioMed Diagnostics Inc.

1388 Antelope Road White City OR 97503-1619, US Phone: (541) 830-3000; Fax: (541) 830-3001 Toll-free phone: (800) 964-6466 Web: www.biomed1.com E-mail: [email protected]

KEY PERSONNEL: Robert D. Hall; Chairman and Exec. VP






BUSINESS STRATEGY: Provide test methodologies that can be performed without sophisticated equipment or highly skilled personnel Utilize company's patented and proprietary packaging concepts to extend shelf life and improve performance of various media

AGREEMENTS: Name Products Content of Agreement Date CMS/Fisher Healthcare

InPouch and InTray systems

distribution agreement for the U.S.

7/98

PRODUCTS ON MARKET: InPouch™ and InTray™ systems for detecting protozoa and fungi

Custom contract packaging

PRODUCTS IN DEVELOPMENT: Name Status Group B strep in field trials

Biomeda Corp.

1191 Chess Drive, Suite F Foster City CA 94404, US Phone: (650) 341-8787; Fax: (650) 341-7095 Toll-free phone: (800) 341-8787 Web: www.biomeda.com; E-mail: [email protected]

KEY PERSONNEL: Ron Walraven; Chairman Pete Derrico; CEO




BUSINESS STRATEGY: Develop, manufacture and sell the highest quality immunochemicals

RESEARCH & DEVELOPMENT: Immunology, cell biology, cell culture, molecular biology products

PRODUCTS ON MARKET: Quality Leaders: -Primary antibodies -Secondary antibodies -ELISA -Detection systems -Mounting media -Sera

Biomedical Technologies Inc.

378 Page Street Stoughton MA 02072, US Phone: (781) 344-9942; Fax: (781) 341-1451 Web: www.btiinc.com; E-mail: [email protected]

KEY PERSONNEL: Maurice Lamarque; President



PRODUCTS ON MARKET: Cell growth factors

Cell culture products EIA kits RIA kits



Assay kits and components MAbs, polyclonals, and proteins Specialty plastic labware

BioMerieux INDUSTRY

595 Anglum Road Hazelwood MO 63042-2320, US Phone: (314) 731-8500; Fax: (314) 731-8678 Toll-free phone: (800) 634-7656 Web: www.biomerieux-vitek.com E-mail: [email protected]

KEY PERSONNEL: Alain Merieux; Chairman and CEO, bioMerieux sa Tom O'Brien; Director, U.S. Industry Sales Karen Mullen; Sr. Market Manager; Pharma Mike Bullard; National Business Manager, Pharma Lee Doughton; Corporate Account Manager, Pharma


HISTORY: Began biotech R&D in 1966 Founded in 1977

FACILITIES: Headquarters in St. Louis, Mo. Manufacturing facilities in St. Louis, Mo., and Rockland, Mass.

STOCK-FINANCIAL HISTORY: Privately held by parent

SUBSIDIARIES/DIVISIONS: BioMerieux Inc. 100 Rodolphe Street Durham, NC 27717, USA Phone: (919) 620-2000

SUBSIDIARY OF: BioMerieux SA (see separate entry)

BUSINESS STRATEGY: Develop and manufacture microbiology and immunoassays

AGREEMENTS: Name Products Content of Agreement Date Affymetrix Inc. DNA probe arrays using

Affymetrix GeneChip technology

development agreement for bacteriology testing

9/96

Gen-Probe Inc. probe assays for Vidas development agreement

5/97

MRL The Surveillance Network (TSN)

global surveillance partnership

5/97

OraVax Inc. human diagnostic products incorporating CagA for H. pylori detection


11/96

RESEARCH & DEVELOPMENT: Microbiology, immunoassays, pharmacy

PRODUCTS ON MARKET: Vitek Vidas mini-Vidas API Slidex Chromogenic media TheraTrac 2 TSN



BioMerieux SA

376 Chemin de l'Orme Marcy l'Etoile F-69280, France Phone: +33 04 78 87 20 00; Fax: +33 04 78 87 20 90 Web: www.biomerieux.com

KEY PERSONNEL: Alain Merieux; Chairman Benoît Adelus; Exec. VP Christophe Merieux; Sr. VP, R&D and Medical Affairs Frederic Benoliel; Corp. VP, Asia Pacific Thierry Bernard; Corp. VP, Europe, Middle East, Africa Xavier Fargetton; Corp. VP, Global Marketing and Strategic Development Jocelyne Latour; Corp. VP, Quality Assurance and Regulatory Affairs Jean-Francois de Lavison; Corp. VP, Public and International Affairs Marc Mackowiak; Corp. VP, R&D Pierre Piffeteau; Corp. VP, Industrial Operations and Purchasing Alexandre Merieux; Corp. VP, Industrial Microbiology Henri Thomasson; Corp. VP, Finance Peter Kaspar; Corp. VP and Head, Molecular Biology



Began biotech R&D in 1963 Changed name from Institut Merieux (1974) Acquired API System (1987) Acquired VITEK Systems (1988) Acquired the diagnostics unit of Organon Teknika, a division of Akzo Nobel (2001) Sold its hemostasis range of products to Trinity Biotech plc (6/06)

FACILITIES: Corporate headquarters facilities in France with 2,100 employees Operations and facilites in over 130 countries, with more than 110 distributors Nine research centers worldwide

STOCK-FINANCIAL HISTORY: Listed on the Premier Marche of Euronext, Paris (FR0010096479 – BIM) Net sales EUR993.6M (YE 05) compared to EUR929.3M (YE 04) Net income EUR90.1M (YE 05) compared to EUR79.7M (YE 04) Earnings per share EUR2.28/share (YE 05) compared to EUR2.04/share (YE 04) Total assets EUR906.1M (YE 05) compared EUR838.6M (YE 04)

SUBSIDIARIES/DIVISIONS: Thirty-three subsidiaries in 130 countries Two business areas: Clinical diagnostics: Focuses on diagnosing infectious diseases, such as hepatitis B, HIV, tuberculosis, respiratory infections and increasingly pathologies, such as cardiovascular diseases and cancers Industrial diagnostics: Focuses on controlling the microbiological quality of an industrial or environmental sample

BUSINESS STRATEGY: Become a key player in the in vitro diagnostics field of infectious diseases and other pathologies, such as cardiovascular diseases or cancers. It has implemented the following strategy: -Focusing its development on applications with a high potential -Launching new products to better satisfy the needs of patients and the imperatives of public health in general -Reinforcing its worldwide network to seize growth opportunities -Continuing with its sustained effort in research and development -Investing in new technologies via strategic alliances and targeted purchases that guarantee growth and technological independence -Pursuing a balanced financial strategy to seize on growth opportunities



AGREEMENTS: Name Products Content of Agreement Date Affymetrix Inc. detection of nucleic

acids in bacteriology, virology and industrial microbiological control applications

R&D agreement 12/03

Apibio molecular biology research

R&D agreement 12/03

Applied NeuroSolutions Inc.

biologic test for diagnosis of Alzheimer's disease


12/04

B·R·A·H·M·S AG Procalcitonin as a diagnostic marker for severe bacterial infections

non-exclusive licensing agreement

3/05

Cepheid molecular biology platforms

R&D agreement 1/04

DiagnoSwiss development, manufacturing and marketing of electrochemical microchips


7/05

ExonHit Therapeutics

new blood diagnostics in the area of early cancer detection

discovery and development agreement, extended 10/05

2003

Genome Express Genome Express to carry out bacterial analyses

licensing agreement

5/05

Gen-Probe Inc. Gen-Probe's ribosomal RNA technologies and bioMerieux's genetic mutation detection IP

non-exclusive licensing agreements

10/04

IDI new targets in microbiology applications

R&D agreement 4/04

Primagen Holding BV

coronavirus CoV-NL63 exclusive licensing agreement

2/06

Proteome Sciences plc

Proteome's biomarkers for use in stroke diagnostics

licensing agreement

5/06

Roche Diagnostics

development, manufacturing and marketing of immunoassays for congestive heart failure and acute coronary syndrome


4/05

RESEARCH & DEVELOPMENT: Bacteriology Immunoassays Molecular biology Hemostasis Instrumentation Software Genetics Pharmacogenomics Proteomics, biocomputing Micro-technologies (micro-fluidic, electronic, etc.)



PRODUCTS ON MARKET: PHARMACEUTICALS, COSMETICS and BIOTECHNOLOGY: Identification of micro-organisms API® strips mini API® Vitek® Vitek®2 apiweb® Microbiological control for sterile and non sterile products Bactometer® BacT/Alert® 3D Pharmaceutical, cosmetics and biotechnology Culture media - Pharmaceutical, cosmetics and biotech range Environmental control Culture media Culture media - Environmental control range Air Monitoring air Ideal® NucliSens EasyQ® Influenza H5 and N1 - avian flu test (for research) FOOD: Culture media Culture media - Food range Identification API® strips mini API® Vitek® FoodExpert-ID® apiweb® Pathogen immunodetection Vidas® Environment Vidas® Next Day Vidas® 2nd Generation Vidas® Safety Quality indicators Bactometer® Sterility testing BacT/Alert® 3D Food Tempo® microbial enumeration system BLOOD BANK and TISSUE BANK: Culture media Culture media - environmental control range Quality control testing of apheresis platelets BacT/Alert® 3D System WATER TESTING: Culture media Legionella GVPC medium Identification API® strips mini API® Vitek® apiweb®



Biomol GmbH

Waidmannstrasse 35 Hamburg D-22769, Germany Phone: +49 40 85 32 600; Fax: +49 40 85 32 6022 Toll-free phone: (800) 246-6651 Web: www.biomol.de E-mail: [email protected]

KEY PERSONNEL: Dr. Eckhard Renken; Managing Director Carsten Schulz; Head, Finance Dr. Thomas Wiesemann; Head, Marketing Dr. Hans-Jurgen Heilmann; Head, Project Management




AGREEMENTS: Name Products Content of Agreement Date Biomol Research Laboratories

signal transduction reagents eicosanoids, lipids

agency agreement for Germany, Austria, and Eastern Europe

1989

Geneka Biotechnology Inc.

Immunological and molecular biology products for transcription factors and functional genomics

agency agreement for Germany, Austria and Switzerland

1999

StressGen Inc. heat shock proteins and antibodies

agency agreement for Germany

1991

Upstate Biotechnology Inc.

signal transduction antibodies

sales agreement and agency agreement for Germany, Hungary, Poland, and the Czech Republic

1990

PRODUCTS ON MARKET: Antibodies

Arrays Compound libraries EIA kits/plate assays Enzymes and proteins Lectins Plasmid/vectors

Bionas GmbH

Friedrich-Barnewitz-Strasse 3 Rostock 18119, Germany Phone: +49 381 5196-241; Fax: +49 381 5196-246 Web: www.bionas.de E-mail: [email protected]

KEY PERSONNEL: Dr. Ralf Ehret; CEO Dr. Michael Schulze; Head, Sales and Marketing


HISTORY: Founded 2001




BUSINESS STRATEGY: Bionas specializes in analyzing systems and services for in-vitro profiling of the metabolic activity of cells to understand cellular function. Bionas® 2500 analyzing system is a bench-top instrument that measures multiple metabolic parameters simultaneously like acidification, oxygen consumption and adhesion of living cells. The label-free and non-invasive live cell-based assay employs sensor chips that replace the conventional bottom of culture wells. Various cell types including primary cells have been successfully tested. The readout is carried out continuously over long periods of time and can be watched online revealing a deeper insight in cellular function than possible with endpoint-based assays. Regeneration and recovery effects can also be monitored. Bionas® 2500 analyzing system closely mimics the in vivo situation and allows a more precise selection of promising drug candidates for preclinical development; reduces needless, expensive and time consuming animal studies; and saves money due to reduction of development time (faster time-to-market).

PRODUCTS ON MARKET: Bionas 2500 analyzing system

Bionov CNP Inc.

4495, boul. Wilfrid-Hamel Quebec G1P 2J7, Canada Phone: (418) 653-4422; Fax: (418) 653-3583 Toll-free phone: (800) 267-4422 Web: www.qbc.clic.net/~bionov E-mail: [email protected]

KEY PERSONNEL: Yvan Pouliot; President




SUBSIDIARIES/DIVISIONS: Nutrimer enr.

BUSINESS STRATEGY: Partnering strategy: Bionov is looking for: -Animal food wholesalers interested in the distribution of petfood products (frozen form in aquarium, seaworld and zoo, and dried form in petshop) -Companies in the food flavoring industry searching for new raw material for seafood flavoring -Food processing plant looking for the development of new products

RESEARCH & DEVELOPMENT: Aquatic and marine resources: Development of new products, nutritional

characteristics, upgrading of new resources or by-products, survey of natural resource, biomass production (aquaculture) Environment: Ecological management (pollution control, aesthetic, biodiversity), control of nuisances (bacteria, algae, weeds), ecological study and environmental evaluation (contamination), Nordic environment

PRODUCTS ON MARKET: Fish food (from amphipods) Amphipods



BIOPAC Systems Inc.

42 Aero Camino Goleta CA 93117, US Phone: (805) 685-0066; Fax: (805) 685-0067 Web: www.biopac.com; E-mail: [email protected]

KEY PERSONNEL: Alan Macy; President and CEO Marc Wester; CFO William McMullen; VP



FACILITIES: 10,000 sq. ft. headquarters 3,000 sq. ft. R&D facility 3,000 sq. ft. manufacturing facility


BUSINESS STRATEGY: Provide products for medical research and educational markets

RESEARCH & DEVELOPMENT: High-speed data acquisition platform (MP150)

Computerized student physiology laboratory

PRODUCTS ON MARKET: MP100 System MP 150 System Biopac Student Lab MP30/35 AcqKnowledge waveform analysis software AcqKnowledge GLP Biopac Science Lab MP40

PRODUCTS IN DEVELOPMENT: Name Status MP200 in development Telemetry in development

BioPro International Inc.

P.O. Box 156, 265 Conklin Street Farmingdale NY 11735, US Phone: (516) 249-0099; Fax: (516) 249-0494 Web: www.biopro.com; E-mail: [email protected]

KEY PERSONNEL: Rene Lohser; President and CEO John Campagnola; Sales and Service Manager Marc Lohser; Head, Marketing Therese Furger; Treasurer Denise Lohser; Head, Administration




BUSINESS STRATEGY: Market and service processing equipment and instruments used for research, development and production of biochemicals, therapeutic drugs, enzymes, vaccines, antibodies and other biological products

AGREEMENTS: Name Products Content of Agreement Date Aquasant AG (Switzerland)

sensors custom sensor design

1993

Bioengineering AG (Switzerland)

fermenter/bioreactors custom equipment design

1993



Bioxplore (UK) multiple fermenters custom fermenter design

1996

Dairei (Denmark) Ultra-Low Temperature Freezer

custom design 2005

Fedegari (Italy) autoclaves custom designed autoclaves for labs

2002

Graber (Switzerland)

vibrating mixer custom design 1993

Kuhner AG (Switzerland)

biological shakers custom shaker design

1993

M. Christ (Germany)

Freeze Driers and vacuum concentrators

custom designs for drug discovery

1999

Prior (Austria) preparative continuous annular chromatography

custom design 1999

Riebesam (Germany)

glassware washing machines

custom design 2000

RESEARCH & DEVELOPMENT: Bioreactors, fermenters, shakers

PRODUCTS ON MARKET: Marketing and service of processing equipment and instruments from global sources used for research, development and production of biochemicals, therapeutic drugs, enzymes, vaccines, antibodies and other biological products Processes and designs for chemical engineering and environmental technology

Bioriginal Food & Science Corp.

102 Melville St. Saskatoon S7J 0R1, Canada Phone: (306) 975-1166; Fax: (306) 242-3829 Web: www.bioriginal.com E-mail: [email protected]

KEY PERSONNEL: Joe Vidal; President and CEO Johan Kamphuis; Exec. VP, Global Marketing and Sales Gene Gerspacher; VP, Finance Dr. Jim Nugent; Director, Product Development Manny Sabares; Director, Marketing




PRODUCTS ON MARKET: Condition-Specific Products

Borage Products (oils, softgels, powders) EPA/DHA Products (oils, softgels, powders) Flax Products (oils, softgels, powders) EPO Products (oils, softgels, powders)



Bioscience Inc.

1550 Valley Center Parkway, Suite 140 Bethlehem PA 18017, US Phone: (610) 974-9693; Fax: (610) 691-2170 Toll-free phone: (800) 627-3069 Web: www.bioscienceinc.com E-mail: [email protected]

KEY PERSONNEL: Thomas G. Zitrides; CEO


HISTORY: Founded in December 1984


BUSINESS STRATEGY: Provide innovative products and services for environmentally-sound and efficient treatment of wastewater, wastewater sludge, contaminated soils and biotreatment for aquaculture and agriculture

PRODUCTS ON MARKET: Microbial products for bioaugmentation

Process improvement and stabilization of wastewater plants Activated sludge plants Plumbing systems Soil reclamation/bioremediation Aquaculture programs Analytical instruments and test kits Heater blocks and colorimeters for monitoring wastewater parameters Package biotreatment plants, aerators, product feeders and related instrumentation Laboratory biodegradation and biotreatability testing Engineering scale-up for bioremedial projects and in-house technical services Environmentally-friendly degreasers and oily water treatment and management programs

BioScreen Testing Services Inc.

3892 Del Amo Boulevard Torrance CA 90503, US Phone: (310) 214-0043; Fax: (310) 370-3642 Web: www.bioscreen.com E-mail: [email protected]

KEY PERSONNEL: Bradford L. Rope; President and CEO Dr. Richard Sullivan; Director, R&D Dr. Lawrence Rheins; VP, Clinical Services



FACILITIES: Facilities in Phoenix, Ariz., and Shawnee Mission, Kan.


SUBSIDIARIES/DIVISIONS: Pharmaceutical and Biotechnology Services Medical Device Cosmetic, Household & Industrial Products Midwest Clinical Trials (Human Clinical and Claim Substantiations)



RESEARCH & DEVELOPMENT: Microbiology, chemistry and toxicology testing Medical devices Pharmaceuticals Water testing

BioSure Inc.

12301 Loma Rica Drive, Suite G Grass Valley CA 95945-9355, US Phone: (530) 273-5095; Fax: (530) 273-5097 Toll-free phone: (800) 345-2267 Web: www.biosure.com; E-mail: [email protected]

KEY PERSONNEL: J. R. Riese; CEO


HISTORY: Founded and began biotech research in 1986

FACILITIES: 5,000 sq. ft. headquarters 1,500 sq. ft. R&D facilities 2,000 sq. ft. manufacturing facilities


BUSINESS STRATEGY: Provide unique products and expert technical assistance to research, industry, clinical laboratories, hospitals and medical/dental facilities worldwide The company focuses on biological safety, biological controls and standards and regulatory conformance in the manufacturing of biomedical devices and reagents

RESEARCH & DEVELOPMENT: Biological controls and reagents for flow cytometry, immunocytometry and

DNA analysis

PRODUCTS ON MARKET: BioSure® steam sterilization integrators for verification of autoclave cycles and sterility BioSure® flow cytometry biological controls, DNA controls, reagents and buffers Consulting services, custom products and packaging

Biosynth International Inc.

1665 West Quincy Avenue, Suite 155 Naperville IL 60540, US Phone: (630) 305-8400; Fax: (630) 305-8420 Toll-free phone: (800) 270-2436 Web: www.biosynth.com E-mail: [email protected]

KEY PERSONNEL: Urs Spitz, Ph.D.; Chairman and CEO



FACILITIES: Worldwide headquarters: Biosynth AG Rietlistr. 4 Postfach 125 9422 Staad, Switzerland Phone: +41 (0)71 858 20 20 Fax: +41 (0)71 858 20 30




BUSINESS STRATEGY: Innovate, develop and produce reagents and biochemicals for the life science and pharmaceutical industries

RESEARCH & DEVELOPMENT: Manufacture of substances for the detection of enzyme activity indicative of

health conditions in clinical samples Identification of bacterial infections in clinical, food and environmental samples or products for hygiene monitoring Rare biochemicals such as culture media additives, biological detergents, plant growth hormones, and biochemical reagents used in standard assays Synthesis of indole derivatives

PRODUCTS ON MARKET: Biochemicals: Biological detergents, plant growth regulators and biochemical reagents, including diagnostic reagents, cosmetic ingredients, pharmaceutical ingredients, biochemical substances Carbohydrates and inositols: Monosaccharides, disaccharides, oligosaccharides, polysaccharides and inositols Culture media additives: Carbohydrates, growth inhibitors, C-390, bile acids, keto acids, L-amino acids and SPS Dyes, stains, labels and indicators: Colorimetric and fluorometric reagents, dyes and stains, indicators and labels Enzyme substrates: Glycosidases, peptidases, esterases, phosphatases, peroxidases, sulfatases, phospholipases, luciferases and enzyme reagents Fine chemicals: Alcohols, aldehydes, ketones; amines, amides, guanidines, ureas; amino acid derivatives; carboxylic and inorganic acids and derivatives; phenols, quinones, coumarines and other aromatics; heterocycles and alkaloids; steroids and bile acids Indole derivatives: Mono-substituted indoles, di-substituted indoles, tri-substituted indoles, higher substituted indoles, tryptamines, serotonins, tryptophans, tryptophols, gramines, harmines and harmanes, fluoroindoles, azaindoles and indolines Lipids and Phospholipids: Propanol-based lipids, glycol-based lipids, glycerol-based lipids, other lipids, propanol-based phospholipids, glycol-based phospholipids, glycerol-based phospholipids, other phospholipids Life science reagents: Biochemistry tools, cell biology tools, molecular biology tools, receptor agonists and antagonists and reducing agents

Biotal Ltd.

Collivaud House, Ocean Way Cardiff CF24 5PD, UK Phone: +44 (0)29 2047 5550; Fax: +44 (0)29 2047 5598 Web: www.biotal.co.uk

KEY PERSONNEL: Stuart Patterson; Director




SUBSIDIARIES/DIVISIONS: Agricultural business Equine business Garden products business Industrial products business



BUSINESS STRATEGY: Develop products based on microbial and enzyme technology

RESEARCH & DEVELOPMENT: Agricultural business: Focus is on the research, development, manufacture

and supply of forage additives using naturally occurring micro-organisms and enzyme formulations

PRODUCTS ON MARKET: BioCrimp Biograin Biostraw Wholecrop Wholecrop Legume Axcool Solo Axphast Supersile SoloMaize MaizeCool Top-Treat SC yeast range Equine Gold Garden cleaners Compost Maker Water Clear Fountain Clear Refresh and Refresh Plus Soil Restore Biotal GD Biological urinal/toilet cleaner

Bio-Technical Resources

1035 South 7th Street Manitowoc WI 54220, US Phone: (920) 684-5518; Fax: (920) 684-5519 Web: www.biotechresources.com E-mail: [email protected]

KEY PERSONNEL: Tom Jerrell; President Reinhardt A. Rosson, Ph.D.; VP and Director, R&D Michele T. Schmidt; VP, Operations Julia Maurina-Brunker; Director, Business Development Dr. Linsheng Song; Sr. Research Scientist

EMPLOYEES: 30 employees, 22 scientists and engineers


FACILITIES: 15,000 sq. ft. facility with extensive analytical equipment, fully equipped molecular biology laboratory, isotope rooms and fermenters (1 to 250 liters)


SUBSIDIARY OF: Arkion Life Sciences LLC

PRINCIPAL INVESTORS: Arkion Life Sciences LLC

BUSINESS STRATEGY: Develop process technologies based on microbial fermentation and biocatalysis Provide laboratory and consulting services--including recombinant and classical strain improvement, industrial expression systems, fermentation and downstream process development and scale-up, metabolic engineering and microbial screening--on a contract basis



RESEARCH & DEVELOPMENT: Microbial screening Strain improvement, classical and recombinant Fermentation development, recovery and scale-up Metabolic engineering Molecular biology Biocatalysis, enzyme and whole cell Expression systems

Biotechnology Research Institute

6100 Royalmount Avenue Montreal H4P 2R2, Canada Phone: (514) 496-5329; Fax: (514) 496-5007 Web: www.irb-bri.cnrc-nrc.gc.ca E-mail: [email protected]

KEY PERSONNEL: Dr. Michel Desrochers; Director General Dr. Andrew Storer; Director, Health Sector Dr. Bernard Massie; Director, Bioprocess Platform Adrien Pilon; Director, Environmental Sector Eileen Raymond; Director, Industrial Affairs Sector

EMPLOYEES: 812 employees (277 NRC employees, 304 employees from private companies, 210 students and guest researchers)

HISTORY: Established by National Research Council of Canada in 1984 to conduct state-of-the-art research in molecular biology and biochemical engineering with specific applications to the pharmaceutical and environment and resource industries

FACILITIES: 315,000 sq. ft. of laboratories, offices, pilot plants and spaces leased to industry


PRINCIPAL INVESTORS: National Research Council of Canada

BUSINESS STRATEGY: Make a significant contribution to the wealth-generating capability in Canada and represent a source of expertise for both industry and the scientific community Work with companies through collaboration research, contract and licensing agreements

RESEARCH & DEVELOPMENT: Molecular design strategies for the development of peptidyl and nonpeptidyl

blockers as potential therapeutic agents (cancer, cardiovascular, and degenerative and inflammatory diseases) Development of biotechnology products, development of new bioprocesses, improvement of existing bioprocesses, scale-up of bioprocesses to industrial levels using microorganisms, animal cells or enzymes as catalysts Bioremediation of contaminated soils, air, groundwater and sediments Biological monitoring, biosensors and biopesticides



Biotecx Laboratories Inc.

6023 South Loop East Houston TX 77033, US Phone: (713) 643-0606; Fax: (713) 643-3143 Toll-free phone: (800) 535-6286 Web: www.biotecx.com E-mail: [email protected]

KEY PERSONNEL: Dr. Mohan Mehra; President





BUSINESS STRATEGY: Develop products for molecular biology and clinical diagnostics Find partners for OEM distribution and direct selling

RESEARCH & DEVELOPMENT: ELISA products for infectious disease

Hormone assays

PRODUCTS ON MARKET: Ultraspec RNA RNA Tack DNA Multriprep BioPlaz Ezout Expresep Ontrack Prokay OptiCoat ELISA kits for TORCH, thyroids, fertility hormones

Biotehnos SA

18, Dumbrava Rosie Street, District 2 Bucharest 020464, Romania Phone: +40 21 210 20 15; Fax: +40 21 210 97 05 Web: www.bth.ro E-mail: [email protected]

KEY PERSONNEL: Prof. Dr. Ioan Manzatu; President and CEO Liliana Manzatu; Deputy Director General Iuliana Zaharia; Financial Director Stefan Badusi; Commercial Director Alexandru Stoica; Marketing Director Laura Olariu; Director, R&D Mariana Ghica; Production Director Viorica Dinga; QA Director; Quality Control Ruxandra Elisa Dobos; Head, QC Department Ludmila Turcanu; Scientific Director


HISTORY: Began biotech R&D in 1983 Founded in 1991


PRINCIPAL INVESTORS: Tehman Ltd.--20%



INVESTMENTS: National Institute of Biotechnologies--$30K Biotehnos and Tehman Association--$5M

BUSINESS STRATEGY: Develop, market and export biopharmaceuticals and biocosmetics

AGREEMENTS: Name Products Content of Agreement Date Artur-K pharmaceuticals distribution

agreement

Biotechman GmbH

pharmaceuticals and cosmetics

Commercialization of yeast extracts, marketing, tehnology transfer, new products registration, GMP rules implementation

CMS GmbH biotechnology joint venture for R&D, production and marketing

1997

Falbi pharmaceuticals distribution agreement

Farmotehnos SA pharmaceuticals and cosmetics

Joint venture for products registration, distribution, promotion of new technologies and production

Guangzhou Economic and Technological Development District (China)

pharmaceuticals and cosmetics


1997

Interfarma pharmaceuticals distribution agreement

Lenniichimmash-Centrofarm

pharmaceuticals distribution agreement

Masung Co. Ltd. (Seoul)

pharmaceuticals sales agreement for the Far East

1996

North Pharmaceutical Network

pharmaceuticals distribution agreement

Planeta pharmaceuticals distribution agreement

Protec pharmaceuticals distribution agreement

Rompharm Co. pharmaceuticals distribution agreement

Travel Medinsure pharmaceuticals distribution agreement

PRODUCTS ON MARKET: Biopharmaceuticals: Alflutop®/Alflutop® gel, Armon®, Gelisept®, Alflutop® vet, Salvapoderm®, Salvaderm®, Rhinogel® vet, Cervisalva® vet Biocosmetics: Biounda skin care products and body care products, Solarmon sunbathing products Plant extracts Structured water



Biothane Corp.

2500 Broadway, Drawer 5 Camden NJ 08104, US Phone: (856) 541-3500; Fax: (856) 541-3366 Web: www.biothane.com E-mail: [email protected]

KEY PERSONNEL: Robert I. Sax, Ph.D.; President Jay Murphy; Exec. VP Jelte Lanting; Technology Manager Jill Jordan; Technical Services Manager



FACILITIES: 12,500 sq. ft. headquarters 36,000 sq. ft. manufacturing facility


SUBSIDIARIES/DIVISIONS: Biothane Systems International Tanthofdreef 21 P.O. Box 5068 2600 GB Delft, The Netherlands Phone: +31 15 270 0111 Fax: +31 15 256 0927 E-mail: [email protected] Biothane Asia Pacific Ventura Building, 9th floor Suite 903 Jl. R.A. Kartini no 26 Jakarta 12430, Indonesia Phone: +62 (0)21 750 4707 Fax: +62 (0)21 750 4708 E-mail: [email protected] Biothane Systems Ltd. 446 Houldsworth Mill Business Centre Houldsworth Street Reddish, Stockport SK5 6DA, UK Phone: +44 (0) 161 975 6052 / 6051 Fax: +44 (0) 161 975 6053 E-mail: [email protected]

SUBSIDIARY OF: Joseph Oat Holding Inc.

PRODUCTS ON MARKET: Biothane high rate anaerobic wastewater treatment process

Biobed high rate anaerobic wastewater treatment process Biopuric Hydrogen Sulfide biogas scrubber SEAD- Shear Enhanced Anaerobic Digestion process



BioTime Inc.

6121 Hollis Street Emeryville CA 94608, US Phone: (510) 350-2940; Fax: (510) 350-2948 Web: www.biotimeinc.com; E-mail: [email protected]

KEY PERSONNEL: Judith Segall; VP, Technology and member of office of president Hal Sternberg, Ph.D.; VP, R&D and member of office of president Harold Waitz, Ph.D.; VP, Regulatory and member of office of president Jeffrey B. Nickel, Ph.D.; VP, Business Development and Marketing Stephen Seinberg; CFO


HISTORY: Founded in November 1990 Began biotech R&D in 1991

FACILITIES: 5,244 sq. ft. of leased space in Emeryville, Calif.

STOCK-FINANCIAL HISTORY: OTC BB--BTIM Subscription rights offering--283K shares at $20/share (2/97) 3:1 stock split (10/97) Revenue $903.200K (YE 05) compared to $688.377K (YE 04) Net loss <$2.074M> (YE 05) compared to <$3.085M> (YE 04) Loss per share <$0.12/share> (YE 05) compared to <$0.18/share> (YE 04) Average shares outstanding 17.903M (YE 05) compared to 17.454M (YE 04) Total assets $1.959M (YE 05) compared to $1.522M (YE 04)

PRIVATE PLACEMENTS: Raised $1.8M in rights offer of stock and warrants (12/05)

BUSINESS STRATEGY: Develop blood plasma volume expanders, blood replacement solutions for hypothermic surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment and other applications

AGREEMENTS: Name Products Content of Agreement Date Abbott Laboratories

Hextend plasma-expanding product

$40M licensing agreement--Abbott paid $1.4M licensing fee (7/97)

4/97

Barrow Neurological Institute of St. Joseph's Hospital

blood substitute for low-temperature surgery

research agreement

1993

Baylor College of Medicine (Houston, TX)

Hextend artificial blood plasma solution

research agreement

12/95

Bronx Veterans Affairs Medical Center

blood replacement solutions

research agreement

1993

Davies Medical Center--Buncke Clinic

freeze-protecting solutions to preserve full thickness skin grafts

research agreement

1993

McGaw Inc. Hextend production agreement

12/94

Metropolitan Hospital

blood replacement solution

research agreement

1993

Mt. Sinai Medical Center

blood replacement solution

research agreement

1993

Summit Pharmaceuticals International Corp.

Hextend and PentaLyte for the Japanese market

development agreeement

12/05

RESEARCH & DEVELOPMENT: Synthetic solutions that can be used as blood plasma volume expanders,

blood replacement solutions during hypothermic surgery, and organ preservation solutions



PRODUCTS ON MARKET: Hextend® blood substitute solution for low-temperature surgical procedures

PRODUCTS IN DEVELOPMENT: Name Status Pentalyte in Phase II clinicals Hetacool in discovery Hetafreeze in discovery

BioVectra dcl

16 McCarville Street Charlottetown PE--C0A 1H0, Canada Phone: (902) 566-9116; Fax: (902) 628-2045 Toll-free phone: (866) 883-2872 Web: www.biovectra.com E-mail: [email protected]

KEY PERSONNEL: Dr. Rejis Duffy; Chairman Ron Keefe; President Dale Zajicek; COO Gordon Rogers; CFO Dr. Gary R. Reid; VP, R&D Dr. Tibor Breining; Director, R&D Dr. Richard Bethell; Sr. Scientist Patrick Duffy; Purchasing Manager

EMPLOYEES: 200+ employees, 7 Ph.D.s



SUBSIDIARIES/DIVISIONS: Diagnostic Chemicals Limited

BUSINESS STRATEGY: Custom manufacturing Provide bioprocessing reagents and services

Bioxel Pharma Inc.

3075 Chemin des Quatre-Bourgeois, Suite 440 Sainte-Foy G1W 4Y5, Canada Phone: (418) 654-9666; Fax: (418) 654-9655 Web: www.bioxelpharma.com E-mail: [email protected]

KEY PERSONNEL: Andre P. Boulet, Ph.D.; Chairman Pascal Delmas; CEO and President Louis McGuire; VP, Finance and CFO Paul Metz; Exec. VP, Commercial Operations Andre Lalonde; VP, Biomass Louis Estaque, Ph.D.; VP, Production



STOCK-FINANCIAL HISTORY: TSX--BIP Public offering--13.571M common shares at $0.70/share, $9.5M (3/03) Revenue $1.834M (YE 05) compared to $2.352M (YE 04) Net loss <$3.646M> (YE 05) compared to <$4.402M> (YE 04) Loss per share <$0.07/share> (YE 05) compared to <$0.09/share> (YE 04) Average shares outstanding 55.699M (YE 05) compared to 47.396M (YE 04) Total assets $9.587M (YE 05) compared to $13.004M (YE 04)



PRIVATE PLACEMENTS: Raised $4.5M in private placement of 6.429M common shares at $0.70/share (8/03) Raised $3.3M in private placement of 8.041M units at a $0.41/unit (9/04) Raised $4.7M in private placement of 13.817M common shares at $0.34/share (2/06) Raised $2.7M from 7.980M common shares at $0.34/share, received upon the exercise of an equivalent number of warrants (4/06)

SUBSIDIARIES/DIVISIONS: U.S. office: 2429 Ginny Way Lafayette, CO 80026 Phone: (303) 926-9878 Fax: (303) 926-9877

BUSINESS STRATEGY: Manufacture and distribute taxane pharmaceutical ingredients, including paclitaxel, docetaxel, 9-DHB and 10-DAB

RESEARCH & DEVELOPMENT: Portfolio of new products that include docetaxel, paclitaxel via a semi-

synthetic route of production and innovative taxane-based drugs

PRODUCTS ON MARKET: natural paclitaxel 9-DHB 10-DAB

Biozyme Laboratories Ltd.

Unit 6, Gilchrist Thomas Estate, Blaenavon Torfaen NP4 9RL, UK Phone: +44 1495-790678; Fax: +44 1495-791780 Web: www.biozyme.com E-mail: [email protected]

KEY PERSONNEL: John Chesham; Managing Director Ken Murray; Sales and Marketing Manager Jane Howells; Sales and Marketing Coordinator John O'Shea; Quality Manager


HISTORY: Established in December 1971 at Bourne End, Buckinghamshire, as manufacturer of enzymes for diagnostic reagents

FACILITIES: Two manufacturing facilities in the U.K. Sales and marketing office in San diego, Calif. Worldwide network of distributors


SUBSIDIARIES/DIVISIONS: Biozyme Laboratories International Ltd. 9939 Hibert Street, Suite 101 San Diego, CA 92131-1029 Phone: (858) 549-4484; Toll-free phone: (800) 423-8199 Fax: (858) 549-0138 E-mail: [email protected]

SUBSIDIARY OF: Theratase plc

BUSINESS STRATEGY: Develop and manufacture high purity enzymes and proteins

RESEARCH & DEVELOPMENT: Enzymes as active pharmaceutical ingredients, for example, high activity

hyaluronidase for applications other than opthalmology Protein purification specializing in extraction from plant and animal tissues using chromatography and other methods Product assay



PRODUCTS ON MARKET: Highly purified enzymes and related biochemicals for clinical diagnostics, immunodiagnostics, biosensors, diagnostic probe and research applications (includes alkaline phosphatase, peroxidase, glucose oxidase, urease, catalase, aldehyde dehydrogenase, hexokinase, phospho-enolpyruvate carboxylase, glycerol-3-phosphate dehydrogenase, ascorbate oxidase, cholesterol esterase, xanthine oxidase, alpha-glucosidase, elastase, enterokinase, deoxyribonuclease and ribonuclease)

Boojum Research Ltd.

139 Amelia Street Toronto M4X 1E6, Canada Phone: (416) 861-1086; Fax: (416) 861-0634 Web: www.boojumresearch.com; E-mail: [email protected]

KEY PERSONNEL: Margarete Kalin; President

EMPLOYEES: 2 employees, 4 specialty contractors


FACILITIES: 850 sq. ft. headquarters


BUSINESS STRATEGY: Seek marketing, investment and joint venture opportunities

RESEARCH & DEVELOPMENT: Wetland microbiology and ecosystem recovery

Bioremediation of mining sites Environmental mining

PRODUCTS ON MARKET: Chara process Microbiological AMD treatment Biological polishing Ecological engineering ARUM (acid reduction using microbiology) process Project management for clean-up of mine sites

Boston Life Sciences Inc.

85 Main Street Hopkinton MA 01748, US Phone: (508) 497-2360; Fax: (508) 497-9964 Web: www.bostonlifesciences.com E-mail: [email protected]

KEY PERSONNEL: Peter G. Savas; Chairman and CEO Mark J. Pykett, Ph.D.; President and COO Kenneth L. Rice Jr.; Exec. VP, Finance and CFO Mark R. Hurtt, M.D.; CMO Irene Gonzalez, Ph.D.; Sr. VP, Protein Development Noel J. Cusack, Ph.D.; Sr. VP, Preclinical Development Richard Thorn, Ph.D.; Sr. VP, Program Operations Sharon Correia; Director, Corporate Communications and Investor Relations


HISTORY: Founded in 1992 by the Castle Group and Dr. Marc Lanser Completed reverse merger with Greenwich Pharmaceuticals Inc. to become a public company (6/95) Member--Biotechnology Industry Organization Member--Massachusetts Biotechnology Council



FACILITIES: 5,900 sq. ft. office facility in Hopkinton, Mass. 3,300 sq. ft. laboratory facility in Baltimore, Md. 2,500 sq. ft. office facility in Woburn, Mass.

STOCK-FINANCIAL HISTORY: NASDAQ--BLSI One-for-five reverse stock split (2/05) Net loss <$11.501M> (YE 05) compared to <$11.251M> (YE 04) Loss per share <$1.03/share> (YE 05) compared to<$1.73/share> (YE 04) Average shares outstanding 11.806M (YE 05) compared to 6.795M (YE 04) Total assets $10.515M (YE05) compared to $2.545M (YE 04)

PRIVATE PLACEMENTS: Raised $2.2M through issuance of 7% senior bridge notes (6/95) (notes converted into 157K shares of common stock in 1st quarter 1996) Raised $1.8M in private placement of 320K shares (11/95) Raised $24M in private placement of 240K shares of Series A preferred stock and warrants to purchase 600K shares at $6.70/share (1/96) Raised $5M in private placement of 500K shares (7/96) Raised $8M in private placement of convertible preferred stock and warrants (12/03) Raised $5M in private placement of 2M shares of common stock at $2.50/share (3/05) Raised $12.8M in private placement of 6M shares of common stock at $2.13/share (8/05)

BUSINESS STRATEGY: Research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders such as Parkinson’s disease, essential tremor, ADHD, stroke, traumatic brain injury, spinal cord injury and ocular indications

AGREEMENTS: Name Products Content of Agreement Date Children’s Hospital Boston

key factors that inhbit the inhibitors of axon regeneration

exclusive, worldwide licensing and sponsored research agreements

5/06

Children’s Hospital Boston

key factors that promote axon regeneration

exclusive, worldwide licensing and sponsored research agreements, amended 5/06

12/98

Harvard University Altropane molecular imaging agent for ADHD

exclusive, worldwide licensing, amended 5/04

3/00

Harvard University Altropane molecular imaging agent for PD

exclusive, worldwide licensing agreement, amended 5/04

12/93

Harvard University BCLx-gamma gene that controls apoptosis

licensing agreement

3/98

Zeneca Pharmaceuticals

small molecule inhibitors of MHC Class II gene transcription factors to treat autoimmune diseases

exclusive R&D agreement

6/95

RESEARCH & DEVELOPMENT: 1) Molecular imaging program focused on molecular imaging agents used

as an aid in diagnosing Parkinson's disease and ADHD with SPECT, PET and MRI 2) Dopamine transport blocker program as a therapeutic and in potential disease modification for Parkinson's disease 3) Axon regeneration program focused on treatments for stroke, TBI, SCI and ocular diseases



BRAIN (Biotechnology Research and Information Network AG)

Darmstadter Strasse 34-36 Zwingenberg 64673, Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 Web: [email protected] E-mail: [email protected]

KEY PERSONNEL: Dr. Holger Zinke; Chairman and CEO Dr. Jurgen Eck; CSO Dr. U. Dechert; Sr. Scientist Dr. M. Krohn; Unit Head Dr. M. Langer; Corporate Development Dr. P. Lorenz; Unit Head Dr. G. Meurer; Unit Head


HISTORY: Founded in 1993 Began biotech R&D in 1994 Spun off VISCUM AG (2000)

FACILITIES: 1,074 sq. ft. headquarters 537 sq. ft. R&D facilities


BUSINESS STRATEGY: Discover and develop novel bioactives, biocatalysts and enzymes

AGREEMENTS: Name Products Content of Agreement Date BASF AG new oxidoreductases R&D cooperation 2005 Ciba AG microorganisms for

production of speciality chemicals

R&D cooperation 2005

Degussa AG new ADH for production of chiral alkohols


Genencor International

BRAIN's metagenome to develop enzyme platform

R&D agreement 2004

Henkel KGaA new detergent enzymes R&D cooperation 2005 Nutrinova GmbH nutraceuticals development

agreement 2004

Sandoz GmbH enzymes for biotech

prod of ß-lactam antibiotics

R&D agreement 2004

Schering AG design of micro-organisms for production of steroid drugs


Sudzucker AG functional carbohyrates R&D cooperation 2005

RESEARCH & DEVELOPMENT: Expression systems Secondary metabolites Microbial strain optimisation Bioactive compounds Industrial enzymes Technical enzymes and biocatalysts Cellular based assays



Bunge Ltd.

50 Main Street White Plains NY 10606, US Phone: (914) 684-2800

KEY PERSONNEL: Alberto Weisser; Chairman and CEO Andrew J. Burke; Managing Director, New Business, Bunge Ltd. Archibald Gwathmey; Managing Director, Agribusiness Division, Bunge Ltd., and CEO, Bunge Global Markets Inc. Joao Fernando Kfouri; Managing Director, Food Products Division, Bunge Ltd. Flavio Sa Carvalho; Chief Personnel Officer William M. Wells; CFO Mario A. Barbosa Neto; CEO, Bunge Fertilizantes SA Jean Louis Gourbin; CEO, Bunge Europe Carl L. Hausmann; CEO, Bunge North America Inc. Raul Padilla; Bunge Argentina SA Sergio Roberto Waldrich; Bunge Alimentos SA


HISTORY: Founded in 1818 as a grain trading company in Amsterdam, the Netherlands In the second half of the 1800s, expanded grain operations in Europe and entered the South American agricultural commodities market Entered the South American food products industry (1888) Started U.S. operations (1923) Entered the fertilizer industry in Brazil (1938)

FACILITIES: More than 500 facilities in 32 countries: Agribusiness: 275 grain storage facilities, approximately 50 oilseed processing plants and approximately 25 international marketing offices Fertilizer: Four phosphate mines in Brazil, 35 processing plants in Brazil Food products operations: Approximately 50 refining and bottling facilities and 20 other facilities

STOCK-FINANCIAL HISTORY: NYSE--BG IPO--17.6M shares at $16/share (8/01) Net sales $24.275M (YE 05) compared to $25.168M (YE 04) Net income $530M (YE 05) compared to $469M (YE 04) Earnings per share $4.73/share (YE 05) compared to $4.42/share (YE 04) Average shares outstanding 112,132b (YE 05) compared to 106,016b (YE 04) Total assets $11.446M (YE 05) compared to $10.907M (YE 04)

SUBSIDIARIES/DIVISIONS: Three divisions: Agribusiness, fertilizer and food products, which include four reporting segments: Agribusiness, fertilizer, edible oil products and milling products Subsidiaries: U.S.A.: AGRI-Bunge LLC, Bunge North America (East) LLC, Bunge North America Foundation, Sabina Bunge LLC, Bunge North America Inc., Bunge Milling Inc., The Crete Mills Inc., Lauhoff Finance Corp., Bunge Oils Inc., Bunge North America (OPD West) Inc., Bunge Mexico Holdings Inc., Bunge North America Capital Inc., Bunge Mextrade LLC, Delphos Terminal Co. Inc., CSY Holdings Inc., CSY Agri-Finance Inc., Universal Financial Services LP, Batavia Leasing Co., Bunge Chicago Inc., International Produce Inc., Bunge NA Holdings Inc., Bunge Global Markets Inc., Bunge Finance North America Inc., Bunge Management Services Inc., Bunge Funding Inc., Bunge Asset Funding Corp., Bunge Ltd. Finance Corp., Solae Holdings LLC, Bunge Canada Investments Inc., DDO Processing LLC Canada: Bunge of Canada Ltd., Bunge Canada, Bunge Canada Holdings I ULC, Bunge Canada Holdings II ULC, CF Oils Investments Inc., Leblanc & Lafrance Inc., Neptune Bulk Terminals (Canada) Ltd.



Mexico: Controladora Bunge SA de CV, Agroproductos Bunge SA de CV, Harinera La Espiga SA de CV, Inmobiliaria A Gil SA, Inmobiliaria Gilsa SA, Servicios Bunge SA de CV, Molinos Bunge SA de CV, Bunge Comercial SA de CV Bermuda: Ceval Holdings Ltd., Brunello Ltd., Greenleaf Ltd., Bunge Finance Ltd., Serrana Holdings Ltd., Bunge Global Markets Ltd., Fertimport International Ltd. Barbados: Bunge Export Sales (Barbados) Corp. Cayman Islands: Bunge Fertilizantes International Ltd., Santista International Ltd., Santista Export Ltd., Ceval Export Securitization Ltd., Ceval International Ltd., Bunge Trade Ltd. Argentina: Terminal Bahia Blanca SA, Bunge Argentina SA, Terminal 6 SA, Terminal 6 Industrial SA Guide SA, Fertimport SA, Bunge Inversiones SA Brazil: Fosbrasil SA, Serrana Logistica Ltda., Amoniasul Servicos de Refrigeracao Industrial Ltda., Bunge Alimentos SA, Bunge Fertilizantes SA, Fertilizantes Ouro Verde Ltda., Fertilizantes Fosfatados SA, Ultrafertil SA, Fertifos Administracao e Participacoes SA, Macra Administracao e Servicos Ltda., Agrisat Solucos Integradas Ltda., IFC Industria de Fertilizantes de Cubatao SA, Bunge Armazens Gerais Ltda., Ceval Centro Oeste SA, Terminal de Graneis do Guaruja SA, Terminal Maritimo do Guaruja SA (TERMAG), IFC - Industria de Fosfatados Catarinense Ltda., Cereol do Brasil Ltda., MBB Comercio e Servicos Ltda., Serra do Lopo Empreendimentos e Participacoes SA, Fertimport SA, Moinho Jauense Industria e Comercio de Alimentos Ltda., Eco Invest Carbon PP Ltda. Uruguay: Bunge Uruguay SA, Dinelsur Corp. SA, Agritrade SA Paraguay: Bunge Paraguay SA Peru: Bunge Peru SAC Venezuela: Almacen Terminal Santana CA Dominican Republic: Bunge Caribe SA Australia: Bunge Global Markets Australia Pty. Ltd. Southeast Asia: Bunge Agribusiness Singapore Pte. Ltd., PT. Bunge Agribusiness Indonesia, Bunge Agribusiness (M) Sdn. Bhd., Bunge (Thailand) Ltd., Bunge Agribusiness Philippines Inc., Grains and Industrial Products Trading Pte. Ltd. China: Bunge International Trading (Shanghai) Co. Ltd. Mauritius: Bunge Mauritius Ltd. Bunge Mauritius Holdings Ltd., International Produce Ltd. India: Bunge India Pvt. Ltd. U.K.: Bunge Corp. Ltd., Bunge UK Ltd. Spain: Bunge Iberica SA, Estacion de Descarga y Carga SA (Esdecasa), Ergransa SA, Bunge Iberica Investment SRL, Moyresa Girasol SL, Biodiesel Bilbao SL France: Bunge France SAS, Bunge Holdings France SAS, Bunge SAS, Novaol France SAS, Saipol SAS, Diester Industries International SAS



Holland: Koninklijke Bunge BV, Bunge Cooperatief UA, Bunge Europe Finance BV, Bunge Brasil Holdings BV, Bunge Finance Europe BV, Bunge Alimentos Holding BV Switzerland: Bunge SA, Oleina SA, Ecoinvest Carbon SA Germany: Bunge Deutschland GmbH, Bunge Handelsgesellshaft mbH Italy: Bunge Italia SpA, Escercizio Raccordi Ferroviari SpA Turkey: Bunge Gida Ticaret AS Cyprus: Bunge Cyprus Ltd., Eastern Agro Investment Ltd., Brea Commodities Ltd. Hungary: Bunge ZRT, Cereol Befektetesi Kft. Portugal: Bunge Iberica Portugal SA, Gardone-Consultoria e Servico, Sociedade Unipessoal Lda. Luxembourg: Bunge Europe SA Austria: Bunge Austria GmbH Latvia: Dan Store LSEZ SIA Ukraine: Suntrade SE, Fisakiyske Khp, DOEP, CJSC Dolynsky Elevator, LLC Oleina Distributors, LLC Lan Elevator, Black Sea Industries Ltd. Romania: SC Unirea SA, Muntenia SA, Interoil SA, Bunge Romania Srl Poland: ZT Kruszwica SA, EWICO S.p.z.o.o., Polska Trade Services S.p.z.o.o., ZPT W Warszawie SA, Olvit Pro S.p.z.o.o. Belgium: Afrique Initiatives Russia: LLC Bunge CIS, LLC Prichalny Complex, Rostov Grain Terminal LLC, LLC Elevatorniy Complex, LLC Elevator, LLC Grain CO Dara, OJS Kholmsky Bulgaria: Kaliakra AD

INVESTMENTS: The Solae Co.--joint venture with DuPont Saipol SAS--joint venture with Sofiproteol Joint venture with Aceitera General Deheza SA for the operation of the Terminal 6 port facility in Argentina and adjacent crushing facility AGRI-Bunge LLC--joint venture with AGRI Industries Fosbrasil SA--joint venture with Astaris Brasil Ltda. and Societe Chimique Prayon Rupel SA EWICO S.p.z.o.o.--joint venture in Poland Harinera La Espiga SA de CV--joint venture with Grupo Neva SA de CV and Cerrollera SA de CV Terminal de Graneis do Guaruja SA--joint venture with Ferronorte SA Diester Industries International SAS--joint venture with Diester Industrie

BUSINESS STRATEGY: Agribusiness division: Purchase, process, store and sell grains and oilseeds Fertilizer: Involved in every stage of the fertilizer business, from mining raw materials to the selling fertilizer products Food products: Two business segments--edible oil products and milling products. Businesses in these segments produce and sell food products such as edible oils, shortenings, margarine, mayonnaise and milled products such as wheat flours and corn products



AGREEMENTS: Name Products Content of Agreement Date DuPont joint venture for the

global production and distribution of specialty food ingredients (starting with soy proteins and lecithins), joint development and commercialization of soybeans with improved quality traits, and development of a broader offering of services and products to farmers

alliance and agreement

1/03

Procter & Gamble and Peter Cremer North America

production and marketing of cholesterol-reducing phytosterol ingredients for pharmaceuticals and foods

alliance 11/04

CABI

Bakeham Lane Egham TW20 9TY, UK Phone: +44 (0)1491-829-080; Fax: +44 (0)1491-829-100 Web: www.cabi.org E-mail: [email protected]

KEY PERSONNEL: Dr. Trevor Nicholls; CEO

EMPLOYEES: 350 employees (220 in the U.K.)

HISTORY: CABI was founded in 1920 Formerly the Commonwealth Mycological Institute, International Mycological Institute (IMI), International Institutes of Entomology (IIE), Parasitology (IIP) and Biological Control (IIBC)

FACILITIES: 4,200 sq. m. in six buildings in the U.K.

STOCK-FINANCIAL HISTORY: Intergovernmental nonprofit enterprise

FINANCIAL INFORMATION: Nonprofit. Financed through sales of services and consultancies to governments, foundations and the corporate sector

BUSINESS STRATEGY: CABI is a leading provider of authoritative and unbiased scientific information in agriculture and the environment. It conducts research into agricultural and environmental issues, aiming to improve peoples’ lives in direct and indirect ways. The organization also publish books, journals and scientific research aiming to further science and its application to real life.


Academia Sinica Institute of Microbiology, Systematic Mycology & Lichenology Laboratory (Beijing, China)

mycological services, publications and cultures

collaborative agreement--research, training courses, exchange of specimens and cultures, and production and sale of books

2/88



Biosystematics Research Centre Agriculture Canada (Ottawa, Canada)

mycological services, publications and cultures

collaborative agreement--identification of fungi, research, consultancy and project work in biosystematics

5/86

Fundaçao Tropical de Pesquisas e Tecnologia (FTPT) (Campinas, Brazil)

mycological services, publications, cultures and training on databases

collaborative agreement--exchange of specimens and cultures, training courses and staff exchanges

8/90

Institute of Genetics, Uzbekistan

research and cultures collaborative agreement

12/96

N. G. Kholodny Institute of Botany, Ukrainian Academy of Sciences

mycological specimens and cultures, publications, geographical data and training

collaborative agreement--exchange of specimens and cultures, scientific data, training courses and staff exchanges

11/91

ODNRI (Overseas Development & Natural Resources Institute)

consulting and advisory services in plant pathology

staff support at IMI 1990

M. S. Swaminathan Research Foundation India

research and training, especially in bioindicators and biomonitors

collaborative agreement--ecosystem research, training courses in applied mycology and exchange of scientific data

11/91

University of Al-Azhar (Egypt)

research and training collaborative agreement

3/93

Universidade Federal do Rio Grande do Sul (UFRGS) Brasil

research and training collaborative agreement

5/94

RESEARCH & DEVELOPMENT: Systematic and applied bioscience

PRODUCTS ON MARKET: Identification services Information services Contract research Consultancy Publications Fungal and bacterial cultures Training courses



Calzyme Laboratories Inc.

3443 Miguelito Court San Luis Obispo CA 93401, US Phone: (805) 541-5754; Fax: (805) 541-8301 Toll-free phone: (800) 523-9127 Web: www.calzyme.com; E-mail: [email protected]

KEY PERSONNEL: Dr. Muzaffar Iqbal; Chairman, President and CEO Umer Iqbal; Director, R&D Usman Iqbal; Purchasing Manager



FACILITIES: Production and research facility on more than 300 acres in Tulelake, Calif. European sales and research office in Croydon, England


SUBSIDIARIES/DIVISIONS: Calzyme Laboratories Ltd. 102-104 Park Lane Croydon, Surrey CRO 1JB, UK

BUSINESS STRATEGY: Custom manufacture enzymes and related biochemicals

PRODUCTS ON MARKET: Enzymes

Proteins Coenzymes Substrates Related biochemicals

Cambio Ltd.

The Irwin Centre, Scotland Road, Dry Drayton Cambridge CB3 8AR, UK Phone: +44 (0)1954-210 200 Fax: +44 (0)1954-210 300 Web: www.cambio.co.uk; E-mail: [email protected]

KEY PERSONNEL: Peter Dean; Managing Director Bethy Booth.; Development Manager Shani Jamieson; Export Manager Margaret Fox; Office Manager Paula Cooper; Support Ian Rushton; Financial Manager


HISTORY: Founded in 1986 as a division of Cambridge Life Sciences Acquired by management buyout in 1987 IS09002 accreditation (1995)

FACILITIES: Access to R&D laboratories and several production facilities


AGREEMENTS: Name Products Content of Agreement Date Biontex entire range of products distribution

agreement

Biotech Support Group

entire range of products distribution agreement

2001

BioVentures entire range of products distribution agreement

1992



Epicentre Technologies Corp. (now Epicentre Biotechnologies Corp.)


1990

Gene Bridges entire range of products distribution agreement

2004

Glen Research Corp.


1989

Minerva entire range of products distribution agreement

2002

MoBio entire range of products distribution agreement

1997

Open Biosystems entire range of products distribution agreement

2003

Princeton Separations


2003

University of Cambridge

STAR*FISH chromosome paints


1992

RESEARCH & DEVELOPMENT: Developing novel DNA amplification and processing systems

Contract antibody production

PRODUCTS ON MARKET: Contract RNA and DNA production and technology transfer Products for DNA, RNA synthesis More than 3,000 antibodies Most restriction enzymes Most modification enzymes Most polymerases (DNA and RNA) Wide range of Chromosome Painting kits and DNA probes for various species Superior nucleic acid purification kits from MoBio Mycoplasma detection and elimination Extract protein by precipitation leaving DNA and RNA unaffected High quality tools required to unlock the functions of human genes and proteins and their relationships to disease development Gene regulation enzymes Plasmid extraction kits

Cambrex Corp.

One Meadowlands Plaza East Rutherford NJ 07073, US Phone: (201) 804-3000; Fax: (201) 804-9852 Web: www.cambrex.com

KEY PERSONNEL: James A. Mack; Chairman, CEO and President Luke M. Beshar; Exec. VP and CFO Paulo Russolo; President, Cambrex Profarmaco Shawn Cavanagh; Sr. VP and GM, Bioproducts Thomas N. Bird; VP, Business Development Dan Marshak, Ph.D.; VP and CTO, Biotechnology Ron D. Carroll, Ph.D.; VP and CTO, Pharmaceutical Technology


HISTORY: Founded in 1981 Began biotech R&D in 1997 Acquired BioWhittaker Inc. (1997) Acquired Bioproducts Division of FMC (1999) Acquired LumiTech (2000) Acquired Cambrex Biosciences (2001)



Cambrex France SARL acquired Genolife SA (10/04) Cambrex Bio Science Walkersville Inc. to acquire Cutanogen Corp. (as of 2/06)

STOCK-FINANCIAL HISTORY: NYSE--CBM Revenue $455.097M (YE 05) compared to $443.657M (YE 04) Net income $12.890M (YE 05) compared to $19.987M (YE 04) Loss per share $0.49/share (YE 05) compared to $0.77/share (YE 04) Average shares outstanding 26.456M (YE 05) compared to 26.094M (YE 04)

SUBSIDIARIES/DIVISIONS: Cambrex Karlskoga AB Cambrex Charles City Inc. Cambrex North Brunswick Inc. Cambrex Landen NV Cambrex Cork Ltd. Cambrex Milan S.r.l. Cambrex France SARL Cambrex BioScience Baltimore Inc. Cambrex BioScience Hopkinton Inc. Cambrex BioScience Verviers s.p.r.l. Cambrex BioScience Walkersville Inc. Cambrex BioScience Wolkingham Ltd. Cambrex BioScience Nottingham Ltd. Cambrex BioScience Rockland Inc. Cambrex BioScience Copenhagen AB

INVESTMENTS: Osiris--$5M Synthon Chiragenics--$3M

BUSINESS STRATEGY: Maintain a position as a global, diversified life sciences company dedicated to essential products and services to accelerate drug discovery and commercialization for our pharmaceutical, biopharmaceutical, biotechnology and research customers

AGREEMENTS: Name Products Content of Agreement Date Ortec International Inc.

Orcel marketing and distribution agreement

10/04

PRODUCTS ON MARKET: ApoGlow™

BioWhittaker® endotoxin detection products (LAL) BioWhittaker cell culture media, sera, buffers, reagents and antibiotics Clonetics® human cells and media Poietics™ human stem cells and media GelBond® film GelStar® nucleic acid gel stain I.D.NA® agarose InCert® agarose IsoGel® IEF plates Latitude® precast agarose gels Long Ranger®--DNA sequencing MetaPhor® agarose--DNA separation MDE™ gel solutions--mutation detection NuSieve® agarose--PCR separation PAGEr™ precast acrylamide gels ProSieve® protein separation Reliant® precast agarose gels SeaPlaque® agarose--DNA separation SeaKem® agarose--DNA separation SeaPrep® agarose SYBR® gel stains--nucleic acid detection SYPRO® gel stain--protein separation ViaLight™ Contract development and manufacturing services for small molecule APIs, biologics and cell therapies



Canadian Forest Service

Natural Resources Canada, 580 Booth Street Ottawa KIA OE4, Canada Phone: (613) 947-7341; Fax: (613) 947-7397 Web: www.nrcan.gc.ca/cfs-scf E-mail: [email protected]/cfs-scf

KEY PERSONNEL: Brian Emmett; Assistant Deputy Minister Geoff Munro; Director, General Sciences



FACILITIES: Research centers in Victoria, BC; Edmonton, Alberta; Sault Ste. Marie, Ontario; Sainte-Foy, Quebec; and Fredericton, New Brunswick


SUBSIDIARY OF: Natural Resources Canada

BUSINESS STRATEGY: Mission:

To promote the sustainable development of Canada's forests and competitiveness of the Canadian forest sector for the well-being of present and future generations of Canadians

RESEARCH & DEVELOPMENT: Tree biotechnology and advanced genetics

Pest management methods Environmental safety research

PRODUCTS ON MARKET: Biopesticides Tissue cultures Diagnostic kits

PRODUCTS IN DEVELOPMENT: Name Status Biopesticides in development Gene isolation in development Genetic markers in development Tissue cultures and tissue culture protocols in development Diagnostic tools in development

Canadian Seed Coaters

P.O. Box 1748 North Battleford , Canada Phone: (306) 445-1077; Fax: (306) 446-0664 Web: www.seedcoaters.com E-mail: [email protected]

KEY PERSONNEL: Kelly Ray; General Manager Lance Tokle; Assistant Manager

EMPLOYEES: 35 employees (10 full-time/25 seasonal)


FACILITIES: 50,000 sq. ft. building


SUBSIDIARY OF: SeedVentures Inc.

BUSINESS STRATEGY: Provide first-class coating technology and superior service



PRODUCTS ON MARKET: Coatings:

Chemseal® (talc based coating for canola) Chemgard (seed treatment with precise chemical application and dispersion) Rhizoseal® and Rhizoseal® Premium (talc based coatings for alfalfa and other legumes) Prill-On® (lime/phosphate coat for legumes and turf grasses) Nutriprill® (lime/phosphate coat for forage and native grasses)


Chemseal Plus in field trials

Cantest Ltd.

Burnaby Life Sciences Centre, 4606 Canada Way Burnaby V5G 1K5, Canada Phone: (604) 734-7276; Fax: (604) 731-2386 Toll-free phone: (800) 665-8566 Web: www.cantest.com; E-mail: [email protected]

KEY PERSONNEL: Donald B. Rix, M.D.; Chairman Don Enns; CEO and President Barbara Morrissey; Director, Forensic Equine Drug Testing Services Simon Mortimer-Lamb; Director, Finance Adrien Musuku, Ph.D.; Director, Research Steve Timuss; Director, Business Development David Gray, Ph.D.; Director, BioPharma Services


HISTORY: Founded in 1969 Member of the CANAM Laboratories Group Acquired JB Laboratories Ltd. (6/04) Acquired SOILCON Laboratories Ltd. (4/04) Acquired Elemental Research Inc. (4/06) Acquired Vizon SciTec Inc. (8/06)


SUBSIDIARIES/DIVISIONS: Offices in British Columbia, Manitoba and Ontario, and affiliates in Canada, the U.S. and southeast Asia

BUSINESS STRATEGY: Operates as a full service laboratory that provides professional analysis and consultation for companies, governments and individuals in environmental, biotechnology, pharmaceutical, food safety and industrial hygiene related fields

AGREEMENTS: Name Products Content of Agreement Date Cantest Ltd. has partnerships with Entech, Consolab and Prime Trials

RESEARCH & DEVELOPMENT: Analytical services

PRODUCTS ON MARKET: BioPharma services: GLP bioanalysis (including clinical bioanalysis and toxicokinetic bioanalysis) Drug discovery support Method development and validation Pharmacokinetic and bioequivalence studies Environmental services: Soil and water contamination Drinking water analysis



Mobile/Field services Mold speciation and identification Food safety services: Nutrition labeling Food microbiology Pestices residues and hormones Nutraceuticals Industrial hygiene services: Air quality testing Bulk insulation identification Compressed breathing air testing Medical gas inspection and certification Mold speciation and identification Equipment rentals Forensic equine drug testing services: Racetrack drug testing Horseshow drug testing Pre-purchase screening Research and development

Cardinal Health - Middleton

8137 Forsythia Street, PO Box 620160 Middleton WI 53562, US Phone: (608) 824-9920; Fax: (608) 824-9930 Web: www.gala.com E-mail: [email protected]

KEY PERSONNEL: Paul Weiss, Ph.D.; President and CEO Boh Branflick; CFO Mike Jenkins; Director, Commercial Operations

EMPLOYEES: 40+ employees, 16 Ph.D.s

HISTORY: Founded and began biotech R&D in May 1996 Changed name from Gala Biotech



SUBSIDIARY OF: Cardinal Health

PRINCIPAL INVESTORS: Cardinal Health

BUSINESS STRATEGY: To partner with clients with protein expression needs

AGREEMENTS: Name Products Content of Agreement Date Cambridge Antibody Technology

cell line engineering collaboration

5/05

RESEARCH & DEVELOPMENT: Post-genomic protein expression Novel gene product expression High-throughtput gene product screening Manufacture scale-in mammalian cells Mammalian cell line production and cGMP manufacture

PRODUCTS IN DEVELOPMENT: Name Status Several development-stage products various stages



Cargill Inc.

P.O. Box 9300 Minneapolis MN 55440-9300, US Phone: (952) 742-7575 Web: www.cargill.com; E-mail: [email protected]

KEY PERSONNEL: Warren R. Staley; Chairman and CEO Gregory R. Page; President and COO Robert L. Lumpkins; Vice Chairman Guillaume Bastiaens; Vice Chairman William Veazey; Sr. VP, CFO David M. Larson; Exec. VP Robbin S. Johnson; Sr. VP, Director of Corporate Affairs David W. Rogers; Sr. VP Ronald L. Christenson; Corp. VP and CTO


HISTORY: Founded in 1865 as a single grain elevator. Now operates more than 1,000 facilities in 61 countries. Acquired ingredients operations operations of Degussa AG (2005) Member--Biotechnology Industry Organization

STOCK-FINANCIAL HISTORY: Privately held Net earnings $2.103b (YE 05) compared to $1.331b (YE 04) Total assets $48.260b (YE 05) compared to $49.243b (YE 04)

SUBSIDIARIES/DIVISIONS: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada, Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed & Processing (joint venture) Food ingredients and applications: Food Ingredients North America (Cargill Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils, Cargill Sweeteners North America, Horizon Milling (joint venture with CHS Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia, Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur, Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America, Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food & Pharma Specialties North America, Cargill Health & Food Technologies (HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley Europe, Sun Valley Foods Canada, Sun Valley Thailand) Industrial: Agricultural Feedstocks (Cargill Dow (joint venture), Cargill Industrial Oils & Lubricants), Steel, Fertilizer (Cargill Fertilizantes Brazil, Cargill Phosphate Production, Saskferco (joint venture)), Salt (Cargill Salt, Cargill Deicing Technology) Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply Chain, Cargill Sugar Risk Management and Financial: Black River Asset Management LLC, Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum, Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade & Structured Finance, Cargill Value Investment, Cargill Ventures



INVESTMENTS: Joint venture with Monsanto Co. to use biotechnology to improve feed for pigs, cattle, poultry and fish (5/98)

BUSINESS STRATEGY: Provide food, agricultural and risk management products and services

AGREEMENTS: Name Products Content of Agreement Date Bayer Crop Science

alliance to produce high stability specialty canola

1/05

Kansas Polymer Research Center (Pittsburg State University, KS)

soy-based polyols for the urethane industry

joint research agreement

8/03

Metamorphix exclusive agreement with Caprock Cattle Feeders and Excel Corp., both part of Cargill, to develop genomic selection tools for consistency and tenderness

11/02

Monsanto Co. Vistive low-linolenic soybeans and marketer of Vistive oil

participating processor of VISTIVE™ soybeans and marketer of VISTIVE oil

10/05

Mycogen Corp. (now Mycogen Seeds)

NatureGard hybrid seed corn with Bt-based insect resistance

distribution agreement under Mycogen™ brand

9/95

Zeneca Mogen fungal resistant canola and sunflower varieties, Binary Vector System for genetic transformation of crop plants


3/96

RESEARCH & DEVELOPMENT: Fermentation systems and enzyme applications

Biobased urethane polyols

PRODUCTS ON MARKET: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada, Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed & Processing (joint venture) Food ingredients and applications: Food Ingredients North America (Cargill Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils, Cargill Sweeteners North America, Horizon Milling (joint venture with CHS Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia, Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur, Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America, Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food & Pharma Specialties North America, Cargill Health & Food Technologies (HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley Europe, Sun Valley Foods Canada, Sun Valley Thailand)



Industrial: Agricultural Feedstocks, NaturedWorks, LLC, Cargill Industrial Oils & Lubricants (Cargill Industrial Bioproducts), Steel, Fertilizer (Cargill Fertilizantes Brazil, Cargill Phosphate Production, Saskferco (joint venture), Salt (Cargill Salt, Cargill Deicing Technology) Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply Chain, Cargill Sugar Risk Management and Financial: Black River Asset Management LLC, Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum, Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade & Structured Finance, Cargill Value Investment, Cargill Ventures

Ceapro Inc.

Suite# 1008 RTF, University of Alberta, 8308 - 114 Street Edmonton T6G 2E1, Canada Phone: (780) 421-4555; Fax: (780) 421-1320 Web: www.ceapro.com E-mail: [email protected]

KEY PERSONNEL: Edward Taylor; Chairman Dr. Mark Redmond; President and CEO Laurie Lanuke; Manager, Customer Service and Logistics Diana Shaw, Ph.D.; Manager, Business Development Sarah Lord; Ph.D.; Manager, Clinical Affairs Shawn McMillan; VP, Finance and CFO David Fielder; VP, Scientific Affairs


HISTORY: Founded and began biotech R&D in 1991 Acquired Minera Animal Health (1996) Amalgamated Vexco Healthcare (12/96)

FACILITIES: 2,500 sq. ft. headquarters 1,000 sq. ft. R&D facilities

STOCK-FINANCIAL HISTORY: TSX Venture Stock Exchange--CZO IPO--C$10M (1/97) Revenue $2.7M (YE 05) compared to $2.420M (YE 04) Net <loss> income <$57K> (YE 05) compared to <$398K> (YE 04) Earnings <loss> per share <$0.00>/share (YE 05) compared to <$0.01/share> (YE 04)

PRIVATE PLACEMENTS: Raised $16M in private placement (9/96) Raised $4M in private placement (1/97) Raised $2.1M in private placement (10/98) Raised $3M in private placement (12/99) Raised $204.8K from private placement of 683K units at $0.30/unit (3/05) Raised $1.3M in financing (12/05)

BUSINESS STRATEGY: Extract natural ingredients from cereal crops and formulate into products for cosmetics and human or veterinary pharmaceutical industries Use strategic alliances for distribution and marketing


Alberta Wheat Pool

oats strategic alliance--Ceapro has exclusive 10-year supply agreement with AWP, AWP to make $4M equity investment with option to invest $2M in next year

2/97



Aventix Veterinary (Canada)

dermal for veterinary applications

8/04

Canderm Pharma Inc.

Lipsorex exclusive licensing agreement--Ceapro to get royalties on sales

6/98

Daisen Sangyo Ltd. (Japan)


marketing agreement

9/96

McCarthy & Sons (Canada)


marketing agreement

12/99

Nutrinova oat extracts for food industry

letter of intent regarding marketing agreement

12/99

Pharmavet (UK) dermal for veterinary applications

10/05

Veterinary Marketing Network (Australia/New Zealand)


marketing agreement

12/99

RESEARCH & DEVELOPMENT: Functional foods and nutraceutidals

Dermal and wound care Diabetes tests and medical foods Immune system stimulants Therapeutic shampoos CeaProve® kit for pets

PRODUCTS ON MARKET: ACTIVE INGREDIENTS: Beta glucan, colloidal oat extract, oat oil VETERINARY THERAPEUTICS: Oat Shampoo, ear cleanser, dermal complex AccuScreen™ - tool for identification of type II diabetes and pre-diabetes

PRODUCTS IN DEVELOPMENT: Name Status Immune stimulant (veterinary) in preclinicals Topical non-steroidal anti-inflammatory in preclinicals Hot spot treatment in Phase I clinicals (veterinary)

Celsis International plc

Suite 15, Lyndon House, Kings Court Newmarket CB8 7SG, UK Phone: +44 (0) 1638 600 151; Fax: +44 (0) 1638 600 160 Web: www.celsis.com; E-mail: [email protected]

KEY PERSONNEL: Jack Rowell; Chairman Jay Lecoque; CEO Christian Madrolle; Finance Director and Company Secretary (U.K.)


HISTORY: Founded in 1992 Celsis floated on LSE in June 1993 Celsis acquired Lumac in September 1996 Acquired SAI (contract testing laboratory in St. Louis, MO) for £4.4M (10/97) Acquired In Vitro Technologies Inc. (IVT) (8/06)

STOCK-FINANCIAL HISTORY: London Stock Exchange (LSE)--CEL IPO--£90M (9/96) Turnover $30.4M (YE 05) compared to $27.595M (YE 04) Profit $5.75M (YE 05) compared to $4.83M (YE 04) Earnings per share 6.83cents/share (YE 05) compared 6.04cents/share (YE 04) Net assets $33.468M (YE 05) compared to $27.209M (YE 04)



PRINCIPAL INVESTORS: Barclays Global Investors Barclays Personal Investment Management Cavendish Asset Management Comdirect Fidelity Investments Gartmore Investment Management Insight Investment Management M&G Investment Management SG Asset Management

BUSINESS STRATEGY: Research, develop and manufacture diagnostic kits and instrumentation for the rapid detection of microorganisms and provide laboratory testing services

AGREEMENTS: Name Products Content of Agreement Date U.K. Government's Defense Evaluation and Research Agency

Adenylate Kinase Assay Technology

technology license agreement

1/98

RESEARCH & DEVELOPMENT: Rapid microbiology methods for enumeration, identification and toxicity measurements

PRODUCTS ON MARKET: Pharmaceutical, personal care and beverage test kits Advance, Advance coupe and CellScan Innovate luminometers

Centre for Innovative Biology and Environmental Technology

Chelammotil Building, National Highway 47, Ambattukavu Aluva-6, Kerala, Kochi 683106, India Phone: +91 484-2631135; Fax: +91 484-2682557 Web: www.cibet.org; E-mail: [email protected]

KEY PERSONNEL: P. Sunil Kumar; CEO Sabu Abdulhameed, Ph.D.; President G. Nagendra Prabhu, Ph.D.; Exec. VP and Director, R&D Jayachandran K., Ph.D.; Exec. VP Rajeev K. Sukumaran, Ph.D.; Sr. Scientist Swapna TS, Ph.D.; Sr. Scientist


HISTORY: Founded in September 2005 Began biotech R&D in October 2005


BUSINESS STRATEGY: Transfer scientific know-how in to viable eco-friendly technologies



Ceres Inc.

1535 Rancho Conejo Blvd. Thousand Oaks CA 91320, US Phone: (805) 376-6500 Web: www.ceres.net E-mail: [email protected]

KEY PERSONNEL: Walter De Logi; Chairman Dr. Richard Hamilton; CEO Dr. Patrick McCroskey; CFO Dr. Richard Flavell; CSO Dr. Anne-Marie Bouckaert; Sr. VP, Technology Planning, Protection and Acquisition Ms. Wilfriede van Assche; Sr. VP, General Counsel and Secretary Dr. Kenneth Feldmann; VP, Agricultural Genomics/Trait Development Dr. Peter Mascia; VP, Product Development Dr. Steven Bobzin; Director, Natural Products Chemistry Dr. Roger Pennell; Director, Trait Development Anna Rath; Director, Business Development Dr. Steven Thomas; Director, Bioproducts

EMPLOYEES: 135 employees HISTORY: Founded in 1997


PRINCIPAL INVESTORS: Ambergate Trust Artal Luxembourg SA GIMV NV Hambrecht & Quist Capital KBC Bank & Insurance Group Monsanto Co. Oppenheimer International Growth Fund Oxford Bioscience Partners QuestMark Partners LP Soros Private Equity Partners

BUSINESS STRATEGY: Develop energy crops such as switchgrass, miscanthus and poplar for cellulosic ethanol Leverage its technologies into established markets through strategic partnerships

AGREEMENTS: Name Products Content of Agreement Date Agricultural Research Service (ARS) at the United States Department of Agriculture

improvement of switchgrass genetics through biotechnology

CRADA 2/06

Aurora Biosciences Corp.

Aurora's fluorescent protein technology for use in agricultural applications

licensing agreement

10/00

Genset agricultural genetics alliance 1/98 Monsanto Co. application of genomics

technologies to provide improvements in certain agricultural crops

discovery and development collaboration

4/02

Oregon State University

use of genomics to enhance biomass-mediated carbon sequestration


9/05



The Institute for Genomic Research (TIGR)

identification of the structure of genes and their encoded proteins in the chromosomes of the plant species Arabidopsis thaliana


12/00

The Samuel Roberts Noble Foundation Inc.

development and commercialization of new, advanced biomass crops for fuel ethanol production

long-term collaboration

6/06

University Of California

Plant Genetics Partnership

4/00

RESEARCH & DEVELOPMENT: Technology platforms: -Sequencing and cDNAs: Generation and sequencing of full-length cDNA -Computational biology: EST/cDNA/protein clustering, Ockham gene prediction, high-throughput functional annotation and expression data analysis -Promoters: Computational programs and a transcription profiling database to identify and analyze novel plant promoters or promoter elements in DNA sequences for trait development, enhancer-trap system for finding useful promoters -Functional genomics: Sequencing of full-length cDNAs; assessment of the concentrations of mRNAs in extracts from plant tissues; evaluation of plants with known genes silenced by insertions within them; studies on plants with new, defined genes inserted into them; screens to find plants with improved phenotypes; characterization of promoters to determine where and when they program gene expression and systems to epigenetically change gene structure and activity; and computational biology analyses of genes -Metabolites: Metabolic profiling platform to provide plants with optimized levels and kinds of metabolites for functional foods, pharmaceutical discovery, feed quality and extractable sources for use in other products -Genetic confinement: Technology for genetically confining a crop by eliminating viable seeds and/or pollen Trait development platform Switchgrass (Panicum virgatum) genomics program for enhancing biomass yield, completed analysis of more than 12,000 switchgrass genes and characterized the genetic variation associated with them (7/06)

Chembiotech Ltd.

Institute of Research and Development Birmingham Research Park, Vincent Drive, Birmingham Edgbaston B15 2SQ, UK Phone: +44 (0)121 414 7029 Web: www.chembiotech.co.uk E-mail: [email protected]

KEY PERSONNEL: Prof. John F. Kennedy, Ph.D.; Director C. J. Knill, Ph.D.; CSO


HISTORY: Founded in 1977 to provide R&D and consultant services and product development in chemistry, biotechnology, biochemistry and medical devices

FACILITIES: Laboratories and offices in the University of Birmingham Research Park




BUSINESS STRATEGY: Deliver world-class contract research and development, and technical and consultancy services that provide effective and cost-efficient solutions to all our clients in the areas of, biotechnology, chemistry and biochemistry of carbohdyrates, proteins and medicine

RESEARCH & DEVELOPMENT: Cellulose and starch

Characterization/modification and design/synthesis of biologically active derivatives Enzyme immobilization and glycoprotein characterization Avoidance methods for river/sea water pollution by carbohydrates Use of by-products from milk and seaweed industries Waste water treatment Downstream processing Novel developments in starch and paper industries Wound management compounds Slow release pharmaceuticals Chromatography--HPLC, GPC, GC, GC-MS Starch chemistry and biotechnology Drug contamination detection Food components--evaluation analysis On-site assessments, trouble shooting, surveys and verificaiton

PRODUCTS IN DEVELOPMENT: Name Status Hylauronan-based products in development Wound management materials in development

Chemeq Ltd.

3 Brodie Hall Drive, Technology Park Bentley WA 6102, Australia Phone: +61 8 9362 0100; Fax: +61 8 9355 0199 Web: www.chemeq.com.au E-mail: [email protected]

KEY PERSONNEL: John Hopkins; Chairman David Williams; CEO Brian Mangano; CFO



FACILITIES: Pharmaceutical production facility in Rockingham, Australia

STOCK-FINANCIAL HISTORY: Austalian Stock Exchange--CMQ IPO--$3.5M (8/99) Revenue $1.1M (YE 05) compared to $905.177K (YE 04) Net loss <$60.7M> (YE 05) compared to <$9.9> (YE 04) Loss per share <63.4cents/share> (YE 05) compared to <11.7cents/share> (YE 04) Total assets $74.388M (YE 05) compared to $75.824M (YE 04)

BUSINESS STRATEGY: Focus on its core competencies and pursue further commercialization of its intellectual property and products through strategic partnerships

PRODUCTS ON MARKET: Chemeq® polymeric antimicrobial (for pigs)

Chemeq® polymeric antimicrobial (for poultry)



ChemGenes Corp.

33 Industrial Way Wilmington MA 01887, US Phone: (978) 694-4503; Fax: (978) 694-4502 Toll-free phone: (800) 762-9323 Web: www.chemgenes.com; E-mail: [email protected]

KEY PERSONNEL: Suresh Srivastava, Ph.D.; President



FACILITIES: Combined R&D and manufacturing facilities


BUSINESS STRATEGY: Form strategic alliances to develop key DNA-based diagnostics for various diseases and DNA-based antisense therapeutics

RESEARCH & DEVELOPMENT: Antisense DNA-based therapeutics for AIDS

PRODUCTS ON MARKET: DNA and RNA phosphoramidites

Antisense phosphoramidites Modified base phosphoramidites Chromophores and ligands Nucleosides Reagents for oligosynthesis Ancillary reagents Solid supports and prepacked columns for DNA/RNA synthesis

Chr. Hansen Inc.

9015 West Maple Street Milwaukee WI 53214, US Phone: (414) 607-5700; Fax: (414) 607-5959 Toll-free phone: (800) 558-0802 Web: www.chr-hansen.com E-mail: [email protected]

KEY PERSONNEL: David R. Carpenter; President and CEO Don Cox; Sr. VP, Sales Dr. Jeff Kondo; Sr. VP of R&D



STOCK-FINANCIAL HISTORY: Parent company listed on Danish Stock Exchange

SUBSIDIARY OF: Chr. Hansen A/S

BUSINESS STRATEGY: To improve the quality of food and health for people all over the world

AGREEMENTS: Name Products Content of Agreement Date Integrated Genomics Inc.

Integrated Genomics' ERGO database and genomic discovery system

licensing agreement

12/04

RESEARCH & DEVELOPMENT: Ingredients for dairy, food and beverage, meat and prepared foods, and

products for food safety, human health and nutrition and animal health and nutrition



PRODUCTS ON MARKET: Dairy, probiotic, meat and wine cultures

Cheese coagulants Colors Flavors Seasonings Sweeteners Natural food safety products Pharmaceutical coatings and excipients Silage inoculants Direct fed microbials

Chunghwa Chemical Synthesis & Biotech Co. Ltd.

1 Tung-Hsing St., Shu-Lin 238, Hsien Taipei, Taiwan Phone: 886-2-8684-3318; Fax: 886-2-8684-3202 Web: www.ccsb.com.tw; E-mail: [email protected]

KEY PERSONNEL: Derek Wang; Chairman Dr. Steve Chang; President


HISTORY: Founded in 1964 Founded Pharmaports LLC (1999)

FACILITIES: 8.7 acre manufacturing site Pilot lab equipped with 100 liter and 250 liter glass reactors, a 75 liter stainless reactor, 5 liter and 100 liter glass-lined reactor fors scale-up activities and process validation Pilot lab equipped with three 20 litre and a 600 litre fermentor for scale-up study and process validation

STOCK-FINANCIAL HISTORY: Privately held SUBSIDIARIES/DIVISIONS: U.S. sales office:

Pharmaports LLC 160 Summit Ave. Montvale, NJ 07645 Phone: (201) 391-3336 Toll-free phone: (800) 203-1340 Fax: (201) 391-8811 E-mail: [email protected]

SUBSIDIARY OF: China Chemical Pharmaceutical Group

BUSINESS STRATEGY: Bulk manufacture of pharmaceuticals Taiwan

RESEARCH & DEVELOPMENT: Products in pipeline: Tacrolimus, Rosuvastatin, Fluvastatin, Lansoprazole,

Perindopril, Terbinafine and Trandolapril Key technologies: Friedel crafts acetylations, alkylations, chiral resolutions, hantzsch pyridine synthesis, dehydration, reduction/oxidation, addition/substitution, ammonolysis, decarboxylation, genetic engineering, strain improvement, microbial fermentation, cell culture, protein purification, enzyme immobilization, bio-conversion and impurity analysis Activities include: Development of innovative and cost-effective manufacturing processes, custom manufacturing for pharmaceutical intermediates and bulk pharmaceuticals, collaborating with major universities and research institutes for technical supports, analysis of impurity profiles for DMFs, development of innovative and cost-effective



manufacturing processes for high value metabolites, recombinant proteins and enzymes, contract research and custom manufacturing for bio-products and pharmaceutical intermediates, quality/regulatory testing and release all raw materials, packaging materials, and final products, provision of manufacturing operations support across operating units and product lines, technology transfer and scale-up activities

PRODUCTS ON MARKET: Pharmaceutical bulk products: ANALGESIC/NSAIDS: Acetaminophen, Bucetin, Oxaprozin ANTI-ANXIETY AGENTS: Alprazolam, Fluoxetine ANTIHYPERGLYCEMICS: Glipizide, Glibenclamide, Moclobemide LAXATIVE: Calcium Polycarbophil ANTIFUNGAL: Fluconazolel ANTIHISTAMINE: Dexbrompheniramine Maleate ANTISEPTIC: Benzalkonium Chloride 50% CARDIOVASCULAR: Nifedipine EXPECTORANT: Guaifenesin ANTILIPEMIC AGENT: Pravastatin Sodium MUSCULOSKELETAL RELAXANTS: Methocarbamol, Carisoprodol EXCIPIENT: Sodium Starch Glycolate IMMUNOSUPPERSSIVE AGENTS: Mycophenolate Mofetil, Rapamycin

Codexis Inc.

200 Penobscot Drive Redwood City CA 94063, US Phone: (650) 980-5600; Fax: (650) 298-5449 Web: www.codexis.com; E-mail: [email protected]

KEY PERSONNEL: Tom Baruch; Chairman Alan Shaw, Ph.D.; President and CEO Robert S. Breuil; Sr. VP, Finance and CFO John Grate, Ph.D.; Sr. VP, R&D and CTO Tassos Gianakakos; Sr. VP and Head, BU Pharmaceuticals David Walshaw; VP, Operations Peter Seufer-Wasserthal, Ph.D.; VP and GM, Codexis Enzymes & Intermediates Gregory Rocklin; VP and Head, BU Generics


HISTORY: Started as the chemicals business unit of Maxygen (since 1997) Founded in February 2002 Private spin-out from Maxygen (2004) Acquired Julich Fine Chemicals GmbH (2/05) Acquired assets and IP from Enzis BV (4/06) Member--Biotechnology Industry Organization


PRIVATE PLACEMENTS: Raised $25M in private financing (10/02) Raised $37M in Series D financing (8/06)

SUBSIDIARIES/DIVISIONS: Julich Chiral Solutions GmbH--independent, wholly-owned subsidiary

SUBSIDIARY OF: Maxygen Inc. (see separate entry)

PRINCIPAL INVESTORS: Bio*One Capital Pte Ltd. ChevronTexaco Technology Ventures CMEA Ventures Maxygen Inc. Pequot Ventures

BUSINESS STRATEGY: Develop innovative bio-based solutions for pharmaceutical chemical process development and manufacturing



AGREEMENTS: Name Products Content of Agreement Date Arch Pharmalabs Ltd.

use of MolecularBreeding technology in manufacturing compound

research and manufacturing agreement

10/05

Bristol-Myers Squibb Co.

pharmaceutical process research

research agreement, extended 1/06

5/05

Cargill Dow LLC novel synthesis for Cargill Dow's NatureWorks PLA (polylactide)


2002

Chevron Research and Technology Co.

novel bioprocesses for specific petrochemical products

three-year development agreement

10/02

Eli Lilly & Co. improved fermentations for Lilly’s natural product drugs


12/02

Gist-brocades NV (subsidiary of DSM NV)

development of novel enzymes for the manufacture of penicillin antibiotics

three-year research and licensing agreement

3/99

Matrix Laboratories Ltd.

API for a high-value pharmaceutical product

development and commercialization agreement

6/05

Novozymes development and bulk production of specific industrial enzymes in fields of laundry detergents, leather processing and pulp and paper manufacturing, among others

five-year strategic collaboration

9/97

Pfizer Inc. biochemical manufacturing of undislcosed pharmaceutical product

extension of 5/98 agreement

9/00

Pfizer Inc. pharmaceutical life cycle management

R&D agreement 7/04

Sandoz process for the

production of a key fermented active pharmaceutical compound of Sandoz


10/03

Schering-Plough Corp.

development of a synthetic process for Schering-Plough

research agreement

3/06

Shasun Chemicals and Drugs Limited

pharmaceutical intermediate for a generic drug

manufacturing and supply agreement

5/05

Teva Pharmaceutical Industries Ltd.

improved processes for manufacturing of an undisclosed pharmaceutical product using Codexis' MolecularBreeding™ directed evolution platform

research collaboration agreement

12/04



RESEARCH & DEVELOPMENT: Codexis' technology platforms can rapidly generate biocatalysts with desired commercial properties. The biocatalysts usually fall into two categories: enzymes and fermentation strains. The technology platforms used to develop the biocatalysts include MolecularBreeding™ directed evolution and WGShuffling™ strain development. The technologies can be used to: -Develop low-cost, efficient catalysts with improved performance for the synthesis of complex molecules -Develop improved chemical production organisms in less than the typical process development time -Develop proprietary syntheses of high-value chemicals by integrating chemistry and biology in new ways -Develop alternative synthesis technologies and intellectual property for use by pharmaceutical and generic companies in life cycle management, can be used to create new patents -Demonstrate the validity of the technology for multiple applications at relevant commercial scale

PRODUCTS ON MARKET: ThoroughBred™ biocatalysts ThoroughBred™ cell lines Active pharmaceutical ingredients

PRODUCTS IN DEVELOPMENT: Name Status More than 15 products and processes in the pipeline, with two products in advanced development

Codon Devices

One Kendall Square, Building 300, Third Floor Cambridge MA 02139, US Phone: (617) 995-7999; Fax: (617) 995-7970 Web: www.codondevices.com E-mail: [email protected]

KEY PERSONNEL: Noubar Afeyan; Chairman John Danner; CEO and President Brian Baynes; CSO Craig D. Muir; Sr. VP, Technical Operations Jennifer Camacho; VP, Intellectual Property and Chief Patent Counsel Michael J. Fitzpatrick; VP, Sales




PRINCIPAL INVESTORS: Flagship Ventures Alloy Ventures Kleiner Perkins Vinod Khosla

BUSINESS STRATEGY: Provide engineered devices for molecular biology research, improve cell engineering for the production of high value chemicals and engineer biotherapeutics

RESEARCH & DEVELOPMENT: Molecular biology: Construction of comprehensive sets of genetic reagents

for basic research and development and in the area of structural/functional genomics, the construction of codon optimized, expression-ready clones and designed variants for protein studies Pharmaceutical: Improved therapeutic protein development, such as engineering therapeutic proteins to improve properties such as stability, potency, binding affinity and immunogenicity; natural and engineered therapeutic production, such as rapidly developing cell lines to explore biosynthetic pathways for improved performance and cost; rapid response vaccines, such as rapidly obtaining putative antigen genes, optionally



coupled to adjuvants, for pandemic and seasonal vaccine development Industrial biotech and bioenergy: Focus is on the development of enzymes with improved properties, including stability, specificity and catalytic efficiency, as well as engineering cell lines to produce large amounts of specialty and commodity chemicals from renewable feed stocks Agriculture: Precision trait engineering, the enhancement of plant genetic traits by engineering at the kilobase- to megabase-scale - more efficiently than traditional breeding

PRODUCTS ON MARKET: Constructed clones and custom vectors Constructed variant libraries Constructed operons and operon variant libraries Genomic engineering

CombiMatrix Corp.

6500 Harbour Heights Parkway, Suite 301 Mukilteo WA 98275, US Phone: (425) 493-2000 Fax: (425) 493-2010 Toll-free phone: (800) 985-CBMX Web: www.combimatrix.com E-mail: [email protected]

KEY PERSONNEL: Amit Kumar, Ph.D.; President and CEO Brooke Anderson, Ph.D.; COO John Besser; CFO Jeffrey Oster, Ph.D.; Sr. VP, Intellectual Property Scott Burell; VP, Finance H. Sho Fuji; VP, Engineering and Production Andy McShea, Ph. D.; VP, Biology and Chemistry


HISTORY: Incorporated in 1999

FACILITIES: Headquarters and R&D facilities in Mukilteo, Wash.

STOCK-FINANCIAL HISTORY: Privately held by parent (NASDAQ--CBMX)

SUBSIDIARIES/DIVISIONS: Acacia Technologies Group CombiMatrix Molecular Diagnostics Inc.

SUBSIDIARY OF: Acacia Research Corp.

BUSINESS STRATEGY: Leverage strengths in technology, innovation and product development by

establishing partnerships for commercialization. CombiMatrix seeks partnerships with organizations that have well-developed infrastructure for manufacturing, sales and distribution. By combining the strengths of our technologies with the distribution and manufacturing capabilities of partners, CombiMatrix seeks to successfully develop and introduce industry-leading products into the life science research, industrial and biothreat markets


Benitec Ltd. Benitec IP related to pools of siRNAs as therapeutic agents for viral diseases, CombiMatrix sequences targeting HIV

cross-licensing and collaboration agreement

2/05

BioDesign Institute at Arizona State University

peptide array synthesizer


8/05



Case Western Reserve University

novel diagnostic for Alzheimer's disease

R&D agreement 2/04

Cell Sciences Ltd. CombiMatrix products and services in Singapore

nonexclusive distribution agreement

12/05

Cyrano Sciences chemical sensors R&D agreement 1/04 InBio CombiMatrix’s

CustomArray microarray products in Australian and New Zealand


1/05

Inter Medical CustomArrays products in Japan

non-exclusive distribution agreement

5/05

J.K. International Inc.

CustomArray microarray products in Japan


7/05

Novavax technique for in-process monitoring of vaccine production


11/05

Oklahoma State University

influenza virus therapeutics

R&D agreement 3/04

Prisma Biotech Corp.

CombiMatrix products in Taiwan, China and other countries

distribution and manufacturing agreement

4/06

Seattle Biomedical Research Institute

RNAi compounds for gene regulation research

R&D agreement 11/03

St. Jude Children's Research Hospital

Influenze A virus therapeutics

R&D agreement 3/04

STMicroelectro-nics

point-of-care diagnostic products

co-development agreement

6/05

Toppan Corp. electrochemical detection microarrays and products

R&D agreement 5/03

U.S. Army Medical Research Institute of Infectious Diseases

environmental and medical detection of biothreat agents

R&D agreement 10/03


custom microarrays for biothreats

R&D agreement 3/04

VWR International Inc.

CustomArrays and CatalogArrays

global distribution agreement

9/05

Washington University

chemical synthesis of non-nucleic acid molecules

R&D agreement 1/04

RESEARCH & DEVELOPMENT: RNAi introduction

Systems biology for drug discovery research

PRODUCTS ON MARKET: CombiMatrix CustomArray™ chip RNAi Express Track program Nanotechnology/Materials Development Product Service Biothreat Detection Technology

PRODUCTS IN DEVELOPMENT: Name Status Ongoing custom array programs various stages of progress



Commercial Microbiology Ltd.

Kettock Lodge, Campus 2, Aberdeen Science Park, Bridge of Don Aberdeen AB22 8GU, UK Phone: +44 (0) 1224-706-062; Fax: +44 (0) 1224-706-012 Web: www.microbio-centre.co.uk E-mail: [email protected]

KEY PERSONNEL: Dr. Stephen Maxwell; Managing Director Iain Spark; Consultant Lisa Graham; Financial Controller Lucille Harries; Chemist




SUBSIDIARIES/DIVISIONS: Commercial Microbiology Inc. 1764 West Sam Houston Pkwy. N. Houston, TX 77043 Phone: (713) 974-1211 Fax: (713) 974-3636 Email: [email protected]

BUSINESS STRATEGY: Offer analytical solutions to problems and processes involving microbiological growth

RESEARCH & DEVELOPMENT: Bacteria in hostile environments

PCR applications in environmental testing Optimization of bacterial growth media

PRODUCTS ON MARKET: Food and hygiene testing and services, hygiene test kits, sampling consumables, equipment for hire, energy/oilfield testing and services, bacterial growth media / test kits, dipslides, Sidestream®, environmental testing and services

Cornell Institute for Biotechnology and Life Science Technologies

Cornell University, 130 Biotechnology Building Ithaca NY 14853-2703, US Phone: (607) 255-2300; Fax: (607) 255-6249 Web: www.biotech.cornell.edu; E-mail: [email protected]

KEY PERSONNEL: Kelvin Lee; Director


HISTORY: Founded in 1983 New York State Office of Science, Technology and Advanced Research (NYSTAR) designated Center for Advanced Technology ; Cornell Center for Life Science Enterprise

FACILITIES: Service laboratories-- plant tissue culture and transformation; fermentation; computing and computational biology; confocal microscopy, imaging, and fluorimetry; DNA sequencing and genotyping; mouse transgenics; microarray; proteomics and mass spectrometry; flow cytometry; protein production and characterization

STOCK-FINANCIAL HISTORY: Partnership of Cornell University, government and industry



BUSINESS STRATEGY: The Institute emphasizes technology, people, and research involved in the life sciences. The Center marries the diversity, discovery, and knowledge base of Cornell University with the jobs, innovation, and impact of NewYork State businesses. The result is a diverse portfolio of projects and expertise that positively impacts human and animal health, agriculture, and the environment, and leads to economic growth and job creation in New York.

RESEARCH & DEVELOPMENT: Agricultural and environmental biotechnology

Biochemistry and biophysics Computational biology Diagnostics and detection technologies Genomics and proteomics Health care and biomedical engineering Nanobiotechnology Science education and public policy

Cosmo Bio Co. Ltd.

Toyo-Ekimae Bldg., 2-20, Toyo 2-Chome, Koto-ku Tokyo 135-0016, Japan Phone: +81 3-5632-9617; Fax: +81 3-5632-9618 Web: www.cosmobio.co.jp E-mail: [email protected]

KEY PERSONNEL: Tamostu Nakamura; President Jihei Suwa; Sr. Exec. Managing Director Takashi Yokomizo; Managing Director, Research Reagent Development Department Yasushi Kuriya; Purchasing Manager


HISTORY: Established in March 1978 as technical development department of Maruzen Oil Co. Ltd. Biochemical department established in 1982 Established Maruzen Oil Biochemical Co. Ltd. in 1983 Changed name to Cosmo Bio Co. Ltd. in 1986


SUBSIDIARIES/DIVISIONS: Cosmo Bio USA

PRINCIPAL INVESTORS: Cosmo Oil Co. Ltd.

BUSINESS STRATEGY: Export, import and sell research reagents, instruments and software, and diagnostics

AGREEMENTS: Name Products Content of Agreement Date Biopool AB hemostasis and blood

group serology exclusive distribution agreement

1996

Cappel Lab MAbs, polyclonal antibodies

exclusive distribution agreement

EY Lab lectin exclusive distribution agreement

Genzyme Corp. lymphokine, cytokine nonexclusive distribution agreement

VMRD Inc. biotech products Cosmo to distribute VMRD's products in Japan

1989

PRODUCTS ON MARKET: Research Reagents for Gene Engineering: Restriction enzymes, modification enzymes, nucleic acids, reagents for detecting genes, PCR-related reagents and equipment



Research Reagents for Tissue Culture: Animal serums, media, culture systems/apparatus and antibiotics Miscellaneous Research Reagents for Biochemistry: Sugars, lipids, lectins, hormones, peptides, amino acids, chemical substances, virus, bacteria, enzymes and enzyme substrates Apparatus for Biochemical Research: Electrophoresis apparatus, cell-gene operation equipment, analysis software, isolation-refining equipment, culture apparatus, measuring instruments, gel photograph devices and related products, disposable products, biohazard safety appliances and auxiliary equipment for experiments such as cold insulation Reagents for Clinical Diagnostics: Reagents for transfusions, blood and serum, bacteria tests and pathological tests

CryoLife Inc.

1655 Roberts Boulevard NW Kennesaw GA 30144, US Phone: (770) 419-3355; Fax: (770) 426-0031 Toll-free phone: (800) 438-8285 Web: www.cryolife.com E-mail: [email protected]

KEY PERSONNEL: Steven G. Anderson; Chairman, President and CEO David M. Fronk; VP, Regulatory Affairs and Quality Assurance Albert E. Heacox, Ph.D.; Sr. VP, R&D D. Ashley Lee; Exec. VP, COO and CFO Gerald B. Seery; Sr. VP, Sales and Marketing



FACILITIES: 200,000 sq. ft. headquarters 11,000 sq. ft. pilot production facility for bioadhesives 18,000 bioprosthesis lab

STOCK-FINANCIAL HISTORY: NYSE--CRY IPO--(2/93) Revenue $69.282M (YE 05) compared to $62.384M (YE 04) Net loss <$19.535M> (YE 05) compared to <$18.749M> (YE 04) Loss per share <$0.85/share> (YE 05) compared to <$0.81/share> (YE 04) Average shares outstanding 23.959M (YE 05) compared to 23.043M (YE 04) Total assets $76.809M (YE 05) compared to $73.261M (YE 04)

PRIVATE PLACEMENTS: Raised $20M private placement (1/04)

BUSINESS STRATEGY: The company cryopreserves and distributes donated living human tissues for use in reconstructive cardiac, vascular, and orthopaedic surgeries. The company’s BioGlue® Surgical Adhesive, is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in Europe and approved in Cananda for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair.


Clearant Inc. Inactivates microorganisms in human tissues



The Magdi Yacoub Institute at Imperial College

methods to improve the utilization of unfixed xenografts for human transplantation

three-year research collaboration

6/05


BioFoam for use in deep wound injuries that occur on the battlefield


RESEARCH & DEVELOPMENT: Bioadhesives, xenograft/allograft implantable heart valves, vascular and

orthopaedic tissues

PRODUCTS ON MARKET: CryoValve® human allograft aortic and pulmonary heart valves CryoVein® human saphenous veins and superficial femoral veins and arteries CryoArtery® aortoiliac artery CryoGraft Tendon – semitendonosus/gracillis and tibialis tendons, quadriceps, achilles and patellar tendons CryoGraft Menisci Osteoarticular (OA) allografts BioGlue® Surgical Adhesive CryoLife-O’Brien porcine heart valves SG Model #100 bovine ureter for arteriovenous (AV) access

PRODUCTS IN DEVELOPMENT: Name Status BioFoam in development BioLastic in development BioDisc in development

CUBIA (University Centre for Algal Biotechnology)

University of Liege B22, Sart-Tilman Liege 4000, Belgium Phone: +32 4-366-3807; Fax: +32 4-366-2926 Web: No Web site E-mail: [email protected]

KEY PERSONNEL: M. Brouers; President and CSO


HISTORY: Founded and began biotech R&D in December 1996

FACILITIES: 250 sq. m. offices and laboratory

STOCK-FINANCIAL HISTORY: Nonprofit university research center

RESEARCH & DEVELOPMENT: Edible microalgae

Extraction of byproducts for food, feed, cosmetic, dietetic and parapharmacy Feasibility studies for construction of industrial microalgae production plant

PRODUCTS ON MARKET: Spirulina algae and byproducts Colorings Wound healing Dietetic complements

PRODUCTS IN DEVELOPMENT: Name Status Algaplan fertilizer in research phase



Cuno Inc.

400 Research Parkway Meriden CT 06450, US Phone: (203) 237-5541; Fax: (203) 238-8977 Toll-free phone: (800) 243-6894 Web: www.cuno.com

KEY PERSONNEL: Mark G. Kachur; CEO and President Frederick C. Flynn Jr.; Sr. VP, Finance and Administration and CFO Thomas J. Hamlin; Sr. VP, R&D Anton McElevey; VP and GM, Europe Geoff Wilcox; Director, Biopharmaceutical Group


HISTORY: CUNO Inc. founded in 1912 Acquired Polymerics Inc. (6/04) Acquired WTC Industries Inc. (8/04) Acquired by 3M (8/05)

STOCK-FINANCIAL HISTORY: Privately held Formerly listed on NASDAQ--CUNO IPO--(9/96) Net sales $$351.611M (YE 04) compared to $288.231M (YE 03) Net income $33.071M (YE 04) compared to $26.796M (YE 03) Earnings per share $1.98/share (YE 04) compared to $1.61/share (YE 03) Average shares outstanding 16.729M (YE 04) compared to 16.661M (YE 03) Total assets $434.558M (YE 04) compared to $288.008 (YE 03)

SUBSIDIARIES/DIVISIONS: Cuno Ltd.--U.K. Cuno Pacific Pty. Ltd.--Australia Cuno Europe SA--France Cuno SA--France Cuno Belux--Belgium Cuno Srl--Italy Cuno Filtration Asia Pte. Ltd.--Singapore Cuno Latina Ltda.--Brazil Cuno Latina Surcusal Argentina Cuno GmbH--Germany Cuno KK--Japan

SUBSIDIARY OF: 3M

BUSINESS STRATEGY: Create enhanced methods of purification and unique separation matrices for use in the biotechnology and bioprocessing industries

RESEARCH & DEVELOPMENT: Filtration/separations for biopharmaceutical process development and

manufacturing Chromatography column protection

PRODUCTS ON MARKET: Zeta Plus® virus reduction filters Zeta Plus® disposable prefilter cartridges Zetapor® nylon membrane filter cartridges Microfluor II® sterile air filters SterAssure™ nylon membrane prefilters Microcheck automated integrity test instrument Sanitary design cartridge filter housings PolyPro® XL pleated high area depth filters PolyNet™ PB polypropylene depth filters



Cyanotech Corp.

73-4460 Queen Kaahamanu Hwy., Suite 102 Kailua-Kona HI 96740, US Phone: (808) 329-4677; Fax: (808) 329-4533 Toll-free phone: (800) 453-1187 Web: www.cyanotech.com E-mail: [email protected]

KEY PERSONNEL: Gerald R. Cysewski; Chairman, President and CEO William R. Maris; VP, Finance and CFO Glenn Jenson; VP, Operations Robert J. Capelli; VP, Sales


HISTORY: Founded in 1983 by Gerald Cysewski (5% equity interest, 6/96) Originally formed from merger of Altex Technology and White Mountain Inc.

FACILITIES: Algae production facility on 90-acre site in Kailua-Kona, Hawaii

STOCK-FINANCIAL HISTORY: NASDAQ--CYAN (Capital Market) Follow-on public offering--1.5M shares at $7/share, $11.445M (3/96) Net sales $11.131M (YE 06) compared to $8.951M (YE 05) Net loss <$268K> (YE 06) compared to <$486K> (YE 05) Loss per share <$0.01/share> (YE 06) compared to <$0.02 /share> (YE 05) Average shares outstanding 20.904M (YE 06) compared to 20.784M (YE 05) Total assets $17.473M (YE 06) compared to $18.542M (YE 05)

PRIVATE PLACEMENTS: Spirulina Research Partners--RDLP for spirulina research--$635K (10/84) $150K, 600K shares (11/83) $276K, 920K shares (6/84) $250K, 625K preferred shares (6/85) $1.5M (7/86) $2.35M, 235K shares (1/94) $1.55M, convertible subordinated debentures and common stock (11/02)

PRINCIPAL INVESTORS: Continental Corp.--$500K, 1.25M preferred shares (1985); 292,430 shares of common stock at $1/share (1986), $1.97M, 79shares of preferred stock (2/90) Cosmo Ventures--$1M, 750K shares (1985, 1986)

BUSINESS STRATEGY: Develop high-value products from microalgae Establish retail marketing subsidiary

AGREEMENTS: Name Products Content of Agreement Date Scripps Research Institute

Scripps' Aldolase Catalytic Antibody 38C2 in microalgae


University of Memphis

microalgae that is toxic to mosquito larvae


RESEARCH & DEVELOPMENT: Algal drying technique permitting dormancy

Pigments for cosmetics, fragrances, food coloring Astaxanthin for aquaculture feeds

PRODUCTS ON MARKET: BioAstin® natural astaxanthin Phycobiliproteins as fluorescent dyes for labeling MAbs in cell sorters and assays Spirulina Pacifica® protein supplement as food supplement NatuRose® natural astaxanthin product Genetic engineering of microalgae to produce transgenic protein



Daiichi Pharmaceutical Co. Ltd.

14-10, Nihonbashi, 3-chome, Chuo-ku Tokyo 103-8234, Japan Phone: +81 3-3272-0611; Fax: +81 3-3272-7348 Web: www.daiichipharm.co.jp E-mail: [email protected]

KEY PERSONNEL: Kiyoshi Morita; President and CEO Tsutomu Une, Ph.D.; Sr. Managing Director Tadao Suzuki, Ph.D.; Sr. Manging Director Hidetoshi Imaizumi; Managing Director Ryuzo Takada; Managing Director Hiroshi Sugiyama; Managing Director Toru Kuroda; Managing Director Akira Nagano; Managing Director


HISTORY: Established in January 1918 Founded as Arsemin Shokai in October 1915 Established Daiichi Sankyo Co. Ltd. with Sankyo Co. Ltd., and became its subsidiary (2005)

FACILITIES: Factories in Osaka, Shizuoka and Akita

Research and development center in Tokyo

STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges Net sales ¥328.534b (YE 05) compared to ¥322.767b (YE 04) Net income ¥37.175b (YE 05) compared to ¥26.661b (YE 04) Earnings per share ¥137.95/share (YE 05) compared to ¥97.25/share (YE 04) Total assets ¥546.555b (YE 05) compared to ¥521.808b (YE 04)

SUBSIDIARIES/DIVISIONS: Daiichi Sankyo Co. Ltd.----Tokyo Daiichi Sankyo Healthcare Co. Ltd.--Tokyo Daiichi Pure Chemicals Co. Ltd.--Tokyo Daiichi Radioisotope Laboratories Ltd.--Tokyo Daiichi Pharmatech Co. Ltd.--Tokyo Daiichi Fine Chemical Co. Ltd. (DFK)--Tokyo Saitama Daiichi Pharmaceutical Co. Ltd.--Saitama Daiichi Asubio Pharma Co. Ltd. (ASB)--Tokyo Tokyo Iyaku Shiki Co. Ltd.--Saitama Nishimura Shiki Co. Ltd.--Osaka Daiichi Estate Co. Ltd.--Tokyo Daiichi Butsuryu Co. Ltd.--Tokyo D.P.C.Medical Co. Ltd.--Tokyo Kanto Daiichi Service Co. Ltd.--Tokyo Daiichi Sankyo Inc.--N.J., U.S. Daiichi Pharmaceuticals UK Ltd.--London Daiichi Pharmaceutical (Beijing) Co. Ltd.--China Daiichi Pharmaceutical Asia Ltd.--Hong Kong Daiichi Pharmaceutical Taiwan Ltd.--Taiwan Daiichi Pharmaceutical Korea Co. Ltd.--Korea Daiichi Pharmaceutical (Thailand) Ltd. Laboratoires Daiichi Sanofi-Aventis--Paris Daiichi Fine Chemicals Inc.--N.Y., U.S. Daiichi Fine Chemical Europe GmbH--Germany Daiichi Asubio Pharmaceuticals Inc.--N.J., U.S. Daiichi Asubio Holdings Inc.--U.S. Daiichi Asubio Medical Research Laboratories LLC (Daiamed)--Cambridge, Mass., U.S.

SUBSIDIARY OF: Daiichi Sankyo Co. Ltd.



AGREEMENTS: Name Products Content of Agreement Date GE Healthcare research and

development of non-nuclear contrast media


9/05

CIMYM BioSciences Inc.

development and marketing rights for nimotuzumab in Japan


Ingenuity Systems Ingenuity's Pathways Analysis


4/06

YM Biosciences Inc.

development and marketing rights to TheraCIM (nimotuzumab) in Japan


PRODUCTS ON MARKET: OTC pharmaceuticals, quasi-pharmaceuticals, pharmaceuticals, cosmetics, medical equipment, food products, beverages, diagnostic reagents, radiopharmaceuticals, radioisotope products, fine chemicals, packaging materials for pharmaceuticals and logistics services

Dainippon Sumitomo Pharma Co. Ltd.

2-6-8 Doshomachi, Chuo-ku Osaka 541-0045, Japan Phone: +81 06-6203-5321; Fax: +81 06-6233-2288 Web: www.ds-pharma.co.jp

KEY PERSONNEL: Yasuo Okamoto; Chairman Kenjiro Miyatake; President


HISTORY: Created from the merger of Dainippon Pharmaceutical Co. Ltd. and Sumitomo Pharmaceuticals Co. Ltd. (10/05) Sumitomo Pharmaceuticals: Founded in February 1984 as a joint venture through merger of respective pharmaceutical divisions of Sumitomo Chemical Co. Ltd. and Inabata & Co. Dainippon Pharmaceutical: Founded in May 1897

STOCK-FINANCIAL HISTORY: Sumitomo Pharmaceuticals: Net sales ¥136.915b (YE 04) compared to ¥138.282b (YE 03) Net income ¥12.048b (YE 04) compared to ¥11.168b (YE 03) Total assets ¥170.489b (YE 04) compared to ¥171.020b (YE 03) Dainippon Pharmaceutical: Net sales ¥170.842b (YE 04) compared to ¥172.161b (YE 03) Net income ¥7.967b (YE 04) compared to ¥6.364b (YE 03) Earnings per share ¥48.05/share (YE 04) compared to ¥88.02/share (YE 03) Total assets ¥193.237b (YE 04) compared to ¥187.416b (YE 03)

SUBSIDIARIES/DIVISIONS: Pharmaceuticals Animal science Food science Fine chemicals Laboratory products

BUSINESS STRATEGY: Manufacture, sell/purchase and import/export pharmaceuticals, diagnostics, medical devices, veterinary products, food additives, industrial chemicals and other chemical products



AGREEMENTS: Name Products Content of Agreement Date Chelsea Therapeutics International Ltd.

rights to L-Threo DOPS (Droxidopa) outside Asia


Conforma Therapeutics

Amrubicin HCl (Amrubicin)


Eisai Co. Ltd. development, manufacturing and marketing of Gasmotin in 10 Asian countries


PRODUCTS ON MARKET: PHARMACEUTICALS UNIT: Amlodin (used in the treatment of hypertension and angina), Gasmotin (used to improve digestive tract function), Prorenal (a peripheral circulation stimulant), and Meropen (a carbapenem antiobiotic preparation) ANIMAL SCIENCE UNIT: disease prevention and treatment products for pet, livestock, and marine use

Dalton Pharma Services

349 Wildcat Road Toronto M3J 2S3, Canada Phone: (416) 661-2102; Fax: (416) 661-2108 Toll-free phone: (800) 567-5060 (Canada only) Web: www.dalton.com E-mail: [email protected]

KEY PERSONNEL: Peter Pekos; President Natalie Lazarowych; Director, R&D


HISTORY: Founded and began biotech R&D in 1986 Changed name from Dalton Chemical Laboratories Inc. (4/05)



BUSINESS STRATEGY: Maintain a position on the forefront of technology in drug discovery, drug synthesis and analysis through provision of chemistry expertise to generate new drugs, optimize the synthesis of potential therapeutic candidates, and provide chemistry expertise to partners in the biotech and pharma fields Continue to focus on small molecule chemistry, developing novel routes and molecules as well as providing focused and directed chemistry for our partners to enhance their own in-house programs and expertise

AGREEMENTS: Name Products Content of Agreement Date As a contract services company, majority of agreements are confidential

RESEARCH & DEVELOPMENT: All research and development under contract of clients

PRODUCTS ON MARKET: Fine chemicals, custom peptides, custom chemical synthesis cGMP manufacturing of active pharmaceutical ingredients and sterile filling of clinical trail drug products



Dextra Laboratories Ltd.

Science and Technology Centre, Earley Gate, Whiteknights Road Reading RG6 6BZ, UK Phone: +44 (0)118 935 7000; Fax: +44 (0)118 926 7917 Web: www.dextra-labs.co.uk E-mail: [email protected]

KEY PERSONNEL: Dr. Andrew Hacking; CEO Dr. C. J. Lawson; CEO Dr. Alex Weymouth-Wilson; Head, Chemistry


HISTORY: Founded in October 1989

FACILITIES: 2,500 sq. ft. of laboratories and offices, small pilot chemical equipment and analytical equipment (HPLC, GC, GC/MS, NMR, DIONEX, DSC, UV, IR)


PRINCIPAL INVESTORS: 3i Group plc--25%

BUSINESS STRATEGY: Exploit emerging technologies related to carbohydrates in medical advances

AGREEMENTS: Name Products Content of Agreement Date Cambrex AB, Karlskoga, Sweden

carbohydrate and chiral intermediates and building blocks

manufacturing, sales

and marketing agreement

10/03

RESEARCH & DEVELOPMENT: Oligosaccharides involved in communication between mammalian cells, cell adhesion molecules, chiral synthons and intermediates Drug discovery, carbohydrates, custom synthesis, analytical services, oligosaccharides, glycoproteins, chiral compounds

PRODUCTS ON MARKET: More than 400 biologically significant oligosaccharides and glycoconjugates including N-linked, O-linked, fucosylated, sialylated, sulphated sugars, monosaccharides and lactones derived by synthesis and extraction from plant and animal tissues

Dextran Products Ltd.

421 Comstock Road Toronto M1L 2H5, Canada Phone: (416) 755-2231; Fax: (416) 755-0334 Web: www.polydex.com E-mail: [email protected]

KEY PERSONNEL: George G. Usher; Chairman Sharon Wardlaw; President


HISTORY: Founded in 1936 by Thomas Usher, moved from U.K. to present location in 1966

FACILITIES: 30,000 sq. ft. factory

STOCK-FINANCIAL HISTORY: Owned by parent

SUBSIDIARY OF: Polydex Pharmaceuticals Ltd. (see separate entry)

BUSINESS STRATEGY: Develop and sell specialty chemicals



AGREEMENTS: Name Products Content of Agreement Date Canadian Bacterial Diseases Network

regulation of macrophage antibacterial activity

research agreement 4/94

RESEARCH & DEVELOPMENT: Developing human drugs for AIDS, arteriosclerosis and cystic fibrosis

PRODUCTS ON MARKET: Dextran derivatives

PRODUCTS IN DEVELOPMENT: Name Status Dextran for lung infections in cystic fibrosis patients

preparing IND application

Ushercell (contraceptive application) in Phase II clinicals Ushercell (HIV indication) in Phase III clinicals

Diagnostic Chemicals Ltd.

West Royalty Industrial Park Charlottetown C1E 2A6, Canada Phone: (902) 566-1396; Fax: (902) 628-6504 Toll-free phone: (800) 565-0265 Web: www.dclchem.com E-mail: [email protected]

KEY PERSONNEL: J. Regis Duffy, Ph.D.; Chairman Ronald J. Keefe, LL.B, MBA, CA; President and Chief Executive Officer Rob Binns; Chief Operating Officer Gordon Rogers, C.A.; VP, Finance and Corporate Systems and CFO Julien Gaudin, Ph.D.; Director, Diagnostic Manufacturing Operations Marlene Walker, M.Sc.; Director of Quality Systems Bob Fredrickson, Ph.D.; Director, Research and New Technology Development Lee Lipski; VP, Sales


HISTORY: Founded in 1970 as a manufacturer of fine chemicals, today its major products are clinical chemistry reagents, fine chemicals and biochemicals


SUBSIDIARIES/DIVISIONS: Biochemical division Diagnostic division Diagnostic Chemicals Ltd. (U.S.) Diagnostic Chemicals Ltd. (Mexico)

BUSINESS STRATEGY: Build on our leadership in clinical chemsitry to develop new and innovative technology for the in vitro diagnostic industry. Develop new biochemicals, pharmaceutical intermediates and new immunodiagnostic procedures.

RESEARCH & DEVELOPMENT: New In vitro-diagnostic products and technologies guided by the specific

needs of our OEM partners. New enzymes utilizing immunochemistry and other proteins as well as enzyme substrates for use in biotechnology. Chemical process development and production of high purity chemical intermediates. Individualized contract manufacturing solutions.

PRODUCTS ON MARKET: Clinical chemistry reagents Calibrators and controls ImmunoDip®



Digene Corp.

1201 Clopper Road Gaithersburg MD 20878, US Phone: (301) 944-7000; Fax: (240) 632-7121 Toll-free phone: (800) DIGENE Web: www.digene.com; E-mail: [email protected]

KEY PERSONNEL: Attila T. Lorincz; Sr. VP, R&D and CSO Joseph Slattery; CFO Belinda O. Patrick; Sr. VP, Manufacturing Operations Robert McG. Lilley; Sr. VP, Global Sales and Marketing Donna Marie Seyfried; VP, Business Development


HISTORY: Founded in 1985 Acquired the molecular diagnostics division of Life Technologies Inc. (12/90) Name changed from Digene Diagnostics Inc. (1996)

FACILITIES: 110,000 sq. ft. R&D and manufacturing facility

STOCK-FINANCIAL HISTORY: NASDAQ--DIGE IPO--$35M (5/96) Public offering--2.25M shares of common stock at $10/share, $22.5M (10/97) Public offering--2M shares of common stock at $28/share, $56M (11/05) Revenue $152.888M (YE 06) compared to $115.142M (YE 05) Net <loss> income $8.439M (YE 06) compared to <$8.167M> (YE 05) Earnings <loss> per share $0.39/share (YE 06) compared to <$0.41/share> (YE 05) Average shares outstanding 21.769M (YE 06) compared to 19.965M (YE 05) Total assets $231.886M (YE 06) compared to $106.845M (YE 05)

SUBSIDIARIES/DIVISIONS: Digene Europe - London, England

BUSINESS STRATEGY: Develop DNA diagnostic and biomedical supply company through internal developments, strategic partnerships and acquisitions

AGREEMENTS: Name Products Content of Agreement Date Asuragen Inc. Asuragen's cystic

fibrosis screening products

worldwide marketing and distribution agreement

4/06

Cytyc Corp. Digene's DNA probe tests and Cytyc's specimen collection and preparation technology


10/96

International Murex Technologies Corp.

five-year exclusive agency agreement for distribution in Europe

2/97


Digene's tests for HIV RNA, hepatitis B and cytomegalovirus

distribution agreement for Europe, the U.K., Africa, the Middle East and Singapore (1993), extended

9/97


infectious disease DNA probe diagnostics

worldwide development and distribution agreement, expanded to include STD products (6/94)

4/98

Mitsubishi Petrochemical Co.

DNA diagnostic probes for disease detection

distribution agreement for Japan

10/98



National Institute of Allergy and Infectious Diseases

herpes simplex virus tests using Hybrid II technology

$750K Phase II SBIR contract

6/98

NCI diagnostic assays for HPV

$600K research contract

11/92

Toray Industries DNA diagnostic probes for disease detection


12/00

RESEARCH & DEVELOPMENT: DNA amplification Enzymes linked to nucleic acid as diagnostic probes Diagnostic probes for HPV, infectious disease and cancer

PRODUCTS ON MARKET: DNA probe kits for HBV, CMV, mycobacteria, HIV and HPV Hybrid Capture System Human Papillomavirus DNA Assay

PRODUCTS IN DEVELOPMENT: Name Status Hybrid Capture II CT and GC DNA tests for Chlamydia trachomatis and Neisseria gonorrhea for collection out of liquid cytology

filed three 510(k)s--one for each test individually and one for simultaneous testing

Diversa Corp.

4955 Directors Place San Diego CA 92121-1609, US Phone: (858) 526-5000; Fax: (858) 526-5551 Web: www.diversa.com E-mail: [email protected]

KEY PERSONNEL: James H. Cavanaugh, Ph.D.; Chairman Edward T. Shonsey; CEO Anthony E. Altig; Sr. VP, Finance and CFO William H. Baum; Exec. VP, Bioscience Products Patrick Simms; Sr. VP, Operations


HISTORY: Founded and began biotech R&D in May 1994 Name changed from Recombinant BioCatalysis Inc. (8/97) Member--Biotechnology Industry Organization

FACILITIES: 75,000 sq. ft. headquarters and R&D facilities

STOCK-FINANCIAL HISTORY: NASDAQ--DVSA IPO--8.34M shares at $24/share, $200.1M (2/00) 47.1M shares outstanding (6/1/06) Revenue $54.3M (YE 05) compared to $57.5M (YE 04) Net loss <$89.718M> (YE 05) compared to <$33.425M> (YE 04) Loss per share <$2.04/share> (YE 05) compared to <$0.77/share> (YE 04) Average shares outstanding 44.064M (YE 05) compared to 43.416M (YE 04) Total assets $98.069M (YE 05) compared to $184.056M (YE 04)

PRIVATE PLACEMENTS: Raised $21M in oversubscribed round of venture capital financing (10/97)

SUBSIDIARIES/DIVISIONS: Innovase LLC

PRINCIPAL INVESTORS: HealthCare Ventures Syngenta AG T. Rowe Price Rho Management



BUSINESS STRATEGY: Diversa delivers unparalleled enzyme performance for alternative fuels, industrial, and health/nutrition processes. Diversa’s patented gene mining and DirectEvolution technologies have yielded the world’s largest bank of biodiverse enzymes. These enzymes enable manufacturers to make products more efficiently and inexpensively while protecting the environment. Diversa’s goal is to be the leadiing provider of industrial enzymes and biologically active compounds for use in unique, economically attractive applications. The key elements of Diversa’s strategy are to: Further enhance their technology leadership position Continue strong focus on alternative fuel markets Expand their existing DNA libraries through access to novel genetic material and utilize our proprietary technologies to discover new genes and gene pathways Deploy their technologies across diverse markets in order to maximize their return on investment Pursue additional strategic alliances with market leaders to access funding and industry-specific expertise Independently develop and commercialize products in specific markets to capture their full economic value Discover, modify and commercialize protein-based enzyme catalysts for chemical synthesis and industrial processes Discover new lead drug compounds from bioactive pathways in microorganisms and transgenic application of enzymes to plants for insect and disease control


BASF AG Diversa to discover and optimize new enzymes, BASF responsible for product and process development and commercialization

alliance 2/06

Cargill Health and Food Technologies

enzymes for the cost- effective production of a proprietary product


4/05

Merck & Co. Inc. therapeutic antibodies using Diversa's MedEv platform

development agreement, expanded 6/05

1/05

RESEARCH & DEVELOPMENT: Alternative energy Specialized industrial processes Health and nutrition

PRODUCTS ON MARKET: Valley Ultra-Thin™ improves ethanol production Luminase™ enzyme Phyzyme™ XP enzyme (for pigs and chickens) Quantum Phytase™ (for pigs and chickens) Pyrolase™ 160 enzyme ThermalAce™ DNA Polymerase Bayovac® SRS (vaccine for farmed salmon, available in Chile)

PRODUCTS IN DEVELOPMENT: Name Status Sordarins antifungal in preclinicals Purifine (converts biomass to biofuel) in development Amylase-T in regulatory review (U.S.) Enzyme cocktail for cellulosic ethanol production (unnamed)

in development

Phytase-T in development Various antibodies, anti-SARs, anti-anthrax and anti-plague antibodies

in development



DNA Technologies Inc.

201 Perry Parkway, Suite 1 Gaithersburg MD 20877, US Phone: (301) 956-1065; Fax: (301) 963-2156 Web: www.dnati.com; E-mail: [email protected]

KEY PERSONNEL: Dr. Javed Siddiqi; Chairman, President and CEO



FACILITIES: 3,000 sq. ft. R&D facility 3,000 sq. ft. manufacturing facility


BUSINESS STRATEGY: Market kits for DNA research Market contract research for molecular biology

RESEARCH & DEVELOPMENT: Molecular biology research

PRODUCTS ON MARKET: Cloning and screening kits Gene expression kits Premade Western blots

DOE Joint Genome Institute

2800 Mitchell Drive Walnut Creek CA 94598, US Phone: (925) 296-5670 Web: www.jgi.doe.gov E-mail: [email protected]

KEY PERSONNEL: Dr. Edward M. Rubin; JGI Director Dr. Steven Chu; Director, Lawrence Berkeley National Laboratory


HISTORY: Founded in 1997, JGI is a collaboration of Lawrence Livermore, Lawrence Berkeley, and Los Alamos National Laboratories funded by the Department of Energy's Office of Biological and Environmental Research

FACILITIES: 56,600 sq. ft. Production Genomics Facility (PGF) in Walnut Creek, Calif.


SUBSIDIARIES/DIVISIONS: JGI partner institutions include Oak Ridge National Laboratory (genome annotation), Pacific Northwest National Laboratory (proteomics) and Stanford Genome Center (finishing)

SUBSIDIARY OF: U.S. Department of Energy (DOE)

FINANCIAL INFORMATION: Funding for JGI is predominantly from the Office of Biological and Environmental Research in DOE’s Office of Science, with additional support from NIH, NSF, USDA and NASA

BUSINESS STRATEGY: Develop and exploit new sequencing and other high-throughput, genome-scale and computational technologies as a means for discovering and characterizing the basic principles and relationships underlying the organization, function and evolution of living systems Leverage the unique capabilities of the Department of Energy National Laboratory system to achieve these goals, and to use the resulting understanding to address key DOE missions related to energy, the environment and human susceptibilities



RESEARCH & DEVELOPMENT: PROGRAMS:

Computational Genomics Evolutionary Genomics Production Sequecing Vertebrate Biology Microbial Genome Analysis Microbial Ecology Technology Development Community Sequencing Program (CSP): www.jgi.doe.gov/CSP GENOMES: Human Chromosomes 5, 16, 19, Poplar, Xenopus tropicalis, Fugu rubripes, Ciona intestinalis, over 200 microbes and microbial communities. COMPUTATIONAL/BIOINFORMATIC TOOLS: Integrated Microbial Genome (IMG) analysis data management system: http://img.jgi.doe.gov/v1.1/main.cgi

Dojindo Laboratories

2025-5 Tabaru, Mashiki-machi, Kamimashiki-gun Kumamoto 861-2202, Japan Phone: +81-96-286-1515 Fax: +81-96-286-1525 Web: www.dojindo.co.jp, www.dojindo.com E-mail: [email protected], [email protected]

KEY PERSONNEL: Eiji Noda; President Mutsuo Yoshida; Marketing Director, Japan Yasuo Okumura; Marketing Director, USA Kenichi Mitsuda; Marketing Director, China


HISTORY: Founded in September 1978


SUBSIDIARIES/DIVISIONS: Dojin Glocal Corp. Dojin East Dojindo Molecular Technologies Inc. Dojindo China Republic (Shanghai)

RESEARCH & DEVELOPMENT: Labeling reagents for protein analysis

Cell viability and cytotoxicity assay Oxidative stress detection Nitric oxide research Spin trap compounds Intracellular fluorescent probes New water-soluble tetrazolium salts Reagents for self-assembled monolayers Detergents for life science research and industry

PRODUCTS ON MARKET: Reagents for life science research, Miscellaneous biochemical reagents, Organic analytical reagents, Quick test kits, Specialty organic materials, Reagents for peptide synthesis, Bifunctional cross-linking reagentsm, Reagents for cell biology, Tetrazolium salts, Calcium chelators Ionophores Colloid titration kits Reagents for research into NO pathway



Don Whitley Scientific Ltd.

14 Otley Road Shipley BD17 7SE, UK Phone: +44 (0)1274-595-728; Fax: +44 (0)1274-531-197 Web: www.dwscientific.co.uk; E-mail: [email protected]

KEY PERSONNEL: Don Whitley; Chairman Paul Walton; Managing Director Dr. Peter Silley; Research Director Nyk Kosmirak; Director, Finance Andrew Pridmore; Head, Microbiology Sally Shelton; Export Manager




BUSINESS STRATEGY: Develop, manufacture and sell innovative scientific instruments and associated products for microbiological applications worldwide, ranging from simple reagents through automated instrumentation for the detection and enumeration of micro-organisms to specialised workstations

AGREEMENTS: Name Products Content of Agreement Date AES Laboratoire dilumat 3 media

preparation exclusive distribution agreement for the U.K.

7/95

Synoptics Ltd. protocol (image analysis)

exclusive distribution agreement for the U.K.

2/92

Warnex inc. Genevision pcr for food exclusive distributorship in the U.K.

9/04

RESEARCH & DEVELOPMENT: Focus is on the enhancement of existing technologies and the development

of novel microbiological products and services

PRODUCTS ON MARKET: Modular Atmosphere Controlled Systems (MACS) Whitley Automatic Spiral Plater (WASP) Rapid Automated Bacterial Impedance Technique (RABIT) Contract microbiological services (GLP compliant laboratory) Autoclaves (65 to 150 liters)

Dong-A Pharmaceutical Co. Ltd.

252 Yongdu-Dong, Dongdaemun-Gu Seoul, Korea Phone: +82 2 920 8220; Fax: +82 2 925 4026 Web: www.donga.co.kr E-mail: [email protected]

KEY PERSONNEL: Kang Shin-Ho; Chairman Yu Chung-Sik; Vice Chairman Kim Won-Bea; President


HISTORY: Founded in December 1932 Incorporated in 1949

STOCK-FINANCIAL HISTORY: KSE--000640.KS Sales W533.625b (YE 05) compared to W541.214b (YE 04) Net income W25.413b (YE 05) compared to W26.575b (YE 04)



Earnings per share W2.886K/share (YE 05) compared to W3.239K/share (YE 04) Total assets W576.726b (YE 05) compared to W556.434b (YE 04)

SUBSIDIARIES/DIVISIONS: Dong-A America Corp. 5348 Lindbergh Lane Bell, CA 90201 Phone: (323) 261-9400 Fax: (323) 261-9500

AGREEMENTS: Name Products Content of Agreement Date Toyama Chemical Co. Ltd.

quinolone antibacterial eye drops TN-3262a (tosufloxacin tosilate)


PRODUCTS ON MARKET: Biologicals: Eporon, Growtropin II, Leucostim, Stifol and Viteron Ethical drugs: Alofia, Caltonin, Cholesnone, Closerinn, Diflex, Gabapentin, Gemcit, Glimel, Melanon, Melocox, Orodipine, Pantoline, Riopedone, Stillen, Vasotrol, Zydena OTC: Bacchus, Bacchus Sugar Free, Bacchus-D, Baccus-X, Korean Ginseng Royal Jelly, Korean Ginseng Ginkgo, Panpyrin® F Liquid, Panpyrin® F capsule, Champ Cold®, Amcilon® Tablet, Garglin Mint® Mouth Wash, Garglin Dent® Mouth Wash, Garglin toothpaste, Tempo®, Circulan capsule, Kyean, Pompolic Liquid APIs: Cycloserine, epirubicin hydrochloride, formoterol fumarate, gemcitabine hydrochloride, terizidone, topiramate, voglibose Cosmetics

PRODUCTS IN DEVELOPMENT: Name Status DA-3801 for infertility in Phase III clinicals DA-6034 for ulcerative colitis and Crohn's disease

in Phase II clinicals

VMDA-3601 for ischemic disease in Phase II clinicals GX-12 for AIDS in Phase I clinicals DA-9102 for atopic dermatitis in Phase II clinicals

Dow AgroSciences LLC

9330 Zionsville Road Indianapolis IN 46268, US Phone: (317) 337-3000; Fax: (317) 337-4096 Toll-free phone: (800) 208-4049 Web: www.dowagro.com E-mail: [email protected]

KEY PERSONNEL: Jerome Peribere; President and CEO Rogelio Lara; VP, Finance


HISTORY: DowElanco joint venture founded (1989) Acquired majority ownership in Mycogen Seeds (1996) Acquired by The Dow Chemical Co.; name changed to Dow AgroSciences (1997) Member--Biotechnology Industry Organization


SUBSIDIARIES/DIVISIONS: Agricultural and Specialty Chemicals

Plant Genetics and Biotechnology



SUBSIDIARY OF: The Dow Chemical Co. (see separate entry)

BUSINESS STRATEGY: Provide pest management and biotechnology products to improve the quality of the earth's food supply and contribute to the health and quality of life of the world's population


Chlorogen Inc. use of Chlorogen's chloroplast technology to produce animal health products in plant cell cultures

research agreements

9/05

Monsanto Co. new technology options and more choice in products for farmers

global business agreement

1/06

MTI GmbH exclusive rights to MTI's U.S. corn product development pipeline

licensing agreement

4/06

Sangamo BioSciences Inc.

ZFP TFs and ZFNs for plant agriculture

research and commercial licensing agreement

10/05

University of Melbourne

development of plant-made production systems for an avian Influenza vaccine


12/05

RESEARCH & DEVELOPMENT: Plant-cell-produced vaccines and antibodies for animals Improvement of crop production and delivery of improved agricultural outputs for a multitude of food and feed uses Improvement of plant components Use of conventional breeding techniques and biotechnology to produce oils low in saturated fat and trans fat free

PRODUCTS ON MARKET: Herbicides Insecticides Fumigants Fungicides Agronomic seeds and traits Healthy oils

PRODUCTS IN DEVELOPMENT: Name Status Concert Plant-Cell-Produced System approved

Dragon Pharmaceutical Inc.

650 West Georgia Street, Suite 310 Vancouver V6B 4N9, Canada Phone: (604) 669-8817; Fax: (604) 669-4243 Toll-free phone: (877) 388-DRUG (3784) Web: www.dragonbiotech.com; E-mail: [email protected]

KEY PERSONNEL: Yanlin Han; CEO Zhanguo Weng; VP, China Garry Wong; CFO Maggie Deng; COO


HISTORY: Founded in September 1998 Acquired Oriental Wave Holding Ltd. (1/05) To sell part of its formulation business to C&Y Pharmaceutical Investment Holdings Ltd. (as of 7/06)



FACILITIES: 258,300 sq. ft. manufacturing facility (for Pharma Division) in the Datong Economic and Technology Development Zone in Datong City, Shanxi Province, China 947,200 sq. ft. Chemical and Biotech Division facilities in Datong City

STOCK-FINANCIAL HISTORY: OTC BB--DRUG / TSX--DDD / BBSE--DRP

Net sales $56.245M (YE 05) compared to $29.023M (YE 04) Net income $182.6K (YE 05) compared to $6.362M (YE 04) Earnings per share $0.00/share (YE 05) compared to $0.14/share (YE 04) Average shares outstanding 62.274M (YE 05) compared to 44.502M (YE 04) Total assets $101.566M (YE 05) compared to $90.338M (YE 04)

SUBSIDIARIES/DIVISIONS: Chemical division--bulk pharmaceutical chemical Biotech division--recombinant drugs (EPO and G-CSF) Pharma division--prescription and over-the-counter drugs

AGREEMENTS: Name Products Content of Agreement Date Suzhou Zhongkai Bio-Pharmaceuticals Co. Ltd.

commercialization of rhG-CSF worldwide, excluding China

licensing agreement 2004

PRODUCTS ON MARKET: Prescription and over-the-counter generic drugs Bulk pharmaceutical chemicals Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF)

Droycon BioConcepts Inc.

315 Dewdney Avenue Regina S4N 0E7, Canada Phone: (306) 585-1762; Fax: (306) 585-3000 Web: www.dbi.sk.ca E-mail: [email protected]

KEY PERSONNEL: Dr. D. R. Cullimore; President and CEO Natalie Ostryznuik; Exec. VP Vincent Ostryzniuk; Operations Manager




BUSINESS STRATEGY: Specialize in applied microbial technology used in environmental diagnostics and bioremediation Focus on marketing of products and services

RESEARCH & DEVELOPMENT: Microbial technology as applied to biodetection and bioremediation in soil

and waste water

PRODUCTS ON MARKET: BART™ biodetector systems--portable devices for measuring water filtration and other properties of soil BART-READ--computer assisted BART measurement



DSM

P.O. Box 6500 Heerlen 6401 JH, Netherlands Phone: +31 45 578 81 11; Fax: +31 45 571 97 53 Web: www.dsm.com E-mail: [email protected]

KEY PERSONNEL: Peter Elverding; Chairman Arnold Gratama Van Andel; acting CFO Paul Fuchs; Corporate Secretary Rob van Leen; Chief Innovation Officer Bernard van Schaik; Communications


HISTORY: Founded in 1902 Aquired Chemie Linz and Deretil (1996) Aquired Gist-brocades (1998) Aquired Catalytica Pharmaceuticals (2000) Aquired Roche's Vitamins and Fine Chemicals Division (10/03) Acquired NeoResins (2/05)

FACILITIES: More than 250 offices and production sites in more than 40 countries

STOCK-FINANCIAL HISTORY: EURONEXT--DSMN

Net sales EUR8.195b (YE 05) compared to EUR7.832b (YE 04) Net profit EUR527M (YE 05) compared to EUR293M (YE 04) Earnings per share EUR2.68/share (YE 05) compared to EUR1.41/share (YE 04) Total assets EUR10.025b (YE 05) compared to EUR9.626b (YE 04)

SUBSIDIARIES/DIVISIONS: Nutrition--DSM Nutritional Products (Human nutrition and health, Animal nutrition and health), DSM Food Specialties Pharma--DSM Pharmaceutical Products, DSM Anti-Infectives Performance Materials--DSM Elastomers, DSM Engineering Plastics, DSM Resins and DSM Dyneema Industrial Chemicals--DSM Fibre Intermediates, DSM Melamine, DSM Agro and DSM Energy DSM Venturing and Business Development

BUSINESS STRATEGY: Create innovative products and services that help improve the quality of life in the areas of human and animal nutrition and health, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics and electronics

AGREEMENTS: Name Products Content of Agreement Date Genomatica Inc. Genomatica's

SimPheny and licensing agreement

4/05

Genomatica Inc. implementation of Genomatica's metabolic modeling and simulation technologies and capabilities to help DSM develop improved biological processes for product production

expanded multi-year collaboration and licensing agreement

6/06

PRODUCTS ON MARKET: Products for the pharmaceutical, food and feed and agrochemical industries

High-quality materials such as UV-coatings for optical fibers, elastomers, engineering plastics and resins for dry and wet paints and for the production of pipes, tanks and containers Production of fiber feedstock, melamine and fertilizers Production of HPPE fiber for life protection, leisure, marine and medical applications



DSM Fine Chemicals

P.O. Box 43 Sittard 6130 AA, Netherlands Phone: +31 (46) 4773487; Fax: +31 (46) 4773172 Web: www.dsm.com E-mail: [email protected]

KEY PERSONNEL: Jan Wolters; Business Group Director, DSM Fine Chemicals Andrea Pollak; Business Unit Director, DSM ACTIS Frank Teeuwisse; Business Unit, Director DSM Minera Jan Vriens; Business Unit Director, Special Products

EMPLOYEES: 2,700 employees HISTORY: Acquired BMS Regensburg (fine chemicals activities)

Acquired 70% of Chemie Linz (Austria) (1/96) Acquired Deretil (9/96)

FACILITIES: Plant in Holland to produce aspartame Multipurpose plants for fine chemical intermediates produced by enzyme technology Biotech R&D facility


SUBSIDIARIES/DIVISIONS: Three business units: DSM ACTIS DSM Minera DSM Special Products

SUBSIDIARY OF: DSM (see separate entry)

INVESTMENTS: Holland Sweetener Co.--joint venture with TOSOH Corp. for aspartame

Chemferm--joint venture with Gist-brocades for semi-synthetic cephalosporines Bio-Intermediair International Holding BV--7%

BUSINESS STRATEGY: Mission: To become the partner of choice for innovative life science companies based upon: -A superior technology toolbox -Optimal production facilities -Service throughout the product life cycle To ensure our customers benefit from our global leadership and extensive expertise in: -The manufacturing of standard and advanced intermediates -The manufacturing of active ingredients -Upscaling from kg- to ton-scale -New process development -Exclusive synthesis and custom development

RESEARCH & DEVELOPMENT: Aspartame

L- and D-amino acids via enzymatic resolutions, as well as other optically active compounds

PRODUCTS ON MARKET: REGULAR PRODUCTS: Acetaldehyde oxime, Acetonyl succinic acid diethylester, 2-Acetylnicotinic Acid, Allantoin, 2-Amino-4,6-dimethoxypyrimidine, D,L-Aspartic acid, L-Aspartic acid, Benzaldehyde, Benzoic acid, Benzylalcohol, N-Bromosuccinimide, N-tert.-Butylacrylamide, N-Butyl levulinate, Carbethoxypyrazolone, N-Chlorosuccinimide, Cinnamic alcohol, Cinnamic aldehyde, Copper iodide, 1,3-Cyclohexanedione, 1,4-Cyclohexanedione, Cyclohexanone oxime, Diacetone acrylamide, 1,4-Diaminobutane, N,N’-Dibenzylethylenediamine diacetate, N,N-Dibenzylamine, 1,3 Dibromo-5,5-dimethylhydantion, 2,2 Dichlorophenylacetic acid ethylester, Diethyl maleate, Diethyl succinate,



Diethylacetal succinate, Diisopropyl succinate, Dimethyl maleate, Dimethyl succinate, Dimethyl succinylo succinate, Dimethylacetyl succinate, 2,3-Dimethylpyridine (2,3-Lutidine), Di-n-butyl fumarate, Di-n-butyl maleate, Dioctylfumarate, Dioctylmaleate, Fumaric acid, Glyoxylic acid 50%, Glyoxylic acid methylester methylhemiacetal, sec.-Guanidine phosphate, Iodine, Levulinic acid, Maleic acid, Maleic anhydride, Methyl iodide, Monosodium fumarate, D,L-Phenylalanine, 3-Phenylpropanol-1, o-Phthalaldehyde, Potassium benzoate, Potassium iodate, Potassium iodide, Potassium iodide with Ca-Stearate, Potassium iodide with tixosil, 2,3-Pyridine dicarboxylic acid, Pyrrolidine, Pyruvic acid ethylester (ethyl pyruvate), Pyruvic acid methylester (methyl pyruvate), Sodium benzoate, Sodium iodide, Sodium metaperiodate, Succinic acid, Succinic anhydride, Succinimide, 1,2,4-Triazole, 1,2,4-Triazole, sodium salt (sodium triazole), Trimethylsulfoxonium iodide DEVELOPMENT PRODUCTS: Adipic acid dihydrazide, (R)-2-Chloro-mandelic acid, Diethoxyethyl acetate, Diethyl succinylo succinate, 2,5-Dimethoxytetrahydrofuran, Diphenyl acetic acid, Glyoxylic acid ethylester ethylhemiacetal, Glyoxylic acid methylester, Glyoxylic acid monohydrate, 2-Hydroxymethylpyrimidine, 1,8-Octanedialtetramethylacetal, 1,8-Octanediol, N-tert.-Octyl-acrylamide, 4-Oxobutanoic acid methylester, Phthalazine, 2-Picolinic acid, Pyridine-2-aldehyde

DuPont

Chestnut Run Plaza 728/1307 Wilmington DE 19880, US Phone: (866) 476-7662 Toll-free phone: (866) 476-7662 Web: www.sorona.dupont.com

KEY PERSONNEL: Charles O. Holliday Jr.; Chairman and CEO Richard R. Goodmanson; Exec. VP and COO Jeffrey L. Keefer; Exec. VP and CFO James C. Borel; Sr. VP, Human Resources Terry Caloghiris; Group VP, Coatings & Color Technologies Uma Chowdhry; Sr. VP, CSO and CTO Thomas M. Connelly; Exec. VP and Chief Innovation Officer J. Erik Fyrwald; Group VP, Agriculture & Nutrition Diane H. Gulyas; Group VP, Performance Materials John C. Hodgson; Sr. VP and Chief Marketing and Sales Officer W. Donald Johnson; Chairman and Representative Director, DuPont KK Ellen J. Kullman; Exec. VP, Safety & Protection, Coatings & Color Technologies, Marketing & Sales and Safety & Sustainability Stacey J. Mobley; Sr. VP and Chief Administrative Officer and General Counsel Craig G. Naylor; Group VP, Electronic & Communication Technologies Gary M. Pfeiffer; Sr. VP Mark P. Vergnano; Group VP, Safety & Protection Mathieu Vrijsen; Sr. VP, Operations & Engineering



FACILITIES: Operates in more than 70 countries More than 40 R&D and customer service labs in the U.S., and more than 35 labs in 11 other countries

STOCK-FINANCIAL HISTORY: NASDAQ--DD Net sales $26.639b (YE 05) compared to $27.340b (YE 04) Net income $2.053b (YE 05) compared to $1.780b (YE 04) Earnings per share $2.08/share (YE 05) compared to $1.78/share (YE 04)



SUBSIDIARIES/DIVISIONS: Agriculture and Nutrition Coatings and Color Technologies Electronic and Communication Technologies Performance Materials Pharmaceuticals Safety and Protection Subsidiaries: Agar Cross SA--Argentina Antec International Ltd.--U.K. Building Media Inc.--Delaware ChemFirst Inc.--Mississippi Christiana Insurance Ltd.--Bermuda Destination Realty Inc.--Delaware DPC (Luxembourg) SARL DPC S/A Brazil DPC South America--Brazil DSRB Ltda. Brazil DuPont Kansai Automotive Coatings Co.--Delaware DuPont (Australia) Ltd. DuPont (Korea) Inc. DuPont (New Zealand) Ltd. DuPont (South America) Holdings LLC--Delaware DuPont (Thailand) Co. Ltd. DuPont (U.K.) Investments DuPont (U.K.) Ltd. DuPont Agricultural Caribe Industries Ltd.--Bermuda DuPont Agricultural Chemicals Ltd.--China DuPont Agro Hellas SA--Greece DuPont Argentina SA--Argentina DuPont Asia Pacific Ltd.--Delaware DuPont Beteiligungs GmbH--Austria DuPont BVco BV--Netherlands DuPont Capital Management Corp.--Delaware DuPont Chemical and Energy Operations Inc.--Delaware DuPont China Holding Co. Ltd. DuPont China Ltd.--Hong Kong DuPont China Ltd. (U.S.)--Delaware DuPont Coatings SAS France DuPont Company (Singapore) Pte. Ltd. DuPont Conid SpA Delaware DuPont Coordination Center NV--Belgium DuPont CZ sro--Czech Republic DuPont DACI Beteiligungs GmbH--Austria DuPont Danmark ApS--Denmark DuPont de Colombia SA DuPont de Nemours (Belgium) BVBA DuPont de Nemours (Deutschland) GmbH--Germany DuPont de Nemours (Flandre) SA--France DuPont de Nemours (France) SAS DuPont de Nemours (Luxembourg) SARL DuPont de Nemours (Nederland) BV DuPont de Nemours Development SA--Switzerland DuPont de Nemours Groupe SARL--France DuPont de Nemours International SA--Switzerland DuPont de Nemours International SA--South Africa DuPont de Nemours Italiana Srl DuPont Deutschland Holding GmbH & Co. KG--Germany DuPont Diagnostics Inc.--Delaware DuPont Display Enhancements Inc.--California DuPont Displays Inc.--California DuPont do Brasil SA DuPont Performance Elastomers LLC--Delaware DuPont Eastern Europe BV--The Netherlands DuPont Elastomers Inc.--Delaware



DuPont Electronic Materials Inc.--Delaware DuPont Electronics Microcircuits Industries Ltd.--Bermuda DuPont Energy Co. LLC--Delaware DuPont Engineering Products SARL--Luxembourg DuPont Environmental Remediation Services Inc.--Delaware DuPont Far East Inc.--Delaware Dupont Far Eastern Petrochemicals Ltd.--China DuPont Feedstocks Co.--Delaware DuPont Flandre Finance--France DuPont Foreign Sales Corp.--Virgin Islands DuPont Global Operations Inc.--Delaware DuPont Herberts Automotive Systems Services BVBA--Belgium DuPont Holdco Spain I SL--Spain DuPont Holdco Spain II SL--Spain DuPont Holographics Inc.--New York DuPont Iberica SL--Spain DuPont India Ltd.--Delaware DuPont International (Luxembourg) SCA DuPont International Trading Inc.--Delaware DuPont Kabushiki Kaisha--Japan DuPont KGA BV--The Netherlands DuPont Khimprom--Russia DuPont Medical Products Inc.--New York DuPont Mexico SA de CV DuPont North America Inc.--Delaware DuPont NLco BV--The Netherlands DuPont Operations (Luxembourg) SARL DuPont Operations Inc.--Delaware DuPont Operations Worldwide Inc.--Delaware DuPont Orient Operations Ltd.--Delaware DuPont Performance Coatings France SAS DuPont Performance Coating Nederland BV DuPont Performance Coatings (Thailand) Ltd. DuPont Performance Coatings (U.K.) Ltd. DuPont Performance Coatings Austria GmbH DuPont Performance Coatings GmbH & Co KG--Germany DuPont Performance Coatings Iberica SL--Spain DuPont Performance Coatings Polska Spolka zoo--Poland DuPont Performance Coatings Pty. Ltd.--Australia DuPont Performance Coatings Scandinavia AB--Sweden DuPont Performance Coatings Inc.--Delaware DuPont Performance Coatings Tintas e Vernizes SA--Portugal DuPont Pharma Inc.--Delaware DuPont Poland BV--The Netherlands DuPont Poland Sp zoo--Poland DuPont Polimeros Ltda.--Brazil DuPont Polyester Europe Aps--Denmark DuPont Polymer Powder SARL--Switzerland DuPont Powder Coatings (Malaysia) Sdb. DuPont Powder Coatings Andina SA--Colombia DuPont Powder Coating Belgium NV DuPont Powder Coatings France SAS--France DuPont Powder Coatings Iberica SL--Spain DuPont Powder Coatings Saudia Co. Ltd.--Saudi Arabia DuPont Powder Coatings Scandinavia AB--Sweden DuPont Powder Coatings U.K. Ltd. DuPont Powder Coatings USA Inc.--Delaware DuPont Protective Apparel Marketing Co.--Delaware DuPont Pulverlack Deutschland GmbH & Co. KG--Germany DuPont Quimica de Venezuela CA DuPont SA de CV--Mexico DuPont Scandinavia GmbH--Germany DuPont Services BV--The Netherlands DuPont Specialty Grains (dba Optimum Quality Grains LLC)--Delaware DuPont Taiwan Ltd.



DuPont Textile Fibers SA--China DuPont Textiles & Interiors (South America) Holdings LLC--Delaware DuPont Textiles & Interiors Holdings Inc.--Delaware DuPont Trading (Shanghai) Co. Ltd.--China DuPont Treasury Ltd.--U.K. DuPont Vespel Parts and Shapes Inc.--Pennsylvania DuPont Wirex Ltd.--Taiwan E.I. du Pont Canada Co. E. I. DuPont India Private Ltd. India EID Singapore Inc.--Delaware Electronic Materials DuPont Dongguan Ltd.--China Entek Corp.--Delaware Entek Europe Inc.--Delaware Granirex--California Griffin Brasil Ltda. Griffin Colombia SA Griffin LLC--Delaware Helmstedter Lack-und Chemische Fabrick GmbH & Co. KG--Germany Herberts America Inc.--Delaware Herberts Mexico SA de CV Herberts Plascon Pty. Ltd.--Delaware Hickory Holdings Inc.--Delaware Holding DP SA de CV--Mexico Huajia Chemical Co.--China IDAC Belgium – EP Branch BVBA Initiatives de Mexico SA de CV International Dioxcide Inc.--Delaware Liqui-Box Corp.--Ohio Permatex Italia Srl Pioneer Hi-Bred International Inc.--Iowa Pitt-Consol Chemical Co.--New Jersey PT DuPont Agricultural Products--Indonesia PT DuPont Powder Coatings--Indonesia Renner DuPont SA Brazil Sentinel Transportation LLC--Delaware Solae Holdings LLC--Delaware Solae LLC (dba The Solae Co.)--Missouri Spies-Hecker GmbH--Switzerland Sporting Goods Properties Inc.--Delaware Teodur BV--The Netherlands UNIAX Corp.--California Verdia Inc.--Delaware Verniplast SA--Switzerland

INVESTMENTS: Joint venture with Tate & Lyle plc--formed to produce 1,3-propanediol (PDO)

BUSINESS STRATEGY: Offer a wide range of products and services for markets including agriculture, nutrition, electronics, communications, safety and protection, home and construction, transportation and apparel

AGREEMENTS: Name Products Content of Agreement Date Affinergy Inc. R&D of new line of bio-

based products for DuPont's BioSurfaces business


BP development, production and marketing of a next generation of biofuels

partnership 6/06

RESEARCH & DEVELOPMENT: Core Research Competencies of DuPont R&D: Chemical science and catalysis: Chemical synthesis, all fields of chemistry, catalysis, combinatorial chemistry, discovery chemistry, fine particle synthesis



Leveraged technologies: Analytical science, information science, image processing, computer science, modeling and simulation, properties modeling Biology: Agronomy, Ag environmental chemistry, Ag formulation science, biochemistry, biochemical engineering, bioinformatics, cell culture, ecosphere modeling, genetics, genomics, microbiology, molecular biology, plant science Material science and engineering: Polymerization fundamentals, polymer modifications, multi-component polymer systems, interfacial science, polymer recycling, polymer characterization, polymer process development, polymer fabrication, fiber science and engineering, fibrous/fibrid systems engineering, composite structures, coatings, photosensitive coatings and materials, color science, interfacial science, polymer synthesis, solidification, image substrate materials Process science and engineering: Digital imaging systems; environmental engineering; hazards evaluation and control; materials engineering; operations optimization; particle technology; process development/scale-up; process measurement and control; process modeling and simulation; process synthesis; reaction engineering; thermodynamics, kinetics, mechanisms; transport phenomena; unit operations; experimental design and empirical modeling

PRODUCTS ON MARKET: Autograph® non-stick coating for cookware DuPont™ Air Filters DuPont™ Biodegradable Stakes™ DuPont™ Bird Netting™ DuPont™ Deer Netting™ Corian® solid surface DuPont™ Carbon Monoxide Alarms DuPont™ Car Care Products DuPont™ FlameResist™ Blanket DuPont™ Frost Blanket™ DuPont™ Garden Products™ Granite Certified by DuPont GreenVista™ garden products Kevlar® ballistic protection DuPont™ Pool Care System DuPont™ Self-Charging Smoke Alarms DuPont™ Spa Care System DuPont™ Seed Bed Cover™ DuPont™ Seed Germination Blanket™ Kevlar® StormRoom™ residential in-home storm shelter SentryGlas® safety glass interlayer Simplicity™ solid surfaces Solae® soy protein Stain Protectors Teflon® surface coatings Tyvek® envelopes Tyvek® fibers Tyvek® HomeWrap® Tyvek® StuccoWrap® Tyvek® tape Tyvek® ThermaWrap™ DuPont™ Vinyl Flooring DuPont™ Garden Products™ Weed Control Fabric Water Filtration Zodiaq® solid surface



Dyadic International (USA) Inc.

140 Intracoastal Pointe Drive, Suite 404 Jupiter FL 33477-5094, US Phone: (561) 743-8333; Fax: (561) 743-8343 Web: www.dyadic-group.com; E-mail: [email protected]

KEY PERSONNEL: Mark Emalfarb; Chairman, President and CEO Wayne Moor; CFO Dr. Glenn Nedwin; CSO Kent Sproat; Exec VP, Enzymes Ray Chandra; Sr. VP, Marketing, Biotech Systems Alexander (Sasha) Bondar; VP, Corporate Development Charles W. (Bill) Kling IV; VP, Sales and Marketing, Enzymes Dan Michalopoulos, Ph.D.; VP, Pulp and Paper Richard Burlingame, Ph.D.; Exec. Director, R&D



STOCK-FINANCIAL HISTORY: AMEX--DIL Revenue $15.9M (YE 05) compared to $16.7M (YE 04) Net loss <$10.5M> (YE 05) compared to <$6.1M> (YE 04) Loss per share <$0.48/share> (YE 05) compared to <$0.37/share> (YE 04)

PRIVATE PLACEMENTS: Raised $2.1M in warrants and options exercise (5/06)

SUBSIDIARIES/DIVISIONS: Enzyme Business Biosciences Business

BUSINESS STRATEGY: Leverage its technology platform to discover novel genes and biological products for use by its strategic partners, and to further the company’s own R&D efforts Seek strategic alliances with leaders in the agricultural, biological, industrial, chemical and biopharmaceutical industries that have in-house genomic capabilities. Collaborate with companies whose genomic capabilities are limited in order to discover and express biological materials for these strategic partners Commercialize enzymes for use in targeted markets including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries

RESEARCH & DEVELOPMENT: Discover, develop and manufacture novel products derived from the DNA of

complex living organisms (including humans) Development of biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries Discovery and expression of eukaryotic genes and manufacturing for commercial application

Dynavax Europe

Eichsfelder Strasse 11 Dusseldorf 40595, Germany Phone: +49 (0)211 7 58 45 0; Fax: +49 (0)211 7 58 45 130 Web: www.rheinbiotech.de E-mail: [email protected]

KEY PERSONNEL: Zbigniew Janowicz, Ph.D.; CEO, Dynavax Europe Petra Zimmer; CFO Oliver Bartelsen, Ph.D.; Director, Business Development




HISTORY: Founded and began biotech R&D in 1985 Acquired by Berna Biotech AG (2002) Acquired by Dynavax Technologies Corp. (4/06) Changed name from Rhein Biotech GmbH (4/06)


SUBSIDIARY OF: Dynavax Technologies Corp. (see separate entry)

BUSINESS STRATEGY: Develop proprietary biopharmaceutical products and establish strategic

alliances designed to leverage and add value to the company's core capabilities in the areas of process, analytical and preclinical development, quality control, quality assurance, manufacturing and technology transfer Through marketing and sales of recombinant antigens on the diagnostic market, leverage the value of the established vaccine production technologies

EMD Biosciences Inc./Merck Biosciences

10394 Pacific Center Court San Diego CA 92121, US Phone: (858) 45005500; Fax: (858) 453-3552 Web: www.emdbiosciences.com

KEY PERSONNEL: Douglas S. Brown; President and CEO Hans Ahl; GM, European Sales and Marketing


HISTORY: Established in 1952 as a manufacturer of research biochemicals

Sold to Hoechst Corp. in 1977 Sold to Biodor in 1988 Sold to Warburg, Pincus and Alex Brown in 1992 Acquired Oncogene Science Research Products division (8/95) Changed name from Calbiochem-Novabiochem International (7/96) Acquired Novagen (12/97) Acquired by Merek KGaA, Dormstadt, Germany (12/98) Changed name from CN Biosciences Inc. (2/03) The company, an affiliate of Merck KGaA, is known as EMD Biosciences in North America and as Merck Biosciences in all other countries

FACILITIES: Manufacturing facilities in San Diego, Calif.; Cambridge, Mass.; Madison, Wis.; and Switzerland


SUBSIDIARY OF: Merck KGaA (see separate entry)

AGREEMENTS: Name Products Content of Agreement Date Chromagen Inc. Chromagen's Direct

Read RNA and DNA assays and other products in life sciences research market

multiyear marketing and distribution agreement--CN Biosciences' subsidiary Calbiochem-Novabiochem Corp. gains exclusive access to certain research uses of products and technology that Chromagen has developed for other markets

3/98



Epitome Biosystems

products based on Epitome's EpiTag technology

licensing and development agreement

9/05

German Resource Center for Genome Research

genome research cooperative agreement

11/04

RESEARCH & DEVELOPMENT: Molecular biology kits and reagents Cellular reagents, including caged compounds, antibodies, intracellular probes, inhibitors, signal transduction tools, apoptosis tools, proteins, amino acid derivatives, peptides, buffers, detergents, combinatorial chemistry linkers and resins Development of custom products on contractual basis

PRODUCTS ON MARKET: More than 15,000 products on the market, including signal transduction reagents, molecular biology kits and reagents, apoptosis reagents, cancer study reagents, combinatorial chemistry, Buffers, Zwittergent® detergents, Ultrol® grade detergents and buffers, Pronase® protease, Pansorbin® cells, reagents for peptide synthesis, peptides, inhibitors, enzymes, proteins, antibodies, immunochemicals, antibodies to signaling proteins, calcium modulators, neurochemicals and neurotoxins

eMembrane Inc.

4 Richmond Square, Suite 500 Providence RI 02906, US Phone: (401) 861-9770; Fax: (401) 861-9777 Web: www.emembrane.com E-mail: [email protected]

KEY PERSONNEL: William Lee, Ph.D.; President and CEO


HISTORY: Founded in November 2000


PRIVATE PLACEMENTS: Raised $370K in three rounds of financing

PRINCIPAL INVESTORS: Slater Technology Fund --Angels

BUSINESS STRATEGY: Vision: Be the world leader in research, development and commercialization of Multifunctional Polymeric Materials and Membranes for chemical and biological applications Mission: To enable chemical and biotech companies to create innovative and cost-effective solutions to problems of separating and handling chemical and biological materials by using proprietary technology to functionalize polymeric materials and membranes used in systems and devices

RESEARCH & DEVELOPMENT: Nano-grafting of combinatorial functionalized polymer brushes



EnSolve Biosystems Inc.

3209 Gresham Lake Road, Suite 147 Raleigh NC 27615, US Phone: (919) 954-6196; Fax: (919) 954-6197 Web: www.ensolve.com E-mail: [email protected]

KEY PERSONNEL: Dr. Jason Caplan; Chairman, President and CEO




BUSINESS STRATEGY: Develop biospecialty products that eliminate pollutants from air, water and soil using biotechnology

AGREEMENTS: Name Products Content of Agreement Date Bath Iron Works Petroliminator, Oily

Water Separator marketing agreement for U.S. Navy projects

8/01

Burlington Chemical

specialty chemicals--EnSolve's GreaseFeast biocleanser

sales and distribution agreement

1/97

PRODUCTS ON MARKET: PetroLiminator® bilge water treatment system

GF 2010™ multi-purpose liquid detergent EnCell™ bioreactor EnFlow Air Filter GreaseFeast® biocleanser Oxi-Blast™ non-polluting cleaner EnSorb, granular formulation of EnSolve's oil degrading microbes

Enviro-Zyme International LLC

2885 Bartells Drive Beloit WI 53511, US Phone: (800) 882-9904; Fax: (608) 361-9883 Toll-free phone: (800) 882-9904 Web: www.envirozyme.com E-mail: [email protected]

KEY PERSONNEL: Jay Silverstein; Chairman and President Karen Silverstein; VP


HISTORY: Founded in March 1989

FACILITIES: 20,000 sq. ft. headquarters and manufacturing facility in Beloit, Wis.


BUSINESS STRATEGY: Manufacture products that are all biodegradable, non-toxic, non-corrosive and non-volatile

PRODUCTS ON MARKET: Degradation of hydrocarbons in wastewater treatment facilities, septic

systems, and grease traps in kitchens and bioremediation of oil, aliphatic, aromatic chemical pollutants, and composting BR--Bioremediation of aliphatic and aromatic pollutants C--degradation of cellulose COMP--for composting mulch and sludge DIN--for nitrification and denitrification (liquid)



DOC--biological odor control EZ--sludge reduction and odor control GT--degradation of grease, oils and fats in kitchen grease traps L--degradation of animal fats, oils and greases LGD--liquid for kitchen grease traps N--to control foaming, bulking or rising sludge caused by filamentors bacteria O--wintergreen fragrance and sludge reduction and odor control P--for phosphorus reduction Pouch--for lift stations, wet wells and pump stations R--for septic systems T--for hydrogen sulfide reduction XC--degradation of grease oils and fats in kitchen grease

Enzyme Research Laboratories Ltd

15 Sketty Road Swansea SA2 OEU, UK Phone: +44 (0)1792 466166; Fax: +44 (0)1792 466366 Web: www.enzymeresearch.co.uk E-mail: [email protected]

KEY PERSONNEL: Nils von Sicard, Ph.D.; Managing Director Michael Morris; Exec. VP Hazel Pannett; Office Manager

EMPLOYEES: 5 employees; 2 Ph.D.s



SUBSIDIARIES/DIVISIONS: Enzyme Research Laboratories Inc.

412 S. Lafayette South Bend, IN 46601 USA Phone: (574) 288-2268 Fax: (574) 288-2272

PRINCIPAL INVESTORS: Private LTD Co.

BUSINESS STRATEGY: A drug discovery company R&D targets new anticoagulant products for the treatment of blood clots, heart attacks and stroke

RESEARCH & DEVELOPMENT: Anticoagulants from blood sucking animals

PRODUCTS ON MARKET: ERL provides a number of high quality coagulation reagents to scientist involved in haemostasis and thrombosis research. Products include coagulation factors, polyclonal and monoclonal antibodies to coagulation factors, ELISA kits, haematological diagnostic kits and factor deficient plasmas

PRODUCTS IN DEVELOPMENT: Name Status TEPI (anticoagulant) in preclinicals



Epicore Networks (U.S.A.) Inc.

4 Lina Lane Eastampton NJ 08060, US Phone: (609) 267-9118; Fax: (609) 267-9336 Toll-free phone: (877) 374-2673 Web: www.epicorebionet.com E-mail: [email protected]

KEY PERSONNEL: Hugh C. Hart; Chairman William P. Long; CEO Paul Massam; Director, Business Development Nancy Robinson; Scientist William Castner; Purchasing Manager


HISTORY: Founded and began biotech R&D in March 1994

FACILITIES: 2,100 sq. ft. R&D facility 7,650 sq. ft. manufacturing facility

STOCK-FINANCIAL HISTORY: Parent company: TSX--EBN

SUBSIDIARIES/DIVISIONS: Epicore Ecuador SA Attn: Lorena Vanoni 9 de Octubre 2305 y Tungurahua Primer Piso- Dept. #1 Guayaquil, Ecuador Phone: 5939 783 5875 Fax: 5934 237 4167 E-mail: [email protected]

SUBSIDIARY OF: Epicore BioNetworks Inc.

BUSINESS STRATEGY: Grow through biological product sales

RESEARCH & DEVELOPMENT: Aquaculture environment treatments

Animal waste digestion Aquaculture feeds

PRODUCTS ON MARKET: Aquaculture: Epicin hatchery and pond treatment Epifeed LHF 1&2&3 liquid feed for hatcheries Epibal 150, 300 & 500 granular feed for hatcheries Epifeed MBF maturation feed Epizym VMC vitamin mineral concentrate Epizym BGM growth medium for Epicin Epizym AGP algae growth promoter Agriculture and Horticulture: Epizym AW animal waste liquifier and deodorizer Photozym liquid foliar spray and seed treatment Epithatch biological thatch digestor Bioremediation: Epizym HC microbial ecosystem for hydrocarbon digestion Nutripak companion product for Epizym HC Emulsifier companion product for Epizym HC Waste Water Management: Epizym 100 microbial ecosystem for municipal and industrial wastewater treatment Epizym 200 microbial ecosystem for biodegradation of hydrocarbons in wastewater



Cleaning and Sanitation: Epizym ST septic and RV tank treatment Epizym CU carpet and upholstery shampoo Epizym DT drain and grease trap cleaner Epizym DG aqueous cleaner and degreaser Epizym HS hard suface cleaner Epizym SR scale remover

Epidauros Biotechnologie AG

Am Neuland 1 Bernried 82347, Germany Phone: +49 (0)8158-9985 - 0; Fax: +49 (0)8158-9985 - 48 Web: www.epidauros.com E-mail: [email protected]

KEY PERSONNEL: Falk Nuber; Chairman Dr. Michael Lutz; CEO Hubert Wechner; VP, Human Resources, IT, and Finances Dr. Karl Kleine; VP, Quality Management Hans Peter Arnold, Ph.D.; Sr. Director, Business Development, Sales and Marketing Dr. Katrin Granderath; Director Genotyping Services Dr. Elke Roschmann; Sr. Manager, Business Development and Marketing Vera Sturma; Sr. Manager, Business Development and Marketing Dr. Stephan Reschauer; Director, Patents and Licensing




PRINCIPAL INVESTORS: DEWB

BUSINESS STRATEGY: Make drug development and therapy safer, more focused, and more cost efficient through pharmacogenetic research and application that investigates the genetic factors that influence a person's response to a drug Investigate and characterize variations of genes (polymorphisms) that encode drug transporter proteins and drug metabolizing enzymes, as well as investigate genes encoding drug targets to which drugs bind Offer pharmaceutical and biotechnology companies a comprehensive package of proprietary pharmacogenetic assays and services which will significantly improve the results of clinical studies and drug treatment


Focuc Clinical Drug Developemnt GmbH

R&D and co-marketing agreement

Parexel International

R&D and co-marketing agreement

Pharmacia Corp. R&D and co-marketing agreement

Tm Bioscience Corp.

Epidauros' patents on a biomarker related to the P450-CYP2D6 gene

co-exclusive commercial licensing agreement

3/06



PRODUCTS ON MARKET: Genotyping services Pharmacogenetic contract research Consulting

Eurogentec SA

LIEGE Science Park, Rue Bois Saint Jean 5 Seraing B-4102, Belgium Phone: +32 4 372 74 00; Fax: +32 4 372 75 00 Web: www.eurogentec.com E-mail: [email protected]

KEY PERSONNEL: Joseph Martial, Ph.D.; Chairman Jean-Pierre Delwart; CEO Gottfried Proess; Production Manager Veronique Distexhe; CFO Daniel Radoux; Sales and Marketing Manager Philippe Cronet; Biologics Business Unit Director


HISTORY: Founded in 1985 as a spin-off of the University of Liege Began biotech R&D in 1987 Established Nippon EGT joint venture in Japan (8/03)


PRIVATE PLACEMENTS: EUR5M private placement (2001)

SUBSIDIARIES/DIVISIONS: Subsidiaries: Eurogentec France s.a.s.u. Eurogentec Deutschland GmbH Eurogentec Nederland b.v. Eurogentec s.a., succursale de Genève Nippon EGT Co., Ltd. RB EGT (Singapore) Eurogentec North America, Inc. Eurogentec Ltd. Biotech-related divisions: Genomics Proteomics Biologics

BUSINESS STRATEGY: Design and deliver reliable and innovative services and products for the life science community Act as a leading supplier for genomic and proteomic research, in offering the company's customers integrated solutions, whether they use DNA, antibodies, peptides or proteins as research tools Offer research and development services for the biopharmaceutical industry


Alnylam Pharmaceuticals

research products and services in RNAi under Alnylam's Kreutzer-Limmer patent family

nonexclusive licensing agreement

7/05



EvoGenix Ltd.

2/37 Bligh Street Sydney NSW 2000, Australia Phone: +61 2 8257 3393 Fax: +61 2 8257 3399 Web: www.evogenix.com E-mail: [email protected]

KEY PERSONNEL: Christopher Harris; Chairman Merilyn Sleigh, Ph.D.; CEO Steffen Nock, Ph.D.; President, Evogenix Inc. and Exec. Director Robert Crombie, Ph.D.; COO and VP, Business Development David Wilson, Ph.D.; VP, Antibody Products George Kopsidas, Ph.D.; Director, Protein Technologies


HISTORY: Founded and began biotech R&D in August 2001 Acquired Absalus Inc. (4/05)

FACILITIES: Headquarters: Head office in the Sydney CBD Corporate and R&D facilities in Parkville, Melbourne EvoGenix Inc.: Leased facilities in Mountain View, Calif. Manufacturing: access to medium scale fermentation for protein production

STOCK-FINANCIAL HISTORY: Australian Stock Exchange--EGX IPO--36M shares at A$0.25/share, A$9M (7/05)

PRINCIPAL INVESTORS: Startup Australia Ventures Pty. Ltd.--33% BioFusion Capital Pty. Ltd.--6% CRC for Diagnostics--9%

BUSINESS STRATEGY: Utilise technology platform for protein optimisation by molecular evolution to build improved and novel therapeutic products for partners and internal pipeline. Through acquisition of US-based Absalus Inc., now Evogenix Inc., provide access to integrated humanization and optimisation for developing novel antibody products. Technology is also available for licensing.

AGREEMENTS: Name Products Content of Agreement Date Absalus Inc. combine technology strategic alliance 5/04 BresaGen Ltd. protein production

protocols R&D agreement 7/02

Cooperative Research Centre for Diagnostics

protein discovery and optimization technology patents

licensing agreement

7/01

CSL Ltd. EvoGenix to apply its technologies to CSL antibody products, in order to generate superior antibodies

technology collaboration

5/06

DiNonA Inc. antibody for treatment of leukemia


9/05

Domantis Ltd. affinity improve single domain antibodies

R&D agreement 8/03

Genesis R&D Corp.

select receptor-specific proteins

R&D agreement 5/03

GlaxoSmithKline plc

application of EvoGenix’s EvoGene technology to the optimisation of GSK compounds

research and collaboration agreement

10/05



University of Massachusetts Medical School

anticancer antibody licensing agreement

4/06

Viventia Biotech Inc.

affinity improve antibody products

R&D agreement 6/04

RESEARCH & DEVELOPMENT: Antibody optimization projects on behalf of partner companies (4)

commencing April 2003 Internal project for improvement in specificity of a therapeutic growth factor for large unmet market need Several antibodies for large markets under development Continuing strategies for development of technology to improve its efficiency and scope Development of Evibody framework for display of peptide libraries for drug discovery and imaging applications

PRODUCTS ON MARKET: EvoGene™ technology for finetuning of the properties of proteins via a random mutagenesis and selection approach; antibody humanization/optimization through acquisition of US-based Absalus Inc.

PRODUCTS IN DEVELOPMENT: Name Status Evibody technology - novel human protein framework for display of binding peptides as a tool in drug discovery, diagnostics and therapeutics

in research

EGX010 - engineered growth factor for treatment of bone cancer

in preclinicals

EGX020 - humanized monoclonal antibody for treatment of infectious diease

in research

EGX030 - humanised monoclonal antibody for treatment of primary liver cancer

in research

EGX040 - humanized monoclonal for treatment of leukaemia

in research

EGX050 - humanized monoclonal for treatment of melanoma/lung cancer

in research

Evolva SA

Hagmattstrasse 6 Allschwil CH-412, Switzerland Phone: +41 61 485 2000; Fax: +41 61 485 2001 Web: www.evolvabio.com E-mail: [email protected]

KEY PERSONNEL: Jean-Philippe Tripet; Chairman Neil Goldsmith; CEO Alexandra Santana Sorensen; VP, R&D Pascal Longchamp; VP, Business Development Melya Hughes Crameri; VP, Alliances and IP Michael Naesby; Head, Library Creation


HISTORY: Founded and began biotech R&D in 2001 Acquired certain assets of Poalis A/S (9/05)

STOCK-FINANCIAL HISTORY: Privately held PRIVATE PLACEMENTS: Raised EUR12M in Series A financing (8/04)

SUBSIDIARIES/DIVISIONS: Evolva A/S Bulowsveg 25 1870 Fredericksberg C Denmark Phone: +45 3536 4429 Fax: +45 3528 3885



Evolva India Pvt. Ltd. IICT, Uppal Rd. Hyderabad 500 007 India Phone: +91 93 4673 8534

PRINCIPAL INVESTORS: APIDC-VC Aravis Astellas Venture Capital LLC Danish Growth Fund Danish Innovation Investment (Dansk Innovationsinvestering) Novartis Venture Fund Symbion Capital

BUSINESS STRATEGY: Fundamentally improve the logistics and success rates of small molecule therapeutic discovery, development and manufacturing through the application of advanced evolutionary technologies, while sharing in the value generated by these improvements, and the molecules that result, through selective partnering, as well as the development of the Company's own compound pipeline

AGREEMENTS: Name Products Content of Agreement Date AnalytiCon Discovery GmbH

generation and optimization of nuclear receptor agonists and related compounds

research alliance 7/05

RESEARCH & DEVELOPMENT: Compounds for the treatment of cancer and diabetes, as well as anti-infectives Watchmaker® technology platform

F. Hoffmann-La Roche Ltd.

Grenzacherstrasse 124 Basel CH-4070, Switzerland Phone: +41 61-688-1111; Fax: +41 61-691-9391 Web: www.roche.com E-mail: [email protected]

KEY PERSONNEL: Dr. Franz B. Humer; Chairman and CEO Dr. Erich Hunziker; CFO Prof. Dr. Jonathan K.C. Knowles; Head, Research William M. Burns; CEO, Pharmaceuticals Division Dr Severin Schwan; CEO, Diagnostics Division


HISTORY: Founded F. Hoffmann-La Roche & Co. in 1896 (Ltd. Since 1919)

Roche Holdings Inc. incorporated in Delaware in 1987 Scientists at Basel Institute for Immunology (Roche-sponsored) awarded Nobel Prizes in 1984 and 1987 Founded Roche Holding Ltd. In 1989 Sold Medi-Physics in 1990 Acquired 60% equity in Genentech for $2.1b, with an option to acquire the remaining interest until June 1999 (9/90) Sold plant-protection business to Ciba-Geigy Ltd. (9/90) Acquired worldwide PCR rights (1991) Roche Biomedical Laboratories merged with National Health Laboratories to become the Laboratory Corporation of America (1994) Acquired Syntex Corp. for $5.3b (10/94) and renamed it Roche Bioscience (see separate entry) Sold the Syntex animal health products business to American Home Products Corp. (7/95)



Acquired flavors producer Tastemaker (2/97) Acquired Corange group (Boehringer Mannheim and DePuy) (3/98), received approval from U.S. FTC to acquire Corange on condition that Roche not acquire dominant position in the thrombolytics market, Roche also agreed to sell rights to Retevase to Centocor Inc. (2/98) Sold DePuy to Johnson & Johnson (7/98) Changed name from F. Hoffmann-La Roche to Roche Holding Ltd. (8/00) Roche alliance with Chugai (Japan), majority shareholders--50.1% (10/02) Acquired Disetronic and Igen (2003) Acquired GlycoArt Biotechnology AG (7/05) Member--Biotechnology Industry Organization

FACILITIES: Facilities in Switzerland and more than 50 countries worldwide Expanding research and production facilities

STOCK-FINANCIAL HISTORY: Shares and nonvoting equity securities are listed on the Basel, Zurich and Geneva stock exchanges Sales CHF35.511b (YE 05) compared to CHF29.522b (YE 04) Net income CHF6.730b (YE 05) compared to CHF7.063b (YE 04) Earnings per share CHF7.68/share (YE 05) compared to CHF5.72/share (YE 04)

SUBSIDIARIES/DIVISIONS: American subsidiaries include: Hoffmann-La Roche Inc.--Nutley, N.J. American Roche International Inc.--Clifton, N.J. Genentech Inc. Roche Holdings Inc.--Dover, Del. Roche Diagnostic Systems Inc.--Indianapolis, Ind. Roche Molecular Systems Inc.--Pleasanton, Calif. Roche Professional Service Centers Inc.--Paramus, N.J. Roche Bioscience Divisions: pharmaceuticals, diagnostics

INVESTMENTS: Laboratory Corp. of America Genentech--about 66% Foundations: Roche Research Foundation, Basel (1996) Roche Organ Transplant Research Foundation--$16.5M (7/98)

BUSINESS STRATEGY: Focus on health care, especially innovative drugs, biotech products, and molecular diagnostics Invest in own research and form strong relationships with biotech companies and universities Use synergies between diagnostics and drug development to offer integrated health care solutions


454 Life Sciences development, promotion, sale and distribution of 454's Genome Sequencing Systems

exclusive five-year worldwide agreement

5/05

Actelion Ltd. development and

commercialization of Actelion's selective S1P1 receptor agonist

exclusive worldwide collaboration

7/06

Affymetrix Inc. Genechip technology for research in genomics

research agreement--joint development agreement through Roche Molecular Systems

12/95

Alanex Corp. screening libraries 4/97 Ambit Biosciences Corp.

Ambit's kinase-screening platform

licensing agreement

8/04



Ambrx Inc. next generation proteins and peptides

development and licensing agreement

12/05

Amira Pharmaceuticals

two clinical-stage compounds from Roche

alliance and option agreement

1/06

ArQule Inc. combinatorial chemistry 9/96 BioCryst Pharmaceuticals Inc.

development and commercialization of BioCryst's BCX-4208


11/05

BioFocus (service division of Galapagos NV)

BioFocus to supply Roche with chemical compoound libraries

three-year collaboration

4/06

Borean Pharma A/S

Trimeric Apo A-I Roche to acquire 5/06

Caliper ultra high-throughput screening (UHTS)

10/96

Cardinal Health Tamiflu manufacturing and packaging agreement

7/06

Cell Therapeutics Roche's bisplatinum compounds


12/04

CombiChem Inc. combinatorial chemistry 12/96 Crucell NV Crucell's PER.C6 licensing

agreement 2/05

deCODE genetics Inc.

phosphodiesterase 4 (PDE4) inhibitors


11/04

deCODE genetics Inc.

disease genes based on studies of Iceland's relatively isolated populations

five-year genomics collaboration--Roche to make equity investment, provide research funding and make milestone payments,

2/98

Entelos Inc. metabolic disease research

two-year collaboration

5/06

Epitomics Inc. Epitomics' rabbit monoclonal antibody technology (RabMab technology)

licensing agreement

10/05

Evotec AG two compounds for Alzheimer's disease


1/06

Evotec AG compounds against a target for CNS diseases and other indications


6/06

Exonhit Therapeutics SA

identification of bovine spongiform encephalopathy (BSE), or mad cow disease

research agreement

7/02

Gene Logic Inc. Roche drug candidates that did not pass Phase II or III

drug repositioning and development agreement

12/05

Genedata AG Genedata Screener technology to estimate the biological potency of compounds

multiyear expansion of existing collaboration

12/05

Genentech Inc. Herceptin (trastuzumab) for metastatic breast cancer

exclusive marketing agreement outside the U.S.--Roche to pay up-front fee plus milestones

7/98



Genentech Inc. IL-8 and LFA/ICAM antagonists


1994

Genentech Inc. platelet GPIIb/IIIa antagonists


1994

Genentech Inc. DNase to treat cystic fibrosis and chronic bronchitis

joint development and joint marketing agreement

1992

Glycart Biotechnology AG

therapeutic antibodies development and marketing agreement

9/04

Hitachi High-Technologies Corp.

laboratory automation solutions in immunochemistry market


5/04

Memory Pharmaceuticals Corp.

PDE4 inhibitors research agreement, extended 7/04, amended 8/05

2002

Millennium Pharmaceuticals Inc.

obesity and Type II diabetes

development and worldwide licensing agreement, Roche has identified lead obesity gene, triggering an undisclosed milestone to Millennium (4/98)

3/94

MorphoSys AG therapeutic antibodies against Alzheimer's disease

R&D agreement, expanded 3/06

9/00

Pharmasset Inc. Pharmasset's hepatitis C drug program

licensing and R&D agreement

10/04

Praecis Pharmaceuticals Inc.

PPI-149 hormone antagonist

development and marketing agreement

6/98

Progenics Pharmaceuticals Inc.

T cell chemokine receptor assays for HIV drugs

research contract 12/97

Protein Design Labs Inc.

Zenapax (daclizumab) development and commercialization agreement, expanded 11/05

9/04

Sanofi-Aventis shikimic acid by fermentation for Roche's Tamiflu supply chain

production agreement

3/06

RESEARCH & DEVELOPMENT: Basic research: Immunology, molecular biology, cell biology, gene regulation, neurosciences, molecular oncology, virology and genome research Pharmaceutical research: Infectious diseases: antibacterials (Basel) CNS disorders and chronic degeneration: antidepressants, antiparkinsonian, drugs for the treatment of Alzheimer's disease; hypnotics, anesthetics (Basel) Cardiovascular diseases: antihypertensives, antithrombotics, chronic heart failure and arteriosclerosis (Basel) Metabolic diseases: obesity, NIDDM, osteoporosis (Nutley, NJ) Peripheral nervous system disorders, inflammation/autoimmune diseases (Palo Alto, CA) Antifungal drugs (Kamakura, Japan) Oncology (Penzberg, Bavaria)



Nonclinical development (Basel, Nutley, NJ) Diagnostics: Clinical chemistry, immunology, hematology, molecular diagnostics (PCR), diagnostic equipment

PRODUCTS ON MARKET: Pharmaceutical specialties: Antibacterials (Bactrim, Rocephin, Globocef) Anticancer drugs (Roferon-A, Furtulon, Xeloda, Vesanoid, Mabthera) Antidepressants (Aurorix) Antiepileptic (Rivotril) Antifungals (Loceryl) Antimalarials (Fansidar, Lariam, Fansimef) Antiparkinsonian (Madopar, Tasmar) Antirheumatic, pain (Tilcotil, Naprosyn/Aneprox, Toradol) Antivirals (Roferon-A, Hivid, Invirase/Fotovase, Viracept, Cymevene/Cytovene) Anxiolytics (Valium Roche, Lexotan, Nobrium, Librium) Hypnotics and anesthetics (Dormicum/Versed, Rohypnol, Dalmadorm/Dalmane) Benzodiazepine antagonist (Anexate, Romazicon) Cardiovascular (Inhibace, Ticlid, Cardene, Coreg, Dilatrend, Reteplase) Dermatologicals (Accutane/Roaccutane, Tigason, Neotigason) Hematological drugs (Neupogen, Recormon) Immunosuppressant (Cellcept, Zenapax) Metabolic drugs (Xenical, Rocaltrol, Euglucon, Cedur) Others (Pulmozyme) OTC drugs: vitamins, analgesics, antacids

FibroGen Inc.

225 Gateway Boulevard South San Francisco CA 94080, US Phone: (650) 866-7200; Fax: (650) 866-7201 Web: www.fibrogen.com; E-mail: [email protected]

KEY PERSONNEL: Thomas B. Neff; Chairman and CEO Russell H. Ellison; VP, Clinical Development William Hodder; VP, Business Development Wilbert Lee; VP, CFO and Treasurer David Y. Liu, Ph.D.; VP, Research Claire J. Lockey; VP, Regulatory Affairs Tim C. Opler; VP, Strategy James W. Polarek, Ph.D.; VP, Collagen and Gelatin Development Leanne C. Price; VP, Intellectual Property David A. Yeowell, Ph.D.; VP, Product Development


HISTORY: Incorporated in September 1993 Began R&D operations in 1994

FACILITIES: FibroGen Inc.--South San Francisco, Calif. (Headquarters, R&D) FibroGen Europe Corp.--Helsinki, Finland (R&D)


PRIVATE PLACEMENTS: 5 offerings totalling $94.1M (through 9/00) Raised $100M from placement of convertible preferred stock (2/05) FibroGen Europe Ltd.--2 offerings totalling $13.5M

SUBSIDIARIES/DIVISIONS: FibroGen Europe Corp. Tukholmankatu 8 B (Biomedicum II) FIN-00290 Helsinki Finland Phone: +358 9 56 373 220 Fax: +358 9 56 373 224



PRINCIPAL INVESTORS: Adage Capital Management Apothecary Capital American Express Astellas Pharma Inc. Brookside Capital BankInvest Biomedical Development Bio Fund Ventures II Oy Blue Anchor Holdings Corp. Corriente Biotechnology Partners Credit Suisse London Nominees Duquesne Capital Management Franklin Fairview Franklin Templeton Goldman Sachs Janus Capital Merlin BioMed Group Och-Ziff Capital Management The Parthenon Group Pictet Bank Privat Kredit Bank The Rosewood Corp. Sedgefield Investments Sigma Capital Management SITRA SMBC Capital Taisho Pharmaceutical Co. Ltd. Three Arch Bay Health Science Fund I LP T. Rowe Price Wagner & Brown

BUSINESS STRATEGY: Discovery, development and commercialization of novel biomaterials and therapeutics utilizing expertise in extracelluar matrix biology

AGREEMENTS: Name Products Content of Agreement Date Astellas Pharma Inc.

rights to certain hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of anemia, including FG-2216 and FG-4592, in Europe, CIS, Middle East and South Africa

licensing agreement

4/06

Astellas Pharma Inc.

FG-2216 in Japan licensing agreement

9/04

Medarex Inc. human monoclonal antibodies


1998

PPL Therapeutics recombinant collagen produced in transgenic animals

agreement for PPL to produce recombinantcollagen using transgenic animals

6/97

TEKES recombinant collagen funding for development of recombinant human collagen technology for use in medical and commercial applications

5/97

Thomas Jefferson University

collagen biosynthesis license agreement 11/95

University of Miami

CTGF research and development agreement

11/95



University of Oulu, Finland

recombinant collagen research and license agreement

4/94

University of South Florida

CTGF license agreement 6/95

University of Wisconsin

collagen biosynthesis research and license agreement

4/96

Zeneca LifeScience Molecules (now AstraZeneca)

recombinant human collagen

process development/ scale-up

3/99

RESEARCH & DEVELOPMENT: Recombinant collagens and gelatin

Anti-fibrotic therapeutics Wound repair/tissue engineering

PRODUCTS IN DEVELOPMENT: Name Status FG-3019 (patients with diabetic nephropathy)

in Phase Ib clinicals

FG-3019 (patients with idiopathic pulmonary fibrosis)

completed Phase I

FG-3019 (patients with pancreatic cancer) IND filed FG-2216 for anemia in Phase II clinicals FG-4592 for iron processing deficiency in Phase I clinicals FG-5017 - cosmetic dermal filler to begin pivotal efficacy and

safety trial in 2006 FG-4539 for ischemic disease in preclinicals FG-5016 completed safety study FG-5009 completed safety study

First Link (UK) Ltd.

1, Valepits Road, Garretts Green Birmingham B33 0TD, UK Phone: +44 121 783 8139; Fax: +44 121 786 2747 E-mail: [email protected]

KEY PERSONNEL: Mick Terry; Director Dr. Yvette Goward; Director and Company Secretary


HISTORY: Formed by original management of Advanced Protein Products Ltd. (1995)



BUSINESS STRATEGY: Research, develop, manufacture, and supply in field of biological chemicals, especially contract manufacturing

RESEARCH & DEVELOPMENT: Large-scale media for mammalian cell culture

Contract process development Develop culture media for transplantation of natural and artificial organs

PRODUCTS ON MARKET: High-purity bovine serum albumin and porcine serum albumin Density gradient media for cell separation Native and recombinant growth factors Sera and proteins for cell culture and research



Fraunhofer Institute for Interfacial Engineering and Biotechnology

Nobelstrasse 12 Stuttgart 70569, Germany Phone: +49 (0) 7 11/9 70-40 01; Fax: +49 (0) 7 11/9 70-42 00 Web: www.igb.fraunhofer.de E-mail: [email protected]

KEY PERSONNEL: Prof. Dr. Herwig Brunner; Managing Director Dr. Steffen Rupp; Head, Department Molecular Biotechnology Prof. Dr. Walter Troesch; Head, Department Environmental Biotechnology and Bioprocess Engineering Prof. Dr. Heike Mertsching; Head, Department Cell and Tissue Engineering Dr. Christian Oehr; Head, Department Interfacial Technology and Material Science Dr. Gunter Tovar; Head, Department Biomimetic Interfaces Dr. Thomas Schiestel; Head, Department Inorganic Interfaces and Membranes




SUBSIDIARY OF: Fraunhofer-Gesellschaft

BUSINESS STRATEGY: New technologies for health, the environment and industry

RESEARCH & DEVELOPMENT: Molecular biotechnology for diagnostic, pharma, and fine chemistry:

Research in infectious diseases and drug screening, assay development, biochip technologies (genomics and proteomics), protein expression, fermentation and downstream processing. Tissue Engineering for medical technology, diagnostics, drug development, and individual therapy: Three-dimensional organoid human test systems, biocompatibility testing, 3-D autologous transplants, cell sorting and cell therapy, GMP-compliant manufacturing of tissue engineering products. Functional interfaces for technology and medicine: Molecularly defined and smart surfaces, ultra-thin layers, biomimetic and biofunctional surfaces, nanobiotechnology, nanoparticles, carbon nanotubes, membranes. Sustainable bioprocess engineering for industry, urban infrastructure and the environment: Reprocessing and conversion of organic raw and waste materials, generation of biogas, wastewater purification and urban water management, production of natural substances (vitamins, neutraceuticals) and energy by microalgae.

PRODUCTS ON MARKET: Two-stage high performance plant for digestion of organic waste In-Vitro whole skin model as test system Cartilage transplant



Galderma SA

Tour Europlaza - La Defense 4, 20 avenue Andre Prothin Levallois-Perret 92927, France Phone: +33 1 58 86 45 45; Fax: +33 1 58 86 45 00 Web: www.galderma.com E-mail: [email protected]

KEY PERSONNEL: Humberto C. Antunes; CEO


HISTORY: Founded in 1981 as a joint venture between Nestle and L’Oreal

FACILITIES: Headquarters in Switzerland Three R&D centers (in France, the U.S. and Japan) Three manufacturing sites (in France, Canada and Brazil)


SUBSIDIARIES/DIVISIONS: 32 affiliates

BUSINESS STRATEGY: Mission: As the global leading company in dermatology, Galderma will contribute to the treatment of dermatological diseases and conditions by developing and marketing products to meet the needs of dermatologists and patients

RESEARCH & DEVELOPMENT: Acne, rosacea, psoriasis, seborrheic dermatitis, fungal nail infections,

melasma, non-melanoma skin cancer

PRODUCTS ON MARKET: Arcolan® (ketoconazole), Benzac® (benzoyl peroxide), Calmurid® (urea), Capex® (fluocinolone acetonide), Cetaphil®, Clindagel® (clindamycin), Clobex® (clobetasol), Desowen® (desonide), Differin® (adapalene), Efficort® (hydrocortisone aceponate), Ell Cranell®/Avixis® (alpha-oestradiol), Eryacne® (erythromycine), Loceryl® lacquer (amorolfine), Metvix® (methylaminolevulinate), Nutracort® (hydrocortisone), Nutraderm®, Nutraplus® (urea), Rozex®/Metro® (metronidazole), Silkis® (calcitriol), Tetralysal® (oral lymecycline), Tri-Luma® (hydroquinone/tretinoin/fluocinolone/acetonide)

Genencor International Inc.

925 Page Mill Road Palo Alto CA 94304, US Phone: (650) 846-7500; Fax: (650) 845-6507 Web: www.genencor.com

KEY PERSONNEL: Robert Mayer; Chairman and CEO Thomas J. Pekich; President Michael V. Arbige, Ph.D.; Sr. VP, Technology Carole Beth Cobb; Sr. VP, Global Supply


HISTORY: Founded in 1990 as a joint venture between Eastman Chemical Co. and Cultor Ltd. Member--Enzyme Technology Association Member--Soap and Detergent Association Member--Biotechnology Industry Organization Sold dairy and dietary enzyme business to Gist-brocades International BV (7/97) Acquired by Danisco A/S (4/05)



FACILITIES: European headquarters in Leiden R&D Facilities in Palo Alto, Calif.; Leiden; Netherlands Manufacturing facilities in Rochester, N.Y.; Wuxi, China; Arroyito, Argentina; Hanko and Jamsankoski, Finland; Bruges, Belgium; and Beloit, Wis.

STOCK-FINANCIAL HISTORY: Privately held by parent Formerly listed on NASDAQ--GCOR: Revenue $410.417M (YE 04) compared to $383.162M (YE 03) Net income $26.178M (YE 04) compared to $22.808M (YE 03) Earnings per share $0.32/share (YE 04) compared to $0.26/share (YE 03) Average shares outstanding 59.434M (YE 04) compared to 58.767M (YE 03) Total assets $752.113M (YE 04) compared to $712.422M (YE 03)

SUBSIDIARY OF: Danisco A/S

BUSINESS STRATEGY: Develop, manufacture and market products for healthcare, agriculture, industrial, and consumer markets using molecular biology and protein chemistry

AGREEMENTS: Name Products Content of Agreement Date Ablynx Ablynx's Nanobody

platform against tumor targets specified by Genencor

drug discovery collaboration

9/04

BioMarin Pharmaceutical Inc.

Genencor to perform research services for BioMarin

contract research agreement

4/06

CAMR sterilization process for medical instruments, rendered animal material and human blood supply

R&D agreement 8/01

Cargill biocatalysts for wet corn milling facilities

exclusive supply agreement

1/01

Gyros microfluidics technology collaboration

5/01

Integrated Genomics

microbial genome sequencing technologies

licensing agreement

9/01

Mayo Clinic transgenic mouse for celiac disease

cooperative R&D agreement

1/01

Protein Polymer Technologies

Genencor biomaterials and technology and personal care product applications

licensing and development agreement, expanded 3/05

12/00

RESEARCH & DEVELOPMENT: Industrial enzymes for use in cleaning, textile, starch, animal feed, food and biochemical industries Protein chemistry and genetic engineering High-expression fungal and bacterial technology Fine and specialty chemicals based on novel biocatalysts and diols technology Biosynthetic peptides Human Immunology platform Conversion of biomass to ethanol to reduce the USA's dependence on foreign oil

PRODUCTS ON MARKET: Through utilization of our i-biotech™ solution, more than 250 biotechnology products, including: IndiAge® and Primafast® (textile processing) Laminex® (brewing enzymes) Spezyme® (grain processing enzymes) Multifect® (food enzymes) Euro® (textile cellulases)



Xylanase enzyme for pulp and paper processing Aromatic amino acids L-sugars (food and pharmaceutical) Purafect® (detergent enzymes) Fermgen™ (acid fungal protease enzyme product) Glucose oxidase and catalase for industrial and food use

PRODUCTS IN DEVELOPMENT: Name Status Bioingredients in development Biomaterials in development Therapeutics in development

General Electric Global Research

1 Research Circle Niskayuna NY 12309, US Phone: (518) 387-7914; Fax: (518) 387-7911 Web: www.crd.ge.com E-mail: [email protected]

KEY PERSONNEL: Michael Idelchik; VP and Acting Director, GE Global Research

EMPLOYEES: 2,500 employees, 835+ Ph.D.s

HISTORY: Founded in 1900 as GE and the U.S.'s first industrial research laboratory

FACILITIES: 525-acre Global Research Center Headquarters campus in Niskayuna, N.Y.

STOCK-FINANCIAL HISTORY: NYSE--GE (parent)

SUBSIDIARIES/DIVISIONS: China Technology Center - Shanghai, China John F. Welch Technology Centre - Bangalore, India GE Global Research - Europe - Munich, Germany Technicare--acquired from Johnson & Johnson (7/86)

SUBSIDIARY OF: General Electric Co.

INVESTMENTS: Progene Partners--joint venture with Proteus International and Genelabs Technologies to design and develop DNA-binding drugs for viral infections and cancer

BUSINESS STRATEGY: Develop innovative technology that ensures that the customer is always its first beneficiary and use it to accelerate growth

AGREEMENTS: Name Products Content of Agreement Date U.S. Department of Defense

TCE biodegradation joint research agreement

9/98

U.S. Department of Energy

PCB biodegradation joint research agreement

7/99

U.S. Environmental Protection Agency


9/94

U.S. Environmental Protection Agency

PCB biodegradation joint research agreement

12/99

U.S. Department of Energy


9/97

RESEARCH & DEVELOPMENT: Core technology areas: Biosciences: Research in applied biology and biomedicine, with an emphasis in diagnostic imaging, pharmaceutical discovery technologies and protein separations Ceramic and Physical Metallurgy Technologies: Development of advanced ceramic, composite, electronic, and metallic materials; material life and



reliability research; coating composition and process development; joining, repair and refurbishment studies; and the utilization of novel processes including high temperature, high pressure and thermal-mechanical, to achieve the desired material responses for a broad range of products Computing and Decisioning Sciences: Next generation solutions to take health care to the next level of personalized medicine and to identify novel biomedical applications for all GE industries Electronics and Energy Conversion: Alternative energy and energy systems, including wind, solar, solar desalination, renewable energy grids; electrical power distribution and control technologies; mobile electric power systems; electrical machines; communication systems: controls, diagnostics and embedded controls and systems; sensor, security and lighting electronics systems; optoelectronic devices and systems; electrophysics, electrophysiology, plasma systems, high voltage and vacuum electronics Energy and Propulsion Technologies: Developing low-emissions combustion for gas turbines, aircraft engines, and locomotives; fuel Cells, micro turbines, and other advanced distributed power generation systems; computational and experimental fluid dynamics for turbo machinery and other components of aircraft engines and power plants; cooling and sealing technologies for propulsion, power generation and other industrial and consumer products; propulsion technology beyond conventional turbine engines and diesels; technology for remote monitoring and prognostics of high-value assets towards condition-based maintenance; technologies for hydrogen production from coal, natural gas and water; coal gasification and integrated gasification combined cycle; and methods of liquid fuel purification and conversion Imaging Technologies: New applications for imaging in both the security and industrial non-destructive testing spaces, molecular imaging Material Analysis and Chemical Sciences: Analysis of materials to understand their chemical composition, surface and bulk structure and physical properties; development of chemical and biological sensors, especially the sampling technology and detection chemistry; high-throughput experimentation to accelerate materials discovery as accomplished via creation of materials in miniaturized arrays using automation, followed by rapid testing for desirable properties; application of chemistry and chemical engineering to environmental issues, such as pollution prevention, remediation, environmental monitoring and water treatment; and toxicology, especially as applied to environmental and health issues Material Systems Technologies: Development of high-performance material systems to deliver new product breakthroughs and applications for GE businesses and customers Micro and Nano Structures Technologies Polymer and Specialty Chemical Technologies: Development of new and specialized materials for GE’s Industrial Business, water technologies (membranes and coatings) and in support of alternate energy activities (wind turbines, fuel cells and photovoltaics); identification of emerging technologies (such as nanotechnology, photonics and organic light emitting diodes) In addition, GE has an increased focus on six advanced technology programs: Molecular imaging and diagnostics Nanotechnology Pulse detonation propulsion Sustainable energy Energy conversion



Genesearch Pty. Ltd.

Gold Coast Technology Park, 14 Technology Drive Arundel 4214, Australia Phone: +61 7-5594-0299; Fax: +61 7-5594-0562 Web: www.genesearch.com.au E-mail: [email protected]

KEY PERSONNEL: Dr. John L. Reichelt; CEO Dr. Robin Craig; Director, R&D Dr. Bonni Y. Reichelt; Director, R&D Sarah Reichelt; Scientist Keith Pyle; Scientist Joy Pyle; Scientist Tim Reichelt; Administration





SUBSIDIARIES/DIVISIONS: Ecosearch (waste treatment)

BUSINESS STRATEGY: Conduct in-house R&D to develop products internally, as well as contract research in microbial genetics and fermentation

RESEARCH & DEVELOPMENT: R&D is focused on:

Enzymes for molecular biology Microalgal products Bioplastics Bioinsecticides Waste treatment products and processes Probiotics Silage inoculants Microbial genetics and fermentation The company performs in-house R&D to develop its own products, and conducts contract research in microbial genetics and fermentation, including: Industrial and feed chemicals from bacteria (e.g. amino acids), biodegradable plastics from bacteria grown on sugar, and biopesticides

PRODUCTS ON MARKET: Restriction enzymes Ecobac powdered bacterial product for waste treatment Waste treatment processes for food wastes Si-Lac silage inoculant



Geneva Scientific

P.O. Box 408 Fontana WI 53125, US Phone: (262) 245-1500; Fax: (262) 245-6678 Web: www.geneva-scientific.com E-mail: [email protected]

KEY PERSONNEL: John Urlakis; President



PRODUCTS ON MARKET: Laboratory equipment

Caseworks Fume hoods Autoclaves Sterilizers Bio safety cabinets Glassware washers Rack washers Tunnel washers Refractometers Environmental rooms Refrigerators and freezers Scraping stations Downdraft tables Backdraft stations Hydraulic tables Vacuum waste management and disposal systems Automated dump stations Bulk bag bedding vacuum transfer systems Automated bedding dispensers Necropsy tables

Genomatica Inc.

5405 Morehouse Drive, Suite 210 San Diego CA 92121, US Phone: (858) 824-1771; Fax: (858) 824-1772 Web: www.genomatica.com E-mail: [email protected]

KEY PERSONNEL: Christophe Schilling, Ph.D.; President and CSO Thomas Reed; VP, Finance and Corporate Development




FINANCIAL INFORMATION: Received a $750K Phase II Small Business Innovation Research Grant from the U.S. Department of Energy (9/04)

BUSINESS STRATEGY: As a leader in computational systems biology, use validated technology to deliver industry-leading solutions for the modeling and simulation of metabolis. These solutions drive a powerful new paradigm wherein computer models are used to accelerate biological research and discovery across the life sciences. To advance to frontiers of biological discovery and the development of innovative products in medical and industrial biotechnology while streamlining existing product development and enhancing the overall business efficiency of our clients



AGREEMENTS: Name Products Content of Agreement Date DSM Genomatica's

SimPheny licensing agreement 4/05

DSM implementation of Genomatica's metabolic modeling and simulation technologies and capabilities to help DSM develop improved biological processes for product production

expanded multi-year collaboration and licensing agreement

6/06

Kyowa Hakko Kogyo Co. Ltd.

Genomatica's modeling and simulation platform


Unilever expansion of projects started in 2005--use of Genomatica's metabolic modeling and simulation technologies to develop ingredients to improve Unilever products

multi-year collaboration and licensing agreement

8/06

RESEARCH & DEVELOPMENT: Computational systems biology Medical and industrial biotechnology

PRODUCTS ON MARKET: SimPheny™ modeling platform

Gentra Systems Inc.

13355 10th Avenue N, Suite 120 Minneapolis MN 55441, US Phone: (763) 543-0678; Fax: (763) 543-0699 Toll-free phone: (800) 866-3039 Web: www.gentra.com E-mail: [email protected]

KEY PERSONNEL: Ruth M. Shuman, Ph.D.; CEO and President Dennis Thalhuber; CFO Robert Kwiatkowski, Ph.D.; VP, R&D


HISTORY: Founded in 1988 Acquired by Qiagen NV (5/06)


BUSINESS STRATEGY: Develop and market manual and automated nucleic acid purification products that address the need for high quality nucleic acid, ease of use and increased throughput for clinical and clinical research laboratories

RESEARCH & DEVELOPMENT: Nucleic acids purification

PRODUCTS ON MARKET: DNA and RNA purification products including: Puregene® DNA Purification Kit Generation® Purescript® Autopure ls® DNA Purification Instrument Versagene™ RNA Versagene™ RNA purification Kit Clotspin® De-clotting Tubes Autotech Automated Nucleic Acid Purification Instrument



Genzyme Corp.

500 Kendall Street Cambridge MA 02142, US Phone: (617) 252-7500; Fax: (617) 252-7600 Web: www.genzyme.com; E-mail: [email protected]

KEY PERSONNEL: Henri A. Termeer; Chairman, President and CEO Mara G. Aspinall; President, Genetics Mark R. Bamforth; Sr. VP, Corporate Operations and Pharmaceuticals John Butler; President, Genzyme Renal Earl M. Collier Jr.; Exec. VP, Cardiovascular and Oncology Thomas J. DesRosier; Sr. VP, General Counsel and Chief Patent Counsel Richard H. Douglas, Ph.D.; Sr. VP, Corporate Development David D. Fleming; Group Sr. VP Georges Gemayel; Exec. VP, Therapeutics, Transplant and Renal James A. Geraghty; Sr. VP Elliott D. Hillback Jr.; Sr. VP, Corporate Affairs Alison Lawton; Sr. VP, Regulatory Affairs and Corporate Quality Systems Evan M. Lebson; VP and Treasurer Roger W. Louis; VP, Healthcare and Regulatory Counsel and Chief Compliance Officer Mary McGrane; VP, Government Relations John M. McPherson, Ph.D.; Sr. VP, Cell and Protein R&D David Meeker, M.D.; President, Lysosomal Storage Disorder Therapeutics Ann Merrifield; President, Genzyme Biosurgery Richard A. Moscicki, M.D.; Sr. VP, Medical, Clinical and Regulatory Affairs and CMO Donald E. Pogorzelski; President, Genzyme Diagnostics Alan E. Smith, Ph.D.; Sr. VP, Research and CSO Sandford D. Smith; President, International Group Peter T. Traynor; VP and Corporate Controller Peter Wirth; Exec. VP, Legal, Corporate Development and Drug Discovery, Chief Legal Officer and Secretary Michael S. Wyzga; Exec. VP, Finance, CFO and CAO


HISTORY: Founded in June 1981 by Henry Blair and Sherry Snyder Began operations by acquiring Whatman Biochemicals Ltd., U.K. Member--Biotechnology Industry Organization Founded 16 labs (1990) Formed Neozyme Corp. to fund development of programs (10/90) Formed Neozyme II to fund the research, development, and clinical testing of biotherapeutic products for the treatment of cystic fibrosis (4/92) Subsidiary IG Laboratories Inc. purchased Genetic Design Inc., a privately held genetic testing company (6/92) Acquired phospholipid business of Enzymatix Ltd. (6/92) Acquired Medix Biotech Inc. (6/92) Acquired Vivigen Inc., in exchange for stock valued at $40M (11/92) Neozyme I buyback of four programs, $49M (12/92) Established Genzyme Transgenics (now GTC Biotherapeutics) for producing human biotherapeutic products in the milk of transgenic animals (2/93) Acquired diagnostic business Virotech System-Diagnostika GmbH (4/93) Acquired diagnostic business Omnia Res srl (5/93) Neozyme I buyback of two programs, $49M (12/93) Acquired Swiss pharmaceutical manufacturer, Sygena Ltd. (7/94) Subsidiary Genzyme Transgenics purchased TSI, a publicly held clinical testing and production company (10/94) Created Genzyme Tissue Repair by acquiring BioSurface Technology Inc. and combining with several of Genzyme Corp.'s tissue repair programs (12/94) Acquired all shares of IG Laboratories Inc. (9/95)



Formed Aristogen GmbH with Symbiomed (Germany) to offer genetic diagnostic services in Germany (3/96) Acquired Genetrix Inc. (4/96) Acquired Deknatel Snowden Pencer Inc., $250M (7/96) Neozyme II Corp. buyback, $109M (9/96) Formed Genzyme Molecular Oncology Division after acquisition of PharmaGenics Inc. (6/97) Acquired ABIOMED Inc. for $15M (7/97) Sold research products business to Techne Corp. for $65.5M (6/98) Acquired GelTex Pharmaceuticals Inc. (12/00) Acquired Novazyme Pharmaceuticals (9/01) Ceased trading of Genzyme Biosurgery and Genzyme Molecular Oncology stock (7/03) Acquired Sangstat Medical Corp. (12/03) Acquired ILEX Oncology Inc. (12/04) Acquired Verigen AG (2/05) Acquired Bone Care International (7/05) Acquired AAV gene therapy assets from Avigen Inc. (12/05)

FACILITIES: 75 locations in 32 countries, including 15 manufacturing facilities and 9 genetic testing laboratories

STOCK-FINANCIAL HISTORY: NASDAQ--GENZ IPO--2.9M common shares at $10/share (6/86) Public offering--2.9M common shares at $13.125/share (12/89) Public offering--4.025M shares of common stock at $35.50/share (3/91) Authorized shares of Genzyme Corp. common stock redesignated as General Division Common Stock (GENZ); second class of common stock, Tissue Repair Division common stock (GENZL), authorized to effect acquisition of BioSurface Technologies (12/94) Public offering--2.9M shares of common stock at $51.25/share (10/95) Two-for-one stock split (7/96) Two-for-one stock split (6/01) Revenue $2.735b (YE 05) compared to $2.201b (YE 04) Net income $441.489M (YE 05) compared to $86.527M (YE 04) Earnings per share $1.73/share (YE 05) compared to $0.64/share (YE 04) Average shares outstanding 254.758M (YE 05) compared to 228.175M (YE 04) Total assets $6.879b (YE 05) compared to $6.069b (YE 04)

PRIVATE PLACEMENTS: $10M RDLP to fund clinicals and manufacturing of GCR for Gaucher's disease (closed 9/87) Formed $36.75M limited partnership to fund development of surgical products (11/89) $100M of 6.75% convertible subordinated notes due Oct. 2001 (10/91) Sold $250M in 5.25% convertible subordinated notes due 2005 (5/98)

SUBSIDIARIES/DIVISIONS: Genzyme General Division Genzyme Biosurgery Division Genzyme Molecular Oncology Division Genzyme de Argentina SA Genzyme do Brasil Ltda. Genzyme Chile Ltda. Genzyme Colombia SA Genzyme Mexico S. de RL de CV Genzyme Middle East FZ LLC Genzyme Turkey Ltd. Genzyme Israel Ltd. Genzyme Austria G.m.b.H Genzyme Flanders BVBA/SPRL--Belgium Genzyme Belgium NV/SA Genzyme Europe BV--Czech Republic Genzyme A/S--Denmark Genzyme SAS--France Genzyme Polyclonals SAS--France Genzyme GmbH--Germany Genzyme CEE GmbH--Germany



Genzyme Virotech GmbH--Germany Genzyme Hellas LLC--Greece Genzyme Europe BV Kepviselet--Hungary Genzyme Ireland Ltd. Genzyme Italy Genzyme Polska Sp. z o.o.--Poland Genzyme Portugal Genzyme Barcelona Genzyme Madrid Genzyme GmbH--Switzerland Genzyme Sygena--Switzerland Genzyme Cambridge--U.K. Genzyme Ltd.--U.K. Genzyme Oxford--U.K. Verigen Australia Pty. Ltd.--Australia Genzyme China Genzyme Asia Ltd. Genzyme Tokyo Genzyme Korea Genzyme Singapore Pte. Ltd. Genzyme GmbH Russia Genzyme Taiwan

INVESTMENTS: Genzyme Clinical Partners LP--reacquired the assets for 1.4M shares of Genzyme common stock (2/90) RenaGel LLC--joint venture with GelTex Pharmaceuticals, Inc. to handle development and commercialization of GelTex's RenaGel non-absorbed phosphate binder Abiomed Inc.--14% 50/50 joint venture with Genzyme Transgenics Corp.--$33M (7/97) Joint venture with BioMarin Pharmaceutical Inc. Joint venture with Pharming Group NV (7/98)

AGREEMENTS: Name Products Content of Agreement Date Acadia Pharmaceuticals Inc.

Acadia's cell-based screening technology and Genzyme's library of more than 1M compounds

collaborative screening agreement

10/97

Alcon Labs (Nestle)

ophthalmic products using hyaluronic acid such as Surgicoat


Angiotech Pharmaceuticals Inc.

identification, development and commercialization of therapies for cancer patients undergoing surgical removal of tumors

strategic collaboration agreement

5/06

Aronex Pharmaceuticals Inc.

Atragen development and marketing agreement (9/93), amended--Genzyme has option to commercialize

3/97

ArQule Inc. drug candidates for

identifying cancer, infectious diseases and autoimmune/inflammatory diseases

development agreement--ArQule to provide Genzyme with access to Mapping Array program for identifying new lead compounds against Genzyme's targets

4/97



Bayer AG Genzyme's small molecule library

licensing agreement--Genzyme will receive up-front and service fees and milestones

12/97

Behringwerke AG amylase substrate licensing agreement

11/91

Biogen Idec Inc. Avonex (interferon beta-1a) for MS

commercialization and exclusive distribution agreement for Japan

9/98

Celtrix Pharmaceuticals Inc.

TGF-B2 for tissue repair, treatment of MS, and other systemic applications

product development, licensing, and marketing agreement through Genzyme Tissue Repair

6/94

Crucell NV production of monoclonal antibodies

nonexclusive STAR research licensing agreement

12/05

Cubist Pharmaceuticals Inc.

small molecule compounds targeting bacterial and fungal infections

drug discovery alliance--Cubist will screen Genzyme's compound library, once potential therapeutic compounds are discovered, Cubist and Genzyme will negotiate development terms

3/97

Cyclacel Group plc

Licensing of two of Cyclacel's Cyclin-Dependent Kinase inhibitors

option agreement 9/05

Daiichi Pure Chemicals Co. Ltd.

HDL cholesterol blood test


1/96

De Novo Pharmaceuticals Ltd.

De Novo to apply its molecular structure generating technology to focus on a disease target that is of interest to Genzyme

drug discovery collaboration agreement

1/06

DiagnoCure Inc. 40 genes for potential use in detecting lung cancer

licensing agreement

11/05

Dyax Corp. Dyax's phage display patents

non-exclusive patent licensing agreement, including signing fees, milestone payments and royalties, Dyax gets access to related patented technology owned by licensee

1996

Dyax Corp. Dyax's human plasma Kallikrein inhibitor (EPI-KAL-2)

letter of intent for development agreement

12/98



Dyax Corp. antibody phage-display libraries for the discovery of human antibodies

license and research agreement

6/04

GelTex Pharmaceuticals Inc.

RenaGel phosphate binder

development and commercialization agreement--Genzyme to pay GelTex up to $27.5M upon FDA approval of product

6/97

Imperial Cancer Research Fund (ICRF)

gene therapies for cancer


1/96

Institut Merieux glucocerebrosidase (GCR) products to treat Gaucher's disease

technology license and supply agreement

9/89

IntroGene BV (Netherlands)

gene therapy for Gaucher's disease

licensing agreement--Genzyme to make equity investment and provide research, milestone, and royalty payments

10/94

Johns Hopkins University School of Medicine

cardiovascular gene therapy

devleopment collaboration

5/98

Kaken Pharmaceutical Co. Ltd.

Seprafilm and Sepracoat for prevention of post-operative adhesions

marketing agreement for Japan

2/97

LeukoSite Inc. drug candidates for treating autoimmune and inflammatory diseases

screening agreement--LeukoSite will have access to more than 800K compounds in Genzyme's library and will screen against its biological targets related to cell adhesion and inflammatory bowel disease; after screening is complete, companies will negotiate research collaboration covering development and commercialization of compounds discovered in screening

6/97

Macrozyme Corp. exploration of applications of Macrozyme's small molecule library

exclusive collaboration

11/05

Mass General Hospital

gene therapy treatments for chronic hepatitis B and liver cancer

development collaboration

6/97



Medtronic Inc. treatments for cardiovascular disease

joint venture named MG Biotherapeutics

6/04

Molecular Informatics Inc.

MI's BioMerge software to integrate and analyze genomics information

licensing agreement

7/97

National Cancer Institute

gene therapy for metastatic melanoma

three-year collaborative R&D agreement

10/96

Partners HealthCare System

research in oncology, orthopedics, tissue repair, genetic metabolic diseases, cardiovascular disease, surgical research, genetics, gene therapy and neurology

non-exclusive basic and clinical research alliance--Genzyme to provide research tools, probes and reagents, Genzyme to provide $300K grant to fund exchange program

9/97

RenaMed Biologics Inc.

development and commercialization of RenaMed's Bio-Replacement Therapy™

strategic collaboration

9/05

St. Elizabeth's Medical Center

cardiovascular gene therapy

development collaboration

5/98

Tm Bioscience Corp.

undisclosed development and supply agreement

11/04

University of California at Los Angeles (UCLA) Jonsson Cancer Center

gene mutations believed to be associated with drug resistance to Gleevec®

licensing agreement

10/05

University of Pittsburgh

gene therapy for Gaucher's disease


11/94

Valentis Inc. Valentis' GeneSwitch technology, Genzyme's static mixer intellectual property

expanded licesing agreement

9/04

ViaCell Inc. diabetes R&D agreement 3/05 Vical Inc. nonviral vector gene

therapies for treating cystic fibrosis using Vical's cytofectins

multiyear R&D agreement--includes option for Genzyme to exclusively license Vical's cytofectins for CF therapy in exchange for licensing fee, as well as research, milestone, and royalty payments (10/93), Genzyme paid $1M in exercise of option for exclusive license

10/90

Wyeth Pharmaceuticals

Synvisc Genzyme to buy back rights in USA and five European countries

11/04

RESEARCH & DEVELOPMENT: Chronic kidney disease, cancer treatments, transplantation medicine,

autoimmune disease, orthopaedics, adhesion prevention, cardiovascular disease, diagnostic products and services



PRODUCTS ON MARKET: Lysosomal Storage Disorders Cerezyme® (imiglucerase for injection) for Type 1 Gaucher disease Fabrazyme® (agalsidase beta) for Fabry disease Aldurazyme® (laronidase) for Mucopolysaccharidosis I Myozyme® (alglucosidase alfa) for Pompe disease Renal Disease Renagel® (sevelamer hydrochloride) Hectorol® (doxercalciferol) Orthopaedics Synvisc® (hylan G-F 20) Carticel® (autologous cultured chondrocytes) MACI®, (Matrix-induced Autologous Chondrocyte Implantation) Transplant and Immune Diseases Thymoglobulin® (anti-thymocyte globulin, rabbit) Oncology Campath® (alemtuzumab for injection) for the treatment of B-cell chronic lymphocytic leukemia Clolar® (clofarabine for intravenous infusion) Thyrogen® (thyrotropin alfa for injection)

GL Biochem (Shanghai) Ltd.

351 Guo Shoujing Road Shanghai 201203, China Phone: +86 21-54925326; Fax: +86 21-64189186 Web: www.glschina.com; E-mail: [email protected], [email protected]

KEY PERSONNEL: Hongyan Xu, Ph.D.; President Zhou Min; General Manager



FACILITIES: 17,000 sq. m. manufacturing facility


BUSINESS STRATEGY: Research, develop, manufacture and market diverse biochemicals and fine chemicals, especially peptide, peptide reagents and related products

PRODUCTS ON MARKET: Coupling reagents

Labeling reagents Linkers for solid phase synthesis N-protecting reagents Unusual amino acids Amino acids derivatives Boc-amino acids Fmoc-amino acids Z-amino acids Amino alcohols N-methyl amino acids Fmoc-amino acids attached to wang resin Amino acids attached to 2-chlorotrityl-chloride-resin Resins Generic and custom peptides Specialty chemicals Custom peptide synthesis Custom antibody services Custom organic synthesis



HaloSource Inc.

14716 NE 87th Street Redmond WA 98052, US Phone: (425) 881-6464; Fax: (425) 882-2476 Web: www.halosource.com E-mail: [email protected]

KEY PERSONNEL: John Kaestle; President and CEO Jeffrey F. Williams, Ph.D.; Sr. VP and CTO James Thompson; VP and CFO Everett J. Nichols, Ph.D.;VP, R&D Eric B. Robinson; VP, Operations


HISTORY: Founded in 1989 Merged with HaloSource Corp. (5/02) Changed name from Vanson Inc. Changed name from Vanson HaloSource Inc. (2/06)



PRIVATE PLACEMENTS: Raised $5M in financing (3/05)

PRINCIPAL INVESTORS: Mars Inc. Alexander Hutton Venture Partners LP Buerk Dale Victor LLC

BUSINESS STRATEGY: Provide reliable, tested and proven solutions in the product categories of safe water, infection control and healing enhancement

RESEARCH & DEVELOPMENT: Antimicrobial and disease prevention solutions that reliably and effectively

kill germs

PRODUCTS ON MARKET: HaloPure®--Drinking water purification solutions SeaKlear®--Water treatment solutions for the pool and spa industry StormKlear® and Klarify®--Waste and storm water treatment solutions HaloPure FT™--Industrial fluid treatment solutions HaloShield®--Coating solutions that harness the antimicrobial power of chlorine Biomedical--Hemostasis and wound-healing solutions

Hammen Corp.

4200 Fox Farm Road Missoula MT 59802, US Phone: (406) 728-5897; Fax: (406) 728-5924

KEY PERSONNEL: Richard F. Hammen, Ph.D.; President Mary Gordon; Manager, Marketing



FACILITIES: Headquarters, executive offices, and laboratories located in Missoula, Mont.


PRINCIPAL INVESTORS: Montana Science & Technology Alliance (MSTA)



BUSINESS STRATEGY: Seek partners to develop technology for removal of toxic metals from water and to develop drug master files for biotechnology products

PRODUCTS ON MARKET: HiPAC® affinity chromatography columns

Harvard Bioscience Inc.

84 October Hill Road Holliston MA 01746, US Phone: (508) 893-8066; Fax: (508) 429-5732 Toll-free phone: (800) 272-2775 Web: www.harvardbioscience.com E-mail: [email protected]

KEY PERSONNEL: Chane Graziano; CEO David Green; President Susan Luscinski; COO Bryce Chicoyne; CFO Mark Norige; COO, Harvard Apparatus David Strack; President, Genomic Solutions and Union Biometrica David Parr; Managing Director, Biochrom


HISTORY: Founded in March 1996, when it acquired a portion of the assets of Harvard Apparatus (founded in 1901) Changed name from Harvard Apparatus Inc. (12/00) Asys Hitech GmbH acquired select assets of the microplate reader and washer product lines from Anthos Labtec Instruments GmbH (6/06)

FACILITIES: 43,750 sq. ft. leased facility in Holliston, Mass. (corporate headquarters) 28,000 sq. ft. leased facility in Cambridge, U.K. 22,600 sq. ft. leased facility in San Francisco, Calif. 18,000 sq. ft. leased facility in Warwickshire, U.K. 15,500 sq. ft. owned facility in Edenbridge, U.K. 9,000 sq. ft. leased facility in March-Hugstetten, Germany 7,500 sq. ft. leased facility in Hamden, Conn. 4,700 sq. ft. leased facility in Eugendorf, Austria Additional leased facilities for sales and administrative support in Geel, Belgium; Les Ulix, France; and Montreal, Canada

STOCK-FINANCIAL HISTORY: NASDAQ--HBIO IPO--7.4M shares, $58.9M (12/00) Revenue $67.431M (YE 05) compared to $64.745M (YE 04) Net income <$31.877M> (YE 05) compared to $2.329M (YE 04) Earnings per share <$1.05/share> (YE 05) compared to $0.08/share (YE 04) Average shares outstanding 30.442M (YE 05) compared to 30.269M (YE 04) Total assets $92.152M (YE 05) compared to $139.881M (YE 04)

SUBSIDIARIES/DIVISIONS: HBIO Securities Corp.--U.S. Harvard Apparatus FSC Inc.--U.S. Virgin Islands Warner Instruments LLC--U.S. Union Biometrica Inc.--U.S. Harvard Apparatus Ltd.--U.K. Harvard Apparatus SARL--France Biochrom Ltd.--U.K. Scie-Plas Ltd.--U.K. Asys Hitech GmbH--Austria Hugo Sachs Elektronik Harvard Apparatus GmbH--Germany Union Biometrica GmbH--Germany Maia Scientific NV--Belgium Ealing Scientific Ltd. Canada (dba Harvard Apparatus, Canada) Genomic Solutions Inc.--U.S.



Cartesian Technology Inc.--U.S. Genomic Solutions Ltd.--U.K. Genomic Solutions Canada Inc.--U.S. Genomic Solutions Inc.--Canada Hoefer Inc.--U.S. KDS Inc.--U.S.

BUSINESS STRATEGY: Have a broad range of specialized products that hold strong positions in

niche markets focused on the bottlenecks in drug discovery research in order to reduce the risk of being dependent on a single technology, to reduce head-to-head competition; and to position ourselves to achieve above-average revenue growth and above-average margins

RESEARCH & DEVELOPMENT: Focus is on the development of products that address bottlenecks within the

drug discovery process, in particular, for application in the areas of ADMET screening, molecular biology, genomics, proteomics and high-throughput/high-content screening

PRODUCTS ON MARKET: ADMET screening products, including absorption diffusion chambers, 96 well equilibrium dialysis plate for serum protein binding assays, organ testing systems, precision infusion pumps, cell injection systems, ventilators, electroporation products Molecular biology products, including spectrophotometers; DNA/RNA/Protein calculators; multi-well plate readers; amino acid analysis systems; low volume, high-throughput liquid dispensers; gel electrophoresis systems

Hawaii Biotech Inc.

99-193 Aiea Heights Drive, Suite 200 Aiea HI 96701, US Phone: (808) 486-5333; Fax: (808) 792-1343 Web: www.hibiotech.com E-mail: [email protected]

KEY PERSONNEL: Nicholas Mitsakos; Chairman David G. Watumull; President and CEO Samuel F. Lockwood, M.D.; Medical Director Carolyn Weeks-Levy, Ph.D.; VP, Research, Preclinical Development and Regulatory Affairs Richard L. Sherman; Sr. VP, Business Development and General Counsel


HISTORY: Founded in 1982 Began biotech R&D in 1983 Merged vaccine business with Avantogen Ltd.'s vaccine business (5/06) Member--Biotechnology Industry Organization

FACILITIES: 9,000 sq. ft. headquarters and R&D facility


PRIVATE PLACEMENTS: Raised $8.5M in Series A financing Raised $4M in federal funding (2003) Raised $8M (2004) Raised $7.8M in Series C financing (1/06)

INVESTMENTS: PanThera Biopharma Inc.

FINANCIAL INFORMATION: Received $15.5M through three awards from the NIH for West Nile Virus and dengue vaccine development (12/04)




Avantogen Ltd. evaluation of Avantogen's GPI-0100

worlwide, nonexclusive licensing agreement

10/05

Cobra Biomanufacturing plc

material for clinical trials of vaccines against dengue fever and West Nile disease

manufacturing and supply agreement

3/05

RESEARCH & DEVELOPMENT: rDNA, cell tissue culture, purification (lab-scale), hybridoma/cell fusion Dengue vaccine Immunoassays for marine natural products Taxol immunoassays Prodrugs Enteric pathogens

PRODUCTS ON MARKET: Immunoassay kits for Taxol and Taxanes Marine toxins for palytoxins and derivatives lyngbyatoxin A Antitoxin moonoclonal antibodies for mAG 73D3, neutralizing anti-palytoxin; mAGT20G110, neotralizing antitetrodotoxin

Helmholtz Centre for Infection Research

Mascheroder Weg 1 Braunschweig D-38124, Germany Phone: +49 (0) 531-6181-0; Fax: +49 (0) 531-6181-515 Web: www.helmholtz-hzi.de E-mail: [email protected]

KEY PERSONNEL: Dr. Peter Lange; Chairman, Supervisory Board Prof. Rudi Balling; Scientific Director Dr. Georg Frischmann; Administrative Director


HISTORY: Founded by Stiftung Volkswagenwerk in 1965 State-owned research institute since 1976 Changed name from Gesellschaft fur Biotechnologische Forschung mbH (German Research Centre for Biotechnology) (7/06) Member--Biotechnology Industry Organization Member--Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren (HGF) Partner--BioRegioN

STOCK-FINANCIAL HISTORY: Private government agency

PRINCIPAL INVESTORS: German Federal Government (BMBF)--90% State of Lower Saxony--10%

BUSINESS STRATEGY: Establish collaborative agreements with industrial partners and universities Contract manufacturing and research for clients from universities and industry Non-profit organization (governmental research centre) Research and development, technology transfer via patents, licensing National and international cooperation with universities, institutes and companies

RESEARCH & DEVELOPMENT: Cell and immune biology

Microbiology Molecular biotechnology Structural biology Biochemical engineering



Hercules Inc.

Hercules Plaza, 1313 North Market Street Wilmington DE 19894-0001, US Phone: (302) 594-5000; Fax: (302) 594-5400 Web: www.herc.com E-mail: [email protected]

KEY PERSONNEL: Craig A. Rogerson; President and CEO Edward V. Carrington; VP, Human Resources Richard G. Dahlen; Chief Legal Officer Israel J. Floyd; Corp. Secretary and General Counsel John E. Panichella; VP and President, Aqualon Paul C. Raymond III; VP and President, Paper Technologies and Ventures Group Allen A. Spizzo; VP and CFO



Sold Aerospace division for $439M to Alliant Techsystems (3/95) Acquired Quantum Hi-Tech Co. Ltd. (12/03) Agreed to purchase the guar and guar derivative manufacturing business of Benchmark Polymer Products LP (subsidiary of Benchmark Performance Group Inc.) (1/06)

STOCK-FINANCIAL HISTORY: NYSE--HPC Three-for-one stock split (1/95) Net sales $2.069b (YE 05) compared to $1.997b (YE 04) Net income <$29.8M> (YE 05) compared to $28.1M (YE 04) Earnings per share <$0.27/share> (YE 05) compared to $0.26/share (YE 04) Average shares outstanding 108.7M (YE 05) compared to 107.3M (YE 04) Total assets $2.548b (YE 05) compared to $2.720b (YE 04)

SUBSIDIARIES/DIVISIONS: Two major operating segments: Aqualon Group: Aqualon--Leader in products that modify the physical properties of water-based systems Pinova--Leader in pine chemistry since 1920, the world's only pale wood rosin derivatives producer Paper Technologies and Ventures Group

BUSINESS STRATEGY: Continuously improve to better serve our customers and extend our competitive advantage Maximize cash flow, reduce financial leverage and return to investment grade credit rating Grow profitably and increase ROIC Mitigate and reduce legacy liabilities

AGREEMENTS: Name Products Content of Agreement Date Barbara Ann Karmanos Cancer Institute (Wayne State University), University of Michigan

citrus pectin for cancer R&D agreement 12/95

Uniqema (business of ICI Americas)

synthetic lubricants extended manufacturing agreement

7/06

RESEARCH & DEVELOPMENT: In-house program in functional foods Biochemical production of natural food ingredients via fermentation and enzyme processing, pharmaceutical coatings, excipients, nutraceuticals



PRODUCTS ON MARKET: Aqualon--thickeners used in water-based products such as latex paint FiberVisions--staple fiber used in hygienic products and automotive textiles Pinova--adhesives, flavor and beverage, construction, fragrance, household and industrial Pulp and Paper--solutions for pulp and paper manufacturing needs Industrial Specialities--thickeners used in water-based products such as latex paint

Hidex Oy

Mustionkatu 2 Turku 20750, Finland Phone: +358 2 275 0557; Fax: +358 2 241 0075 Web: www.hidex.com E-mail: [email protected]

KEY PERSONNEL: Haaslahti Jukka; CEO Ville Haaslahti; Product Specialist Risto Juvonen; Product Manager




PRINCIPAL INVESTORS: Sitra

PRODUCTS ON MARKET: Plate Chameleon multi technology plate reader, Triathler portable

multitechnology vial reader, Consumables and reagents for our readers, Radiowater Generator for Positron Emission Tomography (PET) studies.

PRODUCTS IN DEVELOPMENT: Name Status Micro-Plate Automation / Screening Systems

Huntingdon Life Sciences

Woolley Road, Alconbury Huntingdon PE28 4HS, UK Phone: +44 (0) 1480 892 000; Fax: +44 (0) 1480 890 693 Web: www.huntingdon.com E-mail: [email protected]

KEY PERSONNEL: Andrew Baker; Chairman Brian Cass; Managing Director Dr. M.J. Butler; Pharmaceutical Services Director Dr. D.R. Hawkins; Agrochemical and Food Services Director Dr. P.C. Brooker; Industrial Chemical Services Director




SUBSIDIARY OF: Life Sciences Research

BUSINESS STRATEGY: Provide biological and chemical contract safety evaluation services to pharmaceutical, biotechnology, agrochemical and industrial chemical markets



Hybrizyme Corp.

2801 Blue Ridge Road, Suite G-70 Raleigh NC 27607, US Phone: (919) 783-9595; Fax: (443) 494-0005 Web: www.hybrizyme.com E-mail: [email protected]

KEY PERSONNEL: Randy Allen, Ph.D.; CEO




BUSINESS STRATEGY: Develop proprietary testing methods that incorporate the latest innovations in molecular and cellular toxicology either as a replacement for existing protocols or as new tests for compounds that cannot be accurately measured using current technology

RESEARCH & DEVELOPMENT: Diagnostic tests for environmental toxins and other compounds

PRODUCTS ON MARKET: Wallac Victor2 (with PerkinElmer Life Sciences) Delfia reagents AhRC PCR™ assay

PRODUCTS IN DEVELOPMENT: Name Status Dioxin and Furan assay in development

ICPbio

P. O. Box 1607, 26 Waipareia Avenue Auckland , New Zealand Phone: +64 9-838-4205; Fax: +64 9-838-4209 Web: www.icpbio.com E-mail: [email protected]

KEY PERSONNEL: Dr. Earl Stevens; Managing Director Kelvin Hunter; CFO Annette Nickless; Financial Controller Dr Jerome Demmer; Manager, R&D Ben Perrin; Marketing Manager Alan Cocks; Sales Manager Greg Shewfelt; Manager, Business Development Karen Munro; Production Manager Praveena Rawls; QA and QC Manager




BUSINESS STRATEGY: Commercialize research to provide innovative technical and commercial solutions to the animal health and pharmaceutical industries

RESEARCH & DEVELOPMENT: Laboratory and process scale protein purification to levels suitable for

animal trials. Protein purification process development. Analytical protein chemistry. Development of enzyme immunoassays. Development of embryo handling products. Bulk formulation of sterile solutions. Sterile lyophilisation. Clean room facilities.



PRODUCTS ON MARKET: Confirm, animal pregnancy test using milk or faeces sample Emcare, new media for freezing/thawing/culturing animal embryos (phosphate-free) Ovagen, an FSH product for superovulation of livestock Bovine serum albumin for cell culture and laboratory use

Idaho National Laboratory

P.O. Box 1625 Idaho Falls ID 83415, US Phone: (208) 526-0111 Web: www.inl.gov

KEY PERSONNEL: John J. Grossenbacher; Laboratory Director Art Clark; Deputy Laboratory Director, Operations Dr. David Hill; Deputy Laboratory Director, Science and Technology Juan Alvarez; Deputy Laboratory Director, Management Systems Dr. James Lake; Associate Laboratory Director, Nuclear Programs Dr. KP Ananth; Associate Laboratory Director, National and Homeland Security Dr. J.W. (Bill) Rogers Jr.; Associate Laboratory Director, Science and Technology and Chief Research Officer David L. Kudsin; Associate Laboratory Director, Specific Manufacturing Capability David Richardson; Associate Laboratory Director, Nuclear Operations Fran B. Williams; Director, Environment, Safety, Health and Quality Dr. Brian Sack; Director, Business Management and CFO Dwayne Coburn; Director, Facilities and Site Services John Lindsay; Director, Communications Dr. Ralph Bennett; Director, Science and Technology Strategic Planning Dr. Susan B. Arnold; Director, Human Resources and Diversity Programs Carol Johnson; Director, Infrastructure, Optimization, Integration and Planning John J. (Jack) Lance; Director, Technology Partnerships Mark D. Olsen; General Counsel Dr. Andrew C. Klein; Director, Education, Training, and Research Partnerships Dr. Leonard J. Bond; Director, Center for Advanced Energy Studies


HISTORY: Founded in 1949 as the National Reactor Testing Station

FACILITIES: 890-square-mile area in southeastern Idaho Materials and Fuels Complex (formerly Argonne National Laboratory-West) Reactor Technology Complex (formerly Test Reactor Area) Science and Technology Campus


SUBSIDIARIES/DIVISIONS: Divisions and departments: Physical Science: Physics, Material Sciences, Chemical Sciences, Analytical Chemistry & Instrumentation, Advanced Modeling & Simulation, Prototype Engineering Life & Earth Science: Biological Sciences, Ecological Sciences, Geosciences, Modeling & Measurement Engineering Technology: Environmental Engineering, Process Engineering, Nuclear Materials Disposal & Engineering, Applied Mechanics & Sustainable Design, Systems Engineering Energy & Technology Systems: Fossil Energy, Renewable Energy, Transportation Technology, Industrial Technology, Robotics & Human Systems



RESEARCH & DEVELOPMENT: Science and Technology: Developing America's hydrogen economy and alternative fuels and energy systems. Supports the development of advanced energy storage and transportation systems, critical energy infrastructure and water resources. Manages the environmental consequences of energy development and use. Research on compressed and liquefied natural gas, high powered batteries and ultra capacitors, integrated fuel processors and fuel cell systems, renewable energy systems, carbon capture and sequestration, hazardous waste management treatment, advanced offgas treatment systems, advanced welding systems, surface and subsurface monitoring systems, sustainable building design, and autonomous unmanned aerial and ground vehicles. National and Homeland Security: Global security, homeland security, national defense, energy security and special programs Nuclear programs: Nuclear safety analysis, irradiation services, nuclear operations, management of spent nuclear fuel, biocorrosion of fuels

Idexx Laboratories Inc.

One IDEXX Drive Westbrook ME 04092, US Phone: (207) 856-0300; Fax: (207) 856-0346 Toll-free phone: (800) 548-6733 Web: www.idexx.com E-mail: [email protected]

KEY PERSONNEL: Jonathan W. Ayers; Chairman, President and CEO William C. Wallen, Ph.D.; Sr. VP and CSO Merilee Raines; VP and CFO Conan R. Deady; VP, General Counsel and Secretary Sam Fratoni, Ph.D.; VP and CIO Robert Hulsy; VP, Laboratory Services Jennifer Joiner; VP, North American Commercial Operations Laurel LaBauve; VP, Worldwide Operations Quentin Tonelli, Ph.D.; VP, Rapid Assay and Production Animal Services


HISTORY: Founded in 1983 Purchased certain assets of Baxter Diagnostics (2/91) Purchased diagnostics business of Fermenta Animal Health Co. (10/91) Purchased assets of VetTest, a manufacturer of biochemical monitoring tests for animal health care, acquisition completed (1/92) Acquired Environetics Inc., a manufacturer and marketer of environmental diagnostics (2/93) Acquired Amis, a commercial veterinary laboratory in Japan (9/94) Acquired Cardiopet Inc., which provides veterinary, cardiology, internal medicine, and other consulting services (5/95) Acquired VetLab Inc., veterinary laboratory (3/96) Acquired Grange Laboratories, veterinary laboratory (4/96) Acquired Veterinary Services Inc., veterinary laboratory (5/96) Acquired Idetek Inc. (1996) Acquired Blue Ridge Pharmaceuticals (10/98) Acquired veterinary laboratory business of Sonora Quest Laboratories (3/99) Acquired veterinary laboratory business of Tufts University School (12/99) Acquired Sierra Veterinary Laboratory (3/00) Acquired Veterinary Pathology Services Pty Ltd. (7/00) Acquired Genera Technologies Ltd. (9/01) Acquired Syracuse Bioanalytical Inc. (8/04) Acquired Bommeli Diagnostics (12/04) Acquired Vet Med Lab (11/04)



FACILITIES: 329,000 sq. ft. of leased office and manufacturing space in Westbrook, Maine 97,500 sq. ft. of leased industrial space in Memphis, Tenn. 40,000 sq. ft. of leased office and manufacturing space in Eau Claire, Wis. 48,000 sq. ft. of leased warehouse and office space in the Netherlands

STOCK-FINANCIAL HISTORY: NASDAQ--IDXX IPO--1.6M shares at $15/share (6/91) Public offering--1.5M shares of common stock at $20.50/share (4/92) Two-for-one common stock split (10/93) Two-for-one common stock split (6/95) Public offering--4.6M shares of common stock at $35/share (9/95) Revenue $638.095M (YE 05) compared to $549.181M (YE 04) Net income $78.254M (YE 05) compared to $78.332M (YE 04) Earnings per share $2.41/share (YE 05) compared to $2.29/share (YE 04) Average shares outstanding 32.521M (YE 05) compared to 34.214M (YE 04) Total assets $490.676M (YE 05) compared to $514.237M (YE 04)

SUBSIDIARIES/DIVISIONS: Three business segments: Companion Animal Group (CAG), Water testing business and Food Diagnostics Group

BUSINESS STRATEGY: Manufacture, develop and market rapid test kits for food safety, quality control, environmental testing and veterinary testing

AGREEMENTS: Name Products Content of Agreement Date Alteon Inc. pimagedine as oral

therapeutic for diabetes and aging in companion animals

licensing agreement

6/97

Banfield, The Pet Hospital®

Idexx to provide Idexx VetLab laboratory system and rapid assay products to Banfield hospitals

five-year agreement

5/05

Beckman Instruments Inc.

Icon immunoassay technology for veterinary diagnostics and agricultural applications


6/86

Becton Dickinson and Co.

BD's hematology products and technology for veterinary markets


10/93

RESEARCH & DEVELOPMENT: Molecular biology, cellular biology, MAbs, immunoassays, membrane filter delivery systems Expansion of current EIA test system and micro fabrication technology Immuno-based optical biosensors Bacterial Ice Nucleation Diagnostic (BIND) pathogen test kits Antibody development for antibiotics, toxins, microbial pathogens, pesticides and environmental contaminants New immunoassay formats for multi-analyte, one-step testing

PRODUCTS ON MARKET: More than 100 products, including over 50 immunoassays for infectious diseases in swine, cattle, poultry, horses, cats and dogs Tests for contaminants on food production surfaces and in milk or grain Clinical chemistry, hematology, and electrolyte systems and reagents Tests for environmental monitoring--E. coli, coliforms, and enterococci ELISA test for B. abortus LacTek™ residue screening test kits for milk LacTek™ antibiotic residue test system Sultamethazine serum/plasma test kit Phytodetek™ plant growth regulator Quantix workstation for petroleum/hydrocarbon contamination measurement in soil and water



Quantix labstation test kits for pesticides, petroleum and TNT contaminants BIND® salmonella one-day pathogen test SNAP® Heartworm Antigen test NAVIGATOR® (32% nitazoxanide) Antiprotozoal oral paste treatment for equine protozoal myeloencephalitis

IGENE Biotechnology Inc.

9110 Red Branch Road Columbia MD 21045-2024, US Phone: (410) 997-2599; Fax: (410) 730-0540 Web: www.igene.com E-mail: [email protected]

KEY PERSONNEL: Michael G. Kimelman; Chairman Stephen F. Hiu, Ph.D.; President, CTO and Director, R&D Edward J. Weisberger; CFO Patrick F. Monahan; VP and Director, Manufacturing Per A. Benjaminsen; Director, Sales and Marketing


HISTORY: Founded in October 1981 by Robert Milch and William Hall Formerly called Genetic Research Corp. and IGI Biotechnology Inc. Formed a wholly-owned subsidiary, Igene Chile Comercial Ltda. (2000) Acquired ProBio Nutraceuticals AS (2001) Sold ProBio Nutraceuticals AS (2/03)

FACILITIES: Leases approximately 8,500 sq. ft. of space in the Oakland Ridge Industrial Park located in Columbia, Md.--2,000 sq. ft. of the space is used for executive and administrative offices; 2,500 sq. ft. for R&D activities; and 4,000 sq. ft. for the company's intermediate-stage or scale-up pilot plant facility Leased manufacturing facilities at Fermic SA de CV in Mexico City Leased warehouse space for product storage in Mexico City 220 sq. ft. of leased office space in Chile

STOCK-FINANCIAL HISTORY: OTC BB IPO--800K shares at $6/share, $4.8M (7/86) Net sales $10.961M (YE 05) compared to $5.650M (YE 04) Net loss <$1.415M> (YE 05) compared to <$1.310M> (YE 04) Loss per share <$0.01/share> (YE 05) compared to <$0.01/share> (YE 04)

PRIVATE PLACEMENTS: Private placement 796K share/warrant units (12/83) Subscription offering of 50K shares (3/85) Subscription offering of 375K share/note units (2/86) Private placement 625K shares (9/87) Private placement 450K shares (6/90) Private placement 4.596M shares (3/91) Private placement 681K shares (6/92) Private placement 1.2M shares (8/95)

SUBSIDIARIES/DIVISIONS: Igene Chile Comercial Ltda.

INVESTMENTS: Formed 50:50 joint venture to produce AstaXin® for the aquaculture industry with Tate & Lyle plc (3/03)

BUSINESS STRATEGY: Developing, market and manufacture specialty ingredients for human and animal nutrition

AGREEMENTS: Name Products Content of Agreement Date Fermic SA de CV AstaXin renewed


5/00



RESEARCH & DEVELOPMENT: Development of proprietary processes to convert selected agricultural raw materials or feedstocks into commercially useful and cost effective products for the food, feed, flavor and agrochemical industries

PRODUCTS ON MARKET: AstaXin® yeast with high level of astaxanthin pigment

Imperial Innovations Ltd.

Electrical and Electronic Engineering Building Imperial College London, South Kensington London SW7 2AZ, UK Phone: +44 020-7581-4949 Fax: +44 020-7589-3553 Web: www.imperialinnovations.co.uk E-mail: [email protected]

KEY PERSONNEL: Martin Knight; Chairman Susan Searle; CEO Julian Smith; CFO and COO Jon Page; Head, New Ventures Naiem Hussain; Head, Asset and Investment Management Tony Hickson; Head, Biosciences Team Brian Graves; Head, Engineering and Technology Team


HISTORY: Name changed from RPMS Technology Ltd. (1998) Created more than 60 spin-out companies

STOCK-FINANCIAL HISTORY: University-funded research center

PRIVATE PLACEMENTS: Raised US$37.9M in private placement (5/05)

SUBSIDIARY OF: Imperial College London

BUSINESS STRATEGY: Conduct technology transfer from research program of Imperial College

Industrial Biotechnology Corp.

2033 Main Street, Suite 400 Sarasota FL 34237, US Phone: (941) 925-2500; Fax: (941) 925-2503 Web: www.industrialbiotechnology.com E-mail: [email protected]

KEY PERSONNEL: Andy Badolato; CEO David L. West; CFO Mark Truei, Ph.D.; VP, Manufacturing Gary Howell, Ph.D.; VP, Business Development Gurinder Shahi, M.D., Ph.D.; Chief Technologist J. Ron Doran; Director, Sales and Marketing Tom Hentschell; VP, Operations and Marketing Jack Hensley; VP, Investor and Public Relations Dr. Eric I. Tsao; Chief Scientist


HISTORY: Acquired Bio-Repellant Technologies Inc. (BRT) from UTEK Corp. (5/06) Acquired assets of Bio-Flavorance Technologies and Research Inc. (1/06) Acquired Advanced Pheromone Technologies Inc. (9/06)

STOCK-FINANCIAL HISTORY: Pink Sheets--IBTY



BUSINESS STRATEGY: Commercializes technologies and intellectual property in the field of biologically produced chemicals Through licensing, partnerships and direct sales, IBC will bring to market new and established chemicals for use in flavors and fragrances, fine chemicals, pharmaceutical, agricultural, environmental and bio-energy applications

AGREEMENTS: Name Products Content of Agreement Date Isis Innovation Ltd. (technology transfer company of Oxford University)

Cytochrome P-450 technology and two patented technologies


7/06

UTEK Corp. UTEK to assist in the identification of IP acquisitions

strategic alliance agreement

1/06

RESEARCH & DEVELOPMENT: Two platform technologies: The Oxford Cytochrome P450 Designer Enzyme Technology Platform The Rice FPP Biosynthesis Technology Platform

PRODUCTS ON MARKET: ALCHEMx Production Platforms™--Processes for the design, development, scale-up and optimization of specific chemical compounds

Industrial Technology Research Institute – Biomedical Engineering Center

Room 607, Building 51, Sec. 4, 195 Chunghsing Rd. Hsin Chu 31040, Taiwan Phone: +886 3-591-2686; Fax: +886 3-582-0464 Web: www.itri.org.tw; E-mail: [email protected]

KEY PERSONNEL: Hsin-I Lin; Chairman Dr. Johnsee Lee; President Dr. Jyuo-Min Shyu; Exec. VP Dr. Hsin-Sen Chu; Exec. VP Dr. Yeou-Gong Hsu; VP Dr. Shing-Yuan (Bill) Tsai; VP


HISTORY: Founded in 1973 by the Ministry of Economic Affairs (MOEA) to attend to the technological needs of Taiwan's industrial development Spun off United Microelectronices Corp. (UMC) (1979) Spun off Taiwan Semiconductor Manufacturing Company Ltd. (TSMC) (1987) Spun off Taiwan Mask Corp. (TMC) (1988) Spun off Mirle Automation Corp. (1989) Spun off Vanguard International Semiconductor Corporation (VIS) (1994)

FACILITIES: Seven laboratories and four centers


SUBSIDIARY OF: Industrial Technology Research Institute

BUSINESS STRATEGY: Mission: -Engage in applied research and technical services to accelerate the industrial development of Taiwan -Develop key, compatible, forward-looking technologies to meet industrial needs and strengthen industrial competitiveness -Disseminate research results to the industrial sector in a timely and appropriate manner, in accordance with the principles of fairness and openness



-Foster the technology development of small and medium-sized businesses, and cultivating industrial technology human resources for the benefit of the nation

RESEARCH & DEVELOPMENT: Research projects in the following areas:

Communications and Optoelectronics Precision Machinery and MEMS Materials and Chemical Engineering Sustainable Development Biotechnology and Medicine Nanotechnology

inGenious Targeting Laboratory Inc.

LIHTI Building, Suite 106, 25 Health Sciences Drive Stony Brook NY 11790-3350, US Phone: (631) 444-6640; Fax: (631) 444-6645 Web: www.genetargeting.com E-mail: [email protected]

KEY PERSONNEL: Wel Weng; President and CEO Paul Sheiffele; Exec. VP Ellen Chen; Exec. VP


HISTORY: Founded in Febuary 1998 Began biotech R&D in November 2000

FACILITIES: 8,500 sq. ft. headquarters located in Stony Brook, N.Y. 2,000 sq. ft. animal facility located in Stony Brook, N.Y. 3,000 sq. ft. warehouse located in Islip, N.Y.


SUBSIDIARIES/DIVISIONS: mouse-knockout technology

BUSINESS STRATEGY: Improve the R&D conditions and business results for scientists and companies by offering effective and well defined knockout animals

RESEARCH & DEVELOPMENT: Improve technology for mouse knockout production; search for novel animal

models for drug discovery

Institute for Biological Research and Technology

University of South Carolina Coker Life Sciences Building, Room 403 Columbia SC 29208, US Phone: (803) 777-2468; Fax: (803) 777-4002 Web: www.cosm.sc.edu/biotech E-mail: [email protected]

KEY PERSONNEL: Austin L. Hughes; Director Travis Glenn; Associate Director Robert P. Lawther, Director, DNA Synthesis and Licor Sequencing Facility Loren Knapp; Director, Monoclonal Antibody Facility Bert Ely; Director, Biotechnology Training Laboratory Lewis Bowman; Director, Bioinformatics Resources Laszlo Marton; Director, Plant Genetic Engineering Facility Michael Dewey; Director, Transgenic Mouse Facility Thomas Borg; Director, Integrated Microscopic Analysis Facility




HISTORY: Founded in 1988 by scientists at the University of South Carolina who had worked together to acquire the equipment needed to facilitate the use of biotechnological innovations in their research programs

STOCK-FINANCIAL HISTORY: University research center

BUSINESS STRATEGY: Promote the use of biotechnology and make facilities available to scientists, industry and other institutions throughout the region

RESEARCH & DEVELOPMENT: Basic research in genetics, molecular biology, biochemistry and

environmental biotechnology

Institute of Food Research

Norwich Research Park, Colney Norwich NR4 7UA, UK Phone: +44 1603 255000; Fax: +44 1603 507723 Web: www.ifr.ac.uk; E-mail: [email protected]

KEY PERSONNEL: Prof. David White; Director Dr. Roger Fenwick; International Coordinator Mrs. Catherine Reynolds; Head of Communications Prof. Sue Southon; Head of Enterprise


HISTORY: Formerly AFRC Institute of Food Research A company limited by guarantee, grant-aided by the Biotechnology and Biological Science Research Council

FACILITIES: Laboratory in Norwich


SUBSIDIARIES/DIVISIONS: IFR Enterprises Ltd. Food and Health Network (FHN) National Collection of Yeast Cultures (NCYC) (see separate entry)

BUSINESS STRATEGY: Fundamental research applicable to the marketplace Innovation via patenting, joint ventures, and confidential development

RESEARCH & DEVELOPMENT: Protein and enzyme science for biotransformations of food functional

molecules Molecular biology Microbial genetics Natural preservation Metabolic engineering Novel polysaccharides Personalized nutrition

International Flavors & Fragrances Inc.

521 West 57th Street New York NY 10019, US Phone: (212) 765-5500; Fax: (212) 708-7132 Web: www.iff.com E-mail: [email protected]

KEY PERSONNEL: Robert M. Amen; Chairman and CEO Jim Dunsdon; COO Dennis M. Meany; Sr. VP, General Counsel and Secretary



Douglas J. Wetmore; Sr. VP and CFO Clint D. Brooks, Ph.D.; Sr. VP, R&D Steven J. Heaslip; Sr. VP, Human Resources Joe Faranda; VP and Chief Marketing Officer Nicolas Mirzayantz; Sr. VP, Fine Fragrances and Beauty Care and Regional Manager, North America


HISTORY: Founded in 1909 Purchased Auro Tech, a Wisconsin biotechnology company specializing in a broad range of natural dairy flavors, dairy and meat cultures, natural cheese and other flavor products (1992) Acquired Bush, Boake Allen Inc. (2000)

FACILITIES: 62 facilities in 30 countries 30 manufacturing facilities

STOCK-FINANCIAL HISTORY: NYSE--IFF Repurchase of up to 15M shares of common stock authorized (9/92, 9/96) Three-for-one stock split (12/93) Net sales $1.993b (YE 05) compared to $2.034b (YE 04) Net income $193.066M (YE 05) compared to $196.071M (YE 04) Earnings per share $2.06/share (YE 05) compared to $2.08/share (YE 04) Average shares outstanding 93.584M (YE 05) compared to 94.143M (YE 04) Total assets $2.623b (YE 05) compared to $2.363b (YE 04)

BUSINESS STRATEGY: Create and manufacture flavor and fragrance products used by other manufacturers to impart or improve flavor or fragrance in a wide variety of consumer products

AGREEMENTS: Name Products Content of Agreement Date Johns Hopkins Medical School

odor binding protein collaborative neuroscience research agreement

1988

Xinanjiang Perfumery Factory

fragrance ingredients using Chinese raw materials

joint venture agreement

1993

RESEARCH & DEVELOPMENT: Enzymology and fermentation to improve ingredients and develop natural flavor molecules Large-scale commercial manufacturing Olfactory biochemistry Specialty chemicals Head space analysis techniques for capture and synthesis of fragrance/flavor molecules from flowers and fruits Recombinant DNA for production of natural flavoring materials and food ingredients Microemulsion preparation for clear beverages Fragrances with organoleptic properties to provide natural insect and mosquito repellancy

PRODUCTS ON MARKET: Flavors and fragrances for beverages, dairy products, fabric care, fine fragrances, home care, ingredients, oral and pharmaceuticals, toiletries, foods



Iogen Corp.

310 Hunt Club Rd. East Ottawa K1V 1C1, Canada Phone: (613) 733-9830; Fax: (613) 733-0781 Web: www.iogen.ca E-mail: [email protected]

KEY PERSONNEL: Patrick Foody, Sr.; Chairman Brian Foody; President and CEO Patrick Foody Jr.; COO Grant Blanchard; CFO Jeff Passmore; Exec. VP Ray Barnes; Exec. VP and General Manager, Iogen Bio-Products Nancy Clark; VP, Human Resources Ron Paradis; VP, Ethanol and Co-Product Marketing



FACILITIES: Enzyme manufacturing plant--Produces food-grade and industrial-grade enzymes for use in the pulp and paper, textile and animal feed industries Cellulose ethanol demonstration facility--Designed to process about 40 tonnes per day of feedstock, and to produce 3 to 4 million litres of ethanol per year


PRINCIPAL INVESTORS: Goldman Sachs Royal Dutch/Shell Group Petro-Canada Government of Canada

BUSINESS STRATEGY: Specializes in cellulose ethanol Develop, manufacture and market enzymes used to modify and improve the processing of natural fibres within the textile, animal feed, and pulp and paper industries

AGREEMENTS: Name Products Content of Agreement Date DSM (formerly Roche Vitamins)

exclusive manufacturing and distribution of Roxazyme G2 animal feed enzymes

supply agreement 1991

National Research Coucil of Canada

enzymes for the pulp and paper industry


1994

Petro-Canada develop cellulose ethanol technology

partnership 1997

Royal Dutch/Shell Group

commercialization of biofuels


2002

Technology Partnerships Canada (TPC)

partnership 1/99

Volkswagen and Shell

assess the economic feasibility of producing cellulose ethanol in Germany

joint study 1/06

RESEARCH & DEVELOPMENT: Enzymes for fiber modification in pulp and paper, textile and animal feed

industries Cellulase and xylanase enzymes Ethanol from biomass

PRODUCTS ON MARKET: Fiber modifying enzymes able to enhance yield or reduce viscosity



Isolagen Inc.

405 Eagleview Boulevard Exton PA 19341, US Phone: (484) 713-6000; Fax: (484) 713-6001 Web: www.isolagen.com; E-mail: [email protected]

KEY PERSONNEL: Nicholas J. Teti; Chairman and CEO Susan Ciallella; President Declan Daly; CFO and Exec. VP Steven Trider; Sr. VP, Global Business and Market Development Dr. Marie Lindner; Sr. VP, Medical and Business Affairs


HISTORY: Founded in 1995 Acquired a 57% interest in Agera Laboratories Inc. for $2.655M (8/06)

FACILITIES: 86,500 sq. ft. leased facility for manufacturing and product development

STOCK-FINANCIAL HISTORY: AMEX--ILE IPO--12/02 Public offering--7M shares of common stock at $8.50/share, $61.2M (6/04) Revenue $8.754M (YE 05) compared to $4.179M (YE 04) Net loss <$35.778M> (YE 05) compared to <$21.474M> (YE 04) Loss per share <$1.18/share> (YE 05) compared to <$0.71/share> (YE 04) Average shares outstanding 30.245M (YE 05) compared to 30.117M (YE 04) Total assets $90.180M (YE 05) compared to $128.121M (YE 04)

PRIVATE PLACEMENTS: Raised $10.1M from sale of 2.895M shares of Series A Convertible Preferred Stock at $3.50/share (7/02) Raised $4.4M from sale of 155.750K shares of Series B Convertible Preferred Stock at $28/share (5/03) Raised $20.5M in private placement (8/03)

SUBSIDIARIES/DIVISIONS: UK office: Isolagen Europe Ltd. 59/61 Park Royal Road London NW10 7JJ England Phone: +44 (0) 20 8834 1080 Fax: +44 (0) 20 8834 1165 Email: [email protected] Australia Office 2 Lincoln Street Lane Cove NSW 2066 Australia Tel: 1300 303 906 Fax: 02 9808 4442 Email: [email protected] Web: www.isolagen.com.au

PRINCIPAL INVESTORS: Heartland Advisors U.S. Bancorp Asset Management Perceptive Life Sciences Stark Investments

INVESTMENTS: Agera Laboratories Inc.

BUSINESS STRATEGY: Establish and formalize strategic partnering relationships on a global scale Accelerate current research efforts in ACS technology Expand cellular production capacity of laboratory facilities Expand business development, sales, production and distribution resources Supplement and leverage existing advisory relationships Facilitating the company's marketing strategies to supplement and leverage existing physician and corporate relationships



RESEARCH & DEVELOPMENT: Autologous cellular system (ACS) technology, with applications in cosmetic

dermatology, cosmetic surgery, periodontal disease, and reconstructive dentistry, among other therapies

PRODUCTS IN DEVELOPMENT: Name Status treatment for dermal defects in Phase III clinicals treatment of facial wrinkles in Phase III clinicals autologous fibroblasts for gingival disease in Phase I clinicals

Israel Institute for Biological Research (IIBR)

P.O. Box 19 Ness-Ziona 74100, Israel Phone: (972) 8-9381656; Fax: (972) 8-9401404 Web: www.iibr.gov.il E-mail: [email protected]

KEY PERSONNEL: Avigdor Shafferman, Ph.D.; General Director Arie Ordentlich, Ph.D.; Head, Biological Sciences Zvi Teitelbaum, Ph.D.; Head, Medicinal Chemistry Avraham Lacser, Ph.D.; Head, Environmental Sciences Baruch Velan, Ph.D.; Coordinator, Biotechnological Projects Natan Rosenbaum; Head, Personnel Ariella Raz; Head, Marketing

EMPLOYEES: 350 employees, 150 scientists


FACILITIES: Research facility Biotechnological and chemical pilot plants Pharmacological screening facilities including animal housing and behavioral laboratory

STOCK-FINANCIAL HISTORY: Government applied research institute

SUBSIDIARIES/DIVISIONS: Life Science Research Israel (LSRI)--commercial arm of IIBR to promote and commercialize IIBR-generated intelligence and applied research projects (established in 1978) Three scientific divisions--Biology, Medicinal Chemistry and Environmental Sciences

BUSINESS STRATEGY: Establish R&D agreements with other companies that could lead to joint ventures with equity investments

AGREEMENTS: Name Products Content of Agreement Date Snow Brand Milk Products Co. Ltd.

novel treatment for senile dementias of the Alzheimer's type

research contract with rights

5/84

RESEARCH & DEVELOPMENT: Biology: Diagnosis of infectious diseases; development of rapid, sensitive and specific diagnostic methods (and reagents) for pathogen detection and identification; viral and bacterial pathogenesis mechanisms in order to design strategies for vaccine and drug development, for the evaluation of novel modes of therapy and for diagnostic purposes; functional genomics and proteomics, including microbial genomes, gene selection from various pathogens; vaccine development and evaluation; engineering of proteins and enzymes, including molecular design, engineering of novel proteins, protein and peptide chemistry, chemical modification of engineered proteins, manipulation of post-translation processing and customized protein derivatives; generation of human or mammalian cell clones; evaluation of recombinant producer cells; development of efficient cultivation systems of mammalian anchorage-dependent cells in surface propagators; fixed-bed reactors and stirred microcarrier cultures; development of batch, fed batch



and perfusion cultures of suspended cells; development of monoclonal antibodies and antigens from cell culture; development of recombinant enzymes from animal cells, development of bacterial and viral veterinary vaccines, subunit vaccines, and human and veterinary recombinant lymphokines; fuel and environmental biotechnology R&D projects in petroleum microbiology, biodeterioration, biohydrometallurgy and bioremediation Medicinal Chemistry: Therapeutics for Alzheimer's disease; pharmacological and neuroscience projects include the treatment and therapy of the effects caused by toxic compounds used in agriculture and industry, prevention, treatment and therapy of the effects caused by chemical and thermal burns, ocular studies of chemical and physical injuries to the cornea and retina, and their prevention and treatment; physiological studies of seizure activity and prevention of the resulting irreversible brain damage; stress mechanisms and preventive therapeutic means against aging and stress-induced neuronal damage; investigation of inflammatory modulators using ex-vivo and tissue-culture methods; pharmacokinetic studies and investigation of drug delivery systems, and drug-receptor interactions and physiological responses mediated by distinct neurotransmitter receptor sub-types; design and synthesis of biologically active molecules Environmental Sciences: Air pollution meteorology and risk assessment, including air pollution measurements on site, occupational air quality measurements, environmental surveys, meteorological measurements, granulometric, aerodynamic and image analyses, risk assessment, air pollution modelling; real time chemical and granulometric analyses--portable GC, FTIR, MIRAN, Spraytech, Aerosizer, Knollenberg; optics in the atmosphere; physical protection group; and detectors and biosensors

Itochu Corp.

5-1, Kita-aoyama, 2-chome, Minato-ku Tokyo 107-8077, Japan Phone: +81 3-3497-7300; Fax: +81 3-3497-7389 Web: www.itochu.co.jp; E-mail: [email protected]

KEY PERSONNEL: Uichiro Niwa; Chairman Eizo Kobayashi; President and CEO Akira Yokota; Exec. VP Kouhei Watanabe; Exec. VP Toshihito Tamba; CFO Shigeki Nishiyama; President, Aerospace, Electronics & Multimedia Masahiro Okafuji; President, Textile Company Yosuke Minamitani; President, Chemicals, Forest Products & General Merchandise Company Shigeharu Tanaka; President, Food Company Takanobu Furuta; President, Machinery Company Yoichi Kobayashi; President, Energy, Metals & Minerals Company Takao Shiomi; President, Finance, Realty, Insurance & Logistics Services Company Yoshio Akamatsu; President and CEO, Itochu International Inc. Yoshihisa Suzuki; President, Itochu Canada Ltd. Toyoshige Yamada; General Manager, Strategic Business Development Department Takeyoshi Ide; General Manager, European Operations Yuji Fukuda; COO, Chemicals Division


HISTORY: Founded in 1858 Incorporated in December 1949 Formerly named C. Itoh & Co. Ltd., changed name (10/92)



FACILITIES: 18 offices in Japan and 135 offices overseas

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock exchanges Net income ¥145.146b (YE 06) compared to ¥77.792b (YE 05) Earnings per share ¥91.74/share (YE 06) compared to ¥49.16/share (YE 05) Total assets ¥4,797b (YE 06) compared to ¥4,472b (YE 05)

SUBSIDIARIES/DIVISIONS: Energy, Metals and Minerals: Itochu Non-Ferrous Materials Co. Ltd.--Japan Marubeni-Itochu Steel Inc.--Japan Itochu Enex Co. Ltd.--Japan Itochu Petroleum Japan Ltd. Itochu Energy Marketing Co. Ltd.--Japan Itochu Oil Exploration Co. Ltd.--Japan Itochu Minerals & Energy of Australia Pty. Ltd. Itochu Petroleum Co. (Singapore) Pte. Ltd. Chemoil Corp.--U.S. Galaxy Energy Group Ltd. IPC (USA) Inc. Chemicals, Forest Products & General Merchandise: Dailite Co. Ltd.--Japan Itochu Plastics Inc.--Japan Itochu Techno-Chemical Inc.--Japan Chemical Logitec Co. Ltd.--Japan The Japan Cee-Bee Chemical Co. Ltd. CI Kasei Co. Ltd.--Japan Takiron Co. Ltd.--Japan VCJ Corp.--Japan Illums Japan Co. Ltd. Sankyu Pharmaceutical Co. Ltd.--Japan Itochu Forestry Corp.--Japan Itochu Kenzai Corp.--Japan Itochu Pulp & Paper Corp.--Japan Itochu Ceratech Corp.--Japan PPG-CI Co. Ltd.--Japan Itochu Windows Co. Ltd.--Japan Beaver Tozan Corp.--Japan Hexa Color (Thailand) Ltd. Itochu Plastics Pte. Ltd.--Singapore Tetra Chemicals (Singapore) Pte. Ltd. Bonset America Corp.--U.S. Itochu Tekstil Kimya Ltd. Sti.--Turkey Shanghai Jinchang Engineering Plastics Co. Ltd.--China Shanghai Baoling Plastics Co. Ltd.--China Thaitech Rubber Corp. Ltd.--Thailand CIPA Lumber Co. Ltd.--Canada Albany Plantation Forest Co. of Australia Pty. Ltd. Food: Fuji Oil Co. Ltd.--Japan Itochu Sugar Co. Ltd.--Japan Itochu Feed Mills Co. Ltd.--Japan Japan Foods Co. Ltd. Shibushi Silo Co. Ltd.--Japan Cholburi Sugar & Trading Corp. Ltd.--Thailand Palmaju Edible Oil Sdn. Bhd.--Malaysia CGB Enterprise Inc.--U.S. PT Aneka Tuna Indonesia Winner Food Products Ltd.--Hong Kong



BUSINESS STRATEGY: Aim to become a high-profit corporate group earning over ¥100b in consolidated net income in a steady and sustainable manner by: Taking on the challenge of expanding earnings Creating new businesses Enhancing solid management

AGREEMENTS: Name Products Content of Agreement Date Baxter Hemoglobin Therapeutics Inc.

DNA probe licensing agreement 1989

Bioreactor Technology

bioreactor marketing agreement

6/86

British Technology Group

chemiluminescence licensing agreement 1991

Innogenetics NV cytokinin growth factor, hepatitis C virus kit

import agreement 1991

Repligen Corp. rProtein A import agreement 1986

PRODUCTS ON MARKET: Chemicals, Forest Products & General Merchandise: Logs, lumber, wooden building materials, wood chips, wood pulp, recycled paper, cotton linter, paper, paperboard, paper products, natural rubber, tyres, footwear, furniture, glass, cement, slag, landscape materials, refractory materials and products, natural gypsum, chemical feedstock, olefin, aromatics, raw materials for synthetic resins, tar chemicals, raw materials for synthetic fibers, organic chemicals, methanol, ethanol, solvents, speciality chemicals, inorganic chemicals, chemical fertilizers, vinyl chloride, polyolefin, synthetic rubbers, carbon black, thermoplastic and thermosetting resins, resin additives and glass fibers Energy, Metals & Minerals: Iron ore, direct reduced iron, coking coal, thermal coal, ferro alloy and its materials, steel scrap, pig iron, metal powder, electrodes, activated carbon, steel plates, hot and cold rolled sheets, galvanised steel, steel for machinery, stainless steel, high tensile steel, various specialty steel materials, construction materials, welded steel pipes, seamless steel pipes, steel wires, marine steel structures, bridges, prefabricated steel for buildings, rails, non-ferrous metals, non-ferrous/light metal products, rare metals, aluminum, alumina, aluminum rolled products, aluminum extrusion products, electric wires, optical fiber cables, electronic materials and products, crude oil, natural gas liquid (NGL), gasoline, naphtha, kerosene, jet fuel, gas oil, fuel oil, bunker oil, lubricant, asphalt, liquefied petroleum gas (LPG), liquefied natural gas (LNG), dimethyl ether (DME) and nuclear fuel Food: Wheat, barley, wheat flour, rice, starches, soybeans, sunflower oil, olive oil, palm oil, coconut oil, corn, soybean meal, rapeseed meal, fish meal, alfalfa pellets, raw sugar, sweeteners, high-fructose corn syrup, dairy products, nuts, coffee, cocoa, fruit juice, liquor, soft drinks, beef, pork, chicken, fruits and vegetables, processed foods, frozen foods, canned foods, pet foods and consulting services for food business

J. Craig Venter Institute

9704 Medical Center Drive Rockville MD 20850, US Phone: (240) 268-2605; Fax: (240) 268-4000 Web: www.venterinstitute.org E-mail: [email protected]

KEY PERSONNEL: J. Craig Venter, Ph.D.; President, and Group Leader, Environmental Genomics Robert L. Strausberg, Ph.D.; Group Leader, Human Genomic Medicine Hamilton O. Smith, M.D.; Group Leader, Synthetic Biology and Biological Energy




HISTORY: Formed from the consolidation of The Center for the Advancement of Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA) and the J. Craig Venter Science Foundation Joint Technology Center (JTC) (9/04) Member--Biotechnology Industry Organization

FACILITIES: Joint Technology Center--60,000 sq. ft. 5 Research Place Rockville, MD 20850 Phone: (240) 243-1500 Fax: (240) 243-0600

STOCK-FINANCIAL HISTORY: Nonprofit research institute

BUSINESS STRATEGY: The J. Craig Venter Institute is dedicated to the advancement of the science of genomics, understanding its implications for society, and communicating those results to the scientific community, public and policymakers.

RESEARCH & DEVELOPMENT: Genomic medicine with an emphasis on cancer genomics and human

genome resequencing and analysis Environmental genomic analysis with an emphasis on microbial biodiversity, ecology and evolution Use of molecular and genomic methods to develop biological sources of clean energy Synthetic genome development Policy research on the ethical, legal and economic issues associated with genomic science and technology

Johnson Matthey Pharma Services

35 Patton Road Devins MA 01434, US Phone: (978) 784-5000; Fax: (978) 784-5000 Web: www.jmpharmaservices.com E-mail: [email protected]

KEY PERSONNEL: Roger Kilburn; Exec. VP and GM Lee Piver; Sr. Director, Industry Relations Mike McKinley; Director, Finance and Materials Management Harwood Stiles; Director, Quality Paula J. Lorence; Director, Sales and Marketing Daniel J. Coughlin, Ph.D.; Director, Medicinal Chemistry Heather Taft, Ph.D.; Director, Chemical Development Tony Chong, Ph.D.; Director, Chemical Development and Pilot Plant


HISTORY: Founded in 1972 Began biotech R&D in 1984 Acquired by Johnson Matthey (2001) Changed name from Pharm-Eco (12/04)

FACILITIES: 50,000 sq. ft. headquarters and R&D facilities 20,000 sq. ft. manufacturing facilities

STOCK-FINANCIAL HISTORY: Privately held--Parent company Johnson Matthey is a public company

SUBSIDIARY OF: Johnson Matthey

BUSINESS STRATEGY: Provide API chemistry services to clients throughout the drug development process, from early stage discovery services to commercial manufacturing.



RESEARCH & DEVELOPMENT: Services provided for small molecule drugs; broad range of therapeutic areas including, but not limited to: oncologics, Alzheimer's disease, AIDS, infectious diseases, Parkinson's disease, memory enhancement and schizophrenia

PRODUCTS ON MARKET: Services: medicinal chemistry, chemical development, process research, process development, process optimization, process scale-up, process validation, production of intermediates, high potency compounds and production of APIs, commercial manufacturing, separation technologies, catalytic services, analytical and regulatory services

Kanebo Ltd.

20-20 Kaigan, 3-chome, Minato-ku Tokyo 108-8080, Japan Phone: +81 3-5446-3002; Fax: +81 3-5446-3027 Web: www.kanebo.co.jp E-mail: [email protected]

KEY PERSONNEL: Akiyoshi Nakajima; Chairman Tetsuo Komori; President


HISTORY: Established in May 1887 as Tokyo Cotton Trading Co. Renamed Kanegafuchi Spinning Co. (Kanegafuchi Boseki KK) (1893) EstablishedKanebo Service Co. (1931) Established Kanegafuchi Industrial Co. (1938) Established Kanebo Haris Inc. (1964) Absorbed Tachibana Confectionery Co. (1964) Entered pharmaceutical industry by takeover of Yamashiro Pharmaceutical Co. (1966) Established Kanebo Cosmetics Sales Co. (1967) Began biotech research in the 1970s Established Kanebo Soap Sales Co. (later Kanebo Home Products) (1971) Established Kanebo Soap Manufacturing Co. (1971) Absorbed Izumi Confectionery Inc. (1971) Established Kanebo Synthetic Chemicals Co. (1971) Established Kanebo-Stevens Co. (1971) Established Kanebo Engineering Co. (1971) Established Kanebo Pharmaceuticals Co. (1972) Absorbed Watanabe Confectionery Co. (1972) Established the Laboratory for Herbal Medicine (1976) Established Japan Synthetic Textile Co. with Asahi Kasei (1978) Established Kanebo Fashion Research Ltd. (1979) Established Kanebo Cosmetics (Europe) Ltd. (1980) Opened the Kanebo Museum of Textiles (1986) Changed name to Kanebo Ltd. (2000) Established the Kanebo Beauty Care Laboratory (2004) Sold Synthetic Fiber Division (2005) Established Kanebo Trinity Horldings Ltd. (2006)

FACILITIES: Plants: Tsushima (Toiletries) Second Takatsuki, Takaoka (Pharmaceuticals) First Takatsuki, Shinmachi, Fukuchiyama (Foods)

STOCK-FINANCIAL HISTORY: Formerly listed on the Tokyo and Osaka stock exchanges; delisted in 2005

SUBSIDIARIES/DIVISIONS: Toiletries, pharmaceuticals and foods divisions



AGREEMENTS: Name Products Content of Agreement Date Ontogen Corp. compounds to treat skin

diseases development agreement

6/96

Protein Design Labs Inc. (now PDL BioPharma Inc.)

Smart HUM195 antibody for acute myelogenous leukemia


2/92

PRODUCTS ON MARKET: Toiletries division: Skin care products, body soaps, shampoos, hair conditioners, hair rinse, hair styling, and bath products Pharmaceuticals division: Prescription and OTC products Foods division: chewing gum, confectionaries, powdered drinks and frozen desserts

PRODUCTS IN DEVELOPMENT: Name Status KB-195 to treat acute myelogenous leukemia

in Phase I clinicals

Kaneka Corp.

3-2-4, Nakanoshima, Kita-ku Osaka 530-8288, Japan Phone: +81-6-6226-5050; Fax: +81-6-6226-5037 Web: www.kaneka.co.jp; E-mail: [email protected]

KEY PERSONNEL: Masatoshi Takeda; Chairman Masami Onishi; President Uichiro Shimomi; Exec. VP Hideo Yasui; Exec. Officer Kimikazu Sugawara; Exec. Officer Yoichi Shima; Exec. Officer Satomi Takahashi; Exec. Officer Kiyomi Imou; Exec. Officer Masatoshi Hatori; Exec. Officer Toshiji Kanou; Exec. Officer Toshihiro Suzuki; Exec. Officer



FACILITIES: Plants in Takasago, Osaka, Shiga and Kashima Research institutes: Life Science R&D Center Advanced Polymer Materials R&D Center Polymer Designing & Processing Product Development Center Electronics R&D Center Production Technology R&D Center Foods R&D Center High Performance Materials Research Laboratories Additional locations in the U.S. Belgium, Singapore, Malaysia, Australia and China

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and Nagoya stock exchanges Net sales ¥464.310b (YE 06) compared to ¥438.001b (YE 05) Net income ¥28.100b (YE 06) compared to ¥24.746b (YE 05) Earnings per share ¥80.80/share (YE 06) compared to ¥70.65/share (YE 05) Total assets ¥453.159b (YE 06) compared to ¥224.143 (YE 05)

SUBSIDIARIES/DIVISIONS: Kaneka Singapore Co. (Pte.) Ltd.--Singapore (sales and manufacture of pharmaceutical intermediates) Kaneka Consulting (Shanghai) Co. Ltd.--China (technical consulting for Kaneka products)



Kaneka Technical Service Co. Ltd.--China (technical service of functional plastics) Kaneka Eperan (Suzhou) Co. Ltd.--China (manufacture of expandable plastics and products) Hifua Fiber Co. Ltd.--China (manufacture of synthetic fibers) Kaneka (Malaysia) Sdn. Bhd.--Malaysia (sales and manufacture of functional plastics) Kaneka Electec Sdn. Bhd.--Malaysia (sales and manufacture of electronic products) Kaneka Eperan Sdn. Bhd.--Malaysia (sales and manufacture of expandable plastics and products) Kaneka Paste Polymers Sdn. Bhd.--Malaysia (sales and manufacture of specialty PVC resins) TGA Pastry Company Pty Ltd.--Australia (sales and manufacture of foodstuffs products) Kaneka Texas Corp. (sales and manufacture of functional plastics and expandable plastics and products) Kaneka Nutrients LP--U.S. (sales and manufacture of functional foodstuffs) Kaneka America LLC--U.S. (marketing and technical consulting for Kaneka products) Kaneka Pharma America LLC--U.S. (sale of medical devices) Kaneka Belgium NV (sales and manufacture of functional plastics and expandable plastics and products) Kaneka Pharma Europe NV--Belgium (sale of functional foodstuffs and medical devices)

BUSINESS STRATEGY: Manufacture and sell chemicals, functional plastics, expandable plastics and products, foodstuffs products, life science products, electronic products and synthetic fibers

RESEARCH & DEVELOPMENT: Life Science R&D Center: Controlling R&D activities related to fine

chemicals, medical devices and foodstuffs based on the company's bio and synthesis technologies Performance Materials R&D Center: R&D for the synthetic resinsmodifiers, functional (performance) polymers and synthetic fibers based on Kaneka's macromolecular technology Electronics R&D Center: Controlling R&D related to information, communication and clean energy businesses based on high-polymer material designing, high-polymer fabrication, functional thin-film fabrication and systematizing technologies Foods R&D Center: Controlling R&D related to a foodstuff field based on biotechnologies in cooperation with the Life Science R&D Center Polymer Designing & Processing Product Development Center: Development of products related to formed plastics based on the technologies of high-polymer material designing and forming, mold designing and plastics fabrication Production Technology R&D Center: Development of production technologies ranging from facility-intensive processes to plastisc fabrication based on reaction analysis, simulation and process designing technologies in cooperation with each R&D center related to product development

PRODUCTS ON MARKET: Chemicals: Polyvinyl chloride (PVC), caustic soda, hydrochloric acid, flexible

PVC compounds, rigid PVC compounds, paste PVC and chlorinated PVC Functional Plastics: Modifier resins, heat-resistant ABS resins, self-extinguishing ABS resins, modified silicone polymer (MS polymer) and Allyl (Silyl) terminated polyisobuthylenes (Epion®)



Expandable Plastics and Products: Extruded polystyrene foam boards, insulating PVC sash windows, polystyrene foam sheets, polyolefin foam (beads and moldings) and expandable polystyrene Foodstuffs: Margarine and shortening, confectionary fats, bakery yeast Life Science Products: Ubidecarenone (Coenzyme Q10), anti-hypertensive drug intermediates, intermediates for antibiotics, liposorber system (LDL-cholesterol adsorption system) and Lixelle® (Adsorption column for dialysis-related amyloidosis)

Kikkoman Corp. (Biochemicals Division)

2-1-1 , Nishi-Shinbashi, Minato-ku Tokyo 105-8428, Japan Phone: +81 3-5521-5490; Fax: +81 3-5521-5498 Web: www.kikkoman.co.jp/bio E-mail: [email protected]

KEY PERSONNEL: Yuzaburo Mogi; Chairman and CEO, Kikkoman Corp. Takashi Ushiku; President and COO, Kikkoman Corp. Shigetaka Ishii; Sr. Corp. Officer, R&D and Biochemicals



STOCK-FINANCIAL HISTORY: Kikkoman Corp. is listed on the Tokyo and Osaka stock exchanges: Net sales ¥359.906b (YE 06) compared to ¥344.625b (YE 05) Net income ¥10.125b (YE 06) compared to ¥9.487b (YE 05) Earnings per share ¥51.80/share (YE 06) compared to ¥48.16/share (YE 05) Total assets ¥331.781b (YE 06) compared to ¥295.802b (YE 05)

SUBSIDIARIES/DIVISIONS: Kikkoman Corp.: R&D Division Biochemicals Division

RESEARCH & DEVELOPMENT: Fermentation processes, rDNA, pharmaceuticals, research reagents

(enzymes), luciferase Protease

PRODUCTS ON MARKET: Nutritional supplements Pharmaceutical raw materials Reagents for clinical diagnostics Checklite 250 Plus luciferase kit to detect microorganisms via bioluminescence LuciPac device for hygiene monitoring ZeptoLite ABC kit for enzyme immunoassay via bioluminescence InteLite AB kit for enzyme immunoassay via bioluminescence Cyclic AMP Ellagic acid dihydrate Proanthocyanidins Maltooligosaccharides Tannase Protease (acid-stable) B-glucosidase Glucoamylase Sarcosine oxidase Creatine amidinohydrolase Uricase Sucrose phosphorylase Maltase phosphorylase B-phosphoglucomutase



PRODUCTS IN DEVELOPMENT: Name Status Diagnostic enzymes in development High sensitive bioluminescent enzyme immunoassay methods

in development

Kraeber GmbH & Co.

Waldhofstr 14 Ellerbek 25474, Germany Phone: +49 4101 3053 0; Fax: +49 4101 3053 90 Web: www.kraeber.de E-mail: [email protected]

KEY PERSONNEL: Jens-Uwe Kraeber; President Birgit Petroschka; Director, R&D Gabriele Weiss; Head, Pharmaceutical Chemicals division


HISTORY: Founded in January 1980 Began biotech R&D in 1987 Acquired Biospa, Wedel (1992)


SUBSIDIARIES/DIVISIONS: Six divisions: 1. Pharmaceutical Chemicals: Active pharmaceutical ingredients, excipients and intermediates supplied to the pharmaceutical and cosmetic industry as well as refined materials in bulk for sale to the laboratory chemical sector. 2. Biopharmaceuticals: Active biopharmaceutical ingredients and excipients, cosmeceuticals and nutraceuticals are supplied to the human and veterinary pharmaceutical, cosmetic, health food and pet food industries. 3. Animal Blood Fractions: Manufacturer of animal blood fractions presently reared from 18 spezies for supply to the biotechnology, diagnostic, pharmaceutical and cosmetic industries. 4. Production: Extraction and separation from other tissues. 5.Distribution Seagarden AS and Maripro AS. 6. Kraeber UK Ltd. 16 The Street Saxon Street nr. Newmarket CB8 9RU, UK Phone: +44 1638-731297 Fax: +44 1638-731291 E-mail: [email protected]

INVESTMENTS: Kraeber U.K. Ltd.

BUSINESS STRATEGY: Produce animal blood fractions in Europe for biotechnology, pharmacy and cosmetics

PRODUCTS ON MARKET: Animal blood fractions in various qualities

Pharmaceutical raw materials Biopharmaceutical raw materials



Kuraray Co. Ltd.

Shin-Hankyu Building, 1-12-39, Umeda, Kita-ku Osaka 530-8611, Japan Phone: +81 6-348-2111; Fax: +81 6-6348-2165 Web: www.kuraray.co.jp E-mail: [email protected]

KEY PERSONNEL: Hiroto Matsuo; Chairman Yasuaki Wakui; President Junsuke Tanaka; Sr. Managing Director Seiji Wajiki; Managing Director Osamu Asaba; Managing Director Nobuo Iwawaki; Managing Director Yoichi Ninagawa; Managing Director Fumio Ito; Managing Director


HISTORY: Established in 1926 Began biotech research in 1983

FACILITIES: Headquarters in Tokyo and Osaka, Japan

STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange Net sales ¥354.874b (YE 05) compared to ¥332.149b (YE 04) Net income ¥18.465b (YE 05) compared to ¥15.181b (YE 04) Earnings per share ¥50.13/share (YE 05) compared to ¥40.81/share (YE 04) Total assets ¥454.941b (YE 05) compared to ¥413.227b (YE 04)

SUBSIDIARIES/DIVISIONS: Specialty Resins and Films: Poval Resin Co., Poval Film Co., EVAL Co. Fibers and Textiles: Fibers and Industrial Materials Co., Clarino Co., Kuraray Fastening Co. Ltd., Kuraray Kuraflex Co. Ltd. Chemicals: Methacrylate Division, Chemicals Division, Elastomer Division, Genestar Division Affiliated companies: Kuraray Trading Co. Ltd., Kuraray America Inc., Kuraray Europe GmbH, Kuraray Specialities Europe, Kuraray Plastics Co. Ltd., Kuraray Medical Inc., Kuraray Chemical Co. Ltd., Kuraray Engineering Co. Ltd., Kuraray Interior Co. Ltd., Kuraray Family Products Co. Ltd., Kuraray Techno Co. Ltd., Techno Soft Co. Ltd.

PRODUCTS ON MARKET: Chemicals and resins, fibers and textiles, high performance material,

medical products

Kyorin Pharmaceutical Co. Ltd.

5, Kanda Surugadai 2-chome, Chiyoda-ku Tokyo 101-8311, Japan Phone: +81 03-3293-3411 Fax: +81 03-3293-3470 Web: www.kyorin-pharm.co.jp

KEY PERSONNEL: Hiroshi Uchida; Chairman Ikuo Ogihara; President and CEO Yoshizumi Amano; Exec. Director Keiji Hirai; Exec. Director Masahiro Yamashita; Exec. Director Minoru Hogawa; Exec. Director Shinichi Saito; Exec. Director Akihiro Tanaka; Exec. Director Takayoshi Ishizaki; Exec. Director




HISTORY: Founded in 1923 Established in 1940 Acquired ActivX Biosciences Inc. (2/05)

STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange

SUBSIDIARIES/DIVISIONS: Kyobundo Co. Ltd. Bistner Co. Ltd. Toyo Pharmar Co. Ltd. Dr. Program Co. Ltd. ActivX Biosciences Inc. Kyorin USA. Inc. Kyorin Europe GmbH Nisshin Kyorin Pharmaceutical Co. Ltd. Nippon Rika Co. Ltd.

SUBSIDIARY OF: Kyorin Co. Ltd.

BUSINESS STRATEGY: Manufacture and sell prescription medicines and quasi-drugs, diagnostics and industrial chemicals Build alliances that will capitalize on external resources, allowing the company to further contribute to better the health of people throughout the world Invest management resources in specific therapeutic fields for drug discovery and marketing

AGREEMENTS: Name Products Content of Agreement Date MediciNova Inc. development and

commercialization of MN-001 (except Japan, China Taiwan and South Korea)

licensing agreement

Novartis AG KRP-203 global development and commercialization licensing agreement

2/06

RESEARCH & DEVELOPMENT: Drug discovery operations are centered on three therapeutic fields: Infectious diseases, immunological/allergic and metabolic diseases

PRODUCTS ON MARKET: Gatiflo® tablets Kipres® tablets Mucodyne® Ketas® capsules Baccidal® tablets Aplace® Pentasa® tablets Rocaltrol® capsules Bestron® for ear and nose

Kyowa Hakko Kogyo Co. Ltd.

1-6-1 Otemachi, Chiyoda-ku Tokyo 100, Japan Phone: +81 3-3282-0007; Fax: +81 3-3284-1968 Web: www.kyowa.co.jp/eng; E-mail: [email protected]

KEY PERSONNEL: Dr. Yuzuru Matsuda; President and CEO Yoshito Imai; Sr. Exec. Managing Officer and President, Pharmaceuticals Business Unit Yukinobu Kotani; Sr. Exec. Managing Officer and President, Bio-Chemicals Business Unit




HISTORY: Founded in July 1949 Established Kyowa Hakko Kogyo Co. Ltd. as a secondary company of Kyowa Sangyo Co. Ltd. (1949) Bought out Sanyo Kagaku Co. Ltd. (1954) Established Daikyowa Sekiyu Kagaku Co. Ltd. through joint investment with Daikyo Sekiyu Co. Ltd. (1961) Began the pharmaceutical business (1963) Established Kyowa Yuka Co. Ltd., as a separate company from Daikyowa Sekiyu Kagaku Co. Ltd. (1966) Established Kyowa Hakko USA Inc. (1969) Established Kyowa Hakko Europe GmbH (1973) Established Kyowa Miles, a merger company with United States Miles Inc. (1973) Established Kyowa FD Foods Co. Ltd. to produce freeze-dried foods (1973) Established Ohland Foods Co. Ltd. to start producing and selling frozen dough for bread and cake mix (1974) Established Fermex for the production of feed-grade L-Lysine (1977) Established Janssen-Kyowa Co. Ltd. (1978) Established the Bio Business Division (1981) Established Kyowa Medex Co. Ltd. to develop, produce and sell diagnostic reagents (1981) Established Biokyowa Inc. in the U.S. for the production of amino acids (1984) Established Kyowa Hakko (Thailand) Ltd. (1985) Established Agroferm Hungarian-Japanese Fermentation Industry Ltd., a consolidated company in Hungary (1987) Established Japan Oxocol Co. Ltd. to strengthen the plasticizers business (1988) Acquired all stock of Shinwa Pharmaceutical Co. Ltd. (1989) Established Nutri-Quest Inc., a company for research and development in the U.S. (1989) Established Kyowa Iryo Kaihatsu Co. Ltd. (1989) Established Kyowa Hakko (HK) Co. Ltd. (1989) Merger of Kyowa Yuka Co. Ltd. and Japan Oxocol Co. Ltd. (1991) Established Kyowa Pharmaceutical Inc. in the U.S. (1992) Established Dinavec Research Inc. (1995) Established Shanghai Guan Sheng Yuan Kyowa Amino Acid Co. Ltd. (1998) Established Kyowa America Inc., a holding company in the U.S. (1999) Established J Plus Co. Ltd., a joint venture for the plasticizers business (2000) Established Kyowa Foods (H.K) Co. Ltd. (2000). Transferred alcoholic beverage business (excluding raw alcohol) to Asahi Breweries (9/02) Established Yantai Kyowa Foods Co. Ltd. in China (2002) Established Japan Ethyl Acetate Co. Ltd., a joint venture with Showa Denko KK for the production of ethyl acetate (2003) Established BioWa Inc. in the U.S. to promote Kyowa Hakko’s biopharmaceutical business (2003) Spun off Kyowa Hakko Food Specialties Co. Ltd. (2005)

FACILITIES: 27,000 sq. m. pharmaceutical research facilities

STOCK-FINANCIAL HISTORY: Net sales ¥353.440 (YE 06) compared to ¥358.963b (YE 05) Net income ¥16.273b (YE 06) compared to ¥17.932b (YE 05) Earnings per share ¥38.4/share (YE 06) compared to ¥41.7/share (YE 05) Total assets ¥384.381b (YE 06) compared to ¥374.493b (YE 05)

SUBSIDIARIES/DIVISIONS: The company consists of two business units--Pharmaceuticals Business Unit and Bio-Chemicals Business Unit Overseas network: Kyowa America Inc. 767 Third Avenue, 19th Floor New York, NY 10017 USA Phone: (212) 319-5353



Biokyowa Inc. 5469 Nash Road, P.O.Box 1550 Cape Girardeau, MO 63702-1550 USA Phone: (573) 335-4849 Kyowa Hakko USA Inc. 767 Third Avenue, 19th Floor New York,NY 10017 USA Phone: (212) 319-5353 Web site: www.kyowa-usa.com Kyowa Hakko USA Inc. West Coast Office 85 Enterprise, Suite 430 Aliso Viejo,CA 92656 USA Phone: (949) 425-0707 Select Supplements Inc. 5800 Newton Drive Carlsbad, CA 92008 USA Phone: (760) 431-7509 Kyowa Pharmaceutical Inc. 212 Carnegie Center, Suite 101 Princeton, NJ 08540 Phone: (609) 919-1100 Web site: www.kyowa-kpi.com BioWa Inc. 212 Carnegie Center, Suite 101 Princeton, NJ 08540 USA Phone: (609) 580-7500 Web site: www.biowa.com Kyowa Hakko Europe GmbH Immermannstrasse-3 D-40210, Dusseldorf, Germany Phone: +49 211-17-728-0 Web site: http://www.kyowa.de Kyowa Hakko U.K. Ltd. 258 Bath Road, Slough Berkshire SL1 4DX, UK Phone: +44 1753-566000 Kyowa Italiana Farmaceutici SRL Viale Fulvio Testi 280 20126, Milan, Italy Phone: +39 02-644-704-1 Web site: [email protected] Kyowa Hakko Industry (S) Pte. Ltd. 260 Orchard Road, #12-04 The Heeren, Singapore 238855 Phone: +65 6733-4948 Kyowa Hakko (Malaysia) Sdn. Bhd. 20, Jalan SS 19/5, 47500 Subang Jaya Selangor, Darul Ehsan, Malaysia Phone: +60 3-5634-0669



Kyowa Hakko Kogyo Co. Ltd. Beijing Representative Office Room 701, Beijing Fortune Bldg. 5 Dong San Huan Bei-Lu Chao Yang District, Beijing 100004, China Phone: +86 10-6590-8515 Web site: http://www.kyowa.bj.cn Kyowa Hakko Kogyo Co. Ltd. Shanghai Representative Office Room 1712, Rui Jin Bldg. 205 Maoming Nan Lu, Shanghai 200020 China Phone: +86 21-6466-1222 Kyowa Hakko Kogyo Co. Ltd. Guangzhou Representative Office Room 701, Yi An Plaza No.33 Jianshe 6 Ma Lu, Guangzou 510060, China Phone: +86 20-8364-4123 Kyowa Hakko (H.K.) Co., Ltd. Room 2103, Hang Lung Centre, 2-20 Paterson Street,Causeway Bay Hong Kong, China Phone: +852 2895-6795 Kyowa Hakko (HK) Co. Ltd. Guangzhou Representative Office Room 411, China Hotel Office Tower Liu Hua Road, Guangzhou 510015 China Phone: +86 20-8667-5381 Kyowa Pharmaceuticals (HK) Co. Ltd. Room 2103, Hang Lung Centre 2-20 Paterson Street, Causeway Bay, Hong Kong China Phone: 852-2895-6795 Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd. No.115 QingQju Street, Suzhou Industrial Park Jiangsu 215021, China Phone: +86 512-6283-1082 Shanghai Kyowa Amino Acid Co. Ltd. No.158 Xintuan Road Qingpu Industrial Zone, Shanghai, 201700 China Phone: +86 21-5970-1998 Wuxi Kyowa Food Co. Ltd. No.158 Xu Xiang Lane Li Yuan Wuxi 214072, China Phone: +86 510-8512-9781 Yantai Kyowa Foods Co. Ltd. Zhao Wang Zhuang Town, Laiyang City, Shandong 265225 China Phone: +86 535-761-5778




BioWa Inc. anti IL-5 receptor antibody


3/05

BioWa Inc. development and commercialization of Anti-Fibroblast Growth Factor 8 (FGF8) monoclonal antibody worldwide, except Asia


Bunge Australia activated gluten licensing agreement 10/85 Cephalon Inc. Myotrophin (mecasermin

[recombinant DNA origin]) injection


7/93

Cephalon Inc. small neurotrophic molecules for treating head and spinal injuries and other neurodegenerative disorders


COR Therapeutics Inc.

small molecule pharmaceuticals for treating restenosis following angioplasty

three-year development agreement (12/92), extended for an additional two years

12/95

Eli Lilly and Co. combinatorial chemistry research collaboration--Lilly to provide technology transfer and to receive up-front fees, milestone payments and royalties on first two products to reach market

3/97

Ethical Holdings plc

morphine product distribution agreement for Singapore and Malaysia

10/95

European Organization of Research and Treatment for Cancer (EORTC)

EO9 anticancer agent R&D agreement

Genomatica Inc. Ganomatica's modeling and simulation platform


Geron Corp. Geron's assay for detection of telomerase activity in tumors


Geron Corp. small molecule drugs R&D agreement 5/95 Government of Hungary

genetically engineered lysine

joint venture called Agroferm Hungarian-Japanese Fermentation Industry Ltd., Kyowa is supplying the bacterial host and the manufacturing technology

1991



LeukoSite Inc. CCRI and CXCR3 collaborative R&D and licensing agreement (4/97), expanded to include developing treatments for inflammatory and autoimmune diseases (11/97), extended

4/98

Murex Diagnostics Inc.

MAb-based AIDS diagnostics

development, manufacturing, and marketing agreement through Kyowa Medex Co., Ltd.

6/87

Scotia Pharmaceuticals Ltd.

Scotia's Foscan photosensitizing drug for cancer

licensing agreement--Boehringer Ingelheim gets exclusive rights to develop and market in North and South America and Europe, Kyowa Hakko gets exclusive rights in Japan, Scotia retains rights in other territories--Scotia gets $54M in up-front and milestone payments and will manufacture product for both partners

9/97

RESEARCH & DEVELOPMENT: Therapeutics (modified G-CSF), Mab-based cancer diagnostics and

fermentation strain improvement (enzymes, amino acids, and nucleic acids) Cell fusion technology Plant cell culture Aquaculture rDNA salmon growth hormone Industrial-scale process for cell cultivation, immobilized enzymes Diagnostics to detect HTLV-I

PRODUCTS ON MARKET: PHARMACEUTICALS: Coniel®, Allelock®, Celtect®, Itrizole®, Durotep Patch®, Depakene®, Neu-up®, Inovan®, Mitomycin, 5-FU, Leunase®, diagnostic reagents BIO-CHEMICALS: amino acids, nucleic acids, malic acid, enzymes, citicoline, minocycline, ubidecarenone (CoQ10), agrochemicals, animal health products, feeds, feeds additives, health foods, raw material alcohol CHEMICALS: solvents, plasticizers and their raw materials, organic acids, diols FOOD: seasonings, bakery products and ingredients, freeze-dried foods



Laboratoires Eurobio

7 avenue de Scandinavie Les Ulis 91953, France Phone: +33 (0) 1 69-07-94-77; Fax: +33 (0) 1 69-07-95-34 Web: www.eurobio.fr E-mail: [email protected]

KEY PERSONNEL: Stephane Reveilleau; President



FACILITIES: 2,000 sq. m. of state-of-the-art clean rooms and GMP biological production capacity

STOCK-FINANCIAL HISTORY: Privately held--Wholly-owned by the Reveilleau family

SUBSIDIARIES/DIVISIONS: Human Diagnosis division: Immuno-hematology and viral and bacterial diagnosis Life Science division: molecular biology and cellular culture

BUSINESS STRATEGY: Develop, produce and market reagents intended for research and the biomedical diagnosis

AGREEMENTS: Name Products Content of Agreement Date Hemagen MRL diagnostic kits distribution

agreement 1987

Institut Merieux (now Sanofi Pasteur)

HLA typing antisera exclusive worldwide distribution agreement

2/88

MRL distribution agreement

1990

Roche PCR license 1996

PRODUCTS ON MARKET: Bovine serum Horse serum Other sera Cell culture media Insect cell culture media Powdered and liquid salt solutions Separation media Antibiotics Cell culture buffers Cytogenetics and dissociating reagents Dyes RNA extraction kits RNA/DNA purification Other reagents for nucleic isolation Enzymes for reverse transcription Enzymes for in vitro amplification dNTP's Oligonucleotides Agaroses Acrylamide Electrophoresis buffers/dyes Biochemical products



Lake States

515 West Davenport Street Rhinelander WI 54501, US Phone: (715) 369-4397; Fax: (715) 369-4034 Web: www.wplakestates.com E-mail: [email protected]

KEY PERSONNEL: Linda Fox; Manager Linda Gary; Marketing




STOCK-FINANCIAL HISTORY: Privately owned by parent

SUBSIDIARY OF: Wausau Paper Corp.

BUSINESS STRATEGY: Develop value-added yeast products for the food, biotech, health food, HBA, feed, and pet food markets

RESEARCH & DEVELOPMENT: Yeast related research

PRODUCTS ON MARKET: Inactive torula yeast Autolyzed yeasts Smoked yeasts Yeast extracts

LANXESS AG

Building K 10 Leverkusen 51369, Germany Phone: +49 (0)214 / 30-33333 Web: www.lanxess.com E-mail: [email protected]

KEY PERSONNEL: Dr. Axel Claus Heitmann; Chairman Matthias Zachert; CFO Dr. Martin Wienkenhover; Director, Industrial Relations


HISTORY: Byer Ag founded in 1863 Bayer's chemical activities and one-third of polymer activities combined to form LANXESS Deutschland GmbH (2004) Divested fine chemicals business, which now operates as Saltigo (4/06)

FACILITIES: 50 locations in 18 countries

STOCK-FINANCIAL HISTORY: Listed on the Frankfurt Stock Exchange Sales EUR7.150b (YE 05) compared to EUR6.773b (YE 04) Net loss <EUR63M> (YE 05) compared to <EUR12M> (YE 04) Loss per share <EUR0.75/share> (YE 05) compared to <EUR0.16/share> (YE 04) Total assets EUR4.341b (YE 05) compared to EUR4.577b (YE 04)

SUBSIDIARIES/DIVISIONS: Business units: Performance Rubber: Butyl Rubber, Polybutadiene Rubber, Technical Rubber Parts



Engineering Plastics: Styrenic Resins, Semi-Crystalline Products Chemical Intermediates: Basic Chemicals, Inorganic Pigments Performance Chemicals: Material Production Products, Functional Chemicals, Leather, Textile Processing Chemicals, Paper, Rubber Chemicals, Ion Exhcnage Resins LANXESS Deutschland GmbH--Germany LANXESS Corp.--Pittsburgh, Pa. LANXESS Elastomeres SAS--France LANXESS Inc.--Sarnia, Ontario LANXESS International SA--Switzerland LANXESS NV--Belgium LANXESS Rubber NV--Belgium RheinChemie--Germany

BUSINESS STRATEGY: Develop, produce and market high-quality chemicals, rubber and plastics

Lavipharm SA

Agias Marinas Str. Peania NJ 190 02, Greece Phone: +30 210 6691 000; Fax: +30 210 6645 386 Web: www.lavipharm.gr E-mail: [email protected]

KEY PERSONNEL: Dr. Athanase Lavidas; Chairman and CEO Tania Vranopoulos; COO Spyridon Fotinos; Exec. VP, Corporate Research and Innovation


HISTORY: Founded in 1911 Established Laboratoires Lavipharm (1989) Started Synthelabo-Lavipharm, a joint venture with Synthelabo-France (1992) Started Lavicosmetica, a joint venture with L’Oreal CosmetiqueActive (1992) Lavipharm S.A. listed on the Athens Stock Exchange (1995) Acquired Separex (2000) Acquired Phasex (2000)

FACILITIES: 109,000 sq. m. total area (4,600 sq. m. of facilities) in Princeton, N.J.

STOCK-FINANCIAL HISTORY: Athens Stock Exchange--LAVI Revenue EUR233.189M (YE 05) compared to EUR237.751M (YE 04) Operating profit EUR14.642 (YE 05) compared to EUR18.537M (YE 04) Earnings per share EUR0.08/share (YE 05) compared to EUR0.06/share (YE 04) Total assets EUR194.701M (YE 05) compared to EUR217.571M (YE 04)

SUBSIDIARIES/DIVISIONS: Lavipharm Hellas SA--Rx and OTC Castalia Laboratoires Dermatologiques SA--Dermocosmetics LAS SA--Pharmaceutical wholesaler Pharma Logistics SA--Logistics service provider Pharma Plus SA--Integrated services to pharmacies Lavipharm Pharmaceutical Services Ltd.--joint venture with businessman Efthyvoulos Paraskevaides Lavipharm Distribution Ltd.--Subsidiary of Lavipharm Pharmaceutical Services Ltd. Lavipharm Cyprus Ltd.--Subsidiary of Lavipharm Pharmaceutical Services Ltd. Lavipharm Corp.--Affiliated holding company in the pharmaceutical technology sector Lavipharm Laboratories Inc.--R&D center in the U.S. Phasex SA--Affiliated company specializing in supercritical fluids (SCF) technology



Separex SA--Affiliated French pharmaceutical company pioneering SCF technology Hitex SA--Affiliated company that has SCF extraction and contract manufacturing departments Laboratoires Lavipharm SA--Affiliated company responsible for international promotion of dermocosmetic products

BUSINESS STRATEGY: Develop, manufacture, market and distribute pharmaceutical, cosmetic and consumer health products in Greece and internationally

AGREEMENTS: Name Products Content of Agreement Date GlaxoSmithKline plc

Lavipharm's SCF technology

three-year research collaboration and licenaing agreement

4/03

Intervet Pharma R&D SA (through Lavipharm Corp.)

Intervet compound for veterinary pharmaceutical products


5/02

Senetek PLC Lavipharm to launch line of Kinetin-based skin care products under its Castalia brand


RESEARCH & DEVELOPMENT: Focus is on pioneer technologies of particle design, drug delivery systems, cosmetic delivery systems, and the development of natural products Development of pharmaceutical products containing new drugs that might otherwise have been abandoned because of solubility or other drug delivery problems Modification of existing drugs in order to improve their pharmacokinetic-pharmacodynamic profiles, extend their patent coverage duration and increase their competitive position, thus extending the drug's life cycle

PRODUCTS ON MARKET: Lavipharm Hellas: Algon (pain reliever), Addditiva (vitamins), Ivaliten (anti-lice), Laxemel (laxative), Prot Algon-Antipyretic 'enfants,' Breath Right, RFSU, Lactal Otccastalia Laboratoires Dermatologiques: Laviderm

Lawrence Berkeley National Laboratory

1 Cyclotron Road Berkeley CA 94720, US Phone: (510) 486-6467; Fax: (510) 486-6457 Web: www.lbl.gov; E-mail: [email protected]

KEY PERSONNEL: Steven Chu; Laboratory Director Jeff Fernandez; CFO

EMPLOYEES: 4,000 employees, 1,200 Ph.D.s



SUBSIDIARIES/DIVISIONS: Includes 15 divisions organized within the areas of Computing Sciences, Energy Sciences, Biosciences, General Sciences, and Resources and Operations

BUSINESS STRATEGY: Berkeley Lab conducts unclassified research across a wide range of scientific disciplines with key efforts in fundamental studies of the universe; quantitative biology; nanoscience; new energy systems and environmental solutions; and the use of integrated computing as a tool for discovery. It is organized into 17 scientific divisions and hosts four DOE national user facilities.



AGREEMENTS: Name Products Content of Agreement Date undisclosed

RESEARCH & DEVELOPMENT: Materials Energy efficiency Energy and environment Earth science High energy physics Accelerator and fusion Life science Nanoscience Physical bioscience Genomics Computing science

LG Chem Ltd.

LG Twin Towers, 20, Yeouido-doing, Yeongdeungpo-gu Seoul 150-721, Korea Phone: +82 2-3773-0617, 0618; Fax: +82 2-785-0324 Web: www.lgchem.com E-mail: [email protected]

KEY PERSONNEL: Bahn-Suk Kim; President and CEO Yu-Sig Kang; CEO and Vice Chairman Suk-Jeh Cho; Exec. VP and CFO Kyusok Park; Exec. VP, Industrial Materials Sangjin Hong; VP, LG Chem, China Jin-Nyoung; Exec. VP, LG Chem Research Park


HISTORY: Founded in 1947 Established its central research institute in 1979 Started R&D in genetic engineering field in 1981 Acquired Anjin Pharma Corp., Pharmaceutical Division (1989) Name changed from Lucky Ltd. (1995) Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and LG Household & Healthcare (4/01)

STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange Sales W71.274b (YE 04) compared to W56.725b (YE 03) Net income W5.364b (YE 04) compared to W3.621b (YE 03)

SUBSIDIARIES/DIVISIONS: Three main businesses: Chemicals and polymers, industrial materials, and information and electronic materials Subsidiaries: LG Petrochemical Ltd. LG Dow Polycarbonate Ltd. Tianjin LG Dagu Chemical Co. Ltd. Ningbo LG Yongxing Chemical Co. Ltd. Tianjin LG New Building Materials Co. Ltd. Tianjin LG Window & Doors Co. Ltd. LG Chemical (Guangzhou) Engineering Plastics Co. Ltd. LG Chem (Nanjing) Information & Electronica Materials LG Chemical India Private Ltd. LG Chemical America Inc. LG Chemical Hong Kong Ltd. Compact Power Inc. LG Chem Industrial Materials LG VINA Chemcial LG Chem (China) Investment Co. Ltd. LG Chem (Tianjin) Engineering Plastics Co. Ltd.



Tianjin LG Bohai Chemical Co. Ltd. LG Chem Poland Sp. zoo LG Chem Brasil Ltd. LG Chem Europe GmbH

BUSINESS STRATEGY: Petrochemical and industrial materials business: Consolidate its foothold and position itself as a major player in main growing markets such as China and the U.S. by raising its product quality and cost competitiveness through enhanced R&D and marketing abilities. Information and electronic materials business: Focus on rapid developments of new high-tech products and increasing capacities for its main products such as rechargeable batteries and display materials.

PRODUCTS ON MARKET: Industrial materials: housing and space materials, living materials,

automobile components, interior decoration materials Chemicals and polymers: PVC and plasticizers, acrylates and e-chemicals, polyolefin, AVS/PS, engineering plastics, specialty polymers

LG Life Sciences Ltd.

LG Twin Tower, East Tower, 20, Yoido-dong, Youngdungpo-gu Seoul, Korea Phone: +82 2-3773-1114; Fax: +82 2-3773-7012 Web: www.lgls.co.kr; E-mail: [email protected]

KEY PERSONNEL: Heung-Joon Yang; CEO and Chairman Han-Yong Yang; VP and CFO


HISTORY: Founded in 1947 Established its central research institute in 1979 Started R&D in genetic engineering field in 1981 Acquired Anjin Pharma Corp., Pharmaceutical Division (1989) Name changed from Lucky, Ltd. (1995) Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and LG Household & Healthcare (2001) Spun off from LGCI and name changed to LG Life Sciences (2002) Factive quinolone antibiotics approved by US FDA (2003)

FACILITIES: Two manufacturing facilities and R&D Park located in South Korea Pharmaceutical division has two GMP main factories in Iksan and in Daejeon

STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange Sales W213,636 (YE 04) compared to W179,037M (YE 03) Net income W10,073 (YE 04) compared to W3,225M (YE 03)

SUBSIDIARIES/DIVISIONS: Pharmaceutical Division Agricultural Division LG Life Sciences India Pvt. Ltd. LG Life Sciences Poland Sp. Z.o.o LG Life Sciences Ltd. Beijing representative office

INVESTMENTS: Elitra Pharmaceuticals

BUSINESS STRATEGY: Enhancement of Efficiency in R&D: -Focus all-out efforts on candidate materials for developments that have passed pre-clinical trials -More systematic promotion of R&D projects -Solidify alliances with world-class business enterprises



Advance into Markets for Generic Bio Drugs in Industrialized Countries -Advance into markets in industrialized countries through marketing alliances -Establish local corporations in strategically important areas Firm Up our Position as a Market Leader in the Domestic Market -Continue development of advanced marketing techniques -Focus on the development of products meeting our customers’ specific needs -Strengthen our licensing activities

AGREEMENTS: Name Products Content of Agreement Date Aeterna anti-cancer drug in-licensing

agreement 2003

Anadys Pharmaceuticals Inc.

hepatitis B treatment out-licensing and joint development agreement

2004

Biogen Idec Inc. psoriasis treatment in-licensing agreement

2004

BioPartners sustained-release human growth hormone

out-licensing and joint development agreement

2001

BioPartners genetically-engineered products

joint development and marketing agreement

1997

DepoMed diabetes treatment in-licensing agreement

2004

Eximias liver cancer treatment in-licensing agreement

2002

GlaxoSmithKline plc

new quinolone antibiotic licensing agreement 1997

KYORIN Pharmaceutical Co. Ltd.

development, manufacturing and sales of KRP-197 in Korea

licensing agreement 2005

Oscient Pharmaceuticals

quinolone antibiotics out-licensing agreement

2002

Sinovac Biotech Ltd.

hepatitis B vaccine in China


3/06

Sinovac Biotech Ltd.

hepatitis A vaccine, hepatitis B vaccine, combined hep A and hep B vaccine, avian flu vaccine

letter of intent 5/05

Yamanouchi (now Astellas Pharma Inc.)

treatments for obesity, hyperlipidaemia

R&D collaboration 2001

RESEARCH & DEVELOPMENT: Anti-cancers Anti-infectives QOL (Quality of Life)

PRODUCTS ON MARKET: Factive (Quinolone antibiotics) Intermax gamma (Gamma-IFN) Intermax alpha (Alpha-IFN) LG HCD (hepatitis C diagnostic) LG HBs Ag Elisa (hepatitis B diagnostic) LG Anti-HBs Elisa (hepatitis B diagnostic) LG HCD confirm (hepatitis C diagnostic) Euvax B (hepatitis B vaccine) Eutropin (hGH) Leucogen (GM-CSF) IFN-a Hyruan (Hyaluronic acid) HCD



HBD EPO BGH Ivermectin Ceftiofur

PRODUCTS IN DEVELOPMENT: Name Status NEW CHEMICAL ENTITIES: LB 80380 for hepatitis B in Phase II clinicals LB 84451 for HCV, NASH in Phase I clinicals LB 53280 for obesity in preclinicals LC15-0133 for Type II diabetes in preclinicals Thrombin Inh - DVT, AF in preclinicals HCV inhibitor for hepatitis C completed discovery

LGC (Laboratory of the Government Chemist)

Queens Road Teddington TW11 0LY, UK Phone: +44 (0) 20 8943 7000; Fax: +44 (0)20 8943 2767 Web: www.lgc.co.uk E-mail: [email protected]

KEY PERSONNEL: Ian Kent; Chairman Dr. Nigel Law; CEO Dr. Paul Debenham; Director, Life Sciences Dr. Angela Gallop; Director, LGC Forensics


HISTORY: Founded in 1843 LGC (Holdings) Ltd. is formed (2/93) LGC (Holdings) Ltd. acquired Laboratory of the Government Chemist (4/96) Acquired Pipeline Developments Ltd. (1997) Acquired University Diagnostics Ltd. (1997) Acquired ICI's Runcorn analytical unit (1998) Formed GeneSolve, a joint venture with Dundee University (1999) Acquired the Promochem Group of Companies (2001) Sold Pipeline Developments Ltd. (2002) Acquired Forensic Alliance Ltd. (9/05) Acquired Agowa (1/06)

FACILITIES: Locations in France, Germany, Spain, Sweden, the U.K., Italy and Poland Distribution office in India


BUSINESS STRATEGY: Vision: Be an international business, recognised for setting standards in analytical science and providing best value products, services and solutions To meet its vision, the company will: increase turnover by 15 percent year on year with profit at or above 10 percent of sales, and achieve 25% of its turnover from outside the U.K.


King’s College London

pharmacogenetic screening service that will predict if a patient with schizophrenia will respond positively to clozapine


11/05



Gentris Corp. Gentris can create, use

and sale of diagnostic products and services which include testing for the CYP2D6*4 polymorphism in the U.S.


6/06

RESEARCH & DEVELOPMENT: Bioanalytical and genetic diagnostics and detection methodologies DNA analytical technologies Reference standards

PRODUCTS ON MARKET: Analytical services/consultancy Paternity testing Forensics Livestock genotyping GMOs DNA databasing/analysis BSE testing Reference standards

LifeCell Corp.

One Millennium Way Branchburg NJ 08876-3876, US Phone: (908) 947-1100; Fax: (908) 947-1089 Toll-free phone: (800) 367-5737 Web: www.lifecell.com E-mail: [email protected]

KEY PERSONNEL: Paul G. Thomas; Chairman, President and CEO Steven T. Sobieski; VP, Finance and Administration and CFO Lisa N. Colleran; Sr. VP, Commercial Operations Dr. Bruce Lamb; Sr. VP, Development, Regulatory Affairs and Quality Young C. McGuinn; VP, Manufacturing Operations


HISTORY: Formed in 1986 by a technology transfer from the University of Texas Health Science Center in Houston to commercialize patented biopreservation technology Member--Biotechnology Industry Organization

FACILITIES: 90,000 sq. ft. of leased office, laboratory, production and warehouse space

STOCK-FINANCIAL HISTORY: NASDAQ--LIFC IPO--800K units, each unit consisting of one share of common stock and one warrant to purchase 1/2 share of common stock, at $7.75/unit (2/92) Public offering--4M shares at $4.50/share, $18M (11/97) Revenue $94.398M (YE 05) compared to $61.127M (YE 04) Net income $12.044M (YE 05) compared to $7.184M (YE 04) Earnings per share $0.39/share (YE 05) compared to $0.26/share (YE 04) Average shares outstanding 30.877M (YE 05) compared to 27.553M (YE 04) Total assets $106.998M (YE 05) compared to $72.093M (YE 04)

PRIVATE PLACEMENTS: $5.3M in an offering of 265K units at $20/unit (11/94) Raised $12.4M in private placement (11/96) Raised $15.7M in private placement of 3.7M shares of common stock at $4.25/share (2003)



PRINCIPAL INVESTORS: Medtronic Inc. Essex Woodlands Vector Later-Stage Equity Fund CIBC Wood Gundy

BUSINESS STRATEGY: Develop technology for processing other universally transplantable tissue grafts and extended preservation of transfusable blood products

AGREEMENTS: Name Products Content of Agreement Date LifeCore Biomedical Inc.

AlloDerm for periodontal procedures

exclusive distribution agreement for the U.S.

6/97

Medtronic Inc. porcine-tissue heart valves


US Army Institute of Surgical Research

AlloDerm grafts for use in neurological, dermatological and cardiovascular surgery

development agreement--LifeCell to receive $1.07M over two years in product development funding and will use tissue preservation technology to develop vascular grafts for bypass surgery

1/97

US Navy ThromboSol platelet storage solution

$600K development funding

8/98

RESEARCH & DEVELOPMENT: Universal Tissue Grafts, including skin, vascular conduits and heart valves Products for extending the shelf life of transfusable blood cells including red blood cells and platelets

PRODUCTS ON MARKET: AlloDerm® - processed tissue products for grafting of third degree burns, grafting and guided tissue regeneration in periodontal surgery and tissue repair in plastic reconstructive surgery Cymetra® - version of AlloDerm in particulate form for the correction of soft tissue defects Repliform® - acellular tissue matrix for urologic and gynecologic procedures Graft Jacket® - accelular tissue matrix for orthopedic applications AlloCraft™DBM - for bone grafting procedures

LifeSensors Inc.

271 Great Valley Parkway, Suite 100 Malvern PA 19355, US Phone: (610) 644-8845; Fax: (610) 644-8616 Web: www.lifesensors.com E-mail: [email protected]

KEY PERSONNEL: Tauseef R. Butt, Ph.D.; President and CEO Michael R. Mattern, Ph.D.; VP, Research John Hall; VP, Business Development Bob Griess; Director, Finance


HISTORY: Founded in July 1996 Began biotech R&D December 1996



SUBSIDIARY OF: Gene Transcription Technology



PRINCIPAL INVESTORS: Ben Franklin Technology Partners

BUSINESS STRATEGY: Discover, develops, manufacture and market important protein expression technologies based on advances in cellular and molecular biology Market to academic and government research institutions, and pharmaceutical and biotechnology companies worldwide in efforts to improve the quality of human life

AGREEMENTS: Name Products Content of Agreement Date Embrex Inc. development of a

sensor for the poultry gender sorting market

three-year agreement

1/00

Rohm & Haas Co. development of insect receptor based screening technology

research collabration

12/96

RESEARCH & DEVELOPMENT: Protein expression and biosensors utilizing the benefits of SUMO

PRODUCTS ON MARKET: SUMOpro™ Expression System Split SUMOpro™ Expression System Fusion controls Proteases Expression vectors Prokaryotic, yeast and insect expression kits

PRODUCTS IN DEVELOPMENT: Name Status Estrogen detection biosensor development stage 2nd Generation SUMO Expression Systems

development stage

Link Technologies Ltd.

3 Mallard Way, Strathclyde Business Park Bellshill ML4 3BF, UK Phone: +44 (0) 1698-849911; Fax: +44 (0) 1698-849922 Web: www.linktech.co.uk E-mail: [email protected]

KEY PERSONNEL: Jim Fisher; Chairman Dr. Michael Gray; Managing Director Dr. Douglas Picken; Director, R&D Dr. John Bremner; Director, Business Development


HISTORY: Founded in January 1987 Began biotech R&D in May 1989

FACILITIES: 7,000 sq. ft. laboratory, office and warehouse facility


RESEARCH & DEVELOPMENT: Nonradioactive labeling of oligonucleotides

Antisense DNA reagents Base-modified nucleotides Biomolecule conjugation

PRODUCTS ON MARKET: Range of reagents for DNA synthesis Supported reagents for large-scale synthesis



Lonza Group Ltd.

Muenchensteinerstrasse 38 Basel CH-4002, Switzerland Phone: +41 61-316-8111; Fax: +41 61-316-9111 Web: www.lonza.com E-mail: [email protected]

KEY PERSONNEL: Rolf Soiron, Ph.D.; Chairman Stefan Borgas; CEO Toralf Haag, Ph.D.; CFO Lukas Utiger, Ph.D.; Head, Organic Fine & Performance Chemicals Stephan Kutzer, Ph.D.; Head, Biopharmaceuticals Rosario Valido; Head, Polymer Intermediates


HISTORY: Founded in 1897 Acquired biologics contract manufacturing business of UCB (1/06) Member--Biotechnology Industry Organization

FACILITIES: Headquarters in Basel, Switzerland R&D facilities in Visp, Switzerland; Slough, U.K.; Portsmouth, N.H.; and Guangzhou, China Manufacturing facilities in Visp, Switzerland; Kourim, Czech Republic; Slough, U.K.; Portsmouth, N.H.; and Conshohocken, Pa.

STOCK-FINANCIAL HISTORY: Financial data for the Lonza Group: Sales CHF2.521b (YE 05) compared to CHF2.182b (YE 04) Net income CHF188M (YE 05) compared to CHF138M (YE 04) Earnings per share CHF3.97/share (YE 05) compared to CHF2.91/share (YE 04) Total assets CHF4.331b (YE 05) compared to CHF3.341b (YE 04)

SUBSIDIARIES/DIVISIONS: Exclusive Synthesis & Biopharmaceuticals Organic Fine & Performance Chemicals Polymer Intermediates

BUSINESS STRATEGY: Lonza develops products and processes for fine chemicals and active pharmaceutical ingredients in R&D centres and manufacturing plants in the U.S., Europe and Asia Lonza offers custom manufacturing services in the fields of monoclonal antibodies, therapeutic proteins, biotransformations and fermentation

RESEARCH & DEVELOPMENT: Organic intermediates and APIs

Biotransformation projects Fermentation processes (microbial and mammalian technologies)

PRODUCTS ON MARKET: Lonza offers a wide range of organic intermediates and active substances

Maine Biotechnology Services Inc.

1037R Forest Avenue Portland ME 04103, US Phone: (207) 797-5454; Fax: (207) 797-5595 Toll-free phone: (800) 925-9476 Web: www.mainebiotechnology.com E-mail: [email protected]

KEY PERSONNEL: Joseph P. Chandler, Ph.D.; President Carrie Cloutier; Sales Director, Custom Services Michael Sullivans; Production Manager





FACILITIES: 9,000 sq. ft. headquarters 4,200 sq. ft. R&D and manufacturing facilities


BUSINESS STRATEGY: Provide MAb development and production services and immunodiagnostic reagents to commercial and academic laboratories

Mallinckrodt Inc.

675 McDonnell Boulevard Hazelwood MO 63042, US Phone: (314) 654-2000 Web: www.mallinckrodt.com E-mail: [email protected]

KEY PERSONNEL: Richard J. Meelia; CEO, Tyco Healthcare Michael J. Collins; President, Pharmaceuticals Division Douglas A. McKinney; VP, Finance and CFO Steven Hanley; President, Imaging Division Scott Drake; President, Respiratory Lisa Britt; VP, Human Resources


HISTORY: Divested fertilizer business (now IMC Global Inc.) Bought Mallinckrodt, Inc. from Avon Bought Coopers Animal Health from ICI/Wellcome Changed name from IMCERA Group Inc. (3/94) Name changed from Mallinckrodt Group Inc. (10/96) Acquired Nellcor Puritan Bennett Inc. for $1.9b (7/97) Veterinary Division: Acquired by International Minerals & Chemical Corp. from Johnson & Johnson (3/87) Business is a combination of International Minerals & Chemical Corp.'s feed ingredient division, veterinary products division, Sterwin Poultry Health Division, Coopers Animal Health and Glaxo AH Formerly named Pitman-Moore, Inc., changed name (3/94) Acquired Syntro Corp. (11/95) Acquired poultry and companion animal business from CBM Laboratories, Campinas, Sao Paulo, Brazil, (11/95) Sold animal feeds ingredients business to IMC-Agrico (11/95) Sold sensor systems business (9/96) Divested interest in Tastemaker flavors business (1/97) Agreement reached to sell Mallinckrodt Veterinary to Schering-Plough Acquired by Tyco International Ltd. (10/00)


SUBSIDIARIES/DIVISIONS: Pharmaceuticals, Respiratory and Imaging

SUBSIDIARY OF: Mallinckrodt is a business unit of Tyco Healthcare

BUSINESS STRATEGY: Create value for shareholders through growth in sales and profitability driven by innovation and productivity in human healthcare and specialty chemical businesses


Advanced Magnetics Inc.

MRI contrast agent manufacturing and distribution agreement in the U.S. and Canada

1990



Advanced Warming Systems Inc.

WarmTouch worldwide manufacturing and distribution agreement

1992

Centocor Inc. Myoscint exclusive marketing agreement for Europe, the Middle East, and Africa

9/93

Iradimed Corp. Mridium MRI IV pump in the U.S., Canada and Mexico

sales agreement 5/06

Medi-Physics radiopharmaceuticals rights for Medi-Physics proprietary product line to be distributed through Mallinckrodt's 35 radiopharmacies

1995

Metasyn Inc. MS-325 and other MRI vascular agents

worldwide development and marketing agreement (except Japan)

10/96

Molecular Biosystems Inc.

MBI's Albunex second generation product, FS069 ultrasound imaging agents


4/96

Netherlands Energy Research Foundation

Molybdenum-99 construction of Moly-99 plant

1992

OPTIMEDx optical imaging agents exclusive worldwide

licensing rights to develop optical imaging agents for mammography and nonexclusive license to develop agents for use in other types of cancer

1994

Palatin Technologies Inc.

Palatin's NeutroSpec marketing agreement, extended 6/05

Schering AG (Germany)

MRI contrast agent enables both parties to sell select MRI products under each others' patents

1993

University Hospital Dijkzigt and Sandoz Pharma Ltd.

radiopharmaceuticals for cancer imaging

development, production, and marketing agreement

1991

PRODUCTS ON MARKET: Contrast media and delivery systems Radiopharmaceuticals Urology imaging systems Active pharmaceutical ingredients Addiction treatment products Restoril®7.5mg and 22.5mg (temazepam capsules USP) Tofranil®-PM (imipramine pamoate capsules) Generic pharmaceuticals



Marcor Development Corp.

341 Michele Place Carlstadt NJ 07072-2304, US Phone: (201) 935-2111; Fax: (201) 935-5223 Web: www.marcordev.com E-mail: [email protected]

KEY PERSONNEL: Charles J. Garbarini; President Sar Dorman; Sales Specialist, Biologicals Michael J. Malavasic, Ph.D.; Eastern Sales Manager, Biologicals Patty Powers-Feigel; International Manager




RESEARCH & DEVELOPMENT: Reagents, enzymes

PRODUCTS ON MARKET: Research reagents, enzymes, fermentation nutrients, peptones, yeast extracts

Maruzen Pharmaceuticals Co. Ltd.

14703-10 Mukaihigashi, Onomichi Hiroshima 722-0062, Japan Phone: +81 848-44-2217; Fax: +81 848-44-6851 Web: www.maruzenpcy.co.jp

KEY PERSONNEL: Heishiro Higurashi; Chairman Akifumi Higurashi; President Takao Ikeda; Managing Director




SUBSIDIARIES/DIVISIONS: Longev Co. Ltd. Rooprun Pty. Ltd.

BUSINESS STRATEGY: Manufacture and distribute pharmaceuticals, quasi-drugs, cosmetics, agricultural industrial products, health food, and food. Manufacture and distribute veterinary pharmaceuticals, livestock feed and fertilizers for crops.

RESEARCH & DEVELOPMENT: Antityrosinase agents and radical scavengers for cosmetics

Anti-inflammatory agents for cosmetics Health foods, designer foods Seasonings, low-calorie sweetener

PRODUCTS ON MARKET: Licorice products for foods: Glycymin®, Glycymin® Cool Stevia products for foods: Marumilon Pure, alpha-G Sweet H, alpha-G Sweet PX, MARUMILON RICH A Licorice products for cosmetics: Dipotassium Glycyrrhizinate, Stearyl Glycyrrhetinate, Polyol Soluble Licorice Extract P-T (40) Quillaja saponin preparation Various plant extracts for cosmetics and toiletries Health food ingredients



Mascoma Corp.

161 First Street, Second Floor East Cambridge MA 02142, US Phone: (617) 234-0099; Fax: (617) 868-0408 Web: www.mascoma.com E-mail: [email protected]

KEY PERSONNEL: Vinod Khosla; Chairman Colin South, Ph.D.; President Lee R. Lynd, Ph.D.; CSO Dr. Andrew Richard; CTO Dr. David Hogsett; VP, R&D Herve I. Garant, Ph.D.; Director, Bioprocess Engineering/Operations Siva Subramanian, Ph.D.; Director, Bioprocess Engineering/Design




PRIVATE PLACEMENTS: Secured $4M in Series A financing (7/06)

PRINCIPAL INVESTORS: Khosla Ventures Flagship Ventures

BUSINESS STRATEGY: Develop unique bio and process technology for cost-effective conversion of

cellulosic biomass (grass, wood, agricultural and forestry wastes) Two-pronged strategy of technology development and deployment, including patenting technologies for cellulosic production and forming partnerships to commercialize new cellulosic ethanol technologies and processes

AGREEMENTS: Name Products Content of Agreement Date Dartmouth College

Mascoma to research and produce ethanol from cellulosic biomass based on several patents from Dartmouth

exclusive worldwide license agreement

8/06

Integrated Genomics Inc.

analysis of the genome of a microbe important to breaking down cellulosic biomass for conversion into ethanol

contract 8/06

RESEARCH & DEVELOPMENT: Cellulosic biomass-to-ethanol development and production, based on work developed in Prof. Lee R. Lynd’s labs at Dartmouth College

Matreya LLC

168 Tressler Street Pleasant Gap PA 16823, US Phone: (814) 359-5060; Fax: (814) 359-5062 Toll-free phone: (800) 342-3595 Web: www.matreya.com E-mail: [email protected]

KEY PERSONNEL: Gary C. Walker; VP, Manufacturing Amy Houtz; Office Manager/Purchasing Manager




HISTORY: Founded in 2004 Successor to Matreya Inc., founded in 1988



BUSINESS STRATEGY: Isolate, purify and synthesize bioactive lipids

RESEARCH & DEVELOPMENT: Synthesize sphingolipids

PRODUCTS ON MARKET: 240 lipids and mixtures

Maxxam Analytics Inc.

6740 Campobello Road Mississauga L5N 2L8, Canada Phone: (905) 817-5700; Fax: (905) 890-0370 Toll-free phone: (800) 817-5777 Web: www.maxxam.ca; E-mail: [email protected]

KEY PERSONNEL: John Martin; Chairman Patricia Nielsen; CEO Pierre Beaumier; President Dean Taylor; CFO Andrew Masters; VP, Eastern Operations Bernie Brassard; VP, Western Operations


HISTORY: Founded in 1972 Name changed from Mann Testing Laboratories Ltd. (1994) Merged with Chemex Labs Alberta (1996) Name changed from NOVAMANN (Ontario) Inc. (1997) Merged with PSC Analytical Services (PSC) (10/04)

FACILITIES: 150,000 sq. ft. laboratory facility


SUBSIDIARY OF: Maxxam Analytics International Corp.

BUSINESS STRATEGY: Mission: Provide scientific solutions through innovation and expertise

RESEARCH & DEVELOPMENT: Application of PCR and DNA testing to animal genetics, parentage testing

and microbial testing Agricultural consulting/testing services, residue registration studies Equine drug testing services and research

PRODUCTS ON MARKET: Services include: drug detection, water quality testing, soil and water analysis, toxicity evaluation, air monitoring and analysis, ultra trace contaminant analysis by High Resolution Mass Spectrometry (HRMS), petroleum testing services, field sampling services, laboratory design and set-up, food chemistry and nutrition labeling, paternity tests and animal, plant and food genetics



MBI International

3900 Collins Road Lansing MI 48910, US Phone: (517) 337-3181; Fax: (517) 337-2122 Web: www.mbi.org E-mail: [email protected]

KEY PERSONNEL: Dr. Mark Stowers; President and CEO Kellena D. Daigle; VP and CFO Robert A. DeVries, Ph.D.; Sr. Scientist


HISTORY: Founded in 1981 Began biotech R&D in 1984 Acquired CPC, International Corn Products Co. Technology Portfolio Package--in-licensing of technologies from several major universities and corporations Changed name from Michigan Biotechnology Institute (1995)


SUBSIDIARIES/DIVISIONS: Bio-Business Incubator of Michigan (BBIM)--non-profit subsidiary

AGREEMENTS: Name Products Content of Agreement Date Auxein Corp. plant growth technology

products new company formation to commercialize products

1994

BioPlastics Inc. biocompostable plastic resins

new company formation

1995

EFX Systems Inc. fluid-bed reactor for environmental cleanup applications


1995

Enzyme Design Inc.

enzymes for industrial, consumer and scientific applications


1996

EverCorn Inc. biodegradable plastic resins

joint venture 1993

Lions Adhesives environmentally friendly packaging and wood adhesives


1996

Natura Inc. food ingredients and derivatives


1994

Plexis Biosciences Inc.

expression systems new company formation

1997

Synthon Corp. chiral intermediates new company formation

1993

RESEARCH & DEVELOPMENT: Biomass processing: MBI has licensed the ammonia fiber explosion (AFEX)

process, a leading technology to pretreat biomass; Researching the use of the AFEX process in ethanol plants to recover sugars from corn fiber waste, to produce specialty chemicals in addition to ethanol via fermentation, to produce valued compounds from hemicellulose, in the development of high protein animal feeds, to facilitate the recovery of other valuable compounds locked within corn fiber, to expand the use of agricultural biomass as low cost feedstocks for chemical production and in fiber reinforced composites Succinic acid production: Isolation of several succinic acid producing microorganisms and development of a succinic acid producing bacterium, Actinobacillus succinogenes, and hyperproducing mutants Polyamide amine polymers: A new class of polymers



Biorefinery development: Development of various biochemical and thermochemical routes to fuels, chemicals and materials and perfecting the dry mill biorefinery process Cellulose nanofibers: Production of microcrystalline cellulose nanowhiskers through the utilization of the low-cost AFEX process with surface, interfacial and mechanical properties in order to make them suitable as reinforcements and fillers in polymers

PRODUCTS ON MARKET: Contract Services and Pilot-scale Manufacturing: Production of fragrances, high cell density Escherichia coli fermentation for protein reagents and protein biologicals, and the scale up of a specialty chemical produced via fermentation Bio-Business Incubator of Michigan: Offers assistance with the regulatory approval process, interim CEOs, business planning, business plan development, grant writing, finance and accounting, human resources, corporate filings, secretarial support, laboratory and technical support, and access to equipment and offices/laboratory space

MDS Pharma Services

The Triad, 2200 Renaissance Blvd., Suite 400 King of Prussia PA 19406-2755, US Phone: (610) 239-7900; Fax: (610) 239-7111 Web: www.mdsps.com E-mail: [email protected]

KEY PERSONNEL: David Spaight; President and CEO Riaz Bandali; VP and GM, Global Early Clinical Research Robert Beland; VP, Discovery and Preclinical Robert Butz, Ph.D.; Interim VP and GM, Global Clinical Development Scott Neilson; VP and GM, Central Laboratories John Robson; VP and GM, Global Bioanalytical Services Peter Abram; Sr. VP, Finance Cam Hicks; Sr. VP, Human Resources and Organizational Development Jim McClurg, Ph.D.; Sr. VP and CSO Robert Castellucci; VP, Quality


HISTORY: MDS Pharma Services was formed in 1999 from the merging of eight legacy companies: MDS Harris, MDS Panlabs, MDS Glarif, MDS Analytical Solutions, MDS Clinical Trial Laboratires, MDS Neo-Pharm, MDS Tricon and Phoenix International Life Sciences Sold its Fermentation Technologies business to Panlabs Biologics of Taiwan (12/05)

FACILITIES: Locations in Johannesburg, South Africa; Beijing, China; Yokohama, Japan; Malaysia; Singapore; Taipei, Taiwan; Pyrmont, Australia; Mississauga, Blainville and Saint-Laurent, Canada; Mexico; Phoenix, Ariz.; Irvine, Calif.; Lincoln, Neb.; Neptune and North Brunswick, N.J.; King of Prussia, Penn.; Bothell, Wash.; New Orleans, La.; Buenos Aries, Argentina; Santiago, Chile; Lima, Peru; Brussels, Belgium; Czech Republic; France; Germany; Hungary, Italy; Poland; Romania; Madrid, Spain; Lund, Sweden; Switzerland; Kiev, Ukraine; and the U.K.


SUBSIDIARY OF: MDS International Inc. (see separate entry)

BUSINESS STRATEGY: To be the premier provider of innovative drug discovery and development solutions by offering our expertise in the areas of lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa), bioanalysis, global clinical development (phases IIb-IV) and central lab



MedPharm Ltd.

Business Centre, Sheep Street, Oxfordshire Charlbury OX7 3RR, UK Phone: +44 160 881 9267; Fax: +44 160 881 9268 Web: www.medpharm.co.uk E-mail: [email protected]

KEY PERSONNEL: Dr. Geoffrey Vernon; Chairman Dr. Andrew Muddle; CEO Dr. Mark Brown; CSO Dr. Petra Beck; Director, Pharmaceutical Development Carole Delauney; Head, Development Manager

EMPLOYEES: 35 employees, 30 scientists




BUSINESS STRATEGY: MedPharm is a specialist pharmaceutical development company of

international reputation, focusing in particular on topical (skin, nail, lung and other mucous membranes) drug delivery systems. Projects range from simple feasibility tests, dosage design and optimization through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed smooth technology transfer to manufacturing sites. Developments are performed at MedPharm’s GLP accredited laboratories located in London and at the GMP facility based closed to London. MedPharm develops formulations designed to meet the requirements of its clients while maximizing the chance of clinical success. MedPharm relies on its high level of scientific expertise to develop pharmaceuticals with all types of active pharmaceutical ingredients (APIs) including those difficult to formulate such as small organics with extreme physicochemical properties, DNA, proteins, peptides and plant-derived active substances. As of August 2005, MedPharm has been directly involved in the development of four products currently on the market in the EU and/or U.S. With more than 60 customers worldwide, MedPharm is recognized internationally for its unique and highly specialized service in pharmaceutical contract research and development together with expert project management, all at an extremely competitive price. In parallel to its services, MedPharm invests in its own IP in novel drug delivery technologies which can be licensed to clients.

RESEARCH & DEVELOPMENT: Contract pharmaceutical R&D

Dermal and transdermal patents

Megabase Research Products

2726 N. 48th Street Lincoln NE 68504, US Phone: (402) 467-6499; Fax: (402) 467-6495 Web: www.pcrjet.com; E-mail: [email protected]

KEY PERSONNEL: Michael Nelson; President Dr. Nisha Padhye; Sr. Scientist Dr. Osvaldo Lopez; Sr. Scientist Robyn Hassebrook; Scientist





FACILITIES: Microbiology and biochemistry lab


BUSINESS STRATEGY: Seek partners to manufacture and bring patened technologies to market

AGREEMENTS: Name Products Content of Agreement Date Biologix Research Corp.

technology for the detection of Thiopurine Methyl Transferase (TPMT) from blood

licensing agreement

Roche Molecular Diagnostics

development of a fast, experimental PCRJet for evaluation by Roche Molecular Diagnostics

R&D contract

Toyobo Co. Ltd. development of PCRJet R&D contract and contract to enter licensing agreement

University of Nebraska (Dr. Hendrik Viljoen, Department of Chemical Engineering)

advanced engineering of PCRJet Thermocyclers

research collaborations

ongoing

University of Nebraska Medical Center (Dr. Cathy Gebhart, Molecular Diagnostics Laboratory)

rapid diagnostic DNA tests

research collaborations

ongoing

RESEARCH & DEVELOPMENT: PCRJet®--pressurized gas thermocycler for the high-speed amplification of DNA

Meiji Seika Kaisha Ltd.

4-16, Kyobashi 2-chome, Chuo-ku Tokyo 104-8002, Japan Phone: +81 3-3272-6511; Fax: +81 3-3271-3528 Web: www.meiji.co.jp

KEY PERSONNEL: Ichiro Kitasato; Chairman Naotada Sato; President Akio Takahashi; Sr. Exec. VP Akinobu Otsubo; Exec. VP Masaki Nagasaki; Exec. VP Masahiko Matsuo; Sr. VP Harunobo Tsukanishi; Sr. VP Masayuki Matsunaga; Sr. VP Hirobumi Mori; Sr. VP Hiromichi Kitahara; Sr. VP Tadao Shibasaki; Sr. VP Osamu Makabe; Sr. VP Hideki Takahashi; Sr. VP Yoshihiko Mizoguchi; Sr. VP





STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange Net sales ¥364.018b (YE 05) compared to ¥368.865b (YE 04) Net <loss> income <¥8.240b> (YE 05) compared to ¥348M (YE 04) Earnings <loss> per share <¥21.53/share> (YE 05) compared to ¥0.79/share (YE 04) Average shares outstanding 383.2M (YE 05) compared to 384.7M (YE 04) Total assets ¥339.848b (YE 05) compared to ¥330.059b (YE 04)

SUBSIDIARIES/DIVISIONS: Meiji Food Materia Co. Ltd. Donan Shokuhin Co. Ltd. Zao Shokuhin Kaisha Ltd. Ronde Corp. Meiji Sangyo Co. Ltd. Meiji Chewing Gum Co. Ltd. Azteca Co. Ltd. Okayamaken Shokuhin Co. Ltd. Shikoku Meiji Co. Ltd. Taiyo Shokuhin Co. Ltd. Fuji-Amide Chemical Co. Ltd. Kitasato Pharmaceutical Industry Co. Ltd. Meiji Sports Plaza Ltd. Meiji Seika (Singapore) Pte. Ltd. D.F. Stauffer Biscuit Co. Inc.--York, Pa., U.S. Laguna Cookie Co. Inc.--Santa Ana, Calif., U.S. P.T. Meiji Indonesian Pharmaceutical Industries Thai Meiji Pharmaceutical Co. Ltd.--Bangkok Tedec-Meiji Farma SA--Madrid, Spain Mabo Farma SA--Madrid, Spain Meiji Seika Europe BV--The Netherlands Mecor Inc.--Golden, Colo., U.S. Comercio e Industria Uniquimica Ltda.--Sao Paulo, Brazil Beghin Meiji--France P.T. Ceres Meiji Indotama--Indonesia Guangzhou Meiji Confectionery Co. Ltd.--China Shantou Meiji Pharmaceuticals Co. Ltd.--China Meiji Lukang Pharmaceutical Co. Ltd.--China Meiji Seika (Shanghai) Co. Ltd.

PRINCIPAL INVESTORS: Mizuho Bank Ltd. The Master Trust Bank of Japan Ltd. The Dai-ichi Mutual Life Insurance Co. Nippon Life Insurance Co. Japan Trustee Services Bank Ltd. Fukoku Mutual Life Insurance Co. The Bank of Tokyo-Mitsubishi Ltd. The Tokio Marine and Fire Insurance Co. Ltd. Asahi Mutual Life Insurance Co. The Mitsubishi Trust and Banking Corp.

INVESTMENTS: M. D. Research--joint venture with Daicel Chemical and Japan Key Technology Center

AGREEMENTS: Name Products Content of Agreement Date Allergen-Free Technology Laboratories Inc.

allergen-free grains R&D agreement 3/92

Beghin Say SA fructo-oligosaccharide joint venture to develop and market

Daicel Chemical, Japan Key Technology Center

technology for producing active peptides via rDNA and synthetic processes

joint R&D venture called M. D. Research

3/86

MECOR fructo-oligosaccharide with applications in animal feed, ingredients and health food

joint venture to market in the U.S., Canada, and the Caribbean

11/88

NeuroSearch A/S GABA modulators R&D agreement 10/93



Nippon Roche KK, Eisai Co. Ltd., Kissei Pharmaceuticals

cloning of Werner syndrome gene

joint venture called AGENE

3/93

SIBIA Neurosciences Inc.

SIB-1508Y as first-of-type treatment for Parkinson's disease

development and commercialization agreement--SIBIA will receive licensing fee, milestone payments and royalties on future sales, and will supply product to Meiji for clinical use, SIBIA to retain manufacturing rights

3/97

Tokyo University diagnostics of pancreatic diseases

collaborative research agreement

4/90

PRODUCTS ON MARKET: Anti-infectives: Meiact, Fosmicin, Habekacin, Omegacin, Sword, Ciproxan Central nervous system drugs: Meilax, Depromel, Ebastel Agricultural chemicals: Oryzemate, Herbie Veterinary drugs: Meirich, Meipole, Astop Animal feed supplements: Colistin, Cellulaze Healthfood products: Savas, Karadanavi, Lola, Amino Collagen, Prefect Plus, Protein Diet Over-the-counter drugs: Isodine, Bayer Aspirin Food products: Chocolate, chewing gum, snacks, biscuits, candy

Mercian Corp.

1-5-8 Kyobashi Chuo-Ku Tokyo 104-8305, Japan Phone: +81 3 3231 3927; Fax: +81 3 3276 0151 Web: www.mercian.co.jp E-mail: [email protected]

KEY PERSONNEL: Yuji Okabe; President and CEO Yasuteru Sakamoto; Sr. VP and President, Pharmaceuticals and Chemicals Company Yukimichi Tamura; Sr. VP, Finance Masahide Takai; Sr. VP and President, Liquor Company Masaaki Oshitani; Sr. VP and President, Processing Liquors Company Shuji Tsuchimoto; Sr. VP, Sales Dept.


HISTORY: Founded in 1934 as a liquor manufacturer Showa Brewery Co. Ltd. Merged with Nisshin Brewery Co. Ltd. (1961) Merged with Ocean Co. Ltd. and changed name to Sanraku Ocean Co. Ltd. (1962) Changed name to Sanraku Co. Ltd. (1985) Acquired Napa, Calif.-based Markham Vineyards (10/87) Changed name to Mercian Corp. (9/90)

FACILITIES: Five branch offices, eight factories and two research facilities in Japan One representative office and five production facilities overseas



STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange Net sales ¥99.028b (YE 05) compared to ¥99.231b (YE 04) Net income ¥1.409 (YE 05) compared to ¥2.372b (YE 04) Earnings per share ¥10.04/share (YE 05) compared to ¥16.59/share (YE 04) Total assets ¥87.939b (YE 05) compared to ¥90.616b (YE 04)

SUBSIDIARIES/DIVISIONS: Liquor Company Processing Liquors Company Pharmaceuticals & Chemicals Company Feedstuffs Company

BUSINESS STRATEGY: Maintain position as a leading producer of alcholic beverages, and manufactuer of feedstuffs, chemical products and pharmaceuticals

AGREEMENTS: Name Products Content of Agreement Date ILEX Oncolgy NM-3 license agreement

RESEARCH & DEVELOPMENT: Screening new anticancer drugs and other chemical compounds produced using microorganisms Development of manufacturing processes for chiral compounds utilizing bioconversion Analysis of fermentation characteristics and aroma and taste Breeding of new yeast genes Study of liquor fermentation mechanisms Examination of the health benefits of wine

Merck KGaA

Frankfurter Str. 250 Darmstadt D-64293, Germany Phone: +49 6151-72-0; Fax: +49 6151-72-2000 Web: www.merck.de E-mail: [email protected]

KEY PERSONNEL: Dr. Michael Romer; Chairman Karl-Ludwig Kley; Deputy Chairman



FACILITIES: Production and/or sales operations in 54 countries

STOCK-FINANCIAL HISTORY: Reuters--MRCG / Bloomberg--MRK GY / FSE--ISIN: DE 00065 99905 - WKN: 659 990 IPO--(1995) Sales EUR5.870b (YE 05) compared to EUR5.340b (YE 04) Earnings per share EUR0.85/share (YE 05) compared to EUR1.00/share (YE 04)

SUBSIDIARIES/DIVISIONS: Pharmaceuticals Business Sector--divisions include Ethical Pharmaceuticals, Generics, OTC Chemicals Business Sector--divisions include Liquid Crystals, Performance & Life Science

INVESTMENTS: Agribiotics Holdings Inc. in 3/06 Survac ApS in 11/05 Lumitec OLED R&D project of Schott AG in 2/05 OLED materials (Covion Organic Semiconductors GmbH) and polymer electronics businesses fron Avecia in 4/05

BUSINESS STRATEGY: Focus on business segments in which the company achieves competitive advantages through excellent quality of products, services and systems by concentrating on innovations and research in the pharmaceuticals business and on higher grade products in the chemicals business



AGREEMENTS: Name Products Content of Agreement Date Biomira Inc. Stimuvax (BLP25)

cancer vaccine global development and promotion agreement

1/06

ChemGenex Pharmaceuticals

preclinical support for diabetes, insulin resistance and complications

three-year alliance agreement

1/06

Dyax Corp. Dyax's phage display libraries


8/05

Eli Lilly and Co. Merck’s Ph. I insomnia treatment EMD281014, a 5-HT2a antagonist


Genaissance Pharmaceuticals Inc.

development and commercialization of vilazodone


9/04

Organon NV EMM 310066, a novel combination oral contraceptive

granted worldwide development and marketing rights

5/05

Takeda Pharmaceutical Co. Ltd.

Matuzumab co-development and co- commercialization agreement

9/05

Tioga Pharmaceuticals

Asimadoline, for treatment of Irritable Bowel Syndrome

granted development rights

6/05

RESEARCH & DEVELOPMENT: See annual report or visit our Web site, www.merck.de

PRODUCTS ON MARKET: PHARMA: Glucophage®, Concor®, Euthyrox®, Jodthyrox®, Praxilene®, Neurobion®, Cebion®, Erbitux®

PRODUCTS IN DEVELOPMENT: Name Status angiogenesis inhibitor cilengitide in glioma in Phase II clinicals humanized monoclonal antibody Matuzumab (EMD 72000) in EGFR-expressing tumors

in Phase II clinicals

Liposomal cancer vaccine Stimuvax (L-BLP25) in MUC1-expressing tumors: e.g. non-small cell lung cancer

in Phase II/III clinicals

Metabolix Inc.

21 Erie Street Cambridge MA 02139-4260, US Phone: (617) 492-0505; Fax: (617) 492-1996 Web: www.metabolix.com E-mail: [email protected]

KEY PERSONNEL: Jim Barber; President and CEO Dr. Oliver Peoples; CSO Thomas Auchincloss; CFO and VP, Finance and Corporate Development Johan van Walsem; VP, Manufacturing, Development and Operations Dr. Robert Whitehouse; Director, Applications Development Robert Findlen; VP, Sales and Marketing Dan Gilliland; Director, Business Development Ben Locke; Director, Government Programs


HISTORY: Founded in 1992 Acquired Monsanto's Biopol assets (5/01) Strategic agreement with ADM (11/04) Presidential Green Chemistry Award (2005)




STOCK-FINANCIAL HISTORY: Filed for IPO, NASDAQ--MBLX proposed (7/06)

BUSINESS STRATEGY: Create a compelling, sustainable alternative to petrochemical materials and establish a technology platform that will enable the widespread adoption of PHA bioplastics in the marketplace

AGREEMENTS: Name Products Content of Agreement Date Archer Daniels Midland Co.

commercialization of a new generation of high-performance eco-friendly natural plastics


Microbe Inotech Laboratories Inc.

7259 Lansdowne Avenue, Suite 200 St. Louis MO 63119-3421, US Phone: (314) 645-2177; Fax: (314) 645-2544 Toll-free phone: (800) 688-9144 Web: www.microbeinotech.com; E-mail: [email protected]

KEY PERSONNEL: Bruce C. Hemming, Ph.D.; President and CEO Barry L. Haymore, Ph.D.; Director, Technology Laurence E. Hallas, Ph.D.; Director, Field Services John Kent Morgan; Laboratory Manager


HISTORY: Founded in April 1991 Member--Biotech Industry Organization

FACILITIES: Pharmaceutical, environmental and food microbiology laboratories


BUSINESS STRATEGY: Provide microbiological characterization and identification services for environmental, food and pharmaceutical industries (GC-Fame, Biolog, Ribotyping, 16SrRNA DNA pair sequence, Custom Microarrays)

RESEARCH & DEVELOPMENT: Rapid microbiological diagnostics, environmental mycobacteria detection

Bio-control technologies, bioremediation assays

PRODUCTS ON MARKET: Rapid Gluten Home Test Kit CombiMatrix Catalog Microarrays and Custom Arrays As a full-service microbiology lab, provides testing services for the environmental, food, biotechnological and industrial communities

Microbia Inc.

320 Bent Street Cambridge MA 02141, US Phone: (617) 621-7722; Fax: (617) 494-0908 Web: www.microbia.com E-mail: [email protected]

KEY PERSONNEL: Joseph C. Cook Jr.; Chairman Peter M. Hecht, Ph.D.; CEO Richard Bailey, Ph.D.; VP and GM, Precision Engineering Brian M. Cali, Ph.D.; VP, Program Management Mark G. Currie, Ph.D.; VP, R&D Michael J. Higgins; Sr. VP, Finance and Strategic Planning and CFO Jeffrey M. Johnston, M.D.; VP, Clinical Development and CMO



G. Todd Nilne, Ph.D.; VP, Biology James O'Mara; VP, Business Development John J. Talley, Ph.D.; VP, Drug Discovery


HISTORY: Founded and began biotech R&D in 1998 Member--Biotechnology Industry Organization


PRIVATE PLACEMENTS: Raised $9.8M in Series A financing (2/99) Raised $23M in Series B financing (8/00) Raised $40M in Series D financing (5/04) Raised $75M in Series E financing (2/06)

PRINCIPAL INVESTORS: Aberdare Ventures Alton Ltd. BancBoston Ventures Bio*One Capital Essex Investment Management Co. Fidelity Biosciences Group Invus LP Jennison Associates Linkagene LP Maverick Capital Paperboy Ventures Polaris Venture Partners Sigma Capital Management Venrock Associates

BUSINESS STRATEGY: Utilize revenues from yield improvement service business to fund internal development of novel anti-infectives

AGREEMENTS: Name Products Content of Agreement Date DuPont Central Research & Development

biomanufacturing process for a chemical currently manufactured from petrochemical-based raw materials

CRADA with Microbia's Precision Engineering® business unit

2/06

Ranbaxy Laboratories Ltd.

biomanufacturing processes using Microbia’s Precision Engineering

technology development agreement

2/03

Ranbaxy Laboratories Ltd.

to lower the cost of a Ranbaxy biomanufacturing process


11/05

Teva Pharmaceutical Industries

biomanufacturing processes using Microbia’s Precision Engineering technology

development agreement, expanded

3/04

RESEARCH & DEVELOPMENT: Precision Engineering platform: Applies molecular genetics and proprietary profiling methods to rationally design microbes for the efficient production of commercially valuable metabolites. Applications include the pharmaceutical, food and feed ingredients, specialty chemical industries and industrial biotechnology



Mo Bio Laboratories Inc.

2746 Loker Ave. West Carlsbad CA 92010, US Phone: (760) 929-9911; Fax: (760) 929-0109 Toll-free phone: (800) 606-6246 Web: www.mobio.com E-mail: [email protected]

KEY PERSONNEL: Mark N. Brolaski; CEO and President Liz Brolaski; Exec. VP Ravi Venugopal, Ph.D.; Director, R&D Melissa Stolow, Ph.D.; Sr. Scientist David Stolow, Ph.D.; Sr. Scientist Getachew Sequar, Ph.D.; Scientist



FACILITIES: 11,000 sq. ft. headquarters in Carlsbad, Calif.


SUBSIDIARIES/DIVISIONS: Molecular Biology Manufacturing Contract Testing Services

BUSINESS STRATEGY: Continue with strength in molecular and microbiology product development

RESEARCH & DEVELOPMENT: Molecular, micro and protein biology kit development; kits for DNA, RNA and

protein isolation

PRODUCTS ON MARKET: DNA and RNA isolation kits used by molecular and microbiologists in fields of forensics, anti-biowarfare, environmental microbial analysis, basic research and biopharmaceuticals: DNA Clean-up and Gel Extraction: PowerClean™ DNA Clean-Up Kit, UltraClean™ 15 DNA Purification Kit, UltraClean™ GelSpin™ Kit, UltraClean™ PCR Clean-up™ Kit, UltraClean-htp™ 96 Well PCR Clean-up™ Kit, UltraClean™ 15 Kit Components, UltraClean™ GelSpin™ Kit Components, UltraClean™ PCR Clean-up™ Kit Components Plasmid DNA Isolation: UltraClean™ 6 Minute Mini Plasmid Prep Kit, UltraClean-htp™ 96 Well Plasmid Prep Kit, UltraClean™ Standard Mini Plasmid Prep Kit, UltraClean™ Midi Plasmid Prep Kit, UltraClean™ Maxi Plasmid Prep Kit, UltraClean™ Endotoxin-Free Mini Plasmid Prep Kit, UltraClean™ Endotoxin-Free Midi Plasmid Prep Kit, UltraClean™ Endotoxin-Free Maxi Plasmid Prep Kit, UltraClean™ Endotoxin Removal Kit, UltraClean™ Endotoxin-Free Precipitation Kit, UltraClean™ 6 Minute Mini Prep Kit Components, UltraClean™ Midi Plasmid Prep Kit Components, UltraClean™ Maxi Plasmid Prep Kit Components, UltraClean™ Endotoxin-Free Mini Kit Components, UltraClean™ Endotoxin-Free Midi Kit Components, UltraClean™ Endotoxin-Free Maxi Kit Components, Endotoxin-Free Reagents and Supplies Soil DNA Isolation: PowerSoil™ - htp 96 Well Soil DNA Isolation Kit, PowerClean™ DNA Clean-Up Kit, PowerMax™ Soil DNA Isolation Kit, PowerSoil™ DNA Isolation Kit, UltraClean™ Soil DNA Kit, UltraClean™ Mega Soil DNA Kit, UltraClean-htp™ 96 Well Soil DNA Kit, UltraClean™ Fecal DNA Kit, PowerMax™ Soil DNA Isolation Kit Components, PowerSoil™ DNA Isolation Kit Components, UltraClean™ Soil DNA Kit Components, UltraClean™ Mega Soil DNA Kit Components, UltraClean™ Fecal DNA Kit Components Microbial DNA Isolation: PowerMicrobial™ Midi DNA Isolation Kit, PowerMicrobial™ Maxi DNA Isolation Kit, UltraClean™ Microbial DNA Kit, UltraClean™-htp 96 Well Microbial DNA Kit, UltraClean™ Microbial DNA Kit



Components, PowerMicrobial™ Midi DNA Isolation Kit Components, PowerMicrobial™ Maxi DNA Isolation Kit Components Blood DNA Isolation: UltraClean™ BloodSpin™ Kit, UltraClean™ Mega BloodSpin™ Kit, UltraClean™ Blood DNA Kit (Non-Spin), UltraClean-htp™ 96 Well BloodSpin™ DNA Kit, UltraClean™ BloodSpin™ Kit Components, UltraClean™ Mega BloodSpin™ Kit Components, UltraClean™ Blood DNA Kit (Non-Spin) Components Tissue DNA Isolation: UltraClean™ Tissue DNA Kit, UltraClean-htp™ 96 Well Tissue DNA Kit, UltraClean™ Tissue DNA Kit Components Plant DNA Isolation: PowerPlant™ DNA Isolation Kit, UltraClean™ Plant DNA Kit, UltraClean-htp™ 96 Well Plant DNA Isolation Kit, PowerPlant™ DNA Isolation Kit Components, UltraClean™ Plant DNA Kit Components Water DNA Isolation: UltraClean™ Water DNA Kit (0.45 um), UltraClean™ Water DNA Kit (0.22 um), UltraClean™ Water DNA Kit (No filters), Water Filters, UltraClean™ Water DNA Kit Components Forensic DNA Isolation: UltraClean™ Forensic DNA Kit RNA Isolation: RNA PowerSoil™ Total RNA Isolation Kit, UltraClean™ Tissue RNA Kit, UltraClean™ Plant RNA Kit, UltraClean™ Microbial RNA Kit, RNA PowerSoil™ Total RNA Isolation Kit Components, UltraClean™ Tissue RNA Kit Components, UltraClean™ Plant RNA Kit Components, UltraClean™ Microbial RNA Kit Components Nuclease Detection: RNase Detection Kit, DNase Detection Kit Lab Supplies: Electrophoresis Equipment (Mini Horizontal Gel System; Mini Horizontal Gel Caster; Mini Horizontal Gel Tray; Comb, Polycarbonate; Comb, Teflon; Dual Comb, Polycarbonate; Dual Comb, Teflon; Power Supplies), Electrophoresis Reagents (TAE Buffer, 50X (Tris-acetate-EDTA); TBE Buffer, 10X (Tris-borate-EDTA); UltraClean™ Agarose; UltraClean™ Low Melt Agarose; UltraClean™ Low Melt Sieve Agarose; UltraClean™ MS-8 Agarose; UltraClean™ Forensic Agarose; DNA Molecular Weight Markers; Ethidium Bromide Solution; Ethidium Bromide Destaining Tea Bags; Gel Loading Buffer, Bromophenol Blue; Gel Loading Buffer, Bromophenol Blue/Xylene Cyanol), Water (PCR Water, Molecular Biology Grade Water, DEPC Treated Water, Endotoxin-Free Water), Growth Media (TB DRY™ Powder Growth Media; LB Broth Powder Growth Media; LB Agar Powder Growth Media; LB Broth (Lennox) Powder Growth Media; LB Agar (Lennox) Powder Growth Media; Soybean-Casein Digest Medium (TSB), USP; Soybean-Casein Digest Agar Medium (TSA), USP; Yeast Extract; Tryptone; Agar), Vortexes and Adapters (Vortex-Genie® 2; Labnet VX100 Vortex; Vortex Adapters for Vortex-Genie® 2; Vortex Adapters for Labnet VX100 Vortex), Lab Accessories (RNase-Free Gloves, UltraClean™ Lab Cleaner), 96 Well Kit Equipment (96 Well Plate, Shaker, Plate Adapter Set, Tube Adapter Set, UltraVac™ Manifold, Vacuum Pump) and Homogenization Equipment (Precellys® 24 Homogenizer) Samples: MO BIO SAMPLES - No Sales Calls & No Interruptions, UltraClean™ 6 Minute Mini Plasmid Prep Sample Kit, UltraClean™ PCR Clean-up™ Sample Kit, UltraClean™ GelSpin™ Kit Sample, PowerMax™ Soil DNA Isolation Kit Sample, RNA PowerSoil™ Total RNA Isolation Kit Sample, UltraClean™ Forensic DNA Sample Kit, UltraClean™ 15 DNA Purification Kit Sample, UltraClean™ Standard Mini Plasmid Prep Sample Kit, UltraClean™ Midi Plasmid Prep Sample Kit, UltraClean™ Maxi Plasmid Prep Sample Kit, UltraClean™ Endotoxin-Free Mini Plasmid Sample Kit, PowerSoil™ DNA Isolation Kit Sample, UltraClean™ Soil DNA Sample Kit, UltraClean™ Fecal DNA Sample Kit, UltraClean™ Microbial DNA Sample Kit, UltraClean™ Microbial RNA Sample Kit, UltraClean™ BloodSpin™ Sample Kit, UltraClean™ Blood DNA Sample Kit (Non-Spin), UltraClean™ Tissue DNA Sample Kit, PowerPlant™ DNA Isolation Sample Kit, UltraClean™ Tissue RNA Sample Kit, UltraClean™ Plant RNA Sample Kit,



TB DRY™ Powder Growth Media Sample, LB Broth Powder Growth Media Sample, LB Agar Powder Growth Media Sample, LB Agar (Lennox) Powder Growth Media Sample, LB Broth (Lennox) Powder Growth Media Sample Yeast Extract Sample, Tryptone Sample, Agar Sample

MoBiTec GmbH

Lotzestrasse 22a Goettingen 37083, Germany Phone: +49 551-707-220; Fax: +49 551-707-2222 Web: www.mobitec.com; E-mail: [email protected]

KEY PERSONNEL: Jorg Ronnenberg; Chairman




BUSINESS STRATEGY: Provide an extraordinary wide range of innovative tools for molecular and cell biology to make daily lab research faster, easier and more efficient Enzyme technology in research, food technology, pharmaceuticals and environment

RESEARCH & DEVELOPMENT: Pharmaceutical diagnostics

Environmental purification Water purification

PRODUCTS ON MARKET: Cloning vectors Expression systems for E.coli, yeast, B.megaterium, B.subtilis Two- and One-Hybrid Systems Phagemid technology Genomic libraries Antibodies Cytokines and growth hormones Tools for proteomics and genomics Fluorescence technology Affinity chromatography Lab suplies

Molecular Devices Corp.

1311 Orleans Drive Sunnyvale CA 94089-1136, US Phone: (408) 747-1700; Fax: (408) 747-3601 Toll-free phone: (800) 635-5577 Web: www.moleculardevices.com E-mail: [email protected]

KEY PERSONNEL: Joe Keegan; President and CEO Timothy Harkness; Sr. VP, Finance and CFO Gillian M.K. Humphries, Ph.D.; VP, Strategic Affairs Robert Murray; VP, Operations J. Richard Sportsman, Ph.D.; VP, Assay and Reagent R&D Robert Wicke; VP, Engineering Jan Hughes; VP, Marketing Tom Olenic; VP, Sales Pat Sharp; VP, Human Resources




HISTORY: Founded in 1983 by Dr. Harden McConnell Reincorporated in Delaware in 1995 Acquired the Laser Capture Microdissection business of Arcturus Bioscience for $10M (4/06)

FACILITIES: 150,000 sq. ft. facility in Sunnyvale, Calif. (headquarters) Offices in Union City, Calif.; Great Britain; Korea; China; Japan; Downingtown, Pa.; Germany; and Brazil

STOCK-FINANCIAL HISTORY: NASDAQ--MDCC IPO--$11/share (12/95) Revenue $181.215M (YE 05) compared to $148.529M (YE 04) Net income $15.896M (YE 05) compared to $17.233M (YE 04) Earnings per share $0.95/share (YE 05) compared to $1.08/share (YE 04) Average shares outstanding 16.783M (YE 05) compared to 16.028M (YE 04) Total assets $257.301M (YE 05) compared to $255.229M (YE 04)

BUSINESS STRATEGY: Develop innovative bioanalytical systems for life science research and drug discovery

RESEARCH & DEVELOPMENT: Microplate readers and spectrophotometers, multi-mode benchtop readers,

electrophysiology instruments, imaging systems, microarray scanning equipment, amplifiers, software and HTS systems

PRODUCTS ON MARKET: Emax™ Precision Microplate Reader for endpoint analysis VersaMax, SpectraMax Plus 384, SpectraMax 190, Gemini XPS FLIPR Tetra Flourometric Imaging Plate Reader SoftMax Pro® data analysis software SpectraMax 340PC 384 Microplate Spectrophotometer for UV and visible analysis of biomolecules SpectraMax Plus High Throughput Spectrophotometer SpectraMax® M5 five-mode multi-detection microplate reader system Threshold® biosensor assay system for rapid sensitive detection of contaminants in biopharmaceuticals Threshold® Total DNA assay kit for quantitation of DNA in protein solutions Threshold® Immuno-Ligand assay kit for immunoassay and other binding assays in protein solutions Vmax® Kinetic Microplate Reader using vertical beam photometry Lmax II Luminomter IonWorks™ HT Electrophysiology system PatchXpress Electrophysiology system OpusXpress Electrophysiology system GenePix™ 4200AL Microarray Scanner MetaMorp Imaging Software MetaFluor Imaging Software Discovery-1™ Imaging System Axoporator Amplifier ImageXpress Imaging System Analyst HT Multi-Mode System AquaMax DW4 Dispenser/Washer QBT™ Fatty Acid Uptake Assay Kit



Molecular Probes Inc.

P.O. Box 22010, 29851 Willow Creek Road Eugene OR 97402-0469, US Phone: (541) 465-8300; Fax: (541) 335-0504 Toll-free phone: (800) 438-2209 (orders only) Web: www.probes.invitrogen.com E-mail: [email protected]

KEY PERSONNEL: August Sick; General Manager


HISTORY: Founded in 1975 Acquired by Invitrogen Corp. (8/03)


SUBSIDIARIES/DIVISIONS: Molecular Probes Europe BV--wholly owned subsidiary located in the Netherlands

SUBSIDIARY OF: Invitrogen Corp. (see separate entry)

BUSINESS STRATEGY: Be the leading provider of fluorescence-based detection solutions to advance scientific and biomedical research

PRODUCTS ON MARKET: Over 3,000 fluorescent probes for bioscience research listed in the

'Handbook of Fluorescent Probes and Research Chemicals' including Calcium Green™, Live/Dead® viability/cytotoxicity kits, SYBR® Green nucleic acid gel stain, SYPRO® Protein gel stain, FluoSpheres®, Cascade Blue®, Toto®-1, Yoyo®-1 and Bodipy®

Monsanto Co.

800 North Lindbergh Boulevard St. Louis MO 63167, US Phone: (314) 694-1000; Fax: (314) 694-4228 Web: www.monsanto.com E-mail: [email protected]

KEY PERSONNEL: Hugh Grant; Chairman, President and CEO Terrell K. Crews; Exec. VP and CFO Dr. Robert T. Fraley; Exec. VP and CTO Charles W. Burson; Exec. VP, Secretary and General Counsel Carl M. Casale; Exec. VP, North America Commercial Brett D. Begemann; Exec. VP, International Commercial Robert A. Paley; VP and Treasurer Mark J. Leidy; Exec. VP, Manufacturing Gerald A. Steiner; Exec. VP, Commercial Acceptance Steven C. Mizell; Sr. VP, Human Resources Cheryl Morley; Sr. VP, Corporate Strategy Richard B. Clark; VP and Controller Janet M. Holloway; VP and Chief of Staff Scarlett Lee Foster; VP, Investor Relations


HISTORY: Founded in 1901 Agricultural division established (1960) Began biotech R&D in 1979 Acquired the Jacob Hartz Seed Co. (1982) Acquired 49% of Calgene Inc. (3/96) Acquired Agracetus (7/96) Increased ownership of Calgene Inc. to 54.6% through purchase of 6.25M shares (8/96)



Acquired Asgrow agronomics seed business (1997) Acquired Holden's Foundation Seeds Inc., Corn States Hybrid Service Inc. and Corn States International Sarl for up to $1b (1/97) Acquired remaining shares of Calgene for $8/share, $240M (7/97) Monsanto split into two companies--Monsanto Co. (life sciences, agriculture, health and food products) and Solutia Inc. (chemicals and fibers) (9/97) Announced plans to acquire remaining shares of Dekalb Genetics Corp. for $2.5b and Delta & Pine Land Co. for an undisclosed amount (5/98) American Home Products Corp. (now Wyeth) and Monsanto Co. announced plans to merge for $33b in stock and to create new company (6/98) Announced plans to acquire Cargill's international seed operations in Central and Latin America, Europe, Asia and Africa for $1.4b (6/98) Merged with Pharmacia & Upjohn to form Pharmacia Corp. Monsanto is the acknowledged agricultural subsidiary and will retain its name, while Pharmacia owns 85% of Monsanto. The business became a separate legal entity with a stand-alone board of directors and its own publicly traded stock. (4/00) Divested by Pharmacia Corp. in lieu of Pharmacia's merger into Pfizer Inc. (4/03) Formed American Seeds Inc. (ASI) (2004) ASI acquired Channel Bio Corp. (including three seed brands: Crows Hybrid Corn, Midwest Seed Genetics and Wilson Seeds) (2004) Acquired North American canola seed assets of Advanta Seeds from Advanta BV (9/04) Acquired the Stoneville cotton business (including its NexGen brand) (2005) ASI subsidiary acquired NC+ Hybrids Inc. (2005) ASI acquired Fontanelle Hybrids, Stewart Seeds, Trelay Seeds and Stone Seeds (2005) ASI acquired Specialty Hybrids (2005) Acquired agricultural genomics assets of Icoria Inc. (3/05) Acquired Seminis Inc. (3/05) Acquired Emergent Genetics Inc. (4/05) Sold Monsanto Enviro-Chem Systems Inc. (8/05) ASI acquired the seed marketing and sales businesses of Diener Seeds and and Sieben Hybrids (6/06) ASI to acquire Kruger Seed Co. Trisler Seed Farms and the seed marketing and sales business of Campbell Seed (as of 6/06) To acquire Delta and Pine Land Co. for $1.5b (as of 8/06) Member--Biotechnology Industry Organization

FACILITIES: Manufacturing facilities, laboratories, seed production and other agricultural facilities, office space, warehouses and other land parcels in North America, South America, Europe, Asia, Australia and Africa Seed conditioning plants at Bellary, India; Constantine, Mich.; Eluru, India; Grinnell, Iowa; Kearney, Neb.; Oxnard, Calif.; Peyehorade, France; Phitsanoluk, Thailand; Trebes, France; Uberlandia, Brazil; and Villagran, Mexico Chemicals manufacturing facilities at Alvin, Texas; Antwerp, Belgium; Augusta, Ga.; Camacari, Brazil; Luling, La.; Muscatine, Iowa; Sao Jose dos Campos, Brazil; Soda Springs, Idaho; and Zarate, Argentina

STOCK-FINANCIAL HISTORY: NYSE--MON Net sales $6.294b (YE 05) compared to $5.423b (YE 04) Net income $255M (YE 05) compared to $267M (YE 04) Earnings per share $0.94/share (YE 05) compared to $0.99/share (YE 04) Average shares outstanding 266.8M (YE 05) compared to 264.4M (YE 04)

SUBSIDIARIES/DIVISIONS: Two business segments: Seeds and Genomics (global seeds and traits businesses and genetic technology platforms) Agricultural Productivity (crop protection products, animal agriculture businesses and lawn-and-garden herbicide products)

INVESTMENTS: The Liposome Co. Target Therapeutics HybriTech Seed Europe-SNC--joint venture with CACBA Calgene Inc.--100%



Joint venture with Cargill to use biotechnology to improve feed for pigs, cattle, poultry and fish (5/98) Formed American Seeds Inc. (ASI), a holding company to support regional seed businesses (11/04)

BUSINESS STRATEGY: Produce leading seed brands and develop biotechnology traits that assist farmers in controlling insects and weeds Provide other seed companies with genetic material and biotechnology traits for their seed brands Provide lawn-and-garden herbicide products for the residential market Provide animal agricultural products focused on improving dairy cow productivity and swine genetics


Genaissance Pharmaceuticals Inc. and the Agricultural Research Service (part of USDA)

to map single nucleotide polymorphism (SNP) DNA markers in soybeans


Agracetus Inc. transgenic cotton technology

purchased all plant biotech assets from W.R. Grace & Co

4/96

Arcadia Biosciences Inc.

development and commercialization of Arcadia's nitrogen use efficiency technology in canola


ArQule Inc. agrochemicals development agreement

12/96

Calgene Inc. fresh produce and plant oils

R&D agreement 10/95

Calgene Inc. oilseed research programs

cross-licensing agreement--Calgene will receive royalty-free license to current and future Monsanto agronomic technology in combination with Calgene's oils modification genes. Monsanto will pay Calgene royalties and $17M and will receive portion of profits of Calgene's specialty oils business

5/96

Calgene Inc. patented technologies cross-licensing agreements--Monsanto received licenses to Calgene's patents and patents pending in the areas of plant transformation, certain genetically engineered plants, and antisense RNA technology. Calgene received licenses to

4/93



Monsanto's patents and patents pending in the areas of plant transformation technologies, selectable markers, and the right to obtain certain licenses to Monsanto's Bt insect resistance technology for use in cotton

Calgene Inc. Russet Burbank

potatoes genetically modified to resist potato viruses X and Y


California Institute of Technology

instrument design development agreement

Columbia University

patented rDNA extraction process


Dekalb Genetics Corp.

field crops, seeds, produce

R&D collaboration and cross-licensing agreement

2/96

Delta and Pine Land Co.

Bollard gene for selected varieties of cotton

marketing agreement

11/95

Divergence Inc. nematode-resistant soybeans


9/04


new technology options and more choice in products for farmers

global business agreement

1/06

Dyax Corp. Dyax's phage display technology

non-exclusive licensing agreement, including signing fees, milestone payments and royalties, Dyax gets access to related patented technology owned by licensee

5/97

Ecogen Inc. Bt technology for in-plant applications


1/96

Finnfeeds feed microingredients joint venture for for production and marketing of feed microingredients in plants

4/98

GeneTrace Inc. plant and animal genomics

$17M technology collaboration--Monsanto gets exclusive license to GeneTrace's technology for plant and animal genomics, including gene-expression analysis and genotyping

4/98




Incyte's gene expression microarray technology for functional genomics applications in plant, animal and human genomes

3-year, large-scale, genome-wide agreement--Monsanto gets access to up to 50K DNA microarrays for use across its life science programs, Incyte will provide data from custom and prefabricated DNA microarrays, software to manage and analyze data and consulting services

5/98


Incyte's LifeTools software and plant sequences

broad-based genomics and software licensing agreement (9/96), expanded to include LifeSeq®, LifeSeq FL®, LifeSeq Atlas™, LifeSeq GeneAlbum™ cDNA, PathoSeq™ and ZooSeq™

10/97

Japan Tobacco Inc.

high-yield rice joint development agreement

12/95

Mendel Biotechnology Inc.

Monsanto to commercialize technologies developed by Mendel, both companies will develop an integrated framework for predictive control of plant gene expression

partnership, expanded and extended through 2011 (7/06)

1997

Mexican Ministry of Agriculture and Water Resources

genetically engineered potato to resist viral diseases

R&D agreement 7/93


Millennium's genomics technology platform to develop agricultural products

5-year, $218M agreement--Monsanto to pay $118M in licensing and technology transfer fees ($38M up-front, $16M per year for five years), Monsanto could pay an additional $20M/year in milestone payments based on research objectives, Monsanto to form subsidiary in Cambridge, MA with 100 scientists, Millennium retains right to use technologies developed by the subsidiary for non-

10/97



exclusive use outside of plant and agricultural areas

Mitsubishi Kasei Corp.

rDNA and MAbs joint R&D venture in Japan

Modular Genetics Inc.

advancement of Monsanto's protein optimization platform

three-year collaboration

3/05

Molecular Informatics Inc.

BioMerge software for analysis of genomic data

three-year licensing agreement

1/97

North Carolina State University

genetically engineered nematicides

licensing agreement--Monsanto to develop the technology in major agricultural crops in developed countries

4/93

Pioneer Hi-Bred International Inc.

YieldGard insect-protected Bt corn


Sandia National Laboratories

alignment of Sandia's capabilities in bioanalytical imaging and analysis with Monsanto's research in the development of seed-based products, including corn products that may be able to produce more ethanol per bushel

three-year research collaboration

8/06

Sandoz Seeds Ltd.

insect-protected Bt corn nonexclusive worldwide license to Monsanto patents

8/95

Strategic Diagnostics Inc.

GeneCheck R&D and manufacturing agreement

Synteni Inc. gene expression in plants and organisms


6/96

Targeted Growth Inc. (TGI)

development and commercialization of a TGI-developed yield enhancement gene


The Solae Co. soy proteins development and marketing agreement

10/05

RESEARCH & DEVELOPMENT: Insect-protected corn and cotton

Soybeans, canola, cotton, and corn genetically modified to tolerate Roundup® herbicide Virus- and insect-protected potatoes Delayed ripening tomatoes Cholesterol oxidase gene to protect cotton, corn, and potato plants from weevils, worms, and beetles

PRODUCTS ON MARKET: Seeds and Genomics: Roundup Ready traits in soybeans, corn, canola and cotton Bollgard and Bollgard II traits in cotton YieldGard Corn Borer and YieldGard Rootworm traits in corn Agroceres, Asgrow, Dekald, Stoneville and Vistive branded seeds Holden’s Foundation Seeds Monsoy foundation seed American Seeds Inc. branded seed Seminis, Royal Sluis, Asgrow and Petoseed branded seeds



Agricultural Productivity: Roundup and other glyphosate-based herbicides Harness, Degree, Lasso, Machete and other acetanilide-based herbicides Other selective herbicides, such as Maverick, Certainty, Outrider, Leader and Monitor sulfosulfuron herbicides Lawn-and-garden herbicides Posilac bovine somatotropin Monsanto Choice Genetics genetics lines

Morishita Jintan Co. Ltd.

1-30, Tamatsukuri 1-chome, Chuo-ku Osaka, Japan Phone: +81 6-6761-1131; Fax: +81 6-6768-1661 Web: www.jintanworld.com E-mail: [email protected]

KEY PERSONNEL: Yukihisa Aibara; President and CEO


HISTORY: Founded in February 1893

STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges

SUBSIDIARIES/DIVISIONS: Branches in Shizuoka, Kagawa, Toyama and Shiga Pref.

BUSINESS STRATEGY: Develop and sell health foods, medical supplies, unregulated drugs and cosmetics based on Chinese medicines and encapsulation technology for seamless capsules

PRODUCTS ON MARKET: Pharmaceuticals: Bifina Constipation, Solmiran

Health foods and dietary supplements

M-Scan Ltd.

3 Millars Business Centre, Fishponds Close Wokingham RG41 2TZ, UK Phone: +44 (0)118 989 6940; Fax: +44 (0)118 989 6941 Web: www.m-scan.com E-mail: [email protected]

KEY PERSONNEL: Prof. H. R. Morris; Chairman Dr. Fiona M. Greer; Director Dr. Andrew Reason; Director Dr. C. Harbach; Sr. Scientist Dr. David Chapman; Business Manager



FACILITIES: Four analytical laboratories--located in: Wokingham, UK; Geneva, Switzerland; and West Chester, Pa. Marketing offices in Manchester, U.K.; Freiburg, Bonn and Munich, Germany; and South Korea




SUBSIDIARIES/DIVISIONS: M-Scan SA 12, Chemin des Aulx 1228 Plan-les-Ouates Geneva, Switzerland Phone: + 41 (0)22 794 83 74 Fax: + 41 (0)22 794 83 55 E-mail: [email protected] M-Scan Inc. Dr. Mark Rogers 606 Brandywine Parkway West Chester, PA 19380 Phone: (610) 696-8210 Fax: (610) 696-8370 E-mail: [email protected]

RESEARCH & DEVELOPMENT: Use of mass spectrometry for the structure and sequence analysis of

recombinant protein products and analysis of posttranslational modifications

MSE Technology Applications Inc.

P.O. Box 4078, 200 Technology Way Butte MT 59701, US Phone: (406) 494-7100; Fax: (406) 494-7230 Web: www.mse-ta.com E-mail: [email protected]

KEY PERSONNEL: Donald R. Peoples; President Jeff Ruffner; Exec. VP and General Manager Neal Egan; Head, Business Development



FACILITIES: Butte, Mont.--Corporate office, 53-acre Mike Mansfield Advanced Technology Center, Montana Information Technology Enterprise Center, welding and fabrication center


SUBSIDIARY OF: Montana Economic Revitalization and Development Institute

BUSINESS STRATEGY: MSE Technology Applications Inc. is a diversified research and engineering firm. We are a small business headquartered in Butte, Montana, with offices in Washington, Idaho, North Carolina, South Carolina, Washington, D.C., and West Virginia. MSE scientists and engineers are internationally recognized as the very best in their fields--developing and deploying some of the nation’s most sophisticated cutting-edge technology. Business Areas: Remediation Services--MSE provides services to private commercial entities and government agencies for municipal and industrial water treatment, biotechnologies, biological barriers, biological remediation, enhanced oil recovery, and counter chemical and biological terrorism. Site Cleanup and Closure Support--MSE develops, tests, evaluates and deploys innovative technology to address the environmental issues surrounding site closures across the United States. We also identify and develop promising technologies to address the Department of Energy's site waste problems (such as transuranic mixed waste problems). More than 80 projects, at 26 facilities in 21 states, have been completed or are underway, resulting in significant operational cost savings.



Waste Treatment Technology--The Waste Treatment Technology area provides a full range of treatment services to customers including plasma services, facilities and products. We develop and deploy technologies to resolve Department of Energy and Department of Defense waste problems. Facility Modernization and Sustainability--MSE supports infrastructure modernization at troop-based facilities by providing engineering solutions to plant processes. Specifically, modernizing and increasing the efficiency of outdated processes at various ammunition and troop installations around the Army complex. This group’s real strength is providing process modifications through instrumentation and control system modernization as well as chemical and materials handling improvements. Advanced Energy and Aerospace Programs--MSE is conducting cutting edge research for advanced energy and aerospace technology development. Projects have the potential for breakthroughs in aerospace technology and could reduce the cost of commercial and military space operations. MSE is developing an ultrahigh-pressure test system to provide ground testing for aerospace technologies that are crucial to development of the world’s first hypersonic wind tunnel. Plasma Services--MSE is a world leader in the field of plasma technology for waste material treatment and is currently deploying two systems for the U.S. Army in Nevada and West Virginia. Mine Waste Technology Program--MSE demonstrates innovative groundwater remediation technologies in Montana, South Dakota, Nevada, California, Minnesota, Missouri, Utah and Colorado to advance the development of engineering solutions to national environmental issues resulting from mining. Information Technology Services--MSE’s Montana Information Technology Enterprise Center is a complete data center, provides a strategically isolated location, redundant power and fire protection, OCx capacity, triple levels of security and environmental controls. MSE provides contingency planning and implementation, disaster recovery, online data storage/ warehousing/ vaulting, parallel computing, telecommunications, project management, and web services and development.

RESEARCH & DEVELOPMENT: Heavy metals in soils and water

Thermal spray technology Lightweight materials technology Plasma arc treatment technology Biological remediation Counter chemical and biological terrorism Aerospace technology

Nanogen Inc.

10398 Pacific Center Court San Diego CA 92121, US Phone: (858) 410-4600; Fax: (858) 410-4952 Toll-free phone: (877) 626-6436 Web: www.nanogen.com E-mail: [email protected]

KEY PERSONNEL: Howard C. Birndorf; Chairman and CEO David Ludvigson; President and COO Robert Saltmarsh; CFO Graham Lidgard, Ph.D.; Sr. VP, R&D Walt Mahoney; VP, R&D Merl F. Hoekstra; VP, Business Development




HISTORY: Founded in 1993 Acquired SynX Pharma Inc. (4/04) Merged with Epoch Biosciences Inc. (12/04) To acquire Spectral Diagnostic Inc.’s rapid cardiac immunoassay test business (as of 12/05) To acquire the diagnostics division of Amplimedical SpA (as of 4/06)

FACILITIES: 51,000 sq. ft. in San Diego, Calif.

30,000 sq. ft. in Bothell, Wash. 50,000 sq. ft. in Toronto, Canada 2,600 sq. ft. in Helmond, Netherlands

STOCK-FINANCIAL HISTORY: NASDAQ--NGEN IPO--3.9M shares at $11/share, $42.9M (4/98) Secondary offering--$80M (11/00) Revenue $12.544M (YE 05) compared to $5.374M (YE 04) Net loss <$96.494M> (YE 05) compared to <$38.907M> (YE 04) Loss per share <$1.95/share> (YE 05) compared to <$1.21/share> (YE 04) Average shares outstanding 49.585M (YE 05) compared to 32.203M (YE 04) Total assets $98.081M (YE 05) compared to $176.024M (YE 04)

PRIVATE PLACEMENTS: Raised $26.2M through private placement of Series C preferred stock (3/97) Raised $20M through private placement of 6.8M shares and 1M warrants (9/05)

SUBSIDIARIES/DIVISIONS: Molecular Research Products division: 21720 23rd Drive S.E., No. 150 Bothell, WA 98021 Phone: (800) 562-5544 Fax: (425) 482-5550 E-mail: [email protected] Point of Care Diagnostics division: 1 Marmac Drive Toronto , Ontario M9W 1E7 Canada Phone: (877) 246-7593 Fax: (416) 798-3447 E-mail: [email protected] Nanogen Europe BV: Steenovenweg 3 5708 HN Helmond Netherlands Phone: +31 (0)492-507-160 Fax: +31 (0)492-507-179

PRINCIPAL INVESTORS: Birndorf Biotechnology Development Enterprise Partners InterWest Partners Kleiner, Perkins, Caufield and Byers New Leaf Venture Partners

INVESTMENTS: Jurilab Ltd.

FINANCIAL INFORMATION: Completed $3.5M round of venture capital financing (2/94) Completed $9.5M round of venture capital financing (10/95) Received $2M two-year grant from U.S. Department of Commerce (7/95) Received $500K grant from Bude Technology Group (4/96) Received $250K grant from the State of California Defense Conversion Matching Grant (6/96)



BUSINESS STRATEGY: Mission: Become a leading supplier of molecular diagnostic tests by developing commercial applications for our proprietary platform technology and by promoting our technology as the standard for molecular identification and analysis. Key elements of our strategy include: -Developing commercial applications -Developing research and genomics applications -Establishing strategic collaborations -Developing advanced technologies and point-of-care applications


Becton Dickinson and Co.

test systems to diagnose infectious diseases (based on Nanogen's DNA microchip and Becton Dickinson's system for DNA amplification)

worldwide, multi-year collaborative agreement

5/97

Bode Technology Group

forensics one-year development agreement

1996

deCode Genetics new genomics assay using Nanogen products for single nucleotide polymorphism (SNP) discovery, validation and screening

supply and licensing agreement

4/05

Department of Commerce

integrated microelectronic DNA diagnostic system

two-year, $2M development grant

1995

Department of Commerce

portable genetic analysis device for forensic investigations, trauma victim identification, medical diagnostics and environmental monitoring

$2M development grant

3/97

Fisher Scientific International Inc.

molecular diagnostics expanded Fisher's equity investment in Nanogen (3/06) to include R&D collaboration

8/06

Jurilab Ltd. development of diagnostics based on genes and markers discovered by Jurilab


Jurilab Ltd. identification and validatation of prognostic markers for Type II diabetes


5/06

Pathway Diagnostics

Nanogen to develop diagnostic products that detect genetic variations associated with responses to antidepressant and antipsychotic therapeutics

nonexclusive, worldwide licensing agreement

3/05



Prolinx Inc. enhanced sensitivity detection system for use with Nanogen's proprietary electronically addressable microchip array technologies

sponsored research agreement

4/97

U.S. Justice Department (National Institue of Justice)

portable microchip array-based genetic detector for rapid genetic testing and identification at the point of evidence collection

$710K research grant

9/97

RESEARCH & DEVELOPMENT: Integrated system for rapid analysis of charged macromolecules using microelectronics and molecular biology Nanogen APEX (Automated Programmable Electronic Matrix) to move, concentrate, bind, wash and separate charged molecules in electronic field

PRODUCTS ON MARKET: NanoChip™ Molecular Biology Workstation NanoChip™ cartridges Analyte specific reagents (ASRs)

NanoHorizons Inc.

Technology Center, Suite 208, 200 Innovation Blvd. State College PA 16803, US Phone: (814) 861-9909; Fax: (814) 861-9903 Web: www.nanohorizons.com E-mail: [email protected]

KEY PERSONNEL: Stephen Fonash, Ph.D.; Chairman and CTO Robert F. Burlinson; President and CEO Joseph D. Cuiffi, Ph.D.; Head, R&D and Production Daniel J. Hayes, Ph.D.; Head, Operations Dennis I. Schneider; Head, Marketing




PRINCIPAL INVESTORS: Ben Franklin Technology Partners Life Sciences Greenhouse of Central Pennsylvania Pulsar Ventures

BUSINESS STRATEGY: Mission: Develop and produce state-of-the-art nanotechnology products and processes for near term biotechnology, pharmaceutical, chemical and microelectronic applications


Arrow International Inc.

opportunities to apply nanotechnology to emerging cost and performance issues in biomedical technology


3/04

pSiMedica opportunities to utilize NanoHorizon's nanostructured silicon films in areas such as tissue engineering and diagnostics

materials transfer agreement

2/04



Solarity NanoHorizons' solar cell technology


8/06

RESEARCH & DEVELOPMENT: Technologies: Photovoltaics and organic LEDs, sensors and flexible electronics

PRODUCTS ON MARKET: Noble Metal Embedded Nanoparticles - Low-cost line of polymer-compatible anti-odor nanoparticles QuickMass™ - Mass spectrometry targets for high-speed analysis of small molecules for pharmaceutical product development and medical research Humidity Sensors for Respiratory Monitoring - Rapid-response, high-sensitivity

NanoLogix Inc.

87 Stambaugh Avenue, Suite 2 Sharon PA 16146, US Phone: (724) 346-1302; Fax: (724) 346-9596 Web: www.nanologix.net E-mail: [email protected]

KEY PERSONNEL: Mitchell S. Felder, M.D.; CEO David McClelland; President Thomas A Kelly, Ph.D.; Sr. Scientist


HISTORY: Founded and began biotech R&D in 1989 Changed name from Infectech Inc. (4/05)

FACILITIES: 1,700 sq. ft. headquarters 2,100 sq. ft. R&D facility

STOCK-FINANCIAL HISTORY: Pink Sheets--NNLX

SUBSIDIARIES/DIVISIONS: MD-Diagnostics.com Inc.

SUBSIDIARY OF: Nutra Pharma Corp.

BUSINESS STRATEGY: NanoLogix is an R&D company which partners with multi-national corporations for product development

AGREEMENTS: Name Products Content of Agreement Date Brigham & Women's Hospital

Pseudomonas vaccine option agreement 1998

BioRemedial Technologies

bioremediation investment and licensing agreement

1998

RESEARCH & DEVELOPMENT: Technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials

PRODUCTS ON MARKET: M. tuberculosis M. avium (experimental use)

PRODUCTS IN DEVELOPMENT: Name Status M. tuberculosis field testing M. avium field testing Pseudomonus vaccine clinical stage Apoptosis (cancer tx) development stage



Nanophase Technologies Corp.

1319 Marquette Drive Romeoville IL 60446, US Phone: (630) 771-6700; Fax: (630) 771-0825 Web: www.nanophase.com E-mail: [email protected]

KEY PERSONNEL: Donald S. Perkins; Chairman Joseph Cross; CEO and President Jess Jankowski; CFO Richard W. Brotzman; VP, R&D Robert Haines; VP, Operations Daniel S. Bilicki; VP, Sales and Marketing Edward G. Ludwig; VP, Business Development


HISTORY: Founded in 1989 as a spinoff of Argonne National Labs

STOCK-FINANCIAL HISTORY: NASDAQ--NANX

IPO--$8/share (11/97) Revenue $6.802M (YE 05) compared to $5.208M (YE 04) Net loss <$5.384M> (YE 05) compared to <$6.447M> (YE 04) Loss per share <$0.30/share> (YE 05) compared to <$0.37/share> (YE 04) Average shares outstanding 17.938M (YE 05) compared to 17.266M (YE 04) Total assets $18.173M (YE 05) compared to $21.792M (YE 04)

BUSINESS STRATEGY: Provide nanoengineered solutions for multiple industrial product applications such as commercial quantity and quality nanoparticles, coated nanoparticles and nanoparticle dispersions in a variety of media. Sell intermediate products enabling high-value add customer applications. The company has major partnerships (including BASF, Rohm & Haas and BYK Chemie) exploiting broad applications expertise and global distribution channels.

AGREEMENTS: Name Products Content of Agreement Date Alfa Aesar (research chemicals unit of Johnson Matthey)

nanomaterials for research and development applications


10/05

Competitive Technologies

CT to identify nanotechnologies that may be synergistic with Nanophase’s technologies

option, evaluation, licensing and commercialization agreement

10/05

Roche Diagnostics

nanoparticles for a medical diagnostics application through 2014


PRODUCTS ON MARKET: Metal oxides Coated metal oxides Nanoparticle dispersions Custom synthesis



National Collection of Yeast Cultures (NCYC)

Institute of Food Research, Norwich Research Park, Colney Norwich NR4 7UA, UK Phone: (+44) 1603-255000; Fax: (+44) 1603-458414 Web: www.ncyc.co.uk; E-mail: [email protected]

KEY PERSONNEL: Ian N. Roberts, Ph.D.; Curator Chris J. Bond; Deputy Curator Stephen A. James, Ph.D.; Molecular Biologist Georgina A. Pope, Ph.D.; Molecular Biologist Robert Davey, Ph.D.; Bioinformaticist


HISTORY: Collection of more than 4,000 yeast cultures used in brewing, winemaking, biotechnology, and the food industry


SUBSIDIARY OF: IFR Enterprises, Ltd., the technology interaction company of the Institute of Food Research (see separate entry), a company limited by guarantee, grant-aided by the Biotechnology and Biological Sciences Research Council

BUSINESS STRATEGY: Supply the academic and industrial community with yeast cultures and yeast microbiological services

RESEARCH & DEVELOPMENT: Yeast genetics Identification methods Yeast biotechnological information databases

PRODUCTS ON MARKET: Catalog of cultures (yeast cultures) Safe deposit service Patent deposit service Online database Identification service

National Institute of Advanced Industrial Science and Technology (AIST)

1-1-1 Umezono, Tsukuba Ibaraki 305-8568, Japan Phone: +81 29 861 2298; Fax: +81 29 862 6148 Web: www.aist.go.jp; E-mail: [email protected]

KEY PERSONNEL: Dr. Hiroyuki Yoshikawa; President Kisaburo Kodama; Sr. VP


HISTORY: Formed from the amalgamation of 15 research institutes in April 2001

STOCK-FINANCIAL HISTORY: Publicly funded institution

BUSINESS STRATEGY: Pursue advanced research by exploring broad spectra of research fields and integrating multidisciplinary subjects to promote innovation in versatile fields that strengthen the competitiveness of Japanese industries in the world market and create new industries Pursue interdisciplinary and cross-disciplinary research that enables planning long-range governmental policies by exploiting the current and future needs of society Pursue basic research that maintains and strengthens competitiveness of national science and technology by developing and maintaining high standards of scientific and engineering research under the sole responsibility of AIST



RESEARCH & DEVELOPMENT: Life science and technology: Development of new technologies for drugs

and diagnostic agents based on post-genome research; promotion of neuroscience, human-technology and biomedical engineering for health maintenance/improvement; and research for new biofunctions/biomaterials and development of efficient biomaterial production technology Information technology: Research and development of ultra-high density optical storage technology; development of grid middleware; development of ultrafast optical switching technology using intersubband transition; practical application of model checking method to embedded software verification; success in fastest optical fiber quantum crypto transmission; development of porous silica low permittivity (low-k) insulator film; development of film-fabrication technologyfor high permittivity (high-k) gate insulatorfilm; development of miniaturization technology for ultrasonic 3-D tag for measurement of daily human activities; development of the first 4-terminal drive type XMOS-FET; development of technology for therapeutic application of Mental Commitment Robot 'PARO'; development of CONSORTS multiagent computing architecture; and development of application system using grid technology Nanotechnology, materials and manufacturing: Synthesis technology for single-walled carbon nanotubes; on-demand processing using micro-plasma; manufacture of active-targeting DDS nanoparticles; development of analysis method using microreactor; development of highest resolution magnetic force microscope; development of analytical electron microscope with the highest sensitivity; development of synthesis technology for large diamond single crystals; control of interface magnetism of strongly-correlated electron oxides; discovery of the Hall effect of light; elucidation of chemical reaction in supercritical water by computational science; development of room temperature coating technology for ceramic materials; ceramic sintering technology using centrifugal force; development of technology for large magnesium alloy components Environment and energy: Development of new decomposition/detoxification reaction processes for harmful substances, development of in-plant separation/concentration processes and environment-friendly alternative substances; development of distributed energy, including renewable energy, and energy networks, development of clean coal technology and biomass fuels and related application technologies; establishment of methods for estimating resources/energy utilization rates and hazardous substance risk, development of evaluation methods for global warming countermeasures and their social acceptability Geological survey and applied geoscience: Research on volcanoes and development of methods for survey/evaluation/control of soil contamination Metrology and measurement technology: Development and supply of measurement standards, including calibration of measurement instruments, as well as scientific research in metrology

National Institutes of Health (NIH)

Building 1, 1 Center Drive Bethesda MD 20892, US Phone: (301) 496-4000 Web: www.nih.gov E-mail: [email protected]

KEY PERSONNEL: Elias A. Zerhouni, M.D.; Director Raynard S. Kington, M.D., Ph.D.; Deputy Director Norka Ruiz Bravo, Ph.D.; Deputy Director, Extramural Research



Michael Gottesman, M.D.; Deputy Director, Intramural Research Colleen Barros; Deputy Director, Management and CFO



FACILITIES: NIH scientists conduct their research in laboratories located on the main campus in Bethesda, and in several field units across the country and abroad. The 870,000 sq. ft. Mark O. Hatfield Clinical Research Center opened in September 2004. The NIH also has facilities in the Rockville, Md., area and the NCI Frederick Cancer Research and Development Center (FCRDC) at Fort Detrick in Frederick, Md. The National Institute of Environmental Health Sciences' main facility is located in Research Triangle Park, N.C.. Other laboratory facilities include the NIH Animal Center in Poolesville, Md.; the National Institute on Aging's Gerontology Research Center in Baltimore, Md.; the Division of Intramural Research of the National Institute on Drug Abuse, also in Baltimore; the National Institute of Allergy and Infectious Diseases' Rocky Mountain Laboratories in Hamilton, Mt., and several smaller field stations.

STOCK-FINANCIAL HISTORY: Government agency FY 2004 Budget: $27.9b

SUBSIDIARIES/DIVISIONS: Office of the Director (OD)--The Office of the Director is the central office at NIH for its 27 Institutes and Centers. The OD is responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. OD's program offices include the Office of AIDS Research and the Office of Research on Women's Health, among others. National Cancer Institute (NCI)--Established in 1937, the NCI leads a national effort to reduce the burden of cancer morbidity and mortality. Its goal is to stimulate and support scientific discovery and its application to achieve a future when all cancers are uncommon and easily treated. Through basic and clinical biomedical research and training, NCI conducts and supports programs to understand the causes of cancer; prevent, detect, diagnose, treat, and control cancer; and disseminate information to the practitioner, patient, and public. National Eye Institute (NEI)--Established in 1968, the NEI conducts and supports research that helps prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages. NEI-supported research has advanced our knowledge of how the eye functions in health and disease. National Heart, Lung, and Blood Institute (NHLBI)--Established in 1948, the NHLBI provides leadership for a national program in diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Since October 1997, the NHLBI has also had administrative responsibility for the NIH. Woman's Health Initiative--The Institute plans, conducts, fosters, and supports an integrated and coordinated program of basic research, clinical investigations and trials, observational studies, and demonstration and education projects. National Human Genome Research Institute (NHGRI)--Established in 1989, the NHGRI supports the NIH component of the Human Genome Project, a worldwide research effort designed to analyze the structure of human DNA and determine the location of the estimated 30,000 to 40,000 human genes. The NHGRI Intramural Research Program develops and implements technology for understanding, diagnosing, and treating genetic diseases.



National Institute on Aging (NIA)--Established in 1974, the NIA leads a national program of research on the biomedical, social, and behavioral aspects of the aging process; the prevention of age-related diseases and disabilities; and the promotion of a better quality of life for all older Americans. National Institute on Alcohol Abuse and Alcoholism (NIAAA)--Established in 1970, the NIAAA conducts research focused on improving the treatment and prevention of alcoholism and alcohol-related problems to reduce the enormous health, social, and economic consequences of this disease. National Institute of Allergy and Infectious Diseases (NIAID)--Established in 1948, the NIAID research strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)--Established in 1986, the NIAMS supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases. National Institute of Biomedical Imaging and Bioengineering (NIBIB)--Established in 2000, the NIBIB improves health by promoting fundamental discoveries, design and development, and translation and assessment of technological capabilities in biomedical imaging and bioengineering, enabled by relevant areas of information science, physics, chemistry, mathematics, materials science, and computer sciences. National Institute on Deafness and Other Communication Disorders (NIDCD)--Established in 1988, the NIDCD conducts and supports biomedical research and research training on normal mechanisms as well as diseases and disorders of hearing, balance, smell, taste, voice, speech, and language that affect 46 million Americans. National Institute of Dental and Craniofacial Research (NIDCR)--Established in 1948, the NIDCR provides leadership for a national research program designed to understand, treat, and ultimately prevent the infectious and inherited craniofacial-oral-dental diseases and disorders that compromise millions of human lives. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)--Established in 1948, the NIDDK conducts and supports basic and applied research and provides leadership for a national program in diabetes, endocrinology, and metabolic diseases; digestive diseases and nutrition; and kidney, urologic, and hematologic diseases. Several of these diseases are among the leading causes of disability and death; all seriously affect the quality of life of those who have them. National Institute on Drug Abuse (NIDA)--Established in 1973, the NIDA leads the nation in bringing the power of science to bear on drug abuse and addiction through support and conduct of research across a broad range of disciplines and rapid and effective dissemination of results of that research to improve drug abuse and addiction prevention, treatment, and policy. National Institute of Environmental Health Sciences (NIEHS)--Established in 1969, the NIEHS reduces the burden of human illness and dysfunction from environmental causes by, defining how environmental exposures, genetic susceptibility, and age interact to affect an individual's health. National Institute of General Medical Sciences (NIGMS)--Established in 1962, the NIGMS supports basic biomedical research that is not targeted to specific diseases. NIGMS funds studies on genes, proteins, and cells, as well as on fundamental processes like communication within and between



cells, how our bodies use energy, and how we respond to medicines. The results of this research increase our understanding of life and lay the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also supports research training programs that produce the next generation of biomedical scientists, and it has special programs to encourage underrepresented minorities to pursue biomedical research careers. National Institute of Mental Health (NIMH)--Established in 1949, the NIMH provides national leadership dedicated to understanding, treating, and preventing mental illnesses through basic research on the brain and behavior, and through clinical, epidemiological, and services research. National Institute of Neurological Disorders and Stroke (NINDS)--Established in 1950, the mission of the NINDS is to reduce the burden of neurological diseases--a burden borne by every age group, every segment of society, and people all over the world. To accomplish this goal the NINDS supports and conducts research, both basic and clinical, on the normal and diseased nervous system, fosters the training of investigators in the basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders. National Institute of Nursing Research (NINR)--Established in 1986, the NINR supports clinical and basic research to establish a scientific basis for the care of individuals across the life span--from the management of patients during illness and recovery to the reduction of risks for disease and disability; the promotion of healthy lifestyles; the promotion of quality of life in those with chronic illness; and the care for individuals at the end of life. This research may also include families within a community context, and it also focuses on the special needs of at-risk and under-served populations, with an emphasis on health disparities. National Library of Medicine (NLM)--Established in 1956, the NLM collects, organizes, and makes available biomedical science information to investigators, educators, and practitioners and carries out programs designed to strengthen medical library services in the United States. Its electronic data bases, including MEDLINE and MEDLINEplus are used extensively throughout the world by both health professionals and the public. Center for Information Technology (CIT formerly DCRT, OIRM, TCB)--Established in 1964, the CIT incorporates the power of modern computers into the biomedical programs and administrative procedures of the NIH by focusing on three primary activities: conducting-computational biosciences research, developing computer systems, and providing computer facilities. Center for Scientific Review (CSR)--Established in 1946, the CSR is the focal point at NIH for the conduct of initial peer review, the foundation of the NIH grant and award process. The Center carries out peer review of the majority of research and research training applications submitted to the NIH. In addition, the Center serves as the central receipt point for all such Public Health Service (PHS) applications and makes referrals to scientific review groups for scientific and technical merit review of applications and to funding components for potential award. To this end, the Center develops and implements innovative, flexible ways to conduct referral and review for all aspects of science. John E. Fogarty International Center (FIC)--Established in 1968, the FIC promotes and supports scientific research and training internationally to reduce disparities in global health. National Center for Complementary and Alternative Medicine (NCCAM)--Established in 1992, the NCCAM is dedicated to exploring complementary and alternative medical (CAM) practices in the context of rigorous science; training CAM researchers and disseminating authoritative information.



National Center on Minority Health and Health Disparities (NCMHD)--Established in 1993, the mission of NCMHD is to promote minority health and to lead, coordinate, support, and assess the NIH effort to reduce and ultimately eliminate health disparities. In this effort NCMHD will conduct and support basic, clinical, social, and behavioral research, promote research infrastructure and training, foster emerging programs, disseminate information, and reach out to minority and other health disparity communities. National Center for Research Resources (NCRR)--Established in 1962, the NCRR advances biomedical research and improves human health through research projects and shared resources that create, develop, and provide a comprehensive range of human, animal, technological, and other resources. NCRR's support is concentrated in four areas: biomedical technology, clinical research, comparative medicine, and research infrastructure. Warren Grant Magnuson Clinical Center (CC)--Established in 1953, the CC is the clinical research facility of the National Institutes of Health. As a national resource, it provides the patient care, services, and environment needed to initiate and support the highest quality conduct of and training in clinical research.

SUBSIDIARY OF: NIH is an agency of the U.S. Department of Health and Human Services

BUSINESS STRATEGY: Provide leadership and direction to programs designed to improve the health of the nation by conducting and supporting research: in the causes, diagnosis, prevention, and cure of human diseases; in the processes of human growth and development; in the biological effects of environmental contaminants; in the understanding of mental, addictive and physical disorders; in directing programs for the collection, dissemination, and exchange of information in medicine and health, including the development and support of medical libraries and the training of medical librarians and other health information specialists NIH is the steward of medical and behavioral research for the nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability. The goals of the agency are as follows: 1) foster fundamental creative discoveries, innovative research strategies, and their applications as a basis to advance significantly the nation's capacity to protect and improve health; 2) develop, maintain, and renew scientific human and physical resources that will assure the nation's capability to prevent disease; 3) expand the knowledge base in medical and associated sciences in order to enhance the nation's economic well-being and ensure a continued high return on the public investment in research; and 4) exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.


Numerous NIH programs relating to grants, contracts, licensing, and collaborations

varied NIH sponsors various projects that support the extramural research community of more than 50,000 non-Federal scientists located at more than 1,700 universities, research institutions, and medical centers across the United States and abroad



RESEARCH & DEVELOPMENT: NIH is involved in hundreds of research projects, including:

GENOMICS Human Genome Project Human Sequence Databases Human Genetic Variation Cancer Diagnosis Genes and Aging Genes and Environment Gene Hunting for Schizophrenia and Manic-Depressive Illness Birth Defects and Inherited and Developmental Disorders Genes for Diabetes Genetics of Addiction Mouse Genome Mouse Mutants Genomes of Bacteria, Viruses, and Parasites ADVANCED TECHNOLOGIES Structural Genomics Toxic Chemicals New Organs and Tissues Repair and Replacement of Tissues of the Face and Head Drugs for Neurological Disorders Drug Addiction Understanding Alcohol Addiction Chemical Libraries Assistive Devices for the Visually Impaired DISEASE PREVENTION, DIAGNOSIS and TREATMENT Early Cancer Detection Alternative Cancer Therapies Treating Diabetes Blocking the Effects of Alzheimer's Disease Preventing and Treating Parkinson's Autism Centers of Excellence Treating Mental Illness in Children Ear Infections in Children Heart, Lung, and Blood Diseases Acute Stroke Centers AIDS Prevention and Treatment HIV Transmission to Infants Musculoskeletal Medicine Overcoming Salivary Gland Problems Drug Abuse Treatment Nicotine Addiction INTERDISCIPLINARY TRAINING AND COLLABORATIVE RESEARCH Computer Analysis of Biological Data Virtual Cell Research Women's Health Sex and Gender Differences in the Immune System Alcohol and the Brain HEALTH DISPARITIES Cancer Centers for Population Health Reducing Preterm Births. Reducing Sudden Infant Death Geographic and Racial Differences in Stroke Hepatitis C in Minority Populations Programs to Train Minority Scientists Clinical Research Training at Institutions That Serve Minorities Specialized Neuroscience Research Programs (SNRPs) at Minority Institutions Ensuring Access to Information Services Diabetes in Minority Populations



PRODUCTS ON MARKET: NIH research has contributed to numerous therapies, drugs, programs, innovations and diagnostics that address myriad health issues and conditions

PRODUCTS IN DEVELOPMENT: Name Status NIH research has contributed to the progress of many products and technologies that advance through the clinical development stages

National Research Council of Canada

1200 Montreal Road, Bldg. M-58 Ottawa K1A 0R6, Canada Phone: (613) 993-9101; Fax: (613) 952-9907 Toll-free phone: (877) NRC-CNRC (672-2672) Web: www.nrc-cnrc.gc.ca E-mail: [email protected]

KEY PERSONNEL: Dr. Pierre Coulombe; President Dr. Sherif Barakat; VP, Engineering Don T. Di Salle; VP, Corporate Services Patricia Mortimer; Acting VP, Technology and Industry Support Dr. Richard Normandin; VP, Physical Sciences Dr. Roman Szumski; VP, Life Sciences Marielle Piche; Acting Secretary General


HISTORY: Created by the Canadian government in 1916, NRC fulfills three main responsibilities: as a partner with industry in R&D; as a source of basic scientific and engineering strength for the national interest; and as a contributor to the development of the national science and technology infrastructure Member--Biotechnology Industry Organization


SUBSIDIARIES/DIVISIONS: NRC Plant Biotechnology Institute (NRC-PBI), Saskatoon, SK--plant cell biotechnology NRC Institute for Biological Sciences (NRC-IBS), Ottawa, ON--cell biology of neurodegenerative diseases; immunochemistry of vaccines; diagnostics; immunotherapeutics for human and veterinary applications NRC Biotechnology Research Institute (NRC-BRI), Montreal, PQ--seeks to exploit biotechnological processes in collaboration with Canadian industries NRC Institute for Marine Biosciences (NRC-IMB), Halifax, NS--marine plant biology and biochemistry NRC Institute for Biodiagnostics (NRC-IBD), Winnipeg, MB--research in developing more sophisticated diagnostic techniques NRC Institute for Nutrisciences and Health (NRC-INH), Charlottetown, PE-- naturally-occurring compounds to benefit human and animal health—impact of nutraceuticals and bioactives on neurologic, obesity-related disorders; and infection and immunity Fourteen other nonbiotech institutes nationwide Industrial Research Assistance Program Office--supports research in a number of Canadian industries, including biotechnology Canada Institute for Scientific and Technical Information (CISTI)

SUBSIDIARY OF: Government of Canada

INVESTMENTS: NRC's Biotechnology Program is a founding member of Genome Canada and contributes to Canadian innovation in genomics through the NRC Genome and Health Initiative (GHI), which was launched in 1999

BUSINESS STRATEGY: Enter into agreements with Canadian industries to facilitate creation of products



RESEARCH & DEVELOPMENT: All areas of science and technology, including biotechnology, plant

biotechnology, marine biosciences, molecular sciences, and microstructural sciences, either as active participants or as consultant/advisors Research areas include: Bioinformatics, environmental and sustainable development technologies, fuel cells, genomics, nanotechnology, photonics, nutraceuticals, proteomics

Nature Plus Inc.

555 Lordship Boulevard Stratford CT 06115, US Phone: (203) 380-0316; Fax: (203) 380-0358 Web: www.nature-plus.com E-mail: [email protected]

KEY PERSONNEL: Dr. Sheldon R. Murphy; President and CEO




BUSINESS STRATEGY: Expand current products into international sales

RESEARCH & DEVELOPMENT: Ingredients, concentrates

PRODUCTS ON MARKET: TerraZyme® soil stabilizer EcoCare® odor eliminator products NaturCare® cleaning and odor control products SAFE home products Pool and medical products

NatureWorks LLC

P.O. Box 5830 Minnetonka MN 55440-5830, US Phone: (989) 633-1746 Toll-free phone: (877) 423-7659 Web: www.natureworksllc.com

KEY PERSONNEL: Dennis McGrew; President and CEO Lisa Owen; Global Business Leader, Rigid Packaging


HISTORY: Founded in 1997 as Cargill Dow LLC, a 50:50 joint venture between Cargill and The Dow Chemical Co. Acquired completed by Cargill (1/05)

FACILITIES: Plant in Blair, Neb.


SUBSIDIARY OF: Cargill

BUSINESS STRATEGY: Produce and sell renewable-resource-based resin derived from the sugar found in common field corn

PRODUCTS ON MARKET: NatureWorks® PLA--bottles packaging, packaging for consumer goods,

food and serviceware Ingeo® fibers (www.ingeofibers.com)



Neogen Corp.

620 Lesher Place Lansing MI 48912-1595, US Phone: (517) 372-9200; Fax: (517) 372-2006 Toll-free phone: (800) 234-5333 Web: www.neogen.com E-mail: [email protected]

KEY PERSONNEL: James Herbert; Chairman and CEO Lon M. Bohannon; President and COO Richard R. Current; VP and CFO Edward L. Bradley; VP, Food Safety Sales and Marketing Kenneth Kodilla; VP, Manufacturing Joseph M. Madden, Ph.D.; VP, Scientific Affairs Anthony E. Maltese; VP, Corporate Development Terri A. Morrical; VP, Animal Safety Sales and Marketing Mark A. Mozola, Ph.D.; VP, R&D Paul S. Satoh, Ph.D.; VP, Basic and Exploratory Research


HISTORY: Founded in 1981 Began biotech research in 1982 Purchased WTT Inc. (now ELISA Technologies), a developer of immunoassay diagnostics for the equine and dog racing industries and research markets (9/92) Acquired plant diagnostics product lines of Quantix Systems (3/93) Purchased assets of Enzytec of Kansas City, MO (10/93) Acquired AMPCOR Diagnostics Inc. of Camden, NJ (8/94) Acquired International Diagnostic Systems' animal diagnostics product line (6/95) Acquired Triple Crown Veterinary Pharmaceuticals (7/97) Acquired assets of Vetoquinol U.S.A. (ImmunoVet products) (1/98) Acquired Acumedia (2000) Acquired Adgen Ltd. (3/03) Acquired Hacco Inc. and Hess & Clark (11/03) Acquired distribution business of BiologischeAnalysensysteme GmbH (BAG) (10/04) Acquired UCB's dairy antibiotic testing business (12/05) Acquired Centrus International Inc. (2/06)

FACILITIES: Headquarters in Lansing, Mich.

25,000 sq. ft. food safety diagnostic manufacturing facility near Lansing, Mich. 30,000 sq. ft facility for veterinary instruement operations in Lansing, Mich. 80,000 sq. ft. Animal Safety Division facility in Lexington, Ky.

STOCK-FINANCIAL HISTORY: NASDAQ--NEOG IPO--1.2M shares, $7.2M (10/89) Five-for-four stock split (12/03) Public offering--800K shares (6/06) Revenue $72.433M (YE 06) compared to $62.756M (YE 05) Net income $7.941M (YE 06) compared to $5.916M (YE 05) Earnings per share $0.92/share (YE 06) compared to $0.70/share (YE 05) Total assets $87.990M (YE 06) compared to $63.884M (YE 05)

SUBSIDIARIES/DIVISIONS: Food Safety Division Animal Safety Division Life Sciences Division Acumedia Neogen Europe Ltd.

BUSINESS STRATEGY: Become dominant company in the development and marketing of solutions for food and animal safety



AGREEMENTS: Name Products Content of Agreement Date CPI International Colitag water test

system distribution agreement

6/04

RESEARCH & DEVELOPMENT: Food and animal safety--all animals: mycotoxin diagnostics; Food Allergens; veterinary delivery instrument, microbiological tests and drug detection diay.

PRODUCTS ON MARKET: More than 200 diagnostic test kits, including: Agri-Screen® aflatoxin B1 diagnostic kit Agri-Screen® Ticket pesticide detection kit Agri-Screen® vomitoxin diagnostic kit Agri-Screen® nitrate diagnostic kit Agri-Screen® pH diagnostic kit Agri-Screen® triazine herbicide resistance test in weeds Agri-Screen® fumonisins diagnostic test Agri-Screen® ochratoxin diagnostic test Alert® for histamine Alert® for sulfites Ideal® line of veterinary instruments Bot Tox-B Clostridium botulinum type B vaccine Alert® disease detection kit ELISA Technologies® racing kits for detection of drugs of abuse in horses and dogs ELISA Technologies® research kits K-Blue Substrate® K-Gold™ Substrate Veratox® vomitoxin diagnostic kit Veratox® T-2 toxin diagnostic kit Veratox® aflatoxin quantitative diagnostic kit Veratox® zearalenone diagnostic kit Veratox®-AST aflatoxin single diagnostic test kit Veratox® for fumonisin quantitative diagnostic kit Ticket™ pesticide detector Reveal® for E. coli 0157:H7 Reveal® for Salmonella Reveal® BioPlate for E. coli Reveal® for listeria REVIVE media EqStim® ImmunoRegulin® MycAseptic™ MycAseptic E™

New Brunswick Scientific Co. Inc.

44 Talmadge Road Edison NJ 08817, US Phone: (732) 287-1200; Fax: (732) 287-4222 Toll-free phone: (800) 631-5417 Web: www.nbsc.com E-mail: [email protected]

KEY PERSONNEL: David Freedman; Chairman and CEO Jim T. Orcutt; President and COO Thomas E. Bocchino; VP, Finance and CFO Dr. Lee Eppstein; VP, Technology


HISTORY: Founded in 1946 by David and Sigmund Freedman Acquired RS Biotech Laboratory Equipment Ltd. (11/03)




STOCK-FINANCIAL HISTORY: NASDAQ--NBSC Second stock offering (1983) Net sales $67.616M (YE 05) compared to $62.124M (YE 04) Net <loss> income $2.494M (YE 05) compared to $1.931M (YE 04) Earnings <loss> per share <$0.28/share> (YE 05) compared to <$0.22/share> (YE 04) Average shares outstanding 8.959M (YE 05) compared to 8.741M (YE 04) Total assets $54.966M (YE 05) compared to $53.795M (YE 04)

SUBSIDIARIES/DIVISIONS: New Brunswick Scientific (U.K.) Ltd. (see separate entry) New Brunswick Scientific NV Kerkenbos 1101 6546 BC Nijmegen, The Netherlands Phone: +31 (0)24 3717 600; Fax: +31 (0)24 3717 640 E-mail: [email protected]; Web site: www.nbsc.com/bv New Brunswick Scientific GmbH In der Au 14 D-72622 Nurtingen, Germany Phone: +49 (0)7022-932490 Fax: +49 (0)7022-32486 E-mail: [email protected] Web site: www.nbsgmbh.de New Brunswick Scientific NV-SA Stationsstraat 180/4 B-3110 Rotselaar Belgie/Belgique Phone: +32 (0) 16 562 831 Fax: +32 (0) 16 572 753 E-mail: [email protected] New Brunswick Scientific SarL 12-14, Rond Point des Champs Elysees 75008 Paris, France Phone: +33 (0)1 53 53 15 11 Fax: +33 (0)1 53 53 15 57 E-mail: [email protected] New Brunswick Scientific Sales Office A903, 904 Yin Hai Building No. 250, Cao Xi Road Shanghai, 200235, China Phone: +86-21-64845955, +86-21-64845966 Fax: +86-21-64845933 E-mail: [email protected]

BUSINESS STRATEGY: Design, manufacture and market advanced systems for growth, detection and storage of cultures. Products include the world’s largest line of biological shakers and a full line of bench-to-production-scale fermentors and bioreactors used to produce therapeutic drugs, enzymes, biochemicals, antibiotics, vaccines and more. NBS also manufactures ultra-low temperature freezers, CO2 incubators, air samplers, automated media preparation equipment and roller drums.

PRODUCTS ON MARKET: Biological shakers (Innova® and Excella™)

Fermentation systems, bench-to- production-scale (BioFlo®) Spinners, Mammalian cell culture bioreactors, bench-to-production-scale (FibraStage Disposable Cell Culture System, Spinner Basket™, CelliGen Plus®, BioFlo®) Bioprocessing software (BioCommand®) Roller drums Air samplers (STA) Media sterilization and dispensing equipment (AgarMatic and PourMatic)



New England BioLabs Inc.

240 County Road Ipswich MA 01938-2723, US Phone: (978) 927-5054; Fax: (978) 921-1350 Toll-free phone: Ordering: (800) 632-5227; Technical Service: (800) 632-7799 Web: www.neb.com; E-mail: [email protected]

KEY PERSONNEL: James V. Ellard; CEO Richard J. Roberts, Ph.D.; CSO Elisabeth Raleigh, Ph.D.; Director, R&D



FACILITIES: State-of-the-art 140,000 sq. ft. research and production laboratory


SUBSIDIARIES/DIVISIONS: Organic synthesis division German, Canadian and U.K. subsidiaries

RESEARCH & DEVELOPMENT: Restriction and modification of DNA

Protein analysis and modifications Parasitic diseases

PRODUCTS ON MARKET: Restriction enzymes for DNA research, oligonucleotides, DNA synthesis kits Kits for molecular biology Protein modification/analysis reagents

New Horizons Diagnostics Corp.

9110 Red Branch Road Columbia MD 21045, US Phone: (410) 992-9357; Fax: (410) 992-0328 Web: www.nhdiag.com E-mail: [email protected]

KEY PERSONNEL: Lawrence Loomis; President David Trudil; VP and General Manager



FACILITIES: 14,000 sq. ft. facility in Columbia, Md.


AGREEMENTS: Name Products Content of Agreement Date Power3 Medical Products Inc.

antibody-based diagnostics for neurogenerative diseases


3/05

RESEARCH & DEVELOPMENT: Direct Salmonella and E. coli tests

Infectious disease diagnostics for the hospital lab and physician's office Bioluminescent probes technology for food, environment, biowarfare, water, and bioluminescence test for urinary infections Membrane strip technology for direct diagnostic tests, especially for antigen detection Develop tests for NASA and U.S. military Develop tests for detection of food- and water-borne pathogens



PRODUCTS ON MARKET: Gonogen II™ (N. gonorrhoeae) diagnostic test reagents using Mab Bioluminescence test for human, food, environmental, biowarfare Trust™--Syphilis detection test Smart II™--diagnostic kit for E. coli and Salmonella STD tests: GonoGen II and TRUST Cholera test kits Environmental testing Profile-1 bioluminescence test for detection of food, water, environment and human-borne pathogens Biowarfare detection kits

New Zealand Pharmaceuticals Ltd.

P. O. Box 1869, 68 Weld Street Palmerston North 4440, New Zealand Phone: +64 6-952-3800; Fax: +64 6-952-3801 Web: www.nzp.co.nz E-mail: [email protected]

KEY PERSONNEL: Dr. Richard Garland; Managing Director Andrew Lewis; General Manager Barry Old; Marketing and Technical Director Selwyn Yorke; Market Development Manager Michael Callagher; Commercial Manager



FACILITIES: Two pilot plants with a total area of 188 sq. m., one of which has explosion protected operations. Three factory and one more under construtcion.


INVESTMENTS: Just the Berries Ltd.--joint venture between NZP Holdings Ltd. and Just the Berries Holdings Ltd. (2/03)

BUSINESS STRATEGY: Manufacture plant and animal extracts for biotechnology, pharmaceutical and health food and cosmetics industries. Chemical synthesis of specialty carbohydrates and related compounds.

PRODUCTS ON MARKET: Peptones, cholic acid, deoxycholic acid, dehydrocholic acid, taurocholate,

glycocholate taurodeoxycholate, methyl cholate, bile salts, heparin, chiro-inositol, chondroitin sulphate, ferritin, pinitol, galactasomine, and acetylmannosamine, mannosamine, sialic acid, actinidin, evening primrose polyphenolic antioxidants, actinidin, cartilage products.

PRODUCTS IN DEVELOPMENT: Name Status Carbohydrates in pilot plant Blackcurrant extracts in pilot plant

Nigu Bioselect

Beuthener Strasse 2 Waldkraiburg D-84478, Germany Phone: +49 86 38-962-0; Fax: +49 86 38-962-287 Web: www.nigu.de E-mail: [email protected]

KEY PERSONNEL: Dr. Klaus Engel; Chairman, Degussa Joachim Semel, Ph.D.; Managing Director, Nigu Chemie




HISTORY: Chemische Werke LOWI founded in 1947 Spun off NIGU Chemie (1964) NIGU Chemie acquired by SKW Trostberg AG (from 1987 to 1991) Became a subsidiary of Degussa AG when SKW Trostberg AG merged with Degussa-Huls AG

FACILITIES: State-of-the-art, GMP-conform production facilities for ultrapure guanidine salts and a worldwide unique recycling plant for guanidine-containing process waste


SUBSIDIARIES/DIVISIONS: Nigu Bioselect is a business area of Nigu Chemie GmbH

SUBSIDIARY OF: Degussa AG

BUSINESS STRATEGY: Develop, produce and distribute fine and biochemicals for the pharmaceutical, diagnostic and life science industry

PRODUCTS ON MARKET: Ultrapure guanidine hydrochloride

Ultrapure guanidine thiocyanate Guanidine und derivatives Recycling of guanidine containing process waste

Nippon Kayaku Co. Ltd.

Tokyo Fujimi Bldg., 11-2, Fujimi 1 chome, Chiyoda-ku Tokyo 102-8172, Japan Phone: +81 3-3237-5046; Fax: +81 3-3237-5081 Web: www.nipponkayaku.co.jp E-mail: [email protected]

KEY PERSONNEL: Koichiro Shimada; President Masao Komaki; Director, Functional Chemicals Group Akira Mandai; Director, Pharmaceuticals Group Yoshiyuki Ikeda; General Manager, Safety Systems Division Yoshiaki Fukushima; Director, Fine Chemicals Group Hidetoshi Kitazawa; Director, Strategic Corporate Planning Group and Director, R&D Group Koichi Chiba; Director, Administration Group Koichi Takase; President, Polatechno Co. Ltd.


HISTORY: Established in June 1916 Began biotech research in 1980 Formed Kayaku Asta Medica, joint venture with Asta Medica AG, to develop the anticancer drugs Cetrorelix and D21266 (6/95)

FACILITIES: Plants located in Tokyo, Takasaki, Kasima, Fukuyama, Asa, and Himeji; plus four laboratories Biotech production facility located at Takasaki plant

STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange Net sales ¥134.205b (YE 05) compared to ¥128.016b (YE 04) Net income ¥5.315b (YE 05) compared to ¥3.926b (YE 04) Earnings per share ¥28.87/share (YE 05) compared to ¥21.22/share (YE 04)

SUBSIDIARIES/DIVISIONS: Organizaton: Strategic Corporate Planning Group Administration Group Technical Operations Group Research & Development Group: Research & Development Planning Division, Intellectual Property Division, Functional Chemicals R&D Laboratories, Pharmaceuticals Laboratories, Safety Systems Development Laboratories, Agrochemicals Laboratories



Functional Chemicals Group: Functional Materials Division, Electronic Materials Division, Catalysts Division Pharmaceuticals Group: Pharmaceuticals Marketing Division, Specialty Chemicals & Diagnostics Division, Regulatory Affairs Division, Pharmaceuticals Technical Operations Division, Pharmaceuticals Development Division, Licensing Division Fine Chemicals Group: Agrochemicals Division, Color Chemicals Division, Explosives Division Group companies: Functional Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon Kayaku Tokyo Co. Ltd., Nippon Kayaku Fukuyama Co. Ltd., Tomusu Co. Ltd., Naigai Nikka Co. Ltd., Nippon Kayaku (Taiwan) Co. Ltd., Kayaku Chemical (Wuxi) Co. Ltd., Itabashi Chemical Ind. Co. Ltd., Polatechno Co. Ltd., Nippon Kayaku America Inc., Kayafloc Co. Ltd., Wuxi Polatechno Optics Co. Ltd., Moxtek Inc., Polatechno (Hong Kong) Co. Ltd., Kayaku MicroChem Corp., Dejima Tech BV, Dejima Optical Films BV, Minoshima Sangyo Co. Ltd. Fine Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon KayakuTokyo Co. Ltd., Nippon Kayaku Fukuyama Co. Ltd., Naigai Nikka Co. Ltd., N.S. Color Techno Co. Ltd., Shinwa Sangyo Co. Ltd., Sanko Kagaku Kogyo Co. Ltd., Dalian Advanced Chemical Co. Ltd., Hokuyou Kayaku Co. Ltd., Zhaoyuan Advanced Chemical Co. Ltd., Wuxi Advanced Kayaku Chemical Co. Ltd., Kayatech Co. Ltd., Techno Green Co. Ltd., P.T. Petrokimia Kayaku, Shikoku ANFO Inc. Pharmaceuticals Group: Nac Co. Ltd., Gunnan Sangyo Co. Ltd., Euro Nippon Kayaku GmbH, Nippon Kayaku (Taiwan) Co. Ltd., Nippon Kayaku America Inc., JHMS Corp., Nanotherapy Co. Ltd., Kayaku Zentaris Co. Ltd., Nippon Kayaku Food Techno Co. Ltd., Nippon Kayaku MedicalCare Co. Ltd., Nippon Kayaku Medinet Co. Ltd., Naigai Nikka Co. Ltd. Safety Systems Division: Toyotomi Kogyo Co. Ltd., Indet Safety Systems AS, LifeSparc Inc., NKNM Ltd. Other Businesses: Wako Toshi Kaihatsu Co. Ltd., Tocos Co. Ltd., Okiura Golf Center Co. Ltd., Nikos Co. Ltd., Kayaku Akzo Corp.

BUSINESS STRATEGY: Maintain a strong focus on markets and customers, and rapidly execute business strategy for targeting niche markets by utilizing a fusion of technologies within and beyond the company. Based on this basic strategy, Nippon Kayakyu has identified three growth fields: information/communications, health care, and safety systems

AGREEMENTS: Name Products Content of Agreement Date Astellas Pharma Inc.

Gelpart exclusive licensing agreement

2/05

Axiom Biotechnologies Inc./Zaiya Inc.

small-molecule cancer drugs

research agreement--Axiom to receive research funding for three years, license fees, milestones and royalties, Nippon Kayaku gains Asian marketing and manufacturing rights and options for other territories outside North America

11/97

National Cancer Center (Japan)

MAbs for stomach cancer diagnostics


Pasteur Merieux Connaught Canada (now Sanofi Pasteur)

BCG vaccine for bladder cancer


9/95



Research Development Corp. of Japan (JRDC)

anticancer drug-carrier complex for missile therapy

¥1b commercialization agreement

11/90

Signal Pharmaceuticals Inc.

small molecule NGF mimetics for neuropathy

R&D agreement 2/98

Silenus Laboratories

hemoglobin-specific MAb for GI cancer diagnosis

licensing and supply agreement

1988

SunPharm Corp. diethylnorspermine for cancer

exclusive development and marketing rights in Japan

3/94

RESEARCH & DEVELOPMENT: Development of cancer-related products Fusing technologies from within and beyond the company to accelerate the development of a broad range of anti-cancer drug products Development of a drug delivery system in which an anti-cancer drug is contained inside nano-size polymer micelles Development of anti-cancer drugs that are effective against hormone-dependent cancer Development of heat immunotherapy, in which heat is used to treat cancer

PRODUCTS ON MARKET: Epoxy resins (EOCN-1020, EPPN-500, NC-3000, BREN)

Hardeners for epoxy resins (Kayahard) Photo-curing resins (Kayarad, Kayamer, Kayacure) Polyamide/polyimide resins Polymer flocculants (Kayafloc) acrylic acids, methacrylic acids and other catalysts used in manufacturing Anti-cancer and cancer-related drugs: Calsed, Epirubicin, IA Call, Oncovin, Exal, Carbomerck, Immucyst, Hycamtin®, MS-Twicelon, Coforin, Fareston, Odyne, Starasid, Pinorubin, Lastet, Bestatin, Randa, Pepleo, Bleo Immunosuppressants: Spanidin Cardiovascular Drugs: Millisrol, Adehl, Millistape, Nitropen Tablets, Nitroglycerine Tablets Neurological Drugs: Saligren, Muscalm Other Drugs: Astric Dry Syrup Diagnostic Agents: Lana Mammo Card CEA, Lana TP Auto, Lana 1.5AG Auto Liquid, Lanazyme BFP Plate, Lanazyme ST-439 Plate Active pharmaceutical ingredients and intermediates Agrochemicals: Diazinon, Matric, Safrotin, Evisect, Cyclosal, MCPB, Chloropicrin, Cucumeris, Ratden, Simetryn, Chlorpic-Flow Color chemicals: Kayalon Polyester, Kayacryl-ED, Kayacelon React, Kayarus, Kayacion, Kayaaffect, Kayaphor Liquid, Kayaset Explosives: Dynamite, slurried explosives, ammonium nitrate fuel oil explosive (ANFO explosive), black powder, electric detonators

Nitto Denko Corp.

2-5-25, Umeda, Kita-ku Osaka 530-0001, Japan Phone: +81 726-22-2981; Fax: +81 726-26-1505 Web: www.nitto.com; E-mail: [email protected]

KEY PERSONNEL: Masamichi Takemoto; CEO and COO Yukio Nagira; Deputy COO Yasuo Ninomiya; CTO



Tatsunosuke Fujiwara; CFO Wataru Kitao; CSO


HISTORY: Founded in October 1918 as Nitto Electric Industrial Co. Ltd. Formed Nitto Denko America Inc. (1969) Formed Nitto Europe N.V. (1974) Formed Nitoms Inc. (1975) Acquired Acquires Hydranautics (1987) Acquired Permacel (1988) Acquired Graphic Technology Inc. (1989) Formed Jinsec Corp. (1990) Formed Nitto Medical Corp. and Nitto Lifetec Corp. (1996) Formed Nitto Shinko Corp., Nitto Denko Material (Thailand) Co. Ltd. and P.T. Nitto Materials Indonesia (1997) Formed Nitto Denko Packaging System Corp., Nitto Denko Vietnam Co. Ltd. and Korea Nitto Optical Co. Ltd. (1999) Formed Nitto Americas Inc., Mie Nitto Denko Corp., Nitto Denko Himawari Corp., Korea Nitto Denko, Nitto Denko Matex Corp. and Nitto Denko Technical Corp. (2000) Formed Nitto Denko Tape Materials (Vietnam) Co. Ltd., Nitto Denko Philippines Corp. and Nitto Denko (Suzhou) Co. Ltd. (2001) Formed Nitto Electronics kyusyu Corp. and Aichi Nitto Denko Corp. (2002) Acquired Elan Transdermal Technologies Inc. (2003) Formed Kinovate Life Siences Inc. and Nitto Denko Fine Circuit Technology Co. Ltd. (2004) Formed Optmate Corp., Nitto Denko (Tianjin) Co. Ltd. and Shanghai Nitto Optical Co. Ltd. (2005)

FACILITIES: Plants in Tohoku, Kanto, Toyohashi, Kameyama, Shiga and Onomichi

STOCK-FINANCIAL HISTORY: Traded on the Tokyo and Osaka stock exchanges IPO--1962 Net sales ¥626.316b (YE 06) compared to ¥514.867b (YE 05) Net income ¥55.306b (YE 06) compared to ¥41.842b (YE 05) Earnings per share ¥332.30/share (YE 06) compared to ¥252.72/share (YE 05) Total assets ¥556.934b (YE 06) compared to ¥443.264b (YE 05)

SUBSIDIARIES/DIVISIONS: Japan: Nitto Shinko Co. Ltd. Nitto Denko CS System Corp. Nitoms Inc. Kyoshin Co. Ltd. Nissho Corp. Nitto Denko Matex Co. Ltd. East Asia: Nitto Denko (China) Investment Co. Ltd. Nitto Denko (Shanghai Songjiang) Co. Ltd. Nitto Denko (Shanghai Pu Dong New Area) Co. Ltd. Nitto Denko (Suzhou) Co. Ltd. Nitto Denko Xiamen Co. Ltd. Nitto Denko (HK) Co. Ltd. Nitto Denko Materials (Shenzhen) Co. Ltd. Shanghai Nitto Optical Co. Ltd. Nitto Denko (Taiwan) Corp. Taiwan Nitto Optical Co. Ltd. KoreaNitto Denko Co. Ltd. Korea Nitto Optical Co. Ltd. South Asia: Nitto Denko (Singapore) Pte. Ltd. Nitto Denko Electronics (Malaysia)Sdn. Bhd. Nitto Denko Materials (Malaysia) Sdn. Bhd. Nitto Denko Material (Thailand) Co. Ltd.



Nitto Denko Vietnam Co. Ltd. Nitto Denko Tape Materials (Vietnam) Co. Ltd. Nitto Denko Philippines Corp. PT Nitto Materials Indonesia Nitto Denko (Australia) Pty. Ltd. Europe: Nitto Europe NV Nitto U.K. Ltd. Nitto France Sarl Nitto Deutschland GmbH Nitto Scandinavia AB Nitto Italia SRL Nitto Polska SP Zoo U.S. Nitto Americas Inc. Nitto Denko America Inc. Permacel Permacel Automotive Inc. Hydranautics Aveva Drug Delivery Systems Inc. Nitto Denko Technical Corp.

AGREEMENTS: Name Products Content of Agreement Date Eisai Corp. transdermal adhesive

preparation of Aricept joint develop agreement

5/06

PRODUCTS ON MARKET: Industrial products: Double-coated adhesive tapes, surface-protection films,

advanced sealing materials Electronics products: Polarizing films, retardation films, polarization conversion films, semiconductor encapsulating resins, thin metal core boards for MR heads, protection sheet and laminating device applicator for semiconductor wafer processing Functional products: Transdermal therapeutic patches, surgical tapes, tissue-cultured ginseng, high-polymer separation membrane modules, fluoroplastic porous films, fluoroplastic adhesive tapes

Norac Technologies Inc.

Edmonton Research Park, 9110-23 Avenue Edmonton T6N 1H9, Canada Phone: (403) 414-9595; Fax: (403) 450-1016 Web: www.noractech.com E-mail: [email protected]

KEY PERSONNEL: Dr. D. A. Evans; President Jaime Calderon; Head, R&D



FACILITIES: Supercritical Fluid Extraction Plant--20,000 sq. ft. facility


SUBSIDIARY OF: Newly Weds Foods Co.

BUSINESS STRATEGY: Develop and manufacture natural botanicals and biological extractives with companies from the food, beverage, cosmetic, and pharmaceutical industries, commercial extraction available

RESEARCH & DEVELOPMENT: Supercritical extraction/fractionation of natural materials; separations;

flavors; antioxidants; biologicals; and process development, design, and commercialization



PRODUCTS ON MARKET: Fractionated spice oleoresins SC, broad spectrum essential oils SC, food colorants SC, natural rosemary antioxidants SC, natural vanilla extracts SC, fractionated cereal oils, de-fatted cereal germs, brans and flours, low-fat/low-cholesterol egg powders, nutriceutical oils, botanical gums and beta-glucans, de-caffeinated tea and coffee, hops resins and oils Services: Proprietary product manufacturing, toll processing, SFE product and process development, system design and scale-up, laboratory analytical services, biomass recoveries, cryogenic grinding, drying (vacuum and freeze), homogenization, product formulating and packaging, economic modeling and costings, marketing of SFE products

North Carolina Biotechnology Center

P.O. Box 13547, 15 T.W. Alexander Drive Research Triangle Park NC 27709-3547, US Phone: (919) 541-9366; Fax: (919) 990-9544 Web: www.ncbiotech.org E-mail: [email protected]

KEY PERSONNEL: Leslie M. Alexandre, Ph.D.; President and CEO Ken Tindall, Ph.D.; Sr. VP, Science and Business Development John Richert; VP, Business and Technology Development William O. Bullock; Bioscience Industrial Development Director Cynthia J. Sollod, Ph.D.; Bioscience Industrial Development Specialist John Richert; VP, Business and Technology Development Rob Lindberg, Ph.D.; Technology Development Director Steven Casey; Business Development Director Steven Burke; Sr. VP, Corporate Affairs Lori Greenstein; Sr. VP, Corporate Administration and CFO


HISTORY: Established as a non-profit organization in 1984 by State of North Carolina as the United States' first statewide initiative in biotechnology Member--Biotechnology Industry Organization

FACILITIES: Located in Research Triangle Park, N.C. 47,000 sq. ft., $6M headquarters, including 22,000 sq. ft. program management center, 2,000 sq. ft. library, and 19,000 sq. ft. conference and education facility, on 120-acre campus Regional offices in Asheville, Winston-Salem, Greenville, and Wilmington, N.C.


BUSINESS STRATEGY: Mission: The North Carolina Biotechnology Center provides long-term economic and societal benefits to North Carolina by supporting biotechnology research, business and education statewide Goals: 1. Strengthen North Carolina's academic and industrial biotechnology research capabilities 2. Foster North Carolina's biotechnology industrial development 3. Work with business, government and academia to move biotechnology from research to commercialization in North Carolina 4. Inform North Carolinians about the science, applications, benefits and issues of biotechnology 5. Enhance the teaching and workforce-training capabilities of North Carolina's educational institutions 6. Establish North Carolina as a preeminent international location for the biotechnology industry



RESEARCH & DEVELOPMENT: The center does not conduct laboratory research, but supports and funds biotechnology R&D at the state's universities, institutions, and biotechnology companies through grants programs and low-interest loan programs.

NOVA Chemicals Corp.

1000 Seventh Avenue S.W., P.O. Box 2518 Calgary T2P 5C6, Canada Phone: (403) 750-3600 Web: www.novachem.com E-mail: [email protected]

KEY PERSONNEL: J.E. (Ted) Newell; Chairman Jeffrey M. Lipton; CEO and President Larry A. MacDonald; Sr. VP and CFO Christopher D. Pappas; Sr. VP and President, Styrenics Dale H. Spiess; Sr. VP and President, Olefins/Polyolefins John L. Wheeler; Sr. VP and CIO Albert Terrence Poole; Exec. VP, Corporate Strategy and Development


HISTORY: NOVA Corp. of Alberta was incorporated in 1954

Acquired Polysar Energy & Chemical Corp. (9/88) Acquired the styrenics business of ARCO Chemical Co. (9/96) Merged with TransCanada PipeLines Ltd. (7/98) Acquired the majority of Huntsman Corp.’s U.S. and European styrenics businesses (12/98) Changed name to NOVA Chemicals Corp. (1/99) Acquired the European polystyrene and EPS assets, Chilean EPS production and molding assets and associated worldwide sales and marketing operations of The Shell Petroleum Co. Ltd. (1/00) Sold its interest in the Alberta Ethane Gathering System to Fort Chicago Energy Partners LP (12/04) Formed Novidesa SA de CV, a 50:50 joint venture in Mexico Grupo Idesa (10/05) Merged its European styrenic polymers business into a 50:50 joint venture (called NOVA Innovene) with Innovene (the commodity chemicals business of BP plc) (10/05)

FACILITIES: NOVA Chemicals Research & Technology Center--Calgary, Alberta, Canada NOVA Chemicals Technical Center--Calgary, Alberta, Canada Demonstration plant for Advanced SCLAIRTECH technology--Corunna, Ontario, Canada

STOCK-FINANCIAL HISTORY: NYSE/TSX--NCX Revenue $5.616b (YE 05) compared to $5.270b (YE 04) Net <loss> income <$104M> (YE 05) compared to $252M (YE 04) Earnings <loss> per share <$1.26/share> (YE 05) compared to $2.91/share (YE 04) Average shares outstnading 82.4M (YE 05) compared to 84.8M (YE 04) Total assets $5.217b (YE 05) compared to $5.047b (YE 04)

PRIVATE PLACEMENTS: Raised $400M in private placement of senior floating rate notes due in 2013 (10/05)

SUBSIDIARIES/DIVISIONS: Two plastics and chemicals businesses: Olefins/polyolefins, which produces ethylene, polyethylene and a variety of chemical and energy products (commonly known as co-products), and styrenics, which produces styrene monomer, polystyrene and expandable polystyrene (EPS)



Subsidiaries: NOVA Chemicals (Canada) Ltd./NOVA Chimie (Canada) Lt´ee--Canada NOVA Chemicals Inc.--Delaware, U.S. NOVA Chemicals (International) SA--Switzerland Novacor Chemicals Investments BV--The Netherlands NOVA Chemicals Quimica Holdings SL-Spain NOVA Investments (U.S.) Inc.--Delaware, U.S. NOVA Petrochemicals Ltd.--Alberta, Canada

BUSINESS STRATEGY: Produce plastics and chemicals that are essential to everyday life, with a focus on two product chains: ethylene and polyethylene, and styrene and polystyrene

RESEARCH & DEVELOPMENT: Two internally developed technologies for the production of polyethylene—

Sclairtech technology and Advanced Sclairtech technology. NOVA Chemicals also conducts R&D on other polyethylene technologies including gas-phase and high pressure technology In 2005, the company focused on the development and commercialization of Performance Products using Advanced Sclairtech technology NOVA Chemicals has developed three proprietary families of catalyst technology: A family of single-site catalysts for Advanced Sclairtech and other polymer technologies including gas-phase polyethylene; A family of catalysts including Z-N catalysts used for Sclairtech technology and Advanced Sclairtech technologies; and the Novacat family of catalysts for use in gas-phase polyethylene The company owns or has the rights to a portfolio of styrenics technology, in the fields of polymer production and styrenics polymer applications

PRODUCTS ON MARKET: Arcel®: High-performance, moldable foam resin Dylark®: Automotive engineering resins Dylark® FG: High-heat styrenic copolymer Surpass®: Performance film, rotational molding & thin-wall injection molding resins Zylar® EX: Low-temperature, clear acrylic copolymer Sclair®, Novapol® and high-performance Surpass® resins Solid polystyrene (SPS) Expandable polystyrene (EPS)

NovaSep Process

Site Eiffel Boulevard de la Moselle, B.P. 50 Pompey F- 54340, France Phone: +33 3 83 49 70 00; Fax: +33 3 83 49 70 02 Web: www.novasep.com E-mail: [email protected]

KEY PERSONNEL: Thierry Faureau; CEO Jean Blehaut; President


HISTORY: Founded in 1995 Changed name from Separex (1995) Changed name from Separex Chromatographie (1996) Acquired Prochrom S.A. (2000) Acquired Seripharm (2003) Acquired Applexion and Orelis (2004)

FACILITIES: 7,280 sq. m. headquarters and industrial plant


SUBSIDIARIES/DIVISIONS: NovaSep Inc.--Boothwyn, Pa. NovaSep Japan KK--Tokyo, Japan NovaSep Asia--Shanghai, China



SUBSIDIARY OF: Groupe Novasep

PRINCIPAL INVESTORS: Rockwood

BUSINESS STRATEGY: We are a specialist in solving purification and separation needs for the life science industry, from laboratory to large industrial production. Our fields of activities include: Process and product development, systems and APIs.

RESEARCH & DEVELOPMENT: Process modelling and optimisation (chromatography, crystallization,

membranes, adsorption, ion exchange, etc.) Process development Process integration (chromatography / adsorption / crystallization / distillation-evaporation / membranes, etc.) Custom purification of APIs and intermediates in clinical phase Custom synthesis (gram to kilogram) Purification of intermediates and APIs Production of intermediates and APIs Cytotoxic expertise

PRODUCTS ON MARKET: High, medium and low pressure Batch preparative chromatography in liquid and supercritical phase High, medium and low continuous chromatography Adsorption and ion exchange Membranes (micro, nano and ultrafiltration) Evaporation and crystallization

november AG

Ulrich-Schalk-Str. 3 Erlangen 91056, Germany Phone: +49 (0) 9131 750 88 0; Fax: +49 (0) 9131 750 88 99 Web: www.november.de E-mail: [email protected]

KEY PERSONNEL: Dr. Wolf M. Bertling; CEO Alexander G. Offer; CFO Astrid Dickert; CFO


HISTORY: Founded in 1996 Began biotech R&D in 1997 Holding since the end of 2003

FACILITIES: 1,800 sq. m. headquarters 1,300 sq. m. R&D facility (offices of R&D included) 500 sq. m. administration facility

STOCK-FINANCIAL HISTORY: Traded on the Frankfurt Stock Exchange--NBX IPO--(4/00) Traded in segment Prime Standard (since 03/03) Revenue EUR5.586M (YE 04) compared to EUR4.424M (YE 03) Net loss <EUR2.139M> (YE 04) compared to <EUR2.817M> (YE 03) Loss per share <EUR0.29/share> (YE 04) compared to <EUR0.41/share> (YE 03) Average shares outstanding 7.468M (YE 04) compared to 6.860M (YE 03) Total assets EUR27.682M (YE 04) compared to EUR28.646M (YE 03)

SUBSIDIARIES/DIVISIONS: identif GmbH directif GmbH responsif GmbH PEQLAB Biotechnologie GmbH--51%

PRINCIPAL INVESTORS: Dr. Wolf M. Bertling--8.03% Jupiter Technologie GmbH&Co. KGaA--10.31%



BUSINESS STRATEGY: Continue to build on our technological lead in the area of biotechnology and nanotechnology and in the long term to become market leader in the areas of our core competencies. Alone or with competent partners and strategic alliances, we will occupy market niches and develop new markets. The products of november AG are needed worldwide.

RESEARCH & DEVELOPMENT: Labeling/tracing

Product authentication DNA diagnostics Product security and brand protection

PRODUCTS ON MARKET: Molecular fingerprint (DNA codes) and nano-optical seal (cluster codes)= novel marking systems for brand protection & product security

PRODUCTS IN DEVELOPMENT: Name Status Biological eartag: bioactive labeling of livestock

in development

System for fully automated, rapid and laboratory-independent nucleic acid testing

in development

Immune therapies for a variety of medical indications

in clinicals

Noven Pharmaceuticals Inc.

11960 S.W. 144th Street Miami FL 33186, US Phone: (305) 253-5099; Fax: (305) 251-1887 Web: www.noven.com

KEY PERSONNEL: Robert C. Strauss; Chairman, President and CEO Diane M. Barrett; VP and CFO Jeffrey Eisenberg; Sr. VP, Strategic Alliances Juan Mantelle; VP and CTO W. Neil Jones; VP, Sales and Marketing


HISTORY: Incorporated in 1987

FACILITIES: 15-acre facility in Miami-Dade County consisting of multiple buildings totaling 150,000 sq. ft.

STOCK-FINANCIAL HISTORY: NASDAQ--NOVN; Trading halted--12/05 IPO--2.25M shares of common stock (1988) Secondary public offering--2.749M shares of common stock at $7/share (4/92) Revenue $52.532M (YE 05) compared to $45.891M (YE 04) Net income $9.972M (YE 05) compared to $11.224M (YE 04) Earnings per share $0.42/share (YE 05) compared to $0.48/share (YE 04) Average shares outstanding 23.665M (YE 05) compared to 23.332M (YE 04) Total assets $185.910M (YE 05) compared to $201.975M (YE 04)

PRIVATE PLACEMENTS: Raised $800K in private sale of 589K shares of common stock (7/91)

SUBSIDIARIES/DIVISIONS: Novogyne Pharmaceuticals--a women’s health products company jointly owned by Noven and Novartis Pharmaceuticals Corp.

BUSINESS STRATEGY: Maintain a position as a leader in the development of advanced drug delivery technologies, while concurrently striving to become the world’s premier transdermal drug delivery company, through development of a series of groundbreaking products



AGREEMENTS: Name Products Content of Agreement Date Aventis S.A. transdermal

combination estrogen/progestogen system

worldwide licensing agreement (except Canada, US and Japan)

10/99

Endo Fentanyl transdermal delivery system

licensing agreement

2/04

Novartis AG first-generation transdermal estrogen delivery system

co-promotion joint venture with Novogyne

5/98

Novartis AG second-generation transdermal estrogen delivery system

co-promotion joint venture with Novogyne

5/99

P&G Pharmaceuticals Inc.

transdermal delivery system for HSDD


4/03

Shire plc Daytrana (transdermal methylphenidate delivery system) for ADHD


6/02

RESEARCH & DEVELOPMENT: Transdermal and transoral drug delivery systems in development for wide array of drugs

PRODUCTS ON MARKET: Vivelle-Dot™ (second-generation estradiol transdermal system) for

postmenopausal women. World’s smallest estrogen patch. DentiPatch™ lidocaine transoral delivery system, on market in U.S. Vivelle® Menorest® (first-generation estradiol transdermal system) Menorest® advanced transdermal estrogen patch (Europe and elsewhere) CombiPatch® (estradiol/norethindrone acetate) combination estrogen/progestogen patch Estradot® (estradiol transdermal system) world's smallest transdermal estrogen patch (Europe & elsewhere) Estalis®

Novozymes A/S

Krogshoejvej 36 Bagsvaerd 2880, Denmark Phone: +45 88-249999 Web: www.novozymes.com

KEY PERSONNEL: Steen Riisgaard; President and CEO Per Falholt; Exec. VP and CSO Per Mansson; Exec. VP and CFO Peder Holk Nielsen; Exec. VP, Business Operations Arne W. Schmidt; Exec. VP, Development, Production and Quality Anna Lise Mortensen Grandjean; VP, Stakeholder Communications and Sustainability Development Mette Vestergaard; VP, People and Organisation


HISTORY: Spun off from Novo Nordisk A/S in November 2000 Acquired Delta Biotechnology Ltd. from Sanofi-Aventis (7/06) To acquire GroPep Ltd. (as of 8/06)

FACILITIES: Production facilities in Denmark, Sweden, China, North America and South America R&D, production and administration facility in Denmark Research facilities in North America, China and Japan



STOCK-FINANCIAL HISTORY: Listed on the Copenhagen Stock Exchange Sales DKK6.281b (YE 05) compared to DKK5.988b (YE 04) Net profit DKK861M (YE 05) compared DKK775M (YE 04) Earnings per share DKK13.11/share (YE 05) compared to DKK11.19/share (YE 04) Total assets DKK7.309M (YE 05) compared to DKK7.076b (YE 04)

SUBSIDIARIES/DIVISIONS: Austria: Novozymes Austria GmbH Australia: Novozymes Australia Pty. Ltd. Belgium: Novozymes Belgium BV Brasil: Novozymes Latin America Ltda. Denmark: Novozymes Bioindustrial China A/S, Novozymes Bioindustrial Russia A/S, Novozymes Bioindustrial A/S France: Novozymes France SA, Novozymes Biologicals France SA The Netherlands: Novozymes Netherlands BV India: Novozymes South Asia Pvt. Ltd. Italy: Novozymes Italia Srl. Japan: Novozymes Japan Ltd., Novozymes Biologicals Japan Ltd., Novozymes Property Ltd. China: Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Bioprocessing Co. Ltd., Suzhou Hongda Enzyme Co. Ltd. (joint venture) Malaysia: Novozymes Malaysia Sdn. Bhd. Mexico: Novozymes Mexicana SA de CV, Novozymes Mexico SA de CV Sweden: Novozymes Biopharma AB Switzerland: Novozymes Switzerland AG, Novozymes Switzerland Finance AG, Novozymes Switzerland Holding AG Singapore: Novozymes Singapore Pte. Ltd. Spain: Novozymes Spain SA Great Britain: Novozymes UK Ltd. South Africa: Enzymes SA (Pty) Ltd. South Korea: Novozymes Korea Ltd. Turkey: Novozymes Enzim Dis Ticaret Limited Sirketi Germany: Novozymes Deutschland GmbH U.S.: Novozymes North America Inc., Novozymes Biologicals Inc., Novozymes Biotech, Inc., Novozymes US Inc.

BUSINESS STRATEGY: Expand the existing enzyme markets through more focused R&D efforts for new products and applications Target new geographical markets with enzymatic solutions Explore new business opportunities based on the company's core technologies, fermentation and production of proteins

AGREEMENTS: Name Products Content of Agreement Date Celliance Corp. Recombinant Human

Albumin for use in cell culture media formulations

commercialization agreement

7/06

China Resources Alcohol Corp.

research into processes for producing cellulose-based biomass for biofuel in China

three-year cooperation agreement

8/06

Neugenesis development of a new method for the production of antibodies

joint research project

10/02

RESEARCH & DEVELOPMENT: Novozymes' core competencies: 1. Genetic and biochemical diversity: Culture collection, strain screening, genome sequencing, expression cloning 2. Protein design: Protein engineering, gene shuffling, molecular modelling, molecular dynamics, directed evolution, high-throughput screening, epitope mapping 3. Protein chemistry: Protein purification, protein sequencing, protein analysis, protein stability, assay development



4. Pathway engineering: Selection of hosts , genetic engineering, metabolic pathway engineering, homogeneous morphology 5. Strain development and improvement: Promoter selection, manipulation of operons, yield improvement 6. Large-scale production: Process development, lab fermentation, scale-up, recovery, formulation

PRODUCTS ON MARKET: Enzymes for industrial use (technical enzymes, comprising detergent enzymes, those sold to the ethanol industry, and and other technical enzymes; food enzymes; and feed enzymes) Microorganisms for industrial use, such as cleaning, wastewater treatment, aquaculture and biological plant care Biopolymers and pharmaceutical proteins More than 700 different products total

Novozymes Inc.

1445 Drew Avenue Davis CA 95616, US Phone: (530) 757-8100; Fax: (530) 758-0317 Web: www.novozymesbiotech.com E-mail: [email protected]

KEY PERSONNEL: Glenn E. Nedwin, Ph.D.; President Randy M. Berka, Ph.D.; Research Fellow, Core Technologies Debbie Yaver, Ph.D.; Senior Research Manager Joel Cherry, Ph.D.; Director, Bioenergy Alan Sloma, Ph.D.; Director, Molecular Biology Stephen H. Brown, Ph.D.; Research Manager, Microbial Physiology Rasmus Thaisen; Finance Manager Marta L. Hillesheim; Director, People and Organization


HISTORY: Founded in January 1992 Member--Biotechnology Industry Organization Changed name from Novo Nordisk Biotech Inc. (11/00) Changed name from Novozymes Biotech Inc.


STOCK-FINANCIAL HISTORY: Privately held Parent company, Novozymes A/S, traded on Copenhagen stock market

SUBSIDIARY OF: Novozymes A/S

BUSINESS STRATEGY: Focus is on industrial biotechnology R&D and biosolutions: pharma, agri-biotech and biochemical Operates as the U.S. research arm of Novozymes A/S Pursue endeavors and collaborations involving novel enzymes, novel enzyme applications and novel production technology

RESEARCH & DEVELOPMENT: Cloning, expression, mutagenesis, and characterization of industrial

enzymes Develop novel high-level expression systems Functional genomics Detergents, textiles, starch, food, baking, wine, juice, beer, pulp & paper, fats, feed and personal care Low-allergenic protein technology Anti-microbial compounds Biopolymers, e.g., hyaluronic acid



Omex Environmental Ltd.

Estuary Road, Riverside Industrial Estate Kings Lynn PE30 2HH, UK Phone: +44 (0)1553 692380; Fax: +44 (0)1553 770684 Web: www.omex.co.uk E-mail: [email protected], [email protected]

KEY PERSONNEL: Alistair Marsh; Head, Sales, U.K. Gerry Spoors; Head, Sales, Magmex U.K. Adrian Gebbett; Head, Sales, Europe Gavin Inglis; Head, Sales, Scotland Philip Sheppardson; Head, Sales, Anomex U.K.



FACILITIES: Three fully equipped laboratories in the U.K.


SUBSIDIARIES/DIVISIONS: Two divisions: Wastewater Control Deicers

SUBSIDIARY OF: Omex Group

BUSINESS STRATEGY: Offer in-depth analysis and treatment of all the potential problems surrounding modern effluent and septicity treatment systems, from on all aspects of industrial wastewater treatment, from pre-treatment to sludge disposal

PRODUCTS ON MARKET: Anti bulking chemicals

Nutrients pH control Coagulates Products for septicity control Ice control products

OmniChem

Industrial Research Park Fleming Louvain-la-Neuve B-1348, Belgium Phone: +32 (10) 48-31-11; Fax: +32 (10) 45-06-93 Web: www.omnichem.be E-mail: [email protected]

KEY PERSONNEL: Jean-Claude Bourmanne; Managing Director


HISTORY: Incorporated as Omnium Chimique in 1980 Changed name to OmniChem (1980) Acquired by Ajinomoto Co. Inc. (1989)

FACILITIES: cGMP chemical facilities


SUBSIDIARY OF: Ajinomoto Co. Inc. (see separate entry)

AGREEMENTS: Name Products Content of Agreement Date Under secrecy agreements



RESEARCH & DEVELOPMENT: Industrial expertise in the handling of: Aluminium and hydrides, azide reagent, boranes, boron trifluoride, butyllithium, carbon disulphide, chlorine, dimethyl sulfate, epichlorohydrin, ethylene oxide, hydrazine sodium azide, hydrogen peroxide, lithium diisopropylamide, methyl bromide, nitric acid, oxalyl chloride, peracids, phosgene, phosphorus oxychloride, phosphorus pentachloride, sodium amide, sodium cyanide, sulfonitric acid In-house manufacture or in situ generation of: Azido alkyl acetate, boc-chloride, diazo ethyl acetate, diphenylphosphorylazide (DPPA), N-vinyl-O-alkyl carbamate, ruppert reagent: CF3-Si (CH3) 3, trimethylsilylazide (TMS-N3) Reaction portfolio: Aldol condensation, Baeyer-Villiger oxidation, Claisen condensation, Chloromethylation, Diazo coupling, Diels-Alder reaction, Friedel-Crafts reaction, Hydroxyethylation, Knoevenagel condensation, Mannich reaction, Methylation, Reimer-Tiemann reaction, Vilsmeier formylation, Wittig reaction

PRODUCTS ON MARKET: Generic drugs: Synthetic and botanical Synthetic intermediates: Tetrazoles, nitro compounds, phosgene derivatives Services: API supply, custom manufacturing, project manufacturing

PRODUCTS IN DEVELOPMENT: Name Status Under secrecy agreements

OmniGene Bioproducts Inc.

763-D Concord Avenue Cambridge MA 02138, US Phone: (617) 576-1966; Fax: (617) 547-9256 Web: www.omnigenebioproducts.com E-mail: [email protected]

KEY PERSONNEL: Janice G. Pero, Ph.D.; Chairman and President Dr. R. Rogers Yocum; Sr. Program Director


HISTORY: Founded in September 1995 Began biotech R&D in October 1995 Formerly a division of OmniGene Inc. and BioTechnica International Inc.; acquired bioproducts division from OmniGene Inc.

FACILITIES: 1,500 sq. ft. headquarters 6,000 sq. ft. R&D facility


BUSINESS STRATEGY: Contract research and licensing Expand bioproducts R&D

AGREEMENTS: Name Products Content of Agreement Date BASF AG specialty chemicals licensing agreement 1/99 F. Hoffmann-La Roche AG

specialty chemicals licensing agreement 1/88

Genencor International Inc.

industrial enzymes licensing agreement 1/99

RESEARCH & DEVELOPMENT: Genetic engineering of microorganisms to produce specialty products, such as vitamins, amino acids, enzymes, other proteins and fine chemicals



Optigenex Inc.

750 Lexington Avenue, 6th Floor New York NY 10022, US Phone: (212) 905-0189 Toll-free phone: (866) OPTIGNX Web: www.ac-11.com E-mail: [email protected]

KEY PERSONNEL: William Walters; Chairman Richard Serbin; CEO Anthony Bonelli; President and COO Joseph McSherry; CFO


HISTORY: Founded in July 2002 as Idunna Inc. Changed name to Kronogen Sciences Inc. (11/02) Changed name to Optigenex Inc. (7/03) Acquired some assets of CampaMed LLC (11/03)

FACILITIES: 6,125 sq. ft. of leased space in New York, N.Y.

STOCK-FINANCIAL HISTORY: OTC BB--OPGX Net sales $277.831K (YE 05) compared to $339.065K (YE 04) Net loss <$6.996M> (YE 05) compared to <$5.793M> (YE 04) Loss per share <$0.69/share> (YE 05) compared to <$0.72/share> (YE 04) Average shares outstanding $10.128M (YE 05) compared to $8.071M (YE 04) Total assets $6.106M (YE 05) compared to $7.885M (YE 04)

PRIVATE PLACEMENTS: Raised $4M from private placement of 625M shares (9/05)

INVESTMENTS: Formed a joint venture called PMO Products Inc. to develop and market professional hair care products that contain AC-11 (11/04) Formed a joint venture company with Prometheon Holding LLC to develop and market a new line of nutraceutical products containing Optigenex's AC-11® as its core ingredient (8/05)

BUSINESS STRATEGY: develops and markets proprietary products that are designed to counter the negative effects of aging by supporting the body's natural ability to repair and maintain its DNA

RESEARCH & DEVELOPMENT: AC-11™ is a compound derived from the plant Uncaria tomentosa, which is

native to the Amazon rainforest as well as tropical areas in South and Central America. AC-11™ has demonstrated activity in DNA repair, autoimmune enhancement, anti-inflammatory and anti-tumor areas.

PRODUCTS ON MARKET: Activar™ AC-11™ Activar™ Age Manager™ (AC-11™, with vitamins and minerals)

Optronics

175 Cremona Drive Goleta CA 93117, US Phone: (805) 968-3568; Fax: (805) 968-0933 Toll-free phone: (800) 796-8909 Web: www.optronics.com E-mail: [email protected]

KEY PERSONNEL: Doug Merker; General Manager



FACILITIES: 18,000 sq. ft. headquarters, R&D and manufacturing facility




SUBSIDIARY OF: Karl Storz Imaging

BUSINESS STRATEGY: Manufacture scientific grade digital cameras and software for research microscopy

PRODUCTS ON MARKET: Digital microscope cameras: MicroFire color & Monochrome, MacroFire

Color & Momochrom, QuantiFire Microscope video cameras PictureFrame Digital Video Medical Recorders (DVMR) Cables and accessories

Organo Corp.

2-8, Shinsuna 1-chome, Koto-ku Tokyo 136, Japan Phone: +81 3-5635-5100; Fax: +81 3-3699-7030 Toll-free phone: (800) 272-2876 Web: www.organo.co.jp; E-mail: [email protected]

KEY PERSONNEL: Masahiko Denda; Chairman Kiyoshi Hashimoto; President, CEO and COO


HISTORY: Founded in 1946 as a pioneer in water and wastewater treatment Began biotech research in 1978 Formerly named Japan Organo Co. Ltd.

FACILITIES: Factories in Satte, Tukuba, Nagasaki and Iwaki Offices in Shanghai and Hongo Branch offices in Sappro, Sendai, Nagoya, Osaka, Hiroshima, Fukuoka and Taiwan

STOCK-FINANCIAL HISTORY: Traded on the Tokyo Stock Exchange Net sales ¥75.700b (YE 05) compared to ¥77.613b (YE 04) Net profit ¥2.090b (YE 05) compared to ¥1.803b (YE 04)

SUBSIDIARIES/DIVISIONS: Hokkaido Organo Shoji Co. Ltd. Tohoku Organo Shoji Co. Ltd. Tokyo Organo Shoji Co. Ltd. Chubu Organo Shoji Co. Ltd. Kansai Organo Shoji Co. Ltd. Kyushu Organo Shoji Co. Ltd. Organo Plant Service Corp. Organo Acty Co. Ltd. Organo High Tech Co. Ltd. Danisco Organo Food Tech Co. Ltd. Eco-Techno Corp. Organo (Asia) Sdn. Bhd. Organo (Asia) Sdn. Bhd. (Penang branch) Organo (Asia) Sdn. Bhd. (Kulim branch) Organo (Singapore) Pte. Ltd. Organo (Thailand) Co. Ltd. Ortech Chemical Co. Ltd. Organo (UK) Ltd. PT.Organo Indonesia PT.Organo Indonesia (Surabaya office) Organo (Philippines) Inc. Organo (Shanghai) Water Treatment Co. Ltd. Organo (Shanghai) Water Treatment Co. Ltd. (Guangzhou office) Organo (Suzhou) Water Treatment Co. Ltd.



PRINCIPAL INVESTORS: Tosoh Corp.--$16M

AGREEMENTS: Name Products Content of Agreement Date Bioremediation Technology

R&D agreement

Biosensor R&D agreement

PRODUCTS ON MARKET: Water treatment equipment: Water softeners, water deionizers, Uultrapure water systems, condensate filters and demineralizers, multi-functional water systems, sterile purified water systems, distilled water production equipment, sea water desalination systems and high-speed filtration equipment Municipal water works and sewage water treatment: Coagulation/sedimentation equipment, high-rate filters, activated carbon filters, membrane-type water purifiers, advanced water treatment, sewage treatment facilities, deodorizing systems, pumping facilities, sludge treating facilities, sewage waste water reclamation Environment-related equipment: Industrial wastewater treatment equipment, treatment systems for power station wastewater, recovery and recycling equipment for industrial wastewater, dual piping water facilities, domestic wastewater treatment equipment, denitrification and dephosphorization systems, Closed systems for semiconductor factories, wastewater treatment equipment for cleaning facility, treatment facility for drainage, agricultural chemicals removal equipment for golf links Soil remediation systems: Ground water treatment facilities, off-gas treatment equipment, soil contamination survey system, soil vapor purification system, bioremediation system Separation and refining equipment: Decolorization and refining system for sugars solution, refining and concentration equipment, chromatographic separation system Small-scale standard equipment: Water deionizer series, water softener series, filter series, ultrapure water production equipment, sub-systems, small-sized supercritical water oxidation equipment, various types of filters, homogenizers, distillation stills, various types of water quality analyzers Water treatment chemicals: Boiler water treatment chemicals, cooling water treatment chemicals, cleaning and rinsing chemicals, wastewater treatment chemicals, drinking water treatment chemicals, chemicals feeding equipment, sanitation chemicals, HACCP-related equipment Analysis business: Ultra-microanalysis of ultrapure water and evaluation, analysis of harmful substances in water, soil, and waste materials, general analysis Waste disposal facilities and equipment Food processing materials and food additives



Pacific Biodiesel Inc.

40 Hobron Avenue Kahului HI 96732, US Phone: (808) 877-3144; Fax: (808) 877-5030 Web: www.biodiesel.com E-mail: [email protected]

KEY PERSONNEL: Robert King; President Kelly Takaya King; VP, Communications and Marketing William Smith; Production Technology Amanda Stewart; Production Technology


FACILITIES: Two Hawaii biodiesel processing plants; Oregon plant; Texas plant


SUBSIDIARIES/DIVISIONS: Maui Plant

Central Maui Sanitary Landfill Pulehu Road Kahului, Hawaii Contact Maui Office: (808) 877-3144 Oahu Biofuels Facility Honolulu, Hawaii George Aiwohi, Hawaii Operations Manager

BUSINESS STRATEGY: Maintain a position as a leader in the production of biodiesel fuel that is derived from waste oils and grease as well as virgin crop oil, in order to minimize the environmental impact of such waste materials and optimize the conservation of traditonal fuel sources; promote community-based biodiesel production that utilizes local resources and distributes product locally

RESEARCH & DEVELOPMENT: Conversion of discarded cooking oil and grease trap oil into biofuels;

processing of virgin crop oil into biodiesel; minimizing wastestream; on-going improvements in process technology and quality control protocol

PRODUCTS ON MARKET: Biodiesel - renewable fuel produced in Hawaii, made from recycled cooking oil and used in commercial diesel fleets, private vehicles, farm equipment, generators and marine vessels Biofuel--vegetable oil burner fuel, made from waste grease trap oil Biodiesel processing plants (technology, process and construction)

Pacific Northwest National Laboratory

P.O. Box 999 Richland WA 99352, US Phone: (509) 375-2121 Toll-free phone: (888) 375-PNNL Web: www.pnl.gov E-mail: [email protected]

KEY PERSONNEL: Dr. Leonard K. Peters; Director Dr. David W. Koppenaal; Chief Research Officer (interim) Dr. Donald M. Boyd; Deputy Laboratory Director for Operations

EMPLOYEES: 4,200 employees, 892 Ph.D.s




FACILITIES: 495,623 sq. ft. of active laboratory space


SUBSIDIARIES/DIVISIONS: Environmental Molecular Sciences Laboratory Marine Sciences Laboratory

BUSINESS STRATEGY: VISION: To be recognized worldwide and valued regionally for leadership in rapidly translating discoveries into solutions. . . for challenges in energy, national security and the environment. . .by integrating the chemical, physical and biological sciences MISSION: Perform basic and applied research to deliver energy, environmental and national security for the nation

AGREEMENTS: Name Products Content of Agreement Date Micell Technologies

use of supercritical fluids for the creation of medical device surface modifications

research and licensing collaboration, expanded 8/06

RESEARCH & DEVELOPMENT: More than 100 ongoing R&D projects annually

Pall Corp.

2200 Northern Boulevard East Hills NY 11548-1248, US Phone: (516) 484-5400; Fax: (516) 484-5228 Toll-free phone: (800) 645-6532 Web: www.pall.com; E-mail: [email protected]

KEY PERSONNEL: Eric Krasnoff; Chairman and CEO Marc Wilson; President Lisa McDermott; CFO Donald Stevens; COO and President, Pall Industrial Steven Chisholm; Sr. VP and President, Microelectronics Group Roberto Perez; Sr. VP and President, Pall Life Sciences Jim Western; Sr. VP and President, Aerospace Group


HISTORY: Founded in July 1946 Acquired Gelman Sciences (2/97) Acquired Rochem Environmental (1/98) Acquired the Filtration and Separations Group (2002) Acquired BioSerpa process chromatography business from Ciphergen Biosystems Inc. (11/04)

FACILITIES: Offices and plants throughout the world

STOCK-FINANCIAL HISTORY: NYSE—Pll Net sales $1.902b (YE 05) compared to $1.771b (YE 04) Net income $140.8M (YE 05) compared to $1.121/share (YE 04) Total assets $2.265b (YE 05) compared to $2.183 (YE 04)

SUBSIDIARIES/DIVISIONS: Life Sciences business—Medical, Biopharmaceuticals, Laboratory Industrial business—General Industrial, Aerospace and Microelectronics, Food & Beverage

BUSINESS STRATEGY: Pursue Growth through aggressive R&D approach that advances company’s products and creates niche applications across many markets, industries and geographies

PRODUCTS ON MARKET: Filtration, separation and purification systems for total fluid management in

the industrial and life sciences markets



Paprican

570 Boulevard St. Jean Pointe-Claire H9R 3J9, Canada Phone: (514) 630-4101; Fax: (514) 630-4134 Toll-free phone: (888) PAPRICAN Web: www.paprican.ca E-mail: [email protected]

KEY PERSONNEL: Frank Dottori; Chairman Joseph Wright; President and CEO Dave McDonald; VP, Research and Education Lucie Lapointe; VP, Administration Richard Berry; Program Manager, Chemical Pulping Brian O'Connor; Program Manager, Environment Tom Browne; Program Manager, Mechanical Pulping and Sustainability Ivan Pikulik; Program Manager, Papermaking Maurice Douek; Program Manager, Analytical Services and Standards Christian Thompson; Program Manager, Engineering Development Jean Hamel; Program Manager, Product Performance Paul Watson; Program Manager, Fibre Supply and Quality



FACILITIES: Headquarters in Pointe-Claire, PQ, Canada Laboratories in Quebec and British Columbia

STOCK-FINANCIAL HISTORY: Non-profit agency

SUBSIDIARIES/DIVISIONS: Vancouver: 3800 Wesbrook Mall Vancouver BC, V6S 2L9 Canada Phone: (604) 222-3201 Fax: (604) 222-3207 Paprican Prince George: P.O. Box 21018 Pulp Mill Road Prince George, BC V2N 7A5 Canada Phone: (250) 561-3991 Fax: (250) 561-4412

BUSINESS STRATEGY: Paprican, the Pulp and Paper Research Institute of Canada, provides valuable technology transfer and cost-competitive research addressing both the short-term and strategic needs of its members

AGREEMENTS: Name Products Content of Agreement Date University collaborations with McGill University, the University of British Columbia and Ecole Polytechnique de Montreal

RESEARCH & DEVELOPMENT: Consortium research: -Fibre Supply and Quality: Capturing more value from fibre resources and enhancing performance of market pulps -Chemical Pulping: Producing superior kraft pulps and the next generation of bleaching technologies



-Mechanical Pulping: Developing the next generation of superior-performance thermomechanical pulps -Papermaking: Improving wet-end chemistry, designing and developing highly-filled printing papers -Product Performance: Delivering state-of-the-art end use properties from advances in surfaces, coatings and web structures -Sustainability and Environment: Minimizing environmental impact, reducing total emissions,optimizing energy efficiencies in response to climate change and economic drivers Multiclient projects: Minimizing linting in mechanical printing grades, optimization of the use of hardwood pulp, recycling, chemimechanical pulps, mechanical pulp bleaching, sulphite pulping and packaging

PBR Laboratories Inc. (PBR)

9960 - 67 Ave., N.W. Edmonton T6E OP5, Canada Phone: (780) 450-3957; Fax: (780) 450-3960 Toll-free phone: (866) 450-3957 Web: www.pbr.ca E-mail: [email protected]

KEY PERSONNEL: Dr. Ram D. Mehta; Chairman, President, and CEO Dr. Ram K. Bishnoi; Director, Lab Operations



FACILITIES: 6,000 sq. ft. laboratory and office space


BUSINESS STRATEGY: Become a leading provider of contract research and bioanalytical services to environmental, chemical, and human health industries, and to develop innovative technologies and products

RESEARCH & DEVELOPMENT: Focus is on the development of diagnostic kits and test methods for rapid

detection of environmental toxins and pathogenic bacteria and fungi

PRODUCTS ON MARKET: Genetic and cellular toxicology testing services, environmental toxicology testing, food and water microbiological analysis, product safety and efficacy evaluation, and microbial strains for biodegradation Fast assays for freshwater algal toxins and shellfish toxins Indoor air quality monitor for mold and bacterial (including endotoxin) contamination

PCI Membranes

Jays Close, Viables Estate Basingstoke RG22 4BA, UK Phone: +44 1256 303800; Fax: +44 1256 303801 Web: www.pcimem.com E-mail: [email protected]

KEY PERSONNEL: Mike Hughes; General Manager Alan Merry; Technical Director Martin Peer; Sr. Scientist John Hughes; Purchasing Manager




FACILITIES: R&D, system building and tubular membrane manufacturing facility


SUBSIDIARIES/DIVISIONS: PCI Membrane Systems Inc. 1615 State Route 131 Milford, OH 45150 Phone: (513) 575-3500 Fax: (513) 575-7393 www.pcims.com

SUBSIDIARY OF: ITT Corporation Inc.

RESEARCH & DEVELOPMENT: Specific application separation studies

PRODUCTS ON MARKET: Membrane separation products and systems

Pentapharm Ltd.

Engelgasse 109 Basel CH-4002, Switzerland Phone: +41 61 7064848; Fax: +41 61 3199619 Web: www.pentapharm.com E-mail: [email protected]

KEY PERSONNEL: Caspar V. Sturm; CEO Thomas Grieder; CFO Dr. Eric J.M. Meier; Head, Quality Management Markus K. Luthy; Director, Sales and Marketing Christian Witzig; Head, Production Dr. Thomas Schreier; Head, R&D



FACILITIES: Headquarters in Basel, Switzerland Snake venom facilities in Brazil and Bolivia


SUBSIDIARIES/DIVISIONS: Pentapharm do Brasil Ltda. Pentapharm en Bolivia

RESEARCH & DEVELOPMENT: Extraction of active ingredients from natural sources

Purification and characterization of snake venom enzymes Synthesis of small peptides and peptide like substances Biotechnological manufacturing of active ingredients

PRODUCTS ON MARKET: Pefakit® Defibrase® Pefachrome® Pefabloc® Protac® Botrocetin® Prionex®



PeproTech Inc.

Princeton Business Park, 5 Crescent Ave., P.O. Box 275 Rocky Hill NJ 08553-0275, US Phone: (609) 497-0253; Fax: (609) 497-0321 Toll-free phone: (800) 436-9910 Web: www.peprotech.com; E-mail: [email protected]

KEY PERSONNEL: Irwin Libeskind; VP, Worldwide Marketing




SUBSIDIARIES/DIVISIONS: PeproTech EC Ltd. PeproTech House 29 Margravine Road London W6 8LL UK Phone: (0)20 7610 3055; Fax: (0)20 7610 3430 E-mail: [email protected]; Web site: www.peprotechec.com CytoLab Ltd. 12 Hamada Street Biet Tamar Entrance A, 2nd floor Rehovot, Israel Phone: +972 (0) 8 946 0948 Fax: +972 (0) 8 946 0861 E-mail: [email protected] Web site: www.cytolab.com Peprotech Mexico SA dec V Montecito 38, Piso 30 Oficina 27 Colonia Napoles CP 03810 Mexico Phone: +52-55-9000-35-62 Fax: +52-55-9000-35-64 E-mail: [email protected] PeproTech Brazil FUNPEC Av. Presidente Vargas 2627 14020-260 Ribeirao Preto Brazil Phone: +55 (16) 620 1251 Fax: +55 (16) 621 1991 E-mail: [email protected] Web site: www.funpecrp.com.br

BUSINESS STRATEGY: Develop and manufacture cytokines, chemokines, neurotrophic factors, growth factors, and paired monoclonal and polyclonal antibodies

RESEARCH & DEVELOPMENT: The company has developed high yield, low cost methods for the

commercial production of over 300 recombinant cytokines and related antibodies

PRODUCTS ON MARKET: Human growth factors and cytokines Human, murine and rat chemokines Murine and rat growth factors and cytokines Human and rat neurotrophins Additional recombinant proteins Monoclonal antibodies Antigen-affinity purified polyclonal antibodies Biotinylated polyclonal antibodies ELISA development kits



Peptides International Inc.

11621 Electron Drive Louisville KY 40299, US Phone: (502) 266-8787; Fax: (502) 267-1329 Toll-free phone: (800) 777-4779 Web: www.pepnet.com E-mail: [email protected]

KEY PERSONNEL: Jackie B. Spatola; Chair Dr. Bryce V. Johnson; CEO and President Krzysztof Darlak, Ph.D.; Director, Research DeAnna Wiegandt Long, Ph.D.; Director, Sales and Marketing Miroslawa Darlak; Quality Control Manager



FACILITIES: R&D, manufacturing and distribution facilities


BUSINESS STRATEGY: Focus on proprietary products Expand upon success in high quality/purity custom synthesis market Develop strategic joint ventures

AGREEMENTS: Name Products Content of Agreement Date University of Louisville

Cyclic peptide libraries exclusive licensing agreement

2004

University of Minnesota

Clear resin solid supports


1997

RESEARCH & DEVELOPMENT: Novel amino acids Peptide backbone modifications Peptide mimetics Peptide and pseudopeptide libraries New resins for solid phase synthesis Solid supports for solid phase synthesis

PRODUCTS ON MARKET: Resins: Clear and Clear-OX™; mini-Peg™ Linkers; TAPI inhibitors, Urantide™ and other various biologically active peptides, enzyme inhibitors, substrates and peptide-related products for research purposes, combinatorial chemistry reagents and supplies

Pfeiffer Vacuum Ltd.

2-4 Cromwell Business Centre, Howard Way, Interchange Park NewPort MK16 9QS, UK Phone: +44 1908 500600; Fax: +44 1908 500601 Web: www.pfeiffer-vacuum.co.uk E-mail: [email protected]

KEY PERSONNEL: Wolfgang Dondorf; CEO Manfred Bender; CFO Peter Knight; GM Rob Vaughan; Manager, IT and QA Jackie Williamson; Accounts Administrator Susan Dixon; Company Secretary


HISTORY: Founded in 1890 Changed name from Balzers Pfeiffer (1/96)



STOCK-FINANCIAL HISTORY: Parent company: NYSE--PV

SUBSIDIARY OF: Pfeiffer Vacuum Technology AG

PRODUCTS ON MARKET: Prisma

Omnistar Thermostar Mass spectrometers Vacuum pumps and gauges

Pfizer Inc.

235 East 42nd Street New York NY 10017-5755, US Phone: (212) 573-2323; Fax: (212) 573-7851 Web: www.pfizer.com E-mail: [email protected]

KEY PERSONNEL: Henry (Hank) A. McKinnell, Ph.D.; Chairman Jeffrey B. Kindler; CEO John LaMattina, Ph.D.; President, Pfizer Global Research and Development Ian Read; President, Worldwide Pharmaceuticals Operations Joe Feczko, M.D.; CMO Sylvia Montero; Head, Worldwide Talent Development and Human Resources Allen Waxman; General Counsel Rich Bagger; Head, Worldwide Public Affairs and Policy


HISTORY: Member--Biotechnology Industry Organization Founded in 1849 Signed letter of intent to sell food science group to Cultor Ltd. (11/95) Acquired Warner-Lambert Co. (6/00) Acquired Agouron Pharmaceuticals Inc. (2000) Merged with Pharmacia Corp. (4/03) Acquired Esperion Therapeutics (2/04) Acquired Meridica Ltd. (11/04) Acquired Angiosyn Inc. (4/05) Acquired Idun Pharmaceuticals Inc. (4/05) Acquired Bioren Inc. (8/05) Acquired Vicuron Pharmaceuticals Inc. (9/05) Acquired worldwide rights to Exubera from Sanofi-Aventis (3/06) Acquired Rinat Neuroscience Corp. (6/06) Acquire exclusive worldwide rights to fesoterodine from Schwarz Pharma AG (6/06) To sell its Pfizer Consumer Healthcare (PCH) business to Johnson & Johnson (as of 6/06)

FACILITIES: Corporate headquarters: New York, N.Y. Research & Development: Groton and New London, Conn.; Sandwich, England; Ann Arbor and Kalamazoo, Mich.; St. Louis, Mo.; La Jolla, Calif.; Cambridge, Mass,; and Nagoya and Tokyo, Japan Veterinary medicine research and development operations in Henrietta and Richland Township, Mich.; Lincoln, Neb.; Sandwich, England; and Melbourne, Australia Consumer Health Care: Morris Plains, N.J.



STOCK-FINANCIAL HISTORY: NYSE--PFE / London--PFZ Also listed on Euronext and Swiss stock exchanges Two-for-one stock split (6/95) Three-for-one stock split (6/99) Revenue $51.298b (YE 05) compared to $52.516b (YE 04) Net income $8.085b (YE 05) compared to $11.361b (YE 04) Earnings per share $1.09/share (YE 05) compared to $1.49/share (YE 04) Average shares outstanding 7.361b (YE 05) compared to 7.531b (YE 04)

SUBSIDIARIES/DIVISIONS: Three business segments: Human Health, Consumer Healthcare and Animal Health Other businesses: Manufacture of empty soft-gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals Subsidiaries: 412357 Ontario Inc--Canada A S Ruffel (Mozambique) Limitada A.S. Ruffel (Private) Ltd.--Zimbabwe A/O Pfizer--Russia ACO AB--Sweden Adenylchemie GmbH--Germany Agouron Pharmaceuticals Inc.--California Alginate Industries (Ireland) Ltd. American Food Industries Inc.--Delaware Amicore Inc.--Delaware Andean Services SA--Colombia Angiosyn Inc.--Delaware Backsvalan 6 Handelsbolag--Sweden Balverda SRL--Italy Bharti Healthcare Ltd.--India BINESA 2002 SL--Spain Biocor Animal Health Inc.--Delaware Bioindustria Farmaceutici SRL--Italy Bioptics SARL--France Bioren Inc.--Delaware Biosearch Manufacturing Srl--Italy C.P. Pharmaceuticals International CV--Netherlands Capsugel (Thailand) Co. Ltd.--Thailand Capsugel AG--Switzerland Capsugel Belgium BVBA--Belgium Capsugel France Capsugel Japan Inc. (KK) Capsugel Ploermel--France CARDEL--France Carlo Erba OTC SpA--Italy Centrofarma, Sociedad Anonima--Guatemala Ceuticlab Laboratorios de Produtos Farmaceuticos Lda.--Portugal Charlie Papa Operations LLC--New Jersey CHC Direct LLC--Delaware Compania Farmaceutica Upjohn SA--Guatemala Consumer Health Products (Minority Interests) Co.--U.K. Continental Farmaceutica SL--Spain Continental Pharma Inc.--Delaware Corporacion Pharmacia de Mexico S de RL de CV--Mexico CPPI/CV Six (Gibraltar) Ltd. Davis Medica, Sociedad Limitada, Sociedad Unipersonal--Spain Diabel GmbH & Co. KG--Germany Distribuidora Mercantil Centro Americana SA--Delaware Duchem Laboratories Ltd.--India Esperion AB--Sweden Esperion LUV Development Inc.--Delaware Esperion Therapeutics Inc.--Delaware Euronett Inc.--Delaware Eversharp Canada Inc.--Canada Exchic CA Ltd.--Bermuda



Farminova Produtos Farmaceuticos de Inovacao Lda.--Portugal Farmitalia Carlo Erba Ltd.--U.K. Farmogene Productos Farmaceuticos Lda.--Portugal Fyrcia HB--Sweden G. D. Searle & Co. Ltd.--U.K. G. D. Searle (Philippines) Inc. G. D. Searle (Thailand) Ltd.--Thailand G. D. Searle International Capital LLC--Delaware G. D. Searle Land Corp.--Philippines G. D. Searle LLC--Delaware G. D. Searle South Africa Pty. Ltd.--South Africa Godecke GmbH--Germany Godecke OTC Beteiligungs GmbH--Germany Greenstone Ltd.--Delaware Heinrich Mack Nachf. GmbH. & Co. KG--Germany Heumann Beteiligungs GmbH--Germany Heumann PCS GmbH--Germany Idun Pharmaceuticals Inc.--Delaware International Affiliated Corp. LLC--Delaware Inter-World Insurance Co. Ltd.--Bermuda Invicta Farma SA--Spain Island Pharmaceuticals Ltd.--Ireland J B Tillott Ltd.--U.K. Jouveinal Holland BV--Netherlands Kenfarma SA--Spain Keystone Chemurgic Corp.--Delaware Kiinteisto Oy Helsingin Tietokuja--Finland Kommanditbolaget Hus Gron--Sweden Korea Pharma Holding Co. Ltd.--Hong Kong Laboratoires Pfizer SA--Morocco Laboratorios Laprofa, Sociedad Anonima--Guatemala Laboratorios Parke Davis SL--Spain Laboratorios Pfizer de Chile Laboratorios Pfizer Ltda.--Brazil Laboratórios Pfizer Lda.--Portugal Laboratorios Visine SL--Spain Lambert Chemical Co. Ltd.--U.K. Losbanos Ltd.--Ireland Lothian Developments V SPRL--Belgium MED Urological Inc.--Minnesota Meridica Ltd.--U.K. Monterey Kelp Corp.--California MTG Divestitures Handels GmbH--Austria MTG Divestitures Ltd.--U.K. MTG Divestitures LLC--Delaware Nefox Farma SA--Spain Nostrum Farma SA--Spain NPF YK--Japan O.C.T. (Thailand) Ltd. Omni Laboratories Inc.--Canada Orsim--France P&UFSC Inc.--Virgin Islands PanServ Personalberatungs- und Anzeigenservice GmbH--Germany Paris Montrouge II BV--Netherlands Paris Montrouge II SARL--France Parke Davis & Co. Ltd.--Isle of Jersey Parke Davis Del Ecuador CA--Ecuador Parke Davis European Distributors Ltd.--Ireland Parke Davis International Ltd.--Bahamas Parke Davis Productos Farmaceuticos Lda.--Portugal Parke Davis Pty. Ltd.--Australia Parke, Davis & Co. Ltd.--Pakistan Parke, Davis & Co. LLC--Michigan Parke-Davis GmbH--Germany Parke-Davis Manufacturing Corp.--Delaware



Parke-Davis Sales Corp.--Virgin Islands P-D Co. Inc.--Delaware Pfidev3 SAS--France Pfidev4 SAS--France Pfizer (China) Research and Development Co. Ltd. Pfizer (Malaysia) Sdn Bhd--Malaysia Pfizer (Perth) Pty. Ltd.--Australia Pfizer SAS--France Pfizer (Thailand) Ltd. Pfizer AG--Switzerland Pfizer A/S--Norway Pfizer AB--Sweden Pfizer Africa & Middle East for Pharmaceuticals, Animal Health & Chemicals SAE--Egypt Pfizer Afrique de L'Ouest--Senegal Pfizer Algerie Sante et Nutrition Animale spa--Algeria Pfizer Animal Health BV--Netherlands Pfizer Animal Health Korea Ltd.--South Korea Pfizer Animal Health SA--Belgium Pfizer Antilles Holdings NV--Netherlands Antilles Pfizer ApS--Denmark Pfizer Asia Holdings BV--Netherlands Pfizer Asia Pacific Pte. Ltd.--Singapore Pfizer Australia Holdings Pty. Ltd.--Australia Pfizer Australia Pty. Ltd.--Australia Pfizer Australia Superannuation Pty. Ltd.--Australia Pfizer BV--Netherlands Pfizer Beteiligungs GmbH--Germany Pfizer Canada Inc.--Canada Pfizer Caribe Ltd.--Guernsey Pfizer Century Holdings--Ireland Pfizer CHC GmbH--Germany Pfizer Chile SA--Chile Pfizer Cia. Ltda.--Ecuador Pfizer Consumer Health Care Mexico S de RL de CV--Mexico Pfizer Consumer Health Products Co.--U.K. Pfizer Consumer Healthcare--U.K. Pfizer Consumer Healthcare BV--Netherlands Pfizer Consumer Healthcare Comm.VA--Belgium Pfizer Consumer Healthcare GmbH--Germany Pfizer Consumer Healthcare Ireland Pfizer Consumer Healthcare S.Com.p.A--Spain Pfizer Consumer Healthcare Srl--Italy Pfizer Consumer Inc.--Japan Pfizer Convention III LLC--Delaware Pfizer Convention IV LLC--Delaware Pfizer Co-Promotions Ltd.--Isle of Jersey Pfizer Cork Ltd.--Ireland Pfizer Corp.--Panama Pfizer Corp. Austria Gesellschaft mbH--Austria Pfizer Corp. Hong Kong Ltd.--Hong Kong Pfizer Croatia d.o.o.--Croatia Pfizer Deutschland GmbH Pfizer Distribution Co.--Ireland Pfizer Distribution Services--Belgium Pfizer Domestic Ventures Ltd.--Isle of Jersey Pfizer Dominicana SA--Dominican Republic Pfizer Dublin Ltd.--Ireland Pfizer Egypt SAE--Egypt Pfizer Enterprises Inc.--Delaware Pfizer Enterprises SARL--Luxembourg Pfizer Esbjerg A/S--Denmark Pfizer ESP Pty. Ltd.--Australia Pfizer Europe MA EEIG--U.K. Pfizer European Service Center BVBA--Belgium



Pfizer Export AB--Sweden Pfizer Export Co.--Ireland Pfizer Finance GmbH & Co. KG--Germany Pfizer Finance International Ltd.--Ireland Pfizer Finance Verwaltungs GmbH--Germany Pfizer Financial Services NV/SA--Belgium Pfizer Fundings International--Ireland Pfizer Global Holdings BV--Netherlands Pfizer Global Supply--Ireland Pfizer Global Trading--Ireland Pfizer GmbH--Germany Pfizer Group Ltd.--U.K. Pfizer H.C.P. Corp.--New York Pfizer Health AB--Sweden Pfizer Health Solutions Inc.--Delaware Pfizer Healthcare Ireland Pfizer Hellas AE--Greece Pfizer HK Service Co. Ltd.--Hong Kong Pfizer Holding France SCA--France Pfizer Holding Italy SpA Pfizer Holding und Verwaltungs GmbH--Germany Pfizer Holding Ventures--Ireland Pfizer Holdings BV--Netherlands Pfizer Holdings Europe--Ireland Pfizer Holdings International Luxembourg (PHIL) Sarl Pfizer Holdings Ireland Pfizer Holdings Mexico S de RL de CV Pfizer Holdings Netherlands BV Pfizer Holdings Turkey Ltd.--Isle of Jersey Pfizer Holland Pharmaceuticals BV--Netherlands Pfizer Hungary Asset Management LLC Pfizer Ilaclari Ltd. Sirketi--Turkey Pfizer International Bank Europe--Ireland Pfizer International Corp.--Panama Pfizer International Holdings Ltd.--Ireland Pfizer International LLC--New York Pfizer International Luxembourg SA Pfizer International Portfolio Investments--Ireland Pfizer Inventory Co.--Delaware Pfizer Investment Capital--Ireland Pfizer Investment Co. Ltd.--China Pfizer Ireland Pharmaceuticals Pfizer Ireland Ventures Pfizer Italia Srl--Italy Pfizer Japan Inc. Pfizer Jersey Capital Ltd.--Isle of Jersey Pfizer Jersey Co. Ltd.--Isle of Jersey Pfizer Jersey Finance Ltd.--Isle of Jersey Pfizer Laboratories (Pty.) Ltd.--South Africa Pfizer Laboratories Ltd.--Kenya Pfizer Laboratories Ltd.--Pakistan Pfizer Ltda.--Angola Pfizer Ltd.--Tanzania Pfizer Ltd.--Thailand Pfizer Ltd.--Uganda Pfizer Ltd.--U.K. Pfizer Ltd. (Taiwan) Pfizer Luxco Holdings Sarl--Luxembourg Pfizer Luxco Production SARL--Luxembourg Pfizer Luxembourg SARL Pfizer Manufacturing Belgium NV Pfizer Manufacturing LLC--Delaware Pfizer Manufacturing Services--Ireland Pfizer Medical Technology Group (Belgium) NV Pfizer Medical Technology Group (Netherlands) BV



Pfizer Medical Technology Group Ltd.--U.K. Pfizer Middle East--Egypt Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals SAE--Egypt Pfizer Namibia (Proprietary) Ltd. Pfizer New Zealand Ltd. Pfizer Overseas Pharmaceuticals--Ireland Pfizer Overseas Inc.--Delaware Pfizer Oy--Finland Pfizer Participations SARL--Luxembourg Pfizer Pension Trustees (Ireland) Ltd. Pfizer Pension Trustees Ltd.--U.K. Pfizer PGM SAS--France Pfizer PGRD SAS--France Pfizer Pharm Algerie Pfizer Pharma GmbH--Germany Pfizer Pharma Trade LLC--Egypt Pfizer Pharmaceutical (Wuxi) Co. Ltd.--China Pfizer Pharmaceutical India Pvt. Ltd. Pfizer Pharmaceutical Trading Ltd. Liability Co. (Pfizer Kft. or Pfizer LLC)--Hungary Pfizer Pharmaceuticals BV--Netherlands Pfizer Pharmaceuticals Israel Ltd. Pfizer Pharmaceuticals Jersey Ltd.--Isle of Jersey Pfizer Pharmaceuticals Korea Ltd.--South Korea Pfizer Pharmaceuticals Ltd.--Cayman Island Pfizer Pharmaceuticals LLC--Delaware Pfizer Pharmaceuticals Ltd.--China Pfizer Pharmaceuticals Tunisie Sarl Pfizer Pharmaceuticals Inc.--Delaware Pfizer Pigments Inc.--Delaware Pfizer Polska Sp. z.o.o.--Poland Pfizer Precision Holdings SARL--Luxembourg Pfizer Pvt. Ltd.--Malaysia Pfizer Pvt. Ltd.--Singapore Pfizer Production LLC--Delaware Pfizer Products Inc.--Connecticut Pfizer Products India Pvt. Ltd.--India Pfizer Romania SRL Pfizer SA--Colombia Pfizer SA--Peru Pfizer SGPS Lda.--Portugal Pfizer SRL--Argentina Pfizer SA (Belgium) Pfizer Saidal Manufacturing--Algeria Pfizer Sante Grand Public (SCA)--France Pfizer Science and Technology Ireland Ltd. Pfizer Service Company BVBA--Belgium Pfizer Service Co. Ireland Pfizer Services 1 (SNC)--France Pfizer Services 2 (SNC)--France Pfizer Services LLC--Delaware Pfizer Servicios de Mexico SA de CV Pfizer Shared Services--Ireland Pfizer Shareholdings Intermediate SARL--Luxembourg Pfizer Singapore Trading Pte. Ltd. Pfizer Specialties Ltd.--Nigeria Pfizer SPOL s.r.o.--Czech Republic Pfizer Sterling Investments Ltd.--Isle of Jersey Pfizer Suzhou Animal Health Products Co. Ltd.--China Pfizer Technologies Ltd.--U.K. Pfizer Trading Polska sp.z.o.o.--Poland Pfizer Tunisie SA Pfizer UK Group Ltd.--U.K. Pfizer Venezuela SA--Venezuela



Pfizer Ventures Ltd.--Isle of Jersey Pfizer Warner Lambert Luxembourg SARL Pfizer Zona Franca SA--Costa Rica Pfizer Inc.--Philippines Pfizer SA--Costa Rica Pfizer SA (Pfizer Pharmaceutical)--Spain Pfizer SA de CV--Mexico Pharmacia & Upjohn AG--Switzerland Pharmacia & Upjohn Cambridge Ltd.--U.K. Pharmacia & Upjohn Co. LLC--Delaware Pharmacia & Upjohn Holding Co.--Delaware Pharmacia & Upjohn LLC--Delaware Pharmacia & Upjohn Management Co. Ltd--U.K. Pharmacia & Upjohn SpA--Italy Pharmacia & Upjohn Trading Corp.--Michigan Pharmacia & Upjohn SA de CV--Mexico Pharmacia (South Africa) (Pty.) Ltd. Pharmacia Africa Ltd.--U.K. Pharmacia Animal Health AB--Sweden Pharmacia Animal Health Ltd.--U.K. Pharmacia Asia Ltd.--Hong Kong Pharmacia Australia Pty. Ltd. Pharmacia BV--Netherlands Pharmacia Brasil Ltda. Pharmacia Corp.--Delaware Pharmacia de Centroamerica SA--Panama Pharmacia de Centroamerica Sociedad Anonima--Guatemala Pharmacia de Mexico SA de CV--Mexico Pharmacia Diagnostics Verwaltungs GmbH--Germany Pharmacia Enterprises Sarl--Switzerland Pharmacia Europe EEIG--U.K. Pharmacia GmbH--Germany Pharmacia Grupo Pfizer SL--Spain Pharmacia Hepar Inc.--Delaware Pharmacia Holding AB--Sweden Pharmacia Ilac Sanayi ve Ticaret Ltd.--Turkey Pharmacia Industrifastigheter AB--Sweden Pharmacia Inter-American LLC--Michigan Pharmacia International BV--Netherlands Pharmacia International Inc.--South Dakota Pharmacia International SARL--Switzerland Pharmacia International Trading (Shanghai) Ltd. Pharmacia Ireland Ltd. Pharmacia Korea Ltd.--South Korea Pharmacia Laboratories Ltd.--U.K. Pharmacia Learning Center Corp.--Delaware Pharmacia Ltd.--U.K. Pharmacia Ltd. Co.--Michigan Pharmacia Malaysia Sdn Bhd Pharmacia Pakistan (Pvt.) Ltd. Pharmacia-Pfizer EEIG--U.K. Pharmacia Pharmatrade LLC--Hungary Pharmacia Polska Sp.z.o.o.--Poland Pharmacia SpA--Italy Pharmacia Searle Ltd.--U.K. Pharmacia Singapore Pte. Ltd. Pharmacia UK Holding Co. Pharmacia UK Ltd. Pharmacia United Inc.--Philippines Plaistow Ltd.--Ireland Promotora IPSA SA--Mexico ProRe SA--Luxembourg Prosec (Ireland) Ltd. Prosec Forsakrings AB (Prosec Insurance Co. Ltd.)--Sweden PT Capsugel Indonesia



PT Pfidex Pharma--Indonesia PT Pfizer Indonesia PUCN Ltd. Partnership--Nevada PUCN LLC--Nevada Quigley Co. Inc.--New York Reactine SRL--Italy Renrall LLC--Wyoming Rivepar--France Roerig AB--Sweden Roerig BV--Netherlands Roerig Produtos Farmaceuticos Lda.--Portugal Roerig SA--Chile Roerig Inc.--Philippines Roerig SA--Venezuela Searle & Co.--Delaware Searle Argentina SRL Searle Belgium BVBA--Belgium Searle Chemicals Inc.--Delaware Searle de Mexico SA de CV--Mexico Searle GmbH--Germany Searle Holdings BV--Netherlands Searle Invest BV--Netherlands Searle Laboratorios Lda.--Portugal Searle LLC--Nevada Searle Ltd.--Bermuda Searle Pharma LLC--Russia Sefarma Srl--Italy Sensus Drug Development Corp.--Delaware Shiley International--California Shiley LLC--California Sinergis Farma-Produtos Farmaceuticos Lda.--Portugal Site Realty Inc.--Delaware Smith Brothers Cough Drops Canada Ltd. SmithKline Beecham Animal Health (SWA) (Pty.) Ltd.--Namibia Solinor LLC--Delaware Sopaco SRL--Italy Substantia SAS--France Sugen Inc.--Delaware Suzhou Capsugel Ltd.--China Swordfish Heimtierbedarf Verwaltungsgesellschaft mbH--Germany Swordfish Holding GmbH--Germany Tabor Corp.--Delaware The Kodiak Co. Ltd.--Bermuda The Upjohn Holding Co. M LLC--Delaware The Upjohn Manufacturing Co. LLC--Delaware Thorney Co.--Ireland Unicliffe Ltd.--U.K. Upjohn International Holding Co.--Delaware Upjohn International Inc.--Michigan Upjohn Laboratorios Lda.--Portugal Upjohn Pharmaceuticals Ltd.--Delaware Upjohn Suzhou Pharmaceutical Co. Ltd.--China Viagra Ltd.--U.K. Vicuron Pharmaceuticals Inc.--Delaware Vicuron Pharmaceuticals Italy Srl--Italy Vinci Farma SA--Spain Warner Lambert (UK) Ltd. Warner Lambert Bolivia SA Warner Lambert Co. (M) Sdn Bhd--Malaysia Warner Lambert Consumer Healthcare Pty. Ltd.--Australia Warner Lambert del Uruguay SA Warner Lambert Ilac Sanayi ve Ticaret Ltd.--Turkey Warner Lambert Poland Sp.z.o.o Warner Lambert Pty. Ltd.--Australia Warner Lambert Zimbabwe (Pvt.) Ltd.



Warner-Lambert (East Africa) Ltd.--Kenya Warner-Lambert (Nigeria) Ltd. Warner-Lambert (Singapore) Pvt. Ltd. Warner-Lambert (Tanzania) Ltd. Warner-Lambert (Thailand) Ltd. Warner-Lambert (West Indies) Ltd.--Jamaica Warner-Lambert Co. AG--Switzerland Warner-Lambert Co. LLC--Delaware Warner-Lambert de Costa Rica SA Warner-Lambert de El Salvador SA de CV Warner-Lambert de Honduras, Sociedad Anonima Warner-Lambert de Panama, Sociedad Anonima Warner-Lambert de Puerto Rico Inc. Warner-Lambert GmbH--Germany Warner-Lambert Guatemala, Sociedad Anonima Warner-Lambert Hungary KFT--Hungary Warner-Lambert International NV--Netherlands Antilles Warner-Lambert Ireland Warner-Lambert Kenya Ltd. Warner-Lambert Manufacturing (Ireland) Ltd.--Cayman Islands Warner-Lambert Pottery Road Ltd.--Ireland Warner-Lambert SA (Pty.) Ltd.--South Africa Warner-Lambert SA--Delaware Wilcox Sweets (Pty.) Ltd.--South Africa W-L (Europe)--U.K. W-L (Portugal)--U.K. W-L (Spain)--U.K. WL de Guatemala, Sociedad Anonima W-L Holding SCA--France W-L LLC--Delaware Yusafarm D.O.O.--Serbia and Montenegro

INVESTMENTS: Anaderm Research Corp.--joint venture with OSI Pharmaceuticals Inc. Gensia Inc.--$5M equity investment OSI Pharmaceuticals Inc.--587.5K shares, $2.9M Perlegen Sciences Inc.--$50M (12/05)

BUSINESS STRATEGY: Discover, develop, manufacture and market leading prescription medicines for humans and animals

AGREEMENTS: Name Products Content of Agreement Date 250+ collaborations, including the following:

Abgenix Inc. Abgenix's XenoMouse to make antibodies against undisclosed antigen targets

development agreement--Pfizer will make equity investment as part of up-front payment, Pfizer will pay milestones, research costs, license fees and provide royalties from sales of any products

12/97

AccuMed International Inc.

antifungal susceptibility R&D agreement 10/92

ActivX Biosciences Inc.

discovery to developmental stage projects

strategic collaborative agreement

3/06

Advanced Polymer Systems Inc.

APS's microsponge technology

marketing agreement

4/90



AEA Technology drug discovery based on genomics research

R&D agreement 3/95

Affymetrix Inc. Affymetrix GeneChip expression technology


ALZA Corp. Glucotrol XL joint promotion agreement

10/94

Astex Therapeutics

Cytochrome P450 licensing agreement 1/06

Atrix Laboratories Inc. (QLT USA Inc.)

Atrix's delivery technology and Pfizer's veterinary drug

feasibility study 3/97

Bayer AG nifedipine GITS exclusive marketing rights for Bayer overseas

7/88

Bayer Pharmaceuticals Corp.

Bayer's DGAT-1 inhibitors


6/06

BIOSTAR Inc. genetically engineered vaccines for animals

licensing, research, and supply agreements through Pfizer Animal Health

12/91

Calgene Inc. genetically engineered plants

cooperative research agreement through Pfizer Food Science Group

2/95

Cambridge Antibody Technology Ltd.

phage antibody display and selection technologies


2/96

Cantab Pharmaceuticals plc

veterinary vaccines developed with Cantab's proprietary Disc-Virus technology

joint development agreement with Pfizer's Animal Health Group

1995

ChemTrak Inc. disposable quantitative finger stick whole blood test for one of Pfizer's drugs in development using ChemTrak's AccuMeter technology


6/98

ChondroGene Limited

access to ChondroGene's database of osteoarthritis tissue-specific clinical and gene expression information

two-year research collaboration

12/04

Chromos Molecular Systems Inc.

development of cell lines using the ACE system for production of Pfizer recombinant proteins


12/04

Chromos Molecular Systems Inc.

ACE System non-exclusive commercial licensing agreement

5/05

Chrysalis International Corp.

genomics research for two major disease targets

two-year R&D agreement

1/98

Codexis Inc. pharmaceutical life cycle management--use of Codexis' MolecularBreeding technology

R&D agreement 7/04



Coley Pharmaceutical Group

development, manufacturing and commercialization of Coley's ProMune (CPG 7909)

exclusive global licensing agreement

3/05

Collaborative Research, The Dow Chemical Co.

rennin for making cheese by genetic manipulation of yeast

research, licensing, and worldwide marketing agreement--Dow assigned marketing rights to Pfizer

1/88

Corvas International Inc.

neutrophil inhibitory factor (NIF) for acute ischemic stroke

R&D agreement with license option (10/95), Pfizer agreed to pay $1M plus $29M in development funding and milestones, Pfizer receives worldwide license to develop, manufacture and market NIFR&D agreement with license option, Pfizer paid $1M milestone after starting Phase I clinical trial (2/98)

2/97

Crucell NV Crucell's West Nile virus vaccine for horses


1/04

Cubist Pharmaceuticals Inc.

antibacterial agents R&D collaboration (12/95), licensing agreement extended

7/97

Deprenyl Animal Health, Inc. (Draxis Health Inc.)

Anipryl for canine Cushing's disease and canine cognitive dysfunction

worldwide licensing, marketing and distribution agreement--Draxis received $15M up-front payment (12/97), Draxis to receive $10M upon FDA approval of cognitive dysfunction supplementary claim and up to $16M contingent upon regulatory approval for Anipryl® in specific markets

11/97

Eyetech Pharmaceuticals

Macugen pegaptanib VEGF-binding aptamer to treat age-related macular degeneration (AMD) and diabetic macular edema (DME)


12/02

G. D. Searle & Co. Searle's celecoxib and its second-generation compound

copromotion and development agreement--Searle will receive $85M up-front payment

2/98



Immunicon Corp. reagents for the

detection of undisclosed antigens on circulating tumor cells (CTCs)

R&D agreement; amended 4/04, expanded 12/04, extended 3/06

2/03

Immusol Inc. target validation collaboration

3/98

Incyte Corp. Incyte's LifeSeq genomics database, expanded to include LifeSeq FL database and LifeSeq GeneAlbum DNA clone set

database subscription (6/94), extended three years and expandedexpanded

2/98

Incyte Corp. development,

manufacture and marketing of novel oral CCR2 antagonists

research and license agreement

11/05

Inhale Therapeutic Systems

pulmonary delivery system for insulin

development agreement, completed Phase I clinicals

1/95

Inpharmatica Ltd. identification, prioritization and validation of the suitability of drug targets

subscription agreement

2/01

Isis Pharmaceuticals

identification of second-generation antisense drugs for the treatment of ophthalmic disease

multi-year drug discovery collaboration--Isis will receive a $1M technology access fee, research funding, milestone payments and royalties

5/05

LifeSpan BioSciences Inc.

LifeSpan's DrugTarget Database

multiyear agreement

12/05

Medarex Inc. up to 50 antibody products over 10 years


9/04

Metabasis Therapeutics Inc. (Gensia Sicor Inc.)

adenosine regulating agents (ARA) as broad-spectrum analgesic drugs for treating pain

research collaboration (5/96), extended through May 1999, Metabasis gets additional research funding plus milestones and royalties if Pfizer selects product for clinical development

3/98

Microcide Pharmaceuticals Inc.

antibiotic for animal health applications


1/99

Microcide Pharmaceuticals Inc.

drugs to treat resistant bacterial infections

five-year collaboration (3/96), Microcide received $1M milestone payment related to identification, validation and sequencing of genes

2/97



Microvascular Systems, MPS (IGI)

liposome formulations for injectable animal vaccines


9/87


fungal diseases research, licensing, and product development agreement (3/95), expanded--Millennium to add research personnel to focus on application of transcript profiling and ultra-high-throughput screening technologies

12/97

Mitokor Inc. target and drug discovery in certain neurodegenerative diseases

R&D agreement 1998

Moleculon Poroplastic controlled-release disc used in Paratect antiparasitic bolus system


Monogram Biosciences Inc.

Monogram's HIV Co-Receptor Tropism Assay to be made available globally

nonexclusive collaboration agreement

5/06

Myco Pharmaceuticals

drug discovery based on genomics technology

R&D agreement 3/95

NAEJA Pharmaceutical Inc.

anti-infectives contract research agreement

3/01

Neogen Corp. immunoassay diagnostic kits for the poultry industry

development and supply agreements

8/92

Neurogen Corp. drugs to treat obesity and eating disorders

three- to five-year joint R&D agreement--Pfizer to receive worldwide exclusive license to market any drugs developed through the collaboration and to fund Neurogen's R&D program. Neurogen will retain option to manufacture the products for NAFTA countries. Neurogen will retain a profit-sharing option for NAFTA countries (11/95). funded research portion extended for one year beginning in 11/98

5/98



Neurogen Corp. drugs to treat sleep

disorders three-year R&D agreement--Pfizer to fund Neurogen's R&D program in exchange for worldwide manufacturing and marketing rights to any sleep drugs developed through the collaboration (7/94), expanded for two years

12/96

Neurogen Corp. drugs to treat anxiety

and enhance cognition five-year joint R&D agreement--Pfizer to fund Neurogen's R&D program in exchange for worldwide manufacturing and marketing rights to anxiolytic or cognition enhancing drugs developed through the collaboration (2/92), extended for additional year (10/95), expanded for two years

12/96

Neurosearch A/S Neurosearch's automated patch clamp technology


12/97

NicOx SA NicOx nitric oxide-donating compounds

R&D and licensing agreement

8/04

NicOx SA NicOx's nitric oxide-donating technology


Noxxon Pharma AG

discovery and development of Spiegelmer products

multi-year global collaboration

3/06

Odyssey Thera Inc.

use of Odyssey Thera's Protein-fragment Complementation Assay (PCA) technology to evaluate selectivity of Pfizer compounds

multi-year collaboration agreement

9/06


compounds to treat baldness, wrinkles and pigmentation disorders

three-party collaboration agreement with New York University and Anaderm Research Corp.

4/96


cancer therapeutics that target oncogenes and tumor suppressor genes

five-year R&D agreement (7/88), extended for five years (12/90), extended for additional five years

3/96



Oxford Asymmetry drug discovery based on genomics research

R&D agreement (3/95), extended for one year, Pfizer will pay £5.4M over three years

4/97

Oxford Glycosciences plc.

OGS' proteomics technology to identify disease-specific proteins as potential diagnostics, clinical markers and drug targets in Alzheimer's disease

$50M research collaboration--Pfizer invested in OGS' IPO and will fund research for two years

4/98

Peptide Therapeutics Group plc.

Peptide's broad spectrum allergy vaccine for veterinary market

development agreement--Pfizer will have exclusive option to worldwide license and will pay costs of research and clinical development for evaluating the vaccine

1/98

Perlegen Sciences Inc.

identification of genes associated with major diseases

four-year research agreement

12/05

Perlegen Sciences Inc.

discovery of genes using Perlegen's DNA sample preparation


12/02

Phyton Inc. (now Phyton Biotech Inc.)

collaborative development agreement

1996

Phytopharm plc. obesity drug collaboration and licence agreement

8/98

Renovis Inc. research, development and commercialization of small molecules that target VR1

worldwide collaboration and licensing agreement

5/05

Repligen Corp. growth factor inhibitors research collaboration, Repligen received milestone payment (12/97)

12/95

Repligen Corp. small molecule compounds that stimulate immune system responses


1/97

Rigel Pharmaceuticals Inc.

development of inhaled products for allergic asthma and other respiratory diseases

research and licensing agreement

1/05

Sangamo BioSciences Inc.

Sangamo's zinc finger DNA binding protein technology for use in Pfizer's mammalian cell- based protein pharmaceutical production


Schering AG Schering's ADP receptor antagonist program


Schwarz Pharma fesoterodine licensing agreement 6/06



The Liposome Co. Inc.

TLC D-99 licensing agreement--Pfizer to have worldwide marketing rights

11/90

TheraTech Inc. drug delivery systems R&D agreement (8/92), extended for two years

8/94

RESEARCH & DEVELOPMENT: Pharmaceuticals: antibiotics, antifungals, nonsteroidal anti-inflammatory

agents for arthritis and autoimmune disease, cardiovascular agents, CNS agents, diabetes agents, respiratory diseases Improved microorganisms for production of fermentation products Broad range of fermentation-derived products, enzymes (rennet, proteases), EOR, specialty chemicals, rDNA rennin Interferons, antibiotics, renin inhibitors Animal health, including antibiotic and vitamin feed supplements Antiviral R&D, including AIDS research (Pfizer U.K.)

PRODUCTS ON MARKET: KEY PHARMACEUTICAL PRODUCTS: Aricept® (donepezil hydrochloride tablets), Celebrex® (celecoxib), Diflucan® (fluconazole), Lipitor® (atorvastatin calcium) tablets, Neurontin® (gabapentin), Norvasc® (amlodipine besylate), Viagra® (sildenafil citrate) tablets, Xalatan® (latanoprost ophthalmic solution), Zithromax® (azithromycin), Zoloft® (sertraline HCI), Macugen® (pegaptanib sodium injection), Chantix™ (varenicline) KEY CONSUMER HEALTH CARE PRODUCTS: Benadryl®, Cortizone®, Desitin®, e.p.t.®, Listerine®, Lubriderm®, Neosporin®, Rolaids®, Sudafed®, Visine® KEY ANIMAL HEALTH PRODUCTS: Clavamox®, Synulox®, Equimax®, Naxcel®/Excenel®, Rimadyl®, Dectomax®, Respisure®/Stellamune®, Revolution®/Stronghold®

PRODUCTS IN DEVELOPMENT: Name Status 235 projects in development, including 152 new molecular entities and 83 product-line extensions. More than 400 projects in discovery research.

Pharmbiodyn Consulting Group

Ferdinand-Porsche-Str. 5/1 Denzlingen D-79211, Germany Phone: +49 7666-2025; Fax: +49 7666-7255 Web: www.pharmbiodyn.com E-mail: [email protected]

KEY PERSONNEL: Dr. G. Friedrich; President




RESEARCH & DEVELOPMENT: Development of products for automation of liquid chromatography

biotechnology, cell and tissue culture

PRODUCTS ON MARKET: Products: Customer designed fully automated HPLC / LC-MS Robo-Caesar-Set



Consulting services: Automation in analytical and preparative chromatography Development and adapting of methods for full automation of procedures in liquid chromatography Services: Installation service, services for own products, services for clients in collaboration with partners, including in vitro and in vivo preclinical and clinical studies (analytics, drug efficacy, metabolism, pharmacokinetics); free radicals in vitro and in vivo (preclinical, clinical studies); and cell therapy, stem cells, their products in different stages of differenciation

Pioneer Hi-Bred International Inc.

7100 NW 62nd Avenue, PO Box 1014 Johnston IA 50131-1014, US Phone: (515) 248-4800; Fax: (515) 270-3581 Web: www.pioneer.com; E-mail: [email protected]

KEY PERSONNEL: Dean Oestreich; Pioneer President Diane C. Bridgewater; VP CFO Dennis Byron; VP, Crop Development Bill Fleet; VP, North America Sales Ian Grant; VP, Maize Development Mike Gumina; VP, Supply Management Bob Iwig; VP, Strategic Marketing Daniel Jacobi; VP and General Counsel Michael Lassner; VP, Trait Discovery Giuseppe Manara; VP, Global Sales Strategy Barbara Mazur; VP, Trait Technologies William Niebur; VP, DuPont Crop Genetics R&D Franci Phelan; VP, Human Resources Frank Ross; VP and Business Director, North America Operations Paul Schickler; VP and Business Director, International Operations Steve Waite; VP, Information Management and CIO Thomas G. West; VP, Biotech Affairs and Business Support


HISTORY: Founded in 1926 Member--Biotechnology Industry Organization Purchased the assets of Allelix Crop Technologies (12/90) Purchased Plant Cell Research Institute's RFLP program (3/91) Purchased Native Plants, Inc.'s RFLP program (4/91)

FACILITIES: Research at more than 140 locations in 30 countries worldwide


SUBSIDIARIES/DIVISIONS: Pioneer Argentina SA Pioneer Hi-Bred Australia Pty. Ltd. Pioneer Hi-Bred Services GmbH--Austria Carter's General Stores--Barbados Pioneer Hi-Bred Northern Europe Sales Division GmbH--Belgium Midwest Steel & Agro Supplies Co. Ltd.--Belize Semillas Villacruz SRL--Bolivia Du Pont do Brasil SA (Divisao Pioneer Sementes) Pioneer Semena Bulgaria Pioneer Hi-Bred Ltd.--Canada Semillas Pioneer Chile Ltda. Shandong Denghai-Pioneer Seeds Co.--China DuPont de Colombia SA Agricola Piscis SA--Costa Rica Pioneer Sjeme DOO--Croatia Pioneer Hi-Bred Services GmbH--Czech Republic Productora de Semillas Dominicanas--Dominican Republic



Misr Pioneer Seed Co.--Egypt Duwest--El Salvador Pioneer Hi-Bred Seeds (Ethiopia) plc Pioneer Semences SAS--France Pioneer Hi-Bred Northern Europe Sales Division GmbH--Germany Pioneer Hi-Bred Hellas SA--Greece Duwest--Guatemala Duwest--Honduras Pioneer Hi-Bred Magyarorszag Kft.--Hungary PHI Seeds Ltd.--India PT DuPont Indonesia Pioneer Hi-Bred Italia Srl Pioneer Hi-Bred Japan Co. Ltd. Farmchem Seedlinks Ltd.--Kenya Chemicals & Marketing Co. Ltd.--Malawi PHI Mexico SA de CV--Mexico Pioneer Hi-Bred Northern Europe Sales Division GmbH--The Netherlands Genetic Technologies Ltd.--New Zealand Duwest--Nicargua Pioneer Pakistan Seed Ltd.--Pakistan Grupo Melo--Panama Representaciones Agricolas de Miguel Villanueva EIR Ltda.--Peru Pioneer Hi-Bred Philippines Inc. Pioneer Hi-Bred Services GmbH--Poland Pioneer Hi-Bred Sementes de Portugal SA Pioneer Hi-Bred Puerto Rico Inc. Pioneer Hi-Bred Seeds Agro SRL--Romania Pioneer Semena Holding GmbH--Russia Pioneer Hi-Bred Services GmbH--Serbia and Montenegro Pioneer Hi-Bred Slovensko SRO--Slovakia Pioneer Semena Holding GmbH--Slovenia Pioneer Hi-Bred RSA (Pty.) Ltd.--South Africa O.M.C.--South Korea Pioneer Hi-Bred Spain SL Pioneer Hi-Bred Switzerland SA Bytrade Tanzania Ltd. Pioneer Hi-Bred (Thailand) Co. Ltd. Sheppard Enterprises Ltd.--Trinidad and Tobago Pioneer Tohumculuk AS--Turkey Pioneer Nasinnya Ukraine LLC Pioneer Hi-Bred Northern Europe Service Division GmbH--U.K. Agar Cross Uruguaya SA Semillas Pioneer de Venezuela Farmchem Services Ltd.--Zambia Pioneer Hi-Bred Zimbabwe (Pvt.) Ltd.

SUBSIDIARY OF: DuPont

BUSINESS STRATEGY: Produce, market and sell hybrid seed corn in nearly 70 countries worldwide Market and sell hybrids or improved varieties of sorghum, sunflower, soybean, alfalfa, canola, wheat, forage and grain additives

AGREEMENTS: Name Products Content of Agreement Date Affymetrix Inc. agricultural research feasibility

collaboration 4/97

CuraGen Corp. seed and agricultural products

$25M research collaboration--Pioneer made $7.5M equity investment and commitment to fund research for 5 years (6/97), expanded

4/98

Devgen NV develop superior crop varieties with resistance to plant pests


5/06



DFS Inc. measure levels of digestible energy in corn grain for animal feed

joint research collaboration

10/05


Herculex joint development agreement

E. I. Du Pont genomics and enabling technologies

research alliance, joint venture and equity stake

8/97

Ecogen Inc. seed corn containing Ecogen's Bt genes


Human Genome Sciences Inc.

corn genome collaboration agreement

1/96

InsectiGen InsectiGen's BtBooster technology


Kimeragen Inc. agricultural applications of Kimeragen's gene enhancement technology


Monsanto Co. YieldGard insect-protected Bt corn


Mycogen Corp. (now Mycogen Seeds)

agricultural seeds for corn, soybean, sunflower, canola, sorghum, and other crops with Bt-based insect resistance


12/95

Plant Genetics Systems NV

genetically engineered vegetable seeds

licensing agreement

Zeneca Mogen (now AstraZeneca)

fungal resistance technology

collaborative research and licensing agreement

2/94

OGS (Oxford, Glyco Sciences)

Proteomics research collaboration, proteomics technology, for improving agricultural seed products

9/98

RESEARCH & DEVELOPMENT: Hybrids of corn, sorghum, sunflower and canola, and varieties of soybean, alfalfa, wheat and canola Plant tissue culture, bioengineering of agricultural crops Gene transfer by DNA-coated tungsten particles (microprojectile bombardment) and other methods Specialty hybrids and varieties for end users

PRODUCTS ON MARKET: Hybrid corn, canola, sorghum and sunflower seeds, and seeds of soybeans, alfalfa and wheat varieties Silage, hay and high-moisture corn inoculants Software programs for farm production information Pioneer Information Network--project to link farmers and agribusiness with agriculture information



PLANTON GmbH

Am Kiel-Kanal 44 Kiel D-24106, Germany Phone: +49 431 380 15-0; Fax: +49 431 380 15-11 Web: www.planton.de E-mail: [email protected]

KEY PERSONNEL: Dr. Michael Kleine; CEO Prof. Dr. Florian Grundler; Director, R&D


HISTORY: Established in 2001

FACILITIES: 440 sq. m. total


BUSINESS STRATEGY: Develop and produce protein-based biopharmaceuticals

Polium Technologies Inc.

2155 Stonington Ave., Suite 119 Hoffman Estates IL 60195, US Phone: (847) 310-8725; Fax: (847) 310-8725 Web: www.polium.com E-mail: [email protected]

KEY PERSONNEL: Michael Gololobov, Ph.D.; President


HISTORY: Founded and began R&D in 2000


BUSINESS STRATEGY: Use its proprietary technology and products to accelerate drug discovery and pharmaceutical development

RESEARCH & DEVELOPMENT: Patented technology for the immobilization and recovery of enzymes and

small molecule catalysts

PRODUCTS ON MARKET: Finezyme™ systems Free enzymes Free ligands Rexalyst™ systems Beta amino acids Chiral intermediates SoluScav™ systems Fine chemicals Custom R&D services



Polydex Pharmaceuticals Ltd.

421 Comstock Road Toronto M1L 2H5, Canada Phone: (416) 755-2231; Fax: (416) 755-0334 Web: www.polydex.com E-mail: [email protected]

KEY PERSONNEL: George G. Usher; Chairman, President and CEO Sharon Wardlaw; Exec. VP


HISTORY: Founded in 1969 Began biotech R&D in 1974 Acquired Vet Labs of Lenexa, Kan. Sold Vet Labs in early 2004

FACILITIES: 28,000 sq. ft. Toronto production facility

STOCK-FINANCIAL HISTORY: NASDAQ--POLXF / Boston Stock Exchange--PXL Sales $5.265M (YE 06) compared to $6.372M (YE 05) Net loss <$1.489M> (YE 06) compared to <$1.140M> (YE 05) Earnings <loss> per share <$0.49/share> (YE 06) compared to $0.38/share (YE 05) Average shares outstanding 3.059M (YE 06) compared to 3.042M (YE 05)

PRIVATE PLACEMENTS: American Heritage Fund--1M shares at $1.75/share (12/94) SUBSIDIARIES/DIVISIONS: Dextran Products Ltd.--Scarboro, ON (see separate entry)

Corporate office: Polydex Pharmaceuticals Ltd. Sandringham House 83 Shirley Street Nassau, Bahamas Phone: (242) 322-8571 Fax: (242) 328-6919

PRINCIPAL INVESTORS: American Heritage Fund--$2.25M Continental Grain Co.--$3.6M

BUSINESS STRATEGY: Conduct research related to dextran

AGREEMENTS: Name Products Content of Agreement Date Canadian Bacterial Disease Network

Dextran research and licensing agreements

RESEARCH & DEVELOPMENT: Cystic fibrosis therapeutics Contraceptive gel (cellulose sulfate)

PRODUCTS ON MARKET: Iron dextran (veterinary and human) Dextran sulfate for hybridoma Veterinary generics

PRODUCTS IN DEVELOPMENT: Name Status Dextran for cystic fibrosis in clinicals Ushercell - contraceptive prophylactic in Phase II/III clinicals



Polysciences Inc.

400 Valley Road Warrington PA 18976, US Phone: (215) 343-6484; Fax: (215) 343-0214 Toll-free phone: (800) 523-2575 Web: www.polysciences.com E-mail: [email protected]

KEY PERSONNEL: Michael H. Ott; President Walter Baker; VP, Operations Dr. D. Templer; VP, Technology and Business Development Dr. Mark DeGrandpre; Director, Technology and Business Development Joe Dudenbostel; Purchasing Manager



FACILITIES: More than 150,000 sq. ft. at four U.S. locations 5,000 sq. ft. facility in Eppelheim, Germany


SUBSIDIARIES/DIVISIONS: Polysciences Europe GmbH Handelsstr. 3 Eppelheim D-69214, Germany Phone: +49 6221-765767 Fax: +49 6221-764620 E-mail: [email protected]

PRODUCTS ON MARKET: Diagnostic reagents, electrophoresis and chromatography supplies, electron

and light microscopy supplies, dyes and stains, polymeric biomaterials for medicine and dentistry, custom packaging and formulations Sponsored research on confidential basis (FDA facility) Latex microparticles for antibody coupling and precision size standards Tetrazolium salts, embedding waxes, and plastic embedding media Custom reagent synthesis and custom packaging Magnetic particles and flow cytometry particles

POS Pilot Plant Corp.

118 Veterinary Road Saskatoon S7N 2R4, Canada Phone: (306) 978-2800; Fax: (306) 975-3766 Toll-free phone: (800) 230-2751 Web: www.pos.ca; E-mail: [email protected]

KEY PERSONNEL: Robert E. Morgan, President and CEO Colin Luciuk; CFO Paul Fedec; VP, Scientific and Regulatory Affairs Karen Connell; Director, Finance


HISTORY: Founded in July 1977 as an applied research facility for grains and oilseeds processing

FACILITIES: 54,000 sq. ft. facility, including five pilot plant processing areas and 11 laboratories


BUSINESS STRATEGY: Provide contract R&D and custom processing services that facilitate the development of value added processing of agri-products for industries such as agbiotech, food, nutrachemicals, feed and fine chemicals.



PRODUCTS ON MARKET: Services include:

Process/Product development Laboratory services Analytical services Mini-scale product development Toll processing Quality assurance Chromatography Consulting services Support services

PrimeSyn Lab Inc.

11 Deer Park Drive, Suite 205 Monmouth Junction NJ 08852, US Phone: (732) 274-0660; Fax: (732) 274-0907 Toll-free phone: (877) Prime-03 Web: www.primesyn.com E-mail: [email protected]

KEY PERSONNEL: Surendra Chaturvedi, Ph.D.; CEO Barry Lynn; Exec. VP



FACILITIES: Headquarters, R&D and manufacturing facilities in Monmouth Junction, N.J.


BUSINESS STRATEGY: Provide products and services for contract research, product development and assay development within the bio-pharmaceutical industry

AGREEMENTS: Name Products Content of Agreement Date Biosearch Technologies

Quasar, CAL Fluor and Black Hole Quencher products


Premier Biosoft International

Array Designer, Beacon Designer, Primer Premier, SimVector and Xpression Primer software

marketing and distribution agreement

4/05

RESEARCH & DEVELOPMENT: Expertise is in organic synthesis and analysis to method development

PRODUCTS ON MARKET: PrimeSyn Lab Inc. is a recognized leader in the area of custom DNA/RNAi

synthesis and purification within the U.S. PrimeSyn Lab specializes in ULTRA PURE Oligonucleotides and ASRs for: Cloning, mutagenesis, fluorescent sequencing, microarrays, diagnostics and therapeutics. PrimeSyn Lab also provides analytical lab services: protein analysis, mass spectral analysis, protein purification / characterization, analytical methods development, small molecule synthesis and analysis.



Primm S.R.L.

Via Olgettina 58 Milan 20132, Italy Phone: +39 02 2104031; Fax: +39 02 2640355 Web: www.primm.it E-mail: [email protected]

KEY PERSONNEL: Paolo Sarmientos; CEO



FACILITIES: Laboratories, manufacturing facilities and commercial offices in Italy, Switzerland and the U.S. Animal facility located in the area of Treviso, Italy


SUBSIDIARIES/DIVISIONS: Animal Care Unit Via dell'Artigianato 2 Dosson di Casier, Treviso, Italy Phone: +39 0422 490200; Fax: +39 0422 490445

Primm GmbH Hochbordstrasse 9 Dubendorf, Zuerich CH-8600 Phone: +41 1 9423848; Fax: +41 1 9423986 E-mail: [email protected] PrimmBiotech Inc. Box 425695 Kendall Square Cambridge, MA 02142, USA Toll-free phone: (800) 893-4388 Fax: (617) 325-2703 E-mail: [email protected] Web: www.primmbiotech.com

Naples Facility: Via P. Castellino 111 80131 Naples, Italy Phone: +39 081 6132295 Fax: +39 081 19571728

BUSINESS STRATEGY: Provide biotechnology products (DNA, peptides, antibodies), R&D and contract R&D for an international market

AGREEMENTS: Name Products Content of Agreement Date Axxam aim is to set up an

automated high throughput sequencing platform

technological collaboration

6/02

RESEARCH & DEVELOPMENT: -Design, synthesis and pharmaceutical development of novel bioactive peptides for various therapeutical applications -Use of peptides to investigate problems such as the ligand-receptor interactions or to study the tridimensional structure of specific protein domains -Development of recombinant strains and technologies for the industrial production of biopharmaceuticals. In the last few years, Primm has developed technologies for the manufacturing of selected recombinant proteins in heterologous systems

PRODUCTS ON MARKET: Service and product divisions: DNA and RNA synthesis Peptide synthesis



Peptide nucleic acids Gene cloning and expression Analysis of proteins and peptides Monoclonal and polyclonal antibodies custom service Animal services

Procter & Gamble Co.

1 Procter and Gamble Plaza Cincinnati OH 45202, US Phone: (513) 983-1100; Fax: (513) 562-4500 Toll-free phone: (800) 764-7483 Web: www.pg.com E-mail: [email protected]

KEY PERSONNEL: Alan G. Lafley; Chairman, President and CEO Clayton C. Daley Jr.; CFO G. Gilbert Cloyd; CTO Richard L. Antoine; Global Human Resources Officer R. Keith Harrison Jr.; Global Product Supply Officer James J. Johnson; Chief Legal Officer and Secretary Mariano Martin; Global Customer Business Development Officer Charlotte R. Otto; Global External Relations Officer Filippo Passerini; Chief Information Officer and Global Services Officer James R. Stengel; Global Marketing Officer


HISTORY: Founded in 1837 by William Procter and James Gamble Member--Biotechnology Industry Organization Acquired the Philippine Manufacturing Company (1935) Acquired Charmin Paper Mills (1957) Acquired Nippon Sunhome Company (1973) Acquired Norwich Eaton Pharmaceuticals (1982) Acquired Noxell (1989) Acquired Shulton's Old Spice product line (1990) Acquired Max Factor and Betrix (1991) Acquired VP Schickedanz (1994) Acquired the Iams Company (1999) Acquired Recovery Engineering Inc. (1999) Acquired the Clairol business from Bristol-Myers Squibb Co. (2001) Acquired The Gillette Co. (2005)

FACILITIES: 39 manufacturing facilities in 23 states in the U.S. 107 manufacturing facilities in 42 other countries

STOCK-FINANCIAL HISTORY: NYSE--PG Net sales $56,741M (YE 05) compared to $51,407M (YE 04) Net income $7,257M (YE 05) compared to $6,481M (YE 04) Earnings per share $2.66/share (YE 05) compared to $2.46/share (YE 04) Total assets $61,527M (YE 05) compared to $57,048M (YE 04)

SUBSIDIARIES/DIVISIONS: Modern Products Co.--Saudi Arabia P&G Interamericas Inc.--Buenos Aires, Argentina P&G Australia Pty. Ltd. P&G Austria GmbH Procter & Gamble--Minsk, Belarus P&G Belgium BVBA P&G Trgovacko Drusvo djl--Sarajevo P&G do Brazil Procter & Gamble OOD--Sofia, Bulgaria P&G Inc.--Toronto, Canada Procter & Gamble Representation Office--Kazakhstan P&G Guangzhou Ltd.--China P&G Chile Inc. Agencia--Santiago



Procter & Gamble Interamericas--San Jose, Costa Rica P&G Colombia SA--Bogota Procter & Gamble doo--Zagreb, Croatia P&G Rakona AS--Prague, Czech Republic Procter & Gamble DK A/S--Denmark Distribuidora Corripio/Division P&G--Santo Domingo, Dominican Republic P&G Egypt--Cairo P&G El Salvador--San Salvador Procter & Gamble--Kalmistu, Estonia Procter & Gamble Oy--Espoo, Finland P&G France Procter & Gamble GmbH--Germany P&G Hellas--Athens, Greece P&G Interamericas Inc.--Guatemala City, Guatemala P&G Hong Kong Ltd. Procter & Gamble KTT--Budapest, Hungary P&G India Ltd. GO--Bombay, India P&G Indonesia--Jakarta P&G Ireland Ltd. P&G Israel--Tel-Aviv P&G Srl--Rome, Italy Procter & Gamble Far East Inc.--Japan Procter & Gamble Almaty--Kazakhstan P&G East Africa Ltd.--Nairobi P&G Korea Inc.--Seoul P&G Marketing Latvia Ltd. P&G Mfg Co. of Lebanon SAL P&G (M) Sdn Bhd--Malaysia P&G de Mexico S de RL de CV Industries Marocaines Modernes--Casablanca, Morocco Procter & Gamble Nederland BV--Rotterdam, The Netherlands P&G NPD Inc.--Auckland, New Zealand P&G Nigeria Ltd. Procter & Gamble Norway A/S--Oslo P&G Pakistan Pvt. Ltd. Procter & Gamble del Peru SA--Lima P&G Philippines Inc. P&G Operations Polska SA--Warsaw, Poland P&G Portugal SA P&G Commercial Co.--Puerto Rico P&G Marketing Romania SRL Procter and Gamble OOO--Russia P&G (S) Pte. Ltd.--Singapore Procter & Gamble Spol. Sro--Slovak Republic Procter & Gamble doo--Slovenia Procter and Gamble SA (Pty) Ltd.--Johannesburg, South Africa P&G Espana SA--Madrid, Spain Procter & Gamble Nordic Inc.--Stockholm, Sweden Procter & Gamble International Operations SA--Geneva, Switzerland Procter & Gamble Taiwan Ltd.--Taipei P&G Manufacturing (Thailand) Ltd.--Bangkok Procter & Gamble Tuketim Mallari Sanayi AS--Turkey P&G Ukraine--Kiev P&G Gulf FZE--Dubai Procter & Gamble UK--England The Procter & Gamble Co.--Cincinnati, Ohio Procter & Gamble Representative Office--Uzbekistan Procter & Gamble de Venezuela CA--Caracas Procter & Gamble Vietnam Ltd. P&G Yemen Ltd. P&G c/o Nelt--Belgrade, Yugoslavia



BUSINESS STRATEGY: Purpose: Provide branded products and services of superior quality and value that improve the lives of the world's consumers. As a result, consumers will reward us with leadership sales, profit, and value creation, allowing our people, our shareholders, and the communities in which we live and work to prosper

AGREEMENTS: Name Products Content of Agreement Date Advanced Polymer Systems Inc.

Microsponge systems containing dimethicone for use in baby wipe products

licensing and supply agreement

7/96

Advanced Tissue Sciences Inc.

human tissue system to screen oral drugs


6/91

Advanced Tissue Sciences Inc.

in vitro assay to test products for eye safety combining ATS's Skin2™ with P&G's procedure for conducting eye irritation studies

licensing agreement--ATS granted exclusive worldwide rights to market

9/92

Alimentary Health Ltd.

therapies for gastrointestinal disorders


12/05

Alza Corp., Hoechst Marion Roussel Inc.

Ditropan (oxybutynin chloride) for treating urge urinary incontinence

Alza acquired Canadian marketing rights and right to use Ditropan® trademark in Canada with other Alza products, Hoechst will manufacture and package product, Alza will submit marketing application for Ditropan® XL in Canada

4/98

Allelix capillary immunoassays

for home market R&D and marketing agreement through Richardson-Vicks

4/87

Biopulping Consortium (University of Wisconsin and USDA)

lignin degrading fungi collaborative research agreement

Calgene Inc. rDNA rapeseed for

specialty oil as food additive


1985

Curis Inc. treatments for hair growth using Curis' Hedgehog agonist technology

research and development agreement

9/05

Cygnus Inc. smoking cessation products


2/94

Epoch Pharmaceuticals Inc.

Epoch's periodontal diagnostic test

development agreement--P&G will have first option to license the test for exclusive distribution in the U.S. and Canada

10/93



Gene Logic Inc. genetic targets for drug development in heart failure and two undisclosed diseases

$75M drug development ageement

6/97

Geron Corp. Geron's human telomerase reverse transcriptase technology


Lederle Laboratories

Ziac (bisoprolol and hct) joint marketing agreement

12/92

Locus Pharmaceuticals Inc.

treatment for diabetes research agreement 7/04

MGI Pharma Inc. Didronel IV infusion MGI bought exclusive rights to IV form for oncology market (P&G to retain rights to oral form)

1/90

Oxford Molecular Group plc.

Oxford's RS3 Discovery and RS3 Discovery High-Throughput Screening research information management software in P&G's discovery research programs


Quidel Corp. Quidel's QuickVue 1-step H. pylori test and P&G's Helidac therapy

one-year, renewable copromotion agreement

1/97

Regeneron Pharmaceuticals Inc.

treatments for muscle diseases and disorders

drug discovery collaboration (12/96), P&G made equity investment by purchasing $10M of Regeneron stock (3/97), expanded to include obesity related to Type II diabetes (9/97), P&G made $5M milestone payment

7/98

Sanofi-Aventis Actonel (risedronate sodium tablets); includes option for P&G to acquire oral health care brands from sanofi-aventis

continuation of R&D and commercialization agreement

10/04

Synergen Inc. collagenase inhibitor for treatment of periodontal disease


3/86

TheraTech Inc. estradiol and estradiol/progestin

worldwide development and distribution agreement excluding parts of Asia

3/95

TheraTech Inc. transdermal testosterone and combination estradiol/testosterone hormone replacement patches for women

development agreement--P&G will fund all development, TheraTech gets R&D payments and

12/97



milestones of $35M as well as royalties, TheraTech will manufacture products and retains certain copromotion rights, P&G gets worldwide rights (except Asia)

Trega Biosciences Inc.

Trega's combinatorial chemistry libraries

screening agreement. P&G identified series of lead compounds and has exercised option to exclusive worldwide license to further develop these compounds, Trega received undisclosed milestone payment (5/98)

1/95

Zila Inc. Zila's diagnostic test for oral cancer

exclusive marketing rights

2/96

RESEARCH & DEVELOPMENT: P&G Health Sciences Institute focuses on gastrointestinal health, pain relief, respiratory products and safe drinking water Recent R&D efforts include: --Dryel®, a way to care for dry-clean-only clothes in the home --The first recombinant detergent enzymes, developed in collaboration with Genencor, for use in liquid laundry detergents --Actonel®, the first osteoporosis therapy to consistently demonstrate a reduction in the incidence of spinal fractures after one year of treatment --Physique®, a hair care line using polymers and cleaning/conditioning systems --Impress®, a new form of food wrap --Febreze®, a spray that uses chemistry to capture odor-causing materials --Iams® Hairball Care™, which uses fiber technology in cats' diets to prevent hair ball formation --Crest Whitestrips™, a way to whiten teeth 10 times better than the leading whitening toothpaste

PRODUCTS ON MARKET: Markets more than 300 branded products in more than 160 countries, including: FABRIC AND HOME CARE: Tide, Ariel, Downy, Lenor, Dawn, Fairy, Joy, Gain, Ace Laundry and Bleach, Swiffer, Dash, Bold, Cascade, Mr. Clean, Febreze, Bounce, Cheer, Era, Bonux, Dreft, Daz, Flash, Vizir, Salvo, Viakal, Maestro Limpio, Rindex, Myth, Alomatik BEAUTY CARE: Pantene, Olay, Head & Shoulders, Clairol’s Herbal Essences, Nice ‘n Easy, Natural Instincts and Hydrience, Cover Girl, SK-II, Max Factor, Hugo Boss, Safeguard, Rejoice, Secret, Old Spice, Zest, Vidal Sassoon, Pert, Ivory, Lacoste, Aussie, Infusium 23, Camay, Noxzema, Infasil, Joy Parfum, Valentino, Sure, Wash&Go, Wella, Koleston, Wellaflex, Shockwaves, Rochas, Escada, Gucci, Always, Whisper, Tampax, Naturella, Evax, Ausonia, Orkid BABY AND FAMILY CARE: Pampers, Luvs, Kandoo, Dodot, Charmin, Bounty, Puffs, Tempo



HEALTH CARE: Crest, Iams, Eukanuba, Actonel, Vicks, Asacol, Prilosec OTC, Metamucil, Fixodent, PUR, Scope, Macrobid, Pepto-Bismol, Didronel, ThermaCare, Blend-a-med SNACKS AND BEVERAGES: Pringles, Folgers, Millstone

Prokaria ehf

Gylfaflot 5 Reykjavík IS - 112, Iceland Phone: +354 570 7903; Fax: +354 570 7901 Web: www.prokaria.com E-mail: [email protected]

KEY PERSONNEL: Prof. Jakob K. Krist; President and CEO Valborg Guomundsdottir; CFO Dr. Gudmundur Oli Hreggvidsson; VP, R&D Dr. Arnbor AEvarsson; Manager, Bioinformatics and Marketing Dr. Sigríour Hjorleifsdottir; Manager, Operations


HISTORY: Founded in June 1998 as Islenskar hveraorverur Merged with Islensk natturuefni (Icelandic Natural Substances) (1/00)


PRIVATE PLACEMENTS: Raised US$13.5M (9/00)

BUSINESS STRATEGY: Discover, develop and produce industrial enzymes for food, feed and chemical applications Develop, produce and market thermostable molecular enzymes, such as DNA polymerase, ssDNA ligase and other for genetic research and diagnostics Offer DNA analytical services for fish, animals and the environment


bitop AG screening and development program for novel compatible solutes from extremophilic microorganisms

partnership agreement

5/03

Blue Lagoon Ltd. investigations of the biodiversity


deCODE genetics strategic alliance 12/98 Marine Research Institute of Iceland (MRI)

fish genetics collaboration agreement

1/04

Nestle Research Center

screening program program for the discovery of natural components for food applications


Novartis Animal Health Inc.

Prokaria's novel biomolecules for screening purposes


Novozymes A/S Prokaria's industrial enzyme specialties


Roquette Frere novel industrial enzymes


3/03



PRODUCTS ON MARKET: Services: DNA sequencing Genotyping Microbial species analysis: Species composition of unculturables, species identification of cultivated organisms Screening assay development Preparation of HTS extracts for small molecular screening (pharma, cosmetics) Discovery and development of extremophilic genes and enzymes Provision of test samples

Prometic BioSciences Inc.

155 Willowbrook Boulevard, Suite 460 Wayne NJ 07470, US Phone: (973) 812-9880; Fax: (973) 812-9881 Toll-free phone: (888) 472-4225 Web: www.prometic.com E-mail: [email protected]

KEY PERSONNEL: Pierre Laurin; Chairman, President and CEO, Prometic Life Sciences Inc. Steven J. Burton; CEO, Prometic BioSciences Ltd. Christopher L. Penney; VP and CSO, Therapeutics



Began biotech R&D in 1995 Acquired Affinity Chromatography Ltd. UK Member--Biotechnology Industry Organization


SUBSIDIARY OF: Prometic Life Sciences Inc. (see separate entry)

BUSINESS STRATEGY: Discover and develop proprietary drugs in the fields of cancer and

autoimmune diseases Actively looking for partners to co-develop and eventually market PBI-1402 and PBI-1393

AGREEMENTS: Name Products Content of Agreement Date American Red Cross

prion removal/det collaborative R&D 1999

American Red Cross

plasma proteins collaborative R&D agreement

1997

BioMena SA ProMetic's Enabling Technology


Euroflow process columns large scale process data

2003

GlaxoSmithKline plc

Prometic's purification technology


7/04

Menarini purification of avidiplas R&D manufacture agreement

2001

Novo Nordisk University of Cambridge UK

proteins collaborative R&D 1995

Octapharma AG ProMetic's advanced Mimetic Ligand affinity technology for Octapharma protein product


1/05



RESEARCH & DEVELOPMENT: Specific affinity ligands for targeting therapeutic proteins Large scale plasma Avidiplas purification Therapeutic protein screening from yeast, plasma and transgenic milk

PRODUCTS ON MARKET: Mimetic™ affinity adsorbents Bioprocess chromatography media mAB binding adsorbents

PRODUCTS IN DEVELOPMENT: Name Status PBI-1402 for peripheral arterial disease in Phase Ib/II clinicals PBI-1393 ready to begin clinicals

Proteus SA

70, allee Graham Bell, Parc Georges Besse Nimes 30000, France Phone: +33 (0)4 66 70 64 64; Fax: +33 (0)4 66 70 64 60 Web: www.proteus.fr E-mail: [email protected]

KEY PERSONNEL: Daniel Dupret; Chairman, President and CEO Marc Vander Linden; CFO Gilles Ravot; CSO Jean-Marie Sonet; VP, Business Development and Marketing Jean Francois Bloch; VP; Intellectual Property and Licensing



FACILITIES: 2,500 sq. m. R&D facility


PRINCIPAL INVESTORS: Axa Placement Innovation

FCJE Natexis Ventech Sofilars Sofimac Soridec Viveris Management

BUSINESS STRATEGY: Contract research A strategic biotech R&D resource for the industry

AGREEMENTS: Name Products Content of Agreement Date Aventis Animal Nutrition

enzymes for animal feed

R&D agreement 1999

CEA LETI (Commissariat a l’energie atomique)

biochips for biodefense collaborative R&D agreement

2000

Degussa enzymes for specialty chemistry

R&D agreements and alliance

19992000 2004

ELF extremophilic micro-organism

screening for novel enzyme from extremophilic micro-organism

1999

Girffioth University, Brisbane, Australia

extremophilic micro-organism


2000



Hebrew University of Jerusalem



1999

I.R.D. (Institute of R&D)



1999

Ifremer extremophilic micro-organism


1999

Russian Academy of Science



2005

Thales systems for detection and identification of biological attack

R&D agreements 1999200020022003

University of Bern chemistry for high throughput funcitonal screening

collaborative R&D agreements

20002004

University of Buenos Aires



2005

RESEARCH & DEVELOPMENT: Novel proteins, novel industrial enzymes, new industrial chemo-biocatalytoc routes, biodiversity screening, protein engineering, development of gene based assay for the industry

Qbiogene

15 Morgan Irvine CA 92618-2005, Canada Phone: (440) 337-1200; Fax: (949) 421-2675 Toll-free phone: (800) 854-0530 Web: www.qbiogene.com E-mail: [email protected]

KEY PERSONNEL: Milan Panic; Chairman and CEO, MP Biomedicals Dr. Garth Cumberlidge; President and CEO Steve Peronne; CFO


HISTORY: Founded in 1991 Began biotech R&D in 1993 Began sales in 1996 Aquired Appligene-Oncor, Strasbourg, France Merged with Bio-101, Inc. and changed name from Quantum Biotechnologies (7/00) Acquired Alexis Biochemicals, Switzerland Acquired Bio-101, Carlsbad, California Acquired by MP Biomedicals

STOCK-FINANCIAL HISTORY: Privately held SUBSIDIARY OF: MP Biomedicals

BUSINESS STRATEGY: Develop and market novel and innovative products for gene delivery, gene therapy applications and molecular biology applications related to the study of the structure and function of the human genome



AGREEMENTS: Name Products Content of Agreement Date BTC nucleotides, enzymes,

probes supply agreement 1995

Hoffmann-La Roche Ltd./Perkin-Elmer Corp.

native and recombinant Taq DNA polymerase and other thermostable enzymes for use in polymerase chain reaction process

development, manufacturing and marketing agreement

3/98

INRA CNRS baculovirus expression systems

technology development agreement

1996

NCI AFP expression vectors distribution license and CRADA

1996

NRC Canada adenovirus expression system

exclusive worldwide agreement

2/92

NRC Canada recombinant yeast lytic enzyme


10/91

NRC Canada site-directed mutagenesis


10/91

Universite de Montreal

pGATA cloning system technology development agreement

1996

RESEARCH & DEVELOPMENT: Gene delivery systems

Custom services - Adinoviral

PRODUCTS ON MARKET: FISH kits and buffers DNA polymerases Baculovirus expression system and custom services Peptide coupling reagents Cloning vectors Gene delivery systems DNA panels Yeast lytic enzyme Adenovirus and bacterial (Alkaline Phosphatase [PhotA*} fusion)expression systems Autofluorescent proteins Positive selection vector Custom peptide synthesis Embyonal tissue mRNAs and cDNAs Custom services (Adenovirus, antibodies and peptides) Bio-101 systems Media Purification--DNA/RNA Fast Prep system

PRODUCTS IN DEVELOPMENT: Name Status Second-generation adenoviral vectors in development Transfection systems in development Two-hybrid systems in development



Quip Laboratories Inc.

1500 Eastlawn Avenue Wilmington DE 19802, US Phone: (302) 791-2600; Fax: (302) 761-2611 Toll-free phone: (800) 424-CHEM (2436) Web: www.quiplabs.com E-mail: [email protected]

KEY PERSONNEL: Timothy B. Hidell; President



FACILITIES: 30,000 sq. ft. building for administrative offices, R&D, quality control, and production and shipping facilities


PRODUCTS ON MARKET: ACID CLEANERS:

Acid Detergents: Acidulate, Acidulate 28, Acidulate 30HF, Acidulate 45-C, Acidulate 45T, Acidulate 50, Acidulate 60, Acidulate 150, Acidulate ATG, Acid 50-W Acid Neutralizers: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 1500 Acid Neutralizers Caustics: Enviro-Kleen 500N, WWN-1 ALKALINE CLEANERS Alkaline Detergents: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 700, Enviro-Kleen 900, Enviro-Kleen 900S, Enviro-Kleen 1100, Enviro-Kleen 1200, Enviro-Kleen 1500, Spray Kleen LV, WWN-1 Alkaline Neutrailizers: Acidulate, Acidulate 45C, Acidulate 50 Hard Surface Disinfectants/Cleaners: Anlage 20, Anlage QTB, Iodex AR/18, MB-2000, MB-10 tablets Chlorine Dioxide Products: MB-10 tablets, MB DeoTrex-30 sachets ICS Iodine Solutions: ICS iodine blocks, ICS iodine drain gel powder, ICS iodine links, Iodex GS25, Iodex hand soap, Iodex AR/18

Ramot at Tel Aviv University Ltd.

P.O. Box 39296, 32 Haim Levanon Street Tel Aviv 61392, Israel Phone: +972 3-640-6608; Fax: +972 3-640-6675 Web: www.ramot.org; E-mail: [email protected]

KEY PERSONNEL: Prof. Hagit Messer-Yaron; Chairman Yehuda Niv, Ph.D.; CEO Ze'ev Weinfeld, Ph.D.; Exec. VP, Business Development Irit Ben Chlouch; Director, Business Development, Life Sciences Nissim Chen, Ph.D; Director, Business Development, Life Sciences Amiram Porath; Business Development European Projects Coordinator Tamar Raz, Ph.D.; Director, Business Development, Life Sciences Hanan Terkel; VP, Business Development Ronen Cohen; CFO Larissa Shniderman; Director, R&D Budget and Control



FACILITIES: R&D facilities on Tel Aviv University campus




SUBSIDIARY OF: Tel Aviv University Economic Corp.

BUSINESS STRATEGY: Technology transfer company of Tel Aviv University, dedicated to promoting research collaboration between the university and industry, through licensing agreements, joint ventures, start up companies and sponsored research collaborations

RESEARCH & DEVELOPMENT: The full spectrum of life sciences research

PRODUCTS ON MARKET: Technologies available in agrotech, bioinformatics, biotechnology, computer science, diagnostics, engineering, medical devices and pharmaceuticals

Randox Laboratories Ltd.

55 Diamond Road, Ardmore Crumlin BT29 4QY, UK Phone: +44 (0) 28 9442 2413; Fax: +44 (0) 28 9445 2912 Web: www.randox.com E-mail: [email protected]

KEY PERSONNEL: Dr. S. Peter Fitzgerald; Managing Director Wilhelmena Fitzgerald; Director R. J. Fitzgerald; Facilities Director C. D. M. Fitzgerald; Sales Director


HISTORY: Founded in April 1982

FACILITIES: 200,000 sq. ft. of production, R&D and office facilities


FINANCIAL INFORMATION: Wholly owned by Fitzgerald family

BUSINESS STRATEGY: Reinvest all profits in company to continue a policy of extensive development of new products

PRODUCTS ON MARKET: evidence®

evidence investigator™ RX daytona™ Antioxidant tests Riqas (EQA scheme) 247 software package Clinical chemistry products ELISA kits for detection of drug residues in meat, serum and urine Proteins Recombinant proteins Polyclonal antibodies

Reanal Finechemical Co.

Telepes UT 53. Budapest 1147, Hungary Phone: +36 (1) 46 77 533; Fax: +36 (1) 384 3102 Web: www.reanal.hu E-mail: [email protected]

KEY PERSONNEL: Dr. Istvan Nagy; President Gyorgy Orosz, Ph.D.; Director, Marketing and Sales Tamas Nagy; Head, Fine Chemicals, Agrochemicals



Zsolt Horvath; Head, Laboratory Reagents, Diagnostics Andras Lengyel; Director, Production and Engineering Iren Huszkane Szimuj; Director, Finance



RESEARCH & DEVELOPMENT: Protected amino acids and amino acids derivatives

Peptide reagents Resins

PRODUCTS ON MARKET: Protected amino acids and amino acids derivatives Peptide reagents Resins Crown ethers Biological buffers Cellulose ion exchangers Agrochemicals Other fine chemicals

RECO Biotechnology

710 Hospital Street Richmond VA 23219, US Phone: (804) 644-2800; Fax: (804) 643-1335 Web: www.recobio.com E-mail: [email protected]

KEY PERSONNEL: Mike Schleinkofer; President and CEO Shane Kasper; Project Engineer Charles A. Firth; Sales Manager


HISTORY: Founded in 1914 Began biotech R&D in 1993 Reco Biotechnology is the trade name for Aqua Clean Environmental of Virginia LLC

FACILITIES: 20,000 sq. ft. headquarters 165,000 sq. ft. indoor treatment, recycling and waste management facility


SUBSIDIARIES/DIVISIONS: Biotechnology Environmental Division

BUSINESS STRATEGY: Operate as a comprehensive provider for non-hazardous waste management services Offer obioremediation, physical and chemical liquids treatment, fuel recycling, processing and disposal for a variety of industrial and environmental clean-up residuals

RESEARCH & DEVELOPMENT: Remediation of environmental contaminants using xenobacteria



Recordati SpA

Via M. Civitali, 1 Milan 20148, Italy Phone: +39 2-487871; Fax: +39 2-40073747 Web: www.recordati.com; E-mail: [email protected]

KEY PERSONNEL: Giovanni Recordati; Chairman and CEO Walter Bevilacqua; VP and Director, Corporate Development Giorgio Oberrauch; VP and GM, Pharmaceutical Chemicals Abraham Sartani; VP and Director, Pharmaceutical R&D Division Fritz Squindo; CFO Franco TomasniI; VP and Director, Purchasing and Logistics


HISTORY: Founded in 1926 Acquired Merckle GmbH's branded pharmaceutical business (2/05) To acquire Jaba Farmaceutica (as of 7/06)

STOCK-FINANCIAL HISTORY: Italian Stock Exchange--(Reuters REC.MI) (Bloomberg REC IM) (ISIN IT 003074447) IPO--1984 Revenue EUR576.1M (YE 05) compared to EUR479.2M (YE 04) Net income EUR64.5M (YE 05) compared to EUR53.1M (YE 04)

PRIVATE PLACEMENTS: Raised $100M in private placement (10/04)

SUBSIDIARIES/DIVISIONS: Recordati SA--Luxembourg Innova Pharma SpA--Italy Bouchara Recordati SAS--France Recodati Hellas Pharmaceuticals SA--Greece Recordati Corp.--U.S. Recordati SA--Switzerland Recordati Espana SL--Spain Merckle Recordati GmbH--Germany Recordati Ireland Ltd. Recordati Pharmaceuticals Ltd.--U.K.

AGREEMENTS: Name Products Content of Agreement Date Allergan Imidazyl, Herbe distribution

agreement 1994

Angelini prulifloxacin non-exclusive licensing agreement

9/04

ASINEX Ltd. micturition disorders drug discovery collaboration

10/04

BYK Gulden Peptazol (pantoprazole) non-exclusive licensing agreement

1/02

Dexcel Ltd. oral formulation of cyclosporin

exclusive liensing agreement

10/02

Digital Gene Technologies Inc.

Digital's gene expression technology and Recordati's calcium channel blocker (Lercanidipine) against atherosclerosis

licensing agreement--Digital received $3M up front and could receive milestone payments and royalties

4/97

Eurand International SpA

modified-release formulation of lercanidipine (Zanidip)


9/04

Grupo Uriach rupatadine licensing agreement 9/04 InfaCare Pharmaceutical Corp.

development and marketing of Stanate (stannsoporfin)


6/05

Kissei Pharmaceutical Co. Ltd.

silodosin licensing agreement 10/04



Kowa pitavastatin licensing agreement 10/01 Labopharm Europe

once-daily tramadol licensing and distribution agreement for the UK

11/05

Lavipharm Laboratories Inc.

transdermal patch containing the narcotic analgesic fentanyl

multi-territorial license agreement

7/05

LifeCycle Pharma A/S

modified-release formulation of Lercanidipine


4/04

Lundbeck escitalopram (Gaudium) marketing and licensing agreement

1/02

Mylan Technologies Inc.

nitroglycerin transdermal patch


5/01

Ono Pharmaceuticals

alprostadil alpha-ciclodextrin

licensing-in agreement

1989

Pharmacia Corp. treatments for overactive bladder


8/00

Syntex-Roche Cymevene, Gynestrel, Naprosyn, Synflex, Syntaris, Toradol


1961

Tsumurab lercanidipine licensing-out agreement for Japan

1996

Warner-Lambert Co.

Acequin (quinapri), Acequide (quin+HCTZ)


1988

RESEARCH & DEVELOPMENT: Urogenital and cardiovascular therapeutic areas

PRODUCTS ON MARKET: Fienamina® Proctolyn® Lomexin® Influvit® Tossoral™ Lacto™ Imidazyl® Imidazyl® Antistaminico e Eumill™ Antispasmina Colica® Solvobil® Alovex® Antoral® Dent Oral® Naprosyn Gel® Valontan® Transcop® transdermal patch Indusil® Alomed ™

Regis Technologies Inc.

8210 Austin Avenue Morton Grove IL 60053, US Phone: (847) 967-6000; Fax: (847) 967-1214 Toll-free phone: (800) 323-8144 Web: www.registech.com E-mail: [email protected]

KEY PERSONNEL: Louis Glunz IV.; President Louis Glunz III, Ph.D.; CEO Sean Bradley, Director, Business Development, Custom Manufacturing Division





FACILITIES: Full service cGMP custom manufacturing facility


BUSINESS STRATEGY: Develop proprietary separations technology for the life sciences industry Provide contract manufacturing for pharmaceuticals in a GMP facility

AGREEMENTS: Name Products Content of Agreement Date Research Corp. Technologies

chiral stationary phases research agreement 4/93

RESEARCH & DEVELOPMENT: Chiral HPLC columns IAM column for predicting drug permeability Custom organic synthesis Analytical method development Process research

PRODUCTS ON MARKET: Regisil (BSTFA) Whelk-O Pinkerton column Luciferin

Renessen LLC

520 Lake Cook Road, Suite 220 Deerfield IL 60015, US Phone: (847) 236-5101; Fax: (847) 236-5146 Web: www.renessen.com E-mail: [email protected]

KEY PERSONNEL: Michael Stern, Ph.D.; CEO Neal Jakel; Ethanol Project Manager


HISTORY: Founded in 1999 Joint venture between Cargill Inc. and Monsanto Co.

FACILITIES: Building a pilot plant with higher-value ethanol production at Cargill's Iowa Bioprocesssing Center campus in Eddyville, Iowa (scheduled to open in 1/07)


SUBSIDIARIES/DIVISIONS: Argentina office:

Panamericana Ramal Pilar. km 49.5 Edificio Bureau Office 2.2.7 (1629) Pilar, Buenos Aires, Argentina Phone: +54 2322.473.821 Fax: +54 2322.473.816 E-mail: [email protected]

SUBSIDIARY OF: Cargill Inc. and Monsanto Co.

BUSINESS STRATEGY: Develop improved ingredients/inputs for the feed and processing industry Use biotechnology and breeding to produce corn and soybeans with higher levels of nutrients (such as oil, protein and amino acids) that are important in feeding animals and processing grain



RESEARCH & DEVELOPMENT: Agricultural biotechnology: Application of plant biotechnology to improve the energy content, essential amino acids, protein and fiber composition of corn and oilseeds for animal nutrition. Use biotechnology to improve crop processing (for example, oil and starch processing, meal, ethanol and biodiesel production) Corn processing technology: Pilot plant under construction will test processing technologies that extract the trait value of the new Mavera high value corn. The technology is expected to make ethanol manufacturing more profitable and to provide the opportunity for farmers to grow net revenue enhancing crops on broad acres.

PRODUCTS ON MARKET: Mavera™ program for growers and animal producers

Renovo Group plc

The Manchester Incubator Building, 48 Grafton Street Manchester M13 9XX, UK Phone: +44 (0) 161 606 7222; Fax: +44 (0) 161 606 7333 Web: www.renovo.com E-mail: [email protected]

KEY PERSONNEL: Rodger Pannone; Chairman Prof. Mark Ferguson; CEO Dr. Sharon O’Kane, Exec. Director, R&D Andrew Kay; Exec. Director, Commercial Robin Cridland; Exec. Director, Finance and Business Development



STOCK-FINANCIAL HISTORY: LSE--RNVO IPO--87p/share, £50M

PRIVATE PLACEMENTS: Raised £21M (US$33M) in financing (12/02) Raised £2M (US$3.2M) in over-subscription to its second round of financing (1/03)

PRINCIPAL INVESTORS: Atlas Venture

BioVeda Capital (Pte.) Ltd. Care Capital LLC HealthCap JPMorgan Partners Temasek

BUSINESS STRATEGY: Leverage extensive scientific knowledge to develop commercial product

candidates in scar prevention and reduction Be first-to-market with a pharmaceutical product to prevent and reduce scarring Continue to advance and expand the company's clinical and preclinical pipeline Extend the significant market potential for the company's lead product candidates to multiple body sites and fibrotic disorders Pursue a commercialization strategy working with partners to increase speed and depth of market penetration

RESEARCH & DEVELOPMENT: Prevention and reduction of scarring throughout the body, including skin,

vascular restenosis, eyes, nerves, adhesions and strictures, tendons and ligaments, fibrotic disorders



Ongoing research focused on: Investigating the biology of scarring and wound healing Genomic microarray analysis and the ensuing inhouse databases Comparison of scar-free embryonic healing with scar-forming adult healing Hypothesis testing using in vitro and in vivo experimentation Keloids Focused proteomics Focused chemistry

PRODUCTS IN DEVELOPMENT: Name Status Juvista in Phase II clinicals Juvidex in Phase II clinicals Prevascar in Phase II clinicals Zesteem in Phase II clinicals

Research Organics Inc.

4353 East 49th Street Cleveland OH 44125, US Phone: (216) 883-8025; Fax: (216) 883-1576 Toll-free phone: (800) 321-0570 Web: www.researchorganics.com E-mail: [email protected]

KEY PERSONNEL: Rob Sternfeld; President and CEO



FACILITIES: 40,650 sq. ft. production facilities, laboratories, offices, quality control division, shipping and receiving, and warehouses


BUSINESS STRATEGY: Develop, manufacture, and supply highly purified biochemicals for molecular biology, cloning applications, diagnostic chemicals and cell culture

RESEARCH & DEVELOPMENT: Biological buffers

Fluorescent labels, bulk biochemicals, research biochemicals, enzyme test substrates Buffers

PRODUCTS ON MARKET: Biological buffers, reagent biochemicals, molecular biology grade products, enzyme substrates, fluorescent compounds, amino acids and derivatives, ACS reagents, USP and FCC products, neurochemicals and plant tissue culture reagents

Research Triangle Park Laboratories Inc.

8109 Ebenezer Church Road Raleigh NC 27612-7307, US Phone: (919) 510-0228; Fax: (919) 510-0141 Toll-free phone: (800) 291-4RTP (4787) Web: www.rtp-labs.com; E-mail: [email protected]

KEY PERSONNEL: Alston Sykes; President


HISTORY: Founded in October 1993 Began biotech R&D in 1996 Spun off from a division of Corning Inc. in 1997



FACILITIES: 4,000 sq. ft. R&D facility


BUSINESS STRATEGY: Support biotech and pharmaceutical industries with R&D analytical services

RESEARCH & DEVELOPMENT: Air toxics testing for hazardous and cancer causing chemicals in products,

pollution sources, landfill gases, ambient and indoor air, and pesticide/herbicide testing Chemical emissions testing of building materials, office equipment, printers, toys, microwavable food and its packaging, paper products, printing inks, foam insulation products, adhesives and pest control devices Herbal/botanical nutraceuticals and pharmaceutical industries: Testing for active compound purity, identification of impurities, stability, cleaning validations, controlled substances and special projects Manufacturing industries: Testing of products to support R&D and regulatory testing activities

Response Biomedical Corp.

100-8900 Glenlyon Parkway Burnaby V5J 5J8, Canada Phone: (604) 456-6010; Fax: (604) 456-6066 Toll-free phone: (888) 591-5577 Web: www.responsebio.com E-mail: [email protected]

KEY PERSONNEL: Dr. Richard Bastiani; Chairman Bill Radvak; President and CEO Brian G. Richards; COO Robert G. Pilz; VP, Finance and CFO Joanne Stephenson; VP, Business Development Paul Harris, Ph.D.; VP, R&D Reed Simons; VP, Manufacturing



FACILITIES: 12,000 sq. ft. leased space

STOCK-FINANCIAL HISTORY: TSX-V--RBM / OTCBB--RPBIF Revenue C$3.49M (YE 05) compared to C$2.677M (YE 04) Net loss <$8.4M> (YE 05) compared to <C$4.939M> (YE 04) Loss per share <C$0.12/share> (YE 05) compared to <C$0.08/share> (YE 04)

PRIVATE PLACEMENTS: Raised $1.741M in private placement (12/03)

Raised $3M in private placement (7/04) Raised $2.9M in private placement (12/04) Raised $12M in private placement (3/06)

SUBSIDIARIES/DIVISIONS: Response Biomedical Inc. Response Development Inc.

BUSINESS STRATEGY: Develop and commercialize point-of-care (POC) diagnostic tests for use with its RAMP System for clinical and environmental applications, providing reliable information in minutes, anywhere, every time.


3M Co. POC clinical infectious disease test based on Response Biomedical's RAMP technology


11/04



Adapco Inc. RAMP West Nile virus test

exclusive US distributor

12/03

General Dynamics Canada Ltd.

BiodefenseTechnology Integration Program

Military and Homeland Security Agencies Internationally

2/04

International Biotech Company

rapid quantitative test to detect biotech traits in grain


6/04

Roche Diagnostics

NT-proBNP nonexlusive licensing agreement

7/05

Shionogi & Co. Ltd.

rapid quantitative BNP test for congestive heart failure in Japan


10/04

Shionogi & Co. Ltd.

commercialization of a rapid quantitative RAMP test in Japan for BNP

marketing and supply agreement

5/06

RESEARCH & DEVELOPMENT: Diagnostic testing systems for point-of-care health, environmental and food quality testing MIniRamp™ - quantitative handheld analyzer

PRODUCTS ON MARKET: RAMP® System RAMP® Troponin I Assay RAMP® Biodetection System RAMP® West Nile Virus (WNV) Test

Roal Oy

P.O.B. 57, Tykkimaentie 15 Rajamaki 05200, Finland Phone: +358 (9) 290-420; Fax: +358 (9) 290 42 111 Web: www.roal.fi E-mail: [email protected]

KEY PERSONNEL: Heinz-Peter Schwarte; Managing Director Pentti Honkamaki; Financial Manager Dr. Jari Vehmaanpera; Research Director


HISTORY: Founded in 1992 Began biotech R&D in September 1997


SUBSIDIARY OF: ABF Overseas Ltd. (50%), Altia Corp. (50%)

RESEARCH & DEVELOPMENT: Gene technology for fungi and bacteria

PRODUCTS ON MARKET: Industrial enzymes for baking, beverage, feed, textile, and pulp and paper applications



RTI International

P.O. Box 12194, 3040 Cornwallis Road Research Triangle Park NC 27709-2194, US Phone: (919) 541-6000 Toll-free phone: (866) RTI-1958 Web: www.rti.org E-mail: [email protected]

KEY PERSONNEL: Victoria Franchetti Haynes, Ph.D.; President Lon E. Maggart; Sr. VP and Chief of Staff James J. Gibson; Exec. VP and CFO J. Scott Merrell; Sr. VP and CLO


HISTORY: Founded in 1958 to conduct R&D as contractor for industry and government worldwide RTI offers innovative research and technical solutions to governments and businesses worldwide in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, democratic governance, economic and social development, energy and the environment

FACILITIES: 180-acre campus 40,000 sq. ft. facilities in other locations

STOCK-FINANCIAL HISTORY: Nonprofit corporation

BUSINESS STRATEGY: Provides R&D services to biotech and pharmaceutical companies in drug discovery, clinical pharmacology, pharmaceutical R&D, preclinical pharmacology and safety, drug delivery, natural products, pharmacoeconomics, statistics, chemical engineering and biomedical engineering

RESEARCH & DEVELOPMENT: Psychoactive agents, cancer drugs, hormonal agents, natural products

PRODUCTS ON MARKET: Sudaan version 7.5--software for statistical analysis of correlated data

SafePath Laboratories LLC

5909 Sea Lion Place, Suite D Carlsbad CA 92008, US Phone: (760) 929-7744; Fax: (760) 431-7759 Web: www.safepath.com E-mail: [email protected]

KEY PERSONNEL: Paul Hansen; Chairman, President and CEO David Lambillotte; Exec. VP and Director, R&D


HISTORY: Founded and began biotech R&D in 1993 Changed name from LMD Agro-Vet, LLC. (1998)


BUSINESS STRATEGY: Continue its record of innovation in the development, manufacturing and marketing of high performance immunoassays

RESEARCH & DEVELOPMENT: Diagnostics for food animials, water quality and other targeted opportunities

Immunoassay-based diagnostics for food animals, food quality, water quality, and other targeted opportunities

PRODUCTS ON MARKET: Immunoassays: Trichinae for swine Toxoplasma for swine



E. coli O157 for meat Verotoxin for meat Salmonella Giardia in water Cryptosporidium in water Giardia Iamblia Camphylobacter Listeria Food Allergens: milk, soy, egg, peanut

Sakai Chemical Industry Co. Ltd.

1-1-23, Ebisuno-cho-nishi, Sakai Osaka 590-8502, Japan Phone: +81 72 223 4111; Fax: +81 72 223 8355 Web: www.sakai-chem.co.jp E-mail: [email protected]

KEY PERSONNEL: Kazunobu Abe; President


HISTORY: Founded in June 1918 Established in February 1932 Began biotech R&D in 1964 Merged with titanium dioxide business of Tohkem Products Corp. (4/00) Acquired Kyodo Chemical Co. Ltd. (10/02)

FACILITIES: Branch offices in Tokyo and Osaka Factories in Semboku, Nagano, Yumoto and Otsurugi Research center in Osaka

STOCK-FINANCIAL HISTORY: Listed on Osaka Securities Exchange and Tokyo Stock Exchange IPO--3/50 (Osaka), 10/61 (Tokyo)

SUBSIDIARIES/DIVISIONS: Sakai Division: 5-1, Ebisujima-cho, Sakai Osaka 590-0985 Phone: +81 72-223-4114 Fax: +81 72-223-6365 Onahama Division: 110, Aza Tajuku, Izumi-machi Shimogawa Iwaki, Fukushima 971-8183 Phone: +81 246 56 5111 Fax: +81 246 53 5223

BUSINESS STRATEGY: Provide a stable supply of high quality products through the development of advanced technologies, always striving to create new and useful value

AGREEMENTS: Name Products Content of Agreement Date SR Pharma SRP-299 exclusive

development and sales agreement in Japan

11/99

Bioglan ES-Gel exclusive development and sales agreement in Japan

2/00

Theratechnologies TH9507 exclusive development and sales agreement in Japan

5/02



PRODUCTS ON MARKET: Titanium dioxide Stabilizers and metallic soaps Barium and strontium products Zinc products Electronic materials Pharmaceuticals Catalysts Fine organic chemicals

Sanyo Chemical Industries Ltd. (Sanyo Kasei)

11-1 Ikkyo Nomoto-cho, Higashiyama-ku Kyoto 605, Japan Phone: +81 75-541-4311; Fax: +81 75-551-2557 Web: www.sanyo-chemical.co.jp E-mail: [email protected]

KEY PERSONNEL: Tetsuo Kakehi; Chairman Masaaki Ienaga; President Fusayoshi Masuda; Exec. VP


HISTORY: Founded in November 1949 Began biotech research in 1975

STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges Net sales ¥85,062M (YE 04) compared to ¥82,183M (YE 03) Net income ¥3,101M (YE 04) compared to ¥3,255M (YE 03) Earnings per share ¥27.31 (YE 04) compared to ¥27.97 (YE 03) Total assets ¥112,633M (YE 04) compared to ¥115,013M (YE 03)

RESEARCH & DEVELOPMENT: Immobilized enzyme technology, enzyme immunodiagnostics, specialty

chemicals Pharmaceuticals Diagnostic MAbs Agglutination agent

PRODUCTS ON MARKET: TOILETTRIES AND HEALTHCARE: Superabsorbent Polymers, Surfactants for Hair Care Products, Surfactants for Detergents, Base Materials for Cosmetics, Base Materials for Pharmaceuticals, Antibacterial Agents, EIA Diagnostic Reagents, Potting Resins for Artificial Kidneys, Pressure-sensitive Adhesives, Hot Melt Adhesives MACHINES AND AUTOMOBILES: Base Materials for Polyurethane Foam, Polyurethane Beads for Powder Slush Molding, Lubricating Oil Additives, Additives for Fuel Oils, Dewaxing Aids, Base Materials for Synthetic Lubricants, Water-soluble Cutting Fluid, CFC-free Cleaning Agents PLASTICS: Pigment Dispersants, Permanent Antistatic Agents, Resin Modifiers, Base Materials for Polyurethane Elastomer, Epoxy Resin Curing Agents, Epoxy Systems, Emulsifiers for Emulsion Polymerization, Paint Resins TEXTILES: Agents for Textile Manufacturing, Scouring Agents, Dyeing Auxiliaries, Textile Finishing Agents, Modifiers for Polyester Fibers, Flame Retardants for Polyester Fibers, Polyurethane Resins for Synthetic Leather, Agents for Fiber Glass ELECTRONICS AND INFORMATION: Toner Resins, Electrolytes for Aluminum Electrolytic Capacitors, Electrolytes for Electric Double-layer Capacitors, Etching Fluids, UV/EB Curing Resins



ENVIRONMENTAL PROTECTION AND CONSTRUCTION: Polymer Flocculants, Polymers for Enhanced Crude Oil Recovery, Synthetic Wood for Models, Water-swellable Sealants, Adhesives for Elastic Paving Materials, Permeable Paving Materials, Waterproofing Agents for Concrete, Polyurethane for Heat-insulating Materials

Scion - Cellwall Biotechnology Centre

Te Papa Tipu Innovation Park, Private Bag 3020, 49 Sala Street Rotorua, New Zealand Phone: +64 7 343 5899; Fax: +64 7 348 0952 Web: www.scionresearch.com E-mail: [email protected]

KEY PERSONNEL: Dr. Tom Richardson; CEO Dr. Tim Strabala; Unit Leader, CellWall Biotechnology Centre Dr. Julia Charity; Sr. Scientist, CellWall Biotechnology Dr. Phillip Wilcox; Sr. Scientist, CellWall Biotechnology Dr. Christian Walter; Sr. Scientist, CellWall Biotechnology Dr. Armin Wagner; Sr. Scientist, CellWall Biotechnology Dr. Lynette Grace; Sr. Scientist, CellWall Biotechnology


HISTORY: Founded in 1947 Commenced molecular biology in 1990


BUSINESS STRATEGY: The current focus of the CellWall Biotechnology Centre is to provide fundamental knowledge on plant cell wall development, genetics, and biochemistry. The overall purpose is to spawn science discovery and technological innovation, which will create new products and services for both forestry and the emerging renewable plant materials markets.

RESEARCH & DEVELOPMENT: Genome mapping

DNA profiling Marker aided selection Genetic diversity surveys Gene transformation in conifers and model plants Gene isolation Promoter isolation and analysis Gene expression Analysis and manipulation of lignin biosynthesis In vitro propagation of forest trees Analysis and manipulation of reproductive development in conifers Isolation and characterisation of endogenous conifer promoters Engineering of insect and pathogen resistance in conifers Engineering of herbicide resistance in conifers

PRODUCTS ON MARKET: DNA testing for forest trees Transformation protocols for conifer species Somatic embryogenesis technology for conifer species Endogenous promoters for gene expression Propagation systems for forest trees



PRODUCTS IN DEVELOPMENT: Name Status DNA markers for wood properties in development Transformation protocols for other conifer species

in commercial evaluation

Non-flowering radiata pine in development Conifers with altered lignin content and/or composition

in development

Efficient methods for mapping ESTS in commercial development Power of alternative experimental designs for QTL detection

in development

Sensient Technologies Corp.

777 East Wisconsin Avenue Milwaukee WI 53202-5304, US Phone: (414) 271-6755; Fax: (414) 347-4795 Toll-free phone: (800) 558-9892 Web: www.sensient-tech.com E-mail: [email protected]

KEY PERSONNEL: Kenneth P. Manning; Chairman, President and CEO Peter Bradley; President, Color Group Richard Carney; VP, Administration Richard F. Hobbs; VP, CFO and Treasurer Ralph G. Pickles; President, Flavors and Fragrances Group Stephen J. Rolfs; VP, Controller and Chief Accounting Officer Ho-Seung Yang, Ph.D.; VP, Marketing and Technology


HISTORY: Founded as Meadow Springs Distillery in 1882 Company's development focused on yeast through the 1950s In the 1960s, the company diversified into consumer foods through acquisitions and internal product development, including biotechnology Acquired 20 companies since 1997

FACILITIES: 74 locations in 30 countries World headquarters in Milwaukee, Wis. Flavors and Fragrances Group--Indianapolis, Ind. Color Group--St. Louis, Mo. Asia Pacific Group--Singapore

STOCK-FINANCIAL HISTORY: NYSE--SXT Revenue $1.024b (YE 05) compared to $1.047b (YE 04) Net income $44.195M (YE 05) compared to $73.918M (YE 04) Earnings per share $0.95/share (YE 05) compared to $1.59/share (YE 04) Average shares outstanding 46.746M (YE 05) compared to 46.562M (YE 04)

SUBSIDIARIES/DIVISIONS: Flowers and Fragrances Group Color Group Asia Pacific Group

BUSINESS STRATEGY: Supply flavors, fragrances and colors used to make foods and beverages, pharmaceuticals, cosmetics, home and personal care products, printing and imaging products, computer imaging and industrial colors

PRODUCTS ON MARKET: Dyes, pigments and natural colors

Flavors and flavoring systems Dehydrated vegetable products Bioactive antioxidants Bioactive plant extracts Formulation systems for food, beverage and dietary supplement products Pigments and dyes for cosmetics



Severn Biotech Ltd.

Unit 2, Park Lane Kidderminster DY11 6TS, UK Phone: +44 (0)1562 825286; Fax: +44 (0)1562 825284 Web: www.severnbiotech.com E-mail: [email protected]

KEY PERSONNEL: Andrew Smart; Managing Director/Owner Kate Fox; Sales Manager



FACILITIES: 5,000 sq. ft. headquarters 500 sq. ft. R&D facilities 4,500 sq. ft. manufacturing facilities


PRODUCTS ON MARKET: DNA, RNA and peptide synthesis

General reagents Electrophoretic media Reagent buffers Service solutions Nucleotides

Showa Denko KK

13-9, Shiba-Daimon, 1-chome, Minato-ku Tokyo 105-8518, Japan Phone: +81 3-5470-3235; Fax: +81 3-3436-2625 Web: www.sdk.co.jp E-mail: [email protected]

KEY PERSONNEL: Mitsuo Ohashi; Chairman Kyohei Takahashi; CEO and President Hiroshi Nishimoto; Exec. Officer, Petrochemicals Tetsuo Tamada; Exec. Officer, Inorganics Norio Masubuchi; Exec. Officer, Chemicals Koji Kudo; Sr. Corp. Officer and CTO Ichiro Nomura; Director, Corp. Services, IR and Finance

EMPLOYEES: 11,118 employees (consolidated)

HISTORY: Founded in June 1939 through the merger of Nihon Denki Kogyo KK and Showa Hiryo KK Began biotech R&D in 1970

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and four other domestic stock exchanges Net sales ¥811.899b (YE 05) compared to ¥740.706b (YE 04) Net income ¥15.647b (YE 05) compared to ¥7.596b (YE 04) Earnings per share ¥13.70/share (YE 05) compared to ¥6.66/share (YE 04) Total assets ¥986.233b (YE 05) compared to ¥943.908b (YE 04)

SUBSIDIARIES/DIVISIONS: Showa Highpolymer Co. Ltd. Showa Denko Plastic Products Co. Ltd. Heisei Polymer Co. Ltd. Kokusai Eisei Co. Ltd. Nippon Polytech Corp. Showa Titanium Co. Ltd. Showa Denko Kenso Co. Ltd. Tohoku Metal Chemical Co. Ltd. Showa Aluminum Can Corp.



Showa Denko Aluminum Trading KK Showa Denko Packaging Co. Ltd. Showa Engineering Co. Ltd. Showa Denko Kenzai KK Shoko Co. Ltd. Fuyo Perlite Co. Ltd. Union Showa KK

PRINCIPAL INVESTORS: Japan Trustee Services Bank Ltd. The Master Trust Bank of Japan Ltd. Fukoku Life Insurance Co. Sompo Japan Insurance Inc. The Dai-ichi Mutual Life Insurance Co. Nippon Life Insurance Co. Mizuho Corporate Bank Ltd. Meiji Yasuda Life Insurance Co. Showa Denko Employee Stock Ownership Trust & Custody Services Bank Ltd.

BUSINESS STRATEGY: Development of new compounds and leading-edge technologies through biotechnology and organic synthesis technology

RESEARCH & DEVELOPMENT: Technology platforms:

Oranic electronic materials Batteries Capacitors Magnetic/recording media materials Crystal growth process Thin film deposition process Precision fabricating process Micro-system process Functional gases Ultimate conditions process Heat transfer system Castion process Plasticity process Bonding Functional metallic materials Functional molecular design Controlled reaction design High-performance catalysts Specialty polymer design Fine particles Biochemistry Organic chemicals manufacturing process Surface and interface chemistry

PRODUCTS ON MARKET: Petrochemicals: Ethylene, propylene, C4 fraction, cracked fuel oil, acetaldehyde, acetic acid, vinyl acetate, ethyl acetate, allyl alcohol, allyl ester resin Chemicals: Oxygen, nitrogen, argon, mixed gases, fusing ethylene, hydrogen, liquefied hydrogen, helium, Nitrogen/JP (laughing gas), AnesoxynT (inhaled painkiller), FumitoxinT (aluminum phosphide), AnesoxynT (system for treating excess anesthetic gas), Elaslen™ (Chlorinated polyethylene), Ecoflamer (environmentally-friendly elastomer), Showflamer (non-plasticizer chlorinated elastomer), Showa Denko Chloroprene (Chloroprene rubber), Showpalon (Chlorinated rubber), industrial amino acids for food additives, feed additives, cosmetic ingredients, amino acids for perm agents, chelating agents, biodegradable chelating agents, raw materials for photographic chemicals, Acrylonitrile (AN), High-purity FC-14, High-purity HFC-23, High-purity HFC-32, High-purity FC-116, High-purity FC-C318, High-purity boron trichloride, High-purity chlorine, High-purity hydrogen bromide, High-purity sulfur hexafluoride, High-purity nitrogen trifluoride, High-purity ammonia, High-purity nitrogen monoxide, High-purity HFC-41, High-purity FC-218, High-



purity FC-2316, High-purity tantalum pentaethoxide, High-purity nitrogen monoxide (for electronic materials), treatment equipment for acid gases discharged from the dry etching process, treatment equipment for global-warming PFC emissions discharged from the dry etching process, fluorine generators, erosion/wear resistance surface treatment, leak detectors, fluorine/chlorine resistance bellows seal valves, ozone depleting gas scrubber, Ascorbic acid PM (APM; water-soluble, stable vitamin C derivative), Ascorbic acid PS (APS; water-soluble, stable vitamin C derivative), Apprecier (highly permeable, water-soluble vitamin C derivative), MaxlightT TS/F-TS (silica-coated TiO2), MaxlightT ZS (silica-coated ZnO), AminofectT (biosurfactant), PhospitanT C (stabilized vitamin C for food additive), Shodex™ (high-speed liquid chromatographic columns and instruments), Autoprep™ (pre-treatment for analysis), functional monomers, intermediates, Nanomax™ (UV interception zinc oxide masterbatch), Nanoallomer™ (titanium dioxide masterbatch for optical catalyst), Nanocoat™ (titanium dioxide suitable for optical catalyst coating), Monogermane GeH4, Xenon difluoride, Triflic acids (trifluoromethanesulfonic acids) CF3SO3H, Sodium borohydride NaBH4, CHITOSAR (chitosan -containing fertilizer), IR-photosensitive dyes, organic borate, DMP Metal Complex (Materials for MOCVD) Inorganic materials: Alumina products, aluminum hydroxide products (Higilite™), alumina electrical filler materials, fused materials for refractory, fluxes, super abrasives, abrasive grains, lapping and polishing materials, polishing materials, lubrication and mold-release agents, plasma spraying materials, fine ceramics materials, shaped productions of fine ceramics materials, materials for photocatalyst applications, materials for heat-radiation fillers, graphite electrodes, Carbon nanofiber (VGCF™ series), Negative-electrode material for lithium-ion batteries (SCMG™), Artificial graphite powder (UF-G), Glassy carbon composite (SG, SR)

SibEnzyme Ltd.

Ak. Timakova Str., 2/12, 117, Academtown Novosibirsk 630117, Russia Phone: +7 383-333-4991; Fax: +7 383-333-6853 Web: www.sibenzyme.com; E-mail: [email protected]

KEY PERSONNEL: Victoria Sit’ko, Ph.D.; Head, International Operations

EMPLOYEES: 70 employees, 12 Ph.D.s, 45 M.D.s



BUSINESS STRATEGY: Specialize in R&D, manufacture and bulk sale mostly of new enzymes. Product range includes enzymes of nucleic acids methabolism and related products for the research in molecular biology and genetic engineering

PRODUCTS ON MARKET: 170 Restriction Enzymes, most of them (including unique) were discovered

and characterized at SibEnzyme Ltd. Other enzymes for molecular biology application, DNA preparations, DNA Markers, Nucleotides



Solomon Park Research Laboratories

12815 NE 124th Street, Suite I Kirkland WA 98034, US Phone: (425) 650-2000; Fax: (425) 650-2008 Toll-free phone: (800) 769-7774 Web: www.solomonpark.com E-mail: [email protected]

KEY PERSONNEL: Patric A. Clapshaw, Ph.D.; Director Julie Nebeker; Office Manager Mary Zimmer; Laboratory Manager Kimberly Anderson; Shipping Manager


HISTORY: Founded in 1984 as a supplier of apolipoprotein

FACILITIES: 2,000 sq. ft. of fully equipped biochemistry, histology and tissue culture facilities


BUSINESS STRATEGY: Supply phlebotomy services, as well as human blood products for external quality controls, proficiency testing and calibrators

PRODUCTS ON MARKET: Serum and plasma for custom pools for calibrators, internal controls,

external controls, standards and proficiency testing materials Lipid reference controls

Spark Holland BV

P. O. Box 388 Emmen 7800 AJ, Netherlands Phone: +31 591-631700; Fax: +31 591-630035 Toll-free phone: (866) 772-7515 Web: www.spark.nl; E-mail: [email protected]

KEY PERSONNEL: Rob Castien; President Marcel Jansen; Manager, Sales and Marketing Rob van der Knaap; Manager, R&D H. van Oort; Purchasing Manager J. Crutchfield; General Manager, USA Operations



FACILITIES: 2,250 sq. m. facility


SUBSIDIARIES/DIVISIONS: Spark Holland Inc.--US sales and service office 666 Plainsboro Road, Suite 1336 Plainsboro, NJ 08536, USA Phone: (609) 799-7250 Fax: (609) 799-8250 E-mail: [email protected]

BUSINESS STRATEGY: Mission: Provide the analytical laboratory with innovative sample introduction, extraction and separation technology, enabling seamless integration of automated front end sample preparation into analytical systems such as HPLC, MS, GC and NMR. By pro-active gathering customer feedback we seek to understand the analytical problems in the mentioned markets. This knowledge will direct our R&D efforts. We aim to market our technology



under private label as front-end system solutions and through OEM partnering as customized system components. Our organization will operate with mutual trust and respect to our customers, suppliers, employees, shareholders and other parties. Honesty and the right values will be the basis for our activities. We want to create excellent shareholder value and achieve sustainable growth by investing in research and development. We will nurture innovation and continue to look for ways to improve our products and services.

RESEARCH & DEVELOPMENT: Develop and manufacture automatic sample handling and sample

preparation systems for LC and LC MS

PRODUCTS ON MARKET: Symbiosis system ( automated sample preparation system) Mistral column oven Triathlon Endurance autosampler Midas autosampler Reliance autosampler Basic Marathon autosampler

Spherix Inc.

12051 Indian Creek Court Beltsville MD 20705, US Phone: (301) 419-3900; Fax: (301) 210-4908 Web: www.spherix.com E-mail: [email protected]

KEY PERSONNEL: Dr. Gilbert V. Levin; Chairman and Exec. Officer for Science Richard C. Levin; CEO and President Roger A. Downs; VP, Operations Steven M. Wade; VP, Information Technology Jeffrey T. Lowe; VP, Corporate Communications Katherine M. Brailer; Corporate Secretary


HISTORY: Founded in 1967 Sold Environmental & Laboratory Service Division to ManTech Environmental Corp. (3/96)

FACILITIES: 95,000 sq. ft. office facility 12,700 sq. ft. regional office located in Cumberland, Md.

STOCK-FINANCIAL HISTORY: NASDAQ--SPEX Two-for-one stock split (5/96) Revenue $23.046M (YE 05) compared $22.348M (YE 04) Net loss <$2.849M> (YE 05) compared to <$2.822M> (YE 04) Loss per share <$0.24/share> (YE 05) compared to <$0.24/share> (YE 04)

SUBSIDIARIES/DIVISIONS: InfoSpherix Inc. (wholly-owned subsidiary) BioSpherix Division

BUSINESS STRATEGY: Create value and increase the wealth of our shareholders through innovations that benefit our clients and the human condition

AGREEMENTS: Name Products Content of Agreement Date Albert Einstein College of Medicine

certain medicinal uses of Naturlose


GleneaglesCRC Naturlose for the treatment for Type II diabetes

GleneaglesCRC to conduct Phase IIII trials

5/06

MD Foods Ingredients amba (Denmark)

D-tagatose licensing agreement 1/97



Tetra Technologies Inc.

PhoStrip wastewater treatment technology

patent rights in exchange for payments and continuing royalties on sales

4/91

RESEARCH & DEVELOPMENT: Nonfattening sugars, antidiabetes agent, information systems, and database management in health and education

PRODUCTS ON MARKET: Call center for reservations Telephone hotlines and information management for clinical trials applicants (for major pharmaceutical companies) PhoStrip® system for phosphorus removal from wastewater Tagatose nonfattening sweetner

PRODUCTS IN DEVELOPMENT: Name Status Naturlose for Type II diabetes to begin Phase III

SRI International

333 Ravenswood Avenue Menlo Park CA 94025-3493, US Phone: (650) 859-2000; Fax: (650) 859-2889 Toll-free phone: (866) 451-5998 Web: www.sri.com/biosciences E-mail: [email protected]

KEY PERSONNEL: Samuel H. Armacost; Chairman Curtis R. Carlson; CEO and President Thomas J. Furst; Senior Vice President and CFO Dennis Beatrice; VP, Policy Division Lawrence H. Dubois; VP, Physical Sciences William Mark; VP, Information and Computing Sciences Walter Moos; VP, Biosciences Division John W. Prausa; VP, Engineering and Systems Division Leonard Polizzotto; VP, Business Development and Marketing Alice R. Resnick; VP, Corporate and Marketing Communications Norman Winarsky; VP, Ventures and Strategic Programs


HISTORY: Founded as Stanford Research Institute in 1946 Spun out Artificial Muscle Inc. and Bridge Pharmaceuticals (2004) To acquire Quality Clinical Labs (as of 4/06) Member--American Association for Cancer Research Member--American Association of Pharmaceutical Scientists Member--American Chemical Society Member--Biotechnology Industry Organization Member--Drug Information Association

FACILITIES: Headquarters on 63-acre campus with more than 1.4M sq. ft. in Menlo Park, Calif. Offices located in the U.S., Europe and Asia

STOCK-FINANCIAL HISTORY: Private, nonprofit contract research organization

SUBSIDIARIES/DIVISIONS: Sarnoff Corp.--Princeton, N.J. Five divisions: Engineering and Systems, Policy, Information and Computing Sciences, Biosciences and Physical Sciences

BUSINESS STRATEGY: Grow by building and leveraging our assets--client relationships, our intellectual property and staff--in important markets



AGREEMENTS: Name Products Content of Agreement Date Biosource Technologies

oncology, infectious disease, and inflammation treatments

joint R&D agreement

1/96

Dura Pharmaceuticals

SRI's jet milling process for protein and peptide formulations of dry powder drugs for use with Dura's Spiros™ pulmonary drug delivery technology


MDS Panlabs, Tripos Inc., Genelabs Technologies Inc.

combinatorial chemistry libraries for designing small molecule compounds that bind double-stranded DNA

technology access agreement--Tripos will design compounds via molecular modeling, MDS Panlabs will synthesize compounds, SRI (working independently) will use solid-phase combinatorial synthesis to make molecules to Genelabs specifications

3/98

Taiho Pharmaceutical Co. Ltd.

endocrine approach for chemotherapy in estrogen-dependent breast cancer


RESEARCH & DEVELOPMENT: Pharmaceutical Discovery and Screening: custom drug design, synthesis and efficacy screens for drug development of: antibacterials; antivirals; anticancer agents; lipid-lowering agents; neurobiological therapeutics; women's health therapeutics; steroids (anti-inflammation, hormone analogs, vitamin analogs, neuroprotection); and other synthetic drugs (anticancer, anti-inflammation, anti-angiogenesis, nootropics, cardiovascular, CNS, neuroprotection), combinatorial chemistry; radiolabeled synthesis; process development; scale-up Biopharmaceutical Development: pharmacology, mammalian toxicology; molecular and genetic toxicology; microbiology, pharmacokinetic and metabolism studies; in vitro comparative metabolism; immunology and immunotoxicology; cGMP manufacturing; formulation design; preformulation; stability monitoring; analytical chemistry Drug Delivery: transdermal; topical; controlled release; standard formulations (oral, injectable, topical); alternative drug delivery (aerosols, nasal, controlled release, microencapsulation, taste masking, bioerodable polymers, protein peptide delivery)

PRODUCTS IN DEVELOPMENT: Name Status Edatrexate (with Memorial Sloan Kettering) in Phase I clinicals Tirapazamine (with Sanofi) in Phase III clinicals SR 4980 in preclinicals SR 14005 in preclinicals SR 14110 in preclinicals SR 14115 in preclinicals SR 4554 (with CRCT) in preclinicals SR 16234 (TAS-108) (with Taiho) in preclinicals *pipeline as of 10/05



Stewart Agricultural Research Services Inc.

P.O. Box 509 Macon MO 63552, US Phone: (660) 762-4240; Fax: (660) 762-4295 Web: www.stewartag.com E-mail: [email protected]

KEY PERSONNEL: Ellsworth R. Stewart; President and Treasurer David R. Johnson, Ph.D.; VP Patricia A. Stewart; Secretary

EMPLOYEES: 25 employees, 6 Ph.D.s, 6 M.D.s.

HISTORY: Independent company which has been providing services to the life science and chemical industries since 1975

FACILITIES: 832 acre research farm in north central Missouri Offices in Arlington, Va. and Columbia, Mo. Facilities and headquarters in Macon, Mo.


BUSINESS STRATEGY: Provide a broad spectrum of services to its clients that enable them to identify, register, develop, and commercialize successful products

PRODUCTS ON MARKET: Services include: screening, efficacy testing, study monitoring, regulatory

project coordination, efficacy project coordination, market assessment, marketing agreements, new product technology, product development, QA monitoring, registration, reregistration, organizational development, technology management, licensing agreements, data package development, strategic planning, training, seminars, diagnostics

Stratagene Corp.

11011 N. Torrey Pines Road La Jolla CA 92037, US Phone: (858) 373-6300; Fax: (858) 535-0034 Toll-free phone: (800) 424-5444 Web: www.stratagene.com; E-mail: [email protected]

KEY PERSONNEL: Joseph A. Sorge, M.D.; Chairman and CEO Steve R. Martin; VP and CFO Ronni L. Sherman; Exec. VP and General Counsel John R. Pouk; Sr. VP, Global Sales and International Operations Nelson F. Thune; Sr. VP, Operations and GM, Hycor Biomedical Inc.


HISTORY: Founded in 1984 Name changed from Stratagene Cloning Systems (1990) Merged with Hycor Biomedical Inc. (6/04)

FACILITIES: Headquarters and R&D facilities in La Jolla, Calif. Manufacturing facility in Austin, Texas, includes Reagent and Instrument Manufacturing/Production Planning facilities Additional offices in Amsterdam, the Netherlands and Tokyo, Japan

STOCK-FINANCIAL HISTORY: NASDAQ--STGN Revenue $130.285M (YE 05) compared to $84.813M (YE 04) Net income $7.788M (YE 05) compared to $7.438M (YE 04) Earnings per share $0.35/share (YE 05) compared to $0.39/share (YE 04) Average shares outstanding 22.113M (YE 05) compared to 19.308M (YE 04) Total assets $119.182M (YE 05) compared to $80.332M (YE 04)



SUBSIDIARIES/DIVISIONS: Hycor Biomedical Inc.--Garden Grove, Calif. (see separate entry)

AGREEMENTS: Name Products Content of Agreement Date Affymetrix Inc. Stratagene to provide

software for GeneChip data analysis and develop ArrayAssist Life software

nonexclusive alliance

2/05

Jingmei Biotech Co. Ltd.

all products exclusive distribution agreement for China

Layton BioScience Inc.

Layton's hNT human neuronal cell kits, cDNA libraries derived from LNT neuron cells

marketing and distribution agreement for the U.S., Canada, Europe, and the Far East

8/94

Rosetta Inpharmatics LLC

creation of an automated solution for the isolation of nucleic acids from clinical samples


8/06

Strand Life Sciences

suite of next-generation bioinformatics software

development partnership

12/05

RESEARCH & DEVELOPMENT: Research reagents

Transgenic technology for modeling and assaying human diseases Enzymes Human genome mapping technology Genetic diseases

PRODUCTS ON MARKET: More than 1,000 molecular biotechnology products for the research market, including antibodies, bioinformatics software, Quantos™ Cell Proliferation Assay Kit, cloning vectors, DNA extraction and microextraction kits, fluorescent proteins, benchtop coolers, microcentrifuges, Parafilm® dispensers, PCR labware, radioactivity shields, real-time instruments, temperature cyclers, tips and tubes, library construction products, library packaging extracts and host strains, markers and restriction enzymes, mass spectrometry, microarray reagents, modifying enzymes, mutagenesis, cloning kits, PCR instruments, PCR reagents, premade libraries, protein expression systems, QPCR & QRT-PCR reagents, real-time instruments, reference RNA, Absolutely RNA® nanoprep, miniprep and micorprep kits, RT-PCR reagents, RNA, DNA, two-hybrid products and viral gene delivery systems

Strategic Diagnostics Inc.

111 Pencader Drive Newark DE 19702, US Phone: (302) 456-6789; Fax: (302) 456-6770 Toll-free phone: (800) 544-8881 Web: www.sdix.com E-mail: [email protected]

KEY PERSONNEL: Grover Wrenn; Chairman Matthew H. Knight; President and CEO Tony Simonetta; CFO James W. Stave, Ph.D.; VP, R&D Jim Byron; National Sales Manager David Schlecker; Director, Human Resources





Acquired Ohmicron (6/96) Acquired TSD BioServices Inc. (6/96) Acquired EnSys Environmental Products Inc. (12/96) Acquired HTI Bio-Products Inc. (1998) Acquired AZUR Environmental (2001)

FACILITIES: 28,655 sq. ft. headquarters in Newark, Del. 25,600 sq. ft. R&D and technical facility in Newark, Del.

STOCK-FINANCIAL HISTORY: NASDAQ--SDIX Revenue $24.845M (YE 05) compared to $23.705M (YE 04) Net income $584K (YE 05) compared to $1.379M (YE 04) Earnings per share $0.03/share (YE 05) compared to $0.07/share (YE 04) Average shares outstanding 19.741M (YE 05) compared to 19.242M (YE 04) Total assets $36.661M (YE 05) compared to $34.873M (YE 04)

SUBSIDIARIES/DIVISIONS: Strategic BioSolutions (www.strategicbiosolutions.com) SDI Europe

BUSINESS STRATEGY: Strategic Diagnostics is a custom antibody production and services company and a leader in using immunoassay and bio-response technology to assure safety and quality in food, water and other environmental matrices.

AGREEMENTS: Name Products Content of Agreement Date US Biosystems (USB)

SDI's environmental test kits when sold through an analytical, laboratory channel

exclusive distribution agreement

4/05

RESEARCH & DEVELOPMENT: Rapid quantitative lateral flow assays Genetic modified crop test kits

PRODUCTS ON MARKET: GeneChek® RaPID Assay® EnviroGard® DTECH® RapidChek® TraitChek® SeedChek®

Sumitomo Chemical Co. Ltd.

27-1 Shinkawa, 2-chome, Chuo-ku Tokyo 104-8260, Japan Phone: +81 3-5543-5500; Fax: +81 3-5543-5901 Web: www.sumitomo-chem.co.jp E-mail: [email protected]

KEY PERSONNEL: Hiromasa Yonekura; President Masami Nakamoto; Exec. VP Satoshi Kawachi; Exec. VP Shigehiro Oba; Sr. Managing Exec. Officer, Agricultural Chemicals Sector Ichiro Miyawaki; Sr. Managing Exec. Officer, Petrochemicals and Plastics Sector Hideaki Watababe; Sr. Managing Exec. Officer, Basic Chemicals Sector Masashi Araki; Managing Exec. Officer, Fine Chemicals Sector Naoya Kanda; Sr. Managing Exec. Officer Osamu Ishitobi; Sr. Managing Exec. Officer

EMPLOYEES: 20,195 employees HISTORY: Founded in Sepember 1913



FACILITIES: Headquarters in Osaka and Tokyo, Japan Laboratories and research facilities in Takarazuka, Ehime, Chiba, Osaka, Takatsuki, and Tsukuba Manufacturing facilities in Ehime, Oita, Osaka, Chiba, Aomori and Singapore

STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange Net sales ¥1,556b (YE 05) compared to ¥1,296b (YE 04) Net income ¥90.665b (YE 05) compared to ¥64.452b (YE 04) Earnings per share ¥54.796/share (YE 05) compared to ¥38.938/share (YE 04) Total assets ¥2,178b (YE 05) compared to ¥1,649b (YE 04)

SUBSIDIARIES/DIVISIONS: 104 subsidiaries and affiliates, including: Sumitomo Pharmaceuticals Co. Ltd. (see separate entry) Koei Chemical Co. Ltd. Taoka Chemical Co. Ltd. The Polyolefin Company (Singapore) Pte. Ltd. Sumitomo Chemical America Inc. Valent U.S.A. Corp. Nihon Medi-Physics Co. Ltd. Sumika Fine Chemicals Co. Ltd.

BUSINESS STRATEGY: Create new and useful technologies and products in order to improve living standards and alleviate the problems of society

PRODUCTS ON MARKET: Basic chemicals

Petrochemicals and plastics Fine chemicals IT-related chemicals Agricultural chemicals Pharmaceuticals

SunOpta Inc.

2838 Bovaird Drive West Brampton L7A 0H2, Canada Phone: (905) 455-2528; Fax: (905) 455-2529 Web: www.sunopta.com E-mail: [email protected]

KEY PERSONNEL: Jeremy N. Kendall; Chairman and CEO Steven R. Bromley; President and COO John H. Dietrich; VP and CFO Benjamin Chhiba; VP and General Counsel Roger Eacock; VP, Supply Chain Debra A. Boyle; Corp. VP, Public Relations Allan G. Routh; President, SunOpta Grains and Foods Group Arthur J. McEvily; President, SunOpta Ingredients Group Sergio A. Varela; President, SunOpta Fruit Group Joseph J. Stern; President, Organic Ingredients and Exec. VP, SunOpta Fruit Group Stephen B. Easterbrook; President, SunOpta Canadian Food Distribution Group David J. Kruse; President and COO, Opta Minerals Inc. Murray Burke; VP and GM, SunOpta BioProcess Group


HISTORY: Founded in 1973 as Stake Technology Acquired Barnes Environmental International (1995) Created the SunOpta Food Group (1999) SunOpta Food Group acquired Sunrich Inc. (8/99) Opta Minerals acquired eorge F. Pettinos (Canada) Ltd. (PECAL) (3/00) SunOpta Food Group acquired Northern Food and Dairy Inc. (9/00)



Opta Minerals acquired Temisca Inc. (11/00) SunOpta Food Group acquired First Light Foods Inc. (3/01) Opta Minerals acquired Virginia Materials and Supplies Inc. (10/01) Opta Minerals acquired a 51% interest in International Materials & Supplies Inc. (10/01) SunOpta Food Group acquired Wild West Organic Harvest Co-operative Association (11/02) SunOpta Food Group acquired Simply Organic Co. Ltd. (12/02) SunOpta Food Group acquired Opta Food Ingredients Inc. (12/02) SunOpta Food Group acquired Kettle Valley Dried Fruit Ltd. (5/03) SunOpta Food Group acquired Pro Organics Marketing Inc. (10/03) Changed name to SunOpta Inc. (10/03) SunOpta Food Group acquired SIGCO Sun Products Inc. (11/03) Opta Minerals acquired the remaining 49% of International Materials (11/03) SunOpta Food Group acquired Sonne Labs Inc. (12/03) SunOpta Food Group acquired Distribue-Vie Fruits & Legumes Biologiques Inc. (3/04) SunOpta Food Group acquired Supreme Foods Ltd. (5/04) SunOpta Food Group acquired the assets of Snapdragon Natural Foods Inc. (5/04) SunOpta Food Group acquired Kofman-Barenholtz Foods Ltd. (9/04) SunOpta Food Group acquired 51% of the outstanding shares of Organic Ingredients Inc. (9/04) SunOpta Food Group acquired remaining 49.9% of Organic Ingredients (4/05) Opta Minerals acquired Distribution A&L (4/04) SunOpta Food Group acquired Earthwise Processors LLC (6/05) SunOpta Food Group acquired Cleugh’s Frozen Foods Inc. (6/05) SunOpta Food Group acquired Pacific Fruit Processors Inc. (7/05) Opta Minerals acquired certain assets of the abrasives production division of Hillcrest Industries Inc. (10/05) SunOpta Food Group acquiredLes Importations Cacheres Hahamovitch Inc. (12/05) Opta Minerals acquired Magnesium Technologies Corp. (2/06)

STOCK-FINANCIAL HISTORY: NASDAQ--STKL / TSX--SOY

Revenue $426.101M (YE 05) compared to $306.251M (YE 04) Net earnings $13.558M (YE 05) compared to $11.016M (YE 04) Earnings per share $0.24/share (YE 05) compared to $0.20/share (YE 04) Total assets $301.482M (YE 05) compared to $220.172M (YE 04)

SUBSIDIARIES/DIVISIONS: SunOpta Food Group: Natural, organic and specialty foods markets. Comprised of four operating groups: SunOpta Grains and Foods Group: Bringing identity preserved, non-GMO and organic soybeans, sunflower and corn products to market utilizing vertically integrated business models, and markets value-added soymilk concentrates, powders and ingredients, aseptic and ESL soy and rice beverages and grain snacks SunOpta Ingredients Group: Technical processing and contract manufacturing of value-added food ingredients such as oat fibers, stabilized brans, germs and natural preservatives SunOpta Fruit Group: Global sourcing and processing of organic and natural fruits, fruit ingredients and packaged products for industrial, food service and private label retail customers SunOpta Canadian Food Distribution Group: Distributor of organic, natural, kosher and specialty foods Opta Minerals Inc. (TSX--OPM, 70.6% owned): Processing and recycling silica free abrasives and a wide range of industrial minerals SunOpta BioProcess Group: Processing of biomass for the production of cellulosic ethanol and other bio-products



BUSINESS STRATEGY: Mission: Rapidly grow revenues, profits and shareholder value through an effective balance of internal growth and acquisition, with a focus on integrated business models in the natural, organic and specialty food markets

AGREEMENTS: Name Products Content of Agreement Date Mikro-Technik GmbH & Co. KG

sales, marketing and distribution of Mikro-Technik's wheat and bamboo fibers and powdered cellulose products in North America

exclusive licensing arrangement with

6/06

Royal Nedalco Nedalco's pentose fermenting yeast for the production of cellulosic ethanol in North America


Symbio

38 Bookham Industrial Park, Church Road Great Bookham KT23 3EU, UK Phone: +44 (0) 1372 456101; Fax: +44 (0) 1372 456099 Web: www.symbio.co.uk E-mail: [email protected]

KEY PERSONNEL: Martin Ward; President David Ward, B.Sc.; Sr. Scientist Polly Gearing; Head, Administration Judy Moffat; Head, Accounts and Credit Control


HISTORY: Founded and began biotech R&D in 1990 Commenced sales in 1991 Began international distribution in 1995



BUSINESS STRATEGY: Develop and market biotech solutions for industry and the environment, specifically: waste water and industrial effluent; sports turf and horticulture; forestry and arboriculture; industrial and commercial cleaning; lake and river restoration and management; and soil decontamination

RESEARCH & DEVELOPMENT: Biological plant growth enhancement

Wastewater and industrial effluent treatment

PRODUCTS IN DEVELOPMENT: Name Status Sports turf fungal control in field trials



Syngenta International AG

P.O. Box Basel CH-4002, Switzerland Phone: +41 61 323 11 11 Web: www.syngenta.com

KEY PERSONNEL: Martin Taylor; Chairman Michael Pragnell; CEO John Atkin; COO, Crop Protection Bruce Bissell; Head, Global Operations and Human Resources David Jones; Head, Business Development David Lawrence; Head, R&D Michael Mack; COO, Seeds Christoph Mader; Head, Legal and Taxes Domenico Scala; CFO


HISTORY: Formed in November 2000 from the merger of Novartis and AstraZeneca’s agribusinesses Acquired all outstanding shares of Dia-Engei (2/04) To acquire Emergent Genetics Vegetable A/S (as of 6/06) To acquire Conrad Fafard, Inc. (as of 7/06)

FACILITIES: Four major research sites--Located in Switzerland, the U.K. and the U.S. Two molecular marker laboratories--Located in Stanton Minn., and Toulouse, France

STOCK-FINANCIAL HISTORY: Swiss stock exchange--SYNN / NYSE--SYT Sales $8.104b (YE 05) compared to $7.269b (YE 04) Net income $779M (YE 05) compared to $623M (YE 04) Earnings per share $7.67/share (YE 05) compared to $7.19/share (YE 04) Total assets $11.608b (YE 05) compared to $12.008b (YE 04)

SUBSIDIARIES/DIVISIONS: Syngenta Agro SA--Argentina

Syngenta Crop Protection Pty. Ltd.--Sydney, Australia Syngenta Seeds Pty Ltd.--Australia Syngenta Crop Protection NV--Brussels, Belgium Syngenta Seeds NV--Brussels, Belgium Syngenta Protecao de Cultivos Ltda.--Sao Paulo, Brazil Syngenta Crop Protection Canada Inc.--Guelph, Ontario Syngenta Seeds Canada Inc.--Arva, Ontario Syngenta Agribusiness SA--Santiago, Chile Syngenta (China) Investment Co. Ltd.--Shanghai, China Syngenta Crop Protection Ltd.--Hong Kong Syngenta Seeds (Beijing) Co. Ltd.--Beijing, China Syngenta SA--Bogota, Columbia Syngenta Czech s.r.o.--Czech Republic Syngenta Seeds A/S--Skaelskor, Denmark Syngenta Crop Protection A/S--Copenhagen, Denmark Syngenta Agro SAE--Giza, Egypt Syngenta Agro SAS--France Syngenta Seeds SAS--France Syngenta Agro GmbH--Germany Syngenta Seeds GmbH--Germany Syngenta Hellas AEBE--Athens, Greece Syngenta LAN SA--Guatemala Syngenta Kft--Budapest, Hungary Syngenta India Ltd.--Mumbai, India Syngenta Crop Protection SpA--Milan, Italy Syngenta Japan KK--Tokyo, Japan Syngenta Seeds KK--Japan Syngenta Crop Protection Sdn. Bhd.--Malaysia Syngenta Maroc SA--Casablanca, Morocco



Syngenta Seeds BV--The Netherlands Syngenta Crop Protection BV--The Netherlands Syngenta Pakistan Ltd.--Pakistan Syngenta Crop Protection Lda.--Lisbon, Portugal O.O.O. Syngenta--Moscow, Russia Syngenta Asia Pacific Pte. Ltd.--Singapore Syngenta South Africa (Pty.) Ltd.--Johannesburg, South Africa Syngenta Korea Ltd.--Seoul, South Korea Syngenta Agro SA--Madrid, Spain Syngenta Seeds SA--Barcelona, Spain Syngenta Seeds AB--Sweden Syngenta Crop Protection AG--Basel, Switzerland Syngenta Seeds--Basel, Switzerland Syngenta Crop Protection Schweizerhalle AG--Pratteln, Switzerland Syngenta Crop Protection Munchwilen AG--Switzerland Syngenta Agro AG--Dielsdorf, Switzerland Syngenta Crop Protection Monthey SA--Monthey, Switzerland Syngenta Crop Protection Ltd.--Bangkok, Thailand Syngenta Seeds Ltd.--Bangkok, Thailand Syngenta Tarim Sanayi ve Ticaret AS--Turkey Syngenta Crop Protection UK Ltd.--U.K. Syngenta Seeds Ltd.--U.K. TOV Syngenta--Kiev, Ukraine Syngenta Crop Protection Inc.--Greensboro, N.C. Syngenta Seeds Inc.--Golden Valley, Minn. Syngenta Corp.--Wilmington, Dela. Syngenta Vietnam Ltd.

AGREEMENTS: Name Products Content of Agreement Date COMPO development and

marketing of a comprehensive range of plant protection and pest control products


Delta and Pine Land Co.

biotechnology products for cotton


8/04

Diversa establishment of shared

biotechnology research platform and discovery of products

research and product development collaboration

12/02

Sumitomo Chemical

SYN 523 herbicide development and marketing agreement

2/05

Tanimura & Antle joint venture, Dulcinea Farms LLC, to market Dulcinea brand produce items

partnership 3/04

RESEARCH & DEVELOPMENT: Chemical innovation to discover new active ingredients: Plans to launch one active ingredient per year Product innovation using existing active ingredients New products through plant breeding (vegetables and flowers): Input traits--Full suite of stacked traits in corn, glyphosate tolerance and resistance to leaf and soil insects, Output traits--Corn for animal feed and ethanol production

PRODUCTS ON MARKET: Actara®, Amistar®, Callisto®, Cruiser®, Dual Gold®, Gramoxone®, Karate®, Ridomil Gold®, Score®, Topik®, Touchdown®, Garst®, Golden Harvest®, NK®, Rogers®, S&G®



PRODUCTS IN DEVELOPMENT: Name Status Active ingredients: Mandipropamid in late development Insecticide in late development Fungicides in early development Herbicide 1 in early development Herbicide 2 in early development Corn traits: Corn Root Worm (CRW) in elite breeding, planned

launch in 2007 GT / CRW in elite breeding, planned

launch in 2007 CRW / ECB in elite breeding, planned

launch in 2008 GT / CRW / ECB in elite breeding, planned

launch in 2008 Corn amylase (biofuels) in late development Corn phytase in early development

Synthetech Inc.

1290 Industrial Way Albany OR 97322, US Phone: (541) 967-6575; Fax: (541) 967-9424 Web: www.synthetech.com E-mail: [email protected]

KEY PERSONNEL: Daniel T. Fagan; Chairman Dr. Gregory Hahn; President and COO Gary Weber; CFO and VP, Finance and Administration Dr. Mike Standen; Director, Technology Brett Reynolds; Director, Sales and Marketing


HISTORY: Founded in 1981 by Paul Ahrens Acquired fine chemicals manufacturing facilities in Albany, Ore. (1987) Acquired technology assets and customer lists of Colorado Biotechnology Associates Inc. (1/06)

FACILITIES: 25,000 sq. ft. manufacturing plant, research labs, warehouse and administrative offices 20,000 sq. ft. pilot manufacturing plant

STOCK-FINANCIAL HISTORY: NASDAQ--NZYM IPO--3M shares at $1/share, $3M (1984) Revenue $5.819M (YE 06) compared to $9.751M (YE 05) Net loss <$3.501M> (YE 06) compared to <$8.369M> (YE 05) Loss per share <$0.24/share> (YE 06) compared to <$0.58/share> (YE 05)

PRIVATE PLACEMENTS: $1M private placement of stock and warrants (8/91) $1M exercise of above warrants (3/96)

BUSINESS STRATEGY: Develop and market amino acid derivatives Develop and scale-up bio-organic processes for chiral fine chemicals and pharmaceutical intermediates, especially specialty amino acids and derivatives

AGREEMENTS: Name Products Content of Agreement Date Biomeasure Inc. specialty amino acids supply and

technology agreement

5/89

Miwon Korea aspartame licensing agreement 12/89



RESEARCH & DEVELOPMENT: Focus is on nonnatural amino acids, amino acid derivatives, and small peptides for pharmaceutical applications (peptides, peptidomimetics, small molecules, etc.)

PRODUCTS ON MARKET: Peptide building blocks--more than 400 products on market in 22 countries

Wide range of amino acid derivatives, amino alcohols, and specialty amino acids--capacity from kilos to tons

Synthetic Genomics Inc.

9601 Blackwell Road, Ste. 200 Rockville MD 20850, US Phone: (240) 238-0800; Fax: (240) 238-0888 Web: www.syntheticgenomics.com E-mail: [email protected]

KEY PERSONNEL: J. Craig Venter, Ph.D.; Chairman, CEO and Co-CSO Aristides Patrinos, Ph.D.; President Hamilton O. Smith, M.D.; Exec. VP and Co-CSO David Kiernan, M.D.; Exec. VP and General Counsel


HISTORY: Founded in June 2005


BUSINESS STRATEGY: Develop and commercialize recently discovered and potentially world-changing genomic synthesis technologies

RESEARCH & DEVELOPMENT: Initial focus is on ethanol and hydrogen production


1-1, Doshomachi 4-chome, Chuo-ku Osaka 540-8645, Japan Phone: +81 6-6204-2111; Fax: +81 6-6204-2880 Web: www.takeda.co.jp

KEY PERSONNEL: Kunio Takeda; Chairman Yasuchika Hasegawa; President Hiroshi Akimoto, Ph.D.; Managing Director Makoto Yamaoka; Sr. Managing Director and GM, Pharmaceutical Marketing Division Kiyoshi Kitazawa, Ph.D.; Managing Director and GM, Strategic Product Planning Hiroshi Shinha; GM, Legal Toyoji Yoshida; GM, Corp. Communications Hiroshi Takahara; GM, Finance and Accounting Hiroaki Ogata; GM, Business Development and Global Licensing

EMPLOYEES: 14,510 employees; 7,345 in parent company

HISTORY: Founded in June 1781 Incorporated in January 1925

FACILITIES: ¥53M Tsukuba Research Laboratories, a biotechnology research center in Tsukuba Science City Branches in Sapporo, Tohoku, Kitakanto-Koshinetsu, Tokyo, Yokohama, Chiba-Saitama, Nagoya, Kyoto, Osaka, Kobe, Shikoku, Chugoku, Fukuoka Plants in Osaka, Shonan, Hikari, Takasago, Kashima, Shimizu and Tokuyama



Research laboratories in Osaka and Tsukuba Farm and herbal garden in Fukuchiyama and Kyoto

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock exchanges Net sales ¥1,212b (YE 05) compared to ¥1,122b (YE 04) Net income ¥313.249b (YE 05) compared to ¥277.438b (YE 04) Earnings per share ¥353.47/share (YE 05) compared to ¥313.01/share (YE 04) Total assets ¥3,042b (YE 05) compared to ¥2,545b (YE 04)

SUBSIDIARIES/DIVISIONS: Takeda America Holdings Inc.--New York, N.Y. Takeda Research Investment Inc.--Palo Alto, Calif. Takeda San Diego Inc.--San Diego, Calif. Takeda Pharmaceuticals North America Inc.--Lincolnshire, Ill. Takeda Global Research and Development Center Inc.--Lincolnshire, Ill. TAP Pharmaceutical Products Inc.--Lake Forest, Ill. Takeda Global Research & Development Centre (Europe) Ltd.--London Laboratoires Takeda--France Takeda UK Ltd. Takeda Italia Farmaceutici SpA--Rome, Italy Takeda Pharma GmbH--Germany Takeda Pharma Ges. mbH--Vienna, Austria Takeda Pharma AG--Lachen, Switzerland Takeda Ireland Ltd.--Wicklow, Ireland Takeda Pharma Ireland Ltd.--Dublin, Ireland Tianjin Takeda Pharmaceuticals Co. Ltd.--China Takeda Chemical Industries (Taiwan) Ltd.--Taipei, Taiwan Boie-Takeda Chemicals Inc.--The Phillipines Takeda (Thailand) Ltd.--Bangkok, Thailand P.T. Takeda Indonesia--Indonesia

INVESTMENTS: Wyeth-Lederle (Japan) Ltd.--30% TAP Pharmaceutical Products Inc.--50% (joint venture with Abbott Laboratories) Laboratoires Takeda--100% Takeda Italia Farmaceutici SpA--76.92% (with Finfarma SpA) Tianjin Takeda Pharmaceuticals Co. Ltd.--75% (with Tainjin Lisheng Pharmaceutical Factory)


3M Pharmaceuticals

topical treatment for cervical high-risk HPV infection and cervical dysplasia

exclusive co-development and joint marketing agreement

2/05

Abbott Laboratories

drug for prostate cancer and ulcer

joint venture called TAP Holdings to market drug developed by Takeda

8/77

Affymax Inc. Affymax's Hematide in Japan


2/06

Affymax Inc. Affymax's Hematide in the U.S.


6/06

Ajinomoto risedronate for osteoporosis

codevelopment agreement for Japan and South Korea

1992

Alizyme plc development, manufacturing and marketing of ATL-962 in Japan




Arius Research Inc.

Arius' FunctionFIRST Platform to discover treatments for human disease

three-year, multi-product collaboration

4/06

BioNumerik Pharmaceuticals Inc.

Tavocept (dimesna) marketing agreement (USA and Canada)

10/04

Galaxy Biotech monoclonal antibody development, manufacturing and sales agreement

7/06

Human Genome Sciences Inc.

gene sequence database


6/95

Lexicon Genetics Takeda can select and purchase targets for anti-hypertension medicine discovered in Lexicon's Genome5000 program

partnership 7/04

McNeil Consumer Products Co. (Johnson & Johnson)

McNeil's OTC products marketing agreement for Japan

1997

Merck KGaA Matuzumab co-development and co- commercialization agreement

9/05

Pharmacia & Upjohn (now part of Pfizer)

smoking cessation joint marketing agreement--Takeda to sell P&U smoking cessation products in Japan

1996

PPD Inc. development and marketing rights to PPd's DPP4 inhibitors


Santhera Pharmaceuticals AG

Idebenone (SNT-MC17) development and commercialization agreement

8/05

For all recent agreements, please visit: takeda.co.jp/english/press/press.htm

RESEARCH & DEVELOPMENT: Lifestyle-related diseases

Cancer and urological diseases, gynecological disorders Central nervous system disorders and bone and joint disorders Life-cycle management of drugs for digestive system disorders

PRODUCTS ON MARKET: Diabetes: ACTOS®, BASEN® Cardiovascular: BLOPRESS®, CALSLOT®, ADECUT® Gastrointestinal: PREVACID® Urology and Gynecology: LUPRON DEPOT® Osteoporosis: OSTEN®, BENET® Infection: PANSPORIN®, FIRSTCIN®, BESTCALL®, TAKESULIN®, LILACILLIN®, AMASULIN®, PANSPORIN T® Interferon and Interleukin: CANFERON A®, CELEUK® Central Nervous System: NICHOLIN®, HIRTONIN®, EURODIN® Inflammation: DASEN® Vitamin: ALINAMIN F®, VITANEURIN®, HICEE®, PANVITAN® Allergy: BRONICA®, SOLFA® Vaccine: Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine, Dried Live Attenuated Measles Vaccine, Dried Live Attenuated Mumps Vaccine, Dried Live Attenuated Rubella Vaccine, Japanese Encephalitis Vaccine



Cold Remedies: Benza® Block IP Preparations for Rhinitis: Benza® AL, Benza® AL Spray Gastrointestinal Drugs: That's®, That's® 21, That's® Block Vitamin Products: Alinamin® A25, New Alinamin® A, Alinamin® EX, Hicee®-L, Hicee® 1000, Hicee® white2, Hicee® B Mate2, Hicee® E-class, Vitamin C ‘TAKEDA,’ Vitamin E ‘TAKEDA,’ Panvitan HI Vitamin-containing Tonics (Quasi-drugs): Alinamin® V, Alinamin® V&V, Alinamin® 7, Hicee® CEtime Vitamin-containing Tonics: Alinamin® e Athlete's Foot Treatments: Scorba® LX, Scorba® Laxatives: TAKEDA KANPO BENPIYAKU, Clear®

Teledyne Isco

4700 Superior Street Lincoln NE 68504, US Phone: (402) 464-0231; Fax: (402) 465-3022 Toll-free phone: (800) 228-4373 Web: www.isco.com E-mail: [email protected]

KEY PERSONNEL: David Kennedy, Ph.D.; General Manager

EMPLOYEES: 467 employees worldwide

HISTORY: Founded by Robert W. Allington in 1958 Signed agreement to acquire Suprex Corp. of Pittsburgh, PA (8/96) Signed agreement to acquire Geomation Inc. of Golden, CO (9/97) Acquired STIP Siepmann und Teutscher GmbH (1/98) Merged with subsidiary of Teledyne Technologies Inc. (2004) Changed name from Isco Inc. (2004) Acquired MGD Technologies Inc. (12/05) Teledyne MGD Inc. subsidiary merged into Teledyne Isco (5/06)

FACILITIES: Sales offices in Belgium, Germany, China and Lincoln, Neb. 200,000 sq. ft. plant

STOCK-FINANCIAL HISTORY: Privately held by parent Formerly listed on NASDAQ--ISKO: IPO--$7.43/share (1985)

SUBSIDIARY OF: Teledyne Technologies Inc.

INVESTMENTS: Geomation, Inc. Advanced Flow Technology Co. (AFTCO)--joint venture with AMJ Equipment Corp.

BUSINESS STRATEGY: Growth by internal product development in closely related lines supplemented by product acquisition

PRODUCTS ON MARKET: Instrumentation--LC and HPLC products, optical detectors, fraction

collectors, pumps, electrophoresis apparatus, supercritical fluid extraction systems, and syringe pumps Environmental products--wastewater samplers, parameter monitoring products, and process monitoring products



The Dow Chemical Co.

2030 Willard H. Dow Center Midland MI 48674, US Phone: (989) 636-1000; Fax: (989) 636-1830 Web: www.dow.com

KEY PERSONNEL: Andrew N. Liveris; President, CEO and Chairman Geoffery E. Merszei; Exec. VP and CFO William F. Banholzer; Corp. VP and CTO Bill Weideman; VP and Controller Frank H. Brod; Corp. VP Heinz Haller; Corp. VP, Strategic Development and New Ventures Michael R. Gambrell; Exec. VP, Basic Plastics and Chemicals Portfolio Charles J. Kalil; Corp. VP, General Counsel and Corp. Secretary David E. Kepler; Sr. VP, Shared Services and Environment, Health and Safety and CIO Romeo Kreinberg; Exec. VP, Performance Plastics and Chemicals Portfolio Julie Fasone Holder; Corp.VP, Human Resources, Diversity and Inclusion and Public Affairs Luciano Respini; Corp. VP, Geography Fernando Ruiz; Corp. VP and Treasurer Gary R. Veurink; Corp. VP, Manufacturing and Engineering


HISTORY: Founded in 1897 Began biotech research in 1979 Acquired United AgriSeeds Inc. (crop biotechnology) for $45M (1987) Formed joint venture (Dow Elanco & Co.) with Eli Lilly and Co. by combining their plant-sciences businesses and Dow's industrial pest-control business (10/89) Completed $38/share cash tender offer for 58.5M shares of Marion Laboratories, and acquired 67% of outstanding shares, which finalized merger to create new company, Marion Merrell Dow (12/89) Sold the assets from the Biotech Project of CD Medical Inc. to UniSyn Technologies, a wholly owned subsidiary of Synbiotics Corp. (6/90) Finalized agreement for Hoechst AG to acquire all outstanding shares of Marion Merrell Dow (2Q95) Member--Biotechnology Research and Development Corp (BRDC) Member--Midwest Plant Biotechnology/Consortium Member--Biotechnology Industry Organization

FACILITIES: 165 manufacturing sites in 37 countries

STOCK-FINANCIAL HISTORY: NYSE--DOW Net sales $46.307b (YE 05) compared to $40.161b (YE 04) Net income $4.515b (YE 05) compared to $2.797b (YE 04) Earnings per share $4.62/share (YE 05) compared to $2.93/share (YE 04) Average shares outstanding 963.2M (YE 05) compared to 940.1M (YE 04) Total assets $45.934b (YE 05) compared to $45.885b (YE 04)

SUBSIDIARIES/DIVISIONS: Divisions:

Perfornace Plastics Performance Chemicals Plastics Chemicals Agricultural Science Hydrocarbon & Engergy

INVESTMENTS: Collaborative Research, Inc.--$5M, 5% equity Dow Corning Corp.--joint venture with Corning Inc. Millipore Corp.--9.5% (1984) Haeger & Kaessner GmbH--acquired (1986) United AgriSeeds, Inc.--acquired for $45M (12/87) Montedison SpA--less than 5%



Lamaur, Inc.--acquired (1987) FilmTec Corp. (membrane manufacturer for water purification and separation processes), acquired capital stock for $75M (1987) Essex Chemical Corp.--acquired for $366.1M, $36/share (9/88) Neoprobe Corp.--minority equity Sumitomo Chemical Co.--joint venture to manufacture polycarbonates in Japan (12/89) BOC Group plc--joint venture to develop and market membrane-based air-separation systems (12/89)

BUSINESS STRATEGY: Provide innovative chemical, plastic and agricultural products and services to many essential consumer markets

AGREEMENTS: Name Products Content of Agreement Date Access Pharmaceuticals Inc.

Access' bioresponsive polymer systems and Dow's chelation technology to develop MRI contrast agents, radiopharmaceutical diagnostics and therapeutics

collaboration agreement--Access gets rights to chelation technology. Dow has equity position, manufacturing rights and future royalties

8/97

Caliper Technologies Corp.

Dow's polymer technology to the development and manufacturing of disposable LabChips

R&D collaboration 3/97

Cytogen Corp. radiopharmaceutical to alleviate the bone pain associated with metastatic cancer

exclusive U.S. marketing rights to Cytogen

5/93

Diversa Corp. enzymatic method that modifies a chemical process used by Dow

partnership 8/97

Ecogen Inc. microbial biopesticide collaborative development agreement (through joint venture, Dow Elanco & Co.)

11/89

Kereos Inc. patent portfolios for development and commercialization of imaging agents for diagnosis of cancer and cardiovascular disease


Neoprobe Corp. Dow's licensed MAbs and radiolabeling technology

R&D, supply, and licensing agreement

3/89, 8/92


more than 140,000 of Dow's compounds for screening and potential development of small molecule drugs

exclusive worldwide licensing agreement--Dow received 350K shares of OSI common stock

3/97

Sumitomo Chemical Co. Ltd.

polycarbonates joint venture to manufacture in Japan

12/89

RESEARCH & DEVELOPMENT: Agricultural products, industrial catalysts, cancer therapy and detection rDNA techniques, human health care



PRODUCTS ON MARKET: PLASTICS: automotive products, electronics, engineering plastics, epoxy products, polyolefin products, polystyrene, polyurethane, polyurethane systems, synthetic rubber CHEMICALS: calcium chloride, caustic soda, emulsion polymers, biocides, coolants, heat transfer fluids, polypropylene glycols and copolymers, surfactants, UCAR aircraft deicing fluids, UCAR emulsion systems, acrylate monomers, oxygenated solvents, alkyl alkanolamines, ethanolamines, ethyleneamines, isopropanolamines, glycol ethers and acetates, propylene oxide and propylene glycols, specialty polymers, water soluble polymers AGRICULTURE: fungicides, herbicides, insecticides, soil fumigants, films, seeds, fumigants

The Nitrate Elimination Co. Inc.

334 Hecla Street Lake Linden MI 49945, US Phone: (906) 296-1115; Fax: (906) 296-8003 Toll-free phone: (888) NITRATE (648-7283) Web: www.nitrate.com E-mail: [email protected]

KEY PERSONNEL: Dr. Wilbur H. 'Bill' Campbell, Ph.D.; President Ellen R. Campbell; VP and COO Troy P. Kinnunen-Skidmore; Sr. Lab Technician for Enzyme Production Michael J. Brodeur-Campbell; Lab Technician and Marketing Assistant Thomas A. Rodeheffer; Instrument Technician



FACILITIES: 2,500 sq. ft. R&D facilities and biochemistry lab 1,500 sq. ft. manufacturing facility


BUSINESS STRATEGY: As an environmental biotechnology company, develop and commercialize enzyme-based products for water testing and water treatment, with R&D funding derived from competitive grant awards and collaborative agreements Provide contract protein expression and purification services for nonmedical enzymes, and environmental and industrial enzyme discovery research

AGREEMENTS: Name Products Content of Agreement Date EPA enzymatic nitrate

elimination technology Phase I & II SBIR contract

9/95, 9/97.

NIH Phase I/II expression of nitrate reductase in Pichia

Phase I/II SBIR grants

8/98- 12/03

NIH SBIR nitrate biosensor R&D Phase I SBIR grant (9/99 - 9/00)

NIST Biotechnology Division

biosensors two-year CRADA agreement (8/94), extended three years

7/96

Sigma, Assay Designs, Oxford Biomedical Research

stabilized nitrate reductase

supply agreements 2/95

U.S. Army Corps of Engineers Research Lab

enzymes involved in degradation of nitroaromatic explosives

contract R&D 2/98, 12/00



USDA nitrate test kit for consumers

Phase II SBIR grant 7/96

USDA Phase I/II grants

rapid nitrate test kits for agricultural samples

SBIR awards 3/02- 9/05

USDA SBIR enzyme-based reagent packages for automated equipment

Phase I/II awards 3/02- 9/05

YSI, Inc. enzymes contract production for YSI proprietary products

6/99

RESEARCH & DEVELOPMENT: Enzyme-based biosensors Expression of complex enzymes Immobilized enzyme systems for water treatment and other processes 'Battery powered' enzyme processes Most recent R&D: Enhancement of Nitrate Reductase production, which resulted in the production of a new form of commercial Nitrate Reductase, called New NECi NaR Ag-Nitrate test kits to assist Ag consultants and farmers to easy evaluate the nitrate content of feed, soil and water Discrete analyzer reagent kits (D-ARK) The Nitrate Reductase-linked Nitrate Biosensor: Nitrate Biosensor Enzymatic Nitrate Elimination Technology: EzNET®

PRODUCTS ON MARKET: Nitrate reductase, NADH forms, native and recombinant Nitrate kit for biomedical (NO) research Nitrate test kit for consumers Nitrate test kits for education, research, ag diagnostics, environmental diagnostics, water quality Reagent packs for water analysis equipment

PRODUCTS IN DEVELOPMENT: Name Status Nitrate biosensor prototype Enzymatic process for removal of nitrate from water

prototype

Additional enzymes for analytical applications

in development

TNO Quality of Life

Utrechtseweg 48, P.O.Box 360 Zeist 3700 AJ, Netherlands Phone: +31 (0)30 694 41 44; Fax: +31 (0)30 695 72 24 Web: www.tno.nl/voeding; E-mail: [email protected]

KEY PERSONNEL: Dr. C.L Ekkers; Director Dr. N.J. Snoeij; Director, Marketing and Sales

EMPLOYEES: 750 employees, 80% scientific personnel

HISTORY: Founded in 1940 at Utrecht

FACILITIES: Facilities in Zeist, Leiden and Groningen, Netherlands


SUBSIDIARY OF: TNO, the Netherlands Organization for Applied Scientific Research

BUSINESS STRATEGY: As a contract organization in the field of life sciences, TNO seeks to provide a link of knowledge between fundamental research and its applications to foods, drugs and (agro)chemicals in relation to health, safety and quality as well as product and process innovation



AGREEMENTS: Name Products Content of Agreement Date Dyadic International Inc.

Dyadic's fungal high-throughput screening system

profit-sharing and royalty rights agreement, restructured 12/05

8/03

University of Groningen

carbohydrate bioengineering in the TNO-RUG Centre for Carbohydrate Bioengineering


University of Leiden

plant biotechnology in the TNO-RUL Centre for Biotechnology


University of Utrecht

microbiology in the TNO-UU Centre for Veterinary Health


University of Wageningen

protein technology in the TNO-LUW Centre for Protein Technology


RESEARCH & DEVELOPMENT: Food and feed research Nutrition Toxicology TQM Biochemistry Biopharmaceutical R&D TNO's 23 core technologies: Analytical and Molecular Pharmacology Animal Food Technology Applied Plant Sciences Carbohydrate Technology Damage Assessment and Consultancy Environmental Toxicology Explanatory Toxicology Food and Food Supplement Analysis Food Science and Technology General Toxicology Microbial Physiology and Gene Technology Microbiology and Quality Management Nutritional Epidemiology Nutritional Physiology Packaging Research Protein and Meat Technology Residue Analysis Sensor Technology Target Organ Toxicology Toxicological Risk Assessment

PRODUCTS ON MARKET: Contract research



Toray Industries Inc.

Nihonbashi Mitsui Tower 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo 103-8666, Japan Phone: +81 3-3245-5111; Fax: +81 3-3245-5555 Web: www.toray.com; E-mail: [email protected]

KEY PERSONNEL: Sadayuki Sakakibara; President, CEO and COO Kazuo Tomiita; Exec. VP Kiyoshi Fukuchi; GM, Personnel and Industrial Relations Division Osamu Nakatani; GM, Manufacturing Division Kazuhiro Maruyama; GM, General Administration Division Norihiko Saitou; Chief Investor Relations Officer Hiroaki Kobayashi; GM, Technology Center Munehiro Se; GM, Purchasing and Logistics Division


HISTORY: Founded in January 1926 Began biotech research in 1969

STOCK-FINANCIAL HISTORY: Common stock listed on Tokyo, Osaka, Nagoya, Fukuoka, Sapporo, London and Luxemburg stock exchanges Net sales ¥1,428b (YE 06) compared to ¥1,299b (YE 05) Net income ¥47.4b (YE 06) compared to ¥34.397b (YE 05) Earnings per share ¥33.7/share (YE 06) compared to ¥24.46/share (YE 05) Total assets ¥1,537b (YE 06) compared to ¥1,402b (YE 05)

SUBSIDIARIES/DIVISIONS: 237 subsidiaries and affiliates, including: DuPont-Toray Co. Ltd. Opelontex Co. Ltd. Ogaki Fuso Spinning Co. Ltd. Toray Textiles Inc. Inami Textiles Inc. Matsumoto Textiles Co. Ltd. Toray Coatex Co. Ltd. Towa Orimono Co. Ltd. Toray Monofilament Co. Ltd. Toyo Tire Cord Co. Ltd. Toyo Flocking Co. Ltd. Maruichi Fiber Co. Ltd. Sowa Textile Co. Ltd. Toyo Plastic Seiko Co. Ltd. Toray PEF Products Inc. Toray Advanced Film Co. Ltd. Dow Corning Toray Silicone Co. Ltd. Toray Fine Chemicals Co. Ltd. Soda Aromatic Co. Ltd. Toray ACE Co. Ltd. Toray Engineering Co. Ltd. Toray Precision Co. Ltd. Toray Medical Co. Ltd. Toray Research Center Inc. Toyo Jitsugyo Co. Ltd. Toray Plastics (America) Inc. Toray Resin Co. Toray Carbon Fibers America Inc. Toray Composites (America) Inc. Toray Textiles Europe Ltd. Alcantara SpA Toray Textiles Central Europe s.r.o. Toray Plastics Europe SA Société des Fibres de Carbone SA P.T. Acryl Textile Mills P.T. Century Textile Industry Tbk



P.T. Easterntex P.T. Indonesia Synthetic Textile Mills P.T. Indonesia Toray Synthetics Luckytex (Thailand) Public Co. Ltd. Thai Toray Textile Mills Public Co. Ltd. Thai Toray Synthetics Co. Ltd. Penfabric Sdn. Berhad Penfibre Sdn. Berhad Toray Plastics (Malaysia) Sdn. Berhad Toray Fibers (Nantong) Co. Ltd. Toray Sakai Weaving & Dyeing (Nantong) Co. Ltd. Taltex (Zhuhai) Ltd. Toray Plastics (Shenzhen) Ltd. Toray Film Products (Zhongshan) Ltd. Toray Sanko Precision (Zhongshan) Ltd.

INVESTMENTS: Fujirebio Toray-Fuji Bionics--joint venture of Toray and Fujirebio


Acologix Inc. development and commercialization of Toray's TRK-820 in North America and co-development in Europe

collaboration and licensing agreement

6/05

Acologix Inc. Acologix's AC-200 program in Japan


6/06

Biotech Australia Pty. Ltd.

animal vaccines R&D agreement 1994

Daiichi Seiyaku Feron natural beta-IFN for hepatitis B and C, brain tumors, malignant melanoma


Daiichi Seiyaku, Genentech Inc.

gamma-IFN development and marketing agreement for Japan, clinical studies shared with Daiichi

Digene Corp. DNA diagnostic probes for disease detection


12/90

DNA Chip Research Inc.

high-performance DNA microarrays


12/05

Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

TRK-820 development and marketing agreement

3/05

Maruho Co. Ltd. development and marketing agreement

3/05


compound for urinary incontinence


4/05

Uniqlo Co. Ltd. development of breakthrough material for new product creation, creation of product development system

strategic partnership

6/06



PRODUCTS ON MARKET: Fibers and Textiles: Nylon, Tetoron (polyester), Toraylon (acrylic), Ecsaine, sillook Water Treatment Membranes and Systems: Romenbra, High recovery seawater desalination system, Torayfil, Torayvino (household water purifier) Plastics: Amilan (nylon), Toyolac (ABS), Toraycon (PBT), Torelina (PPS), Toraypef (polyolefin foam) Fine Chemicals: Torayblan (synthetic gypsam), aromatic fine chemicals, high-functional catalysts, specialty chemicals, Intercat (Interferon for cats and dogs) Carbon Fibers and Composite Materials: Torayca, Torayca Prepreg, Torayca composites Pharmaceuticals and Medical Products: Feron (natural interferon preparation), Dorner (oral prostacyclin (PGI2) derivative) and Filtryzer artificial kidneys for dialysis

Toronto Research Chemicals Inc.

2 Brisbane Road North York M3J 2J8, Canada Phone: (416) 665-9696; Fax: (416) 665-4439 Toll-free phone: (800) 727-9240 Web: www.trc-canada.com E-mail: [email protected]

KEY PERSONNEL: Dr. David S. Dime; President Charles E. Dime; Exec. VP



FACILITIES: 42,000 sq. ft. of state-of-the-art laboratory space


BUSINESS STRATEGY: Develop, manufacture and supply fine chemicals for biomedical research Seek pharmaceutical partnerships for joint development of novel therapeutics and contract research opportunities

RESEARCH & DEVELOPMENT: Novel therapeutics as anticancer, anti-AIDS and cardiac active compounds

Contract R&D Custom synthesis and process development

PRODUCTS ON MARKET: Biomedical research chemicals including enzyme inhibitors, oligosaccharides, nitric oxide synthase reagents, phosphoramidites, carbohydrates, detergents, fluorescent probes and crosslinkers Tyrosine kinase inhibitors, signal transduction, protein/ion channel reagents



Union Chemical Laboratories (UCL)

321, Sec. 2, Kuang Fu Road, Kuang Fu Compound, Taiwan Hsinchu 30042, China Phone: (+86) 886-35-732-616; Fax: (+86) 886-35-732-359 Web: www.ucl.itri.org.tw/eng/ E-mail: [email protected]

KEY PERSONNEL: Dr. Wu-Hsun Cheng; General Director

EMPLOYEES: 500+ employees, 230+ Ph.D.s/masters degrees

HISTORY: Officially organized in 1946 as Union Industrial Research Laboratories (UIRL) Merged with the Industrial Technology Research Institute (ITRI) (1973) UIRL changed name to Union Chemical Laboratories (UCL) (1983)

STOCK-FINANCIAL HISTORY: Nonprofit government-sponsored agency

SUBSIDIARY OF: Industrial Technology Research Institute (ITRI)

BUSINESS STRATEGY: Develop technologies in packaging and electronic materials, specialty polymers and resins, metallocene-based catalysts/polymers, nano-polymers, nanochemistry, nanobiochemistry, functional and high-tech fibers and combinatorial chemistry

AGREEMENTS: Name Products Content of Agreement Date Commonwealth Scientific and Industrial Research Organization (CSIRO)

Development of advanced polymerization catalyst technology

cooperative R&D project

6/02

RESEARCH & DEVELOPMENT: Precision polymers Hi-tech polymers Functional and high-tech fibers Nanobio-chemistry Nanochemistry Combinatorial chemistry Specialty chemicals Advanced chemical engineering Optoelectronic/electronic chemicals

PRODUCTS ON MARKET: Services include: R&D in new product/process/application Collaboration in new product/process/application Process modification/optimization Chemical analysis/product testing Technical assistance/consultation/training

UniQuest Pty. Ltd.

Level 2, Cumbrae-Stewart Building, Research Road The University of Queensland Brisbane Q1D 4072, Australia Phone: +61 7 3365-4037; Fax: +61 7 3365-4433 Web: www.uniquest.com.au E-mail: [email protected]

KEY PERSONNEL: Norbury Rogers; Chairman David Henderson; Managing Director Richard Symons; CFO David Henderson; Managing Director



Gary Heyden; GM, Consulting and Research Harleigh Luscombe; GM, International Projects Dean Moss; Manager, Technology Commercialization Andrew Davis; Manager, Technology Commercialization Julia Renaud; Manager, Corp. Development


HISTORY: Founded in July 1983 Incorporated in July 1984


SUBSIDIARY OF: The University of Queensland

BUSINESS STRATEGY: Tech transfer company for The University of Queensland

RESEARCH & DEVELOPMENT: Commercialization of innovations via licenses, patents and establishing

start-ups Assembling multi-disciplinary consulting teams for international development projects Providing government, industry, and the wider community with a wide range of consulting, testing, expert opinion and advisory services as well as research and development projects

University of Nebraska-Lincoln, Center for Biotechnology

P.O. Box 880665, N300 Beadle Center Lincoln NE 68588-0665, US Phone: (402) 472-2635; Fax: (402) 472-3139 Web: www.biotech.unl.edu; E-mail: [email protected]

KEY PERSONNEL: Dr. Michael Fromm; Director Rik Barrera; Manager, Business Office Dr. Yuannan Xia; Manager, Genomics and Flow Cytometry Dr. Tom Clemente; Manager, Plant Transformation Dr. Ron Cerny; Manager, Mass Spectrometry and Proteomic Analysis Dr. Y. (Joe) Zhou; Manager, Microscopy Dr. Jean-Jack M. Riethoven; Manager, Bioinformatics Dr. Hideaki Moriyama; Manager, Structual Biology

EMPLOYEES: 5 employees, 165 faculty associates

HISTORY: Founded in 1989 Member--Biotechnology Industry Organization Affiliated with the University of Nebraska at Lincoln

FACILITIES: Protein sequencing and proteomics, bioinformatics, genomics and DNA sequencing, flow cytometry analysis, plant transformation, mass spectrometry, and microscopy research facilities


BUSINESS STRATEGY: Foster research and development in high priority areas of biotechnology

RESEARCH & DEVELOPMENT: All aspects of molecular life sciences research, leading to improvements in

agriculture, health care and the environment



UVP Inc.

2066 W. 11th Street Upland CA 91786, US Phone: (909) 946-3197; Fax: (909) 946-3597 Toll-free phone: (800) 452-6788 Web: www.uvp.com E-mail: [email protected]

KEY PERSONNEL: Paul Warren; Chairman Leighton Smith; President Alex Waluszko; Exec. VP




SUBSIDIARIES/DIVISIONS: Ultra-Violet Products Ltd. BioImaging Systems Group Laboratory Products Group Ultra-Violet Products Group

PRODUCTS ON MARKET: BioImaging Systems, CCD-based, for fluorescent, chemiluminescent,

chemifluorescent and visible light imaging of gels, blots, membranes, plates, slides, microarrays, film and live specimens

PRODUCTS IN DEVELOPMENT: Name Status analysis software in development imaging systems in development

Valeant Pharmaceuticals International Inc.

Valeant Plaza, 3300 Hyland Avenue Costa Mesa CA 92626, US Phone: (714) 545-0100; Fax: (714) 556-0131 Toll-free phone: (800) 548-5100 Web: www.valeant.com E-mail: [email protected]

KEY PERSONNEL: Timothy C. Tyson; President and CEO Bary G. Bailey; CFO and Exec. VP Eileen C. Pruette; Exec. VP and General Counsel Martin N. Mercer; Exec. VP, Latin America Operations Wesley P. Wheeler; President, Global Marketing and Business Development Charles J. Bramlage; President, Europe David W. Kwo; Exec. VP, Asia, Africa and Australia John I. Cooper; Exec. VP, Global Manufacturing and Supply Geoffrey M. Glass; Sr. VP and CIO


HISTORY: Founded in 1960 by Milan Panic Eastern European venture company ICN Galenika (75% owned by ICN, 25% owned by Galenika) formed in May 1991 (based in Belgrade, former Yugoslavia) Former subsidiaries SPI Pharmaceuticals Inc., Viratek Inc., ICN Biomedicals Inc., and ICN Pharmaceuticals Inc. combined into new corporation named ICN Pharmaceuticals Inc. (11/94) Signed letter of intent to acquire 75% of Tuobin Chemicals and Pharmaceuticals General Corp. (China) (7/95) Acquired 40% of SeaLite Sciences Inc. (11/95)



Acquired Gly Derm Inc., skin care company (2/96) Won bid to purchase 49% of Alkaloida Chemical Co. Ltd. (6/96) Acquired Dosimetry Service from Siemens Medical System Inc. (6/96) Acquired Leksredstva, Russian pharmaceutical company (7/96) Signed letter of intent to manufacture and distribute pharmaceutical products in Bosnia (8/96) Acquired Vuab, manufacturing and research facility in the Czech Republic (6/98) Changed name from ICN Pharmaceuticals (11/03) Sold raw materials and manufacturing operations in Czech Republic to Chemoprojekt, a.s. (8/04) Acquired Xcel Pharmaceuticals (2/05) To purchase Infergen® from InterMune Inc. (as of 11/05)

FACILITIES: Headquarters in Costa Mesa, Calif., and Moscow, Russia Research Products facilities in Aurora, Ohio; Irvine, Calif.; Costa Mesa, Calif.; Sydney, Australia; Tokyo, Japan; Eschwege, Germany; Opera, Italy; Orsay, France; Brussels, Belgium; High Wycombe, UK; and Thame, U.K. Pharmaceuticals facilities in Bryan, OH; Costa Mesa, CA; Bueno Aires, Argentina; Montreal, Canada; Wuxi, China; Mexico City, Mexico; Chelyabinsk, Russia; Moscow, Russia; Kursk, Russia; St. Petersburg, Russia; Tomsk, Russia; Yoshkar-Ola, Russia; Rseczow, Poland; Belgrade, Yugoslavia; Zoetermeer, Holland; and High Wycombe, U.K. Diagnostics facility in Orangeburg, N.Y.

STOCK-FINANCIAL HISTORY: NYSE--VRX Public offering--2.1M shares at $17.50/share (7/86) Public offering--$20M Swiss franc exchangeable certificates, 5.5% (2/87) Public offering--$37M subordinated double convertible bonds, 3.25% (3/87) Public offering--3M shares, $21M (6/96) Public offering--7.2M shares of common stock at $24/share (2/05) Revenue $822.681M (YE 05) compared to $682.520M (YE 04) Net loss <$188.259M> (YE 05) compared to <$169.797M> (YE 04) Loss per share <$2.05/share> (YE 05) compared to <$2.02/share> (YE 04) Average shares outstanding 91.696M (YE 05) compared to 83.887M (YE 04)

SUBSIDIARIES/DIVISIONS: ICN Canada Ltd.--Canada ICN Pharmaceutica SA--Mexico Laboratorios Grossman SA--Mexico ICN Pharmaceuticals Holland BV--Netherlands ICN Biomedicals Inc.--Delaware ICN Yugoslavia--Yugoslavia ICN Biomedicals GmbH--Germany ICN Pharmaceuticals Australasia Pty. Ltd.--Australia ICN Pharmacueticals Japan KK--Japan ICN Iberica--Spain Labsystems Benelux BV--Netherlands Labsystems Benelux NV--Belgium ICN Biomedicals Ltd.--U.K. ICN France SARL--France ICN Biomedicals SRL--Italy ICN Biomedicals NV/SA--Belgium ICN Oktybr--Russia ICN Polypharm--Russia ICN Leksredstva--Russia Wuxi ICN Pharmaceuticals--China ICN Tomsk--Russia ICN Yoshkar-Ola--Russia

INVESTMENTS: SeaLite Sciences Inc. Biomedpreparat (Russia)--joint venture with Allen & Associates International Ltd. Alkaloida Chemical Co. Ltd. (Hungary)--won competitve bid to acquire up to 59% of the company



BUSINESS STRATEGY: Transform from an entrepreneurially focused corporation into an improved, research-based and integrated specialty pharmaceutical company, focused on marketing and distributing pharmaceuticals in the areas of infectious disease, neurology and dermatology

AGREEMENTS: Name Products Content of Agreement Date Alliance Pharmaceuticals

Valeant's Mestinon and Alliance's Symmetrel

co-promotion agreement

11/04

Biocode SA radioimmunoassay kits production agreement

12/02

Fujisawa U.S.A. Inc. (now part of Astellas Pharma Inc.)

compounds related to hGH


Metabasis Therapeutics Inc.

pradefovir (formerly called remofovir)


10/01


ICN's oral ribavirin for hepatitis C

licensing agreement for Europe--ICN retains rights to all other forms of ribavarin and indications

7/98


Virazole in combination with Schering's Intron A


SeaLite Sciences Inc.

AquaLite TSH test for thyroid disorders


11/98

Senetek plc Zeatin exclusive worldwide licensing agreement

5/04

VWR Scientific Products Corp.

biomedical research products

marketing and distribution agreement for U.S., Canada and Puerto Rico

5/99

RESEARCH & DEVELOPMENT: Drugs for the treatment of hepatitis C and hepatitis B and in the areas of neurology and infectious disease

PRODUCTS ON MARKET: More than 575 branded products, including: 8-MOP™ (8 methoxypsoralen) 10 mg capsule for treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy Virazole™ (ribavirin) for treatment of viral diseases including hepatitis, herpes, and childhood diseases such as chickenpox, approved in 43 countries Virazole™ for respiratory syncytial virus (RSV), on market in the U.S., Canada, the U.K., Spain, Australia, Hungary, New Zealand, and 13 other countries Immunodiagnostic reagents and instruments Neonatal thyroxine and thyroid-stimulating hormone diagnostic kits Test for galactosemia in newborns Dermatologicals and myasthenia product lines in U.S. Multiple product lines abroad including antivirals, antibiotics, dermatologicals, cardiovasculars, analgesics, antirheumatics, central nervous systems compounds and vision care lines Tasmar® (tolcapone) (EU)--acquired from Roche (9/04)



Varied Industries Corp.

905 South Carolina Avenue Mason City IA 50401, US Phone: (641) 423-1460; Fax: (515) 423-0832 Toll-free phone: (800) 654-5617 Web: www.vi-cor.com, www.milktothemax.com E-mail: [email protected]

KEY PERSONNEL: Mark Holt; President Michael Lunning; Controller/Purchasing John Oppy; Technical Services Specialist Jodi Ames; Director, Marketing


HISTORY: Founded in 1966 Pioneer in the organic foods industry


SUBSIDIARIES/DIVISIONS: Fermented Products

SUBSIDIARY OF: Vi-COR

BUSINESS STRATEGY: Develop products for the production of naturally grown foodstuffs

RESEARCH & DEVELOPMENT: Biotechnical applications

Production of naturally grown foodstuffs Fermented products Plant extracts Enzymes and microbial products

PRODUCTS ON MARKET: Lactic acid fermentation products Desert plant extracts Enzymes and microbial products

VECTOR State Research Centre of Virology/Biotechnology

SRC VB Vector, Novosibirsk Region Koltsovo 630559, Russia Phone: +7 3832-36-60-10; Fax: +7 3832-36-74-09 Web: www.vector.nsc.ru; E-mail: [email protected]

KEY PERSONNEL: Prof. Lev. S. Sandakhchiev; Director General Jury I. Klimov; Exec. VP Prof. Sergey V. Netesov; Scientific Director Raisa A. Martynyuk; Director, R&D

EMPLOYEES: 1,056 employees, 143 Ph.D.s, 14 M.D.s, 1 D.V.M.


FACILITIES: 259,100 sq. m. headquarters Level 3 and 4 biosafety laboratory Full cycle biotech production facility


SUBSIDIARIES/DIVISIONS: Subsidiaries: Vector-Pharm--production and sales company Vector-Best--joint stock company Vector-BiAlgam--production and sales company



Divisions: Research Institute of Molecular Biology Research Institute of Cell Cultures Research Institute of Bioengineering Research Institute of Aerobiology Research and Design Institute of Biologically Active Substances Institute of Collection of Cultures of Microorganisms WHO Collaborating Center for Orthopoxvirus Diagnosis and Repository for Variola Virus Strains and DNA

BUSINESS STRATEGY: Acknowledge structure function of virus genomes Create highly sensitive diagnostic kits for viruses, prophylactics, and antiviral and anticancer treatments

RESEARCH & DEVELOPMENT: Diagnostics kits

Antivirals Vaccines

PRODUCTS ON MARKET: Diagnostic kit for HIV Diagnostic kits for hepatitis A, B and C Recolin--recombinant interferon Profezyme Reaferon ridostin Hepatitis A vaccine Measles vaccine Nutrient media, sera Enzymes Biochemical reagents for laboratory studies

PRODUCTS IN DEVELOPMENT: Name Status Alpha-interferon analogues in preclinicals Subalin in preclinicals Erythropoietin in preclinicals TNF-beta analogue in preclinicals Alnorin in Phase II clinicals

Virinova GbR

Luisenstrasse. 23 a Burscheid 51399, Germany Phone: +49 (0) 2174 671 9990; Fax: +49 (0) 2174 894501 Web: www.virinova.de; E-mail: [email protected]

KEY PERSONNEL: Prof. H.J. Duerr; Managing Director




BUSINESS STRATEGY: Provide diagnostic technology enables the detection and quantification of viruses without the use of PCR or antibodies

RESEARCH & DEVELOPMENT: Virus diagnostics for AIDS/HIV, hepatitis C (HCV), hepatitis B (HBV), herpes

simplex (HSV-1 and HSV-2), parvo B19, paramyxo virus, adeno virus, rhino viruses, cytomegalo virus (CMV), parapox virus, foot and mouth disease virus, several plant viruses

PRODUCTS ON MARKET: Novel virus diagnostic technology for process control and diagnostic monitoring of viral infections



Vitrolife AB

Faktorvagen 13 Kungsbacka SE-434 37, Sweden Phone: +46 31-721 80 00; Fax: +46 31-721 80 90 Web: www.vitrolife.com E-mail: [email protected]

KEY PERSONNEL: Patrik Tigerschiold; Chairman Dr. Magnus Nilsson; CEO Christer de Flon; Director, Global Sales and Marketing and VP Anna Ahlberg; CFO Stefan Blomsterberg; Director, Logistics Hans Lehmann; Director, Development Goran Mellbin; Director, Quality Assurance and Quality Control Neil Murphy; Director, Production Emma Sjoqvist; Deputy Production Director Tony Winslof; Director, Marketing Nils Sellbom; President, Vitrolife Inc.


HISTORY: Founded in 1993 Vitrolife AB founded in 1997 as the group holding company

STOCK-FINANCIAL HISTORY: Listed on the Stockholm Stock Exchange since 2001

SUBSIDIARIES/DIVISIONS: Vitrolife Sweden AB Faktorvagen 13 SE-434 37 Kungsbacka Sweden Vitrolife Inc. 3601 South Inca Street Englewood, CO 80110 Swemed Lab International AB Billdalsvagen 2 SE-427 36 Billdal Sweden

BUSINESS STRATEGY: Provide innovative enabling technologies and products Develop and market complex but convenient ready-to-use/ready-to-choose solutions Target and work with opinion leaders in marketing/sales and R&D Position Company to benefit from regulatory environment Control in-house manufacturing

RESEARCH & DEVELOPMENT: Cell Therapy:

Media to enable the use of stem cells for therapeutic purposes Transplantation: Solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. New product CE-marked January 2006: Steen Solution™ Fertility: Nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility

PRODUCTS ON MARKET: EmbryoGlue® Culture media Media for micro-manipulation Media for sperm preparation Freeze-Kit1™ (for embryos) Thaw-Kit1™ (for embryos)



VitroHES Perfadex® Steen Solution™ ClearVision™ ETC Needles Pipettes

Vizon SciTec Inc.

BC Research Complex, 3650 Wesbrook Mall Vancouver V6S 2L2, Canada Phone: (604) 224-4331; Fax: (604) 224-0540 Web: www.vizonscitec.com E-mail: [email protected]

KEY PERSONNEL: Brian Nixon; President and CEO


HISTORY: Founded in 1993 Began biotech R&D in 1985 Purchased the assets of the British Columbia Research Corp. from bankruptcy (1993) Acquired Silvagen Inc. Acquired Lockhart Risk Management Formerly operated as BC Research Inc. Acquired by Cantest Ltd. (8/06)

FACILITIES: 185,000 sq. ft.research complex on 10 acres

STOCK-FINANCIAL HISTORY: Privately held PRIVATE PLACEMENTS: Initial investment in new corporation (6/93)

BUSINESS STRATEGY: Contract R&D and joint ventures, product development Commercialize environmental and biotech technologies

AGREEMENTS: Name Products Content of Agreement Date Silvagen Inc. tissue culture spruce exclusive

licensing/partnership agreement

4/91

Various companies

clean fuel engine system


Various companies

process chemistry licensing agreements

RESEARCH & DEVELOPMENT: Forest and agriculture biotechnology, environmental toxicity and chemical analysis, biological and chemical treatment, ocean engineering, clean fuels, automotive structures, ergonomics systems

PRODUCTS ON MARKET: Chemical services: Analytical chemistry, methods development, chemical GLP services, environmental processes, thermochemical processes, electrochemical processes, chemical product development, chemical product evaluation, material and surface science investigation, chemical engineering Biotechnology services: Custom genetic analysis, (DNA fingerprinting, sequencing, cloning, PCR analysis and primer design), seed orchard monitoring, plant bioassays for phytotoxicity assessment, in vitro efficacy testing of antimicrobial compounds, bacterial diversity assessments, applied plant pathology research Toxicology: Aquatic toxicology, evaluation and monitoring of chemicals, contaminants, industrial effluents, and environmental effects



Technology assessment and development: Bench-scale proof-of-concept, pilot plant development and scale up, market assessment, intellectual property management, literature searches and patent assessments Mining: Acid mine drainage, acid rock drainage and metal leaching services (geochemical characterisation, mineralogical analysis, static testing, kinetic testing); mineral processing and hydrometallurgy testing services (project design and management, mineral processing, hydrometallurgy, pilot studies); water and waste water treatment services (laboratory testing and characterisation, pilot scale testing) Energy and environment: Evaluation of technologies designed to improve air quality, reduce greenhouse gas and other emissions and improve energy efficiency; provision of energy market insight to assist customers with technology purchases or other business decisions; assistance with energy management initiatives; third party review of environmental and energy usage implications of business investments; assistance with energy utilities' integrated resource planning activities; verification and monitoring of greenhouse gas offsets, both from the purchaser's and vendor's perspectives Environment, Health and Safety: Safety management, occupational hygiene, risk assessment and management, indoor air quality, industrial training

Wako Chemicals U.S.A. Inc.

1600 Bellwood Road Richmond VA 23237-1326, US Phone: (804) 271-7677; Fax: (804) 271-7791 Web: www.wakousa.com E-mail: [email protected]

KEY PERSONNEL: Hiroshi Shima; President


HISTORY: Founded in 1981 Acquired the LAL business of Haemachem Inc. (2/02)


SUBSIDIARY OF: Wako Pure Chemical Industries Ltd.

BUSINESS STRATEGY: Mission: Assure customers' and vendors' success through: -Integrating our international cultural attributes -Supplying unique and innovative quality products -Committing to safety, employee effectiveness, the highest level of integrity and a strong sense of public responsibility

PRODUCTS ON MARKET: Hemoglobin - Hemoglobin B, UIBC - L-Type UIBC, Ketones,

Hydroxybutyrate - Autokit 3-HB, Fatty Acids, Free - NEFA C, Total Ketone - Autokit Total Ketone Bodies, Albumin - Albumin HR2, Direct Bilirubin - Direct Bilirubin Vanadate, Bile Acids, Total - Total Bile Acids Kit, Total Bilirubin - Total Bilirubin Vanadate, Total Protein - Total Protein 2HA, (CH50) Complement, Total Activity - Autokit CH50, Apolipoprotein A1 - Autokit Apo A1, Apolipoprotein A2 - Autokit Apo A2, Apolipoprotein B - Autokit Apo B, Apolipoprotein C2 - Autokit Apo C2, Apolipoprotein C3 - Autokit Apo C3, Apolipoprotein E - Autokit Apo E, Cholesterol Ester Transfer Protein - CETP Test, HDL-Cholesterol - HDL-Cholesterol E, Triglycerides - L-Type TG H, Creatinine, Lp(a) - Autokit Lp(a), Urine Total Protein - Autokit Micro TP



Waste Stream Technology Inc.

302 Grote Street Buffalo NY 14207-2442, US Phone: (716) 876-5290; Fax: (716) 876-2412 Web: www.sevenson.com/analytical, www.wastestream.com E-mail: [email protected]

KEY PERSONNEL: Joseph V. Giacomazza; Project Manager Dr. James Hyzy; Director of R&D/Operations Manager Dr. Brian Schepart; Laboratory Director Daniel Vollmer; QA/QC Officer Maria Bradley; Radiochemistry Manager Amy J. Toth; R&D Manager Sidney Tyrrell; Assistant Laboratory Director



STOCK-FINANCIAL HISTORY: Parent company financials: NASDAQ--SEVN

PRIVATE PLACEMENTS: $1M in start-up financing (1986-1987)

SUBSIDIARY OF: Sevenson Environmental Services Inc.

PRODUCTS ON MARKET: Analysis for organics by gas chromatography (GC) and GC/mass

spectrometry (GC/MS), analysis for metals by inductively coupled argon plasma (ICAP) and flame/graphite furnace atomic absorption (FAA/GFAA), and wet chemistry

Webs Ltd.

Ashbourne House, Waterperry Court, Middleton Road Banbury OX16 4QG, UK Phone: +44 (1295) 277272; Fax: +44 (1295) 264070 Web: www.websint.com E-mail: [email protected]

KEY PERSONNEL: Francis Saunders; Chairman and Managing Director Stephen Pickin; Technical Director





BUSINESS STRATEGY: Provide toxicity monitor sales, laboratory analysis (water testing) and effluent treatment consulting

RESEARCH & DEVELOPMENT: Toxicity monitors

PRODUCTS ON MARKET: Amtox nitrification inhibition monitor



Wedgewood Analytical Inc.

4123 E. La Palma Avenue, Suite 200 Anaheim CA 92807, US Phone: (714) 577-5600; Fax: (714) 577-5688 Toll-free phone: (800) 835-5474 Web: www.wedgewoodanalytical.com E-mail: [email protected]

KEY PERSONNEL: Dr. Wolfgang Babel; President and CEO Dr. Ian Tribick; VP, Operations


HISTORY: Founded in December 1975 Began biotech R&D in June 1979 Merged Innovative Sensors and Wedgewood Technology (2004) Purchased Stip (2005) Purchased Entech (2005)

FACILITIES: 31,000 sq. ft. manufacturing facility

STOCK-FINANCIAL HISTORY: Privately held by Endress +Hauser AG

BUSINESS STRATEGY: Balance growth through new product development as a liquid analytical 'specialist.' Offer the most complete line of liquid analytical instrumentation, including optical (UV, absorbance, color, cell grwoth), pH, conductivity, chlorine, dissolved oxygen, TSS, turbidity, TOC, BOD, COD, liquid interface monitoring

RESEARCH & DEVELOPMENT: Multi-ion and optical sensors and transmitters

PRODUCTS ON MARKET: Optical: absorbance, ultraviolet, color, suspended solids, turbidity, NIR Electrochemical: pH / ORP, conductivity, dissolved oxygen, chlorine, ISE

Westbridge Research Group

1150 Joshua Way Vista CA 92083, US Phone: (760) 599-8855; Fax: (760) 599-6965 Toll-free phone: (800) 876-2767 Web: www.westbridge.com E-mail: [email protected]

KEY PERSONNEL: Tina Koenemann; President Dr. Lawrence W. Parker; Director, R&D Javier Lopez; Production Manager Nancy Tami; Manager, Quality Control



STOCK-FINANCIAL HISTORY: Publicly held, trading restricted $4.5M initial capital from limited partnership (4/82) Revenue $1.444M (YE 04) compared to $1.210M (YE 03) Net <loss. Income $11.967K (YE 04) compared to <$6.711K> (YE 03) Earnings <loss> per share $0.01/share (YE 04) compared to <$0.03/share> (YE 03) Average shares outstanding 2.103M (YE 04) compared to 2.103M (YE 03)

PRIVATE PLACEMENTS: $1.9M RDLP and $1M equity (4/85) $2.7M Reg D offering (1/88) $892K (9/91) $700K notes (9/91)



SUBSIDIARIES/DIVISIONS: Westbridge Agricultural Products

BUSINESS STRATEGY: Develop and manufacture environmentally safe products for agriculture, turf, lawn and garden, odor control and bioremediation products for agriculture, industrial and municipal wastes

PRODUCTS ON MARKET: Soil Triggrr® plant growth regulator

Foliar Triggrr® plant growth regulator Sunburst® fertilizers ST-12™ odor control BNB 931™ bioremediation nutrient blend BNB Micro™ BNB Micro+™ Suppress® odor control Biolink® organic farm inputs

Weyerhaeuser Co.

33663 Weyerhaeuser Way South Federal Way WA 98003, US Phone: (253) 924-2345; Fax: (253) 924-2685 Toll-free phone: (800) 525-5440 Web: www.weyerhaeuser.com E-mail: [email protected]

KEY PERSONNEL: Steven R. Rogel; Chairman, President and CEO Richard E. Hanson; Exec. VP and COO Susan M. Mersereau; Sr. VP, Information Technology and CIO Richard J. Taggart; Exec. VP and CFO George H. Weyerhaeuser Jr.; Sr. VP, Technology


HISTORY: Founded in 1900 Divested aquaculture and hydroponics business divisions (1988) Divested Personal Care Products and GNA Insurance (1993)

STOCK-FINANCIAL HISTORY: NYSE--WY Three-for-two stock split (6/88) Board authorized issue of 400M shares of common stock (6/88), 202M shares outstanding Net sales $22.629b (YE 05) compared to $21.931b (YE 04) Net income $733M (YE 05) compared to $1.283b (YE 04) Earnings per share $2.98/share (YE 05) compared to $5.43/share (YE 04)

SUBSIDIARIES/DIVISIONS: Five major business segments: Timberlands--Grows and harvests trees in renewable cycles Wood Products--Manufactures and distributes building materials for homes and other structures Pulp and Paper--Produces a variety of papers, and the pulp to produce papers, absorbent products for specialty uses such as photographic film Containerboard Packaging and Recycling--Produces paper, boxes and bags to move products from factory to store to consumer. Collects and recycles wastepaper, boxes and newsprint to make new products Real Estate--Builds single- and multi-family homes and develops land


Biopulping Consortium (University of Wisconsin and USDA)

lignin degrading fungi collaborative research agreement

Chiron Corp. cellulose and other projects

research agreement



Plant Genetics Inc.

embryogenesis and artificial seed

R&D agreement

Plant Genetics Inc.

Gel-Coat technology for specific woody plants and ornamentals


RESEARCH & DEVELOPMENT: Tree cell and tissue culture Economic mass propagation of high-value forest trees Genetic transformation Selection of high-value genotypes and varieties of forest trees Forest establishment and management technologies New biological products, wood-based products Wood processing technologies Environmental research: wildlife, hydrology, fisheries, waste management Pulp, paper, and packaging technologies

PRODUCTS ON MARKET: Forestry products Genetically improved seeds, including loblolly and ponderosa pines and Douglas fir Nursery and garden supply products, chemicals

Xethanol Corp.

1185 Avenue of the Americas, 20th Floor New York NY 10036, US Phone: (646) 723-4000; Fax: (646) 723-4001 Web: www.xethanol.com; E-mail: [email protected]

KEY PERSONNEL: Christopher d’Arnaud-Taylor; Chairman, President and CEO Larry Bellone; CFO Franz A. Skryanz; VP, Secretary and Treasurer Robin Buller; VP, Operations Jim Stewart; VP, Plant Operations and GM, Xethanol BioFuels David Kreitzer; VP, Business Development Mark Austin; Chief Technology Strategist


HISTORY: Founded in January 2000 as Freereal-Timequote.com Inc. Acquired Permeate Refining Inc. (8/03) Merged with Zen Acquisition Corp. (2/05) Acquired Advanced Biomass Gasification Technologies Inc. from UTEK Corp. (6/06)

FACILITIES: Two 25,000 sq. ft. ethanol production facilities in Iowa

STOCK-FINANCIAL HISTORY: AMEX--XNL Formerly listed on the OTC BB--XTHN (through 6/06) Net sales $4.343M (YE 05) compared to $465K (YE 04) Net loss <$11.377M> (YE 05) compared to <$2.571M> (YE 04) Loss per share <$0.83/share> (YE 05) compared to <$0.25/share> (YE 04) Average shares outstanding 13.684M (YE 05) compared to 10.195M (YE 04) Total assets $9.105M (YE 05) compared to $7.525M (YE 04)

PRIVATE PLACEMENTS: Raised $34M in equity capital (4/06)

SUBSIDIARIES/DIVISIONS: Xethanol BioFuels LLC--Blairstown, Iowa

PRINCIPAL INVESTORS: Fusion Capital Fund II LLC



BUSINESS STRATEGY: Increase production capacity at Iowa facilities through physical expansion using cutting-edge engineering design and integrating processing technologies Employ a regional approach to new ethanol production by focusing on port sites and coastal urban areas on the Atlantic and Gulf coasts Employ a sector strategy to expansion by focusing on the forests products industry

AGREEMENTS: Name Products Content of Agreement Date Aventine Xethanol products distribution

agreement

Forest Products Laboratory

engineering of genetically modified yeasts to decrease fermentation time of feedstocks in the production of ethanol and/or xylitol

CRADA

National Renewable Energy Laboratory

Clean Fractionation technology

research agreement

Queens University development of a process to reduce the time required to ferment feedstock in the production of ethanol

research agreement

Virginia Polytechnic Institute

investigation of the effect of newly developed enzymes on feedstocks

research alliance

RESEARCH & DEVELOPMENT: Production of ethanol and related products using locally available biomass

rather than corn as the primary raw material

Yeda Research and Development Co. Ltd.

Weizmann Institute of Science, P.O. Box 95 Rehovot 76100, Israel Phone: +972 8-947-0617; Fax: +972 8-947-0739 Web: www.yedarnd.com; E-mail: [email protected]

KEY PERSONNEL: Prof. Haim Garty; Chairman Amir Naiberg.; CEO Einat Zisman, Ph.D.; CBO Ziv Hermon, Ph.D.; Sr. Licensing Officer Noa Shelach, Ph.D.; Sr. Licensing Officer Gil Granot-Mayer, Adv; General Counsel Cohen Yaacov; CFO Ruth Granoth, Ph.D.; Chief Intellectual Property Officer



FACILITIES: Offices located at the Weizmann Institute of Science

STOCK-FINANCIAL HISTORY: Technology transfer entity

BUSINESS STRATEGY: Serve as a patent and licensing organization that acts as an intermediary with industry and investors interested in licensing technologies from the Weizmann Institute in return for commitment to develop the technologies into products & payment of financial considerations to the Institute.



RESEARCH & DEVELOPMENT: Biochemistry, genetics, immunology, virology, cancer, , neurobiology, industrial and specialty chemicals, nanotechnologies membranes, plant genetics, bioinformatics and proteomics, diagnostics

PRODUCTS ON MARKET: Copaxone® synthetic copolymer for treatment of multiple sclerosis (licensed to Teva Pharmaceuticals) Rebif® (recombinant interferon beta) for multiple sclerosis and several viral diseases (licensed to InterPharm Laboratories Ltd. Dunaliella (beta carotene) health food product with potential anticancer properties (licensed to Nikken Sohosha) GeneCards® bionformatics database Improved crop varieties and hybrid cultivars of cucumbers and melons (licensed to Isreali seed companies)

Yissum Research Development Co.

P.O. Box 39135 Jerusalem 91390, Israel Phone: +972 2-658-6688; Fax: +972 2-658-6689 Web: www.yissum.co.il; E-mail: [email protected]

KEY PERSONNEL: Dr. Giora Yaron; Chairman Nava Swersky Sofer; CEO Tamir Huberman; Director, IT Zvika Weiss; CFO Renee Ben-Israel; VP, Intellectual Property Gustavo Fuchs; Technology Officer Ken Shaked; VP, Portfolio Companies Ziv Shomroni; VP, Nature Science and Agriculture Elena Canetti; VP, Marketing, Scientific Services Yehuda Yarmut; Exec. VP Tami Kfir; VP, Marketing, Healthcare


HISTORY: Founded in 1964 to commercialize R&D developed at the Hebrew University of Jerusalem

FACILITIES: Multipurpose chemical pilot plant Environmental R&D laboratories Pharmacokinetic and biopharmaceutic research laboratory


SUBSIDIARY OF: Hebrew University of Jerusalem

BUSINESS STRATEGY: Establish R&D, licensing, and joint venture agreements with numerous companies worldwide in all areas

AGREEMENTS: Name Products Content of Agreement Date BioLineRx Ltd. BL-3020 licensing agreement 7/06

RESEARCH & DEVELOPMENT: Applied research in biotechnology, agriculture, chemistry, medical sciences and pharmaceuticals using organisms and products of organisms in biological processes, genetic engineering, food sciences, physical sciences and environmental sciences

PRODUCTS ON MARKET: Diagnostic kits for screening of urinary tract infections and detection of antibiotics in milk Cherry tomatoes--cocktail hybrids New Drugs: Doxil--an approved and clinically used anticancer drug Exelon--a new treatment for Alzheimer's disease



YMC Co. Ltd.

YMC Karasuma Gojo Building, 284 Daigo-cho Karasuma Nishiiru, Gojo-dori, Shimogyo-ku Kyoto 600-8106, Japan Phone: +81 75-342-4510; Fax: +81 75-342-4511 Web: www.ymc.co.jp; E-mail: [email protected]

KEY PERSONNEL: Ryuji Yamamura; CEO Masaru Wakeshima; Exec. VP Takamaru Komatsu; Exec. Director Naohiro Kuriyama; Director, R&D

EMPLOYEES: 112 employees, 2 Ph.D.s, 27 M.D.s

HISTORY: Established in 1980 Began biotech R&D in 1983 Established YMC Europe GmbH in 1993

FACILITIES: R&D labs, technology development center and S&S (separation and synthesis) center and production facilities (YSP-2, YSP-3, YSP-4)


SUBSIDIARIES/DIVISIONS: YMC Europe GmbH Seika Corp. of America Kyoto Chromato Co. Ltd. Synthesis and separation division Chromatography division Sales and marketing division

BUSINESS STRATEGY: Meet a greater diversity of markets by offering a wide variety of products

RESEARCH & DEVELOPMENT: Chromatography and purification technology

Fine chemicals synthesis

PRODUCTS ON MARKET: Packed columns and packing materials for HPLC Preparative HPLC instruments Synthensis and separation technology

PRODUCTS IN DEVELOPMENT: Name Status Various peptides in development Glucose and oligosaccharide separation in development Separation and purification system in development Various packing materials for chromatography

in development

Zeltia SA

Jose Abascal St. 2 Madrid 28003, Spain Phone: +34 91 444 4500; Fax: +34 91 593 2954 Web: www.zeltia.com E-mail: [email protected]

KEY PERSONNEL: Jose Maria Fernandez Sousa-Faro; Chairman and CEO Maria Luisa Francia; CFO Teresa Garcia Buey; Director, Corporate Communications Isabel Lozano; Managing Director, PharmaMar Rosario Cospedal; Managing Director, Genomica Gonzalo Duran; Managing Director, Zelnova Jose Benito Mallo; XylaZel





STOCK-FINANCIAL HISTORY: Mercado Continuo--ZEL Net sales EUR471K (YE 05) compared to EUR669K (YE 04) Operating loss <EUR8.397M> (YE 05) compared to <EUR8.701M> (YE 04) Total assets EUR393.722M (YE 05) compared to EUR337.338M (YE 04)

PRIVATE PLACEMENTS: Raised EUR65M through private placement of 10.75M shares at EUR6.05/share (6/05)

SUBSIDIARIES/DIVISIONS: Zeltia Group: PharmaMar SA Genomica SAU Neuropharma SA Xylazel SA Promax SA Zelnova SA Branch offices in France, Germany, Britain and Italy

BUSINESS STRATEGY: Operate as a biopharmaceutical leader in oncology-advancing cancer care through the discovery and development of innovative marine-derived medicines

PRODUCTS ON MARKET: Various products through the Zeltia Group

Zeon Corp.

Shin Marunouchi Center Building, 1-6-2 Marunouchi, Chiyoda-ku Tokyo 100-8246, Japan Phone: +81 3-3216-1772; Fax: +81 3-3216-0501 Web: www.zeon.co.jp E-mail: [email protected]

KEY PERSONNEL: Katsuhiko Nakano; Chairman Naozumi Furukawa; President and CEO Masahiro Yamazaki; Exec. Managing Director Tadao Natsuume; GM, R&D Center


HISTORY: Established in April 1950 by three Japanese companies in the Furukawa Group--Furukawa Electric Co. Ltd., Yokohama Rubber Co. Ltd. and Nippon Light Metal Co. Ltd. Began biotech research in 1981 Formed Syntro Zeon LC, a joint venture between Nippon Zeon of America Inc. and Syntro Venture Corp., to commercialize poultry vaccines resulting from existing development program of parent companies (2/93) Changed name from Nippon Zeon Co. Ltd. (7/00)

FACILITIES: Headquarter facilities in Tokyo Plants in Kawasaki, Tokuyama, Mizushima and Takaoka Offices in Nagoya and Osaka

STOCK-FINANCIAL HISTORY: Tokyo Stock Exchange--ZEON Listed on Osaka Stock Exchange Net sales ¥263.074b (YE 06) compared to ¥231.364b (YE 05) Net income ¥15.249b (YE 06) compared to ¥7.773b (YE 05) Total assets ¥272.674b (YE 06) compared to ¥236.861b (YE 05)

SUBSIDIARIES/DIVISIONS: Rubber Division Latex Division Chemicals Division Specialty Plastics Division Specialty Chemicals Division Specialty Materials Division 53 subsidiaries



BUSINESS STRATEGY: Continually focus on creating new businesses, taking full advantage of steady revenue generated by existing businesses

AGREEMENTS: Name Products Content of Agreement Date Delaware University

fowlpox vectored vaccine for infectious laryngotracheitis vaccine


1994

Syntro Corp., Hoechst-Roussel Agri-Vet Corp.

recombinant viral vaccines for poultry

development agreement--Nippon Zeon to fund Syntro development, testing, and ultimate registration of poultry vaccines--Syntro to get U.S. manufacturing rights, Syntro Zeon to receive domestic marketing rights

9/90

USDA/ARS fowlpox vectored vaccines for coccidiosis


1992

USDA/ARS fowlpox vectored vaccines for Marek's disease and other poultry diseases


1990

RESEARCH & DEVELOPMENT: C5 chemicals technology: Organic synthesis technology and monomer extraction technology Polymer technology: Elastomer technology and cyclo-olefinpolymer technology Precision modeling technology: Film molding and ultra-fine molding technology Bio-technology: Recombinant DNA technology

PRODUCTS ON MARKET: Synthetic rubbers Imaging and electronics materials Specialty plastics Environmental materials Synthetic latices Toner RIM Medical products: Cardiovascular, nutritional and gastrointestinal products (from ZEON Medical Inc.) Chemicals: Quintone 100 series (aliphatic hydrocarbon resin), Quintone 1000 series (alicyclic hydrocarbon resin), Quinhard series (acid anhydride type epoxy resin hardening agent), Quinflow series (polycarboxilic acid sodium or ammonium salt, water type dispersant), Quintac series (styrene isoprene block polymer) Specialty chemicals: Aroma chemicals include cis-3-Hexenol (leaf alcohol) and leaf esters, Claigeon® (methyl dihydrojasmonate), Cepionate® (methyl epi-dihydrojasmonate), Jasmoneige® (methyl jasmonate), Zeppin® (methyl epi-jasmonate), delta-lactones, Triflaige®, alkyl cyclopentanones, hydrocarbons, alcohols, 5-membered ketones, hero compounds, heterocyclic compounds, Zorora®H fluoride compound, Zeorola®-H, Zeonsolve® HP (cyclopentane)



Zuckerforschung Tulln GmbH

Reitherstrasse 21-23 Tulln A-3430, Austria Phone: +43 2272-602-11402; Fax: +43 2272-602-11420 Web: www.zuckerforschung.at E-mail: [email protected]

KEY PERSONNEL: Mag. Gerhard Robl; Commercial Manager Dr. Dietmar Grüll; Technical Manager Dr. Herbert Wesner; Technical Manager


HISTORY: Founded in 1986 Changed name from Raiffeisen-Bioforschung GmbH (1994)

FACILITIES: 2,000 sq. m. of laboratory space Pilot plant with fermentors, chamber filter press, separators, spray-dryer, autoclaves, chemical pilot plant and extruder


PRINCIPAL INVESTORS: Agrana Zucker GesmbH Agrana Starke GesmbH Bioethanol GmbH

BUSINESS STRATEGY: Provide R&D for Austrian sugar, starch & Bioethanol industry Render essential services to agriculture and industry by developing products and technology that promote the use of renewable resources in the manufacturing industry

RESEARCH & DEVELOPMENT: Sugar technology, modified starches for food and non-food, feedstuff,

cereals, baby food, modified proteins, wastewater treatment and improved crops Biotechnology Bioethanol

PRODUCTS ON MARKET: Culture collection (catalog available)



BioWorld®


STATREPORT

SUBJECT INDEX



SUBJECT INDEX Biopreservation A/F Protein Inc. Agrium Inc. Argonne National Laboratory Biologos Inc. Bioscience Inc. BioTime Inc. Chembiotech Ltd. Chr. Hansen Inc. CryoLife Inc. Don Whitley Scientific Ltd. Encelle Inc. Epidauros Biotechnologie AG Geneva Scientific Gentra Systems Inc. Harvard Bioscience Inc. ICPbio Institute of Food Research Lake States LifeCell Corp. Maine Biotechnology Services Inc. Microbe Inotech Laboratories Inc. National Institutes of Health (NIH) North Carolina Biotechnology Center Ramot at Tel Aviv University Ltd. Snamprogetti Services SpA TNO Quality of Life Vizon SciTec Inc. Zeltia SA Bioremediation Agrium Inc. Ag-West Bio Inc. Alberta Research Council Inc. Altus Pharmaceuticals Inc. Aluline Ltd. ARC Geobac Group Inc. Argonne National Laboratory astre Corp. Bayer Corp. Bioclear BV BioGenesis Enterprises Inc. Biogenie Inc. Biolog Inc. Biopraxis Inc. BioPro International Inc. Bioscience Inc. Bio-Technical Resources Biotechnology Research Institute Biotehnos SA Boojum Research Ltd. CABI Chembiotech Ltd. Commercial Microbiology Ltd. Cornell Institute for Biotechnology and Life Science Technologies CUBIA (University Centre for Algal Biotechnology) Diversa Corp.

Droycon BioConcepts Inc. EnSolve Biosystems Inc. Enviro-Zyme International LLC Epicore Networks (U.S.A.) Inc. Epidauros Biotechnologie AG Fraunhofer Institute for Interfacial Engineering and Biotechnology General Electric Global Research Genomatica Inc. HaloSource Inc. Harvard Bioscience Inc. Helmholtz Centre for Infection Research Imperial Innovations Ltd. Institute for Biological Research and Technology Israel Institute for Biological Research (IIBR) Lawrence Berkeley National Laboratory LGC (Laboratory of the Government Chemist) MBI International Microbe Inotech Laboratories Inc. Mo Bio Laboratories Inc. MSE Technology Applications Inc. NanoLogix Inc. National Institutes of Health (NIH) National Research Council of Canada Nature Plus Inc. New Brunswick Scientific Co. Inc. New Horizons Diagnostics Corp. North Carolina Biotechnology Center NOVA Chemicals Corp. Novozymes A/S Novozymes Inc. Omex Environmental Ltd. Organo Corp. Pacific Biodiesel Inc. Pacific Northwest National Laboratory Pall Corp. PBR Laboratories Inc. (PBR) Ramot at Tel Aviv University Ltd. RECO Biotechnology Research Triangle Park Laboratories Inc. RTI International Spark Holland BV Stewart Agricultural Research Services Inc. Symbio The Nitrate Elimination Co. Inc. UniQuest Pty. Ltd. University of Nebraska-Lincoln, Center for Biotechnology Varied Industries Corp. VECTOR State Research Centre of Virology/Biotechnology Vizon SciTec Inc. Waste Stream Technology Inc. Westbridge Research Group Biosensors AEA Technology plc AgResearch Ltd. Ajinomoto Co. Inc. Alderon Biosciences Inc. Altus Pharmaceuticals Inc.



AMDL Inc. Analox Instruments Ltd. Analox Instruments U.S.A. Applied Biosystems Inc. astre Corp. Biocatalysts Ltd. BioForce Nanosciences Inc. BioGenes GmbH Bionas GmbH BIOPAC Systems Inc. Biopraxis Inc. BioPro International Inc. Bio-Technical Resources Biotechnology Research Institute Cornell Institute for Biotechnology and Life Science Technologies Epidauros Biotechnologie AG Eurogentec SA Helmholtz Centre for Infection Research Idexx Laboratories Inc. Israel Institute for Biological Research (IIBR) LGC (Laboratory of the Government Chemist) LifeSensors Inc. MBI International Megabase Research Products Microbe Inotech Laboratories Inc. MoBiTec GmbH Molecular Devices Corp. Molecular Probes Inc. NanoHorizons Inc. National Research Council of Canada North Carolina Biotechnology Center november AG Organo Corp. Pall Corp. PBR Laboratories Inc. (PBR) Pharmbiodyn Consulting Group Ramot at Tel Aviv University Ltd. The Nitrate Elimination Co. Inc. TNO Quality of Life Union Chemical Laboratories (UCL) University of Nebraska-Lincoln, Center for Biotechnology Vizon SciTec Inc. Webs Ltd. Yissum Research Development Co. Cosmetics 3DM Inc. A/F Protein Inc. Acadian Seaplants Ltd. AGI Dermatics Altair Nanotechnologies Inc. Arch Personal Care Products LP Arysta LifeScience Corp. Atrium Biotechnologies Inc. BioMerieux INDUSTRY Bionas GmbH Bioriginal Food & Science Corp. BioScreen Testing Services Inc. Bio-Technical Resources Biotehnos SA BRAIN (Biotechnology Research and Information Network AG)

Cardinal Health - Middleton Ceapro Inc. Celsis International plc Chemeq Ltd. CUBIA (University Centre for Algal Biotechnology) Cyanotech Corp. Daiichi Pharmaceutical Co. Ltd. Diversa Corp. Dong-A Pharmaceutical Co. Ltd. DSM Epidauros Biotechnologie AG F. Hoffmann-La Roche Ltd. FibroGen Inc. Galderma SA Geneva Scientific HaloSource Inc. Harvard Bioscience Inc. IGENE Biotechnology Inc. inGenious Targeting Laboratory Inc. Isolagen Inc. Kanebo Ltd. Kraeber GmbH & Co. Lavipharm SA LGC (Laboratory of the Government Chemist) Maruzen Pharmaceuticals Co. Ltd. MedPharm Ltd. Merck KGaA Morishita Jintan Co. Ltd. Nanophase Technologies Corp. New Brunswick Scientific Co. Inc. New Zealand Pharmaceuticals Ltd. Norac Technologies Inc. North Carolina Biotechnology Center Novozymes A/S Optigenex Inc. Pentapharm Ltd. Pharmbiodyn Consulting Group PLANTON GmbH Polysciences Inc. POS Pilot Plant Corp. Prokaria ehf Proteus SA Ramot at Tel Aviv University Ltd. Renovo Group plc Sensient Technologies Corp. Wako Chemicals U.S.A. Inc. Yissum Research Development Co. Energy/Biomass Abengoa SA Advanta Seeds UK Ltd. Agrium Inc. Ag-West Bio Inc. Alberta Research Council Inc. ARC Geobac Group Inc. Archer Daniels Midland Argonne National Laboratory Athenix Corp. BASF AG Bioclear BV Bionov CNP Inc. Bio-Technical Resources Biotehnos SA



Bioxel Pharma Inc. Canadian Forest Service Canadian Seed Coaters Celsis International plc Ceres Inc. Chembiotech Ltd. Cornell Institute for Biotechnology and Life Science Technologies CUBIA (University Centre for Algal Biotechnology) Diversa Corp. DOE Joint Genome Institute EnSolve Biosystems Inc. Epicore Networks (U.S.A.) Inc. Fraunhofer Institute for Interfacial Engineering and Biotechnology Genencor International Inc. General Electric Global Research Idaho National Laboratory Iogen Corp. Itochu Corp. J. Craig Venter Institute Lake States Mascoma Corp. MBI International National Research Council of Canada North Carolina Biotechnology Center Novozymes A/S Pacific Biodiesel Inc. Pennzoil Co. Pfizer Inc. Recordati SpA Renessen LLC RTI International Scion - Cellwall Biotechnology Centre Snamprogetti Services SpA SunOpta Inc. Synthetic Genomics Inc. University of Nebraska-Lincoln, Center for Biotechnology Xethanol Corp. Environmental Analysis Agrium Inc. Ag-West Bio Inc. Alderon Biosciences Inc. ANU Enterprise Pty. Ltd. Applera Corp. ARC Geobac Group Inc. Argonne National Laboratory Associates of Cape Cod Inc. astre Corp. BASF AG Bayer Corp. BioAssay Works LLC Biocatalysts Ltd. Bioclear BV BioGenes GmbH Biolog Inc. BioMed Diagnostics Inc. BioMerieux INDUSTRY BioMerieux SA Bionov CNP Inc. Bioscience Inc.

Biosynth International Inc. Biotechnology Research Institute Boojum Research Ltd. CABI Cantest Ltd. Celsis International plc Centre for Innovative Biology and Environmental Technology Chembiotech Ltd. Commercial Microbiology Ltd. Cornell Institute for Biotechnology and Life Science Technologies Dojindo Laboratories Don Whitley Scientific Ltd. General Electric Global Research Hammen Corp. Helmholtz Centre for Infection Research Hidex Oy Huntingdon Life Sciences Hybrizyme Corp. Idexx Laboratories Inc. Imperial Innovations Ltd. Institute for Biological Research and Technology Itochu Corp. J. Craig Venter Institute Lawrence Berkeley National Laboratory LGC (Laboratory of the Government Chemist) Maxxam Analytics Inc. MBI International Merck KGaA Microbe Inotech Laboratories Inc. Mo Bio Laboratories Inc. Molecular Devices Corp. M-Scan Ltd. MSE Technology Applications Inc. Nanogen Inc. National Institutes of Health (NIH) National Research Council of Canada NatureWorks LLC Neogen Corp. North Carolina Biotechnology Center Omex Environmental Ltd. Optronics Organo Corp. Pacific Northwest National Laboratory PBR Laboratories Inc. (PBR) Pfeiffer Vacuum Ltd. Randox Laboratories Ltd. Research Triangle Park Laboratories Inc. Response Biomedical Corp. RTI International SafePath Laboratories LLC Spark Holland BV Spherix Inc. SRI International Stewart Agricultural Research Services Inc. Strategic Diagnostics Inc. Symbio Teledyne Isco The Nitrate Elimination Co. Inc. TNO Quality of Life University of Nebraska-Lincoln, Center for Biotechnology UVP Inc.



Varied Industries Corp. Virinova GbR Vizon SciTec Inc. Wako Chemicals U.S.A. Inc. Waste Stream Technology Inc. Webs Ltd. Wedgewood Analytical Inc. Weyerhaeuser Co. Fine Chemicals Abbott GmbH & Co. KG Agrium Inc. Alberta Research Council Inc. Altus Pharmaceuticals Inc. American Radiolabeled Chemicals Inc. Athenix Corp. Axxora Life Science Inc. BACHEM AG BASF AG Be-Long Group Biologos Inc. Biomol GmbH Biosynth International Inc. Bio-Technical Resources Biotecx Laboratories Inc. Bioxel Pharma Inc. Cambrex Corp. Ceapro Inc. Cuno Inc. Daiichi Pharmaceutical Co. Ltd. Dainippon Sumitomo Pharma Co. Ltd. Dalton Pharma Services Dextra Laboratories Ltd. Diagnostic Chemicals Ltd. Diversa Corp. Dojindo Laboratories DSM Fine Chemicals DuPont EMD Biosciences Inc./Merck Biosciences First Link (UK) Ltd. Genencor International Inc. Genomatica Inc. Genzyme Corp. GL Biochem (Shanghai) Ltd. Industrial Biotechnology Corp. Institute of Food Research Israel Institute for Biological Research (IIBR) Itochu Corp. Johnson Matthey Pharma Services Kaneka Corp. Kirin Brewery Co. Ltd. Kraeber GmbH & Co. Laboratoires Eurobio Lake States LG Chem Ltd. LG Life Sciences Ltd. Link Technologies Ltd. Lonza Group Ltd. MBI International Mercian Corp. Merck KGaA Microbia Inc. Molecular Probes Inc. Nanophase Technologies Corp. National Institutes of Health (NIH)

New Zealand Pharmaceuticals Ltd. Nigu Bioselect North Carolina Biotechnology Center OmniChem OmniGene Bioproducts Inc. Optronics PCI Membranes PeproTech Inc. Peptides International Inc. Polium Technologies Inc. Polysciences Inc. POS Pilot Plant Corp. Primm S.R.L. Prokaria ehf Proteus SA Reanal Finechemical Co. Regis Technologies Inc. Research Organics Inc. Sakai Chemical Industry Co. Ltd. Sensient Technologies Corp. Severn Biotech Ltd. Snamprogetti Services SpA Stewart Agricultural Research Services Inc. Sumitomo Chemical Co. Ltd. Toronto Research Chemicals Inc. Union Chemical Laboratories (UCL) University of Nebraska-Lincoln, Center for Biotechnology Wako Chemicals U.S.A. Inc. Xinchem Corp. Yissum Research Development Co. YMC Co. Ltd. Zeltia SA Zeon Corp. Industrial/Laboratory Enzymes AB Enzymes Oy Agrium Inc. Alberta Research Council Inc. Altus Pharmaceuticals Inc. ANU Enterprise Pty. Ltd. Arch Chemicals Inc. Argonne National Laboratory Astellas Pharma Inc. astre Corp. Athenix Corp. Bayou Biolabs Biocatalysts Ltd. Biologos Inc. Biomeda Corp. BioMerieux SA Biomol GmbH Bioscience Inc. Biotal Ltd. Biotehnos SA Biozyme Laboratories Ltd. Cambio Ltd. Canadian Seed Coaters Cardinal Health - Middleton Cargill Inc. Centre for Innovative Biology and Environmental Technology Chembiotech Ltd.



Chunghwa Chemical Synthesis & Biotech Co. Ltd. Codon Devices Cornell Institute for Biotechnology and Life Science Technologies Cosmo Bio Co. Ltd. Diagnostic Chemicals Ltd. Digene Corp. Diversa Corp. Dynavax Europe EMD Biosciences Inc./Merck Biosciences eMembrane Inc. EnSolve Biosystems Inc. Enviro-Zyme International LLC Enzyme Research Laboratories Ltd EvoGenix Ltd. First Link (UK) Ltd. Fraunhofer Institute for Interfacial Engineering and Biotechnology Genencor International Inc. Genesearch Pty. Ltd. Hawaii Biotech Inc. Hercules Inc. IGENE Biotechnology Inc. Industrial Biotechnology Corp. Institute of Food Research International Flavors & Fragrances Inc. Iogen Corp. Itochu Corp. Kikkoman Corp. (Biochemicals Division) Kirin Brewery Co. Ltd. KRKA d.d. Kyorin Pharmaceutical Co. Ltd. Kyowa Hakko Kogyo Co. Ltd. Lake States Marcor Development Corp. MBI International MDS Pharma Services Meiji Seika Kaisha Ltd. Merck KGaA Microbe Inotech Laboratories Inc. Microbia Inc. National Institutes of Health (NIH) National Research Council of Canada New Brunswick Scientific Co. Inc. New England BioLabs Inc. Nitto Denko Corp. North Carolina Biotechnology Center Novozymes A/S Novozymes Inc. Optronics Pall Corp. Paprican PBR Laboratories Inc. (PBR) PCI Membranes Pfizer Inc. PLANTON GmbH Polium Technologies Inc. Prokaria ehf Proteus SA Qbiogene Recordati SpA Roal Oy Sanyo Chemical Industries Ltd. (Sanyo Kasei) Sensient Technologies Corp.

Showa Denko KK SibEnzyme Ltd. Spark Holland BV Stratagene Corp. Symbio Synthetech Inc. The Dow Chemical Co. The Nitrate Elimination Co. Inc. Toray Industries Inc. Union Chemical Laboratories (UCL) University of Nebraska-Lincoln, Center for Biotechnology Valeant Pharmaceuticals International Inc. Varied Industries Corp. Wako Chemicals U.S.A. Inc. Waste Stream Technology Inc. Yeda Research and Development Co. Ltd. Zeltia SA Mining Biotechnology Agrium Inc. astre Corp. Be-Long Group Bioclear BV Boojum Research Ltd. Chembiotech Ltd. Commercial Microbiology Ltd. Diversa Corp. Hammen Corp. MSE Technology Applications Inc. Nature Plus Inc. North Carolina Biotechnology Center PrimeSyn Lab Inc. UniQuest Pty. Ltd. UVP Inc. Vizon SciTec Inc. Oil Recovery Biotehnos SA Biothane Corp. Chembiotech Ltd. Commercial Microbiology Ltd. Diversa Corp. Epicore Networks (U.S.A.) Inc. Geneva Scientific HaloSource Inc. MSE Technology Applications Inc. National Research Council of Canada North Carolina Biotechnology Center Novozymes A/S Novozymes Inc. Pacific Biodiesel Inc. RECO Biotechnology Snamprogetti Services SpA Vizon SciTec Inc. Yissum Research Development Co. Specialty Chemicals Acadian Seaplants Ltd. Agrium Inc. Ajinomoto Co. Inc. Akzo Nobel NV Altus Pharmaceuticals Inc.



Aluline Ltd. American Radiolabeled Chemicals Inc. Applied Biosystems Inc. Arch Chemicals Inc. Arch Personal Care Products LP Archer Daniels Midland Argonne National Laboratory Asahi Kasei Corp. Astellas Pharma Inc. Athenix Corp. Atrium Biotechnologies Inc. Axxora Life Science Inc. BAC BV (Biotechnology Application Centre) BACHEM AG Bachem California Inc. Bangs Laboratories Inc. BASF AG Be-Long Group Biocatalysts Ltd. BioGenesis Enterprises Inc. Bio-Lab Ltd. Biologos Inc. Biomedical Technologies Inc. Biomol GmbH Biopraxis Inc. Bioscience Inc. Bio-Technical Resources Biotecx Laboratories Inc. BioVectra dcl Boston Life Sciences Inc. Calzyme Laboratories Inc. Cambrex Corp. Ceapro Inc. Chembiotech Ltd. ChemGenes Corp. Commercial Microbiology Ltd. Cosmo Bio Co. Ltd. Cyanotech Corp. Dalton Pharma Services Dextra Laboratories Ltd. Dextran Products Ltd. Diagnostic Chemicals Ltd. Diversa Corp. DNA Technologies Inc. Dojindo Laboratories Dow AgroSciences LLC Dragon Pharmaceutical Inc. DSM Fine Chemicals EMD Biosciences Inc./Merck Biosciences EnSolve Biosystems Inc. Evolva SA F. Hoffmann-La Roche Ltd. First Link (UK) Ltd. Genencor International Inc. General Electric Global Research HaloSource Inc. Helmholtz Centre for Infection Research IGENE Biotechnology Inc. International Flavors & Fragrances Inc. Israel Institute for Biological Research (IIBR) Itochu Corp. Johnson Matthey Pharma Services Kaneka Corp. Kraeber GmbH & Co. Kyowa Hakko Kogyo Co. Ltd.

LANXESS AG LG Chem Ltd. LG Life Sciences Ltd. Mallinckrodt Inc. Marcor Development Corp. Matreya LLC MBI International Merck KGaA Microbia Inc. Molecular Probes Inc. Monsanto Co. Nanophase Technologies Corp. Nature Plus Inc. New Zealand Pharmaceuticals Ltd. Nigu Bioselect North Carolina Biotechnology Center Noven Pharmaceuticals Inc. OmniChem OmniGene Bioproducts Inc. Pacific Northwest National Laboratory PCI Membranes Pennzoil Co. Pentapharm Ltd. Peptides International Inc. Pfizer Inc. Polium Technologies Inc. Polydex Pharmaceuticals Ltd. Polysciences Inc. Procter & Gamble Co. Prometic BioSciences Inc. Proteus SA Quip Laboratories Inc. Recordati SpA Regis Technologies Inc. Research Organics Inc. Sanyo Chemical Industries Ltd. (Sanyo Kasei) Sensient Technologies Corp. Showa Denko KK Solomon Park Research Laboratories SRI International Stewart Agricultural Research Services Inc. Sumitomo Chemical Co. Ltd. Symbio Synthetech Inc. Takeda Pharmaceutical Co. Ltd. The Dow Chemical Co. Toray Industries Inc. Toronto Research Chemicals Inc. Union Chemical Laboratories (UCL) University of Nebraska-Lincoln, Center for Biotechnology Valeant Pharmaceuticals International Inc. Vitrolife AB Wako Chemicals U.S.A. Inc. Wedgewood Analytical Inc. Xinchem Corp. Yeda Research and Development Co. Ltd. Zeltia SA Zeon Corp. Waste Treatment Abengoa SA ADI Group Inc. ADI Systems Inc.



AgResearch Ltd. Ag-West Bio Inc. Alltech Inc. Aluline Ltd. ANU Enterprise Pty. Ltd. Applikon Biotechnology Inc. ARC Geobac Group Inc. Arch Chemicals Inc. astre Corp. Be-Long Group Biocatalysts Ltd. Bioclear BV BioGenesis Enterprises Inc. Biogenie Inc. Biolog Inc. Biopraxis Inc. BioPro International Inc. Bioscience Inc. BioSure Inc. Bio-Technical Resources Biotechnology Research Institute Biotehnos SA Biothane Corp. Boojum Research Ltd. Centre for Innovative Biology and Environmental Technology Chembiotech Ltd. Commercial Microbiology Ltd. Cornell Institute for Biotechnology and Life Science Technologies CUBIA (University Centre for Algal Biotechnology) Dojindo Laboratories eMembrane Inc. Enviro-Zyme International LLC Epicore Networks (U.S.A.) Inc. Fraunhofer Institute for Interfacial Engineering and Biotechnology General Electric Global Research Genesearch Pty. Ltd. HaloSource Inc. Hammen Corp. Helmholtz Centre for Infection Research Idaho National Laboratory Imperial Innovations Ltd. Itochu Corp. KRKA d.d. MBI International MSE Technology Applications Inc. National Research Council of Canada Nature Plus Inc. Nigu Bioselect North Carolina Biotechnology Center NOVA Chemicals Corp. Novozymes A/S Novozymes Inc. Omex Environmental Ltd. Organo Corp. Pacific Northwest National Laboratory Pall Corp. Paprican PCI Membranes Proteus SA Ramot at Tel Aviv University Ltd. RECO Biotechnology

RTI International Spherix Inc. Stewart Agricultural Research Services Inc. Strategic Diagnostics Inc. The Nitrate Elimination Co. Inc. UniQuest Pty. Ltd. UVP Inc. Varied Industries Corp. Vizon SciTec Inc. Waste Stream Technology Inc. Webs Ltd. Wedgewood Analytical Inc. Weyerhaeuser Co. Xethanol Corp. Yissum Research Development Co. Zeon Corp. Zuckerforschung Tulln GmbH

bioworld - medical device daily · pdf filethe bioworld executive compensation report –...

Documents